{
  "filename": "2025_ESC_EACTS_Valvular_Heart_Disease_ehaf194.pdf",
  "title": "2025 ESC/EACTS Guidelines for the",
  "type": "valvular_heart_disease",
  "year": 2025,
  "total_pages": 102,
  "extracted_at": "2026-01-15T00:24:54.838633",
  "chapters": [
    {
      "number": "1",
      "title": "2025 ESC/EACTS Guidelines for the management of valvular heart disease",
      "start_page": 1,
      "end_page": 6,
      "content": "2025 ESC/EACTS Guidelines for the \nmanagement of valvular heart disease \nDeveloped by the task force for the management of valvular heart \ndisease of the European Society of Cardiology (ESC) and the \nEuropean Association for Cardio-Thoracic Surgery (EACTS) \nAuthors/Task Force Members: Fabien Praz  *†, (ESC Chairperson) (Switzerland), \nMichael A. Borger  *†, (EACTS Chairperson) (Germany), Jonas Lanz  \n‡, (ESC Task \nForce Co-ordinator) (Switzerland), Mateo Marin-Cuartas  \n‡, (EACTS Task Force \nCo-ordinator) (Germany), Ana Abreu  \n(Portugal), Marianna Adamo (Italy), \nNina Ajmone Marsan (Netherlands), Fabio Barili  \n(Italy), Nikolaos Bonaros  \n(Austria), Bernard Cosyns  \n(Belgium), Ruggero De Paulis  \n(Italy), Habib Gamra  \n(Tunisia), Marjan Jahangiri (United Kingdom), Anders Jeppsson  \n(Sweden),  \nRobert J.M. Klautz  \n(Netherlands), Benoit Mores  \n(Belgium),  \nEsther Pérez-David  \n(Spain), Janine Pöss (Germany), Bernard D. Prendergast \n(United Kingdom), Bianca Rocca  \n(Italy), Xavier Rossello  \n(Spain), Mikio Suzuki \n(Serbia), Holger Thiele  \n(Germany), Christophe Michel Tribouilloy  \n(France), \nWojtek Wojakowski  \n(Poland), and ESC/EACTS Scientific Document Group \n* Corresponding authors: Fabien Praz, Department of Cardiology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland, Tel: +41 31 632 83 50, Email: fabien.praz@insel.ch and \nMichael A. Borger, University Clinic of Cardiac Surgery, Leipzig Heart Center, Leipzig, Germany, Tel: +49 341 865 1422, Email: michael.borger@helios-gesundheit.de \n† The two Chairpersons contributed equally to the document and are joint corresponding authors. \n‡ The two Task Force Co-ordinators contributed equally to the document. \nAuthor/Task Force Member affiliations are listed in author information. \nESC Clinical Practice Guidelines (CPG) Committee: listed in the Appendix. \nESC subspecialty communities having participated in the development of this document: \nAssociations: Association for Acute CardioVascular Care (ACVC), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), \nEuropean Association of Percutaneous Cardiovascular Interventions (EAPCI), European Heart Rhythm Association (EHRA), and Heart Failure Association (HFA) \nWorking Groups: Cardiovascular Pharmacotherapy \nPatient Forum \nDisclaimer. The European Society of Cardiology (ESC)/European Association for Cardio-Thoracic Surgery (EACTS) Guidelines represent the views of the ESC and the EACTS and were produced \nafter careful consideration of the scientific and medical knowledge and the evidence available at the time of their publication. The ESC and the EACTS are not responsible in the event of any contra-\ndiction, discrepancy and/or ambiguity between the ESC/EACTS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation \nto good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EACTS Guidelines fully into account when exercising their clinical judgement, as well as in the \ndetermination and the implementation of preventive, diagnostic or therapeutic medical strategies; however, the ESC/EACTS Guidelines do not override, in any way whatsoever, the individual re-\nsponsibility of health professionals to make appropriate and accurate decisions in consideration of each patient’s health condition and in consultation with that patient and, where appropriate and/or \nnecessary, the patient’s caregiver. Nor do the ESC/EACTS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or \nguidelines issued by the competent public health authorities, in order to manage each patient’s case in light of the scientifically accepted data pursuant to their respective ethical and professional \nobligations. It is also the health professional’s responsibility to verify the applicable rules and regulations relating to drugs and medical devices prior to making any clinical decision and to check whether \na more recent version of this document exists. The ESC and the EACTS warn readers that the technical language may be misinterpreted and decline any responsibility in this respect. \nPermissions. The content of these ESC/EACTS Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC/EACTS \nGuidelines may be translated or reproduced in any form without written permission from the ESC and the EACTS. Permissions can be obtained upon submission of a written request \nto Oxford University Press, the publisher of the European Heart Journal and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oup.com). \nThis article has been co-published with permission in the European Heart Journal and European Journal of Cardio-Thoracic Surgery. All rights reserved. © The European Society of Cardiology and \nthe European Association for Cardio-Thoracic Surgery 2025.  \nThe articles are identical except for minor stylistic and spelling differences in keeping with each journal’s style. Either citation can be used when citing this article.  \nEuropean Heart Journal (2025) 46, 4635–4736 \nhttps://doi.org/10.1093/eurheartj/ehaf194 \nESC GUIDELINES \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nDocument Reviewers: Alec Vahanian, (ESC Review Co-ordinator) (France), Carlos-A. Mestres, (EACTS Review \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa (United Kingdom), Enoch F. Akowuah (United \nKingdom), Elena Arbelo (Spain), Folkert W. Asselbergs (Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani \n(Italy), Margarita Brida (Croatia), Sergio Buccheri (Sweden), Robert A. Byrne (Republic of Ireland), Ovidiu Chioncel \n(Romania), Lenard Conradi (Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Anna Franzone (Italy), \nKristina Hermann Haugaa (Norway), Bettina Heidecker (Germany), Borja Ibanez (Spain), Bernard Iung (France), \nStefan James (Sweden), Lars Køber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf Landmesser (Germany), \nGregory Y.H. Lip (United Kingdom), John William McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham (United Kingdom), Inge Moelgaard (Denmark), \nJens Cosedis Nielsen (Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet (Belgium), Thomas Pilgrim \n(Switzerland), Eva Prescott (Denmark), Eduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba (Spain), \nAnna Sannino (Germany), Felix C. Tanner (Switzerland), Marina Urena (France), Ilonca Vaartjes (Netherlands), \nChristiaan Vrints (Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), Adam Witkowski (Poland), \nand Katja Zeppenfeld (Netherlands) \nAll experts involved in the development of these guidelines have submitted declarations of interest, \nwhich are reported in a supplementary document to the guidelines. See the European Heart Journal online or  \nhttps://www.escardio.org/Guidelines for supplementary documents as well as evidence tables.  \n- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - \nKeywords \nGuidelines • European Society of Cardiology (ESC) • European Association for Cardio-Thoracic Surgery (EACTS) • \nValvular heart disease • Aortic stenosis • Aortic regurgitation • Mitral stenosis • Mitral regurgitation • Tricuspid \nregurgitation • Tricuspid stenosis • Multivalvular disease • TAVI • SAVR • Heart surgery • Transcatheter edge-to- \nedge repair • Transcatheter valve replacement  \nTable of contents \n1. Preamble .............................................................................................................. 4640 \n2. Introduction ....................................................................................................... 4642 \n2.1. What is new .............................................................................................\n4643 \n3. The Heart Team and Heart Valve Centre ............................................ 4649 \n3.1. The Heart Valve Network .................................................................\n4649 \n3.1.1. Composition of the Heart Team ............................................. 4650 \n3.1.2. Procedural volume and clinical outcomes ........................... 4651 \n4. Imaging of patients with valvular heart disease ................................... 4652 \n4.1. Initial valve assessment .........................................................................\n4652 \n4.2. Associated diseases and conditions ................................................\n4653 \n4.3. Evaluation of valvular heart disease dynamics and variability\n4653 \n4.4. Assessment of extravalvular cardiac consequences from \nvalvular heart disease .....................................................................................\n4653 \n4.5. Evaluation of eligibility, planning, and guiding of interventions\n4653 \n5. Clinical evaluation of patients with valvular heart disease ............. 4653 \n5.1. Clinical examination ..............................................................................\n4653 \n5.2. Assessment of comorbidities and risk stratification ................\n4653 \n5.3. Biomarkers ................................................................................................\n4654 \n5.4. Exercise testing .......................................................................................\n4655 \n5.5. Invasive investigations ...........................................................................\n4655 \n5.5.1. Coronary angiography .................................................................. 4655 \n5.5.2. Cardiac catheterization ................................................................ 4655 \n5.6. Patient-centred care and shared decision-making ...................\n4655 \n6. Management of conditions associated with valvular heart disease\n4655 \n6.1. Diagnosis and management of coronary artery disease ........\n4655 \n6.2. Atrial fibrillation ......................................................................................\n4657 \n6.3. Cancer and radiation therapy ...........................................................\n4657 \n6.4. Prophylaxis of rheumatic fever ........................................................\n4658 \n6.5. Cardiogenic shock and acute heart failure ..................................\n4658 \n6.6. Palliative care ............................................................................................\n4658 \n7. Aortic regurgitation ........................................................................................ 4658 \n7.1. Prevalence and aetiology .....................................................................\n4658 \n7.2. Evaluation ...................................................................................................\n4658 \n7.3. Medical therapy .......................................................................................\n4660 \n7.4. Indications for intervention ................................................................\n4660 \n7.5. Follow-up ...................................................................................................\n4660 \n7.6. Special patient populations ................................................................\n4662 \n8. Aortic stenosis .................................................................................................. 4662 \n8.1. Prevalence and aetiology .....................................................................\n4662 \n8.2. Evaluation ...................................................................................................\n4662 \n8.2.1. Echocardiography and cardiac computed tomography . 4662 \n8.2.2. Additional diagnostic and prognostic parameters ............ 4663 \n8.2.3. Procedural planning ....................................................................... 4663 \n8.3. Medical therapy .......................................................................................\n4663 \n8.4. Indication for intervention ..................................................................\n4665 \n8.4.1. Symptomatic severe aortic stenosis ....................................... 4665 \n8.4.2. Asymptomatic severe aortic stenosis .................................... 4665 \n8.4.3. Moderate aortic stenosis ............................................................. 4665 \n8.5. Treatment options .................................................................................\n4667 \n8.5.1. The mode of intervention in candidates for a \nbioprosthesis ................................................................................................. 4667 \n8.5.1.1. Age and life expectancy .......................................................\n4668 \n8.5.1.2. Anatomical features ..............................................................\n4668 \n8.5.1.3. Lifetime management ...........................................................\n4668  \n4636                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n8.6. Follow-up ...................................................................................................\n4671 \n9. Mitral regurgitation ......................................................................................... 4671 \n9.1. Primary mitral regurgitation ..............................................................\n4671 \n9.1.1. Prevalence and aetiology ............................................................. 4671 \n9.1.2. Evaluation ........................................................................................... 4671 \n9.1.2.1. Echocardiography and right heart catheterization ..\n4671 \n9.1.2.2. Biomarkers ................................................................................\n4671 \n9.1.2.3. Cardiac magnetic resonance and computed \ntomography ..............................................................................................\n4672 \n9.1.2.4. Genetic evaluation .................................................................\n4674 \n9.1.3. Medical therapy ............................................................................... 4674 \n9.1.4. Indications for intervention ........................................................ 4674 \n9.1.5. Follow-up ........................................................................................... 4675 \n9.2. Secondary mitral regurgitation .........................................................\n4675 \n9.2.1. Prevalence and aetiology ............................................................. 4675 \n9.2.2. Evaluation ........................................................................................... 4675 \n9.2.3. Definition of atrial secondary mitral regurgitation ........... 4675 \n9.2.4. Management of ventricular secondary mitral  \nregurgitation .................................................................................................. 4676 \n9.2.4.1. Medical and device therapy ...............................................\n4676 \n9.2.4.2. Indications for intervention ...............................................\n4677 \n9.2.4.3. Follow-up ...................................................................................\n4678 \n9.2.5. Management of atrial secondary mitral regurgitation ..... 4679 \n9.2.5.1. Medical therapy and rhythm management .................\n4679 \n9.2.5.2. Indications for intervention ...............................................\n4679 \n9.2.5.3. Follow-up ...................................................................................\n4679 \n10. Mitral stenosis ................................................................................................. 4679 \n10.1. Prevalence and aetiology ..................................................................\n4679 \n10.2. Rheumatic mitral stenosis ................................................................\n4679 \n10.2.1. Evaluation ........................................................................................ 4679 \n10.2.2. Medical therapy ............................................................................. 4680 \n10.2.3. Indications for intervention ..................................................... 4680 \n10.2.4. Follow-up ......................................................................................... 4680 \n10.3. Degenerative mitral stenosis with mitral annular \ncalcification .........................................................................................................\n4680 \n10.3.1. Evaluation ........................................................................................ 4681 \n10.3.2. Indications for intervention ..................................................... 4681 \n11. Tricuspid regurgitation ................................................................................ 4682 \n11.1. Prevalence and aetiology ..................................................................\n4682 \n11.2. Evaluation ................................................................................................\n4683 \n11.3. Medical therapy ....................................................................................\n4683 \n11.4. Indications for intervention .............................................................\n4683 \n11.4.1. Surgery .............................................................................................. 4683 \n11.4.1.1. Patients without indication for left-sided valve  \nsurgery ........................................................................................................\n4685 \n11.4.1.2. Patients with indication for left-sided valve surgery\n4685 \n11.4.2. Transcatheter techniques ......................................................... 4686 \n12. Tricuspid stenosis .......................................................................................... 4687 \n12.1. Prevalence and aetiology ..................................................................\n4687 \n12.2. Evaluation ................................................................................................\n4687 \n12.3. Medical therapy ....................................................................................\n4688 \n12.4. Indications for intervention .............................................................\n4688 \n13. Multiple and mixed valvular heart disease .......................................... 4688 \n13.1. Prevalence and undertreatment ....................................................\n4688 \n13.2. Evaluation and diagnostic pitfalls ...................................................\n4688 \n13.3. Indications for intervention .............................................................\n4688 \n13.3.1. Multiple valvular heart disease ................................................ 4688 \n13.3.2. Mixed aortic valve disease ........................................................ 4690 \n13.3.3. Mixed mitral valve disease ........................................................ 4690 \n13.4. Follow-up ................................................................................................\n4690 \n14. Management of patients with prosthetic valves or valve repair\n4690 \n14.1. Choice of prosthetic valve ...............................................................\n4690 \n14.2. Follow-up of patients with prosthetic valves ...........................\n4691 \n14.3. Antithrombotic therapy in patients with treated valvular \nheart disease .....................................................................................................\n4691 \n14.3.1. Mechanical heart valves ............................................................. 4691 \n14.3.1.1. Post-operative anticoagulation and therapeutic \ntargets .........................................................................................................\n4691 \n14.3.1.2. Prevention and management of bleeding ..................\n4693 \n14.3.1.3. Management of anticoagulation therapy before and \nafter non-cardiac invasive procedures ..........................................\n4693 \n14.3.2. Biological heart valves ................................................................ 4695 \n14.3.2.1. Patients with a surgical biological heart valve and no \nindication for oral anticoagulation ..................................................\n4695 \n14.3.2.2. Patients with a transcatheter heart valve and no \nindication for oral anticoagulation ..................................................\n4695 \n14.3.2.3. Patients with a surgical biological heart valve and an \nindication for oral anticoagulation ..................................................\n4696 \n14.3.2.4. Patients with a transcatheter biological heart valve \nand an indication for oral anticoagulation ...................................\n4696 \n14.4. Management of prosthetic valve dysfunction and \ncomplications ....................................................................................................\n4697 \n14.4.1. Structural valve deterioration ................................................. 4697 \n14.4.2. Non-structural valve dysfunction .......................................... 4698 \n14.4.2.1. Prosthesis–patient mismatch ..........................................\n4698 \n14.4.2.2. Paravalvular leak and haemolysis ..................................\n4698 \n14.4.3. Endocarditis .................................................................................... 4698 \n14.4.4. Valve thrombosis .......................................................................... 4698 \n14.4.4.1. Hypo-attenuated leaflet thickening ..............................\n4698 \n14.4.4.2. Clinically significant valve thrombosis .........................\n4698 \n15. Management during non-cardiac surgery ............................................ 4700 \n15.1. Pre-operative evaluation ...................................................................\n4700 \n15.2. Specific valve lesions ...........................................................................\n4700 \n15.2.1. Aortic stenosis ............................................................................... 4700 \n15.2.2. Mitral stenosis ................................................................................ 4701 \n15.2.3. Aortic and mitral regurgitation .............................................. 4701 \n15.3. Peri-operative monitoring ................................................................\n4702 \n16. Management of valvular heart disease during pregnancy ............. 4702 \n16.1. Management before pregnancy .....................................................\n4702 \n16.2. Management during pregnancy ......................................................\n4703 \n16.2.1. Patients with native valve disease ......................................... 4703 \n16.2.2. Patients with prosthetic valves ............................................... 4703 \n17. Sex-specific considerations in patients with valvular heart \ndisease ........................................................................................................................ 4703 \n17.1. Aortic valve disease ............................................................................\n4703 \n17.2. Mitral valve disease ..............................................................................\n4704 \n17.3. Tricuspid valve disease ......................................................................\n4704 \n18. Key messages .................................................................................................. 4704 \n19. Gaps in evidence ............................................................................................ 4705 \n20. ‘What to do’ and ‘What not to do’ messages from the \nGuidelines ................................................................................................................. 4707 \n21. Evidence tables ............................................................................................... 4710 \n22. Data availability statement ......................................................................... 4710 \n23. Author information ...................................................................................... 4710 \n24. Appendix ........................................................................................................... 4710 \n25. References ........................................................................................................ 4711  \nESC Guidelines                                                                                                                                                                                          4637 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTables of Recommendations \nRecommendation Table 1 — Recommendations for the \nmanagement of chronic coronary syndrome in patients with valvular \nheart disease (see also Supplementary data online, Evidence \nTable 1) ...................................................................................................................... 4656 \nRecommendation Table 2 — Recommendations for the \nmanagement of atrial fibrillation in patients with native valvular \nheart disease (see also Supplementary data online, Evidence \nTables 2 and 3) ....................................................................................................... 4657 \nRecommendation Table 3 — Recommendations on indications for \nintervention in severe aortic regurgitation (see also Supplementary \ndata online, Evidence Tables 4–8) ................................................................... 4662 \nRecommendation Table 4 — Recommendations on indications for \nintervention in symptomatic and asymptomatic severe aortic stenosis, \nand recommended mode of intervention (see also Supplementary data \nonline, Evidence Tables 9–13) ...................................................................................\n4670 \nRecommendation Table 5 — Recommendations on indications for \nconcomitant aortic valve replacement at the time of coronary artery \nbypass grafting or ascending aorta surgery ................................................ 4671 \nRecommendation Table 6 — Recommendations on indications for \nintervention in severe primary mitral regurgitation (see also \nSupplementary data online, Evidence Tables 14–16) .............................. 4674 \nRecommendation Table 7 — Recommendations on indications for \nintervention in secondary mitral regurgitation (see also \nSupplementary data online, Evidence Tables 17–20) .............................. 4679 \nRecommendation Table 8 — Recommendations on indications for \npercutaneous mitral commissurotomy, mitral valve surgery, and \ntranscatheter intervention in clinically severe rheumatic and \ndegenerative mitral stenosis (see also Supplementary data online, \nEvidence Table 21) ........................................................................................ 4682 \nRecommendation Table 9 — Recommendations on indications for \nintervention in tricuspid regurgitation (see also Supplementary data \nonline, Evidence Tables 22 and 23) ....................................................................... 4687 \nRecommendation Table 10 — Recommendations on indications for \nintervention in tricuspid stenosis ................................................................... 4688 \nRecommendation Table 11 — Recommendations on indications for \nsurgery of concomitant left-sided valvular heart disease ..................... 4690 \nRecommendation Table 12 — Recommendations on indications for \nintervention in patients with mixed moderate aortic stenosis and \nmoderate aortic regurgitation (see also Supplementary data online, \nEvidence Table 24) ................................................................................................. 4690 \nRecommendation Table 13 — Recommendations for prosthetic \nvalve selection ......................................................................................................... 4691 \nRecommendation Table 14 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a \nmechanical heart valve ........................................................................................ 4693 \nRecommendation Table 15 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a \nmechanical heart valve undergoing elective non-cardiac surgery or \ninvasive procedures .............................................................................................. 4694 \nRecommendation Table 16 — Recommendations for the \nmanagement of antithrombotic therapy in patients with a biological \nheart valve or valve repair ................................................................................. 4696 \nRecommendation Table 17 — Recommendations for the \nmanagement of prosthetic valve dysfunction (see also \nSupplementary data online, Evidence Table 25) ....................................... 4700  \nList of tables \nTable 1 Classes of recommendations .......................................................... 4641 \nTable 2 Levels of evidence ................................................................................ 4641 \nTable 3 New recommendations .................................................................... 4643 \nTable 4 Revised recommendations ............................................................... 4645 \nTable 5 Requirements for a Heart Valve Centre ................................... 4651 \nTable 6 Complex procedures ideally performed in the most \nexperienced Heart Valve Centres ................................................................. 4651 \nTable 7 Clinical and echocardiographic criteria predicting outcome \nimprovement in patients with severe ventricular secondary mitral \nregurgitation undergoing mitral transcatheter edge-to-edge repair\n4678 \nTable 8 Contraindications for percutaneous mitral \ncommissurotomy in rheumatic mitral stenosis ........................................ 4682 \nTable 9 Echocardiographic pitfalls, robust measures, and \ncomplementary multimodality imaging parameters in multiple or \nmixed valvular heart disease ............................................................................ 4689 \nTable 10 International normalized ratio targets and therapeutic \nranges for patients with a mechanical heart valve .................................. 4693 \nTable 11 Peri-operative management of antithrombotic treatment \nin patients with a mechanical heart valve undergoing non-cardiac \nsurgery based on type of procedure and underlying risk .................... 4694 \nTable 12 Criteria for the diagnosis of moderate or severe aortic \nand mitral haemodynamic valve deterioration ..................................... 4697 \nTable 13 ‘What to do’ and ‘what not to do’ ............................................ 4707   \nList of figures \nFigure 1 The Heart Valve Network .............................................................. 4650 \nFigure 2 Integrative imaging assessment of patients with valvular \nheart disease ........................................................................................................... 4652 \nFigure 3 Central illustration. Patient-centred evaluation for \ntreatment of valvular heart disease ............................................................... 4654 \nFigure 4 Imaging assessment of patients with aortic regurgitation . 4659 \nFigure 5 Management of patients with aortic regurgitation ............... 4661 \nFigure 6 Integrative imaging assessment of patients with aortic \nstenosis ...................................................................................................................... 4664 \nFigure 7 Management of patients with severe aortic stenosis .......... 4666 \nFigure 8 Aortic valve treatment options .................................................... 4667 \nFigure 9 Factors to be considered when selecting the mode of \nintervention for aortic stenosis ....................................................................... 4669 \nFigure 10 Echocardiographic assessment of patients with mitral \nregurgitation ............................................................................................................ 4672 \nFigure 11 Management of patients with severe primary mitral \nregurgitation ............................................................................................................ 4673 \nFigure 12 Most frequently used criteria for the diagnosis of atrial \nsecondary mitral regurgitation ........................................................................ 4676 \nFigure 13 Treatment of severe secondary mitral regurgitation \nwithout concomitant coronary artery disease ......................................... 4677 \nFigure 14 Management of clinically severe rheumatic mitral stenosis \n(mitral valve area ≤1.5 cm2) ............................................................................. 4681 \nFigure 15 Echocardiographic and invasive assessment of tricuspid \nregurgitation ............................................................................................................ 4684 \nFigure 16 Stepwise evaluation of patients with tricuspid \nregurgitation ............................................................................................................ 4685 \nFigure 17 Management of patients with tricuspid regurgitation ....... 4686 \nFigure 18 Antithrombotic therapy following mechanical heart valve \nimplantation .........................................................................................................................\n4692 \nFigure 19 Antithrombotic therapy following biological heart valve \nimplantation or surgical valve repair ............................................................. 4695 \nFigure 20 Management of left-sided obstructive and non-obstructive \nmechanical heart valve thrombosis ............................................................... 4699 \nFigure 21 Management of non-cardiac surgery in patients with \nsevere aortic stenosis .......................................................................................... 4701 \nFigure 22 The Pregnancy Heart Team model of care .......................... 4702  \n4638                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nAbbreviations and acronyms \n2D \nTwo-dimensional \n3D \nThree-dimensional \n4D \nFour-dimensional \nACE-I \nAngiotensin-converting enzyme-inhibitor \nACTIVATION \nPercutAneous Coronary inTervention prIor to \ntranscatheter aortic VAlve implantaTION trial \nAF \nAtrial fibrillation \nAO \nAorta \nAP \nAnteroposterior \nAR \nAortic regurgitation \nARB \nAngiotensin receptor blocker \nAS \nAortic stenosis \nASA \nAcetylsalicylic acid \nATLANTIS \nAnti-Thrombotic Strategy to Lower All \nCardiovascular and Neurologic Ischemic and \nHemorrhagic Events after Trans-Aortic Valve \nImplantation for Aortic Stenosis \nAU \nAgatston units \nAV \nAortic valve \nAVA \nAortic valve area \nAVAi \nAortic valve area indexed for body surface area \nAVATAR \nAortic Valve Replacement Versus \nConservative Treatment in Asymptomatic \nSevere Aortic Stenosis \nAVCS \nAortic valve calcium score \nAVr \nAortic valve repair \nBASILICA \nBioprosthetic or native Aortic Scallop \nIntentional Laceration to prevent Iatrogenic \nCoronary Artery obstruction \nBAV \nBicuspid aortic valve \nBHV \nBiological heart valve \nBNP \nBrain natriuretic peptide \nBP \nBlood pressure \nBSA \nBody surface area \nCABG \nCoronary artery bypass grafting \nCAD \nCoronary artery disease \nCCT \nCardiac computed tomography \nCCTA \nCoronary computed tomography \nangiography \nCHA2DS2-VASc \nCongestive heart failure or left ventricular \ndysfunction, hypertension, age ≥75 (doubled), \ndiabetes, stroke (doubled), vascular disease, \nage 65–74, sex category (female) \nCI \nConfidence interval \nCIED \nCardiac implantable electronic device \nCKD \nChronic kidney disease \nCMR \nCardiac magnetic resonance \nCOAPT \nCardiovascular Outcomes Assessment of the \nMitraClip Percutaneous Therapy for Heart Failure \nPatients with Functional Mitral Regurgitation \nCRT \nCardiac resynchronization therapy \nCT \nComputed tomography \nCW \nContinuous wave \nCYP \nCytochrome P \nDAPT \nDual antiplatelet therapy \nDEDICATE \nRandomized, Multicenter, Event-Driven Trial \nof TAVI versus SAVR in Patients with \nSymptomatic Severe Aortic-Valve Stenosis \nDOAC \nDirect oral anticoagulant  \nDSE \nDobutamine stress echocardiography \nDVI \nDoppler velocity index \nEACTS \nEuropean Association for Cardio-Thoracic \nSurgery \nEARLY TAVR \nEvaluation of TAVR Compared to Surveillance \nfor Patients with Asymptomatic Severe Aortic \nStenosis trial \nECG \nElectrocardiogram \nEDV \nEnd-diastolic velocity \nENVISAGE-TAVI AF \nEdoxaban vs. Standard of Care and Their \nEffects on Clinical Outcomes in Patients \nHaving Undergone Transcatheter Aortic Valve \nImplantation–Atrial Fibrillation \nEOA \nEffective orifice area \nEROA \nEffective regurgitant orifice area \nESC \nEuropean Society of Cardiology \nEuroSCORE \nEuropean System for Cardiac Operative Risk \nEvaluation \nEVoLVeD \nEarly Valve Replacement guided by Biomarkers \nof LV Decompensation in Asymptomatic \nPatients with Severe Aortic Stenosis \nFAC \nFractional area change \nFFR \nFractional flow reserve \nFWS \nFree wall strain \nGALILEO \nGlobal multicenter, open-label, randomized, \nevent-driven, active-controlled study \ncomparing a rivAroxaban-based \nantithrombotic strategy to an \nantipLatelet-based strategy after transcatheter \naortIc vaLve rEplacement (TAVR) to Optimize \nclinical outcomes trial \nGDMT \nGuideline-directed medical therapy \nGLS \nGlobal longitudinal strain \nh \nHour \nHALT \nHypo-attenuated leaflet thickening \nHF \nHeart failure \nHFpEF \nHeart failure with preserved ejection fraction \nHFrEF \nHeart failure with reduced ejection fraction \nHR \nHazard ratio \nHTx \nHeart transplantation \nINR \nInternational normalized ratio \nIU \nInternational unit \nKCCQ \nKansas City Cardiomyopathy Questionnaire \nLA \nLeft atrium/left atrial \nLAAO \nLeft atrial appendage occlusion \nLAAOS \nLeft Atrial Appendage Occlusion Study \nLAMPOON \nLaceration of the Anterior Mitral leaflet to \nPrevent Outflow ObstructioN \nLAVI \nLeft atrial volume index \nLMWH \nLow-molecular-weight heparin \nLV \nLeft ventricle/left ventricular \nLVAD \nLeft ventricular assist device \nLVEF \nLeft ventricular ejection fraction \nLVESD \nLeft ventricular end-systolic diameter \nLVESDi \nLeft ventricular end-systolic diameter indexed \nto BSA \nLVESVi \nLeft ventricular end-systolic volume indexed to \nBSA \nLVOT \nLeft ventricular outflow tract \nMA \nMitral annulus \nMAC \nMitral annular calcification  \nESC Guidelines                                                                                                                                                                                          4639 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nMATTERHORN \nMulticenter, Randomized, Controlled Study to \nAssess Mitral Valve Reconstruction for \nAdvanced Insufficiency of Functional or \nIschemic Origin trial \nMHV \nMechanical heart valve \nMITRA-FR \nPercutaneous Repair with the MitraClip \nDevice for Severe Functional/Secondary Mitral \nRegurgitation trial \nmPAP \nMean pulmonary artery pressure \nMR \nMitral regurgitation \nMRI \nMagnetic resonance imaging \nMS \nMitral stenosis \nM-TEER \nMitral transcatheter edge-to-edge repair \nMV \nMitral valve \nMVA \nMitral valve area \nMVHD \nMultiple valvular heart disease \nN \nNo \nNCS \nNon-cardiac surgery \nNOTION \nNordic Aortic Valve Intervention trial \nNT-proBNP \nN-terminal pro-B-type natriuretic protein \nNYHA \nNew York Heart Association \nOAC \nOral anticoagulation \nPAWP \nPulmonary artery wedge pressure \nPCI \nPercutaneous coronary intervention \nPET \nPositron emission tomography \nPH \nPulmonary hypertension \nPHT \nPressure half-time \nPISA \nProximal isovelocity surface area \nP mean \nMean pressure gradient \nPMC \nPercutaneous mitral commissurotomy \nPMR \nPrimary mitral regurgitation \nPOPular TAVI \nAntiplatelet Therapy for Patients Undergoing \nTranscatheter Aortic Valve Implantation \nPPM \nProsthesis–patient mismatch \nPROM \nPatient-reported outcome measure \nPVL \nParavalvular leak \nPVR \nPulmonary vascular resistance \nRA \nRight atrium/right atrial \nRCT \nRandomized controlled trial \nRECOVERY \nRandomized Comparison of Early Surgery \nversus Conventional Treatment in Very Severe \nAortic Stenosis \nRESHAPE-HF2 \nRandomized Investigation of the MitraClip \nDevice in Heart Failure: 2nd Trial in Patients \nwith Clinically Significant Functional Mitral \nRegurgitation \nRF \nRegurgitant fraction \nRHC \nRight heart catheterization \nRHD \nRheumatic heart disease \nRV \nRight ventricle/right ventricular \nRVEF \nRight ventricular ejection fraction \nRVol \nRegurgitant volume \nSAM \nSystolic anterior movement \nSAPT \nSingle antiplatelet therapy \nSAV \nSurgical aortic valve \nSAVR \nSurgical aortic valve replacement \nSGLT2i \nSodium–glucose co-transporter 2 inhibitor \nSMR \nSecondary mitral regurgitation \nSPAP \nSystolic pulmonary artery pressure  \nSTS \nSociety of Thoracic Surgeons \nSTS-PROM \nSociety of Thoracic Surgeons predicted risk of \nmortality \nSVD \nStructural valve deterioration \nSVi \nStroke volume index \nTAPSE \nTricuspid annular plane systolic excursion \nTAV \nTranscatheter aortic valve \nTAVI \nTranscatheter aortic valve implantation \nTDI \nTissue Doppler imaging \nTEER \nTranscatheter edge-to-edge repair \nTHV \nTranscatheter heart valve \nTMVI \nTranscatheter mitral valve implantation \nTOE \nTransoesophageal echocardiography \nTR \nTricuspid regurgitation \nTRILUMINATE \nClinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the \nTricuspid Valve Repair System trial \nTRISCEND \nEdwards EVOQUE Transcatheter Tricuspid \nValve Replacement: Pivotal Clinical \nInvestigation of Safety and Clinical Efficacy \nusing a Novel Device \nTS \nTricuspid stenosis \nTTE \nTransthoracic echocardiography \nTTR \nTime in therapeutic range \nTV \nTricuspid valve \nUFH \nUnfractionated heparin \nVCA \nVena contracta area \nVHD \nValvular heart disease \nVKA \nVitamin K antagonist \nVmax \nPeak transvalvular velocity \nVSARR \nValve-sparing aortic root replacement \nVTE \nVenous thromboembolism \nVTI \nVelocity time integral \nWHO \nWorld Health Organisation \nWU \nWood unit \nY \nYes \n1. Preamble \nGuidelines evaluate and summarize available evidence with the aim of \nassisting health professionals in proposing the best diagnostic or thera-\npeutic approach for an individual patient with a given condition. ESC/ \nEACTS Guidelines are intended for use by health professionals but \ndo not override their individual responsibility to make appropriate \nand accurate decisions in consideration of each patient’s health condi-\ntion and in consultation with the patient or the patient’s caregiver \nwhere appropriate and/or necessary. It is also the health professional’s \nresponsibility to verify the rules and regulations applicable in each coun-\ntry to drugs and devices at the time of prescription and to respect the \nethical rules of their profession. \nESC Guidelines represent the official position of the ESC on a given \ntopic. Guideline topics are selected for updating after annual expert re-\nview of new evidence conducted by the ESC Clinical Practice \nGuidelines (CPG) Committee. ESC Policies and Procedures for formu-\nlating and issuing ESC Guidelines can be found on the ESC website \n(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ \nGuidelines-development/Writing-ESC-Guidelines). \nThis guideline updates and replaces the previous version from 2021. This \nTask Force was selected by the ESC and the EACTS to include professionals  \n4640                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "valvular",
        "intervention",
        "ct",
        "heart failure",
        "eacts",
        "management",
        "surgery",
        "disease",
        "guidelines",
        "heart",
        "pci",
        "imaging",
        "recommendation"
      ]
    },
    {
      "number": "2",
      "title": "1. Preamble",
      "start_page": 6,
      "end_page": 8,
      "content": "MATTERHORN \nMulticenter, Randomized, Controlled Study to \nAssess Mitral Valve Reconstruction for \nAdvanced Insufficiency of Functional or \nIschemic Origin trial \nMHV \nMechanical heart valve \nMITRA-FR \nPercutaneous Repair with the MitraClip \nDevice for Severe Functional/Secondary Mitral \nRegurgitation trial \nmPAP \nMean pulmonary artery pressure \nMR \nMitral regurgitation \nMRI \nMagnetic resonance imaging \nMS \nMitral stenosis \nM-TEER \nMitral transcatheter edge-to-edge repair \nMV \nMitral valve \nMVA \nMitral valve area \nMVHD \nMultiple valvular heart disease \nN \nNo \nNCS \nNon-cardiac surgery \nNOTION \nNordic Aortic Valve Intervention trial \nNT-proBNP \nN-terminal pro-B-type natriuretic protein \nNYHA \nNew York Heart Association \nOAC \nOral anticoagulation \nPAWP \nPulmonary artery wedge pressure \nPCI \nPercutaneous coronary intervention \nPET \nPositron emission tomography \nPH \nPulmonary hypertension \nPHT \nPressure half-time \nPISA \nProximal isovelocity surface area \nP mean \nMean pressure gradient \nPMC \nPercutaneous mitral commissurotomy \nPMR \nPrimary mitral regurgitation \nPOPular TAVI \nAntiplatelet Therapy for Patients Undergoing \nTranscatheter Aortic Valve Implantation \nPPM \nProsthesis–patient mismatch \nPROM \nPatient-reported outcome measure \nPVL \nParavalvular leak \nPVR \nPulmonary vascular resistance \nRA \nRight atrium/right atrial \nRCT \nRandomized controlled trial \nRECOVERY \nRandomized Comparison of Early Surgery \nversus Conventional Treatment in Very Severe \nAortic Stenosis \nRESHAPE-HF2 \nRandomized Investigation of the MitraClip \nDevice in Heart Failure: 2nd Trial in Patients \nwith Clinically Significant Functional Mitral \nRegurgitation \nRF \nRegurgitant fraction \nRHC \nRight heart catheterization \nRHD \nRheumatic heart disease \nRV \nRight ventricle/right ventricular \nRVEF \nRight ventricular ejection fraction \nRVol \nRegurgitant volume \nSAM \nSystolic anterior movement \nSAPT \nSingle antiplatelet therapy \nSAV \nSurgical aortic valve \nSAVR \nSurgical aortic valve replacement \nSGLT2i \nSodium–glucose co-transporter 2 inhibitor \nSMR \nSecondary mitral regurgitation \nSPAP \nSystolic pulmonary artery pressure  \nSTS \nSociety of Thoracic Surgeons \nSTS-PROM \nSociety of Thoracic Surgeons predicted risk of \nmortality \nSVD \nStructural valve deterioration \nSVi \nStroke volume index \nTAPSE \nTricuspid annular plane systolic excursion \nTAV \nTranscatheter aortic valve \nTAVI \nTranscatheter aortic valve implantation \nTDI \nTissue Doppler imaging \nTEER \nTranscatheter edge-to-edge repair \nTHV \nTranscatheter heart valve \nTMVI \nTranscatheter mitral valve implantation \nTOE \nTransoesophageal echocardiography \nTR \nTricuspid regurgitation \nTRILUMINATE \nClinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the \nTricuspid Valve Repair System trial \nTRISCEND \nEdwards EVOQUE Transcatheter Tricuspid \nValve Replacement: Pivotal Clinical \nInvestigation of Safety and Clinical Efficacy \nusing a Novel Device \nTS \nTricuspid stenosis \nTTE \nTransthoracic echocardiography \nTTR \nTime in therapeutic range \nTV \nTricuspid valve \nUFH \nUnfractionated heparin \nVCA \nVena contracta area \nVHD \nValvular heart disease \nVKA \nVitamin K antagonist \nVmax \nPeak transvalvular velocity \nVSARR \nValve-sparing aortic root replacement \nVTE \nVenous thromboembolism \nVTI \nVelocity time integral \nWHO \nWorld Health Organisation \nWU \nWood unit \nY \nYes \n1. Preamble \nGuidelines evaluate and summarize available evidence with the aim of \nassisting health professionals in proposing the best diagnostic or thera-\npeutic approach for an individual patient with a given condition. ESC/ \nEACTS Guidelines are intended for use by health professionals but \ndo not override their individual responsibility to make appropriate \nand accurate decisions in consideration of each patient’s health condi-\ntion and in consultation with the patient or the patient’s caregiver \nwhere appropriate and/or necessary. It is also the health professional’s \nresponsibility to verify the rules and regulations applicable in each coun-\ntry to drugs and devices at the time of prescription and to respect the \nethical rules of their profession. \nESC Guidelines represent the official position of the ESC on a given \ntopic. Guideline topics are selected for updating after annual expert re-\nview of new evidence conducted by the ESC Clinical Practice \nGuidelines (CPG) Committee. ESC Policies and Procedures for formu-\nlating and issuing ESC Guidelines can be found on the ESC website \n(https://www.escardio.org/Guidelines/Clinical-Practice-Guidelines/ \nGuidelines-development/Writing-ESC-Guidelines). \nThis guideline updates and replaces the previous version from 2021. This \nTask Force was selected by the ESC and the EACTS to include professionals  \n4640                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ninvolved with the medical care of patients with this pathology and to include \npatient representatives and methodologists. The selection procedure in-\ncluded an open call for authors and aimed to include members from across \nthe whole of the ESC region and from relevant ESC Subspecialty \nCommunities. Consideration was given to diversity and inclusion. \nGuidelines Task Forces perform a critical review and evaluation of the \npublished literature on diagnostic and therapeutic approaches including \nassessment of the risk–benefit ratio. Recommendations are based on \nmajor randomized trials and relevant systematic reviews and \nmeta-analyses, when available. Systematic literature searches are con-\nducted in cases of controversy or uncertainty to ensure that all key \nstudies were considered. For recommendations related to diagnosis \nand prognosis, additional types of evidence are included, such as diagnos-\ntic accuracy studies and studies focused on the development and valid-\nation of prognostic models. The strength of each recommendation and \nthe level of evidence supporting it are weighed and scored according \nto pre-defined criteria as outlined in Tables 1 and 2. Patient-Reported \nOutcome Measures (PROMs) and Patient-Reported Experience \nMeasures (PREMs) are also evaluated when available as the basis for re-\ncommendations and/or discussion in these guidelines. \nEvidence tables summarizing key information from relevant studies \nare generated to facilitate the formulation of recommendations, to \nTable 1 Classes of recommendations  \n©\u001f\u001e\u001d\u001c\u001f\u001b\u001d\u001a\u001e\u0019\u0018\u0017\u0018\u0016\n\u001d\u0015\u0014\u0013\u0013\u0012\u0013\u0019\u0011\u0010\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0014\n\t\u0011\f\u0013\n\u001d\u0015\u0014\u0013\u0013\u0019\b\u0019\n\u001f\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0014\f\u000b\u001c\u0011\u000f\u0019\u0006\u0012\f\u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012\r\u0012\f\n\n\u0005\u0014\n\u0019\u0014\u0019\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\t\u0013\n\u0002\u0012\f\u0012\u0001\u000e\t\u0014\u0015\u0019\u0003\u0013\u0012\u0010\u0003\u0015\u0019\u0012\u0012\u000e\n\t\u0007\u0012\u0019\n\u001d\u0011\f\t\u000e\n\t\f\u0006\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0014\f\u000b\u001c\u0011\u000f\u0019\u0014\u0019\u000b\t\u0007\u0012\u000f\u0006\u0012\f\u000e\u0012\u0019\u0011\u0010\u0019\u0011\u0004\t\f\t\u0011\f\u0019\u0014\u0002\u0011\u0003\n\u0019\n\u0005\u0012\u0019\u0003\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0019\n\u0012\u000e\u0014\u000e\u0019\u0011\u0010\u0019\n\u0005\u0012\u0019\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\n\b\u0013\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0012\u000b\u0019\u0011\u000f\u0019\t\u0013\u0019\t\f\u000b\t\u000e\u0014\n\u0012\u000b\n \u0011\u000f\u000b\t\f\u0006\u0019\n\u0011\u0019\u0003\u0013\u0012\n­\u0012\u0001\f\t\n\t\u0011\f\n\u001d\u0015\u0014\u0013\u0013\u0019\b\b\b\u0019\n\u001f\u0007\t\u000b\u0012\f\u000e\u0012\u0019\u0011\u000f\u0019\u0006\u0012\f\u0012\u000f\u0014\u0015\u0019\u0014\u0006\u000f\u0012\u0012\r\u0012\f\n\u0019\n\u0005\u0014\n\u0019\n\u0005\u0012\n\u0006\t\u0007\u0012\f\u0019\n\u000f\u0012\u0014\n\r\u0012\f\n\u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012\u000b\u0003\u000f\u0012\u0019\t\u0013\u0019\f\u0011\n\u0003\u0013\u0012\u0010\u0003\u0015\u001c\u0012\u0012\u000e\n\t\u0007\u0012\u0019\u0014\f\u000b\u0019\t\f\u0019\u0013\u0011\r\u0012\u0019\u000e\u0014\u0013\u0012\u0013\n\r\u0014\u0019\u0002\u0012\u0019\u0005\u0014\u000f\r\u0010\u0003\u0015\u0019\n\b\u0013\u0019\f\u0011\n\u0019\u000f\u0012\u000e\u0011\r\r\u0012\f\u000b\u0012\u000b\n\u0019\u0019 \u0019\u0019\u0019\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0002\n\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0012\u000e\u0014\u000e\u0019\t\u0013\u0019\u0015\u0012\u0013\u0013\u0019\u0012\u0015\u0015\n\u0012\u0013\n\u0014\u0002\u0015\t\u0013\u0005\u0012\u000b\u0019\u0002\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u001c\u0011\u0004\t\f\t\u0011\f\n\u0014\u0019\u0002\u0012\u0019\u000e\u0011\f\u0013\t\u000b\u0012\u000f\u0012\u000b\n\u0019\n\u0019\u0019\u0019\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0014\n \u0012\t\u0006\u0005\n\u0019\u0011\u0010\u0019\u0012\u0007\t\u000b\u0012\f\u000e\u0012\u001c\u0011\u0004\t\f\t\u0011\f\u0019\t\u0013\u0019\t\f\n\u0010\u0014\u0007\u0011\u0003\u000f\u0019\u0011\u0010\u0019\u0003\u0013\u0012\u0010\u0003\u0015\f\u0012\u0013\u0013\u001c\u0012\u000e\u0014\u000e\u0019\n\u001e\u0005\u0011\u0003\u0015\u000b\u0019\u0002\u0012\u0019\u000e\u0011\f\u0013\t\u000b\u0012\u000f\u0012\u000b\n\u001d\u0015\u0014\u0013\u0013\u0019\b\b\u0019\nTable 2 Levels of evidence  \n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0014\n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0013\n\u001f\u001e\u001d\u001e\u001c\u001b\u001a\u0019\n\u001e\u001d\u0018\u0017\u001e\u0016\u0015\u001e\u001b\u0012\n\u0011\u0010\u000f\u0010\u001b\u0017\u001e\u000e\u0018\u001d\u001e\u0017\u001b\u0019\u000e\u001a\r\u001b\r\f\u001c\u000f\u0018\u000b\u001c\u001e\u001b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\u0015\u001c\u0018\u0016\u0018\u0015\u0010\u001c\u001b\u000f\u000e\u0018\u0010\u001c\t\n\u001a\u000e\u001b\r\u001e\u000f\u0010\b\u0010\u0016\u0010\u001c\u0007\t\u001e\t\u0006\n\u0011\u0010\u000f\u0010\u001b\u0017\u001e\u000e\u0018\u001d\u001e\u0017\u001b\u0019\u000e\u001a\r\u001b\u0010\u001b\t\u0018\u0016\u0005\u001c\u001e\u001b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\u0015\u001c\u0018\u0016\u0018\u0015\u0010\u001c\u001b\u000f\u000e\u0018\u0010\u001c\n\u001a\u000e\u001b\u001c\u0010\u000e\u0005\u001e\u001b\u0016\u001a\u0016\b\u000e\u0010\u0016\u0017\u001a\r\u0018\n\u001e\u0017\u001b\t\u000f\f\u0017\u0018\u001e\t\u0006\n\u0012\u001a\u0016\t\u001e\u0016\t\f\t\u001b\u001a\u0019\u001b\u001a\u000b\u0018\u0016\u0018\u001a\u0016\u001b\u001a\u0019\u001b\u000f\u0004\u001e\u001b\u001e\u0003\u000b\u001e\u000e\u000f\t\u001b\u0010\u0016\u0017\u0002\u001a\u000e\u001b\t\r\u0010\u001c\u001c\u001b\t\u000f\f\u0017\u0018\u001e\t\u0001\n\u000e\u001e\u000f\u000e\u001a\t\u000b\u001e\u0015\u000f\u0018\u001d\u001e\u001b\t\u000f\f\u0017\u0018\u001e\t\u0001\u001b\u000e\u001e\u0005\u0018\t\u000f\u000e\u0018\u001e\t\u0006\n©\u0012\u0002\u0014\u0012\u001b\nESC Guidelines                                                                                                                                                                                          4641 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nenhance comprehension of recommendations after publication, and to \nreinforce transparency in the guidelines development process. The ta-\nbles are published in their own section of the guidelines and reference \nspecific recommendation tables. \nAfter an iterative process of deliberations, a first Task Force vote on \nall recommendations is conducted prior to the initiation of rounds of \nreview. A second Task Force vote on all recommendations is con-\nducted after the final round of review and revision. For each vote, \nthe Task Force follows ESC voting procedures and all recommenda-\ntions require at least 75% agreement among voting members to be ap-\nproved. Voting restrictions may be applied based on declarations of \ninterests. \nThe writing and reviewing panels provide declaration-of-interest \nforms for all relationships that might be perceived as real or potential \nsources of conflicts of interest. Their declarations of interest are re-\nviewed according to the ESC declaration-of-interest rules, which can \nbe found on the ESC website (http://www.escardio.org/doi) and are \ncompiled in a report published in a supplementary document with \nthe guidelines. Funding for the development of these ESC/EACTS \nGuidelines was derived entirely from the ESC and the EACTS with \nno involvement of the healthcare industry. \nThe ESC CPG Committee supervises and co-ordinates the prepar-\nation of new guidelines and approves their publication. In addition to \nreview by the ESC CPG Committee, these ESC/EACTS Guidelines \nunderwent multiple rounds of double-blind peer review on a dedicated \nonline review platform. The review was conducted by topic experts, in-\ncluding members from ESC National Cardiac Societies, EACTS \nNetwork of National Cardiac Surgery Societies and from relevant \nESC Subspecialty Communities. The Guideline Task Force considered \nall review comments and was required to respond to all those classified \nas major. After appropriate revisions, the Task Force, the ESC CPG \nCommittee members and the EACTS Council members approved \nthe final document for publication in the European Heart Journal and \nin the European Journal of Cardio-Thoracic Surgery. \nUnless otherwise stated, the guideline content refers to sex, under-\nstood as the biological condition of being male or female, defined by \ngenes, hormones, and sexual organs. Off-label use of medication may \nbe presented in this guideline if a sufficient level of evidence shows \nthat it can be considered medically appropriate for a given condition. \nHowever, decisions on off-label use must be made by the responsible \nhealth professional giving special consideration to ethical rules concern-\ning healthcare, the specific situation of the patient, patient consent, and \ncountry-specific health regulations. \n2. Introduction \nNew evidence has accumulated since the publication of the 2021 \nEuropean Society of Cardiology (ESC)/European Association for \nCardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular \nheart disease, leading to the need for new recommendations (Table 3 \nNew recommendations) and revision of existing recommendations \n(Table 4 Revised recommendations) concerning the following topics: \n• The importance of shared and patient-centred decision-making by \nmultidisciplinary expert Heart Teams working within a regional net-\nwork has been reinforced. Patients with complex conditions or re-\nquiring complex procedures should be referred to high-volume \ncentres, where corresponding expertise is concentrated to ensure \nhigh-quality treatment. \n• Advanced imaging modalities—such as three-dimensional (3D) echo-\ncardiography, cardiac computed tomography (CCT), and cardiac \nmagnetic resonance (CMR) imaging—have gained importance and \nbecome a central aspect in the screening and evaluation of patients \nwith valvular heart disease (VHD). \n• Emphasis is put on the importance of correctly assessing the cause(s) \nand mechanism(s) of all valve diseases. In particular, the distinction \nbetween atrial and ventricular secondary mitral regurgitation (SMR) \nhas clear implications in terms of prognosis and management. \n• New evidence has been published regarding the benefits of \nintervention for the treatment of severe aortic stenosis (AS) irre-\nspective of symptoms, left ventricular ejection fraction (LVEF), and \nflow reserve. \n• The criteria used for decision-making concerning the optimal modal-\nity of AS treatment [transcatheter aortic valve (AV) implantation \n(TAVI) or surgical AV replacement (SAVR)] based on a Heart Team \napproach have been refined, including the combination of key aspects \nsuch as age, procedural risk, and anatomical suitability, incorporating \nestimated life expectancy and lifetime management considerations. \n• Further randomized evidence confirming the mid-term safety and ef-\nficacy of TAVI in low-risk patients has been published. \n• The indications for TAVI in patients with bicuspid AV (BAV) stenosis \nor severe aortic regurgitation (AR) at high surgical risk, based on ana-\ntomical suitability and a comprehensive Heart Team evaluation, are \ndiscussed. \n• Several advancements have been made regarding the treatment of \npatients with primary mitral regurgitation (PMR): refinement of the \ncriteria for intervention in asymptomatic patients; demonstration \nof the value of minimally invasive mitral valve (MV) surgery to reduce \nthe length of hospital stay and accelerate recovery; and large-scale \ndata confirming the role of transcatheter edge-to-edge repair \n(TEER) in high-risk patients. \n• Longer-term follow-up data and two new randomized controlled \ntrials (RCTs) concerning the management of patients with ventricular \nSMR have been published. \n• The evidence for the treatment of tricuspid valve (TV) disease is \ngrowing—including new randomized data supporting concomitant \nTV repair during left-sided valve surgery, and transcatheter options \n(repair and replacement) that reduce tricuspid regurgitation (TR), \npromote reverse right ventricular (RV) remodelling, and improve \nquality of life compared with medical treatment. \n• Efforts have been made to provide improved guidance regarding the \ndiagnostic steps and management of patients with multiple and mixed \nVHD. \n• Definitions of structural valve deterioration (SVD) have been up-\ndated and unified. \n• The recommendations concerning the use of direct oral anticoagu-\nlants (DOACs) in patients with VHD have been updated, and the im-\nportance of education and (self-)monitoring is emphasized. \n• Sex-specific considerations in patients with VHD have been ex-\ntended and regrouped into a new dedicated section (see Section 17).   \nBecause of demographic changes, patients with VHD frequently \npresent with concomitant cardiovascular diseases, increasing the com-\nplexity of treatment strategies. These Guidelines focus on acquired  \n4642                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 7",
          "page": 7,
          "content": "\u0015\u0014\u0013\u0013\u0019\b\b\u0019 | \u0011  \u000e \u0006\u0019\u0012\u0007 \u0012 \u000e\u0012\u0019\u0014 \u0011\u000f\u0019\u0014\u0019 \u0007\u0012\u000f\u0006\u0012 \u000e\u0012\u0019\u0011\u0010\u0019\u0011\u0004 \u0011 \u0019\u0014\u0002\u0011\u0003 \u0019 \u0005\u0012\u0019\u0003\u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0019\n\u0012\u000e\u0014\u000e\u0019\u0011\u0010\u0019 \u0005\u0012\u0019\u0006 \u0007\u0012 \u0019 \u000f\u0012\u0014 \u0012 \u0019\u0011\u000f\u0019\u0004\u000f\u0011\u000e\u0012 \u0003\u000f\u0012\u0019 |  |  | \n |  |  |  | \n\u0019\u0019\u0019 \u0015\u0014\u0013\u0013\u0019\b\b\u0014 |  | \u0012 \u0006\u0005 \u0019\u0011\u0010\u0019\u0012\u0007 \u0012 \u000e\u0012 \u0011\u0004 \u0011 \u0019 \u0013\u0019\n\u0010\u0014\u0007\u0011\u0003\u000f\u0019\u0011\u0010\u0019\u0003\u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0012\u000e\u0014\u000e\u0019 | \u0005\u0011\u0003\u0015 \u0019\u0002\u0012\u0019\u000e\u0011 \u0013 \u0012\u000f\u0012 | \n |  |  |  | \n\u0019\u0019 \u0019\u0019\u0019 \u0015\u0014\u0013\u0013\u0019\b\b\u0002 |  | \u0013\u0012\u0010\u0003\u0015 \u0012\u0013\u0013 \u0012\u000e\u0014\u000e\u0019 \u0013\u0019\u0015\u0012\u0013\u0013\u0019\u0012\u0015\u0015\n\u0012\u0013 \u0014\u0002\u0015 \u0013\u0005\u0012 \u0019\u0002\u0019\u0012\u0007 \u0012 \u000e\u0012 \u0011\u0004 \u0011  | \u0014\u0019\u0002\u0012\u0019\u000e\u0011 \u0013 \u0012\u000f\u0012 | ",
          "rows": 5,
          "cols": 5
        }
      ],
      "keywords": [
        "catheterization",
        "imaging",
        "pulmonary hypertension",
        "mitral regurgitation",
        "antiplatelet",
        "tricuspid regurgitation",
        "tavi",
        "sglt2",
        "pci",
        "echocardiography",
        "intervention",
        "echo",
        "aortic stenosis",
        "mitral stenosis",
        "savr",
        "treatment",
        "anticoagulation",
        "ct",
        "preamble",
        "heart failure"
      ]
    },
    {
      "number": "3",
      "title": "2. Introduction",
      "start_page": 8,
      "end_page": 15,
      "content": "enhance comprehension of recommendations after publication, and to \nreinforce transparency in the guidelines development process. The ta-\nbles are published in their own section of the guidelines and reference \nspecific recommendation tables. \nAfter an iterative process of deliberations, a first Task Force vote on \nall recommendations is conducted prior to the initiation of rounds of \nreview. A second Task Force vote on all recommendations is con-\nducted after the final round of review and revision. For each vote, \nthe Task Force follows ESC voting procedures and all recommenda-\ntions require at least 75% agreement among voting members to be ap-\nproved. Voting restrictions may be applied based on declarations of \ninterests. \nThe writing and reviewing panels provide declaration-of-interest \nforms for all relationships that might be perceived as real or potential \nsources of conflicts of interest. Their declarations of interest are re-\nviewed according to the ESC declaration-of-interest rules, which can \nbe found on the ESC website (http://www.escardio.org/doi) and are \ncompiled in a report published in a supplementary document with \nthe guidelines. Funding for the development of these ESC/EACTS \nGuidelines was derived entirely from the ESC and the EACTS with \nno involvement of the healthcare industry. \nThe ESC CPG Committee supervises and co-ordinates the prepar-\nation of new guidelines and approves their publication. In addition to \nreview by the ESC CPG Committee, these ESC/EACTS Guidelines \nunderwent multiple rounds of double-blind peer review on a dedicated \nonline review platform. The review was conducted by topic experts, in-\ncluding members from ESC National Cardiac Societies, EACTS \nNetwork of National Cardiac Surgery Societies and from relevant \nESC Subspecialty Communities. The Guideline Task Force considered \nall review comments and was required to respond to all those classified \nas major. After appropriate revisions, the Task Force, the ESC CPG \nCommittee members and the EACTS Council members approved \nthe final document for publication in the European Heart Journal and \nin the European Journal of Cardio-Thoracic Surgery. \nUnless otherwise stated, the guideline content refers to sex, under-\nstood as the biological condition of being male or female, defined by \ngenes, hormones, and sexual organs. Off-label use of medication may \nbe presented in this guideline if a sufficient level of evidence shows \nthat it can be considered medically appropriate for a given condition. \nHowever, decisions on off-label use must be made by the responsible \nhealth professional giving special consideration to ethical rules concern-\ning healthcare, the specific situation of the patient, patient consent, and \ncountry-specific health regulations. \n2. Introduction \nNew evidence has accumulated since the publication of the 2021 \nEuropean Society of Cardiology (ESC)/European Association for \nCardio-Thoracic Surgery (EACTS) Guidelines for the management of valvular \nheart disease, leading to the need for new recommendations (Table 3 \nNew recommendations) and revision of existing recommendations \n(Table 4 Revised recommendations) concerning the following topics: \n• The importance of shared and patient-centred decision-making by \nmultidisciplinary expert Heart Teams working within a regional net-\nwork has been reinforced. Patients with complex conditions or re-\nquiring complex procedures should be referred to high-volume \ncentres, where corresponding expertise is concentrated to ensure \nhigh-quality treatment. \n• Advanced imaging modalities—such as three-dimensional (3D) echo-\ncardiography, cardiac computed tomography (CCT), and cardiac \nmagnetic resonance (CMR) imaging—have gained importance and \nbecome a central aspect in the screening and evaluation of patients \nwith valvular heart disease (VHD). \n• Emphasis is put on the importance of correctly assessing the cause(s) \nand mechanism(s) of all valve diseases. In particular, the distinction \nbetween atrial and ventricular secondary mitral regurgitation (SMR) \nhas clear implications in terms of prognosis and management. \n• New evidence has been published regarding the benefits of \nintervention for the treatment of severe aortic stenosis (AS) irre-\nspective of symptoms, left ventricular ejection fraction (LVEF), and \nflow reserve. \n• The criteria used for decision-making concerning the optimal modal-\nity of AS treatment [transcatheter aortic valve (AV) implantation \n(TAVI) or surgical AV replacement (SAVR)] based on a Heart Team \napproach have been refined, including the combination of key aspects \nsuch as age, procedural risk, and anatomical suitability, incorporating \nestimated life expectancy and lifetime management considerations. \n• Further randomized evidence confirming the mid-term safety and ef-\nficacy of TAVI in low-risk patients has been published. \n• The indications for TAVI in patients with bicuspid AV (BAV) stenosis \nor severe aortic regurgitation (AR) at high surgical risk, based on ana-\ntomical suitability and a comprehensive Heart Team evaluation, are \ndiscussed. \n• Several advancements have been made regarding the treatment of \npatients with primary mitral regurgitation (PMR): refinement of the \ncriteria for intervention in asymptomatic patients; demonstration \nof the value of minimally invasive mitral valve (MV) surgery to reduce \nthe length of hospital stay and accelerate recovery; and large-scale \ndata confirming the role of transcatheter edge-to-edge repair \n(TEER) in high-risk patients. \n• Longer-term follow-up data and two new randomized controlled \ntrials (RCTs) concerning the management of patients with ventricular \nSMR have been published. \n• The evidence for the treatment of tricuspid valve (TV) disease is \ngrowing—including new randomized data supporting concomitant \nTV repair during left-sided valve surgery, and transcatheter options \n(repair and replacement) that reduce tricuspid regurgitation (TR), \npromote reverse right ventricular (RV) remodelling, and improve \nquality of life compared with medical treatment. \n• Efforts have been made to provide improved guidance regarding the \ndiagnostic steps and management of patients with multiple and mixed \nVHD. \n• Definitions of structural valve deterioration (SVD) have been up-\ndated and unified. \n• The recommendations concerning the use of direct oral anticoagu-\nlants (DOACs) in patients with VHD have been updated, and the im-\nportance of education and (self-)monitoring is emphasized. \n• Sex-specific considerations in patients with VHD have been ex-\ntended and regrouped into a new dedicated section (see Section 17).   \nBecause of demographic changes, patients with VHD frequently \npresent with concomitant cardiovascular diseases, increasing the com-\nplexity of treatment strategies. These Guidelines focus on acquired  \n4642                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nVHD and do not deal in detail with overlapping cardiovascular diseases \nsuch as infective endocarditis,5 chronic coronary syndrome,6 and atrial \nfibrillation (AF),7 as well as all scenarios of aortic or congenital dis-\nease,8,9 because these topics are covered in separate Guidelines. \nThe 2025 ESC/EACTS Guidelines for the management of valvular heart \ndisease aim to be concise, focused on relevant issues for clinicians and \npatients, and to provide clear and simple practical recommendations, \nassisting healthcare providers in their daily clinical decision-making. A \ncompilation of the evidence considered for new recommendations, or \nthose with an updated class of recommendation or level of evidence, \ncan be consulted online (see Supplementary data online, Evidence \nTables). The Task Force for these Guidelines acknowledges that \nmultiple factors influence and ultimately determine the most appro-\npriate treatment of individual patients within a given community. \nThese factors include the availability of equipment and technology, \nand the expertise and volumes, in complex procedures, such as valve \nrepair or transcatheter interventions. Moreover, given the lack of evi-\ndence on some topics related to VHD, several recommendations are \nthe result of expert consensus opinion. Therefore, deviations from \nthese Guidelines may be appropriate in certain clinical circumstances, \nand decision-making should always be based on a collaborative, multi-\ndisciplinary Heart Team approach centred on individual characteris-\ntics, needs, and prognosis, as well as the preferences of the informed \npatient. \n2.1. What is new  \nTable 3 New recommendations \nRecommendations \nClassa \nLevelb  \nDiagnosis of coronary artery disease—Section 6.1 \nOmission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of sufficient \nquality to rule out significant CAD. \nIIa \nB \nPCI should be considered in patients with a primary indication to undergo TAVI and ≥90% coronary artery stenosis in segments with a \nreference diameter ≥2.5 mm. \nIIa \nB \nIndications for intervention in severe aortic regurgitation—Section 7.4 \nTAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the \nanatomy is suitable. \nIIb \nB \nIndications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention—Section 8.5 \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS \nand LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. \nIIa \nA \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. \nIIb \nB \nIndications for intervention in severe primary mitral regurgitation—Section 9.1 \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  \n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: \n• AF \n• SPAP at rest >50 mmHg \n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm) \n• Concomitant secondary TR ≥ moderate. \nI \nB \nMinimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. \nIIb \nB \nIndications for intervention in secondary mitral regurgitation—Section 9.2 \nMV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal \nmedical therapy. \nIIa \nB \nTEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy \nincluding rhythm control, when appropriate. \nIIb \nB \nMV surgery may be considered in patients with moderate SMR undergoing CABG. \nIIb \nB \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis— \nSection 10.3 \nTMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with \nexpertise in complex MV surgery and transcatheter interventions. \nIIb \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4643 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nIndications for intervention in tricuspid regurgitation—Section 11.4 \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, \nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. \nI \nC \nSurgery of concomitant severe mitral regurgitation—Section 13.3 \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. \nI \nC \nIndications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation—Section 13.3 \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s. \nI \nB \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation, with Vmax ≥4.0 m/s \nand LVEF <50% not attributable to other cardiac disease. \nI \nC \nProsthetic valve selection—Section 14.1 \nAn MHV should be considered in patients with an estimated long life expectancy, if there are no contraindications for long-term OAC. \nIIa \nB \nManagement of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3 \nIt is recommended that INR targets are based on the type and position of MHV, patient’s risk factors, and comorbidities. \nI \nA \nPatient education is recommended to improve the quality of OAC. \nI \nA \nManagement of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive \nprocedures—Section 14.3 \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or \nminimal bleeding. \nI \nA \nInterruption (3–4 days before surgery), and resumption of VKA without bridging, may be considered to reduce bleeding in patients with \nnew-generation aortic MHV and no other thromboembolic risk factors undergoing major non-cardiac surgery or invasive procedures. \nIIb \nB \nManagement of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3 \nSurgical biological heart valve without indication for oral anticoagulation \nLifelong low-dose ASA (75–100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients \nwithout clear indication for OAC. \nIIb \nC \nTranscatheter aortic valve implantation without indication for oral anticoagulation \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. \nIII \nB \nSurgical repair without indication for oral anticoagulation \nLow-dose ASA (75–100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear \nindication for OAC and at high bleeding risk. \nIIb \nB \nSurgical biological heart valve with indication for oral anticoagulation \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. \nI \nB \nDOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC. \nIIb \nB \nSurgical repair with indication for oral anticoagulation and/or antiplatelet therapy \nContinuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an \nantithrombotic therapy. \nIIa \nB \nManagement of mechanical heart valve failure—Section 14.4 \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nManagement of valve thrombosis—Section 14.4 \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. \nI \nC \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BAV, bicuspid aortic valve; BHV, biological heart valve; CABG, \ncoronary artery bypass grafting; CAD, coronary artery disease; CT, computed tomography; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; INR, international normalized \nratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left \nventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; MAC, mitral annular calcification; MHV, mechanical heart valve; MR, mitral \nregurgitation; MV, mitral valve; OAC, oral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; RV, right ventricle/right \nventricular; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TMVI, \ntranscatheter mitral valve implantation; TOE, transoesophageal echocardiography; TR, tricuspid regurgitation; TV, tricuspid valve; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4644                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTable 4 Revised recommendations \nRecommendations in 2021 version \nClassa \nLevelb \nRecommendations in 2025 version \nClassa \nLevelb  \nManagement of coronary artery disease in patients with valvular heart disease—Section 6.1 \nCCTA should be considered as an alternative to \ncoronary angiography before valve surgery in patients \nwith severe VHD and low probability of CAD. \nIIa \nC \nCCTA is recommended before valve intervention in \npatients with moderate or lower (≤50%) pre-test \nlikelihood of obstructive CAD. \nI \nB \nCoronary angiography is recommended before valve \nsurgery in patients with severe VHD and any of the \nfollowing: \n• History of cardiovascular disease \n• Suspected myocardial ischaemia \n• LV systolic dysfunction \n• In men >40 years of age and post-menopausal women \n• One or more cardiovascular risk factors. \nI \nC \nInvasive coronary angiography is recommended before \nvalve intervention in patients with high and very high \n(>50%) pre-test likelihood of obstructive CAD. \nI \nC \nCoronary angiography is recommended in the \nevaluation of severe SMR. \nI \nC \nInvasive coronary angiography is recommended in the \nevaluation of CAD in patients with severe ventricular SMR. \nI \nC \nPCI should be considered in patients with a primary \nindication to undergo TAVI and coronary artery \ndiameter stenosis >70% in proximal segments. \nIIa \nC \nPCI may be considered in patients with a primary \nindication to undergo transcatheter valve interventions \nand coronary artery stenosis ≥70% in proximal \nsegments of main vessels. \nIIb \nB \nPCI should be considered in patients with a primary \nindication to undergo transcatheter MV intervention \nand coronary artery diameter stenosis >70% in \nproximal segments. \nIIa \nC \nManagement of atrial fibrillation in patients with native valvular heart disease—Section 6.2 \nLAAO should be considered to reduce the \nthromboembolic risk in patients with AF and a \nCHA2DS2-VASc score ≥2 undergoing valve surgery. \nIIa \nB \nSurgical closure of the LA appendage is recommended \nas an adjunct to OAC in patients with AF undergoing \nvalve surgery to prevent cardioembolic stroke and \nsystemic thromboembolism. \nI \nB \nConcomitant AF ablation should be considered in \npatients undergoing valve surgery, balancing the benefits \nof freedom from atrial arrhythmias and the risk factors \nfor recurrence (LA dilatation, years in AF, age, renal \ndysfunction, and other cardiovascular risk factors). \nIIa \nA \nConcomitant surgical ablation is recommended in \npatients undergoing MV surgery with AF suitable for a \nrhythm control strategy to prevent symptoms and \nrecurrence of AF, according to an experienced team of \nelectrophysiologists and arrhythmia surgeons. \nI \nA \nConcomitant surgical ablation should be considered in \npatients undergoing non-MV surgery with AF suitable \nfor a rhythm control strategy to prevent symptoms and \nrecurrence of AF, according to an experienced team of \nelectrophysiologists and arrhythmia surgeons. \nIIa \nB \nThe use of DOACs is not recommended in patients \nwith AF and moderate-to-severe MS. \nIII \nC \nThe use of DOACs is not recommended in patients \nwith AF and rheumatic MS with an MVA ≤2.0 cm2. \nIII \nB \nIndications for surgery in severe aortic regurgitation—Section 7.4 \nAV repair may be considered in selected patients at \nexperienced centres when durable results are \nexpected. \nIIb \nC \nAV repair should be considered in selected patients \nwith severe AR at experienced centres, when durable \nresults are expected. \nIIa \nB \nSurgery may be considered in asymptomatic patients \nwith LVESD >20 mm/m2 BSA (especially in patients \nwith small body size) or resting LVEF ≤55%, if surgery is \nat low risk. \nIIb \nC \nAV surgery may be considered in asymptomatic \npatients with severe AR and LVESDi >22 mm/m2 or \nLVESVi >45 mL/m2 [especially in patients with small \nbody size (BSA <1.68 m2)], or resting LVEF ≤55%, if \nsurgical risk is low. \nIIb \nB \nIndications for intervention in symptomatic severe aortic stenosis—Section 8.4.1 \nIntervention is recommended in symptomatic patients \nwith severe low-flow (SVi ≤35 mL/m2), low-gradient \n(<40 mmHg) AS with reduced LVEF (<50%), and \nevidence of flow (contractile) reserve. \nI \nB \nIntervention is recommended in symptomatic patients \nwith low-flow (SVi ≤35 mL/m2), low-gradient \n(<40 mmHg) AS with reduced LVEF (<50%) after \ncareful confirmation that AS is severe. \nI \nB                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4645 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nIntervention should be considered in symptomatic \npatients with low-flow, low-gradient (<40 mmHg) AS \nwith normal LVEF after careful confirmation that the AS \nis severe. \nIIa \nC \nIntervention should be considered in symptomatic \npatients with low-flow (SVi ≤35 mL/m2), low-gradient \n(<40 mmHg) AS with normal LVEF (≥50%) after \ncareful confirmation that AS is severe. \nIIa \nB \nIndications for intervention in asymptomatic severe aortic stenosis—Section 8.5 \nIntervention should be considered in asymptomatic \npatients with severe AS and LV dysfunction (LVEF  \n<55%) without another cause. \nIIa \nB \nIntervention should be considered in asymptomatic \npatients with severe AS and LVEF ≥50%, if the \nprocedural risk is low and one of the following \nparameters is present: \n• Very severe AS (mean gradient ≥60 mmHg or Vmax  \n>5.0 m/s). \n• Severe valve calcification (ideally assessed by CCT) \nand Vmax progression ≥0.3 m/s/year. \n• Markedly elevated BNP/NT-proBNP levels (more \nthan three times age- and sex-corrected normal \nrange, confirmed on repeated measurement without \nother explanation). \n• LVEF <55% without another cause. \nIIa \nB \nIntervention should be considered in asymptomatic \npatients with LVEF >55% and a normal exercise test if \nthe procedural risk is low and one of the following \nparameters is present: \n• Very severe AS (mean gradient ≥60 mmHg or Vmax  \n>5 m/s). \n• Severe valve calcification (ideally assessed by CCT) \nand Vmax progression ≥0.3 m/s/year. \n• Markedly elevated BNP levels (more than three times \nage- and sex-corrected normal range) confirmed by \nrepeated measurements and without other \nexplanation. \nIIa \nB \nMode of intervention in symptomatic severe aortic stenosis—Section 8.5 \nThe choice between surgical and transcatheter \nintervention must be based upon careful evaluation of \nclinical, anatomical, and procedural factors by the Heart \nTeam, weighing the risks and benefits of each approach \nfor an individual patient. The Heart Team \nrecommendation should be discussed with the patient \nwho can then make an informed treatment choice. \nI \nC \nIt is recommended that the mode of intervention is \nbased on Heart Team assessment of individual clinical, \nanatomical, and procedural characteristics, \nincorporating lifetime management considerations and \nestimated life expectancy. \nI \nC \nTAVI is recommended in older patients (≥75 years), or \nin those who are high risk (STS-PROM/EuroSCORE II  \n>8%) or unsuitable for surgery. \nI \nA \nTAVI is recommended in patients ≥70 years of age with \ntricuspid AV stenosis, if the anatomy is suitable. \nI \nA \nSAVR is recommended in younger patients who are low \nrisk for surgery (<75 years and STS-PROM/ \nEuroSCORE II <4%), or in patients who are operable \nand unsuitable for transfemoral TAVI. \nI \nB \nSAVR is recommended in patients <70 years of age, if \nthe surgical risk is low. \nI \nB \nSAVR or TAVI are recommended for remaining \npatients according to individual clinical, anatomical, and \nprocedural characteristics. \nI \nB \nSAVR or TAVI are recommended for all remaining \ncandidates for an aortic BHV according to Heart Team \nassessment.1–4 \nI \nB \nNon-transfemoral TAVI may be considered in patients \nwho are inoperable and unsuitable for transfemoral \nTAVI. \nIIb \nC \nNon-transfemoral TAVI should be considered in \npatients who are unsuitable for surgery and \ntransfemoral access. \nIIa \nB \nIndications for intervention in severe primary mitral regurgitation—Section 9.1.4 \nSurgery should be considered in asymptomatic patients \nwith preserved LV function (LVESD <40 mm and LVEF  \n>60%) and AF secondary to MR or PH (SPAP at rest  \n>50 mmHg). \nIIa \nB \nMV surgery should be considered in asymptomatic \npatients with severe PMR without LV dysfunction \n(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF  \n>60%) in the presence of PH (SPAP at rest  \n>50 mmHg), or AF secondary to MR. \nIIa \nB \nSurgical MV repair should be considered in low-risk \nasymptomatic patients with LVEF >60%, LVESD  \n<40 mm, and significant LA dilatation (volume \nindex ≥60 mL/m2 or diameter ≥55 mm) when \nperformed in a Heart Valve Centre and a durable repair \nis likely. \nIIa \nB \nSurgical MV repair should be considered in low-risk \nasymptomatic patients with severe PMR without LV \ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2, \nand LVEF >60%) in the presence of significant LA \ndilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm), \nwhen performed in a Heart Valve Centre and a durable \nrepair is likely. \nIIa \nB                         \nContinued  \n4646                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTEER may be considered in symptomatic patients who \nfulfil the echocardiographic criteria of eligibility, are judged \ninoperable or at high surgical risk by the Heart Team, and \nfor whom the procedure is not considered futile. \nIIb \nB \nTEER should be considered in symptomatic patients \nwith severe PMR who are anatomically suitable and at \nhigh surgical risk according to the Heart Team. \nIIa \nB \nSevere ventricular secondary mitral regurgitation and concomitant coronary artery disease—Section 9.2 \nIn symptomatic patients who are judged not \nappropriate for surgery by the Heart Team on the basis \nof their individual characteristics, PCI (and/or TAVI) \npossibly followed by TEER (in case of persisting severe \nSMR) should be considered. \nIIa \nC \nPCI followed by TEER after re-evaluation of MR may be \nconsidered in symptomatic patients with chronic severe \nventricular SMR and non-complex CAD. \nIIb \nC \nIndications for intervention in severe ventricular secondary mitral regurgitation without concomitant coronary artery disease—Section 9.2 \nTEER should be considered in selected symptomatic \npatients not eligible for surgery and fulfilling criteria \nsuggesting an increased chance of responding to the \ntreatment. \nIIa \nB \nTEER is recommended to reduce HF hospitalizations \nand improve quality of life in haemodynamically stable, \nsymptomatic patients with impaired LVEF (<50%) and \npersistent severe ventricular SMR, despite optimized \nGDMT and CRT (if indicated), fulfilling specific clinical \nand echocardiographic criteria. \nI \nA \nIn high-risk symptomatic patients not eligible for surgery \nand not fulfilling the criteria suggesting an increased \nchance of responding to TEER, the Heart Team may \nconsider in selected cases a TEER procedure or other \ntranscatheter valve therapy if applicable, after careful \nevaluation for ventricular assist device or heart \ntransplant. \nIIb \nC \nTEER may be considered for symptom improvement in \nselected symptomatic patients with severe ventricular \nSMR not fulfilling the specific clinical and \nechocardiographic criteria, after careful evaluation of \nLVAD or HTx. \nIIb \nB \nValve surgery may be considered in symptomatic \npatients judged appropriate for surgery by the Heart \nTeam. \nIIb \nC \nMV surgery may be considered in symptomatic patients \nwith severe ventricular SMR without advanced HF who \nare not suitable for TEER. \nIIb \nC \nIndications for intervention in tricuspid regurgitation in patients with left-sided valvular heart disease requiring surgery—Section 11.4 \nSurgery is recommended in patients with severe \nprimary TR undergoing left- sided valve surgery. \nI \nC \nConcomitant TV surgery is recommended in patients \nwith severe primary or secondary TR. \nI \nB \nSurgery is recommended in patients with severe \nsecondary TR undergoing left-sided valve surgery. \nI \nB \nSurgery should be considered in patients with moderate \nprimary TR undergoing left-sided valve surgery. \nIIa \nC \nConcomitant TV repair should be considered in \npatients with moderate primary or secondary TR, to \navoid progression of TR and RV remodelling. \nIIa \nB \nSurgery should be considered in patients with mild or \nmoderate secondary TR with a dilated annulus \n(≥40 mm or >21 mm/m2 by 2D echocardiography) \nundergoing left-sided valve surgery. \nIIa \nB \nConcomitant TV repair may be considered in selected \npatients with mild secondary TR and tricuspid annulus \ndilatation (≥40 mm or >21 mm/m2) to avoid \nprogression of TR and RV remodelling. \nIIb \nB \nIndications for intervention in patients with severe tricuspid regurgitation without left-sided valvular heart disease requiring surgery— \nSection 11.4 \nTranscatheter treatment of symptomatic secondary \nsevere TR may be considered in inoperable patients at a \nHeart Valve Centre with expertise in the treatment of \nTV disease. \nIIb \nC \nTranscatheter TV treatment should be considered to \nimprove quality of life and RV remodelling in high-risk \npatients, with symptomatic severe TR despite optimal \nmedical therapy, in the absence of severe RV \ndysfunction or pre-capillary PH. \nIIa \nA \nProsthetic valve selection—Section 14.1 \nA mechanical prosthesis may be considered in patients \nalready on long-term anticoagulation due to the high \nrisk for thromboembolism. \nIIb \nC \nAn MHV may be considered in patients with a clear \nindication for long-term OAC. \nIIb \nC \nManagement of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3 \nOAC using a VKA is recommended lifelong for all \npatients with an MHV prosthesis. \nI \nB \nLifelong OAC with a VKA is recommended for all \npatients with MHVs to prevent thromboembolic \ncomplications. \nI \nA                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4647 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nFor patients with a VKA, INR self-management is \nrecommended provided appropriate training and \nquality control are performed. \nI \nB \nINR self-monitoring and self-management are \nrecommended over standard monitoring in selected, \ntrained patients to improve efficacy. \nI \nA \nIn patients with MHVs, it is recommended to (re)initiate \nthe VKA on the first post-operative day. \nI \nC \nFollowing cardiac surgery with MHV implantation, it is \nrecommended to start UFH or LMWH bridging and \nVKA within 24 h, or as soon as considered safe. \nI \nB \nIn patients who have undergone valve surgery with an \nindication for post-operative therapeutic bridging, it is \nrecommended to start either UFH or LMWH 12–24 h \nafter surgery. \nI \nC \nThe addition of low-dose ASA (75–100 mg/day) to \nVKA may be considered in selected patients with MHVs \nin case of concomitant atherosclerotic disease and low \nrisk of bleeding. \nIIb \nC \nThe addition of low-dose ASA (75–100 mg/day) to VKA \nshould be considered in selected patients with MHVs in \ncase of concomitant symptomatic atherosclerotic disease, \nconsidering the individual bleeding risk profile. \nIIa \nB \nThe addition of low-dose ASA (75–100 mg/day) to \nVKA should be considered after thromboembolism \ndespite an adequate INR. \nIIa \nC \nEither an increase in INR target or the addition of \nlow-dose ASA (75–100 mg/day) should be considered \nin patients with MHVs who develop a major \nthromboembolic complication despite documented \nadequate INR. \nIIa \nC \nDOACs are not recommended in patients with an \nMHV prosthesis. \nIII \nB \nDOACs and/or DAPT are not recommended to \nprevent thrombosis in patients with an MHV. \nIII \nA \nManagement of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive \nprocedures—Section 14.3 \nIt is recommended that VKAs are timely discontinued \nprior to elective surgery to aim for an INR <1.5. \nI \nC \nIt is recommended to discontinue VKA at least 4 days \nbefore major elective non-cardiac surgery, aiming for an \nINR <1.5, and to resume VKA treatment within 24 h \nafter surgery, or as soon as considered safe. \nI \nB \nIn patients with MHVs, it is recommended to (re)initiate \nthe VKA on the first post-operative day. \nI \nC \nTherapeutic doses of either UFH or subcutaneous \nLMWH are recommended for bridging. \nI \nB \nVKA interruption and resumption with bridging should \nbe considered in patients with an MHV and \nthromboembolic risk factors undergoing major \nnon-cardiac surgery. \nIIa \nB \nBridging of OAC, when interruption is needed, is \nrecommended in patients with any of the following \nindications: \n• MHV \n• AF with significant MS \n• AF with CHA2DS2-VASc score ≥3 for women or 2 \nfor men \n• Acute thrombotic event within the previous 4 weeks \n• High acute thromboembolic risk. \nI \nC \nManagement of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3 \nLifelong SAPT is recommended after TAVI in patients \nwith no baseline indication for OAC. \nI \nA \nLow-dose ASA (75–100 mg/day) is recommended for \n12 months after TAVI in patients without indication for \nOAC. \nI \nA \nLong-term (after the first 12 months) low-dose ASA \n(75–100 mg/day) should be considered after TAVI in \npatients without clear indication for OAC. \nIIa \nC \nOAC is recommended lifelong for TAVI patients who \nhave other indications for OAC. \nI \nB \nOAC is recommended for TAVI patients who have \nother indications for OAC. \nI \nB \nOAC with VKA should be considered during the first \n3 months after mitral and tricuspid repair. \nIIa \nC \nOAC, with either VKAs or DOACs, should be considered \nduring the first 3 months after surgical MV or TV repair. \nIIa \nB \nRoutine use of OAC is not recommended after TAVI in \npatients without baseline indication. \nIII \nB \nRoutine use of OAC is not recommended after TAVI in \npatients without baseline indication. \nIII \nA \nManagement of haemolysis and paravalvular leak—Section 14.4 \nDecision on transcatheter or surgical closure of \nclinically significant PVLs should be considered based on \npatient risk status, leak morphology, and local expertise. \nIIa \nC \nIt is recommended that the decision between \ntranscatheter or surgical closure of clinically significant \nPVLs is based on Heart Team evaluation, including \npatient risk, leak morphology, and local expertise. \nI \nC                         \nContinued  \n4648                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n3. The Heart Team and Heart Valve \nCentre \n3.1. The Heart Valve Network \nDespite increasing attention within the medical community, VHD con-\ntinues to be underdiagnosed and undertreated in the general popula-\ntion, and public awareness remains low.10–13 Beside screening using \nauscultation and imaging when appropriate, the co-ordinated imple-\nmentation of Heart Teams, Heart Valve Centres, and Heart Valve \nNetworks at a local level represents an essential step to timely diagnose \nand treat patients with VHD. \nAn integrated regional Heart Valve Network, incorporating out-\npatient Heart Valve Clinics (for initial diagnosis and ongoing surveil-\nlance) and specialist Heart Valve Centres (for advanced imaging and \nsurgical or transcatheter intervention), allows optimal patient care \nthrough timely access to specialist assessment, accurate diagnosis, im-\nproved decision-making, and matching of patients to healthcare provi-\nders with appropriate expertise, experience, and resources (Figure 1).12 \nIn addition, dedicated Heart Valve Clinics ensure consistent application \nof clinical guidelines, efficient use of resources, and overall high-quality \npatient care, which in turn may improve outcomes.14,15 Medical goals \ninclude careful clinical and echocardiographic evaluation, monitoring \nat appropriate time intervals (so-called ‘watchful waiting’), application \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis in patients at high or prohibitive surgical risk. \nIIa \nB \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis. \nIIa \nB \nManagement of biological heart valve failure—Section 14.4 \nReoperation is recommended in symptomatic patients \nwith a significant increase in transprosthetic gradient \n(after exclusion of valve thrombosis) or severe \nregurgitation. \nI \nC \nReintervention is recommended in symptomatic \npatients with significant valve dysfunction not \nattributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation \nin the aortic position should be considered by the Heart \nTeam depending on anatomical considerations, features \nof the prosthesis, and in patients who are at high \noperative risk or inoperable. \nIIa \nB \nTranscatheter transfemoral valve-in-valve implantation \nin the aortic position should be considered in patients \nwith significant valve dysfunction who are at \nintermediate or high surgical risk, and have suitable \nanatomical and prosthesis features, as assessed by the \nHeart Team. \nIIa \nB \nTranscatheter valve-in-valve implantation in the mitral \nand tricuspid position may be considered in selected \npatients at high risk for surgical reintervention. \nIIb \nB \nTranscatheter transvenous mitral or tricuspid \nvalve-in-valve implantation should be considered in \npatients with significant valve dysfunction at intermediate \nor high surgical risk, if the anatomy is suitable. \nIIa \nB \nManagement of mechanical heart valve thrombosis—Section 14.4 \nUrgent or emergency valve replacement is \nrecommended for obstructive thrombosis in critically ill \npatients without serious comorbidity. \nI \nB \nHeart Team evaluation is recommended in patients \nwith acute HF (NYHA class III or IV) due to obstructive \nMHV thrombosis to determine appropriate \nmanagement (repeat valve replacement or low-dose \nslow infusion fibrinolysis). \nI \nB \nFibrinolysis (using recombinant tissue plasminogen \nactivator 10 mg bolus + 90 mg in 90 min with UFH or \nstreptokinase 1 500 000 U in 60 min without UFH) \nshould be considered when surgery is not available or is \nvery high risk, or for thrombosis of right-sided \nprostheses. \nIIa \nB \nManagement of biological heart valve thrombosis—Section 14.4 \nAnticoagulation using a VKA and/or UFH is \nrecommended in BHV thrombosis before considering \nreintervention. \nI \nC \nOAC using VKA is recommended in BHV thrombosis \nbefore considering reintervention. \nI \nB \n© ESC/EACTS 2025\n2D, two-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; \nBSA, body surface area; CAD, coronary artery disease; CCT, cardiac computed tomography; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, congestive heart failure \nor left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, sex category (female); CRT, cardiac resynchronization therapy; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GDMT, guideline-directed medical therapy; h, \nhour; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; \nLMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic volume indexed to BSA; MHV, mechanical heart valve; min, minute; MR, \nmitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OAC, \noral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; PVL, paravalvular leak; RV, right ventricle/right \nventricular; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; STS-PROM, Society \nof Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid \nregurgitation; TV, tricuspid valve; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \nESC Guidelines                                                                                                                                                                                          4649 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 9",
          "page": 9,
          "content": "Recommendations |  | Classa | Levelb | \n | Diagnosis of coronary artery disease—Section 6.1 |  |  | \nOmission of invasive coronary angiography should be considered in TAVI candidates, if procedural planning CT angiography is of suffci ient\nquality to rule out significant CAD. |  | IIa | B | \nPCI should be considered in patients with a primary indication to undergo TAVI and ≥90% coronary artery stenosis in segments with a\nreference diameter ≥2.5 mm. |  | IIa | B | \n | Indications for intervention in severe aortic regurgitation—Section 7.4 |  |  | \nTAVI may be considered for the treatment of severe AR in symptomatic patients ineligible for surgery according to the Heart Team, if the\nanatomy is suitable. |  | IIb | B | \n | Indications for intervention in symptomatic and asymptomatic severe aortic stenosis, and recommended mode of intervention—Section 8.5 |  |  | \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS\nand LVEF ≥50%, as an alternative to close active surveillance, if the procedural risk is low. |  | IIa | A | \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is suitable. |  | IIb | B | \n | Indications for intervention in severe primary mitral regurgitation—Section 9.1 |  |  | \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi\n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfliled:\n• AF\n• SPAP at rest >50 mmHg\n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)\n• Concomitant secondary TR ≥ moderate. |  | I | B | \nMinimally invasive MV surgery may be considered at experienced centres to reduce the length of stay and accelerate recovery. |  | IIb | B | \n | Indications for intervention in secondary mitral regurgitation—Section 9.2 |  |  | \nMV surgery, surgical AF ablation, if indicated, and LAAO should be considered in symptomatic patients with severe atrial SMR under optimal\nmedical therapy. |  | IIa | B | \nTEER may be considered in symptomatic patients with severe atrial SMR not eligible for surgery after optimization of medical therapy\nincluding rhythm control, when appropriate. |  | IIb | B | \nMV surgery may be considered in patients with moderate SMR undergoing CABG. |  | IIb | B | \n | Indications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis—\nSection 10.3 |  |  | \nTMVI may be considered in symptomatic patients with extensive MAC and severe MV dysfunction at experienced Heart Valve Centres with\nexpertise in complex MV surgery and transcatheter interventions. |  | IIb | C | ",
          "rows": 18,
          "cols": 5
        },
        {
          "title": "Table on page 10",
          "page": 10,
          "content": " | Indications for intervention in tricuspid regurgitation—Section 11.4 |  |  | \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,\nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. |  | I | C | \n | Surgery of concomitant severe mitral regurgitation—Section 13.3 |  |  | \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. |  | I | C | \n | Indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation—Section 13.3 |  |  | \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.\nmax |  | I | B | \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation, with V ≥4.0 m/s\nmax\nand LVEF <50% not attributable to other cardiac disease. |  | I | C | \n | Prosthetic valve selection—Section 14.1 |  |  | \nAn MHV should be considered in patients with an estimated long life expectancy, if there are no contraindications for long-term OAC. |  | IIa | B | \n | Management of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3 |  |  | \nIt is recommended that INR targets are based on the type and position of MHV, patient’s risk factors, and comorbidities. |  | I | A | \nPatient education is recommended to improve the quality of OAC. |  | I | A | \n | Management of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive\nprocedures—Section 14.3 |  |  | \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or\nminimal bleeding. |  | I | A | \nInterruption (3–4 days before surgery), and resumption of VKA without bridging, may be considered to reduce bleeding in patients with\nnew-generation aortic MHV and no other thromboembolic risk factors undergoing major non-cardiac surgery or invasive procedures. |  | IIb | B | \nManagement of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3 |  |  |  | \nSurgical biological heart valve without indication for oral anticoagulation |  |  |  | \nLifelong low-dose ASA (75–100 mg/day) may be considered 3 months after surgical implantation of an aortic or mitral BHV in patients\nwithout clear indication for OAC. |  | IIb | C | \n | Transcatheter aortic valve implantation without indication for oral anticoagulation |  |  | \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. |  | III | B | \n | Surgical repair without indication for oral anticoagulation |  |  | \nLow-dose ASA (75–100 mg/day) may be considered after surgical MV or TV repair in preference to OAC in patients without clear\nindication for OAC and at high bleeding risk. |  | IIb | B | \n | Surgical biological heart valve with indication for oral anticoagulation |  |  | \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. |  | I | B | \nDOAC continuation may be considered after surgical BHV implantation in patients with an indication for DOAC. |  | IIb | B | \n | Surgical repair with indication for oral anticoagulation and/or antiplatelet therapy |  |  | \nContinuation of OAC or antiplatelet therapy should be considered after surgical valve repair in patients with a clear indication for an\nantithrombotic therapy. |  | IIa | B | \n | Management of mechanical heart valve failure—Section 14.4 |  |  | \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Management of valve thrombosis—Section 14.4 |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. |  | I | C | ",
          "rows": 31,
          "cols": 5
        },
        {
          "title": "Table on page 11",
          "page": 11,
          "content": "Recommendations in 2021 version | Classa | Levelb | Recommendations in 2025 version | Classa | Levelb\nManagement of coronary artery disease in patients with valvular heart disease—Section 6.1 |  |  |  |  | \nCCTA should be considered as an alternative to\ncoronary angiography before valve surgery in patients\nwith severe VHD and low probability of CAD. | IIa | C | CCTA is recommended before valve intervention in\npatients with moderate or lower (≤50%) pre-test\nlikelihood of obstructive CAD. | I | B\nCoronary angiography is recommended before valve\nsurgery in patients with severe VHD and any of the\nfollowing:\n• History of cardiovascular disease\n• Suspected myocardial ischaemia\n• LV systolic dysfunction\n• In men >40 years of age and post-menopausal women\n• One or more cardiovascular risk factors. | I | C | Invasive coronary angiography is recommended before\nvalve intervention in patients with high and very high\n(>50%) pre-test likelihood of obstructive CAD. | I | C\nCoronary angiography is recommended in the\nevaluation of severe SMR. | I | C | Invasive coronary angiography is recommended in the\nevaluation of CAD in patients with severe ventricular SMR. | I | C\nPCI should be considered in patients with a primary\nindication to undergo TAVI and coronary artery\ndiameter stenosis >70% in proximal segments. | IIa | C | PCI may be considered in patients with a primary\nindication to undergo transcatheter valve interventions\nand coronary artery stenosis ≥70% in proximal\nsegments of main vessels. | IIb | B\nPCI should be considered in patients with a primary\nindication to undergo transcatheter MV intervention\nand coronary artery diameter stenosis >70% in\nproximal segments. | IIa | C |  |  | \nManagement of atrial fibrillation in patients with native valvular heart disease—Section 6.2 |  |  |  |  | \nLAAO should be considered to reduce the\nthromboembolic risk in patients with AF and a\nCHADS -VASc score ≥2 undergoing valve surgery.\n2 2 | IIa | B | Surgical closure of the LA appendage is recommended\nas an adjunct to OAC in patients with AF undergoing\nvalve surgery to prevent cardioembolic stroke and\nsystemic thromboembolism. | I | B\nConcomitant AF ablation should be considered in\npatients undergoing valve surgery, balancing the beneftis\nof freedom from atrial arrhythmias and the risk factors\nfor recurrence (LA dilatation, years in AF, age, renal\ndysfunction, and other cardiovascular risk factors). | IIa | A | Concomitant surgical ablation is recommended in\npatients undergoing MV surgery with AF suitable for a\nrhythm control strategy to prevent symptoms and\nrecurrence of AF, according to an experienced team of\nelectrophysiologists and arrhythmia surgeons. | I | A\n |  |  | Concomitant surgical ablation should be considered in\npatients undergoing non-MV surgery with AF suitable\nfor a rhythm control strategy to prevent symptoms and\nrecurrence of AF, according to an experienced team of\nelectrophysiologists and arrhythmia surgeons. | IIa | B\nThe use of DOACs is not recommended in patients\nwith AF and moderate-to-severe MS. | III | C | The use of DOACs is not recommended in patients\nwith AF and rheumatic MS with an MVA ≤2.0 cm2. | III | B\nIndications for surgery in severe aortic regurgitation—Section 7.4 |  |  |  |  | \nAV repair may be considered in selected patients at\nexperienced centres when durable results are\nexpected. | IIb | C | AV repair should be considered in selected patients\nwith severe AR at experienced centres, when durable\nresults are expected. | IIa | B\nSurgery may be considered in asymptomatic patients\nwith LVESD >20 mm/m2 BSA (especially in patients\nwith small body size) or resting LVEF ≤55%, if surgery is\nat low risk. | IIb | C | AV surgery may be considered in asymptomatic\npatients with severe AR and LVESDi >22 mm/m2 or\nLVESVi >45 mL/m2 [especially in patients with small\nbody size (BSA <1.68 m2)], or resting LVEF ≤55%, if\nsurgical risk is low. | IIb | B\nIndications for intervention in symptomatic severe aortic stenosis—Section 8.4.1 |  |  |  |  | \nIntervention is recommended in symptomatic patients\nwith severe low-fol w (SVi ≤35 mL/m2), low-gradient\n(<40 mmHg) AS with reduced LVEF (<50%), and\nevidence of flow (contractile) reserve. | I | B | Intervention is recommended in symptomatic patients\nwith low-fol w (SVi ≤35 mL/m2), low-gradient\n(<40 mmHg) AS with reduced LVEF (<50%) after\ncareful confirmation that AS is severe. | I | B",
          "rows": 17,
          "cols": 6
        },
        {
          "title": "Table on page 12",
          "page": 12,
          "content": "Intervention should be considered in symptomatic\npatients with low-flow, low-gradient (<40 mmHg) AS\nwith normal LVEF after careful confirmation that the AS\nis severe. | IIa | C | Intervention should be considered in symptomatic\npatients with low-flow (SVi ≤35 mL/m2), low-gradient\n(<40 mmHg) AS with normal LVEF (≥50%) after\ncareful confrimation that AS is severe. | IIa | B\nIndications for intervention in asymptomatic severe aortic stenosis—Section 8.5 |  |  |  |  | \nIntervention should be considered in asymptomatic\npatients with severe AS and LV dysfunction (LVEF\n<55%) without another cause. | IIa | B | Intervention should be considered in asymptomatic\npatients with severe AS and LVEF ≥50%, if the\nprocedural risk is low and one of the following\nparameters is present:\n• Very severe AS (mean gradient ≥60 mmHg or V\nmax\n>5.0 m/s).\n• Severe valve calcification (ideally assessed by CCT)\nand V progression ≥0.3 m/s/year.\nmax\n• Markedly elevated BNP/NT-proBNP levels (more\nthan three times age- and sex-corrected normal\nrange, confrimed on repeated measurement without\nother explanation).\n• LVEF <55% without another cause. | IIa | B\nIntervention should be considered in asymptomatic\npatients with LVEF >55% and a normal exercise test if\nthe procedural risk is low and one of the following\nparameters is present:\n• Very severe AS (mean gradient ≥60 mmHg or V\nmax\n>5 m/s).\n• Severe valve calcification (ideally assessed by CCT)\nand V progression ≥0.3 m/s/year.\nmax\n• Markedly elevated BNP levels (more than three times\nage- and sex-corrected normal range) confrimed by\nrepeated measurements and without other\nexplanation. | IIa | B |  |  | \nMode of intervention in symptomatic severe aortic stenosis—Section 8.5 |  |  |  |  | \nThe choice between surgical and transcatheter\nintervention must be based upon careful evaluation of\nclinical, anatomical, and procedural factors by the Heart\nTeam, weighing the risks and benefits of each approach\nfor an individual patient. The Heart Team\nrecommendation should be discussed with the patient\nwho can then make an informed treatment choice. | I | C | It is recommended that the mode of intervention is\nbased on Heart Team assessment of individual clinical,\nanatomical, and procedural characteristics,\nincorporating lifetime management considerations and\nestimated life expectancy. | I | C\nTAVI is recommended in older patients (≥75 years), or\nin those who are high risk (STS-PROM/EuroSCORE II\n>8%) or unsuitable for surgery. | I | A | TAVI is recommended in patients ≥70 years of age with\ntricuspid AV stenosis, if the anatomy is suitable. | I | A\nSAVR is recommended in younger patients who are low\nrisk for surgery (<75 years and STS-PROM/\nEuroSCORE II <4%), or in patients who are operable\nand unsuitable for transfemoral TAVI. | I | B | SAVR is recommended in patients <70 years of age, if\nthe surgical risk is low. | I | B\nSAVR or TAVI are recommended for remaining\npatients according to individual clinical, anatomical, and\nprocedural characteristics. | I | B | SAVR or TAVI are recommended for all remaining\ncandidates for an aortic BHV according to Heart Team\nassessment.1–4 | I | B\nNon-transfemoral TAVI may be considered in patients\nwho are inoperable and unsuitable for transfemoral\nTAVI. | IIb | C | Non-transfemoral TAVI should be considered in\npatients who are unsuitable for surgery and\ntransfemoral access. | IIa | B\nIndications for intervention in severe primary mitral regurgitation—Section 9.1.4 |  |  |  |  | \nSurgery should be considered in asymptomatic patients\nwith preserved LV function (LVESD <40 mm and LVEF\n>60%) and AF secondary to MR or PH (SPAP at rest\n>50 mmHg). | IIa | B | MV surgery should be considered in asymptomatic\npatients with severe PMR without LV dysfunction\n(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF\n>60%) in the presence of PH (SPAP at rest\n>50 mmHg), or AF secondary to MR. | IIa | B\nSurgical MV repair should be considered in low-risk\nasymptomatic patients with LVEF >60%, LVESD\n<40 mm, and significant LA dilatation (volume\nindex ≥60 mL/m2 or diameter ≥55 mm) when\nperformed in a Heart Valve Centre and a durable repair\nis likely. | IIa | B | Surgical MV repair should be considered in low-risk\nasymptomatic patients with severe PMR without LV\ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2,\nand LVEF >60%) in the presence of significant LA\ndilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm),\nwhen performed in a Heart Valve Centre and a durable\nrepair is likely. | IIa | B",
          "rows": 13,
          "cols": 6
        },
        {
          "title": "Table on page 13",
          "page": 13,
          "content": "TEER may be considered in symptomatic patients who\nfulfli the echocardiographic criteria of eligibility, are judged\ninoperable or at high surgical risk by the Heart Team, and\nfor whom the procedure is not considered futile. | IIb | B | TEER should be considered in symptomatic patients\nwith severe PMR who are anatomically suitable and at\nhigh surgical risk according to the Heart Team. | IIa | B\nSevere ventricular secondary mitral regurgitation and concomitant coronary artery disease—Section 9.2 |  |  |  |  | \nIn symptomatic patients who are judged not\nappropriate for surgery by the Heart Team on the basis\nof their individual characteristics, PCI (and/or TAVI)\npossibly followed by TEER (in case of persisting severe\nSMR) should be considered. | IIa | C | PCI followed by TEER after re-evaluation of MR may be\nconsidered in symptomatic patients with chronic severe\nventricular SMR and non-complex CAD. | IIb | C\nIndications for intervention in severe ventricular secondary mitral regurgitation without concomitant coronary artery disease—Section 9.2 |  |  |  |  | \nTEER should be considered in selected symptomatic\npatients not eligible for surgery and fulfilling criteria\nsuggesting an increased chance of responding to the\ntreatment. | IIa | B | TEER is recommended to reduce HF hospitalizations\nand improve quality of life in haemodynamically stable,\nsymptomatic patients with impaired LVEF (<50%) and\npersistent severe ventricular SMR, despite optimized\nGDMT and CRT (if indicated), fulfilling specifci clinical\nand echocardiographic criteria. | I | A\nIn high-risk symptomatic patients not eligible for surgery\nand not fulfilling the criteria suggesting an increased\nchance of responding to TEER, the Heart Team may\nconsider in selected cases a TEER procedure or other\ntranscatheter valve therapy if applicable, after careful\nevaluation for ventricular assist device or heart\ntransplant. | IIb | C | TEER may be considered for symptom improvement in\nselected symptomatic patients with severe ventricular\nSMR not fulfliling the specifci clinical and\nechocardiographic criteria, after careful evaluation of\nLVAD or HTx. | IIb | B\nValve surgery may be considered in symptomatic\npatients judged appropriate for surgery by the Heart\nTeam. | IIb | C | MV surgery may be considered in symptomatic patients\nwith severe ventricular SMR without advanced HF who\nare not suitable for TEER. | IIb | C\nIndications for intervention in tricuspid regurgitation in patients with left-sided valvular heart disease requiring surgery—Section 11.4 |  |  |  |  | \nSurgery is recommended in patients with severe\nprimary TR undergoing left- sided valve surgery. | I | C | Concomitant TV surgery is recommended in patients\nwith severe primary or secondary TR. | I | B\nSurgery is recommended in patients with severe\nsecondary TR undergoing left-sided valve surgery. | I | B |  |  | \nSurgery should be considered in patients with moderate\nprimary TR undergoing left-sided valve surgery. | IIa | C | Concomitant TV repair should be considered in\npatients with moderate primary or secondary TR, to\navoid progression of TR and RV remodelling. | IIa | B\nSurgery should be considered in patients with mild or\nmoderate secondary TR with a dilated annulus\n(≥40 mm or >21 mm/m2 by 2D echocardiography)\nundergoing left-sided valve surgery. | IIa | B | Concomitant TV repair may be considered in selected\npatients with mild secondary TR and tricuspid annulus\ndilatation (≥40 mm or >21 mm/m2) to avoid\nprogression of TR and RV remodelling. | IIb | B\nIndications for intervention in patients with severe tricuspid regurgitation without left-sided valvular heart disease requiring surgery—\nSection 11.4 |  |  |  |  | \nTranscatheter treatment of symptomatic secondary\nsevere TR may be considered in inoperable patients at a\nHeart Valve Centre with expertise in the treatment of\nTV disease. | IIb | C | Transcatheter TV treatment should be considered to\nimprove quality of life and RV remodelling in high-risk\npatients, with symptomatic severe TR despite optimal\nmedical therapy, in the absence of severe RV\ndysfunction or pre-capillary PH. | IIa | A\nProsthetic valve selection—Section 14.1 |  |  |  |  | \nA mechanical prosthesis may be considered in patients\nalready on long-term anticoagulation due to the high\nrisk for thromboembolism. | IIb | C | An MHV may be considered in patients with a clear\nindication for long-term OAC. | IIb | C\nManagement of antithrombotic therapy in patients with a mechanical heart valve—Section 14.3 |  |  |  |  | \nOAC using a VKA is recommended lifelong for all\npatients with an MHV prosthesis. | I | B | Lifelong OAC with a VKA is recommended for all\npatients with MHVs to prevent thromboembolic\ncomplications. | I | A",
          "rows": 18,
          "cols": 6
        },
        {
          "title": "Table on page 14",
          "page": 14,
          "content": "For patients with a VKA, INR self-management is\nrecommended provided appropriate training and\nquality control are performed. | I | B | INR self-monitoring and self-management are\nrecommended over standard monitoring in selected,\ntrained patients to improve effci acy. | I | A\nIn patients with MHVs, it is recommended to (re)initiate\nthe VKA on the first post-operative day. | I | C | Following cardiac surgery with MHV implantation, it is\nrecommended to start UFH or LMWH bridging and\nVKA within 24 h, or as soon as considered safe. | I | B\nIn patients who have undergone valve surgery with an\nindication for post-operative therapeutic bridging, it is\nrecommended to start either UFH or LMWH 12–24 h\nafter surgery. | I | C |  |  | \nThe addition of low-dose ASA (75–100 mg/day) to\nVKA may be considered in selected patients with MHVs\nin case of concomitant atherosclerotic disease and low\nrisk of bleeding. | IIb | C | The addition of low-dose ASA (75–100 mg/day) to VKA\nshould be considered in selected patients with MHVs in\ncase of concomitant symptomatic atherosclerotic disease,\nconsidering the individual bleeding risk proflie. | IIa | B\nThe addition of low-dose ASA (75–100 mg/day) to\nVKA should be considered after thromboembolism\ndespite an adequate INR. | IIa | C | Either an increase in INR target or the addition of\nlow-dose ASA (75–100 mg/day) should be considered\nin patients with MHVs who develop a major\nthromboembolic complication despite documented\nadequate INR. | IIa | C\nDOACs are not recommended in patients with an\nMHV prosthesis. | III | B | DOACs and/or DAPT are not recommended to\nprevent thrombosis in patients with an MHV. | III | A\nManagement of antithrombotic therapy in patients with mechanical heart valves undergoing elective non-cardiac surgery or invasive\nprocedures—Section 14.3 |  |  |  |  | \nIt is recommended that VKAs are timely discontinued\nprior to elective surgery to aim for an INR <1.5. | I | C | It is recommended to discontinue VKA at least 4 days\nbefore major elective non-cardiac surgery, aiming for an\nINR <1.5, and to resume VKA treatment within 24 h\nafter surgery, or as soon as considered safe. | I | B\nIn patients with MHVs, it is recommended to (re)initiate\nthe VKA on the first post-operative day. | I | C |  |  | \nTherapeutic doses of either UFH or subcutaneous\nLMWH are recommended for bridging. | I | B | VKA interruption and resumption with bridging should\nbe considered in patients with an MHV and\nthromboembolic risk factors undergoing major\nnon-cardiac surgery. | IIa | B\nBridging of OAC, when interruption is needed, is\nrecommended in patients with any of the following\nindications:\n• MHV\n• AF with significant MS\n• AF with CHADS -VASc score ≥3 for women or 2\n2 2\nfor men\n• Acute thrombotic event within the previous 4 weeks\n• High acute thromboembolic risk. | I | C |  |  | \nManagement of antithrombotic therapy in patients with a biological heart valve or valve repair—Section 14.3 |  |  |  |  | \nLifelong SAPT is recommended after TAVI in patients\nwith no baseline indication for OAC. | I | A | Low-dose ASA (75–100 mg/day) is recommended for\n12 months after TAVI in patients without indication for\nOAC. | I | A\n |  |  | Long-term (after the first 12 months) low-dose ASA\n(75–100 mg/day) should be considered after TAVI in\npatients without clear indication for OAC. | IIa | C\nOAC is recommended lifelong for TAVI patients who\nhave other indications for OAC. | I | B | OAC is recommended for TAVI patients who have\nother indications for OAC. | I | B\nOAC with VKA should be considered during the frist\n3 months after mitral and tricuspid repair. | IIa | C | OAC, with either VKAs or DOACs, should be considered\nduring the frist 3 months after surgical MV or TV repair. | IIa | B\nRoutine use of OAC is not recommended after TAVI in\npatients without baseline indication. | III | B | Routine use of OAC is not recommended after TAVI in\npatients without baseline indication. | III | A\nManagement of haemolysis and paravalvular leak—Section 14.4 |  |  |  |  | \nDecision on transcatheter or surgical closure of\nclinically significant PVLs should be considered based on\npatient risk status, leak morphology, and local expertise. | IIa | C | It is recommended that the decision between\ntranscatheter or surgical closure of clinically signifci ant\nPVLs is based on Heart Team evaluation, including\npatient risk, leak morphology, and local expertise. | I | C",
          "rows": 19,
          "cols": 6
        },
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis in patients at high or prohibitive surgical risk. | IIa | B | Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis. | IIa | B\nManagement of biological heart valve failure—Section 14.4 |  |  |  |  | \nReoperation is recommended in symptomatic patients\nwith a signifci ant increase in transprosthetic gradient\n(after exclusion of valve thrombosis) or severe\nregurgitation. | I | C | Reintervention is recommended in symptomatic\npatients with signifci ant valve dysfunction not\nattributable to valve thrombosis. | I | C\nTranscatheter, transfemoral valve-in-valve implantation\nin the aortic position should be considered by the Heart\nTeam depending on anatomical considerations, features\nof the prosthesis, and in patients who are at high\noperative risk or inoperable. | IIa | B | Transcatheter transfemoral valve-in-valve implantation\nin the aortic position should be considered in patients\nwith signifci ant valve dysfunction who are at\nintermediate or high surgical risk, and have suitable\nanatomical and prosthesis features, as assessed by the\nHeart Team. | IIa | B\nTranscatheter valve-in-valve implantation in the mitral\nand tricuspid position may be considered in selected\npatients at high risk for surgical reintervention. | IIb | B | Transcatheter transvenous mitral or tricuspid\nvalve-in-valve implantation should be considered in\npatients with signifci ant valve dysfunction at intermediate\nor high surgical risk, if the anatomy is suitable. | IIa | B\nManagement of mechanical heart valve thrombosis—Section 14.4 |  |  |  |  | \nUrgent or emergency valve replacement is\nrecommended for obstructive thrombosis in critically ill\npatients without serious comorbidity. | I | B | Heart Team evaluation is recommended in patients\nwith acute HF (NYHA class III or IV) due to obstructive\nMHV thrombosis to determine appropriate\nmanagement (repeat valve replacement or low-dose\nslow infusion fbi rinolysis). | I | B\nFibrinolysis (using recombinant tissue plasminogen\nactivator 10 mg bolus + 90 mg in 90 min with UFH or\nstreptokinase 1 500 000 U in 60 min without UFH)\nshould be considered when surgery is not available or is\nvery high risk, or for thrombosis of right-sided\nprostheses. | IIa | B |  |  | \nManagement of biological heart valve thrombosis—Section 14.4 |  |  |  |  | \nAnticoagulation using a VKA and/or UFH is\nrecommended in BHV thrombosis before considering\nreintervention. | I | C | OAC using VKA is recommended in BHV thrombosis\nbefore considering reintervention. | I | B",
          "rows": 10,
          "cols": 6
        }
      ],
      "keywords": [
        "surgery",
        "introduction",
        "ct",
        "recommendation"
      ]
    },
    {
      "number": "4",
      "title": "3. The Heart Team and Heart Valve Centre",
      "start_page": 15,
      "end_page": 18,
      "content": "3. The Heart Team and Heart Valve \nCentre \n3.1. The Heart Valve Network \nDespite increasing attention within the medical community, VHD con-\ntinues to be underdiagnosed and undertreated in the general popula-\ntion, and public awareness remains low.10–13 Beside screening using \nauscultation and imaging when appropriate, the co-ordinated imple-\nmentation of Heart Teams, Heart Valve Centres, and Heart Valve \nNetworks at a local level represents an essential step to timely diagnose \nand treat patients with VHD. \nAn integrated regional Heart Valve Network, incorporating out-\npatient Heart Valve Clinics (for initial diagnosis and ongoing surveil-\nlance) and specialist Heart Valve Centres (for advanced imaging and \nsurgical or transcatheter intervention), allows optimal patient care \nthrough timely access to specialist assessment, accurate diagnosis, im-\nproved decision-making, and matching of patients to healthcare provi-\nders with appropriate expertise, experience, and resources (Figure 1).12 \nIn addition, dedicated Heart Valve Clinics ensure consistent application \nof clinical guidelines, efficient use of resources, and overall high-quality \npatient care, which in turn may improve outcomes.14,15 Medical goals \ninclude careful clinical and echocardiographic evaluation, monitoring \nat appropriate time intervals (so-called ‘watchful waiting’), application \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis in patients at high or prohibitive surgical risk. \nIIa \nB \nTranscatheter closure should be considered for suitable \nPVLs with clinically significant regurgitation and/or \nhaemolysis. \nIIa \nB \nManagement of biological heart valve failure—Section 14.4 \nReoperation is recommended in symptomatic patients \nwith a significant increase in transprosthetic gradient \n(after exclusion of valve thrombosis) or severe \nregurgitation. \nI \nC \nReintervention is recommended in symptomatic \npatients with significant valve dysfunction not \nattributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation \nin the aortic position should be considered by the Heart \nTeam depending on anatomical considerations, features \nof the prosthesis, and in patients who are at high \noperative risk or inoperable. \nIIa \nB \nTranscatheter transfemoral valve-in-valve implantation \nin the aortic position should be considered in patients \nwith significant valve dysfunction who are at \nintermediate or high surgical risk, and have suitable \nanatomical and prosthesis features, as assessed by the \nHeart Team. \nIIa \nB \nTranscatheter valve-in-valve implantation in the mitral \nand tricuspid position may be considered in selected \npatients at high risk for surgical reintervention. \nIIb \nB \nTranscatheter transvenous mitral or tricuspid \nvalve-in-valve implantation should be considered in \npatients with significant valve dysfunction at intermediate \nor high surgical risk, if the anatomy is suitable. \nIIa \nB \nManagement of mechanical heart valve thrombosis—Section 14.4 \nUrgent or emergency valve replacement is \nrecommended for obstructive thrombosis in critically ill \npatients without serious comorbidity. \nI \nB \nHeart Team evaluation is recommended in patients \nwith acute HF (NYHA class III or IV) due to obstructive \nMHV thrombosis to determine appropriate \nmanagement (repeat valve replacement or low-dose \nslow infusion fibrinolysis). \nI \nB \nFibrinolysis (using recombinant tissue plasminogen \nactivator 10 mg bolus + 90 mg in 90 min with UFH or \nstreptokinase 1 500 000 U in 60 min without UFH) \nshould be considered when surgery is not available or is \nvery high risk, or for thrombosis of right-sided \nprostheses. \nIIa \nB \nManagement of biological heart valve thrombosis—Section 14.4 \nAnticoagulation using a VKA and/or UFH is \nrecommended in BHV thrombosis before considering \nreintervention. \nI \nC \nOAC using VKA is recommended in BHV thrombosis \nbefore considering reintervention. \nI \nB \n© ESC/EACTS 2025\n2D, two-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; \nBSA, body surface area; CAD, coronary artery disease; CCT, cardiac computed tomography; CCTA, coronary computed tomography angiography; CHA2DS2-VASc, congestive heart failure \nor left ventricular dysfunction, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vascular disease, age 65–74, sex category (female); CRT, cardiac resynchronization therapy; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; EuroSCORE, European System for Cardiac Operative Risk Evaluation; GDMT, guideline-directed medical therapy; h, \nhour; HF, heart failure; HTx, heart transplantation; INR, international normalized ratio; LA, left atrium/left atrial; LAAO, left atrial appendage occlusion; LAVI, left atrial volume index; \nLMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVAD, left ventricular assist device; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic volume indexed to BSA; MHV, mechanical heart valve; min, minute; MR, \nmitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; NT-proBNP, N-terminal pro-B-type natriuretic peptide; NYHA, New York Heart Association; OAC, \noral anticoagulation; PCI, percutaneous coronary intervention; PH, pulmonary hypertension; PMR, primary mitral regurgitation; PVL, paravalvular leak; RV, right ventricle/right \nventricular; SAPT, single antiplatelet therapy; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery pressure; STS-PROM, Society \nof Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TR, tricuspid \nregurgitation; TV, tricuspid valve; UFH, unfractionated heparin; VHD, valvular heart disease; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \nESC Guidelines                                                                                                                                                                                          4649 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nof guideline-directed medical therapy (GDMT), timely referral, and \npost-procedural follow-up.15,16 Broader aims include patient education, \nthe training of physicians and nurse specialists, swift and efficient access \nto specialist care, and recruitment into clinical trials. \nHeart Valve Centres should ensure that their facilities match institu-\ntional and local statutory requirements (Table 5), report procedural vo-\nlumes and outcomes, and monitor treatment quality. They hold \nresponsibility for the training and education of surgeons, interventional \nand imaging cardiologists, dedicated nurses, and allied professionals.17,18 \nExpertise in the surgical management of coronary artery disease \n(CAD), vascular diseases, and complications must be available. New \ntechniques should be taught by trained mentors using simulator mod-\nels, when feasible, to minimize learning-curve effects. More broadly, \nHeart Valve Centres co-ordinate the management of patients with \nVHD across the entire Heart Valve Network, supporting services at \ncommunity level, encouraging early referral, and promoting education \nand communication with other medical departments, referring cardiol-\nogists, primary care physicians, and rehabilitation clinics. \n3.1.1. Composition of the Heart Team \nThe Heart Team is now an established feature of VHD programmes that \nhas been formally endorsed by previous ESC/EACTS Guidelines19,20 and \ncorresponding organizations worldwide.17 \nThe value of the Heart Team approach has become increasingly \napparent as options for the treatment of VHD have extended to in-\nclude high-risk and inoperable patients (most of whom now undergo \ntranscatheter interventions), and low-risk and asymptomatic pa-\ntients (who derive prognostic benefit from increasingly safe proce-\ndures). Despite significant accumulation of data concerning the \nmanagement of VHD over the last two decades, many patients in \ndaily practice have clinical characteristics that do not match those \nof participants included in clinical trials. The Heart Team approach \nis therefore particularly helpful when there is uncertainty or a lack \nof strong evidence. \nThe Heart Team meeting facilitates balanced presentation of all \nappropriate options for medical, interventional, and surgical \ntreatment, using tools and techniques for shared decision-making. \n\u001f\u001e\u001d\u001c\u001b\u001a\u0019\u001d\u0018\u0017\u001e\u001a\u0016\u0018\u0015\u0014\u0015\u0013\n\u001f\u001e\u001d\u001c\u001b\u001a\u0012\u001e\u001d\u0011\u001a\u0013\u0010\u001c\u001e\u001a\u0011\u001e\u0011\u000f\u001e\u001c\u000e\n\r\f\u001b\u001e\u0014\u000b\u001e\u000b\u001a\u001f\u001e\u001d\u001c\u001b\u001a\u0012\u001e\u001d\u0011\u001a\u001a\n\u001f\u001e\u001d\u001c\u001b\u001d\u001a\u001b\u0019\u0018\u0017\u001b\u0016\n\u0015\u001a\u0014\u001d\u001c\u0019\u0018\u001d\u001e\u0019\u0015\u001c\u0016\u0015\u0013\u0016\u0012\u001d\u001a\u0017\n\u0011\u001a\u0015\u0010\u0019\u001b\u0019\u001c\u0014\u0016\u0014\u000f\u0019\u001b\u0017\u000e\u0019\u001c\u0017\r\u001b\u0019\u001a\u0017\u0012\u001e\u0017\u001b\u0016\n\u001b\u0019\u001d\u0014\u001c\u0015\f\u0019\f\u000b\u0016\u001e\u001a\u0017\u001d\u001e\n\u0017\u001c\u001e\u0016\u001d\u001c\u001b\u0016\n\u0013\u0015\u000e\u000e\u0015\t\r\u000f\u0011\u0016\u0015\u0013\u0016\u0011\u001d\u001e\u0019\u0017\u001c\u001e\f\n\t\u0019\u001e\b\u0016\u0007\u0006\u0005\n\u001f\u001e\u001d\u001c\u001b\u001a\u0019\u001d\u0018\u0017\u001e\u001a\u0016\u001e\u0014\u001b\u001c\u001e\n\u0004\u000e\u0017\u0012\u001e\u001a\u0015\r\n\u0011\b\u0003\f\u0019\u0015\u000e\u0015\u0014\u0019\f\u001e\n\u0002\u001d\u001a\u001b\u0019\u001d\u0012\n\f\u000f\u001a\u0014\u0017\u0015\u001c\n\u0006\u0001\n\u0012\u001d\u001a\u001b\u0019\u0015\u000e\u0015\u0014\u0019\f\u001e\n\u0002\u000e\u0019\u001c\u0019\u0012\u001d\u000e\u0016\u0012\u001d\u001a\u001b\u0019\u0015\u000e\u0015\u0014\u0019\f\u001e\n\t\u0019\u001e\b\u0016\u0017\u0011\u0017\u001a\u001e\u0019\f\u0017\u0016\u0019\u001c\n\u0019\n\u001d\u0014\u0019\u001c\u0014\n\u001c\u001e\u0017\u001a\u0010\u0017\u001c\u001e\u0019\u0015\u001c\u001d\u000e\n\u0012\u001d\u001a\u001b\u0019\u0015\u000e\u0015\u0014\u0019\f\u001e\n\u001c\f\u001e\u0019\u001e\u000f\u001e\u0019\u0015\u001c\u001d\u000e\u0016\u0012\u001d\u001a\u001b\u0019\u0015\u000e\u0015\u0014\u0003\u0016\u001d\u001c\u001b\u0016\n\u0012\u001d\u001a\u001b\u0019\u001d\u0012\u0016\f\u000f\u001a\u0014\u0017\u001a\u0003\u0016\u001b\u0017\u0011\u001d\u001a\u001e\n\u0017\u001c\u001e\f\n\t\u0019\u001e\b\u0016\u0016\b\u0015\u000f\u001a\u0016\u001b\u001d\u0003\u0016\f\u0017\u001a\u0010\u0019\u0012\u0017\f\n\u0006\u0017\u001d\u001a\u001e\u0016 \u0017\u001d\n\u0016\n\u0017\u0017\u001e\u0019\u001c\u0014\u0016\u0015\u001c\u0016\u001d\n\u001a\u0017\u0014\u000f\u000e\u001d\u001a\u0016­\u001d\f\u0019\f\n\u0006\u0019\u0014\b\u0016\u0011\u001a\u0015\u0012\u0017\u001b\u000f\u001a\u001d\u000e\u0016\u0010\u0015\u000e\u000f\n\u0017\n\u0013\u0015\u001a\u0016\b\u0015\f\u0011\u0019\u001e\u001d\u000e\u0016\u001d\u001c\u001b\u0016\u0019\u001c\u001b\u0019\u0010\u0019\u001b\u000f\u001d\u000e\u0016\n\u0015\u0011\u0017\u001a\u001d\u001e\u0015\u001a\f\n\u0005\u001d\u001e\u001d\u0016\u001a\u0017\u0010\u0019\u0017\t\u0016\u001d\u001c\u001b\u0016\u0017\u001b\u000f\u0012\u001d\u001e\u0019\u0015\u001c\n\u0011\u001a\u0015\u0014\u001a\u001d\n\n\u0017\f\n\u000f\u000e\u001e\u0019\n\u0015\u001b\u001d\u000e\u0019\u001e\u0003\u0016\u0019\n\u001d\u0014\u0019\u001c\u0014\n\u0017\u0011\u0017\u001a\u001e\u0019\f\u0017\n\u001f\u0011\u0017\u0012\u0019\u001d\u000e\u0019\u0018\u0017\u001b\u0016\u001c\u000f\u001a\f\u0019\u001c\u0014\n\u0011\u0017\u001a\f\u0015\u001c\u001c\u0017\u000e\u0016\u001d\u001c\u001b\u0016\n\u0015\u001e\b\u0017\u001a\u0016\f\u0011\u0017\u0012\u0019\u001d\u000e\u0019\f\u001e\f\u000b\u0016\n\u0019\u0013\u0016\u001a\u0017\u000f\u0019\u001a\u0017\u001b\n\n\u001e\t\u001e\u001c\u001c\u0015\u0014\b\u001a\u0013\u001d\u001c\u000b\u0015\u0010\u0018\u0010\b\u0015\u000e\u001b\u000e\u001a\u001d\u0014\u000b\u001a\u0007\u001c\u0015\u0011\u001d\u001c\u0006\u001a\u0013\u001d\u001c\u001e\u001a\u0007\u0005\u0006\u000e\u0015\u0013\u0015\u001d\u0014\u000e\n\u0004\u0011\u000f\u0003\u0018\u001d\u001b\u0010\u001c\u0006\u001a\u001c\u001e\u0005\u001d\u000f\u0015\u0018\u0015\u001b\u001d\u001b\u0015\u0010\u0014\u001a\u0007\u001c\u0010\b\u001d\u0011\u0011\u001e\u000e\n\n\u001e\u0005\u001d\u000f\u0015\u0018\u0015\u001b\u001d\u001b\u0015\u0010\u0014\u001a\u0013\u0018\u0015\u0014\u0015\u0013\u000e\nFigure 1 The Heart Valve Network. HF, heart failure; VHD, valvular heart disease.   \n4650                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nThe patient’s preference plays a central role in this process, although \nthe Heart Team recommendation should be based upon key objective \nmedical considerations (particularly the relative risks and benefits of any \nprocedure). \nMeetings should take place on a regular basis with standardized \nminimum datasets (to ensure that all relevant information is avail-\nable) and appropriate administrative support (often provided by \nspecialist nurses with expertise in the care of patients with VHD). \nIn-person meetings of the full Heart Team may not be feasible for \nevery patient, and local standardized protocols may be implemen-\nted to facilitate swift decision-making for specific cohorts (e.g. eld-\nerly TAVI candidates or young patients with BAV disease). Equally, \nthe need for Heart Team evaluation should not paralyse clinical \ndecision-making, and ad hoc discussions remain appropriate in ur-\ngent situations. \nCore members of the Heart Team include the cardiologist treating \nthe patient (who is best placed to present their case and act as their ad-\nvocate), specialists in advanced cardiovascular imaging and peri- \nprocedural guiding,21,22 surgeons, and interventional cardiologists \nwith training and expertise in surgical and transcatheter valve proce-\ndures. Specialized nursing personnel play an essential role to improve \npatient information and education, as well as co-ordinate work-up \nand management steps in high-volume centres (Figure 1; Table 5). \nCardiologists with expertise in heart failure (HF) and electrophysiology, \nas well as geriatricians, cardiovascular anaesthetists, and intensivists in-\nvolved in peri-procedural care, should also be available to facilitate the \ndiscussion of particularly complex clinical scenarios when needed (ex-\ntended Heart Team) (Figure 1; Table 5). \n3.1.2. Procedural volume and clinical outcomes \nThe correlation between high institutional (and individual operator) \nvolume and best procedural outcomes is intuitive, yet complex. \nNevertheless, there is evidence of such a relationship for many cardio-\nvascular procedures including SAVR,23,24 surgical MV repair,25,26 mitral \nand tricuspid TEER,27–30 and TAVI (particularly in centres with an as-\nsociated high-volume SAVR programme).31–33 Studies have shown \nthat an annualized operator volume of approximately 25 surgical mitral \nvalve procedures,26 50 TAVIs (∼100 per centre),33 a cumulative ex-\nperience of ∼50 M-TEER procedures per operator/centre,27 and a \nsite volume of more than 20 T-TEERs/year30 are associated with im-\nproved technical and clinical outcomes. Higher institutional surgical \nvolume is associated with lower complication rates,34–36 improved \nmanagement,37 and better infrastructural support.38,39 \nNational procedural activity varies widely between high-, middle-, and \nlow-income countries,40 and it is therefore difficult to provide \nrecommendations concerning the precise number of institutional or oper-\nator procedures that is required for high-quality care, excellent facilities, \nand processes. Instead, a network approach that highlights the importance \nof centres performing a high volume of procedures (e.g. based upon quar-\ntiles in individual countries or regions) seems more suitable, with complex \nprocedures concentrated in the centres with the highest volumes (Table 6). \nTable 5 Requirements for a Heart Valve Centre \nRequirements  \nCentre performing heart valve procedures with on-site interventional \ncardiology and cardiac surgery departments providing 24-h/7-day services. \nHeart Team core members: Cardiologist with imaging expertise, \ninterventional cardiologist, cardiac surgeon. \nAdditional specialists, if required (Extended Heart Team): \nSpecialized nursing personnel, HF specialist, electrophysiologist, \ncardiovascular anaesthetist, geriatrician, and other specialists \n(e.g. intensive care, vascular surgery, infectious diseases, neurology, \nradiology). \nThe Heart Team must meet on a regular basis and work according to \nlocally defined standard operating procedures and clinical governance \narrangements. \nA hybrid cardiac catheterization laboratory is desirable. \nHigh volume for hospital and individual operators. \nMultimodality imaging (including advanced echocardiography, CCT, CMR, \nand nuclear techniques) and expertise in peri-procedural imaging guidance of \nsurgical and transcatheter procedures. \nHeart Valve Clinic for outpatient assessment and follow-up. \nData review: continuous monitoring, evaluation, and reporting of procedural \nvolumes and quality indicators, including clinical outcomes, as well as PROMs \ncomplemented by local/external audits. \nEducation programmes targeting primary care and referring physicians, \noperators, and diagnostic and interventional imaging specialists. \n© ESC/EACTS 2025\nCCT, cardiac computed tomography; CMR, cardiac magnetic resonance; HF, heart failure; \nPROM, patient-reported outcome measure.  \nTable 6 Complex procedures ideally performed in the \nmost experienced Heart Valve Centres \nTranscatheter interventions \nSurgical interventions  \n• Transfemoral TAVI in patients \nwith high-risk features: \n– Low coronary ostia \n– Difficult femoral anatomy \n– Bicuspid valve \n– Severe calcification protruding \ninto the LVOT \n– Severe LV and/or RV impairment \n– Pure AV regurgitation \n– Multiple valve disease \n– Complex coronary artery disease \n– Severe extracardiac disease \n(e.g. renal failure, PH) \n• Non-transfemoral TAVI \n• Valve-in-valve (including \nTAV-in-TAV) \n• All leaflet modification procedures \n(BASILICA, LAMPOON etc.) \n• PVL closure procedures \n• Complex M-TEERa \n• Redo M-TEER procedures \n• Tricuspid or mitral valve-in-ring or \nvalve-in-valve, valve-in-MAC \n• TMVI \n• All tricuspid procedures \n• High-risk procedures (especially \nin patients with LV and/or RV \nimpairment) \n• Redo procedures \n• Minimally invasive and robotic \nvalve surgery \n• Complex MV repair \n– Barlow disease \n– Anterior or bileaflet prolapse \n– High risk of SAM \n– Severe MAC \n• AV repair \n• Ross procedure \n• Valve surgery combined with \ncomplex surgery of the aorta \n• Endocarditis surgery \n© ESC/EACTS 2025\nAV, aortic valve; BASILICA, Bioprosthetic or native Aortic Scallop Intentional Laceration to \nprevent Iatrogenic Coronary Artery obstruction; LAMPOON, Laceration of the Anterior \nMitral leaflet to Prevent Outflow ObstructioN; LV, left ventricular/left ventricle; LVOT, left \nventricular outflow tract; MAC, mitral annular calcification; M-TEER, mitral transcatheter \nedge-to-edge repair; MV, mitral valve; PH, pulmonary hypertension; PVL: paravalvular leak; RV, \nright ventricular/right ventricle; SAM, systolic anterior movement; TAV, transcatheter aortic \nvalve; TAVI, transcatheter aortic valve implantation; TMVI, transcatheter mitral valve implantation. \naSee Supplementary Table S2.   \nESC Guidelines                                                                                                                                                                                          4651 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nInternal quality assessment (see dedicated document concerning TAVI \nfrom the ESC41), systematic recording, and public availability of the volume \nand outcome data of the performed procedures are essential. Participation \nin national or international registries should be encouraged. These consid-\nerations are of particular importance regarding asymptomatic low-risk pa-\ntients (where low mortality and procedural safety are paramount), those \nwith multiple comorbidities (where the need for multidisciplinary collabor-\nation is essential), and new techniques with a steep learning curve (where \nbetter results may be obtained at experienced centres). \nThere is a pressing need to ensure higher dispersion and adoption of \ninterventions for VHD, especially (but not exclusively) in middle- and \nlower-income countries where rheumatic heart disease (RHD) remains \nthe principal cause of VHD.42,43 Key strategies include awareness pro-\ngrammes, increased public and medical education, simplified and im-\nproved diagnostic tools, and measures to reduce costs and facilitate \naccess to evidence-based treatment options.44 \n4. Imaging of patients with valvular \nheart disease \nMultimodality imaging is now the standard approach in VHD \nmanagement to determine the pathophysiology, assess severity, \nplan interventions, and identify complications (Figure 2). The use \nof imaging for the assessment of each specific valve lesion is de-\nscribed in the corresponding sections. The role of imaging is trans-\nversal from diagnosis to follow-up and should encompass an \nintegrative assessment. \n4.1. Initial valve assessment \nComprehensive transthoracic echocardiography (TTE) is the first-line \nexamination to confirm valve dysfunction, and determine the aetiology, \nmechanism, and severity of VHD, as well as cardiac chamber anatomy \nand damage.45,46 It should be performed by properly trained ima-\ngers.47–49 Quantitative imaging analysis (as opposed to visual) should \nbe the goal in all patients with relevant VHD, complemented by quali-\ntative and semi-quantitative evaluation. The severity of VHD should be \nassessed using an integrative approach of all criteria checked for con-\nsistency. When TTE is of poor quality or inconclusive, transoesophageal \nechocardiography (TOE) and/or additional diagnostic imaging modal-\nities should be applied (e.g. calcium scoring and anatomy of the \nvalve using CCT). In specific clinical scenarios [e.g. thrombosis, pros-\nthetic valve dysfunction, endocarditis, mitral stenosis (MS), assessment \nof MV or TV anatomy], TOE has a central diagnostic role.50,51 \n\u001f\u001e\u001d\n\u001c\u001c\u001f\n\u001c\u001b\u001a\u0019\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u001e\u001a\u001a\u0013\u0012\u0012\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u001e\u000f\u001a\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\r\f\u001a\u000f\u000b\u0012\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u001f\u0011\n\u001f\t\u001e\u0015\b\u0013\u001d\u0019\u0007\u0016\u000f\u000b\u0015\u0013\u0012\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u0006\u0013\u0005\u000b\u001d\u0005\u001b\u0017\u001e\u0018\u0017\u0019\u0010\u001d\u001e\u001a\u0017\u001b\u0016\u0018\n\u0004\u0014\u0016\u001a\u001e\u001d\u001c\u001b\u001e\u000f\u0019\u000e\b\u001d\u0016\u0012\u001b\u0012\n\n\u001b\u001e\u0005\u0018\u0016\u0012\u001b\u0012\u0019\u001e\u0018\u001c\u0019\u0003\u000b\u001e\u0018\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\n\u001c\u0014\u0012\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\t\u001e\u0015\b\u0013\u001d\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001c\u001e\u0015\u001e\u0005\u0013\u0019\u001e\u0018\u001c\u0019\u001d\u0013\u0015\u0016\u001c\u0013\u000f\u000f\u001b\u0018\u0005\n\u0002\u0016\u000f\u000f\u0016\u0001\u000b\n\u001f\u001f\u001d\n\u0011\u0012\u0012\u0016\u001a\u001b\u001e\u0017\u0013\u001c\u0019\u001c\u001b\u0012\u0013\u001e\u0012\u0013\u0012\n\u001e\u0018\u001c\u0019\u001a\u0016\u0018\u001c\u001b\u0017\u001b\u0016\u0018\u0012\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\n\u001c\u0014\u0018\u001e\u0015\u001b\u001a\u0012\u0019\u001e\u0018\u001c\u0019\u0007\u001e\u001d\u001b\u001e\b\u001b\u000f\u001b\u0017\u0014\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u0013\f\u0017\u001d\u001e\u0007\u001e\u000f\u0007\u000b\u000f\u001e\u001d\u0019\n\u001a\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\u0016\u0018\u0012\u0013\u0003\u000b\u0013\u0018\u001a\u0013\u0012\u0019\u0010\u001d\u0016\u0015\u0019\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0013\u000f\u001b\u0005\u001b\b\u001b\u000f\u001b\u0017\u0014\u0019\u0010\u0016\u001d\u0019\n\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0019\u001e\u0018\u001c\u0019\u001d\u001b\u0012\u0019\u0012\u0017\u001d\u001e\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\n\u000f\u001e\u0018\u0018\u001b\u0018\u0005\u0019\u001e\u0018\u001c\u0019\u0005\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012 \n\u001e\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u0016\u0015\u000f\u001b\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\u001b\u0005\t\u0013\u001d\u0019\u001d\u0013\u0012\u0016\u000f\u000b\u0017\u001b\u0016\u0018\u0019\u0017\u0016\u0019\u001e\u0012\u0012\u0013\u0012\u0012\u0019\u0007\u001e\u000f\u0007\u0013\u0019\n\u001e\u0018\u001e\u0017\u0016\u0015\u0014\n\u0004\u0013\u001a\t\u001e\u0018\u001b\u0012\u0015­\u0012\u0019\u0016\u0010\u0019\n\n\u0019\u0007\u001b\u0012\u000b\u001e\u000f\u001b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\u0012\n\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012\nFigure 2 Integrative imaging assessment of patients with valvular heart disease. 3D, three-dimensional; CAD, coronary artery disease; CCT, cardiac \ncomputed tomography; CMR: cardiac magnetic resonance; TOE; transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD, \nvalvular heart disease.   \n4652                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 15",
          "page": 15,
          "content": "Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis in patients at high or prohibitive surgical risk. | IIa | B | Transcatheter closure should be considered for suitable\nPVLs with clinically significant regurgitation and/or\nhaemolysis. | IIa | B\nManagement of biological heart valve failure—Section 14.4 |  |  |  |  | \nReoperation is recommended in symptomatic patients\nwith a signifci ant increase in transprosthetic gradient\n(after exclusion of valve thrombosis) or severe\nregurgitation. | I | C | Reintervention is recommended in symptomatic\npatients with signifci ant valve dysfunction not\nattributable to valve thrombosis. | I | C\nTranscatheter, transfemoral valve-in-valve implantation\nin the aortic position should be considered by the Heart\nTeam depending on anatomical considerations, features\nof the prosthesis, and in patients who are at high\noperative risk or inoperable. | IIa | B | Transcatheter transfemoral valve-in-valve implantation\nin the aortic position should be considered in patients\nwith signifci ant valve dysfunction who are at\nintermediate or high surgical risk, and have suitable\nanatomical and prosthesis features, as assessed by the\nHeart Team. | IIa | B\nTranscatheter valve-in-valve implantation in the mitral\nand tricuspid position may be considered in selected\npatients at high risk for surgical reintervention. | IIb | B | Transcatheter transvenous mitral or tricuspid\nvalve-in-valve implantation should be considered in\npatients with signifci ant valve dysfunction at intermediate\nor high surgical risk, if the anatomy is suitable. | IIa | B\nManagement of mechanical heart valve thrombosis—Section 14.4 |  |  |  |  | \nUrgent or emergency valve replacement is\nrecommended for obstructive thrombosis in critically ill\npatients without serious comorbidity. | I | B | Heart Team evaluation is recommended in patients\nwith acute HF (NYHA class III or IV) due to obstructive\nMHV thrombosis to determine appropriate\nmanagement (repeat valve replacement or low-dose\nslow infusion fbi rinolysis). | I | B\nFibrinolysis (using recombinant tissue plasminogen\nactivator 10 mg bolus + 90 mg in 90 min with UFH or\nstreptokinase 1 500 000 U in 60 min without UFH)\nshould be considered when surgery is not available or is\nvery high risk, or for thrombosis of right-sided\nprostheses. | IIa | B |  |  | \nManagement of biological heart valve thrombosis—Section 14.4 |  |  |  |  | \nAnticoagulation using a VKA and/or UFH is\nrecommended in BHV thrombosis before considering\nreintervention. | I | C | OAC using VKA is recommended in BHV thrombosis\nbefore considering reintervention. | I | B",
          "rows": 10,
          "cols": 6
        },
        {
          "title": "Table on page 17",
          "page": 17,
          "content": "Transcatheter interventions | Surgical interventions\n• Transfemoral TAVI in patients\nwith high-risk features:\n– Low coronary ostia\n– Difficult femoral anatomy\n– Bicuspid valve\n– Severe calcification protruding\ninto the LVOT\n– Severe LV and/or RV impairment\n– Pure AV regurgitation\n– Multiple valve disease\n– Complex coronary artery disease\n– Severe extracardiac disease\n(e.g. renal failure, PH)\n• Non-transfemoral TAVI\n• Valve-in-valve (including\nTAV-in-TAV)\n• All leafel t modifci ation procedures\n(BASILICA, LAMPOON etc.)\n• PVL closure procedures\n• Complex M-TEERa\n• Redo M-TEER procedures\n• Tricuspid or mitral valve-in-ring or\nvalve-in-valve, valve-in-MAC\n• TMVI\n• All tricuspid procedures | • High-risk procedures (especially\nin patients with LV and/or RV\nimpairment)\n• Redo procedures\n• Minimally invasive and robotic\nvalve surgery\n• Complex MV repair\n– Barlow disease\n– Anterior or bileaflet prolapse\n– High risk of SAM\n– Severe MAC\n• AV repair\n• Ross procedure\n• Valve surgery combined with\ncomplex surgery of the aorta\n• Endocarditis surgery",
          "rows": 2,
          "cols": 2
        }
      ],
      "keywords": [
        "intervention",
        "ct",
        "echo",
        "centre",
        "monitoring",
        "valve",
        "risk",
        "severe",
        "symptomatic",
        "heart",
        "team",
        "imaging",
        "diagnosis"
      ]
    },
    {
      "number": "5",
      "title": "4. Imaging of patients with valvular heart disease",
      "start_page": 18,
      "end_page": 19,
      "content": "Internal quality assessment (see dedicated document concerning TAVI \nfrom the ESC41), systematic recording, and public availability of the volume \nand outcome data of the performed procedures are essential. Participation \nin national or international registries should be encouraged. These consid-\nerations are of particular importance regarding asymptomatic low-risk pa-\ntients (where low mortality and procedural safety are paramount), those \nwith multiple comorbidities (where the need for multidisciplinary collabor-\nation is essential), and new techniques with a steep learning curve (where \nbetter results may be obtained at experienced centres). \nThere is a pressing need to ensure higher dispersion and adoption of \ninterventions for VHD, especially (but not exclusively) in middle- and \nlower-income countries where rheumatic heart disease (RHD) remains \nthe principal cause of VHD.42,43 Key strategies include awareness pro-\ngrammes, increased public and medical education, simplified and im-\nproved diagnostic tools, and measures to reduce costs and facilitate \naccess to evidence-based treatment options.44 \n4. Imaging of patients with valvular \nheart disease \nMultimodality imaging is now the standard approach in VHD \nmanagement to determine the pathophysiology, assess severity, \nplan interventions, and identify complications (Figure 2). The use \nof imaging for the assessment of each specific valve lesion is de-\nscribed in the corresponding sections. The role of imaging is trans-\nversal from diagnosis to follow-up and should encompass an \nintegrative assessment. \n4.1. Initial valve assessment \nComprehensive transthoracic echocardiography (TTE) is the first-line \nexamination to confirm valve dysfunction, and determine the aetiology, \nmechanism, and severity of VHD, as well as cardiac chamber anatomy \nand damage.45,46 It should be performed by properly trained ima-\ngers.47–49 Quantitative imaging analysis (as opposed to visual) should \nbe the goal in all patients with relevant VHD, complemented by quali-\ntative and semi-quantitative evaluation. The severity of VHD should be \nassessed using an integrative approach of all criteria checked for con-\nsistency. When TTE is of poor quality or inconclusive, transoesophageal \nechocardiography (TOE) and/or additional diagnostic imaging modal-\nities should be applied (e.g. calcium scoring and anatomy of the \nvalve using CCT). In specific clinical scenarios [e.g. thrombosis, pros-\nthetic valve dysfunction, endocarditis, mitral stenosis (MS), assessment \nof MV or TV anatomy], TOE has a central diagnostic role.50,51 \n\u001f\u001e\u001d\n\u001c\u001c\u001f\n\u001c\u001b\u001a\u0019\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u001e\u001a\u001a\u0013\u0012\u0012\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u001e\u000f\u001a\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\r\f\u001a\u000f\u000b\u0012\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u001f\u0011\n\u001f\t\u001e\u0015\b\u0013\u001d\u0019\u0007\u0016\u000f\u000b\u0015\u0013\u0012\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u0006\u0013\u0005\u000b\u001d\u0005\u001b\u0017\u001e\u0018\u0017\u0019\u0010\u001d\u001e\u001a\u0017\u001b\u0016\u0018\n\u0004\u0014\u0016\u001a\u001e\u001d\u001c\u001b\u001e\u000f\u0019\u000e\b\u001d\u0016\u0012\u001b\u0012\n\n\u001b\u001e\u0005\u0018\u0016\u0012\u001b\u0012\u0019\u001e\u0018\u001c\u0019\u0003\u000b\u001e\u0018\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\n\u001c\u0014\u0012\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\t\u001e\u0015\b\u0013\u001d\u0019\u001e\u0018\u001e\u0017\u0016\u0015\u0014\u0019\u001e\u0018\u001c\u0019\u0010\u000b\u0018\u001a\u0017\u001b\u0016\u0018\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001c\u001e\u0015\u001e\u0005\u0013\u0019\u001e\u0018\u001c\u0019\u001d\u0013\u0015\u0016\u001c\u0013\u000f\u000f\u001b\u0018\u0005\n\u0002\u0016\u000f\u000f\u0016\u0001\u000b\n\u001f\u001f\u001d\n\u0011\u0012\u0012\u0016\u001a\u001b\u001e\u0017\u0013\u001c\u0019\u001c\u001b\u0012\u0013\u001e\u0012\u0013\u0012\n\u001e\u0018\u001c\u0019\u001a\u0016\u0018\u001c\u001b\u0017\u001b\u0016\u0018\u0012\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\n\u001c\u0014\u0018\u001e\u0015\u001b\u001a\u0012\u0019\u001e\u0018\u001c\u0019\u0007\u001e\u001d\u001b\u001e\b\u001b\u000f\u001b\u0017\u0014\n\u0011\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u0013\f\u0017\u001d\u001e\u0007\u001e\u000f\u0007\u000b\u000f\u001e\u001d\u0019\n\u001a\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u001a\u0016\u0018\u0012\u0013\u0003\u000b\u0013\u0018\u001a\u0013\u0012\u0019\u0010\u001d\u0016\u0015\u0019\n\r\u0007\u001e\u000f\u000b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0013\u000f\u001b\u0005\u001b\b\u001b\u000f\u001b\u0017\u0014\u0019\u0010\u0016\u001d\u0019\n\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0019\u001e\u0018\u001c\u0019\u001d\u001b\u0012\u0019\u0012\u0017\u001d\u001e\u0017\u001b\u000e\u001a\u001e\u0017\u001b\u0016\u0018\n\u000f\u001e\u0018\u0018\u001b\u0018\u0005\u0019\u001e\u0018\u001c\u0019\u0005\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012 \n\u001e\u0012\u0012\u0013\u0012\u0012\u0015\u0013\u0018\u0017\u0019\u0016\u0010\u0019\u001a\u0016\u0015\u000f\u001b\u001a\u001e\u0017\u001b\u0016\u0018\u0012\n\u001b\u0005\t\u0013\u001d\u0019\u001d\u0013\u0012\u0016\u000f\u000b\u0017\u001b\u0016\u0018\u0019\u0017\u0016\u0019\u001e\u0012\u0012\u0013\u0012\u0012\u0019\u0007\u001e\u000f\u0007\u0013\u0019\n\u001e\u0018\u001e\u0017\u0016\u0015\u0014\n\u0004\u0013\u001a\t\u001e\u0018\u001b\u0012\u0015­\u0012\u0019\u0016\u0010\u0019\n\n\u0019\u0007\u001b\u0012\u000b\u001e\u000f\u001b\u001e\u0017\u001b\u0016\u0018\u0019\u0016\u0010\u0019\u0007\u001e\u000f\u0007\u0013\u0012\n\u000b\u001b\u001c\u001b\u0018\u0005\u0019\u0016\u0010\u0019\u001b\u0018\u0017\u0013\u001d\u0007\u0013\u0018\u0017\u001b\u0016\u0018\u0012\nFigure 2 Integrative imaging assessment of patients with valvular heart disease. 3D, three-dimensional; CAD, coronary artery disease; CCT, cardiac \ncomputed tomography; CMR: cardiac magnetic resonance; TOE; transoesophageal echocardiography; TTE, transthoracic echocardiography; VHD, \nvalvular heart disease.   \n4652                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nMoreover, in patients with regurgitant lesions, particularly AR, CMR has \ngained key value in clinical practice. \n4.2. Associated diseases and conditions \nImaging plays a crucial role in identifying associated diseases and condi-\ntions. The presence of concomitant left ventricular (LV) systolic or dia-\nstolic dysfunction, RV systolic dysfunction, red flags indicating \ncardiomyopathies (e.g. amyloidosis, hypertrophic cardiomyopathy), \nand aortopathy should prompt further examinations to ensure optimal \nrisk stratification and VHD management. In addition to TTE, advanced \nimaging modalities, like CCT, may be required to assess the aorta, \nsingle-photon emission computed tomography (CT) for detection of \nischaemia/necrosis, positron emission tomography (PET) for inflamma-\ntion, nuclear scintigraphy for cardiac amyloidosis, or CMR for tissue \ncharacterization. \n4.3. Evaluation of valvular heart disease \ndynamics and variability \nSerial imaging studies to detect changes over time, or variability due to \nhaemodynamic conditions or initiation/up-titration of medical ther-\napy, are of utmost importance to guide decisions. The dynamic pat-\ntern of VHD may convey additional prognostic information. \nExercise echocardiography helps to identify the cause of dyspnoea, \nunveil symptoms in apparently asymptomatic patients, identifies dy-\nnamic changes of VHD severity, and can contribute to refinement \nof the indication for an intervention, especially for AS and mitral re-\ngurgitation (MR).52 \n4.4. Assessment of extravalvular cardiac \nconsequences from valvular heart disease \nSeveral studies investigating different valve lesions have established \nthe relevance of extravalvular cardiac damage in terms of progno-\nsis,53–55 recovery after intervention,56 and quality of life.57 The pres-\nence of LV hypertrophy, left atrium (LA) dilatation, LV or RV \ndysfunction and/or remodelling, myocardial fibrosis, and pulmonary \nhypertension (PH) provide important prognostic information, and \nmay influence the timing and type of treatment. Although not neces-\nsarily chronological in their order of appearance, the understanding \nof cardiac damage, particularly damage involving the LV, is essential \nto guide appropriate medical therapy before and after any interven-\ntion. Transthoracic echocardiography (TTE) including global longitu-\ndinal strain (GLS) and CMR can be particularly useful in that \nregard.58–60 \n4.5. Evaluation of eligibility, planning, and \nguiding of interventions \nTransoesophageal echocardiography (TOE) (preferentially 3D) is the \npreferred tool for the assessment of suitability for aortic, mitral, and \nTV repair.45,49,61–63 Risk stratification for an intervention should inte-\ngrate all the points mentioned above. \nTransoesophageal echocardiography (TOE), including standard 3D \nviews, is also the modality of choice to guide atrioventricular trans-\ncatheter interventions and should be performed by specially trained \ninterventional echocardiographers.61,64 Cardiac computed tomog-\nraphy (CCT) is frequently used to evaluate the relationship of the \nvalve with adjacent structures [e.g. coronary arteries and left ventricu-\nlar outflow tract (LVOT)], the extension of calcification [e.g. in mi-\ntral annular calcification (MAC)], and for sizing of the prosthesis. \nCT angiography is frequently employed to evaluate the anatomy \nof surgical, arterial, or venous access routes and detect cardiac or \nextracardiac complications (e.g. bleeding or embolic events). \nCoronary CT angiography (CCTA) is increasingly utilized to assess \nthe presence of CAD. \n5. Clinical evaluation of patients \nwith valvular heart disease \n5.1. Clinical examination \nPatients with VHD can be either asymptomatic or present with a wide \nspectrum of symptoms, including acute or chronic HF. An initial meticu-\nlous history and a comprehensive physical examination of the patient \nwith auscultation, documentation of clinical signs of HF such as dys-\npnoea, impaired physical capacity and fatigue, peripheral oedema, and \npleural effusion, as well as a systematic frailty assessment, are crucial.65 \nIn addition, comorbidities and coexisting cardiac conditions should be \ndocumented (Figure 3). Particular attention should be given to recent \nchanges in symptoms or physical findings indicating a potential worsen-\ning of the valve lesion or ventricular function. \n5.2. Assessment of comorbidities and risk \nstratification \nRisk stratification of patients with VHD has been mainly developed \nbased on surgical populations. The European System for Cardiac \nOperative Risk Evaluation II (EuroSCORE II)66,67 (https://www. \neuroscore.org) and the Society of Thoracic Surgeons predicted risk \nof \nmortality \n(STS-PROM) \nscore68 \n(http://riskcalc.sts.org/ \nstswebriskcalc/calculate) are the most commonly used scoring systems \nto estimate surgical risk. Both risk scores have been calibrated to pre-\ndict post-operative outcomes.69–71 The STS-PROM score is dynamic to \naccount for changes in patient risk profiles, the type of procedure (aor-\ntic, mitral, and tricuspid), and outcomes over time. The outdated (logis-\ntic) EuroSCORE I model systematically overestimated surgical \nmortality.70,72 \nIn patients considered for TAVI, surgical risk scores have lower ac-\ncuracy and tend to overestimate the risk of events.73–75 Discrepancies \nbetween observed and predicted peri-procedural mortality after \nTAVI using surgical risk scores point towards a need for \nTAVI-specific scores. Models predicting short- and medium-term sur-\nvival specifically designed for TAVI are rarely used in daily clinical prac-\ntice due to limitations of their predictive performance.76–79 Specific \nscores have also been developed for patients undergoing mitral \nTEER (M-TEER),80–82 but the high heterogeneity of the population \nwith MR limits their external validity and therefore routine clinical \nuse so far.83 Recently, a dedicated clinical score has been calibrated \nand validated to stratify the risk associated with first-time and repeat \nisolated TV surgery (TRI-SCORE; https://www.tri-score.com/), and its \nuse should be encouraged for patients with TV disease,84,85 as an al-\nternative to the more complex Society of Thoracic Surgeons (STS) \nscore for isolated TV surgery (https://isolatedtvsurgcalc.research.sts. \norg/).  \nESC Guidelines                                                                                                                                                                                          4653 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "echocardiography",
        "intervention",
        "ct",
        "echo",
        "asymptomatic",
        "valvular",
        "follow-up",
        "disease",
        "risk",
        "tavi",
        "mitral stenosis",
        "symptomatic",
        "patients",
        "heart",
        "treatment",
        "imaging",
        "diagnosis"
      ]
    },
    {
      "number": "6",
      "title": "5. Clinical evaluation of patients with valvular heart disease",
      "start_page": 19,
      "end_page": 21,
      "content": "Moreover, in patients with regurgitant lesions, particularly AR, CMR has \ngained key value in clinical practice. \n4.2. Associated diseases and conditions \nImaging plays a crucial role in identifying associated diseases and condi-\ntions. The presence of concomitant left ventricular (LV) systolic or dia-\nstolic dysfunction, RV systolic dysfunction, red flags indicating \ncardiomyopathies (e.g. amyloidosis, hypertrophic cardiomyopathy), \nand aortopathy should prompt further examinations to ensure optimal \nrisk stratification and VHD management. In addition to TTE, advanced \nimaging modalities, like CCT, may be required to assess the aorta, \nsingle-photon emission computed tomography (CT) for detection of \nischaemia/necrosis, positron emission tomography (PET) for inflamma-\ntion, nuclear scintigraphy for cardiac amyloidosis, or CMR for tissue \ncharacterization. \n4.3. Evaluation of valvular heart disease \ndynamics and variability \nSerial imaging studies to detect changes over time, or variability due to \nhaemodynamic conditions or initiation/up-titration of medical ther-\napy, are of utmost importance to guide decisions. The dynamic pat-\ntern of VHD may convey additional prognostic information. \nExercise echocardiography helps to identify the cause of dyspnoea, \nunveil symptoms in apparently asymptomatic patients, identifies dy-\nnamic changes of VHD severity, and can contribute to refinement \nof the indication for an intervention, especially for AS and mitral re-\ngurgitation (MR).52 \n4.4. Assessment of extravalvular cardiac \nconsequences from valvular heart disease \nSeveral studies investigating different valve lesions have established \nthe relevance of extravalvular cardiac damage in terms of progno-\nsis,53–55 recovery after intervention,56 and quality of life.57 The pres-\nence of LV hypertrophy, left atrium (LA) dilatation, LV or RV \ndysfunction and/or remodelling, myocardial fibrosis, and pulmonary \nhypertension (PH) provide important prognostic information, and \nmay influence the timing and type of treatment. Although not neces-\nsarily chronological in their order of appearance, the understanding \nof cardiac damage, particularly damage involving the LV, is essential \nto guide appropriate medical therapy before and after any interven-\ntion. Transthoracic echocardiography (TTE) including global longitu-\ndinal strain (GLS) and CMR can be particularly useful in that \nregard.58–60 \n4.5. Evaluation of eligibility, planning, and \nguiding of interventions \nTransoesophageal echocardiography (TOE) (preferentially 3D) is the \npreferred tool for the assessment of suitability for aortic, mitral, and \nTV repair.45,49,61–63 Risk stratification for an intervention should inte-\ngrate all the points mentioned above. \nTransoesophageal echocardiography (TOE), including standard 3D \nviews, is also the modality of choice to guide atrioventricular trans-\ncatheter interventions and should be performed by specially trained \ninterventional echocardiographers.61,64 Cardiac computed tomog-\nraphy (CCT) is frequently used to evaluate the relationship of the \nvalve with adjacent structures [e.g. coronary arteries and left ventricu-\nlar outflow tract (LVOT)], the extension of calcification [e.g. in mi-\ntral annular calcification (MAC)], and for sizing of the prosthesis. \nCT angiography is frequently employed to evaluate the anatomy \nof surgical, arterial, or venous access routes and detect cardiac or \nextracardiac complications (e.g. bleeding or embolic events). \nCoronary CT angiography (CCTA) is increasingly utilized to assess \nthe presence of CAD. \n5. Clinical evaluation of patients \nwith valvular heart disease \n5.1. Clinical examination \nPatients with VHD can be either asymptomatic or present with a wide \nspectrum of symptoms, including acute or chronic HF. An initial meticu-\nlous history and a comprehensive physical examination of the patient \nwith auscultation, documentation of clinical signs of HF such as dys-\npnoea, impaired physical capacity and fatigue, peripheral oedema, and \npleural effusion, as well as a systematic frailty assessment, are crucial.65 \nIn addition, comorbidities and coexisting cardiac conditions should be \ndocumented (Figure 3). Particular attention should be given to recent \nchanges in symptoms or physical findings indicating a potential worsen-\ning of the valve lesion or ventricular function. \n5.2. Assessment of comorbidities and risk \nstratification \nRisk stratification of patients with VHD has been mainly developed \nbased on surgical populations. The European System for Cardiac \nOperative Risk Evaluation II (EuroSCORE II)66,67 (https://www. \neuroscore.org) and the Society of Thoracic Surgeons predicted risk \nof \nmortality \n(STS-PROM) \nscore68 \n(http://riskcalc.sts.org/ \nstswebriskcalc/calculate) are the most commonly used scoring systems \nto estimate surgical risk. Both risk scores have been calibrated to pre-\ndict post-operative outcomes.69–71 The STS-PROM score is dynamic to \naccount for changes in patient risk profiles, the type of procedure (aor-\ntic, mitral, and tricuspid), and outcomes over time. The outdated (logis-\ntic) EuroSCORE I model systematically overestimated surgical \nmortality.70,72 \nIn patients considered for TAVI, surgical risk scores have lower ac-\ncuracy and tend to overestimate the risk of events.73–75 Discrepancies \nbetween observed and predicted peri-procedural mortality after \nTAVI using surgical risk scores point towards a need for \nTAVI-specific scores. Models predicting short- and medium-term sur-\nvival specifically designed for TAVI are rarely used in daily clinical prac-\ntice due to limitations of their predictive performance.76–79 Specific \nscores have also been developed for patients undergoing mitral \nTEER (M-TEER),80–82 but the high heterogeneity of the population \nwith MR limits their external validity and therefore routine clinical \nuse so far.83 Recently, a dedicated clinical score has been calibrated \nand validated to stratify the risk associated with first-time and repeat \nisolated TV surgery (TRI-SCORE; https://www.tri-score.com/), and its \nuse should be encouraged for patients with TV disease,84,85 as an al-\nternative to the more complex Society of Thoracic Surgeons (STS) \nscore for isolated TV surgery (https://isolatedtvsurgcalc.research.sts. \norg/).  \nESC Guidelines                                                                                                                                                                                          4653 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nOther cardiac conditions and comorbidities—such as CAD, con-\ncomitant multiple valve and aortic disease, and RV dysfunction, as \nwell as chronic kidney disease (CKD)—are not always appropriately \ncaptured in risk models, even if they are known to impact outcomes.86 \nSimilarly, specific unfavourable characteristics like porcelain aorta, mo-\nbile aortic atheroma, and previous mediastinal radiation therapy in-\ncrease the surgical risk, and therefore may favour transcatheter \ntreatment options. Frailty, including nutritional state, represents another \nimportant determinant of outcomes after valve interventions,87–89a \nwhich can be evaluated using appropriate tools as summarized in a re-\ncent consensus statement.90 Several methods have been proposed, \nfrom the simple Fried Frailty Index to more complex scores91 such \nas the Hospital Frailty Risk Score, which has been validated in a large \ncohort of TAVI and M-TEER patients.92 \nThe use of PROMs that engage patients in the co-evaluation of their \nhealth and wellbeing is encouraged. Several scoring systems have been \nproposed and validated for reproducibility and association with clinical \noutcomes, like the Quality of Recovery 15-item PROM or the Kansas \nCity Cardiomyopathy Questionnaire (KCCQ).93–95 \n5.3. Biomarkers \nBiomarker levels indicating either cardiac wall stress [e.g. brain natri-\nuretic peptide (BNP)] or myocardial damage (e.g. troponin), in asymp-\ntomatic and symptomatic patients, may help to monitor VHD \nprogress and determine the most appropriate timing of intervention. \nIn patients with VHD, the natriuretic peptide ratio [the ratio of \nmeasured BNP or N-terminal pro-B-type natriuretic protein \n\u001f\u001e\u001d\u001c\u001b\u001a\u001d\u0019\u0018\n\u0017\u0016\u001b\u0015\u001b\u0016\u001b\u001a\u0014\u001b\u0018\n\u001e\u001a\u0013\u0012\u0011\u0010\u001e\u000f\u0018\n\u001f\u001e\u001d\u001c\u001b\u001a\u0019\u0018\u0017\u001e\u001d\u0016\u001e\u0015\n\u0014\u0017\u0013\u0012\u0019\u0013\u0012\u0016\u0013\u0012\u0011\u0012\u001b\u0017\u0018\u0010\n\u001f\u000f\u0017\u001d\u0017\u000e\u0019\u000f\u0016\u0012\r\u0019\u001a\u0017\u001d\u0019\u0018\u0017\u001e\u001d\n\u001f\u001e\u001a\u001e\u001b\f\u0017\u0014\u0017\u0018\u0017\u0012\u0013\u0016\u000b\n\u0015\u001b\u0019\u0017\u000f\u0018\u0010\n\u001f\u001e\u001d\u000e\u001e\u001a\u0017\u0018\u0019\u001d\u0018\u0016\u000e\u0019\u001b\u0014\u0017\u0019\u000e\n\u000e\u001e\u001d\u0014\u0017\u0018\u0017\u001e\u001d\u0013\n\u000e\r\u001e\u0016\u001b\u0013\u0012\u001d\u0016\u001b\u001e\u001d\f\u001b\u001a\u001d\u0012\u0013\u001b\u0014\u001c\u0018\u001c\u0010\u001a\n\n\t\n\b\n\u0007\n\u000b\u001b\u001e\u0016\u001d\u0012\n\u001b\u001e\f\u0012\u001b\t\u001e\u000f\b\u001e\u001d\u001c\u0010\u001a\n\u0006\u0017\u0013\u0005\u0016\u0013\u0018\u001b\u0019\u0018\u0017\u001c\u000e\u0019\u0018\u0017\u001e\u001d\u0016\u0017\u001d\u000e\u000f\u0004\u0014\u0017\u001d\u0003\u0016\u0004\u0013\u0012\n\u001e\u0015\u0016\u000e\u000f\u0017\u001d\u0017\u000e\u0019\u000f\u0016\u0013\u000e\u001e\u001b\u0012\u0013\u0016\n\u0002\u0017\u001a\u0017\u001d\u0003\u0016\u0019\u001d\u0014\u0016\u0018\u0010\u0001\u0012\u0016\u001e\u0015\u0016\u0018\u001b\u0012\u0019\u0018\u001a\u0012\u001d\u0018\nFigure 3 Central illustration. Patient-centred evaluation for treatment of valvular heart disease.   \n4654                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n(NT-proBNP) to upper limit of normal for age, sex, and assay] \nhas been shown to be a powerful, independent, and incremental \npredictor of mortality.96–98 In patients undergoing AV replacement, \nthe accumulation of several elevated biomarkers of cardiovascular \nstress was associated with higher all-cause and cardiovascular mortal-\nity, and a higher rate of repeat hospitalization.99,100 \n5.4. Exercise testing \nBecause of the slow progression of valve lesions, patients may gradually \nlimit their activity levels over several years and deny having actual symp-\ntoms that can be unmasked by exercise testing.12 This is particularly im-\nportant in cases of AS, because once symptoms occur there is a sharp \nincrease in the risk of sudden cardiac death, unless a valve intervention \nis performed.101–104 Exercise testing may provide additional informa-\ntion about the haemodynamic severity of VHD and help determine \nthe risk and optimal timing of intervention by objectively evaluating \nfunctional capacity.101,103 Cardiopulmonary exercise testing has a \nprognostic role and can assist decision-making in patients with VHD \nof intermediate severity, particularly those with asymptomatic \nAR.101,105,106 \nExercise echocardiography is used for the assessment of LV global \nand segmental function, pulmonary artery pressure, and aortic and mi-\ntral pressure gradients.101,107 It also documents exercise-induced in-\ncrease of MR and TR severity, especially in patients with secondary \ndisease.108,109 Prognostic impact has been shown mainly for AS and \nMR.110,111 Misconceptions regarding its risk and tolerability contribute \nto the overall underuse of exercise testing in patients with VHD,12 des-\npite data confirming its safety in most asymptomatic patients.112,113 \n5.5. Invasive investigations \n5.5.1. Coronary angiography \nCoronary artery assessment is recommended to evaluate the need for \nrevascularization when valve surgery or an intervention is planned. The \ninformation regarding the existence of concomitant CAD should be \navailable at the time of Heart Team discussion. CCTA is recommended \nas an alternative to coronary angiography to rule out CAD in patients \nwho are at low or moderate risk of obstructive CAD. \nCoronary blood flow and fractional flow reserve (FFR) are altered in \nthe setting of concomitant VHD, and functional haemodynamic assess-\nment of CAD in these patients is not well established.114–118 \n5.5.2. Cardiac catheterization \nRight heart catheterization (RHC) should be performed in patients with \nequivocal echocardiographic findings, particularly those with MV dis-\nease, as well as in all candidates for the treatment of severe TR. In ex-\nceptional cases with unclear AS severity, it can be combined with \nmeasurements of the transaortic gradients allowing estimation of the \naortic valve area (AVA). Right heart catheterization contributes to as-\nsess the repercussions of any left-sided VHD or LV impairment on \nthe pulmonary circulation and right side of the heart. It provides infor-\nmation regarding volume state, cardiac output, and vascular resistance, \ndifferentiating between pre- and post-capillary PH, and should be ideally \nperformed in euvolaemia. \nMeasurements of the pulmonary capillary wedge pressure v-wave \ncan inform about MR severity, but are neither sensitive nor specific, \nand may also be increased if the compliance of the LA is reduced or \nin case of diastolic LV dysfunction, as in patients with MS or chronic \nHF.119 \nSimilarly, the height of the right atrium (RA) v-wave, and the pres-\nsure curve mimicking the RV pattern (‘ventricularization’ of the RA \npressure), are signs of relevant TR, which are frequently accompan-\nied by increased RV end-diastolic pressure in case of associated RV \ndysfunction. In patients with severe TR, pulmonary vascular resist-\nance (PVR) should be calculated to unmask pulmonary vascular dis-\nease, which may not be captured by echocardiography due to RV \nsystolic dysfunction or underestimation of pulmonary pressures be-\ncause of TR. \n5.6. Patient-centred care and shared \ndecision-making \nGiven that treatment of VHD typically involves several modalities and \nspecialities, and may result in a complex and sometimes time- \nconsuming decision-making process, patient education and informa-\ntion, using online material and face-to-face conversations, are essen-\ntial at each step. A clearly defined point of contact for all questions \nrelating to the disease or type of treatments should be communicated \nto the patient and their relatives.120 The symptomatic and prognostic \nbenefits, as well as the advantages and disadvantages of any treatment \noption, should be presented in an open and evidence-based manner. \nThis includes mortality and risks of reintervention and complications \n(also over the long term), as well as recovery time and the need for \ncardiac, and if necessary psychological, rehabilitation until return to \nphysical activity and work. Other issues to be discussed before the \nprocedure include the need for oral anticoagulation (OAC) and its \nmonitoring, as well as the noise generated by mechanical heart valves \n(MHVs). Information regarding centre experience and volume for a \nspecific procedure should be provided. Misconceptions (e.g. subject-\nive overestimation of the risk of surgery) should be addressed and po-\ntential interactions with individual lifestyle factors—including social \nactivities, family and professional life, and hobbies—should be dis-\ncussed in detail. \nThe Heart Team recommendation regarding the treatment and its \nmodality must be based on evidence and anatomical considerations, \nbalancing the risks and benefits of available treatment options.16 The \npatient and patient’s relatives need to be well informed about the ra-\ntionale leading to the Heart Team recommendation, and given ample \ntime to share personal preferences.121 At the end of the process, a \nshared decision is made between the treating team and the informed \npatient and relatives (Figure 3). \n6. Management of conditions \nassociated with valvular heart \ndisease \n6.1. Diagnosis and management of \ncoronary artery disease \nThe presence of CAD plays an important role in decision-making \nregarding the timing and modality of treatment, and should be \nassessed before Heart Team discussion. In patients with a low \nor moderate pre-test likelihood of obstructive CAD (≤50%), \nCCTA is recommended to rule out relevant CAD with high sensi-\ntivity.122–124 \nSeveral studies have investigated the value of CCT angiography for \nCAD screening in elderly TAVI candidates. While sensitivity for the de-\ntection of obstructive CAD is high (95%–97%), specificity (68%–73%) is  \nESC Guidelines                                                                                                                                                                                          4655 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "cardiomyopathy",
        "echocardiography",
        "intervention",
        "ct",
        "echo",
        "asymptomatic",
        "evaluation",
        "valvular",
        "disease",
        "risk",
        "symptomatic",
        "patients",
        "clinical",
        "heart",
        "indication",
        "treatment",
        "imaging"
      ]
    },
    {
      "number": "7",
      "title": "6. Management of conditions associated with valvular heart disease",
      "start_page": 21,
      "end_page": 24,
      "content": "(NT-proBNP) to upper limit of normal for age, sex, and assay] \nhas been shown to be a powerful, independent, and incremental \npredictor of mortality.96–98 In patients undergoing AV replacement, \nthe accumulation of several elevated biomarkers of cardiovascular \nstress was associated with higher all-cause and cardiovascular mortal-\nity, and a higher rate of repeat hospitalization.99,100 \n5.4. Exercise testing \nBecause of the slow progression of valve lesions, patients may gradually \nlimit their activity levels over several years and deny having actual symp-\ntoms that can be unmasked by exercise testing.12 This is particularly im-\nportant in cases of AS, because once symptoms occur there is a sharp \nincrease in the risk of sudden cardiac death, unless a valve intervention \nis performed.101–104 Exercise testing may provide additional informa-\ntion about the haemodynamic severity of VHD and help determine \nthe risk and optimal timing of intervention by objectively evaluating \nfunctional capacity.101,103 Cardiopulmonary exercise testing has a \nprognostic role and can assist decision-making in patients with VHD \nof intermediate severity, particularly those with asymptomatic \nAR.101,105,106 \nExercise echocardiography is used for the assessment of LV global \nand segmental function, pulmonary artery pressure, and aortic and mi-\ntral pressure gradients.101,107 It also documents exercise-induced in-\ncrease of MR and TR severity, especially in patients with secondary \ndisease.108,109 Prognostic impact has been shown mainly for AS and \nMR.110,111 Misconceptions regarding its risk and tolerability contribute \nto the overall underuse of exercise testing in patients with VHD,12 des-\npite data confirming its safety in most asymptomatic patients.112,113 \n5.5. Invasive investigations \n5.5.1. Coronary angiography \nCoronary artery assessment is recommended to evaluate the need for \nrevascularization when valve surgery or an intervention is planned. The \ninformation regarding the existence of concomitant CAD should be \navailable at the time of Heart Team discussion. CCTA is recommended \nas an alternative to coronary angiography to rule out CAD in patients \nwho are at low or moderate risk of obstructive CAD. \nCoronary blood flow and fractional flow reserve (FFR) are altered in \nthe setting of concomitant VHD, and functional haemodynamic assess-\nment of CAD in these patients is not well established.114–118 \n5.5.2. Cardiac catheterization \nRight heart catheterization (RHC) should be performed in patients with \nequivocal echocardiographic findings, particularly those with MV dis-\nease, as well as in all candidates for the treatment of severe TR. In ex-\nceptional cases with unclear AS severity, it can be combined with \nmeasurements of the transaortic gradients allowing estimation of the \naortic valve area (AVA). Right heart catheterization contributes to as-\nsess the repercussions of any left-sided VHD or LV impairment on \nthe pulmonary circulation and right side of the heart. It provides infor-\nmation regarding volume state, cardiac output, and vascular resistance, \ndifferentiating between pre- and post-capillary PH, and should be ideally \nperformed in euvolaemia. \nMeasurements of the pulmonary capillary wedge pressure v-wave \ncan inform about MR severity, but are neither sensitive nor specific, \nand may also be increased if the compliance of the LA is reduced or \nin case of diastolic LV dysfunction, as in patients with MS or chronic \nHF.119 \nSimilarly, the height of the right atrium (RA) v-wave, and the pres-\nsure curve mimicking the RV pattern (‘ventricularization’ of the RA \npressure), are signs of relevant TR, which are frequently accompan-\nied by increased RV end-diastolic pressure in case of associated RV \ndysfunction. In patients with severe TR, pulmonary vascular resist-\nance (PVR) should be calculated to unmask pulmonary vascular dis-\nease, which may not be captured by echocardiography due to RV \nsystolic dysfunction or underestimation of pulmonary pressures be-\ncause of TR. \n5.6. Patient-centred care and shared \ndecision-making \nGiven that treatment of VHD typically involves several modalities and \nspecialities, and may result in a complex and sometimes time- \nconsuming decision-making process, patient education and informa-\ntion, using online material and face-to-face conversations, are essen-\ntial at each step. A clearly defined point of contact for all questions \nrelating to the disease or type of treatments should be communicated \nto the patient and their relatives.120 The symptomatic and prognostic \nbenefits, as well as the advantages and disadvantages of any treatment \noption, should be presented in an open and evidence-based manner. \nThis includes mortality and risks of reintervention and complications \n(also over the long term), as well as recovery time and the need for \ncardiac, and if necessary psychological, rehabilitation until return to \nphysical activity and work. Other issues to be discussed before the \nprocedure include the need for oral anticoagulation (OAC) and its \nmonitoring, as well as the noise generated by mechanical heart valves \n(MHVs). Information regarding centre experience and volume for a \nspecific procedure should be provided. Misconceptions (e.g. subject-\nive overestimation of the risk of surgery) should be addressed and po-\ntential interactions with individual lifestyle factors—including social \nactivities, family and professional life, and hobbies—should be dis-\ncussed in detail. \nThe Heart Team recommendation regarding the treatment and its \nmodality must be based on evidence and anatomical considerations, \nbalancing the risks and benefits of available treatment options.16 The \npatient and patient’s relatives need to be well informed about the ra-\ntionale leading to the Heart Team recommendation, and given ample \ntime to share personal preferences.121 At the end of the process, a \nshared decision is made between the treating team and the informed \npatient and relatives (Figure 3). \n6. Management of conditions \nassociated with valvular heart \ndisease \n6.1. Diagnosis and management of \ncoronary artery disease \nThe presence of CAD plays an important role in decision-making \nregarding the timing and modality of treatment, and should be \nassessed before Heart Team discussion. In patients with a low \nor moderate pre-test likelihood of obstructive CAD (≤50%), \nCCTA is recommended to rule out relevant CAD with high sensi-\ntivity.122–124 \nSeveral studies have investigated the value of CCT angiography for \nCAD screening in elderly TAVI candidates. While sensitivity for the de-\ntection of obstructive CAD is high (95%–97%), specificity (68%–73%) is  \nESC Guidelines                                                                                                                                                                                          4655 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nmodest, mainly explained by the high prevalence of coronary artery cal-\ncification and AF in patients with severe AS, which limit imaging reso-\nlution and interpretability.125,126 If CCT angiography obtained during \nstandard pre-TAVI evaluation is of sufficient quality to exclude relevant \nCAD, omission of invasive coronary angiography should be consid-\nered.125–129 \nThe value of invasive functional haemodynamic assessment of CAD \nin patients with severe AS may be limited, because AS impacts coronary \nhaemodynamics. Therefore, caution is warranted in the interpretation \nof functional measurements in the presence of severe AS until more \ndata are available.115,116 \nRecommendations for the management of chronic CAD associated \nwith VHD are provided below (Recommendation Table 1), as well as in \ndedicated guideline documents.6 The indications for coronary artery \nbypass grafting (CABG) in patients undergoing surgery for the treat-\nment of VHD are mainly based on observational data, which do not \nprovide detailed information on the degree of stenosis and the com-\nplexity of CAD.130 It has been demonstrated that subendocardial blood \nflow in the myocardium improves early after SAVR, most likely due to \nimproved cardiac output and reduction of LV wall stress.131 The pres-\nence of CAD is associated with peri-operative and late adverse events \nin patients with AS undergoing SAVR132 that likely outweigh the in-\ncreased risk of peri-procedural adverse events of combined SAVR \nand CABG compared with isolated SAVR. Indeed, in a large observa-\ntional study, patients with CAD demonstrated better long-term sur-\nvival after combined SAVR and CABG compared with SAVR alone, \ndespite longer cross-clamp times.133 In patients with a primary indica-\ntion for valve surgery, CABG is recommended in patients with coron-\nary artery stenosis of ≥70% and should be considered in those with \nstenosis of ≥50%–70%, given the opportunity of concomitant full \nrevascularization. \nThe impact of CAD in patients undergoing TAVI remains under inves-\ntigation. The randomized Nordic Aortic Valve Intervention (NOTION)-3 \ntrial compared a strategy of routine percutaneous coronary interven-\ntion (PCI) versus conservative management in 455 patients with severe \nsymptomatic AS undergoing TAVI, who also had stable CAD and at \nleast one stenosis of ≥90% based on visual angiographic assessment \nor FFR of ≤0.80 in a segment with ≥2.5 mm reference diameter.134 \nPercutaneous coronary intervention was associated with lower risk \nof a composite endpoint event including all-cause death, myocardial in-\nfarction or urgent revascularization at a median follow-up of 2 years. \nExploratory analyses suggest that the increased risk in the conserva-\ntive treatment arm was driven by differences in the risk of myocardial \ninfarction and urgent revascularization in patients with a diameter \nstenosis of ≥90%, rather than those with positive FFR and stenosis \nof <90%. The risk of bleeding was higher in the PCI than in the conservative \ntreatment group. Another multicentre RCT, the PercutAneous Coronary \ninTervention prIor to transcatheter aortic VAlve implantaTION \n(ACTIVATION) trial, was discontinued due to slow recruitment.135 \nIn this underpowered and thus inconclusive trial, a routine PCI strategy \nof ≥70% stenoses in main epicardial vessels (or ≥50% if protected left \nmain or vein graft) did not meet non-inferiority compared with conserva-\ntive CAD treatment with respect to the composite of all-cause death and \nrehospitalization; moreover, PCI was associated with higher bleeding \nrates. Observational data show that TAVI can be performed safely in pa-\ntients with untreated CAD with low short- and long-term rates of acute \ncoronary syndrome and unplanned coronary revascularization.135–139 \nIn two recent meta-analyses of mostly observational data, PCI was not \nassociated with a mortality benefit in patients with chronic CAD \nundergoing TAVI.140,141 \nOptimal timing of PCI in patients undergoing TAVI remains yet to \nbe determined. In NOTION-3, PCI was performed before TAVI in \nthe majority of the patients (concomitantly or shortly after in only \n26% of the patients). Decision-making concerning the timing of \nPCI should take into account the type of valve used for TAVI and \nthe complexity of the coronary lesions.142,143 Valves with a high \nframe—particularly in the context of a narrow aortic root, commis-\nsural misalignment, or valve-in-valve procedures—can pose chal-\nlenges for coronary access following TAVI.144,145 The presence \nof significant CAD should therefore be considered for optimal \ntranscatheter valve selection and reinforces the importance of opti-\nmized implantation technique and commissural alignment.143,146 \nSeveral RCTs comparing the value and timing of PCI with \nmedical therapy are ongoing (NCT04634240, NCT04310046, and \nNCT05078619). \nBased on the available data, PCI should be considered in patients with \na primary indication to undergo TAVI and high-grade (≥90%) coronary \nartery stenosis in large vessels of ≥2.5 mm. In patients with stenosis of \n≥70%, PCI may be considered based on symptom status.142,143 In pa-\ntients with ischaemic ventricular SMR, surgical revascularization of \nCAD has been associated with MR reduction147 and favourable clinical \noutcomes in observational studies.148,149 According to very limited \ndata, improvement of SMR may occur in a minority of patients (about \none-third) after PCI, which may therefore be considered prior to MV \nintervention.150 \nFor patients with VHD presenting with acute coronary syndrome, \ntreatment decisions should be made according to the most recent \nESC Guidelines.151 In patients presenting with non-ST-segment eleva-\ntion acute coronary syndrome, it may be particularly challenging to \ndetermine the leading cause of elevated troponin levels, which are \nalso frequently observed in decompensated VHD. Therefore, the \ntreatment strategy should be determined by the Heart Team, taking \ninto account symptoms, as well as coronary, valve, and access \nanatomy.136,138,139 \nRecommendation Table 1 — Recommendations for the \nmanagement of chronic coronary syndrome in patients \nwith valvular heart disease (see also Supplementary \ndata online, Evidence Table 1) \nRecommendations \nClassa \nLevelb \nDiagnosis of coronary artery disease  \nCCTA is recommended before valve intervention in \npatients with moderate or lower (≤50%) pre-test \nlikelihood of obstructive CAD.122–124 \nI \nB \nInvasive coronary angiography is recommended \nbefore valve intervention in patients with high and \nvery high (>50%) pre-test likelihood of obstructive \nCAD. \nI \nC \nInvasive coronary angiography is recommended in \nthe evaluation of CAD in patients with severe \nventricular SMR. \nI \nC \nOmission of invasive coronary angiography should be \nconsidered in TAVI candidates, if procedural planning \nCT angiography is of sufficient quality to rule out \nsignificant CAD.125–129 \nIIa \nB                         \nContinued  \n4656                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n6.2. Atrial fibrillation \nThe interplay between AF and VHD is complex, and has an essential \nrole in the prognosis and evolution of VHD during the patient’s lifetime. \nValvular heart disease is independently associated with AF and almost \none-third of patients with AF have a history of VHD.152 Conversely, \nAF is the main trigger of the development of atrial secondary MR and \nTR. In a recent cohort study, 8% of individuals with AF developed mod-\nerate or severe TR within 3 years of follow-up compared with only 2% \nin those in sinus rhythm.153 While disturbed annular dynamics have \nbeen postulated,150,154 the exact pathophysiology leading to secondary \natrioventricular VHD in some, but not all patients with AF remains \nlargely unclear. \nDetailed recommendations on the anticoagulation management of \npatients with VHD and AF are provided below (Recommendation \nTable 2) and in Section 14, as well as in specific Guidelines.7 Patients \nwith a combination of VHD and AF have a high incidence of thrombo-\nembolic or bleeding complications.155 DOACs have replaced vitamin K \nantagonists (VKAs) in most clinical scenarios and are recommended for \npatients with VHD presenting with AF, except for patients with a MHV \nor mitral stenosis with a valve area ≤2.0 cm2. The use of apixaban,156 \ndabigatran,157 edoxaban,158 and rivaroxaban159 is supported by sub-\ngroup analyses of large RCTs. Recommendations regarding the antith-\nrombotic treatment of patients with MHVs and biological heart valves \n(BHVs) are described in Section 14 of these Guidelines. \nIn the Left Atrial Appendage Occlusion Study (LAAOS) III trial, sur-\ngical left atrial appendage occlusion (LAAO) in patients with AF and a \nCHA2DS2-VASc [congestive heart failure or left ventricular dysfunc-\ntion, hypertension, age ≥75 (doubled), diabetes, stroke (doubled), vas-\ncular disease, age 65–74, sex category (female)] score of ≥2 points \nundergoing cardiac surgery was associated with a 33% reduction of \nthe risk of stroke or systemic embolism at a mean follow-up of \n3.8 years.160 These findings were confirmed by a large meta-analysis in-\ncluding four RCTs.161 A subanalysis of LAAOS III showed that the bene-\nfit of LAAO remains consistent irrespective of the use of VKAs or \nDOACs, as well as in the absence of OAC (although representing \nonly 10% of the included population).162 In an RCT including patients \nwith severe AS and AF undergoing TAVI, concomitant transcatheter \nLAAO was non-inferior to medical therapy with respect to a composite \nprimary endpoint including all-cause mortality, stroke, and major bleed-\ning at 2 years. Of note, rates of major or life-threatening bleeding were \nsimilar in the two groups and arterial or venous thromboembolisms \nmore frequent in the TAVI/LAAO arm, leaving uncertainty regarding \nthe usefulness of combining both procedures.163 \n6.3. Cancer and radiation therapy \nValvular heart disease is commonly associated with cancer and repre-\nsents a well-known long-term side effect of intensive radiation ther-\napy176 for treatment of Hodgkin or non-Hodgkin lymphoma, breast \ncancer, and other thoracic malignancies.177 Clinically significant VHD \nmost commonly appears decades after radiotherapy. The incidence \nof radiation-induced VHD is increasing owing to longer survival of pa-\ntients with cancer. Risk factors are summarized in Supplementary data \nonline, Table S1. Patients at risk should be screened for VHD using TTE \n10 years after radiation exposure and followed up every 5 years \nthereafter.178 \nIndications for myocardial revascularization \nCABG is recommended in patients with a primary \nindication for valve surgery and coronary artery \nstenosis ≥70%.c \nI \nC \nCABG should be considered in patients with a \nprimary indication for valve surgery and coronary \nartery stenosis ≥50%–70%. \nIIa \nC \nPCI should be considered in patients with a primary \nindication to undergo TAVI and ≥90% coronary \nartery stenosis in segments with a reference \ndiameter ≥2.5 mm.134 \nIIa \nB \nPCI may be considered in patients with a primary \nindication to undergo transcatheter valve \ninterventions and coronary artery stenosis ≥70% in \nproximal segments of main vessels.135–137 \nIIb \nB \n© ESC/EACTS 2025\nCABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary \ncomputed tomography angiography; CT, computed tomography; PCI, percutaneous \ncoronary intervention; SMR, secondary mitral regurgitation; TAVI, transcatheter aortic \nvalve implantation. \naClass of recommendation. \nbLevel of evidence. \ncStenosis ≥50% can be considered for left main stenosis.  \nRecommendation Table 2 — Recommendations for the \nmanagement of atrial fibrillation in patients with native \nvalvular heart disease (see also Supplementary data \nonline, Evidence Tables 2 and 3) \nRecommendations \nClassa \nLevelb \nAnticoagulation  \nDOACs are recommended for stroke prevention in \npreference to VKAs in patients with AF and AS, AR, \nor MR who are eligible for OAC.156–159,164 \nI \nA \nThe use of DOACs is not recommended in patients \nwith AF and rheumatic MS with an \nMVA ≤2.0 cm2.165 \nIII \nB \nSurgical interventions \nConcomitant surgical ablation is recommended in \npatients undergoing MV surgery with AF suitable for a \nrhythm control strategy to prevent symptoms and \nrecurrence of AF, according to an experienced team of \nelectrophysiologists and arrhythmia surgeons.166–173 \nI \nA \nSurgical closure of the LA appendage is \nrecommended as an adjunct to OAC in patients with \nAF undergoing valve surgery to prevent \ncardioembolic stroke and systemic \nthromboembolism.160–162 \nI \nB \nConcomitant surgical ablation should be considered \nin patients undergoing non-MV surgery with AF \nsuitable for a rhythm control strategy to prevent \nsymptoms and recurrence of AF, according to an \nexperienced team of electrophysiologists and \narrhythmia surgeons.167,169,174,175 \nIIa \nB \n© ESC/EACTS 2025\nAF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; DOAC, direct oral \nanticoagulant; LA, left atrium/left atrial; MR, mitral regurgitation; MS, mitral stenosis; MV, \nmitral valve; MVA, mitral valve area; OAC, oral anticoagulation; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence.   \nESC Guidelines                                                                                                                                                                                          4657 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nRadiotherapy may lead to aortic and/or valvular calcification, CAD of \nproximal segments, restrictive cardiomyopathy, pericardial adhesions \nand calcifications with constriction, restrictive lung disease, chest wall \nscarring, and impaired wound healing, especially in patients who under-\nwent radiation by means of older techniques (>20 years ago). The above \nfactors complicate any surgical approach and increase the operative risk, \nwhich is underestimated by traditional risk scores.179–181 TAVI is pro-\nposed as an alternative for patients presenting with radiation-induced \nAS in the 2022 ESC Guidelines on cardio-oncology182 based on favourable, \nbut limited, observational data,183,184 because this category of patients \nhas been excluded from RCTs.183,184 Furthermore, M-TEER in patients \npresenting with radiation-induced MV disease with MR is often limited \nby thickened leaflets with restricted movement and subsequent risk of \niatrogenic stenosis. \nIn patients with active or stable cancer and severe AS, both TAVI and \nSAVR can be considered based on life expectancy, age, prognosis, and \ndisability following cancer treatment, with a trend towards more TAVI \nutilization.185 TAVI procedural complication rates appear similar com-\npared with those of control subjects without cancer.186 To avoid futil-\nity, treatment decisions discussed by the Heart Team should involve the \ntreating oncologists.5,182 \n6.4. Prophylaxis of rheumatic fever \nRheumatic heart disease remains the most common cause of death \nfrom VHD worldwide.187 Prevention should preferentially target the \nfirst occurrence of acute rheumatic fever. Correct diagnosis and early \nantibiotic treatment of group A Streptococcus throat or skin infection \nis key for primary prevention. Large-scale screening combined with \nprophylaxis in children or adolescents with latent RHD appears to be \nan effective strategy to reduce the risk of disease progression and \nRHD prevalence.188–190 In patients with established RHD, secondary \nlong-term prophylaxis with benzathine benzyl penicillin 1.2 million \ninternational units (IU) every 3–4 weeks over 10 years is recom-\nmended to prevent recurrent episodes, especially in children and ado-\nlescents. Long-term prophylaxis into adulthood should be considered \nin high-risk patients according to the severity of VHD and exposure \nto group A Streptococcus.191,192 \n6.5. Cardiogenic shock and acute heart \nfailure \nAcute presentation or decompensation of VHD can result in cardio-\ngenic shock due to rapid haemodynamic deterioration and altered car-\ndiac function. Alternatively, pre-existing VHD can be a bystander of an \nacute cardiovascular condition further exacerbating circulatory impair-\nment until the occurrence of cardiogenic shock. In this setting, assess-\nment of the severity of VHD, as well as its contribution to acute HF, \nmay be difficult. Evidence concerning acute VHD management in this \ncontext is scarce and only exists for the MV and AV.193,194 \nHospital admission for acute decompensated AS is a frequent prob-\nlem seen in up to 25% of AS hospitalizations.195,196 However, only a mi-\nnority of these patients (1.6%–3.2%) present with cardiogenic \nshock.197,198 While intensive care treatment remains the cornerstone \nof haemodynamic stabilization and support, an intervention should be \nconsidered early, because it represents the only way to reverse pro-\ngressive organ dysfunction due to low cardiac output. Balloon aortic \nvalvuloplasty has been used in this context in the past, but has been \nlargely replaced by TAVI in recent years, due to the high risk of severe \nAR and mortality in the acute setting.199–201 Several large observational \nstudies have established the feasibility of TAVI in patients with \ncardiogenic shock with similar device success, even if LVEF is low, al-\nthough 30-day mortality remains higher (13%–19%) compared with \nroutine TAVI.194,197,198 Surgery represents the preferred treatment \nin patients with acute AR, while TAVI has only been described in indi-\nvidual cases or patients with a failed surgical valve (valve-in-valve). Fast \npacing over a temporary pacemaker lead shortens the diastole and may \ntemporarily improve haemodynamics until the intervention.5,8 \nExcept for papillary muscle rupture, acute PMR rarely leads to car-\ndiogenic shock and may be best treated by surgical valve repair or re-\nplacement. In contrast, increasing evidence supports the use of \nM-TEER in patients with acute ventricular SMR, particularly following \nacute myocardial infarction, due to lower mortality compared with sur-\ngery or medical treatment in propensity-matched analyses.194,202,203 \nThis strategy might also be helpful to facilitate weaning from mechanical \ncirculatory support. \n6.6. Palliative care \nIn some patients with advanced VHD not qualifying for surgical or \ntranscatheter therapies, medical HF treatment remains the only, and \nsometimes best, available option. These patients usually present late, \nhave extensive cardiac damage, develop terminal HF during the natural \nevolution of VHD, and are ineligible for mechanical circulatory support \nor heart transplantation (HTx). Early implementation of expert multi-\ndisciplinary palliative and end-of-life care, with the support of HF spe-\ncialists,204–206 reduces the number of hospitalizations and improves \nquality of life and symptom burden, in particular dyspnoea, pain, and \nanxiety.207 Continuous co-ordination between all involved subspecial-\nties, and transparent communication with the patient and their rela-\ntives, are key to ensure high quality of care. \n7. Aortic regurgitation \n7.1. Prevalence and aetiology \nChronic AR is mainly due to intrinsic abnormalities of the AV cusps and/ \nor secondary to progressive dilatation of the aortic root and/or ascend-\ning aorta. In high-income countries, degenerative changes are the lead-\ning cause of AR, while RHD is more frequent in middle- and \nlow-income countries.12 Acute presentations are usually related to in-\nfective endocarditis or extension of aortic dissection into the aortic \nroot. Chronic pure severe AR is more frequent in men and is associated \nwith BAV and concomitant dilatation of the aorta in more than one-half \nof cases.208 \n7.2. Evaluation \nDuring stepwise AR evaluation, the following aspects should be ad-\ndressed: the severity of AR, its mechanism, and aetiology; the haemo-\ndynamic impact on LV function and pulmonary pressure; and \nevaluation of the ascending aorta. While echocardiography is the first- \nline modality, CMR and CCT are more accurate for the measurement \nof specific parameters (Figure 4). The results of the evaluation need to \ntake into consideration the haemodynamic condition of the patient, \nparticularly the blood pressure (BP), since high pressures can lead to \noverestimation of the regurgitant volume (RVol). \nAssessment of AR severity with TTE follows an integrative approach \nconsidering qualitative, semi-quantitative, and quantitative parameters, \nbut remains challenging.45 Consequences of AR on LV size and function \nmust be carefully assessed. Cut-offs for intervention are mostly \nbased on two-dimensional (2D) echocardiographic measurements. \nHowever, 3D echocardiography and CMR allow more accurate  \n4658                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 22",
          "page": 22,
          "content": "Recommendations | Classa | Levelb\nDiagnosis of coronary artery disease |  | \nCCTA is recommended before valve intervention in\npatients with moderate or lower (≤50%) pre-test\nlikelihood of obstructive CAD.122–124 | I | B\nInvasive coronary angiography is recommended\nbefore valve intervention in patients with high and\nvery high (>50%) pre-test likelihood of obstructive\nCAD. | I | C\nInvasive coronary angiography is recommended in\nthe evaluation of CAD in patients with severe\nventricular SMR. | I | C\nOmission of invasive coronary angiography should be\nconsidered in TAVI candidates, if procedural planning\nCT angiography is of sufficient quality to rule out\nsignificant CAD.125–129 | IIa | B",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 23",
          "page": 23,
          "content": " | Indications for myocardial revascularization |  |  | \nCABG is recommended in patients with a primary\nindication for valve surgery and coronary artery\nstenosis ≥70%.c |  | I | C | \nCABG should be considered in patients with a\nprimary indication for valve surgery and coronary\nartery stenosis ≥50%–70%. |  | IIa | C | \nPCI should be considered in patients with a primary\nindication to undergo TAVI and ≥90% coronary\nartery stenosis in segments with a reference\ndiameter ≥2.5 mm.134 |  | IIa | B | \nPCI may be considered in patients with a primary\nindication to undergo transcatheter valve\ninterventions and coronary artery stenosis ≥70% in\nproximal segments of main vessels.135–137 |  | IIb | B | ",
          "rows": 5,
          "cols": 5
        },
        {
          "title": "Table on page 23",
          "page": 23,
          "content": "Recommendations |  | Classa | Levelb | \nAnticoagulation |  |  |  | \nDOACs are recommended for stroke prevention in\npreference to VKAs in patients with AF and AS, AR,\nor MR who are eligible for OAC.156–159,164 |  | I | A | \nThe use of DOACs is not recommended in patients\nwith AF and rheumatic MS with an\nMVA ≤2.0 cm2.165 |  | III | B | \n | Surgical interventions |  |  | \nConcomitant surgical ablation is recommended in\npatients undergoing MV surgery with AF suitable for a\nrhythm control strategy to prevent symptoms and\nrecurrence of AF, according to an experienced team of\nelectrophysiologists and arrhythmia surgeons.166–173 |  | I | A | \nSurgical closure of the LA appendage is\nrecommended as an adjunct to OAC in patients with\nAF undergoing valve surgery to prevent\ncardioembolic stroke and systemic\nthromboembolism.160–162 |  | I | B | \nConcomitant surgical ablation should be considered\nin patients undergoing non-MV surgery with AF\nsuitable for a rhythm control strategy to prevent\nsymptoms and recurrence of AF, according to an\nexperienced team of electrophysiologists and\narrhythmia surgeons.167,169,174,175 |  | IIa | B | ",
          "rows": 8,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "intervention",
        "ct",
        "echo",
        "moderate",
        "asymptomatic",
        "valvular",
        "catheterization",
        "associated",
        "management",
        "surgery",
        "risk",
        "severe",
        "symptomatic",
        "heart",
        "disease",
        "conditions",
        "treatment"
      ]
    },
    {
      "number": "8",
      "title": "7. Aortic regurgitation",
      "start_page": 24,
      "end_page": 28,
      "content": "Radiotherapy may lead to aortic and/or valvular calcification, CAD of \nproximal segments, restrictive cardiomyopathy, pericardial adhesions \nand calcifications with constriction, restrictive lung disease, chest wall \nscarring, and impaired wound healing, especially in patients who under-\nwent radiation by means of older techniques (>20 years ago). The above \nfactors complicate any surgical approach and increase the operative risk, \nwhich is underestimated by traditional risk scores.179–181 TAVI is pro-\nposed as an alternative for patients presenting with radiation-induced \nAS in the 2022 ESC Guidelines on cardio-oncology182 based on favourable, \nbut limited, observational data,183,184 because this category of patients \nhas been excluded from RCTs.183,184 Furthermore, M-TEER in patients \npresenting with radiation-induced MV disease with MR is often limited \nby thickened leaflets with restricted movement and subsequent risk of \niatrogenic stenosis. \nIn patients with active or stable cancer and severe AS, both TAVI and \nSAVR can be considered based on life expectancy, age, prognosis, and \ndisability following cancer treatment, with a trend towards more TAVI \nutilization.185 TAVI procedural complication rates appear similar com-\npared with those of control subjects without cancer.186 To avoid futil-\nity, treatment decisions discussed by the Heart Team should involve the \ntreating oncologists.5,182 \n6.4. Prophylaxis of rheumatic fever \nRheumatic heart disease remains the most common cause of death \nfrom VHD worldwide.187 Prevention should preferentially target the \nfirst occurrence of acute rheumatic fever. Correct diagnosis and early \nantibiotic treatment of group A Streptococcus throat or skin infection \nis key for primary prevention. Large-scale screening combined with \nprophylaxis in children or adolescents with latent RHD appears to be \nan effective strategy to reduce the risk of disease progression and \nRHD prevalence.188–190 In patients with established RHD, secondary \nlong-term prophylaxis with benzathine benzyl penicillin 1.2 million \ninternational units (IU) every 3–4 weeks over 10 years is recom-\nmended to prevent recurrent episodes, especially in children and ado-\nlescents. Long-term prophylaxis into adulthood should be considered \nin high-risk patients according to the severity of VHD and exposure \nto group A Streptococcus.191,192 \n6.5. Cardiogenic shock and acute heart \nfailure \nAcute presentation or decompensation of VHD can result in cardio-\ngenic shock due to rapid haemodynamic deterioration and altered car-\ndiac function. Alternatively, pre-existing VHD can be a bystander of an \nacute cardiovascular condition further exacerbating circulatory impair-\nment until the occurrence of cardiogenic shock. In this setting, assess-\nment of the severity of VHD, as well as its contribution to acute HF, \nmay be difficult. Evidence concerning acute VHD management in this \ncontext is scarce and only exists for the MV and AV.193,194 \nHospital admission for acute decompensated AS is a frequent prob-\nlem seen in up to 25% of AS hospitalizations.195,196 However, only a mi-\nnority of these patients (1.6%–3.2%) present with cardiogenic \nshock.197,198 While intensive care treatment remains the cornerstone \nof haemodynamic stabilization and support, an intervention should be \nconsidered early, because it represents the only way to reverse pro-\ngressive organ dysfunction due to low cardiac output. Balloon aortic \nvalvuloplasty has been used in this context in the past, but has been \nlargely replaced by TAVI in recent years, due to the high risk of severe \nAR and mortality in the acute setting.199–201 Several large observational \nstudies have established the feasibility of TAVI in patients with \ncardiogenic shock with similar device success, even if LVEF is low, al-\nthough 30-day mortality remains higher (13%–19%) compared with \nroutine TAVI.194,197,198 Surgery represents the preferred treatment \nin patients with acute AR, while TAVI has only been described in indi-\nvidual cases or patients with a failed surgical valve (valve-in-valve). Fast \npacing over a temporary pacemaker lead shortens the diastole and may \ntemporarily improve haemodynamics until the intervention.5,8 \nExcept for papillary muscle rupture, acute PMR rarely leads to car-\ndiogenic shock and may be best treated by surgical valve repair or re-\nplacement. In contrast, increasing evidence supports the use of \nM-TEER in patients with acute ventricular SMR, particularly following \nacute myocardial infarction, due to lower mortality compared with sur-\ngery or medical treatment in propensity-matched analyses.194,202,203 \nThis strategy might also be helpful to facilitate weaning from mechanical \ncirculatory support. \n6.6. Palliative care \nIn some patients with advanced VHD not qualifying for surgical or \ntranscatheter therapies, medical HF treatment remains the only, and \nsometimes best, available option. These patients usually present late, \nhave extensive cardiac damage, develop terminal HF during the natural \nevolution of VHD, and are ineligible for mechanical circulatory support \nor heart transplantation (HTx). Early implementation of expert multi-\ndisciplinary palliative and end-of-life care, with the support of HF spe-\ncialists,204–206 reduces the number of hospitalizations and improves \nquality of life and symptom burden, in particular dyspnoea, pain, and \nanxiety.207 Continuous co-ordination between all involved subspecial-\nties, and transparent communication with the patient and their rela-\ntives, are key to ensure high quality of care. \n7. Aortic regurgitation \n7.1. Prevalence and aetiology \nChronic AR is mainly due to intrinsic abnormalities of the AV cusps and/ \nor secondary to progressive dilatation of the aortic root and/or ascend-\ning aorta. In high-income countries, degenerative changes are the lead-\ning cause of AR, while RHD is more frequent in middle- and \nlow-income countries.12 Acute presentations are usually related to in-\nfective endocarditis or extension of aortic dissection into the aortic \nroot. Chronic pure severe AR is more frequent in men and is associated \nwith BAV and concomitant dilatation of the aorta in more than one-half \nof cases.208 \n7.2. Evaluation \nDuring stepwise AR evaluation, the following aspects should be ad-\ndressed: the severity of AR, its mechanism, and aetiology; the haemo-\ndynamic impact on LV function and pulmonary pressure; and \nevaluation of the ascending aorta. While echocardiography is the first- \nline modality, CMR and CCT are more accurate for the measurement \nof specific parameters (Figure 4). The results of the evaluation need to \ntake into consideration the haemodynamic condition of the patient, \nparticularly the blood pressure (BP), since high pressures can lead to \noverestimation of the regurgitant volume (RVol). \nAssessment of AR severity with TTE follows an integrative approach \nconsidering qualitative, semi-quantitative, and quantitative parameters, \nbut remains challenging.45 Consequences of AR on LV size and function \nmust be carefully assessed. Cut-offs for intervention are mostly \nbased on two-dimensional (2D) echocardiographic measurements. \nHowever, 3D echocardiography and CMR allow more accurate  \n4658                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nevaluation of LV volumes and LVEF than 2D echocardiography, and are \nuseful in borderline cases (Figure 4).45,209 Strain imaging can be helpful in \nidentifying subclinical LV dysfunction209–211 and can therefore influence \nthe optimal timing of intervention. Reduced longitudinal strain and con-\ntractile reserve at stress echocardiography,212 elevated biomarkers \n(BNP),213,214 and the presence of myocardial fibrosis detected by \nCMR need to be integrated in the decision-making process, even if \nnot entirely validated yet.209 \nGiven its close relationship with AV function, accurate measure-\nments of the aortic diameter are required at all levels: the annulus, \nsinuses of Valsalva, sinotubular junction, and ascending aorta.8,215,216 \nThe largest diameter is used to indicate the specific aortic pheno-\ntype: root phenotype, ascending phenotypes, and extended or \nmixed forms (see Supplementary data online, Figure S1).8 The mech-\nanism of AR and aortic diameters determine suitability for AV spar-\ning or repair.217,218 \n\u001f\u001e\u001d\u001c\u001b\u001a\u0019\u0018\u0017\u0016\u0019\u0018\u0016\u0015\u0017\u001a\u001c\u001b\u0014\u0013\u001c\u0018\u001c\u0012\u0011\n\u0010\u0018\u0019\u000f\u0018\u0017\u000e\r\f\u0014\n\u000b\u0019\u001b\u0012\u0015\u0017\u000e\u001c\u0019\u0014\n\u0019\n\u000f\u001c\u001d\u0017\t\u0015\b\u0015\u000e\n\u0007\r\f\u0014\u0017\u0014\u001b\u001c\u0018\u0019\u0014\f\u0015\n\u0007\r\f\u0014\u0017\u001b\u0015\n\u001b\u0019\u000e\n\u000f\u001c\u001d\n\u0007\r\f\u0014\u0017\u0014\u0015\u001b\b\u001c\u001b\u0019\n\u000f\u001c\u001d\n\u0006\u0010\u0017\u0017\u0005\u0004\u0003\u0002\u0017\u0001\u0007\u0006\n\u000b\u000f\u0019\n\u000b\u000f\u0019\n\u000b\u0010\u0019\n\u001f\u001c\u001b\n\u000f\u000e\u0017\t\u000f\u0018\u0019\n\u0019\n\u000f\u001c\u001d\u0017\n \u000f\n\u0013\u0017\u000e\r\f\u0014\n\u001a\u0019\u0018\u000e\u001c\u0019\u0014\n\u0019\n\u000f\u001c\u001d\n\u001f\f\f\u0015\f\f\u001a\u0015\u001d\n\u0017\u001c\b\u0017\u001f\u0006\n\u0007\u0006\n\u0007\u0007­\n\u0007\u001b\u000f\n\u0015\u001b\u000f\u0019\u0017\b\u001c\u001b\u0017\n\f\u0015\u0016\u0015\u001b\u0015\u0017\u001f\u0006\n\u000b\u0017\t\u0019\u001a\u0019\u0012\u0015\n\u0015\u000e\u0013\u0019\u001d\u000f\f\u001a\n\u0015\u001d\u0019\u0017\u000e\u001c\u001d\n\u001b\u0019\u000e\n\u0019\u0017\u0005\u0017\u001a\u001a\n­\u0017\u0003\u0003\u0017\u001a\f\n\u000b\u0019\u001b\u0012\u0015\u0017\u000e\u0015\u001d\n\u001b\u0019\u0018\u0017\u0015\n\u0017\u0001≥\u0002\u0017\u001c\b\u0017\u000b­\u0017\t\u000f\u0019\u001a\u0015\n\u0015\u001b\n\u001c\u0018\u001c\t\u000f\u0019\f\n\u001c\u0018\u000f\u000e\u0017\u001c \u0017\u001b\u0015\u0016\u0015\u001b\f\u0019\u0018\u0017\u000f\u001d\u0017\t\u0015\f\u000e\u0015\u001d\t\u000f\u001d\u0012\n\u0019\u001c\u001b\n\u0019\u0017\u0001\u0017≥\u0003\u0017\u000e\u001a\f\n\r\u0019\u0018\u000f\n\u0019\n\u000f\u0016\u0015\n\u0015\u001a\u000f\r\u0019\u001d\n\u000f\n\u0019\n\u000f\u0016\u0015\n\r\u0019\u001d\n\u000f\n\u0019\n\u000f\u0016\u0015\n\u0006\u001f\u0017≥\u0003\u0017\u001a\u001a\n\u0006\u001c\u0018\u0017\u0017≥\u0003\u0017\u001a\u000b\u001e\u0015\u0019\n\u0006\u0010\u0017>\u0003\u0002\u0017\u0001\u0015\u000e\u0013\u001c\nFigure 4 Imaging assessment of patients with aortic regurgitation. AR, aortic regurgitation; CCT, cardiac computed tomography; CMR, cardiac mag-\nnetic resonance; EDV, end-diastolic velocity; EROA, effective regurgitant orifice area; LV, left ventricle/left ventricular; LVEF, left ventricular ejection \nfraction; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic volume indexed to body sur-\nface area; LVOT, left ventricular outflow tract; PHT, pressure half-time; RF, regurgitant fraction; RVol; regurgitant volume. aSee Recommendation Table 3 \nfor specific cut-offs.   \nESC Guidelines                                                                                                                                                                                          4659 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nThe morphology of the AV represents a critical aspect in the diagno-\nsis and treatment of AR. Pure AR in the context of BAV uncommonly \nmanifests with normal aortic diameters, being more often associated \nwith a dilated ascending aorta and/or root. It is important to define \nthe valve phenotype to determine the repair probability and long-term \nresult of AV repair or AV-sparing procedures. The degree of symmetry \nis an important predictor of BAV reparability with better long-term re-\nsults in more symmetric phenotypes.219–221 \n7.3. Medical therapy \nMedical therapy, especially angiotensin-converting enzyme-inhibitors \n(ACE-Is) or dihydropyridine calcium channel blockers, may provide \nsymptomatic improvement in individuals with chronic severe AR for \nwhom surgery is not feasible or contraindicated. The value of ACE-Is \nor dihydropyridines in delaying surgery in the presence of moderate \nor severe AR in asymptomatic patients has not been established, and \ntheir use is not recommended for this indication. The use of beta- \nblockers increases the length of the diastole and therefore the RVol, \nand should be used with caution if indicated for another reason. \nHowever, beta-blockers can be used along with ACE-Is or angiotensin \nreceptor blockers (ARBs) after surgery, if indicated (systolic HF or \nheart rate control).222,223 \n7.4. Indications for intervention \nAcute severe AR usually requires immediate surgery depending on the \naetiology, such as infective endocarditis or spontaneous, traumatic, \nor iatrogenic aortic dissection.5,8 Surgery for the treatment of chronic \nsevere AR is indicated depending on symptoms and/or the effects of \nthe RVol on LV size and function (see Recommendation Table 3 and  \nFigure 5). The presence of associated aortic dilatation dictates surgery, \nirrespective of AR severity. When the patient is symptomatic and AR \nsevere, surgery is recommended unless the anticipated surgical risk is \nprohibitive.224–228 Concomitant surgical treatment of severe AR \nis also recommended, irrespective of symptoms, in patients requiring \nCABG, ascending aorta surgery, or any other cardiac surgical \nprocedures.229,230 \nFor the asymptomatic patient with severe AR, indications for \nsurgery are based on the degree of functional impairment of the \nLV [LVEF ≤50%, left ventricular end-systolic diameter (LVESD)  \n>50 mm, or left ventricular end-systolic diameter indexed to body sur-\nface area (BSA) (LVESDi) >25 mm/m2, especially in those with small \nBSA (BSA <1.68 m2) and elderly patients with low ventricular compli-\nance].226,228,231–234 If surgery is deemed low risk, there is observational \nevidence from echocardiographic studies that early intervention might \nbe beneficial for long-term prognosis when LVEF is ≤55%, LVESDi is \n>22 mm/m2, and/or left ventricular end-systolic volume indexed to \nBSA (LVESVi) is >45 mL/m2.235–239 A volumetric cut-off value of \nLVESVi ≥43 mL/m2 using CMR was recently proposed to guide the \nmanagement of asymptomatic patients240,241 and appears to have bet-\nter predictive value than LV diameter.242 Surgery may also be discussed \nin selected low-risk asymptomatic patients with significant LV dilatation \n(left ventricular end-diastolic diameter >65 mm) and progressive in-\ncrease of LV diameters and/or decrease of LVEF during follow-up. \nExercise testing should be performed, when feasible, in patients with \nsevere AR who do not report symptoms and do not meet criteria \nfor surgery.212 \nAV replacement is still the standard surgical approach in most AR \ncases (see Section 14.1 regarding prosthesis type considerations). \nHowever, owing to a better understanding of the pathophysiology of \nthe aortic root (see Supplementary data online, Figure S1) paralleled \nwith favourable long-term results, valve-sparing aortic root replace-\nment (VSARR) and AV repair are increasingly performed in centres \nwith appropriate expertise (Figure 5).243–255 In patients with root en-\nlargement and good tissue quality (i.e. pliable AV cusps with normal mo-\ntion), a valve-sparing procedure has been demonstrated to be superior \nto the use of a composite valve graft (Bentall procedure) in terms of \nlong-term mortality and overall morbidity (thromboembolism and \nendocarditis, with similar need for reoperation),250–253,255–257 and \nshould be therefore favoured by experienced centres, in particular \nin patients with an estimated long life expectancy.258 Valve preserva-\ntion or valve repair should also be considered for patients with BAV \nbased on age, anatomical presentation, and centre experience \n(Figure 5).220,245,246,259 \nWhen performed by experienced surgeons in well-selected young \nindividuals, pulmonary autograft implantation (Ross operation) may \nalso be a good alternative to prosthetic valve replacement.260–263 \nTAVI may be considered at experienced centres for selected patients \nwith AR who are ineligible for surgery. The use of non-dedicated trans-\ncatheter valves for this indication is off-label and associated with an in-\ncreased risk of valve malpositioning and residual AR, with consecutively \nhigher rates of second valve implantation (about 10%) or surgical con-\nversion, as compared with TAVI in AS.264–268 Dedicated devices appear \nto minimize the risk of valve migration and residual AR in selected pa-\ntients, but are associated with a high new permanent pacemaker im-\nplantation rate (24%).267–269 \nAortic dilatation is closely linked to AR. Dedicated ESC Guidelines \ngive guidance regarding the evaluation and management of aortic \nroot and ascending aortic dilatation.8 The aortic phenotype (see  \nSupplementary data online, Figure S1), degree and rate of progression \nof aortic dilatation, and the underlying aetiology all affect timing of sur-\ngery, with the main indication being maximum aortic diameter.270–272 \nDilation of the aortic root, which typically occurs in Marfan syndrome \nand other patients with connective tissue disease, has a worse progno-\nsis compared with isolated dilatation of the ascending aorta and re-\nquires closer surveillance.270–272 Surgery is recommended in all \npatients with a maximal aortic root or ascending aneurysm diameter \nof ≥55 mm. In the presence of additional risk factors, a threshold of \n50 mm may be considered for selected low-risk patients treated at ex-\nperienced centres.8 If the patient has an established indication for AV \nsurgery (due to AR or AS), concomitant surgery of the aortic root \nor the ascending aorta should be considered at a diameter of \n≥45 mm. This threshold has been more clearly demonstrated in pa-\ntients with BAV and should also be based on the patient’s height273 \nor specific intraoperative findings, such as the shape and thickness of \nthe aortic wall. \n7.5. Follow-up \nA multimodality imaging approach45,274 and biomarkers like BNP213,214 \nmight help identify patients at increased risk of LV damage early \nand guide the appropriate timing of intervention. Yearly follow-up is re-\ncommended in asymptomatic patients with severe AR. Closer follow- \nup (3–6 months) is recommended for those approaching thresholds \nfor surgery, or showing a progressive dilatation of the LV or decrease \nof LVEF. Cardiac magnetic resonance can be especially useful in such \na setting. Patients with moderate AR should be followed on a yearly ba-\nsis, with echocardiography performed every 2 years. \nWhen a dilated ascending aorta is initially diagnosed by TTE, a multi-\nslice electrocardiographic-triggered CCT/CMR scan is recommended  \n4660                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nPatient with AR \nSigniﬁcant aortic root enlargementa \nSevere AR\nSigniﬁcant AR\nVSARR\nBentall\nVSARR\nand AV repair \nSymptoms\nAV surgery \n(Class IIb) \nFollow-up\nAV surgery \n(Class I)\nTAVI\n(Class IIb)\nSAVR\nAV repair\n(Class IIa)\nEligible for surgeryb \nLVEF ≤50% or\nLVESD >50 mm\nor LVESDi >25 mm/m2\nLVEF ≤55% or\nLVESDi >22 mm/m2\nor LVESVi >45 mL/m2\nGood tissue quality\nTeam expertise\nYoung patient\nGood tissue quality\nTeam expertise\nYoung patient\nFigure 5 Management of patients with aortic regurgitation. AR, aortic regurgitation; AV, aortic valve; LVEF, left ventricular ejection fraction; LVESD, \nleft ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body surface area; LVESVi, left ventricular end-systolic \nvolume indexed to body surface area; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve replacement; VSARR, valve-sparing aor-\ntic root replacement. aIndications for surgery on the root/ascending aorta are described in the 2024 ESC Guidelines for the management of peripheral \narterial and aortic diseases.8 bConcomitant replacement of the aortic root or ascending aorta should be considered if the maximal diameter is \n≥45 mm and the predicted surgical risk is low.   \nESC Guidelines                                                                                                                                                                                          4661 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nto confirm maximal diameter, rule out isolated single sinus dilatation, \nand provide a baseline reference. When the baseline aortic diameter \nis >45 mm, a second TTE examination is recommended at 6 months \nto confirm the stability of the finding, followed by serial examinations \non a yearly basis thereafter.275 Any increase of >3 mm should be vali-\ndated by CT angiography/CMR and compared with baseline data.275 \nAfter repair of the ascending aorta, patients with Marfan syndrome \nand other connective tissue diseases remain at risk for dissection of un-\ntreated portions of the aorta, and require lifelong regular multidisciplin-\nary follow-up at an expert centre.8 \n7.6. Special patient populations \nPatients with concomitant VHD and those with AS combined with AR \nare discussed in Section 13.3.3. In patients with moderate AR and indica-\ntion for CABG or MV surgery, the decision to treat the AV should be \ndiscussed by the Heart Team based on the aetiology of AR and other \nclinical factors, like the estimated life expectancy and the operative risk, \nas data show that progression of moderate AR may be very slow.276 \nThe presence of aortic dilation and AR in asymptomatic patients \nposes the problem of limiting the level of physical activity, but consist-\nent data are lacking. Current recommendations for participation in \ncompetitive sport are restrictive, especially regarding isometric exer-\ncise in patients with connective tissue disease,277 while a more liberal \napproach is likely to be appropriate in other patients. \nGiven the familial risk of thoracic aortic aneurysms, screening with \nappropriate imaging studies and testing for genetic abnormalities in \nfirst-degree relatives is indicated in patients with connective tissue dis-\nease.278 Since aortic dilation is present in ∼10% of first-degree relatives \nof patients with a BAV, it is also considered appropriate to encourage \nechocardiographic screening in this specific population.275,279 \n8. Aortic stenosis \n8.1. Prevalence and aetiology \nEven if AS is the most common primary valve lesion referred for inter-\nvention in Europe and North America,12 underdiagnosis and under-\ntreatment remain relevant concerns.10 Degenerative pathogenesis \nwith cusps calcification is most common in developed countries and \nprevalence is rising rapidly because of the ageing population.11,12,187 \nBAVs, or more rarely unicuspid AVs, are prone to earlier degeneration, \nconstitute the dominant valve morphology in younger patients requir-\ning AV replacement, and are frequently associated with dilatation of the \naortic root or ascending aorta.280,281 In low- and middle-income coun-\ntries, rheumatic aetiology remains frequent and AS usually presents \ncombined with rheumatic MV disease.282 \n8.2. Evaluation \n8.2.1. Echocardiography and cardiac computed \ntomography \nAortic stenosis is a disease slowly evolving from mild to severe valve \nobstruction as a consequence of increasing valve fibrosis and calcifi-\ncation, although progression accelerates as haemodynamic severity \nincreases.283 \nEchocardiography is key to confirm the diagnosis and allows compre-\nhensive assessment of the anatomy and severity of stenosis. Evaluation \nof the haemodynamic consequences on cardiac function and geometry, \nand the detection of aortic pathology or concomitant valve disease, \nprovide important prognostic information that may influence manage-\nment.284 Staging of extravalvular damage has been proposed,53 but \nit may be difficult to attribute other cardiac abnormalities to AS itself, \nbecause comorbidities are frequent in patients with AS and the \nobserved damage may not occur in the expected chronological se-\nquence. However, the detection of concomitant cardiac conditions \n[e.g. HF with preserved EF (HFpEF), amyloidosis, or hypertrophic \nRecommendation Table 3 — Recommendations on in-\ndications for intervention in severe aortic regurgitation \n(see also Supplementary data online, Evidence Tables 4–8) \nRecommendations \nClassa \nLevelb \nSevere aortic regurgitation  \nAV surgery is recommended in symptomatic patients \nwith severe AR regardless of LV function.224–228 \nI \nB \nAV surgery is recommended in asymptomatic \npatients with severe AR and LVESD >50 mm or \nLVESDi >25 mm/m2 [especially in patients with small \nbody size (BSA <1.68 m2)] or resting \nLVEF ≤50%.226,228,231,233,234 \nI \nB \nAV surgery is recommended in symptomatic and \nasymptomatic patients with severe AR undergoing \nCABG or surgery of the ascending aorta. \nI \nC \nAV repair should be considered in selected patients \nwith severe AR at experienced centres, when \ndurable results are expected.220,245,246,259 \nIIa \nB \nAV surgery may be considered in asymptomatic patients \nwith severe AR and LVESDi  \n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2 \n[especially in patients with small body size (BSA  \n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical \nrisk is low. \nIIb \nB                                                                                                   \nContinued \nTAVI may be considered for the treatment of severe \nAR in symptomatic patients ineligible for surgery \naccording to the Heart Team, if the anatomy is \nsuitable.264,265,268,269 \nIIb \nB \nConcomitant surgery of the ascending aorta \nValve-sparing aortic root replacement is \nrecommended in young patients with aortic root \ndilatation at experienced centres, when durable \nresults are expected.247,250–253,255 \nI \nB \nWhen AV surgery is indicated and the predicted \nsurgical risk is low, replacement of the aortic root or \nascending aorta should be considered if the maximal \ndiameter is ≥45 mm.d \nIIa \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AV, aortic valve; BSA, body surface area; CABG, coronary artery \nbypass grafting; CMR, cardiac magnetic resonance; LV, left ventricle/left ventricular; LVEF, \nleft ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left \nventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic \nvolume indexed to BSA; TAVI, transcatheter aortic valve implantation. \naClass of recommendation. \nbLevel of evidence. \ncUsing echocardiography or CMR. \ndConsidering age, BSA, the aetiology of the valvular disease, the presence of a bicuspid AV, \nand the intraoperative shape and thickness of the ascending aorta.   \n4662                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "TAVI may be considered for the treatment of severe\nAR in symptomatic patients ineligible for surgery\naccording to the Heart Team, if the anatomy is\nsuitable.264,265,268,269 |  | IIb | B | \n | Concomitant surgery of the ascending aorta |  |  | \nValve-sparing aortic root replacement is\nrecommended in young patients with aortic root\ndilatation at experienced centres, when durable\nresults are expected.247,250–253,255 |  | I | B | \nWhen AV surgery is indicated and the predicted\nsurgical risk is low, replacement of the aortic root or\nascending aorta should be considered if the maximal\ndiameter is ≥45 mm.d |  | IIa | C | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "Recommendations | Classa | Levelb\nSevere aortic regurgitation |  | \nAV surgery is recommended in symptomatic patients\nwith severe AR regardless of LV function.224–228 | I | B\nAV surgery is recommended in asymptomatic\npatients with severe AR and LVESD >50 mm or\nLVESDi >25 mm/m2 [especially in patients with small\nbody size (BSA <1.68 m2)] or resting\nLVEF ≤50%.226,228,231,233,234 | I | B\nAV surgery is recommended in symptomatic and\nasymptomatic patients with severe AR undergoing\nCABG or surgery of the ascending aorta. | I | C\nAV repair should be considered in selected patients\nwith severe AR at experienced centres, when\ndurable results are expected.220,245,246,259 | IIa | B\nAV surgery may be considered in asymptomatic patients\nwith severe AR and LVESDi\n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2\n[especially in patients with small body size (BSA\n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical\nrisk is low. | IIb | B",
          "rows": 7,
          "cols": 3
        }
      ],
      "keywords": [
        "cardiomyopathy",
        "ct",
        "prognosis",
        "aortic",
        "risk",
        "tavi",
        "severe",
        "savr",
        "treatment",
        "aortic regurgitation",
        "diagnosis",
        "regurgitation"
      ]
    },
    {
      "number": "9",
      "title": "8. Aortic stenosis",
      "start_page": 28,
      "end_page": 37,
      "content": "to confirm maximal diameter, rule out isolated single sinus dilatation, \nand provide a baseline reference. When the baseline aortic diameter \nis >45 mm, a second TTE examination is recommended at 6 months \nto confirm the stability of the finding, followed by serial examinations \non a yearly basis thereafter.275 Any increase of >3 mm should be vali-\ndated by CT angiography/CMR and compared with baseline data.275 \nAfter repair of the ascending aorta, patients with Marfan syndrome \nand other connective tissue diseases remain at risk for dissection of un-\ntreated portions of the aorta, and require lifelong regular multidisciplin-\nary follow-up at an expert centre.8 \n7.6. Special patient populations \nPatients with concomitant VHD and those with AS combined with AR \nare discussed in Section 13.3.3. In patients with moderate AR and indica-\ntion for CABG or MV surgery, the decision to treat the AV should be \ndiscussed by the Heart Team based on the aetiology of AR and other \nclinical factors, like the estimated life expectancy and the operative risk, \nas data show that progression of moderate AR may be very slow.276 \nThe presence of aortic dilation and AR in asymptomatic patients \nposes the problem of limiting the level of physical activity, but consist-\nent data are lacking. Current recommendations for participation in \ncompetitive sport are restrictive, especially regarding isometric exer-\ncise in patients with connective tissue disease,277 while a more liberal \napproach is likely to be appropriate in other patients. \nGiven the familial risk of thoracic aortic aneurysms, screening with \nappropriate imaging studies and testing for genetic abnormalities in \nfirst-degree relatives is indicated in patients with connective tissue dis-\nease.278 Since aortic dilation is present in ∼10% of first-degree relatives \nof patients with a BAV, it is also considered appropriate to encourage \nechocardiographic screening in this specific population.275,279 \n8. Aortic stenosis \n8.1. Prevalence and aetiology \nEven if AS is the most common primary valve lesion referred for inter-\nvention in Europe and North America,12 underdiagnosis and under-\ntreatment remain relevant concerns.10 Degenerative pathogenesis \nwith cusps calcification is most common in developed countries and \nprevalence is rising rapidly because of the ageing population.11,12,187 \nBAVs, or more rarely unicuspid AVs, are prone to earlier degeneration, \nconstitute the dominant valve morphology in younger patients requir-\ning AV replacement, and are frequently associated with dilatation of the \naortic root or ascending aorta.280,281 In low- and middle-income coun-\ntries, rheumatic aetiology remains frequent and AS usually presents \ncombined with rheumatic MV disease.282 \n8.2. Evaluation \n8.2.1. Echocardiography and cardiac computed \ntomography \nAortic stenosis is a disease slowly evolving from mild to severe valve \nobstruction as a consequence of increasing valve fibrosis and calcifi-\ncation, although progression accelerates as haemodynamic severity \nincreases.283 \nEchocardiography is key to confirm the diagnosis and allows compre-\nhensive assessment of the anatomy and severity of stenosis. Evaluation \nof the haemodynamic consequences on cardiac function and geometry, \nand the detection of aortic pathology or concomitant valve disease, \nprovide important prognostic information that may influence manage-\nment.284 Staging of extravalvular damage has been proposed,53 but \nit may be difficult to attribute other cardiac abnormalities to AS itself, \nbecause comorbidities are frequent in patients with AS and the \nobserved damage may not occur in the expected chronological se-\nquence. However, the detection of concomitant cardiac conditions \n[e.g. HF with preserved EF (HFpEF), amyloidosis, or hypertrophic \nRecommendation Table 3 — Recommendations on in-\ndications for intervention in severe aortic regurgitation \n(see also Supplementary data online, Evidence Tables 4–8) \nRecommendations \nClassa \nLevelb \nSevere aortic regurgitation  \nAV surgery is recommended in symptomatic patients \nwith severe AR regardless of LV function.224–228 \nI \nB \nAV surgery is recommended in asymptomatic \npatients with severe AR and LVESD >50 mm or \nLVESDi >25 mm/m2 [especially in patients with small \nbody size (BSA <1.68 m2)] or resting \nLVEF ≤50%.226,228,231,233,234 \nI \nB \nAV surgery is recommended in symptomatic and \nasymptomatic patients with severe AR undergoing \nCABG or surgery of the ascending aorta. \nI \nC \nAV repair should be considered in selected patients \nwith severe AR at experienced centres, when \ndurable results are expected.220,245,246,259 \nIIa \nB \nAV surgery may be considered in asymptomatic patients \nwith severe AR and LVESDi  \n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2 \n[especially in patients with small body size (BSA  \n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical \nrisk is low. \nIIb \nB                                                                                                   \nContinued \nTAVI may be considered for the treatment of severe \nAR in symptomatic patients ineligible for surgery \naccording to the Heart Team, if the anatomy is \nsuitable.264,265,268,269 \nIIb \nB \nConcomitant surgery of the ascending aorta \nValve-sparing aortic root replacement is \nrecommended in young patients with aortic root \ndilatation at experienced centres, when durable \nresults are expected.247,250–253,255 \nI \nB \nWhen AV surgery is indicated and the predicted \nsurgical risk is low, replacement of the aortic root or \nascending aorta should be considered if the maximal \ndiameter is ≥45 mm.d \nIIa \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AV, aortic valve; BSA, body surface area; CABG, coronary artery \nbypass grafting; CMR, cardiac magnetic resonance; LV, left ventricle/left ventricular; LVEF, \nleft ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left \nventricular end-systolic diameter indexed to BSA; LVESVi, left ventricular end-systolic \nvolume indexed to BSA; TAVI, transcatheter aortic valve implantation. \naClass of recommendation. \nbLevel of evidence. \ncUsing echocardiography or CMR. \ndConsidering age, BSA, the aetiology of the valvular disease, the presence of a bicuspid AV, \nand the intraoperative shape and thickness of the ascending aorta.   \n4662                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ncardiomyopathy] may help to optimize medical treatment before and \nafter valve intervention.285,286 \nCurrent European recommendations for the echocardiographic \ngrading of AS rely on measurement of the mean pressure gradient \n(most robust parameter), peak transvalvular velocity (Vmax), and effect-\nive AVA. Although AVA is theoretically the ideal parameter for asses-\nsing severity, there are numerous technical limitations associated with \nits calculation.284,287 \nAortic stenosis may be further categorized according to flow state \nbased on stroke volume index (SVi) when there is discordance between \nechocardiographic parameters (Figure 6). A threshold of 35 mL/m2 is \nconventionally accepted to discern low from normal flow, although \nsex-specific thresholds have been proposed.292  \nConcordant criteria: \n• High-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, AVA \n≤1 cm2 (or ≤0.6 cm2/m2)] is considered severe irrespective of LV \nfunction and flow conditions.  \nDiscordant criteria: \n• Low-flow, low-gradient AS with reduced LVEF  \n(mean gradient <40 mmHg, AVA ≤1 cm2, SVi ≤35 mL/m2, LVEF <50%). \n• Low-flow, low-gradient AS with preserved LVEF  \n(mean gradient <40 mmHg, AVA ≤1 cm2, SVi ≤35 mL/m2,  \nLVEF ≥50%). \n• Normal-flow, low-gradient AS with preserved EF  \n(mean gradient <40 mmHg, AVA ≤1 cm2, SVi >35 mL/m2,  \nLVEF ≥50%). \n• Discordant high-gradient AS (mean gradient ≥40 mmHg,  \nAVA >1 cm2).  \nPatients with discordant normal-flow, low-gradient AS usually have \nmoderate stenosis.293–295 Discordant high-gradient AS is considered \nsevere if not caused by a reversible high-flow status.296–298 \nIn patients with low-flow, low-gradient AS with reduced LVEF, dobu-\ntamine stress echocardiography (DSE) can help to discriminate be-\ntween pseudo-severe and true severe AS in the presence of flow \nreserve (increase in stroke volume of ≥20%).289,299 \nCardiac computed tomography calcium AV scoring is readily avail-\nable and provides important adjunctive information in patients with \nlow-flow, low-gradient AS because it correlates with haemodynamic \nseverity, progression, and clinical outcomes.300,301 Values of >2000 \nAgatston units (AU) in men and >1200 AU in women indicate severe \nAS with high sensitivity and specificity (∼85%).302,303 While higher \nthresholds (men >3000 AU, women >1600 AU) are very specific, se-\nvere AS becomes unlikely in patients with calcium AV scoring of \n<1600 AU in men and <800 AU in women.284,302,303 Cautious inter-\npretation is required in patients who can develop severe AS without \npronounced AV calcification such as in BAV, concomitant amyloidosis, \nand predominantly fibrotic stenosis associated with post-rheumatic, \nradiation-induced and inflammatory disease.304–308 \nIn low-flow, low gradient AS with reduced LVEF, CCT AV calcium \nscoring and DSE provide complementary information. If findings are \nequivocal, an integrated assessment considering all available clinical, \nmorphological, and haemodynamic factors is required. \n8.2.2. Additional diagnostic and prognostic \nparameters \nThe ratio of the LVOT to the AV Doppler jet velocity time integral \n(VTI, dimensionless index or velocity ratio) does not require \ncalculation of LVOT area and may assist evaluation when other para-\nmeters are equivocal (<0.25 suggests that severe AS is highly likely).309 \nAssessment of GLS can be useful for risk stratification310 and evalu-\nation of extravalvular cardiac damage.311,312 It provides additional infor-\nmation regarding LV function and a threshold of −15% may contribute \nto identifying patients with severe asymptomatic AS at increased risk of \nclinical deterioration or premature mortality.59 \nEstimated valvuloarterial impedance has been shown to be prognostic \nof adverse clinical outcomes before and after valve replacement.313–315 \nTransoesophageal echocardiography (TOE) allows morphological \nevaluation of the valve, planimetry of AVA and assessment of potential sub-\nvalvular obstruction (unless there is acoustic shadowing caused by calcifi-\ncation), and evaluation of concomitant valve disease, and can be of value for \nperi-procedural imaging in challenging clinical or anatomical scenarios.316 \nNatriuretic peptides can be used to arbitrate the sources of symp-\ntoms in patients with multiple potential causes and help to identify \nthose with high-risk asymptomatic AS who may benefit from early \nintervention.97,317 \nExercise testing can unmask symptoms and haemodynamic intolerance \n(fall in BP >20 mm Hg) and is recommended for risk stratification in \nasymptomatic patients with severe AS.102,318 Exercise echocardiography \nmay provide additional prognostic information by assessing the increase in \nmean pressure gradient and change in LV function.319 Cardiopulmonary \nexercise testing, eventually complemented by echocardiography, can \nhelp to uncover cardiac dysfunction in asymptomatic patients, discrimin-\nate cardiac from pulmonary limitation or deconditioning in patients with \nnon-specific symptoms, and inform risk stratification.105,106,320,321 \nCardiac magnetic resonance is used to identify altered global LV \ngeometry due to remodelling, as well as to quantify myocardial scarring \nand diffuse fibrosis, which are associated with the occurrence of ad-\nverse events.322–324 \nTransthyretin cardiac amyloidosis may coexist with AS in elderly pa-\ntients and the two conditions may causally interrelate.325 When transthyr-\netin cardiac amyloidosis is suspected, the presence of monoclonal protein \nin serum and urine should be excluded using immunofixation and quanti-\ntative determination of free light chains, and diagnosis ascertained by \nmeans of diphosphonate scintigraphy.326 Despite the limited long-term \nprognosis associated with cardiac transthyretin amyloidosis, patients \nwith concomitant severe AS usually benefit from valve intervention.327 \nLV catheterization is not recommended unless there are symptoms \nand signs of severe AS, and non-invasive investigations are inconclusive. \n8.2.3. Procedural planning \nCardiac computed tomography is key to determining suitability for \nTAVI and planning the procedure. It is the preferred imaging tool to as-\nsess AV anatomy including annulus size, dimensions of the aortic root \nand ascending aorta, the extent and distribution of valve and LVOT cal-\ncification, the distance of coronary ostia from the annular plane, optimal \nfluoroscopic projections for transcatheter valve deployment, and the \nfeasibility of vascular access.49,328,329 \nTransoesophageal echocardiography (TOE), which is more operator- \ndependent and does not allow assessment of coronary and peripheral \nvascular anatomy, or CMR may be considered when CCT is difficult to in-\nterpret or relatively contraindicated (e.g. in patients with renal failure).330,331 \n8.3. Medical therapy \nNo medical therapies have been shown to influence the natural \nhistory of AS to date. Neither statins, which demonstrated \nfavourable effects in pre-clinical studies,332–334 nor substances  \nESC Guidelines                                                                                                                                                                                          4663 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nPatient with suspected AS\nVmax ≥4 m/s and mean PG ≥40 mmHg\nAVA ≤1 cm2\n(AVAi ≤0.6 cm2/m2)\nAVA ≤1 cm2\n(AVAi ≤0.6 cm2/m2)\nNon-severe AS\nExclude measurement errorsa\nSVi ≤35 mL/m2\nReversible\nhigh ﬂowb\nLVEF ≥50%\nAVCS\n>1200 AU (female)\n>2000 AU (male)\nSevere AS\nSevere AS\nDSE with ﬂow reserved \nand AVA >1 cm2\nIntegrated\nassessmentf\nPseudo-severe AS\nNormal ﬂow\nlow-gradient AS\n(severe AS less likely)c\nReassess under\nnormal ﬂow\nDSE with ﬂow reserved and AVA ≤1 cm2\nand/ore \nAVCS >1200 AU (female) >2000 AU (male)\nFigure 6 Integrative imaging assessment of patients with aortic stenosis. AS, aortic stenosis; AU, Agatston units; AV, aortic valve; AVA, aortic valve \narea; AVAi; aortic valve area indexed for body surface area; AVCS, aortic valve calcium score; CCT, cardiac computed tomography; CT, computed \ntomography; DSE, dobutamine stress echocardiography; LVEF, left ventricular ejection fraction; LVOT, left ventricular outflow tract; MRI, magnetic \nresonance imaging; mean PG, mean pressure gradient; SVi, stroke volume indexed for BSA; TOE, transoesophageal echocardiography; TTE, transthor-\nacic echocardiography; Vmax, peak transvalvular velocity. aIn particular, verify LVOT diameter and multiwindow Doppler interrogation. bHigh flow may \nbe reversible (anaemia, hyperthyroidism, or arteriovenous fistulae). Upper limit of normal flow using pulsed Doppler: cardiac index 4.3 L/min/m2, SVi \n58 mL/m2.288 cAvailable evidence refers to patients with preserved LVEF. Check for bradycardia or uncontrolled hypertension, which may lead to pro-\nlonged ejection time and reduced flow rate. Depending on symptoms, integrated assessment complemented by CCT AV calcium scoring may be pur-\nsued. dFlow reserve: ≥20% increase in stroke volume in response to low-dose dobutamine or if change in stroke volume of 10%–20%, calculate \nprojected AVA.289,290 eIf one test is not conclusive, complement diagnostics with the other test. fBased on clinical judgement (typical symptoms without \nother explanation), morphological valve changes, LV hypertrophy (in absence of coexistent hypertension), and consistent findings using different modes \nof assessment [TTE and TOE, invasive assessment, AV planimetry by CT or MRI (cut-off 1.2 cm2)]291.   \n4664                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ntargeting calcification pathways alter disease progression.335,336 \nCoexistent hypertension should be treated to avoid additional after-\nload, preferably using renin-angiotensin system blockers, although \ncareful titration is required to avoid symptomatic hypotension.337 \nIn patients with symptomatic severe AS and HF, initiation of medical \ntherapy or temporary improvement in symptoms should not delay \nintervention. Medication frequently requires re-adjustment following \nvalve intervention and preventive therapies should be implemented \naccording to current Guidelines.338 In patients with persisting HF \nand/or reduced LVEF, medical therapy should be introduced before \nand up-titrated after valve intervention according to the current HF \nGuidelines.339,340 \n8.4. Indication for intervention \n8.4.1. Symptomatic severe aortic stenosis \nSymptomatic severe AS has an unfavourable prognosis if left untreated, \nand early intervention is strongly recommended in all patients with an \nestimated life expectancy exceeding 1 year10 (Figure 7). \nIntervention is recommended in all eligible symptomatic patients \nwith high-gradient severe AS. However, management of patients with \nlow-gradient AS is more challenging: \n• Low-flow, low-gradient AS with reduced LVEF: reduced LV func-\ntion usually improves after intervention if it is predominantly \ncaused by excessive afterload.341–343 However, improvement is \nunlikely if the primary cause is fibrosis due to myocardial infarction \nor cardiomyopathy. Intervention is recommended when severe AS \nis confirmed by CCT (calcium scoring) or stress echocardiog-\nraphy,341 while patients with pseudo-severe AS should receive \nGDMT.339,344 Although the absence of flow reserve is associated \nwith increased surgical and long-term mortality, both modes of \nintervention improved LVEF and clinical outcomes in observational \nstudies.341,342,345–347 \n• Low-flow, low-gradient AS with preserved LVEF: outcomes are im-\nproved with intervention (either TAVI or SAVR) compared with \nmedical treatment alone in patients with low-flow, low-gradient AS \nand preserved LVEF.348,349 Intervention should therefore be consid-\nered in patients with symptoms after careful confirmation that AS is \nsevere. \n• Normal-flow, low-gradient AS with preserved LVEF: prognosis \nof these patients is similar to that of moderate AS. Unless \nmultimodality diagnostic evaluation clearly suggests severe \nAS, regular clinical and echocardiographic surveillance is \nrecommended.293,294,350  \n8.4.2. Asymptomatic severe aortic stenosis \nUp to 40% of patients with severe AS do not report symptoms at the \ntime of diagnosis.351,352 In roughly one-third of these, exercise testing \ncan uncover symptoms or reduced exercise capacity attributable to \nAS,102,103,318 and such patients should be treated as symptomatic. \nHowever, exercise testing is not always feasible because of frailty or im-\npaired mobility.353 Intervention is recommended in asymptomatic pa-\ntients with severe AS and an LVEF of <50% without another \ncause.14,102,318,319,354–360 For patients with severe high-gradient AS \nand no adverse prognostic features, close active clinical surveillance, \nso-called ‘watchful waiting’, has previously been the default manage-\nment strategy. However, four RCTs comparing early AV intervention \nwith clinical surveillance suggest that early intervention should be \nconsidered as an alternative in patients at low procedural risk.360–363 \nThis approach is reinforced if additional adverse prognostic features \n(very high Vmax,14,353,364 elevated natriuretic peptides,97,317,365,366 se-\nvere valve calcification,303,364 rapid Vmax progression,353,364 or LVEF \nof <55%14,354,356–359) are present. Restricted local resources (that \nmay impede close surveillance) or long waiting lists (that preclude \nprompt treatment when symptoms develop) are further arguments fa-\nvouring an early intervention. \nThe Evaluation of TAVR Compared to Surveillance for Patients with \nAsymptomatic Severe Aortic Stenosis (EARLY TAVR) trial360 rando-\nmized 901 patients to early TAVI or clinical surveillance and demonstrated \na reduction of 50% in the primary composite endpoint of all-cause mor-\ntality, stroke, or unplanned hospitalization for cardiovascular causes asso-\nciated with pre-emptive intervention.360 The result was driven by 26.2% \nof the patients in the clinical surveillance group who converted to TAVI \nwithin 6 months of randomization due to the development of symptoms \nor adverse prognostic factors. There was no significant difference in \nstrokes and all-cause mortality over 5-year follow-up. \nIn the Early Valve Replacement Guided by Biomarkers of LV \nDecompensation in Asymptomatic Patients with Severe AS \n(EVoLVeD) RCT, which included 224 asymptomatic patients with se-\nvere AS and myocardial fibrosis (late gadolinium enhancement on \nCMR), early valve intervention (with SAVR or TAVI) failed to reduce \nthe incidence of all-cause death or unplanned AS-related hospitalization \ncompared with clinical surveillance.361 However, the study was under-\npowered and the median time to intervention was prolonged to \n5 months in the experimental arm. \nTwo previous smaller trials compared early SAVR with clinical \nsurveillance. In the Randomized Comparison of Early Surgery vs \nConventional \nTreatment \nin \nVery \nSevere \nAortic \nStenosis \n(RECOVERY) trial (145 patients), there was a reduction in all-cause \nmortality following early SAVR over a mean follow-up of 6.2 years.362 \nIn the Aortic Valve Replacement Versus Conservative Treatment \nin Asymptomatic Severe Aortic Stenosis (AVATAR) trial (157 \npatients), a reduction in the composite primary endpoint was noted \nafter a mean follow-up of 2.5 years with a significant reduction in \nHF hospitalizations and mortality at long-term follow-up.363,367 \nLimitations of these surgical studies included their small sample sizes, \nenrolment of selected young populations at low surgical risk (mean \nages 64 and 67 years, respectively), and inclusion of patients with most-\nly very severe AS. \nA meta-analysis of the four RCTs showed that early intervention is \nassociated with a significant reduction in unplanned cardiovascular or \nHF hospitalization and stroke, but not all-cause or cardiovascular mor-\ntality. Limitations of this analysis include the heterogeneity of the \npooled trials and lack of granularity with respect to specific events ow-\ning to the study-level analysis.368 \nAdditional RCTs (NCT04204915 and NCT03972644) will further \ninform and refine the management of patients with severe asymptom-\natic AS. \n8.4.3. Moderate aortic stenosis \nSurgical intervention for moderate AS should only be performed in pa-\ntients undergoing CABG,369 surgery of the ascending aorta or other \nvalve disease (see Section 13). There is evidence of an association be-\ntween moderate AS and adverse outcomes in patients with and with-\nout HF with reduced EF (HFrEF),370–372 but it is unknown whether \nthis is causal or related to comorbidities. In an early terminated trial ran-\ndomizing 178 patients with moderate AS and HFrEF to TAVI or clinical \nsurveillance, no differences with respect to hard clinical endpoints were  \nESC Guidelines                                                                                                                                                                                          4665 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTAVI\n(Class I)\nSAVR\n(Class I)\nSymptomsb\nLVEF <50% without another cause\nPresence of one or more of the following:\n• High-gradient AS\n• Severe valve calciﬁcationc and Vmax progression ≥0.3 m/s/year\n• Elevated BNP or NT-proBNP levels attributable to ASd\n• LVEF <55% attributable to AS\n• Exercise test with sustained fall in BP >20 mmHg \nClose active surveillancee\nHeart Team evaluationf\n(Class I)\nLow procedural risk\nIntervention\n(Class IIa)\nSAVR or TAVI\n(Class I)\nPatients <70 years\nif surgical risk is low\nAll remaining\ncandidates for\na bioprosthesis\nPatients ≥70 years\nwith a tricuspid\naortic valve\nif anatomy is suitable \nPatients with severe ASa\nFigure 7 Management of patients with severe aortic stenosis. AS, aortic stenosis; AVCS, aortic valve calcium score; BNP, brain natriuretic peptide; BP, \nblood pressure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replace-\nment; TAVI, transcatheter aortic valve implantation; Vmax, peak transvalvular velocity. aIntegrative imaging assessment of AS (Figure 6). bConfirmed \nby a normal exercise test, if feasible. cAVCS >2000 in men, >1200 in women. dMore than three times age- and sex-corrected normal range. \neEducate patient and reassess at least every 6 months (or promptly if symptoms occur). fHeart Team assessment based upon individual patient factors \n(Figure 9; Recommendation Table 4). Dashed arrow only applies to asymptomatic patients.   \n4666                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nfound, while patients undergoing TAVI had improved quality of \nlife (change in KCCQ of 12.8 ± 21.9 points vs 3.2 ± 22.8 points; \nP = 0.018).373 Ongoing trials are expected to provide new insights \n(NCT04889872 and NCT05149755). \n8.5. Treatment options \nThe mode of AV intervention depends on the estimated life expect-\nancy, expected prosthesis durability, patient preference, and specific \ntrade-offs associated with different treatment options (Figure 8). \nMost patients with AS undergoing valve intervention in Europe and \nNorth America receive a BHV (by either SAVR or TAVI).374 BHVs \ndo not require long-term anticoagulation but have limited durability \nthat varies between devices and is inversely associated with age.375 \nMHVs are durable but require long-term anticoagulation, with asso-\nciated thromboembolic and bleeding risks.260,376 In general, an MHV \nshould be preferred in patients aged <60 years and a BHV in patients \naged >65 years in aortic position (see Section 14.1). \nThe Ross procedure (replacement of the AV with the patient’s pul-\nmonary autograft combined with homograft pulmonary valve \nreplacement) is associated with excellent long-term survival when per-\nformed in selected patients at centres with high expertise.260,263,377,378 \nAlthough a valuable surgical option in young patients with prolonged life \nexpectancy in whom anticoagulation is undesirable or contraindicated, \nit is associated with procedural complexity and the need for reinterven-\ntion in ∼15% of patients within 15 years (Figure 8).263,377 \nBalloon aortic valvuloplasty may be rarely considered as a bridge to \nTAVI or SAVR in carefully selected patients with decompensated AS, \nand in those with severe AS who require urgent high-risk non-cardiac \nsurgery (NCS) (see Section 15.2.1). The procedure carries significant \nrisks of acute complications.379 \nA substantial increase in the number of patients undergoing AV inter-\nvention has been observed over the past decade as a consequence of the \nintroduction of TAVI, improved diagnostic techniques, and evolving indi-\ncations for intervention.374,380–383 Nevertheless, there is still wide vari-\nation in worldwide access to TAVI as a result of high device costs in \ncomparison with surgical prostheses and variation in healthcare re-\nsources and reimbursement systems between countries.384–386 In add-\nition, registries suggest that late referral and undertreatment remain \nfrequent.12,387 \n8.5.1. The mode of intervention in candidates for a \nbioprosthesis \nThe two modes of BHV replacement, TAVI and SAVR, have been com-\npared in RCTs across the spectrum of surgical risk in predominantly \nelderly patients with tricuspid AS. \nIn patients unsuitable for surgery, TAVI was superior to medical \ntherapy with a number-needed-to-treat of five to prevent one death \nat 1-year follow-up.388 Subsequently, RCTs showed non-inferiority of \nTAVI compared with SAVR in patients at high,389–391 intermedi-\nate,3,392,393 and low surgical risk,1,394,395 with comparable longer-term \noutcomes demonstrated during follow-up periods ranging from 4 to \n10 years.2,4,396–398 Of note, the majority of patients included in \nRCTs were male, while patients with low-flow low-gradient AS or ad-\nverse anatomical characteristics (including BAVs or complex CAD) \nwere excluded per protocol. \nMeta-analyses of RCTs show a risk reduction in all-cause death and \ndisabling stroke with TAVI in low-risk patients at 1 year, but no differ-\nences to SAVR at longer-term follow-up or in patients at intermediate \nor high surgical risk.399,400 The early benefit of TAVI in low-risk patients \nhas since been corroborated in the investigator-initiated Randomized, \nMulticenter, Event-Driven Trial of TAVI vs SAVR in Patients with \nSymptomatic Severe Aortic-Valve Stenosis (DEDICATE), which met \nits non-inferiority target with a composite of death and stroke rate at \n1 year of 5.4% in the TAVI group vs 10.0% in the SAVR group [hazard \nratio (HR), 0.53; 95% confidence interval (CI), 0.35–0.79] and all- \ncause death rates of 2.6% and 6.2% (HR 0.43; 95% CI, 0.24–0.73), \nrespectively.395 \nRates of vascular complications and paravalvular leak (PVL) are con-\nsistently higher after TAVI despite refined transcatheter heart valve \n(THV) designs, whereas severe bleeding, acute kidney injury, and new- \nonset AF are more frequent after SAVR.2,4,399,401 Even though PVL has \nbeen associated with adverse clinical outcomes,402,403 it does not seem \nto impact the comparison of clinical outcomes between TAVI and \nSAVR in RCTs.2,4,395 \nNew pacemaker implantations are more frequent after TAVI, par-\nticularly when using self-expanding valves.3,394,404 Conflicting data exist \nregarding the long-term impact of new pacemaker implantation or \nnew-onset left bundle branch block following AV intervention.405–407 \nPatients undergoing TAVI have quicker recoveries, shorter hospital \n\u001f\u001e\u001d\u001c\u001b\u001a\u001d\u0019\u0018\u0017\u0016\u001c\u0015\u0019\u0017\u0019\u0014\u0013\u0019\u0012\u001d\u001a\u0011\u0012\u0010\n\u001f\u001e\u001d\u001d\n\u001c\u001b\u001e\u001a\u0019\u0018\u0017\u001b\u0019\n\u0016\u0015\u0014\u0015\u0013\u0012\u0013\u0015\u001e\u0011\u001d\n\u000f\u0019\u0012\u000e\u0011\u001c\u0012\u001a\u0016\u0017\u0012\r\u001b\u0013\u0016\u0019\u0014\u001c\u001d\u0010\n\f\u000b\n\u0017\t\u0019\u001b\b\r\u0016\u001c\u0012\u0007\u000e\u001a\u0019\u001b\r\u0006\u0006\u000e\u001a\u0005\u001c\u0012\u0017\u0006\u001c\u001e\u0004\u0003\n\u0002\u001c\u001b\u001c\u001d\u0019\u0018\u0017\u0018\u0001\u0006\u001a\b\u001c\u0016\u001c\u001d\u0010\n\u0010\u0019\u001a\u000f\u0012\u0011\u0015\u001a\u0012\u000e\n\r\u0012\u000e\r\u0019\n\f\u0015\u001e\u001c\u001b\u001e\u001d\u0013\u000f\u0019\u001d\u0015\u001d\n\u000b\u0017\r\u0006\u0017\u000f\u000b\n\n \n\u000b\u0005\u0019\u0017\t\u0010\u0019\u001a\u0006\u001e\u0003\nFigure 8 Aortic valve treatment options. OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve \nimplantation.   \nESC Guidelines                                                                                                                                                                                          4667 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nstays, and more rapid improvements in quality of life compared with \nthose who undergo SAVR.1,2,408,409 \nAvailable data do not suggest systematic differences in durability be-\ntween the two treatment modalities. Randomized controlled trials and \nobservational studies have reported comparable rates of BHV failure re-\nlated to SVD with transcatheter and surgical valves up to 10 years.2,398,410 \nHowever, potential selection and survival bias, the use of variable defini-\ntions of SVD, limited follow-up durations, differential attrition \nrates,2,4,396,400 competing risk of death, and the use of multiple valve \ntypes in the surgical arms of RCTs may limit direct comparison.411 \nAlthough conclusive evidence is still lacking, concomitant non- \ncomplex CAD can be addressed either by CABG or PCI, while \ncomplex CAD favours CABG (see Section 6.1). In the only RCT com-\nparing these two strategies, the transcatheter valve and vessels \n(TCW) trial, randomization of patients with severe AS and concomi-\ntant CAD to FFR-guided PCI plus TAVI resulted in fewer deaths and \nmajor bleeding events compared with combined SAVR plus CABG at \n12 months.412 However, inferences from trial results are limited due \nto early termination, modest sample sizes, event rates deviating from \nthose observed in registries and other RCTs, and a low prevalence of \ncomplex CAD. \n8.5.1.1. Age and life expectancy \nThe relationship between estimated life expectancy and prosthetic heart \nvalve durability determines the likelihood of a future reintervention. \nAlthough life expectancy may be a theoretically better guide than age \nalone for treatment decisions, it is difficult to estimate for an individual pa-\ntient owing to large geographical (https://ghdx.healthdata.org/record/ \nihme-data/gbd-2019-life-tables-1950-2019) and interindividual variabil-\nity.413 In combination with cardiac and extracardiac comorbidities, as \nwell as anatomical factors, age contributes to risk estimation and repre-\nsents a pragmatic surrogate for life expectancy. In addition, age thresholds \ncharacterize the populations enrolled in RCTs better than life expectancy. \nIt is notable that younger patients with AS seem to have lower life expect-\nancy than the general population despite valve replacement, whereas life \nexpectancy almost normalizes after treatment in older cohorts.414,415 \nWhile several trials compared TAVI with SAVR in study populations \naged 70–85 years accross the surgical risk spectrum, the representation \nof patients aged <70 years in RCTs is low and therefore evidence \nlimited.1,394,395,416 \n8.5.1.2. Anatomical features \nThe advantages of TAVI demonstrated in RCTs are largely confined to \npatients treated via the transfemoral approach.401 While SAVR remains \nthe preferred treatment option when iliofemoral artery disease pre-\ncludes transfemoral TAVI, TAVI via a non-transfemoral access (transax-\nillary, transcarotid, transcaval, transinnominate, or transapical) \nconstitutes an alternative supported by observational data in patients \nunsuitable for surgery.417–423 \nOther anatomical factors that favour SAVR or led to exclusion of pa-\ntients from RCTs comparing TAVI with SAVR are  (Figure 9): \n• Aortic annular dimensions that lie outside sizing recommendations \nfor currently available transcatheter devices. \n• Excessive or bulky calcifications of the annulus or LVOT, which in-\ncrease the risk of PVL and annular rupture.424,425 \n• Increased risk of coronary obstruction with TAVI (cusp height greater \nthan coronary height in combination with shallow sinuses of Valsalva, \nor high calcium burden of corresponding cusp).329 \nIn contrast, anatomical findings such as porcelain aorta, severe chest \ndeformation, or intact grafts post-CABG favour TAVI. Right anterior \nthoracotomy or upper hemisternotomy are minimally invasive access \nalternatives to sternotomy for performing SAVR, which are being \nused with increasing frequency.426,427 \nIn BAV patients, severe AS usually occurs earlier compared with tri-\ncuspid AV and is frequently associated with aortopathy.219,281,428 \nPrevalence of BAV anatomy sharply increases in younger AS pa-\ntients.429 BAV anatomy adds complexity to TAVI because of asymmet-\nric AV calcification and elliptical annular shape, as well as the lack of \nstandardization of valve sizing. \nPatients with BAV have been excluded from almost all landmark \nRCTs comparing TAVI with SAVR to date.429,430 In the NOTION 2 \ntrial, the composite of all-cause death, stroke, or valve- or HF-related \nrehospitalization was numerically more frequent (seven vs two events) \nat 1 year in the underpowered subgroup of 100 patients with BAV (HR, \n3.8; 95% CI, 0.8–18.5; P = 0.07).416 Whereas some observational studies \nreport favourable outcomes with TAVI in selected BAV patients,430–432 \nothers suggest higher stroke, annular rupture, and PVL rates as com-\npared with TAVI in tricuspid AS.433 Heavy cusp calcification, particularly \nin conjunction with a calcified raphe, is associated with increased risk \nof aortic root injury, PVL, and mortality after TAVI.434 Data on TAVI \nin two-sinus BAV (Sievers type 0) are scarce.219,435 \nFor the above-mentioned reasons, SAVR remains the primary mode \nof treatment for stenotic BAV, particularly if patients are young or have \ncoexistent aortopathy or unfavourable valve morphology. TAVI may be \nconsidered in patients at increased surgical risk, if anatomy is suitable. \nPatients with small annuli in relation to their body stature are at in-\ncreased risk of prosthesis–patient mismatch (PPM) after valve replace-\nment. Annular enlargement allows for implantation of larger BHVs \nwith SAVR. Given its technical complexity it should be performed \nin experienced centres, and the benefit must be balanced against a \npossibly higher risk of operative mortality.436 Prostheses with \nsupra-annular design reduce PPM risk with TAVI, although randomized \nlong-term data evaluating the impact on clinical outcomes or valve \ndurability are pending.394,437,438 \n8.5.1.3. Lifetime management \nDecision-making concerning the mode of intervention and type of \nprosthesis needs to integrate expected valve durability, and the poten-\ntial risks of future reinterventions (Figure 9). Surgical THV explantation \nfollowed by SAVR is a rare (<1% of all TAVI procedures) but technically \nchallenging procedure.439–441 Although its incidence among patients \nundergoing TAVI is stable, absolute numbers are increasing due to \nthe total increase in TAVI procedures performed and the peri- \noperative risk remains high (early mortality rates as high as 12%– \n17%).440–445 The majority of surgical THV explantations are performed \nin patients at high surgical risk with urgent or emergent, \nnon-SVD-related indication for reintervention (frequently endocardi-\ntis) within 2 years after TAVI.440,442–444 \nImplanting a transcatheter aortic valve inside a surgical (TAV-in-SAV) \nor prior transcatheter valve (TAV-in-TAV) is associated with lower \nperi-procedural risk compared with redo SAVR.446–451 However, \nvalve-in-valve implantation (particularly TAV-in-SAV) increases the \nrisk of severe PPM,448 which has been linked to adverse outcomes in \nobservational studies.452–455 In addition, valve-in-valve implantation im-\nmobilizes the leaflets of the failed prosthesis in an open position, creat-\ning a covered tube (or neo-skirt) that may cause direct coronary \nobstruction in patients with shallow sinuses of Valsalva or indirect  \n4668                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ncoronary flow obstruction as a result of sinus sequestration if the as-\ncending aorta is narrow and the neo-skirt reaches the sinotubular \njunction.456,457 \nThe risk of coronary obstruction varies considerably depending on \nthe index valve type, and is particularly increased if a stentless SAV or \nstented SAV with externally mounted leaflets is in place.457 The risk \nof sinus sequestration at the time of TAV-in-TAV implantation is par-\nticularly increased in supra-annular valves with a high neo-skirt.458,459 \nEven if coronary flow is preserved, coronary access may be difficult \nor impossible in a relevant proportion of patients after valve-in-valve \nimplantation, especially after TAV-in-TAV.460–462 \nIn patients who require a reintervention due to dysfunction of a sur-\ngical or transcatheter bioprosthesis, but are at increased risk of severe \nPPM or coronary obstruction, redo SAVR may be preferable despite \nthe increased surgical risk. Fracture of surgical valves and leaflet modi-\nfication techniques have been proposed for patients at high surgical risk \nand, if contemplated, should be performed in carefully selected patients \nat experienced centres (Table 6).463,464 \nThe need for a meticulous CT-based anatomical analysis is para-\nmount in patients with an estimated life expectancy exceeding the \nassumed valve durability to anticipate future risks at the time of \nthe index valve intervention. Based on individual assessment, the \nfollowing measures should be considered with respect to lifetime \nmanagement: \n• Use of surgical and transcatheter valves with proven long-term dur-\nability to reduce the likelihood of reintervention.2,4,375,410,411,465–467 \n• SAVR with aortic root enlargement or implantation of a supra-annular \ntranscatheter valve in patients with a small annulus at risk of severe \nPPM based on the predicted effective orifice area (EOA).436,438,468,469 \n• No implantation of stentless prostheses or prostheses with external-\nly mounted leaflets in patients at risk of coronary obstruction during \nfuture TAV-in-SAV implantation.457 \n\u001f\u001e\u001d\u001c\u001b\u001a\u0019\u0018\u0017\u001e\u001d\u0016\u0015\u001d\u0014\u0014\u0019\u001b\u001b\u0015\u001b\u0013\u0012\u0011\u001d\u0010\u0016\u0019\u0015\u001a\u0017\u001e\u0015\u001f\u000f\u000e\r\n\f\u0017\u001e\u0014\u0019\u0016\u001d\u0012\u001c\u0015\u001d\u0017\u001e\u0011\u001d\n\r\u001c\u0011\u001d\u0014\u0011\u0015\u0014\u0017\u001e\u0017\u001c\u001d\u001e\u000b\u0015\u001d\u001e\u0011\u0019\u001e\u000b\u0015\u0010\u000b\n\u001d\u001b\u001b\u0015\t\u001e\u001d\u001a\u0011\u001b\n\b\u0019\u0007\u0019\u001e\u0019\u0015\u0014\u0006\u0019\u001b\u0011\u0015\u0005\u0019\u001a\u0017\u001e\u0018\u0012\u0011\u000b\u0015\u0017\u001e\u0015\u001b\u0014\u0017\u0016\u0012\u0017\u001b\u0012\u001b\n\u0004\u0017\u0018\u0017\u001e\u0010\u0012\u0005\u0012\u0011\u0012\u0019\u001b\u0015\u0017\u001e\u0015\u0014\u001d\u001e\u0005\u0012\u001d\u0014\u0015\u0014\u0017\u001c\u0005\u0012\u0011\u0012\u0017\u001c\u001b\n\u0012\u001c\u0014\u001e\u0019\u001d\u001b\u0012\u001c\t\u0015\u001b\u0013\u001e\t\u0012\u0014\u001d\u0016\u0015\u001e\u0012\u001b\u0003\n\u0002\u001e\u001d\u0012\u0016\u0011\u000b\n\b\u0019\u0001\u0013\u0019\u0016\u001d\u0019\u0015\u0017\u001a\u0015\u0014\u0006\u0019\u001b\u0011\u0015\u001e\u001d\u0005\u0012\u001d\u0011\u0012\u0017\u001c\n≥\u0015\u000b\u0019\u001d\u001e\u001b\n\u0017\u001b\u0011\u0012\u0016\u0019\u0015\u001d\u001c\u001c\u0013\u0016\u0013\u001b\u0015\u0017\u001e\u0015\u000e\u001f\u0015\u0014\u001d\u0016\u0014\u0012\u0014\u001d\u0011\u0012\u0017\u001c\n \u0012\u0014\u0013\u001b\n\u0012\u0005\u0015\u001d\u0017\u001e\u0011\u0012\u0014\u0015\u0007\u001d\u0016\u0007\u0019\n\u000f\u001c\u001c\u0013\u0016\u0013\u001b\u0015\u0005\u0012\u0018\u0019\u001c\u001b\u0012\u0017\u001c\u001b\u0015\u0013\u001c\u001b\u0013\u0012\u0011\u001d\u0010\u0016\u0019\u0015\u001a\u0017\u001e\u0015\u001f\u000f\u000e\r\n­\u0012\u001b\u0003\u0015\u0017\u001a\u0015\u0014\u0017\u001e\u0017\u001c\u001d\u001e\u000b\u0015\u0017\u0010\u001b\u0011\u001e\u0013\u0014\u0011\u0012\u0017\u001c\n\u0011\u0006\u0019\u001e\u0015\u001e\u0019\u0016\u0019\u0007\u001d\u001c\u0011\u0015\n\u001e\u0012\u0018\u001d\u001e\u000b\u0015\u000e\n\u0004\u0017\u0018\n\u0016\u0019\u0015\u0004\u000f\n\u000f\u0017\u001e\u0011\u0012\u0014\u0015\u001e\u0017\u0017\u0011\u0015\u0017\u001e\u0015\u001d\u001b\u0014\u0019\u001c\u0005\u0012\u001c\t\u0015\u001d\u0017\u001e\u0011\u0012\u0014\u0015\u001d\u001c\u0019\u0013\u001e\u000b\u001b\u0018\n\b\u0019\n\u0011\u001d\u0016\u0015\u0006\u000b\n\u0019\u001e\u0011\u001e\u0017\n\u0006\u000b\u0015\u001e\u0019\u0001\u0013\u0012\u001e\u0012\u001c\t\u0015\u0018\u000b\u0019\u0014\u0011\u0017\u0018\u000b\n\u0015\u000b\u0019\u001d\u001e\u001b\n\u0002\u001d\u0007\u0017\u0013\u001e\u001b\u0015\u001f\u001e\u001d\u001c\u001b\n\u0002\u001d\u0007\u0017\u0013\u001e\u001b\u001b\u001a\u001e\u001d\u0019\n\u001e\u0018\u0017\n\u001e\u0016\u0015\u0014\u0013\u0012\u0011\u0010\n\u000f\u0017\u0015\u0014\u000e\r\u0017\f\n\u000b\u0013\u0016\u0010\u0013\u0012\u0011\u0014\u0015\u0016\u0014\n\u0010\u0013\u0016\n\u0011\u0014\u0011\u0013\u0016\f\u0015\n\t\u0011\u000f\u0017\u0014\u0011\u0012\u0017\u0015\u0012\u0015\u0016\u0015\u0018\u0017\u0012\u0017\u0016\u0014\b\n\u000f\u001c\u0011\u0012\u0014\u0012\n\u001d\u0011\u0019\u0015\u001e\u0019\n\u0019\u001d\u0011\u0015\n\u001e\u0017\u0014\u0019\u0005\u0013\u001e\u0019\u0015\u0017\n\u0011\u0012\u0017\u001c\u001b\u0015\u001d\u001c\u0005\u0015\u001e\u0012\u001b\u0003\u001b\u0015\u0006\u0019\u001c\u0015\u001b\u0019\u0016\u0019\u0014\u0011\u0012\u001c\t\u0015\u0018\u0017\u0005\u001d\u0016\u0012\u0011\u000b\u0015\u001d\u001c\u0005\u0015\u0007\u001d\u0016\u0007\u0019\u0015\u0011\u000b\n\u0019\u0015\u001d\u0011\u0015\u0012\u001c\u0005\u0019\u0015\n\u001e\u0017\u0014\u0019\u0005\u0013\u001e\u0019\n­\u0019\u0005\u0017\u0015\b\u000f\u000e­\u0015\u001e\u0012\u001b\u0003\u0015\u0017\u001a\u0015\u001e\u0019\u0005\u0017\u0015\u001b\u0013\u001e\t\u0019\u001e\u000b\n\b\u000f\u000e­\u0015\u001d\u001a\u0011\u0019\u001e\u0015\u001f\u000f\u000e\r\u0015\u0012\u001c\u0014\u001e\u0019\u001d\u001b\u0019\u0005\u0015\u001e\u0012\u001b\u0003\u0015\u001d\u001b\u001b\u0017\u0014\u0012\u001d\u0011\u0019\u0005\u0015\u0012\u0011\u0006\u0015\u001f\u000e\u0015\u0019\n\u0016\u001d\u001c\u0011\u001d\u0011\u0012\u0017\u001c\n\u000e\u001d\u0016\u0007\u0019\u0012\u001c\u0007\u001d\u0016\u0007\u0019\u0015\u001f\u000f\u000e\r\u0015\u001e\u0012\u001b\u0003\u0015\u0017\u001a\u0015\u0014\u0017\u001e\u0017\u001c\u001d\u001e\u000b\u0015\u0017\u0010\u001b\u0011\u001e\u0013\u0014\u0011\u0012\u0017\u001c\u0015\u0012\u0018\n\u001d\u0012\u001e\u0019\u0005\u0015\u0014\u0017\u001e\u0017\u001c\u001d\u001e\u000b\u0015\u001d\u0014\u0014\u0019\u001b\u001b\u0015\n\u001e\u0017\u001b\u0011\u0006\u0019\u001b\u0012\u001b\n\u001d\u0011\u0012\u0019\u001c\u0011\u0015\u0018\u0012\u001b\u0018\u001d\u0011\u0014\u0006\nFigure 9 Factors to be considered when selecting the mode of intervention for aortic stenosis. CAD, coronary artery disease; LV, left ventricular; \nLVOT, left ventricular outflow tract; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; THV, transcatheter heart \nvalve; VHD, valvular heart disease. aLV thrombus and infective endocarditis are relative contraindications to TAVI and are therefore not listed. \nbParticularly relevant for patients in whom the anticipated life expectancy is thought to exceed valve durability.   \nESC Guidelines                                                                                                                                                                                          4669 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n• Anticipation of the feasibility and risks of a possible future TAV-in-TAV \nprocedure considering related technical aspects at the index TAVI \n(device choice, neo-skirt height, commissural alignment, and implant-\nation depth).456,470  \nConsidering life-time management aspects and the scarcity of rando-\nmized data in patients younger than 70 years, SAVR remains the pre-\nferred treatment in patients <70 years of age if surgical risk is low. \nTAVI is recommended as the primary treatment modality in elderly pa-\ntients ≥70 years of age with a tricuspid AV, if anatomy is suitable and \ntransfemoral access is feasible, to reduce the risk of early adverse out-\ncomes and accelerate recovery. \nFor all other candidates for a bioprosthesis, the most appropriate \nmode of intervention should be carefully selected by the Heart \nTeam, taking into account procedural risk based on anatomical charac-\nteristics and comorbidities, expected outcomes, lifetime management \nconsiderations, and patient preference (Figure 9; Recommendation \nTable 4). Recommendations for concomitant valve replacement at \nthe time of CABG or ascending aortic surgery are listed in  \nRecommendation Table 5. \nRecommendation Table 4 — Recommendations on indications for intervention in symptomatic and asymptomatic severe \naortic stenosis, and recommended mode of intervention (see also Supplementary data online, Evidence Tables 9–13) \nRecommendations \nClassa \nLevelb \nSymptomatic patients with severe aortic stenosis  \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, \nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)].388,471–474 \nI \nB \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF \n(<50%) after careful confirmation that AS is severe.342,345,346,348,475 \nI \nB \nIntervention should be considered in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with normal \nLVEF (≥50%) after careful confirmation that AS is severe.c 293,348,349,476–481 \nIIa \nB \nAsymptomatic patients with severe aortic stenosis \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.14,354–359 \nI \nB \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS \nand LVEF ≥50% as an alternative to close active surveillance, if the procedural risk is low.360–363,367,368 \nIIa \nA \nIntervention should be considered in asymptomatic patients with severe AS and LVEF ≥50% if the procedural risk is low and one of the \nfollowing parameters is present: \n• Very severe AS (mean gradient ≥60 mmHg or Vmax >5.0 m/s).14,362,363,482–484 \n• Severe valve calcification (ideally assessed by CCT) and Vmax progression ≥0.3 m/s/year.303,353,364 \n• Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confirmed on repeated \nmeasurement without other explanation).97,365 \n• LVEF <55% without another cause.14,354,356–359 \nIIa \nB \nIntervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP (>20 mmHg) during exercise testing. \nIIa \nC \nMode of intervention \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have \non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. \nI \nC \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural \ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. \nI \nC \nTAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.d 1–4,389–397,465,485,486 \nI \nA \nSAVR is recommended in patients <70 years of age, if the surgical risk is low.e 413,429,487 \nI \nB \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.2,4,396,397,429,488–490 \nI \nB \nNon-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.417–423,491–498 \nIIa \nB \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is  \nsuitable.430–432,434,499–502 \nIIb \nB \nBalloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those \nwith severe AS who require urgent high-risk NCS. \nIIb \nC \n© ESC/EACTS 2025\nAS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; BAV, bicuspid aortic valve; BHV, biological heart valve; BNP, brain natriuretic peptide; BP, blood pressure; BSA, body surface area; \nCCT, cardiac computed tomography; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricular ejection fraction; NCS, non-cardiac surgery; NT-proBNP, \nN-terminal pro-B-type natriuretic peptide; SAVR, surgical aortic valve replacement; STS-PROM, Society of Thoracic Surgeons predicted risk of mortality; SVi, stroke volume index; TAVI, \ntranscatheter aortic valve implantation; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence. \ncExplanations (such as measurement errors, uncontrolled blood pressure, and conditions lowering the stroke volume) other than severe AS for a small AVA but low gradient despite \npreserved LVEF are frequent and must be carefully excluded. \ndSuitability regarding transfemoral access, annulus dimensions, device landing zone calcification pattern, and coronary obstruction risk (Figure 9). \neSurgical risk based on STS-PROM (http://riskcalc.sts.org/stswebriskcalc/#/calculate) and EuroSCORE II (http://www.euroscore.org/calc.html) <4% and Heart Team assessment.   \n4670                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n8.6. Follow-up \nThe rate of progression of AS varies widely and asymptomatic patients, \ntheir family, and medical caregivers need careful education, with particu-\nlar emphasis on the importance of regular follow-up (ideally at a Heart \nValve Centre)14 and prompt reporting of symptoms. Asymptomatic pa-\ntients with severe AS should be followed up at least every 6 months to \nallow detection of early symptoms (using exercise testing if complaints \nare inconclusive) and any change in echocardiographic parameters (par-\nticularly LVEF). Serial measurements of natriuretic peptides can provide \nadditional useful information regarding the timing of treatment. \nYounger patients with mild AS and no significant leaflet calcification \nmay be followed up every 2–3 years. With increasing stenosis severity, \nprogression accelerates and follow-up intervals should be gradually re-\nduced.283,503 Several studies suggest that the prognosis of moderate de-\ngenerative AS is worse than previously considered,504,505 particularly if \nthere is significant valve calcification, and these patients should be re- \nevaluated at least annually. \nCardiac rehabilitation is frequently performed after AV intervention, \nespecially after surgery and in elderly patients, and is associated with im-\nproved activities of daily living and 6-minute walking distance.506 After \nvalve intervention, an early echocardiographic examination within the \nfirst weeks after valve replacement is recommended to document base-\nline prosthetic valve function. Cardiological evaluations and echocardio-\ngraphic examinations are recommended annually in patients with a \nbioprosthesis, and whenever changes in clinical symptoms or signs sug-\ngestive of valve dysfunction are noted. \n9. Mitral regurgitation \nChronic MR is one of the most common acquired valve patholo-\ngies,12,187 while acute MR is observed in the context of infective endo-\ncarditis, chordal rupture, or as a complication of myocardial infarction \n(papillary muscle rupture). MR either relates to anatomical changes of \nthe MV apparatus (primary), or to LV or LA dilatation and dysfunction \n(secondary).193 Since natural history, prognosis, and management differ \naccording to aetiologies, populations should be clearly distinguished in \nclinical practice and research.12,507 \n9.1. Primary mitral regurgitation \n9.1.1. Prevalence and aetiology \nPrimary mitral regurgitation relates to an anatomical lesion of one or \nmore of the three main components (not including the annulus) of the \nMV apparatus (valve leaflets, chordae tendineae, and papillary muscles). \nPMR is observed in 55% of patients with MR who require treatment.507 \nWhile degenerative disease related to fibroelastic deficiency or myxoma-\ntous alterations (in its most severe form, Barlow’s disease) are the most \ncommon aetiologies in higher-income countries, RHD is most frequently \nfound in the rest of the world. MV endocarditis is a separate entity of PMR \ncaused by acute or chronic infectious conditions and is discussed in the \ncorresponding Guidelines.5 In a small subgroup of patients, PMR is asso-\nciated with a higher incidence of ventricular arrhythmias, and sudden car-\ndiac death has been reported in individual cases, especially in patients with \nBarlow’s disease.508 The arrhythmogenic burden is independent from MR \nseverity and has been associated with mitral annular disjunction. Atrial dis-\nplacement of the posterior MV leaflet hinge point is assumed to cause ex-\ncessive mobility of the valvular apparatus and increases tension on the \npapillary muscles and the posterobasal myocardium, causing local fibrosis, \nwhich may lead to ventricular arrhythmias and sudden cardiac death.509 \n9.1.2. Evaluation \n9.1.2.1. Echocardiography and right heart catheterization \nEchocardiography is the diagnostic method of choice for the quantifica-\ntion of MR, determination of its aetiology, and identification of cardiac \nconsequences (Figure 10). TTE is used for initial evaluation that includes: \n(i) assessment of valve morphology (presence and location of prolapse \nor flail, calcifications, and/or mitral annular disjunction); (ii) integrative \nseverity grading; and (iii) quantification of LV and LA dimensions and \nfunction, as well as assessment of concomitant RV dysfunction.46 \nQuantitative parameters such as the effective regurgitant orifice area \n(EROA) have prognostic implications.510,511 Volumetric methods pro-\nvide additional information on MR severity [RVol and regurgitant frac-\ntion (RF)].512 Accurate colour flow settings must be used to avoid \noverestimation of MR severity. \nTransoesophageal echocardiography (TOE) represents the method of \nchoice to assess valve anatomy, leaflet quality, motion, and coaptation, as \nwell as to confirm MR severity.513 Three-dimensional TOE provides an \nexcellent morphological and functional view of the different valve seg-\nments, and should be used systematically when planning and performing \nsurgical or transcatheter repair.514 \nExercise echocardiography evaluates dynamic changes in regurgitant jet \nand pulmonary pressures during peak exercise, and might be helpful in pa-\ntients with discordant symptoms and regurgitation severity at rest.515,516 \nIn asymptomatic patients with severe PMR, increased LV or LA di-\nmensions, as well as elevated pulmonary pressures (>50 mmHg at \nrest), moderate or more secondary TR, and AF are important markers \nof worse prognosis, and should be considered for intervention timing \n(Figure 11; Section 9.1.4).517,518 \nRight heart catheterization remains important in patients with PMR \nfor confirmation of pulmonary artery pressures in case of discrepancy \nbetween echocardiographic MR severity and clinical symptoms, as well \nas in the presence of concomitant lung disease.519 \n9.1.2.2. Biomarkers \nCardiac biomarkers are recognized indicators of disease \nseverity with prognostic implications, but may also be non- \nspecific. NT-proBNP levels are directly related to the \nNew York Heart Association (NYHA) functional class in PMR.520 \nRecommendation Table 5 — Recommendations on in-\ndications for concomitant aortic valve replacement at \nthe time of coronary artery bypass grafting or ascending \naorta surgery \nRecommendations \nClassa \nLevelb  \nSAVR is recommended in symptomatic and \nasymptomatic patients with severe AS undergoing \nCABG or surgical intervention on the ascending \naorta. \nI \nC \nSAVR should be considered in symptomatic and \nasymptomatic patients with moderate ASc \nundergoing CABG or surgical intervention on the \nascending aorta. \nIIa \nC \n© ESC/EACTS 2025\nAS, aortic stenosis; AVA, aortic valve area; CABG, coronary artery bypass grafting; SAVR, \nsurgical aortic valve replacement. \naClass of recommendation. \nbLevel of evidence. \ncDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in \nnormal-flow conditions. Clinical assessment is essential to determine whether SAVR is \nappropriate for an individual patient.   \nESC Guidelines                                                                                                                                                                                          4671 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "TAVI may be considered for the treatment of severe\nAR in symptomatic patients ineligible for surgery\naccording to the Heart Team, if the anatomy is\nsuitable.264,265,268,269 |  | IIb | B | \n | Concomitant surgery of the ascending aorta |  |  | \nValve-sparing aortic root replacement is\nrecommended in young patients with aortic root\ndilatation at experienced centres, when durable\nresults are expected.247,250–253,255 |  | I | B | \nWhen AV surgery is indicated and the predicted\nsurgical risk is low, replacement of the aortic root or\nascending aorta should be considered if the maximal\ndiameter is ≥45 mm.d |  | IIa | C | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 28",
          "page": 28,
          "content": "Recommendations | Classa | Levelb\nSevere aortic regurgitation |  | \nAV surgery is recommended in symptomatic patients\nwith severe AR regardless of LV function.224–228 | I | B\nAV surgery is recommended in asymptomatic\npatients with severe AR and LVESD >50 mm or\nLVESDi >25 mm/m2 [especially in patients with small\nbody size (BSA <1.68 m2)] or resting\nLVEF ≤50%.226,228,231,233,234 | I | B\nAV surgery is recommended in symptomatic and\nasymptomatic patients with severe AR undergoing\nCABG or surgery of the ascending aorta. | I | C\nAV repair should be considered in selected patients\nwith severe AR at experienced centres, when\ndurable results are expected.220,245,246,259 | IIa | B\nAV surgery may be considered in asymptomatic patients\nwith severe AR and LVESDi\n>22 mm/m2,226,228,231–234 or LVESVic >45 mL/m2\n[especially in patients with small body size (BSA\n<1.68 m2)],235–241 or resting LVEF ≤55%, if the surgical\nrisk is low. | IIb | B",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 35",
          "page": 35,
          "content": "ESC Guidelines 466 | 9\n\u0002 \u0007\u0017\u0013 \u001b\u001b\u001a \u0019 \u0002 \u0007\u0017\u0013 \u001b\u0015 \u001b\n\u0015 \u0019 \u001b \u0018\u0017 ≥\u0015 \u0019 \u001b\n\u0017\u001b\u0011\u0012\u0016\u0019\u0015 \u0013\u0016\u0013\u001b\u0015\u0017 \u0015\u000e \u0015\u0014 \u0016\u0014\u0012\u0014 \u0011\u0012\u0017 \u001b\u001a\u0019\u0018\u0017 \u0016\u0015 \u0014\u0014\u0019\u001b\u001b\u0015\u001b\u0013\u0012\u0011 \u0010\u0016\u0019\u0015\u001a\u0017 \u0015 \u000f\u000e\n\u0012\u0014\u0013\u001b \u0012\u0005\u0015 \u0017 \u0011\u0012\u0014\u0015\u0007 \u0016\u0007\u0019 \u0016\u0015\u0014\u0013\u0012\u0011\u0010 \u0017 \u0014\u0019\u0016 \u0012 \u0015 \u0017 \u0011\n\u000f \u0013\u0016\u0013\u001b\u0015\u0005\u0012\u0018\u0019 \u001b\u0012\u0017 \u001b\u0015\u0013 \u001b\u0013\u0012\u0011 \u0010\u0016\u0019\u0015\u001a\u0017 \u0015 \u000f\u000e \u000f\u0017\u0015\u0014\u000e \u0017 \u0011 \u0014\u0011\u0015\u0014\u0017 \u0017 \u0015 \u0011\u0019 \u0015\u0010 \u001b\u001b\u0015 \u001a\u0011\u001b\n­\u0012\u001b\u0003\u0015\u0017\u001a\u0015\u0014\u0017 \u0017 \u0015\u0017\u0010\u001b\u0011 \u0013\u0014\u0011\u0012\u0017 \b\u0019\u0007\u0019 \u0019\u0015\u0014\u0006\u0019\u001b\u0011\u0015\u0005\u0019\u001a\u0017 \u0018\u0012\u0011 \u0015\u0017 \u0015\u001b\u0014\u0017\u0016\u0012\u0017\u001b\u0012\u001b\n\u0011\u0006\u0019 \u0015 \u0019\u0016\u0019\u0007 \u0011\u0015 \u0012\u0018 \u0015\u000e \u0004\u0017\u0018\u0017 \u0010\u0012\u0005\u0012\u0011\u0012\u0019\u001b\u0015\u0017 \u0015\u0014 \u0005\u0012 \u0014\u0015\u0014\u0017 \u0005\u0012\u0011\u0012\u0017 \u001b\n\u0004\u0017\u0018 \u0016\u0019\u0015\u0004\u000f \u0013\u0016\u0010\u0013\u0012\u0011\u0014\u0015\u0016\u0014 \u0012 \u0014 \u0019 \u001b\u0012 \u0015\u001b\u0013 \u0012\u0014 \u0016\u0015 \u0012\u001b\u0003\n\u000f\u0017 \u0011\u0012\u0014\u0015 \u0017\u0017\u0011\u0015\u0017 \u0015 \u001b\u0014\u0019 \u0005\u0012 \u0015 \u0017 \u0011\u0012\u0014\u0015 \u0019\u0013 \u001b\u0018 \u0010\u0013\u0016 \u0011\u0014\u0011\u0013\u0016 \u0015 \u0002 \u0012\u0016\u0011\n\b\u0019 \u0011 \u0016\u0015\u0006 \u0019 \u0011 \u0017 \u0006 \u0015 \u0019\u0001\u0013\u0012 \u0012 \u0015\u0018 \u0019\u0014\u0011\u0017\u0018 \b\u0019\u0001\u0013\u0019\u0016 \u0019\u0015\u0017\u001a\u0015\u0014\u0006\u0019\u001b\u0011\u0015 \u0005\u0012 \u0011\u0012\u0017\n\u0011\u000f\u0017\u0014\u0011\u0012\u0017\u0015\u0012\u0015\u0016\u0015\u0018\u0017\u0012\u0017\u0016\u0014\b\n\u000f \u0011\u0012\u0014\u0012 \u0011\u0019\u0015 \u0019 \u0019 \u0011\u0015 \u0017\u0014\u0019\u0005\u0013 \u0019\u0015\u0017 \u0011\u0012\u0017 \u001b\u0015 \u0005\u0015 \u0012\u001b\u0003\u001b\u0015 \u0006\u0019 \u0015\u001b\u0019\u0016\u0019\u0014\u0011\u0012 \u0015\u0018\u0017\u0005 \u0016\u0012\u0011 \u0015 \u0005\u0015\u0007 \u0016\u0007\u0019\u0015\u0011 \u0019\u0015 \u0011\u0015\u0012 \u0005\u0019\u0015 \u0017\u0014\u0019\u0005\u0013 \u0019\n­\u0019\u0005\u0017\u0015\b\u000f\u000e­\u0015 \u0012\u001b\u0003\u0015\u0017\u001a\u0015 \u0019\u0005\u0017\u0015\u001b\u0013 \u0019\n\b\u000f\u000e­\u0015 \u001a\u0011\u0019 \u0015 \u000f\u000e \u0015\u0012 \u0014 \u0019 \u001b\u0019\u0005\u0015 \u0012\u001b\u0003\u0015 \u001b\u001b\u0017\u0014\u0012 \u0011\u0019\u0005\u0015 \u0012\u0011\u0006\u0015 \u000e\u0015\u0019 \u0016 \u0011 \u0011\u0012\u0017\n\u000e \u0016\u0007\u0019\u0012 \u0007 \u0016\u0007\u0019\u0015 \u000f\u000e \u0015 \u0012\u001b\u0003\u0015\u0017\u001a\u0015\u0014\u0017 \u0017 \u0015\u0017\u0010\u001b\u0011 \u0013\u0014\u0011\u0012\u0017 \u0015\u0012\u0018 \u0012 \u0019\u0005\u0015\u0014\u0017 \u0017 \u0015 \u0014\u0014\u0019\u001b\u001b\u0015 \u0017\u001b\u0011\u0006\u0019\u001b\u0012\u001b \u0011\u0012\u0019 \u0011\u0015\u0018\u0012\u001b\u0018 \u0011\u0014\u0006\nFigure 9 Factors to be considered when selecting the mode of intervention for aortic stenosis. CAD, coronary artery disease; LV, left ventricular; | ",
          "rows": 2,
          "cols": 2
        },
        {
          "title": "Table on page 36",
          "page": 36,
          "content": "Recommendations |  | Classa | Levelb | \nSymptomatic patients with severe aortic stenosis |  |  |  | \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s,\nmax\nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)].388,471–474 |  | I | B | \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF\n(<50%) after careful confrimation that AS is severe.342,345,346,348,475 |  | I | B | \nIntervention should be considered in symptomatic patients with low-fol w (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with normal\nLVEF (≥50%) after careful confirmation that AS is severe.c 293,348,349,476–481 |  | IIa | B | \n | Asymptomatic patients with severe aortic stenosis |  |  | \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause.14,354–359 |  | I | B | \nIntervention should be considered in asymptomatic patients (confirmed by a normal exercise test, if feasible) with severe, high-gradient AS\nand LVEF ≥50% as an alternative to close active surveillance, if the procedural risk is low.360–363,367,368 |  | IIa | A | \nIntervention should be considered in asymptomatic patients with severe AS and LVEF ≥50% if the procedural risk is low and one of the\nfollowing parameters is present:\n• Very severe AS (mean gradient ≥60 mmHg or V >5.0 m/s).14,362,363,482–484\nmax\n• Severe valve calcification (ideally assessed by CCT) and V progression ≥0.3 m/s/year.303,353,364\nmax\n• Markedly elevated BNP/NT-proBNP levels (more than three times age- and sex-corrected normal range, confrimed on repeated\nmeasurement without other explanation).97,365\n• LVEF <55% without another cause.14,354,356–359 |  | IIa | B | \nIntervention should be considered in asymptomatic patients with severe AS and a sustained fall in BP (>20 mmHg) during exercise testing. |  | IIa | C | \n | Mode of intervention |  |  | \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have\non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. |  | I | C | \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural\ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. |  | I | C | \nTAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable.d 1–4,389–397,465,485,486 |  | I | A | \nSAVR is recommended in patients <70 years of age, if the surgical risk is low.e 413,429,487 |  | I | B | \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment.2,4,396,397,429,488–490 |  | I | B | \nNon-transfemoral TAVI should be considered in patients who are unsuitable for surgery and transfemoral access.417–423,491–498 |  | IIa | B | \nTAVI may be considered for the treatment of severe BAV stenosis in patients at increased surgical risk, if the anatomy is\nsuitable.430–432,434,499–502 |  | IIb | B | \nBalloon aortic valvotomy may be considered as a bridge to SAVR or TAVI in haemodynamically unstable patients, and (if feasible) in those\nwith severe AS who require urgent high-risk NCS. |  | IIb | C | ",
          "rows": 19,
          "cols": 5
        },
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "Recommendations | Classa | Levelb\nSAVR is recommended in symptomatic and\nasymptomatic patients with severe AS undergoing\nCABG or surgical intervention on the ascending\naorta. | I | C\nSAVR should be considered in symptomatic and\nasymptomatic patients with moderate ASc\nundergoing CABG or surgical intervention on the\nascending aorta. | IIa | C",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "asymptomatic",
        "aortic",
        "imaging",
        "cabg",
        "follow-up",
        "diagnosis",
        "stenosis",
        "echocardiography",
        "echo",
        "aortic stenosis",
        "treatment",
        "recommendation",
        "moderate",
        "ct",
        "mild",
        "surgery",
        "risk",
        "severe",
        "symptomatic"
      ]
    },
    {
      "number": "10",
      "title": "9. Mitral regurgitation",
      "start_page": 37,
      "end_page": 45,
      "content": "8.6. Follow-up \nThe rate of progression of AS varies widely and asymptomatic patients, \ntheir family, and medical caregivers need careful education, with particu-\nlar emphasis on the importance of regular follow-up (ideally at a Heart \nValve Centre)14 and prompt reporting of symptoms. Asymptomatic pa-\ntients with severe AS should be followed up at least every 6 months to \nallow detection of early symptoms (using exercise testing if complaints \nare inconclusive) and any change in echocardiographic parameters (par-\nticularly LVEF). Serial measurements of natriuretic peptides can provide \nadditional useful information regarding the timing of treatment. \nYounger patients with mild AS and no significant leaflet calcification \nmay be followed up every 2–3 years. With increasing stenosis severity, \nprogression accelerates and follow-up intervals should be gradually re-\nduced.283,503 Several studies suggest that the prognosis of moderate de-\ngenerative AS is worse than previously considered,504,505 particularly if \nthere is significant valve calcification, and these patients should be re- \nevaluated at least annually. \nCardiac rehabilitation is frequently performed after AV intervention, \nespecially after surgery and in elderly patients, and is associated with im-\nproved activities of daily living and 6-minute walking distance.506 After \nvalve intervention, an early echocardiographic examination within the \nfirst weeks after valve replacement is recommended to document base-\nline prosthetic valve function. Cardiological evaluations and echocardio-\ngraphic examinations are recommended annually in patients with a \nbioprosthesis, and whenever changes in clinical symptoms or signs sug-\ngestive of valve dysfunction are noted. \n9. Mitral regurgitation \nChronic MR is one of the most common acquired valve patholo-\ngies,12,187 while acute MR is observed in the context of infective endo-\ncarditis, chordal rupture, or as a complication of myocardial infarction \n(papillary muscle rupture). MR either relates to anatomical changes of \nthe MV apparatus (primary), or to LV or LA dilatation and dysfunction \n(secondary).193 Since natural history, prognosis, and management differ \naccording to aetiologies, populations should be clearly distinguished in \nclinical practice and research.12,507 \n9.1. Primary mitral regurgitation \n9.1.1. Prevalence and aetiology \nPrimary mitral regurgitation relates to an anatomical lesion of one or \nmore of the three main components (not including the annulus) of the \nMV apparatus (valve leaflets, chordae tendineae, and papillary muscles). \nPMR is observed in 55% of patients with MR who require treatment.507 \nWhile degenerative disease related to fibroelastic deficiency or myxoma-\ntous alterations (in its most severe form, Barlow’s disease) are the most \ncommon aetiologies in higher-income countries, RHD is most frequently \nfound in the rest of the world. MV endocarditis is a separate entity of PMR \ncaused by acute or chronic infectious conditions and is discussed in the \ncorresponding Guidelines.5 In a small subgroup of patients, PMR is asso-\nciated with a higher incidence of ventricular arrhythmias, and sudden car-\ndiac death has been reported in individual cases, especially in patients with \nBarlow’s disease.508 The arrhythmogenic burden is independent from MR \nseverity and has been associated with mitral annular disjunction. Atrial dis-\nplacement of the posterior MV leaflet hinge point is assumed to cause ex-\ncessive mobility of the valvular apparatus and increases tension on the \npapillary muscles and the posterobasal myocardium, causing local fibrosis, \nwhich may lead to ventricular arrhythmias and sudden cardiac death.509 \n9.1.2. Evaluation \n9.1.2.1. Echocardiography and right heart catheterization \nEchocardiography is the diagnostic method of choice for the quantifica-\ntion of MR, determination of its aetiology, and identification of cardiac \nconsequences (Figure 10). TTE is used for initial evaluation that includes: \n(i) assessment of valve morphology (presence and location of prolapse \nor flail, calcifications, and/or mitral annular disjunction); (ii) integrative \nseverity grading; and (iii) quantification of LV and LA dimensions and \nfunction, as well as assessment of concomitant RV dysfunction.46 \nQuantitative parameters such as the effective regurgitant orifice area \n(EROA) have prognostic implications.510,511 Volumetric methods pro-\nvide additional information on MR severity [RVol and regurgitant frac-\ntion (RF)].512 Accurate colour flow settings must be used to avoid \noverestimation of MR severity. \nTransoesophageal echocardiography (TOE) represents the method of \nchoice to assess valve anatomy, leaflet quality, motion, and coaptation, as \nwell as to confirm MR severity.513 Three-dimensional TOE provides an \nexcellent morphological and functional view of the different valve seg-\nments, and should be used systematically when planning and performing \nsurgical or transcatheter repair.514 \nExercise echocardiography evaluates dynamic changes in regurgitant jet \nand pulmonary pressures during peak exercise, and might be helpful in pa-\ntients with discordant symptoms and regurgitation severity at rest.515,516 \nIn asymptomatic patients with severe PMR, increased LV or LA di-\nmensions, as well as elevated pulmonary pressures (>50 mmHg at \nrest), moderate or more secondary TR, and AF are important markers \nof worse prognosis, and should be considered for intervention timing \n(Figure 11; Section 9.1.4).517,518 \nRight heart catheterization remains important in patients with PMR \nfor confirmation of pulmonary artery pressures in case of discrepancy \nbetween echocardiographic MR severity and clinical symptoms, as well \nas in the presence of concomitant lung disease.519 \n9.1.2.2. Biomarkers \nCardiac biomarkers are recognized indicators of disease \nseverity with prognostic implications, but may also be non- \nspecific. NT-proBNP levels are directly related to the \nNew York Heart Association (NYHA) functional class in PMR.520 \nRecommendation Table 5 — Recommendations on in-\ndications for concomitant aortic valve replacement at \nthe time of coronary artery bypass grafting or ascending \naorta surgery \nRecommendations \nClassa \nLevelb  \nSAVR is recommended in symptomatic and \nasymptomatic patients with severe AS undergoing \nCABG or surgical intervention on the ascending \naorta. \nI \nC \nSAVR should be considered in symptomatic and \nasymptomatic patients with moderate ASc \nundergoing CABG or surgical intervention on the \nascending aorta. \nIIa \nC \n© ESC/EACTS 2025\nAS, aortic stenosis; AVA, aortic valve area; CABG, coronary artery bypass grafting; SAVR, \nsurgical aortic valve replacement. \naClass of recommendation. \nbLevel of evidence. \ncDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in \nnormal-flow conditions. Clinical assessment is essential to determine whether SAVR is \nappropriate for an individual patient.   \nESC Guidelines                                                                                                                                                                                          4671 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nIn a multicentre registry including more than 1300 patients with PMR, \nincreased BNP level was an independent predictor of long-term mor-\ntality under medical treatment. However, pre-operative BNP activation \ndid not impact long-term mortality after surgical treatment.96 \n9.1.2.3. Cardiac magnetic resonance and computed tomography \nCardiac magnetic resonance imaging is an alternative to precisely quan-\ntify RVol and RF in cases of inconclusive or discordant measurements, \nand the gold standard to determine cardiac dimensions and chamber \nvolumes.521,522 The combination of planimetered volumetric methods \nand phase contrast measurement of the MV inflow are used for this \npurpose.523 In patients with Barlow’s disease and mitral annular disjunc-\ntion, CMR-detected myocardial fibrosis524 has been associated with \nventricular arrhythmias and sudden cardiac death.525 \nCardiac computed tomography provides high-resolution anatomical \ndetails of the entire MV apparatus523,526 and increasingly plays a role in \nMV intervention planning, particularly in the assessment of arterial access \nfor extracorporeal circulation and the presence of MV calcification in min-\nimally invasive surgery,527 as well as the feasibility of transcatheter MV im-\nplantation (TMVI) based on annulus size and risk of LVOT obstruction.528 \n\u001f\u001e\u001d\u001c\u001e\u001b\u001e\u001a\u001d\u0019\u001a\u0018\u0017\u001b\u001e\u001d\u0016\u0015\u001a\u001b\u0014\u0013\u001d\u0012\u0018\u001d\u0018\u001c\u0013\u0011\u001b\u0010\u001a\u000f\u001a\u0014\u0018\u0017\u001b\u000e\u001a\r\u001a\u0016\u001a\u001b\u0018\u001a\u0011\u0018\u001c\u0011\u0015\n\f\u001d\u0016\u0015\u001a\u001b\u0014\u001a\u0011\u0018\u0016\u001d\u001e\u001b\u000b\u001a\u0018\n\f\u001d\u0016\u0015\u001a\u001b\n\u0013\u001e\u0013\u000e\t\u000e\u0018\u0013\u001e\u001c\u0014\u001b\u0014\u0013\u0011\r\u001a\u0016\u0015\u001a\u0011\u0014\u001a\u001b\b\u0013\u0011\u001a\n\u0007\u001a\u0011\u001d\u001b\u0014\u0013\u0011\u0018\u0016\u001d\u0014\u0018\u001d\u001b≥7 mm (≥8 mm for biplane)\n\u0006\u0005\u001e\u0004\u0013\u0011\u001d\u0016\t\u001b\r\u001a\u001c\u0011\u001b\u000e\t\u000e\u0018\u0013\u001e\u001c\u0014\u001b\u0019\u0013\u0003\u001b\u0016\u001a\r\u001a\u0016\u000e\u001d\u001e\n\u0002\u0001\u0003\u001d\r\u001a\u001b\u0010\u0013\u0004\u001c\u0011\u001d\u0011\u0018\u001b\u001b\u0004\u000e \n\u0007­\u001b\u0004\u001c\u0018\u0016\u001d\u001e\u001b\u001b\u0007­\u001b\f\u0007­\u001b\n\f\u0007\u0002\u001b≥\u001b\u0004\u0004\n\f\u0007\u0002\u001f\u001b\u001b\u001b\u001b≤60%\n\u001c\u001d\u0004\u001a\u0018\u001a\u0016\u001b≥\u001b\u0004\u0004\n\f\u0007\u001b≥60 mL/m2\n\u0018\u0016\u001c\u001d\u001e\u001b\u0016\u001c\u001e\u001e\u001d\u0018\u001c\u0013\u0011\n\u001e\u001c\u0011\u001c\u0014\u001d\u001e\u001b\u001d\u0011\u0010\u001b\n\u001a\u0014\n\u0013\u0014\u001d\u0016\u0010\u001c\u0013\u0015\u0016\u001d\u0012\n\u001c\u0014\n\u0014\u0016\u001c\u0018\u001a\u0016\u001c\u001d\u001d\n\f\u0007\u0002\u001b≤\u001b\u0004\u0004\n\f\u0007\u0002\u001f\u001b\u001b\u001b\u001b20%−50%\n\u0018\u0016\u001c\u001d\u001e\n\n\u0006\n\u0007\u001a\u0011\u0018\u0016\u001c\u0014\u0005\u001e\u001d\u0016\n\n\u000e\u000e\u001a\u000e\u000e\u0004\u001a\u0011\u0018\u001b\u0013\u000f\u001b\n\u0002\u0014\n\u0013\u0014\u001d\u0016\u0010\u001c\u0013\u0015\u0016\u001d\u0012\n\u001c\u0014\n\u0014\u0016\u001c\u0018\u001a\u0016\u001c\u001d\u001b\u000f\u0013\u0016\u001b\u000e\u001a\r\u001a\u0016\u001a\u001b\n\u001a\u0014\n\u001d\u0011\u001c\u000e\u0004\u000e\n\f\u001a\u000f\u0018\u001b\r\u001a\u0011\u0018\u0016\u001c\u0014\u001e\u001a\n\u0016\u001c\u0018\u001a\u0016\u001c\u001d\u001b\u000f\u0013\u0016\u001b\u001c\u0011\u0018\u001a\u0016\r\u001a\u0011\u0018\u001c\u0013\u0011\n\f\u001a\u000f\u0018\u001b\u001d\u0018\u0016\u001c\u0005\u0004\n\u0006\u0006\u001b>\u001b\u0004\u0004\u0015\u001b\n\u001a\u0014\u0013\u0011\u0010\u001d\u0016\t\u001b­\n≥ moderate\n\u001c\u0015\n\u0018\u001b\n\u001a\u001d\u0016\u0018\n\u0005\u001d\u001e\u001c\u0018\u001d\u0018\u001c\r\u001a\n\u001a\u0004\u001c\u0001\u0005\u001d\u0011\u0018\u001c\u0018\u001d\u0018\u001c\r\u001a\n\u0005\u001d\u0011\u0018\u001c\u0018\u001d\u0018\u001c\r\u001a\n\u0002 ≥40 mm2 (or ≥30 mm2 if elliptical regurgitant orifice area)  \n\u0007\u0013\u001e\u001b≥\u001b\u0004\f\u001b\u0013\u0016\u001b≥\u001b\u0004\f\u001b\u001c\u000f\u001b\u001e\u0013\u0003\u001b\u0019\u0013\u0003\u001b\u0014\u0013\u0011\u0010\u001c\u0018\u001c\u0013\u0011\u000e \u001b\n\u001f\u001b≥\u001b\nFigure 10 Echocardiographic assessment of patients with mitral regurgitation. EROA, effective regurgitant orifice area; LAVI, left atrial volume index; \nLVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVOT, left ventricular outflow tract; MR, mitral regurgitation; PMR, \nprimary mitral regurgitation; RF, regurgitant fraction; RVol, regurgitant volume; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; TR, tricuspid regurgitation; VTI, velocity time integral. aSee Table 7 for criteria predicting outcome improvement.   \n4672                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nPatient with severe primary mitral regurgitation\nSymptoms\nLVEF ≤60% or LV dilatation\n(LVESD ≥40 mm or LVESDi ≥20 mm/m2)\nHigh surgical risk according \nto the Heart Team\nAnatomical suitability\nfor TEERa\nPresence of at least 3 of the following:\n• AF\n• SPAP at rest >50 mmHg\n• LAVI ≥60 mL/m2 or diameter ≥55 mm\n• Concomitant secondary TR ≥moderate\nSigniﬁcant LA dilatation\n(LAVI ≥60 mL/m2 or diameter ≥55 mm)\nand high likelihood of durable repair\nWatchful\nwaiting\nMV surgery\n(preferably\nrepair)\n(Class IIa)\nTEER\n(Class IIa)\nSurgical\nMV repair\n(Class IIa)\nAF or \nSPAP at rest >50 mmHg\nMV surgery\n(preferably\nrepair)\n(Class I)\nTMVI\nif feasible\nHigh risk\nsurgery in \nselected \npatients\nMedical\ntreatment\nFigure 11 Management of patients with severe primary mitral regurgitation. AF, atrial fibrillation; LA, left atrial; LAVI, left atrial volume index; LV, left \nventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic diameter; LVESDi, left ventricular end-systolic diam-\neter indexed to BSA; MV, mitral valve; SPAP, systolic pulmonary artery pressure; TEER, transcatheter edge-to-edge repair; TMVI, transcatheter mitral \nvalve implantation; TR, tricuspid regurgitation. aSee Supplementary data online, Table S2.   \nESC Guidelines                                                                                                                                                                                          4673 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nDue its high sensitivity for detection of calcifications, CCT is instru-\nmental for procedural planning (surgical and transcatheter) in patients \nwith MAC.529 \n9.1.2.4. Genetic evaluation \nThere is increasing evidence that specific mitral pathologies may be as-\nsociated with genetic conditions. A meta-analysis of six genome-wide \nassociation studies identified 14 potential genetic loci associated with \nprimary MR. By comprising epigenetic, transcriptional, and proteomic \ndata, the following genes could be identified as potential genetic sources \nof the pathology: LMCD1, SPTBN1, LTBP2, TGFB2, NMB, and ALPK3.530 \nHowever, genetic testing is not recommended in routine practice. \n9.1.3. Medical therapy \nMedical therapy has a limited role in patients with PMR. Afterload re-\nduction with sodium nitroprusside has been used as a bridge to an \nintervention in patients with acute severe PMR without signs of hypo-\ntension. Inotropic agents and diuretics are usually indicated to reduce \nfilling pressures and control pulmonary congestion, while the implant-\nation of an intra-aortic balloon pump helps to further reduce afterload \nin exceptional cases of acute PMR. \nIn chronic PMR without signs of LV dysfunction or criteria for an \nintervention, there is no evidence supporting prophylactic afterload re-\nduction. Patients with PMR and impaired LV function should receive \nGDMT according to HF Guidelines.340 \n9.1.4. Indications for intervention \nUrgent surgery or transcatheter treatment is indicated in patients with \nacute severe PMR because it is poorly haemodynamically tolerated. In pa-\ntients with papillary muscle rupture and endocarditis, surgical valve replace-\nment is generally required, while acute degenerative chordal rupture can be \ntreated with surgical MV repair or TEER in high-risk patients. \nIndications for surgery in patients with chronic asymptomatic and \nsymptomatic PMR are summarized in Recommendation Table 6 and  \nFigure 11. In cases of severe PMR, restoring the anatomy by surgical \nMV repair, including annuloplasty, is the treatment of choice in operable \npatients when an optimal and durable result is expected. According \nto contemporary data, the procedure can be performed with \na low mortality risk (1.2%) in appropriately selected patients.531 \nCompared with replacement, MV repair has been associated with \nlower peri-operative mortality along with significantly better long- \nterm survival and functional outcomes.532,533 Repair of more com-\nplex pathologies such as valves with annular or leaflet calcifications, \nas well as in cases of RHD, is challenging and should be attempted in \nexperienced Heart Valve Centres.534–536 When MV repair is not \nfeasible, valve replacement with preservation of the subvalvular ap-\nparatus should be performed.537 \nHigh-risk and elderly patients with chronic PMR, though uncommon, \nmay benefit from a less-invasive M-TEER procedure.538 Peri- \ninterventional and mid-term results with regard to residual MR and \nmean transmitral gradient are closely related to patient outcomes.538 \nThe use of latest-generation devices along with a growing team experi-\nence have improved results, and allow for the successful treatment \nof more complex anatomical conditions (Supplementary data online,  \nTable S2).539,540 The decision regarding the mode of intervention or \nconservative treatment should be made by the Heart Team, considering \nclinical and anatomical characteristics, as well as procedural risks and \npatient preference. The longer-term efficacy of TEER compared with \nsurgery is still under investigation in high- (NCT03271762) and \nintermediate-risk PMR patients (NCT04198870), as well as in \nall-risk-category patients >60 years of age (NCT05051033).541 TMVI \nis very effective in abolishing MR in selected high-risk patients, particular-\nly those with complex MV anatomy for TEER (Supplementary data \nonline, Table S2).542,543 The major drawbacks of current TMVI systems \ninclude limited availability, high screening failure rate, as well as the risk of \nLVOT obstruction and valve thrombosis. Limited data exist for PMR pa-\ntients and regarding mid-term prosthesis durability. \nIn patients with asymptomatic PMR with signs of LV dysfunction \n(i.e. LVEF ≤60%, LVESD ≥40 mm, or LVESDi ≥20 mm/m2) the bene-\nfit of early surgery is well established.544–546 Furthermore, there is in-\ncreasing evidence that the presence of LA dilatation [LA volume index \n(LAVI) ≥60 mL/m2 or LA diameter ≥55 mm], AF, systolic pulmonary \nartery pressure (SPAP) at rest of >50 mmHg, and concomitant mod-\nerate or severe secondary TR are associated with worse long-term \nprognosis irrespective of LV function after corrective surgery, and \nshould therefore prompt referral in low-risk patients, particularly if \na high probability of MV repair is expected.517,518,547 A recent study \nshowed that women have a higher risk of long-term mortality after \nMV repair than men, even at lower degrees of ventricular dilatation \nand dysfunction, suggesting the potential usefulness of sex-specific in-\ndexed thresholds.548 Ventricular arrhythmias in patients with MV pro-\nlapse have been linked to impaired prognosis and possibly sudden \ncardiac death, especially in the presence of mitral annular disjunc-\ntion.549–551 Ring annuloplasty stabilizes the posterior annulus, reduces \ntraction on the subvalvular apparatus,552 and may lower the risk of ar-\nrhythmias.553 Minimally invasive surgery via right mini-thoracotomy is \nused with increasing frequency in experienced centres.554–556 A re-\ncent RCT demonstrated similar safety and efficacy compared with \nconventional sternotomy. Mini-thoracotomy was associated with \nshorter hospital stay and improved physical activity within the first \n6 weeks after surgery, a difference that disappeared at 12 weeks.557 \nThe use of minimally invasive MV surgery may therefore be consid-\nered to reduce hospital stay and accelerate recovery in experienced \ncentres. However, in a national registry, these benefits were less \nclear.558 \nRecommendation Table 6 — Recommendations on \nindications for intervention in severe primary mitral \nregurgitation (see also Supplementary data online, \nEvidence Tables 14–16) \nRecommendations \nClassa \nLevelb  \nMV repair is the recommended surgical technique to \ntreat patients with severe PMR when the result is \nexpected to be durable.26,532,533,559,560 \nI \nB \nMV surgery is recommended in symptomatic \npatients with severe PMR considered operable by \nthe Heart Team.26,532,533,561 \nI \nB \nMV surgery is recommended in asymptomatic \npatients with severe PMR and LV dysfunction \n(LVESD ≥40 mm or LVESDi ≥20 mm/m2 or \nLVEF ≤60%).522,544,545 \nI \nB                         \nContinued  \n4674                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n9.1.5. Follow-up \nAsymptomatic patients with severe MR not fulfilling the criteria for an \nintervention, and with documented preserved exercise capacity, should \nundergo clinical and echocardiographic follow-up twice per year (watch-\nful waiting strategy), ideally in the setting of a Heart Valve Clinic.568 \nFollow-up may also include serial measurements of BNP levels, electro-\ncardiogram (ECG) and/or Holter monitoring, and (in selected cases) ex-\nercise echocardiography and CMR to confirm MR severity, and cardiac \nchamber function and dimensions.46 Asymptomatic patients with mod-\nerate MR and preserved LV function can be followed on a yearly basis \nwith echocardiographic assessment every 1 or 2 years. \nThe frequency of follow-up after an intervention depends on the type \nof procedure performed. Very good long-term durability of MV repair in \nPMR due to valve prolapse with a low recurrence rate has been reported \nat experienced centres with freedom from moderate or severe MR of \n87.5% at 20 years.533,559 Serial clinical and echocardiographic follow-up \nin patients without pre-operative LV dysfunction or rhythm abnormal-\nities every 2–3 years thereafter is sufficient. Patients with atrial or ven-\ntricular arrhythmias possibly related to MV disease should be further \nevaluated using continuous ECG monitoring. Patients with recurrent \nMR after surgical ring annuloplasty frequently undergo repeat surgery \n(usually MV replacement), while transcatheter alternatives are reserved \nfor selected high-risk patients because of the risk of increased gradients \n(M-TEER), PVL, and LVOT obstruction (mitral valve-in-ring proce-\ndures).569,570 In patients undergoing MV replacement, closer follow-up \non a yearly basis is required due to the risk of prosthetic valve dysfunction \nor SVD (see Section 14.4). Following TEER, reported rates of residual MR \nand increased transmitral gradients are higher than after surgical repair, \nsuggesting that yearly follow-up is appropriate.571 Although rare, the \nneed for surgical treatment after failed TEER is associated with increased \nperi-operative mortality and low valve repair rates,541,572 while trans-\ncatheter solutions to detach TEER implants and replace the valve have \nbeen described in few cases.573,574 \n9.2. Secondary mitral regurgitation \n9.2.1. Prevalence and aetiology \nSecondary mitral regurgitation is present when the MV structure appears \ngrossly normal but the MV is nonetheless incompetent, due to alterations \nin LV and LA geometry, dyssynchrony, and imbalances between MV clos-\ning and tethering forces.575 The prevalence of severe SMR in patients with \nchronic HF is ∼10% and higher in patients with reduced vs preserved LVEF \n(25% vs 4%).576 Secondary mitral regurgitation can be classified as atrial or \nventricular with different pathophysiological and morphological character-\nistics, as well as contrasting prognostic and therapeutic implications.577 \nVentricular SMR is more common and associated with worse long-term \nprognosis.513,578–580 Dilated or ischaemic cardiomyopathy are the most \nfrequent causes of severe ventricular SMR. Acute HF exacerbation may \noccur in patients with chronic HF due to a renewed ischaemic event, ar-\nrhythmia, infection, or volume overload. Atrial SMR is due to pure mitral \nannular dilation and is observed in patients with long-standing AF and/or \nHFpEF.581 Factors predisposing to atrial SMR include age ≥65 years, fe-\nmale sex, LA dilatation, and diastolic dysfunction.582 From a morphological \npoint of view, ventricular SMR is characterized by leaflet tethering and re-\nstricted motion combined with annular dilation, while annulus enlarge-\nment and flattening leading to planar coaptation are predominantly \nobserved in atrial SMR. The prevalence of atrial SMR has been underesti-\nmated in the past and was occasionally misclassified as PMR due to \npseudo-prolapse with leaflet tethering in advanced stages. \n9.2.2. Evaluation \nEchocardiographic criteria to define significant SMR according to aeti-\nology are reported in Figure 10. Importantly, SMR assessment should \nbe performed after optimization of medical therapy and in a euvolaemic \nand normotensive state. When quantifying EROA and RVol in SMR, \nlower thresholds may apply to define severe regurgitation because of \nthe potential elliptical regurgitant orifice and/or the low-flow state. \nAn EROA of ≥30 mm2 and/or an RVol of ≥45 mL has been identified \nas having a significant impact on outcomes,45 with prognosis improved \nafter treatment.583,584 Cardiac magnetic resonance is used to confirm \nSMR severity and assess cardiac chamber function and dimensions. \nThe extent of myocardial fibrosis, as assessed with CMR, has been as-\nsociated with poor prognosis.585 Owing to the dynamic nature of SMR, \nexercise echocardiography may help to identify patients with severe \nSMR when values at rest are inconclusive.45 \n9.2.3. Definition of atrial secondary mitral \nregurgitation \nCharacteristics distinguishing between atrial and ventricular SMR are \ndisplayed in Figure 12. \nSurgical MV repair is recommended in low-risk \nasymptomatic patients with severe PMR without LV \ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2, \nand LVEF >60%) when a durable result is likely, if at \nleast three of the following criteria are \nfulfilled:517,547,562–564 \n• AF \n• SPAP at rest >50 mmHg \n• LA dilatation (LAVI ≥60 mL/m2 or LA \ndiameter ≥55 mm) \n• Concomitant secondary TR ≥ moderate. \nI \nB \nMV surgery should be considered in asymptomatic \npatients with severe PMR without LV dysfunction \n(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF  \n>60%) in the presence of PH (SPAP at rest  \n>50 mmHg), or AF secondary to MR.517,518,562,565 \nIla \nB \nSurgical MV repair should be considered in low-risk \nasymptomatic patients with severe PMR without LV \ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2, \nand LVEF >60%) in the presence of significant LA \ndilatation (LAVI ≥60 mL/m2 or LA \ndiameter ≥55 mm), when performed in a Heart \nValve Centre and a durable repair is likely.517,565 \nIIa \nB \nTEER should be considered in symptomatic patients \nwith severe PMR who are anatomically suitable and \nat high surgical risk according to the Heart \nTeam.538,540,566 \nIIa \nB \nMinimally invasive MV surgery may be considered at \nexperienced centres to reduce the length of stay and \naccelerate recovery.557,567 \nIIb \nB \n© ESC/EACTS 2025\nAF, atrial fibrillation; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left \nventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular \nend-systolic diameter; LVESDi, left ventricular end-systolic diameter indexed to body \nsurface area; MR, mitral regurgitation; MV, mitral valve; PH, pulmonary hypertension; \nPMR, primary mitral regurgitation; SPAP, systolic pulmonary artery pressure; TEER, \ntranscatheter edge-to-edge repair; TR, tricuspid regurgitation. \naClass of recommendation. \nbLevel of evidence.   \nESC Guidelines                                                                                                                                                                                          4675 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nAtrial SMR is most frequently defined by the presence of the follow-\ning key criteria:513,578–580,586–590 \n• preserved LVEF (≥50%) without regional wall motion abnormalities \nor leaflet tethering; AND \n• no or mildly dilated LV cavity [LV end-diastolic dimension of <56 mm \nin women and <63 mm in men; indexed LV end-diastolic volume of \n<71 mL/m2 (in women) or <79 mL/m2 (in men)]; AND \n• mitral annulus (MA) dilatation [anteroposterior (AP) diameter of \n>35 mm]; AND \n• enlarged LA (LAVI >34 mL/m2).  \nEchocardiography frequently reveals normal leaflet motion with pla-\nnar coaptation, and normal leaflet morphology with a central MR jet in \natrial SMR. However, at advanced stages, an overlap between atrial and \nventricular SMR criteria can be observed in the case of late LV damage \ndue to continuous volume overload.591,592 Clinical criteria (i.e. history \nof AF and/or diagnosis of HFpEF) are also useful and should be taken \ninto consideration. \n9.2.4. Management of ventricular secondary mitral  \nregurgitation \n9.2.4.1. Medical and device therapy \nIn patients with ventricular SMR, GDMT for the treatment of HF is re-\ncommended prior to any MV intervention.339,340 The combination of \nACE-Is/ARBs or angiotensin receptor/neprilysin inhibitors, beta- \nblockers, mineralocorticoid receptor antagonists, and sodium–glucose \nco-transporter 2 inhibitors (SGLT2is) at the maximum tolerated doses \nis recommended according to the HF Guidelines.340 Initiation and up- \ntitration of neurohormonal drugs need to be tailored according to \nthe patient profile, mainly based on BP, heart rate, potassium levels, \nand renal function.593 Notably, GDMT up-titration must be rapid (with-\nin 6 weeks) and take place in the context of close follow-up visits, es-\npecially in the case of a recent hospitalization for acute HF.594 About \n40% of patients with ventricular SMR experience improvement of \nSMR severity after 1–3 months of optimized GDMT.595,596 Cardiac re-\nsynchronization therapy (CRT) should also be considered as part of HF \nmanagement before an MV intervention according to HF guideline cri-\nteria (LVEF ≤35% and wide QRS).597,598 Although no dedicated RCTs \n\u001f\u001e\n\u001d\u001c\n\u001b\u001a\u0019\n\u001f\u0018\n\u0018\u0017\n\u001d\u0018\n\u001f\u001e\n\u001d\u001c\n\u001b\u001a\u0019\n\u001f\u0018\n\u0018\u0017\n\u001d\u0018\n\u001f\u001e\u0016\u0015\u0014≥\u0013\u0012\u0011\u0014\u0010\u000f\u0019\u000e\r\f\u0019\u0014\u000b\u001a\n\u000f\r\t\b\u0007\n\u0010\b\u0007\u0007\u0014\u0006\r\u0019\u000f\r\t\u0014\b\u0005\t\r\u000b\u0006\b\u0007\u000f\u0019\u000f\u001a\u0004\n\u0003\r\u0014\r\u000b\u0014\u0006\u000f\u0007\u0002\u0007\u0001\u0014\u0002\u000f\u0007\b\u0019\u001a\u0002\u0014\u001f\u001e\u0014\b\u000f\u0019\u0001\b\n\u0010\u000f\u0019\u000e\r\f\u0019\u0014\u0007\u001a\b\u001a\u0019\u0014\u0019\u001a\u0019\u000e\u001a\u000b\u000f\t\n\u001d\u000f\u0019\u000b\b\u0007\u0014\b\t\t\f\u0007\f\u0004\u0014\u0002\u000f\u0007\b\u0019\b\u0019\u000f\r\t\n\u0018\u001f \u0013\u0014\u0006\u0006­\n\u0016\t\u0007\b\u000b\n\u001a\u0002\u0014\u001f\u0018\u0014\u001f\u0018\u001e\u0014\u001f \u0014\u0006\u001f\u0006­\n\u001f\u001e\u0016\u0015\u0014\u0013\u0012\u0011\u0014\u0010\u000f\u0019\u000e\u0014\r\u000b\u0014\u0010\u000f\u0019\u000e\r\f\u0019\n\u000b\u001a\n\u000f\r\t\b\u0007\u0014\u0010\b\u0007\u0007\u0014\b\u0005\t\r\u000b\u0006\b\u0007\u000f\u0019\u000f\u001a\u0004\n\u001c\u001a\u0004\u0019\u000b\u000f\u0019\u000f\u001a\u0014\u0007\u001a\b\u001a\u0019\u0014\u0006\r\u0019\u000f\r\t\n\u0010\u000f\u0019\u000e\u0014\u0019\u001a\u0019\u000e\u001a\u000b\u000f\t\n\u0003\r\u000b\u0006\b\u0007\u0014\u0007\u001a\b\u001a\u0019\u0014\u0006\r\u000b\u000e\r\u0007\r\n\u0001\n\u001a\t\u0019\u000b\b\u0007\u0014\r\u000b\u0014\u001a\u001a\t\u0019\u000b\u000f\u0014\u001b\u001a\u0019\n\u001e\u001d\u001c\u001f\u001b\u001a\u0019\u0018\u001d\u001a\u0019\u0017\n\u0003\r\u000b\u0006\b\u0007\u0014\u0007\u001a\b\u001a\u0019\u0014\u0006\r\u0019\u000f\r\t\n\u000f\u0007\b\u0019\u001a\u0002\u0014\u001f\u001e\n\u0003\r\u000b\u0006\b\u0007\u0014\u0007\u001a\b\u001a\u0019\u0014\u0006\r\u000b\u000e\r\u0007\r\n\u0001\n\u000f\u0007\b\u0019\u001a\u0002\u0014\u001f\u0018\n\u0004\f\b\u0007\u0007\u0001\u0014\u001a\t\u0019\u000b\b\u0007\u0014\u001b\u001a\u0019\n\u000f\u0007\b\u0019\u001a\u0002\u0014\u001d\u001e\u0014\b\t\t\f\u0007\f\u0004\n\u0016\u0015\u0015\u0019\u0018\u0019\u0014\u0013\u0017\u0012\u001f\u001d\u001b\u0011\u0014\u001b\u0017\u001a\u0015\u0019\u0014\u0010\u001a\u0017\u000f\u0011\u0019\u001b\u001f\u001b\u001a\u0019\u0018\u001d\u001a\u0019\u0017\u000e\n\u0018\u0019\u000b\u000f\b\u0007\u0014\u0005\u000b\u000f\u0007\u0007\b\u0019\u000f\r\t\n\u0004\u000e\b\u001a\u0006\u000f\u0014\u000e\u001a\b\u000b\u0019\u0014\u0002\u000f\u0004\u001a\b\u0004\u001a\n\u0015\u0016\u0015\n\u000f\u0007\b\u0019\u001a\u0002\u0014\b\u000b\u0002\u000f\r\u0006\u0001\r\b\u0019\u000e\u0001\n\u0016\u0015\u0015\u0019\u0018\u0019\u0014\u0013\u0017\u0012\u001f\u001b\u0012\u0019\u0013\u0019\u001b\u0017\u0012\u001f\u001b\u001a\u0019\u0018\u001d\u001a\u0019\u0017\n\u0016\u0018\u001a\u0019\u0017\u0012\n\r\f\u000b\n\n\u001d\u0013\u0018\u001a\u0019\u001b\t\u0012\u0017\u001a\n\r\f\u000b\nFigure 12 Most frequently used criteria for the diagnosis of atrial secondary mitral regurgitation. AO, aorta; AP, anteroposterior; HFpEF, heart failure \nwith preserved ejection fraction; LA, left atrium/left atrial; LAVI, left atrial volume index; LV, left ventricle/left ventricular; LVEF, left ventricular ejection \nfraction; MA, mitral annulus; MR, mitral regurgitation; MV, mitral valve; SMR, secondary mitral regurgitation. aLV end-diastolic dimension of <56 mm in \nfemales and <63 mm in males; indexed LV end-diastolic volume <71 mL/m2 (in women) or <79 mL/m2 (in men). bAdditional echocardiographic criteria \nfor atrial SMR may no longer be fulfilled in advanced stages.   \n4676                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nexist, SMR reduction by at least one grade has been described in 40%– \n60% of patients and is associated with reverse LV remodelling and im-\nproved clinical outcomes.597,599,600 \n9.2.4.2. Indications for intervention \nThe management of patients with ventricular SMR should be discussed \nby a multidisciplinary Heart Team including HF specialists. The indica-\ntion for intervention is based on the persistence of symptoms (i.e. \nNYHA class II–V) despite adequate GDMT and CRT, if indicated \n(Figure 13). GDMT is the only option for very frail patients or those \nwith limited life expectancy. \nIn the Cardiovascular Outcomes Assessment of the MitraClip \nPercutaneous Therapy for Heart Failure Patients with Functional \nMitral Regurgitation (COAPT) trial, M-TEER was shown to be safe \nand reduced recurrent HF hospitalization and all-cause mortality \nat 2 and 5 years of follow-up, compared with optimized GDMT \nin patients with ventricular SMR without relevant CAD.583,584 \nIn a second study (Percutaneous Repair with the MitraClip Device for \nVentricular SMR\nPersistence of symptoms and SMR\nAtrial SMR\nPatient with severe symptomatic SMR without concomitant CAD\nHigh surgical risk according \nto the Heart Team\nClinical and echocardiographic\ncriteria fulﬁlleda according \nto the Heart Team \nAdvanced HF\nLVAD\nor HTx\nGDMT optimization\nincluding CRT, if indicated\nPersistence of symptoms and SMR\nTEER \n(Class IIb)\nMV surgery\nin patients not\nsuitable for TEERb\n(Class IIb)\nTEER\nin patients with\ncontraindication(s) \nor waiting for\nLVAD or HTx\n(Class IIb)\nMedical therapy\nand follow-up\nOptimization of medical treatment\nincluding rate or rhythm control\nTEER\n(Class I)\nMV\nsurgery\n(Class IIa)\nTEER\n(Class IIb)\nFigure 13 Treatment of severe secondary mitral regurgitation without concomitant coronary artery disease. CAD, coronary artery disease; CRT, \ncardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, heart failure; HTx, heart transplantation; LVAD, left ventricular assist \ndevice; MV, mitral valve; SMR, secondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. aSee Table 7. bSee Supplementary data online,  \nTable S2.   \nESC Guidelines                                                                                                                                                                                          4677 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nSevere Functional/Secondary Mitral Regurgitation, MITRA-FR), no dif-\nferences were demonstrated for the combined primary endpoint of all- \ncause mortality or HF hospitalization at 1 and 2 years.601,602 These di-\nverging results might be explained by effect sizes of the trials, differences \nin trial design, patient selection and follow-up, echocardiographic assess-\nment of SMR severity, use of GDMT, and technical factors.603–605 A \nthird RCT, the Randomized Investigation of the MitraClip Device in \nHeart Failure: 2nd Trial in Patients with Clinically Significant \nFunctional Mitral Regurgitation (RESHAPE-HF-2) trial showed a 36% \nreduction in the rates of HF hospitalization or cardiovascular death \nat 2 years in the intervention arm driven by reduction of first or recur-\nrent HF hospitalization. When considered in isolation, cardiovascular \nmortality was not significantly reduced during the observation period. \nIn addition, there was a significant improvement in quality of life as \nmeasured by the KCCQ overall score (mean difference between study \ngroups, 10.9 points; 95% CI, 6.8–15.0; P <0.001).606 A recent study-level \nmeta-analysis of these three trials showed a significant reduction of HF \nrehospitalization at 24 months (HR, 0.63, 95% CI, 0.50–0.80) and the \ncomposite of death and all-cause hospitalizations (HR, 0.72, 95% CI, \n0.51–0.999).607 However, there was no statistically significant difference \nin death from any cause or cardiovascular death at 24 months. \nTranscatheter edge-to-edge repair is therefore recommended to re-\nduce HF hospitalizations, and improve quality of life, in symptomatic pa-\ntients with persisting severe SMR despite optimized GDMT fulfilling \nspecific clinical and echocardiographic criteria (Table 7). Although less \nchallenging than in PMR, anatomical suitability for TEER needs to be as-\nsessed upfront (Supplementary data online, Table S2). There is also in-\ncreasing observational evidence supporting the use of TEER for the \nimprovement of symptoms, functional capacity, and quality of life in pa-\ntients with ventricular SMR not fulfilling the clinical and echocardio-\ngraphic criteria for outcome improvement.608–612 This particularly \napplies to patients not tolerating GDMT in whom TEER may help up- \ntitration, as well as those with recent myocardial infarction and persist-\nent severe ventricular SMR.203,613 \nTranscatheter implantation of an indirect annuloplasty device into \nthe coronary sinus has been proposed as an alternative that preserves \nvalve integrity. Despite rather modest SMR reduction (22.4% decrease \nin mitral RVol) and no significant effect on quality of life in a small sham- \ncontrolled RCT, symptomatic improvement and reverse remodelling \nwere observed in registries at 1 year.614,615 Heart transplantation or \nleft ventricular assist device (LVAD) implantation should be considered \nin selected patients with severe ventricular SMR and advanced HF. \nIn patients with ventricular SMR without relevant CAD, indications \nfor isolated MV surgery are restrictive owing to procedural risks and \nthe absence of proven mortality benefit.616 The Multicenter, \nRandomized, Controlled Study to Assess Mitral Valve Reconstruction \nfor Advanced Insufficiency of Functional or Ischemic Origin \n(MATTERHORN) trial, which included a mixed population mainly com-\nposed of patients with ventricular SMR (84%), demonstrated that TEER \nis non-inferior to surgical repair or replacement with regard to a com-\nposite endpoint of death, HF hospitalization, MV reintervention, im-\nplantation of an assist device, or stroke within 1 year after the \nprocedure, and showed a better safety profile.617 In patients with se-\nvere ischaemic ventricular SMR and concomitant CAD requiring coron-\nary revascularization, MV surgery at the time of CABG is \nrecommended, unless the patient is at high surgical risk and/or the cor-\nonary anatomy is suitable for PCI. Although isolated undersized mitral \nannuloplasty is the most commonly performed MV repair procedure, \nrecurrent MR rates were high with this technique in an RCT618 and re-\nverse LV remodelling is limited, especially in patients with an increased \ntenting area (>1.35 cm2/m2 BSA),619 in whom MV replacement is usu-\nally required.620 The addition of subvalvular modification in patients \nwith LV dilatation and pronounced MV leaflet tenting may improve re-\nsults for MV repair,621 but durability and impact on HF symptoms with \nthis technique require further investigation. \nThe treatment of moderate ischaemic SMR in patients undergoing \nCABG remains controversial. Meta-analyses, including four RCTs com-\nparing CABG with concomitant MV surgery vs CABG alone, have \nshown lower rates of recurrent MR but no benefit in terms of mortality \nand clinical outcomes.622–624 Therefore, clinical decision-making should \nweigh peri-operative risks of more complex surgery against the long- \nterm risk of MR progression. \n9.2.4.3. Follow-up \nPatients with ventricular SMR need to be followed up carefully after \nintervention by an HF specialist, because they remain at increased \nrisk of events despite intervention. The 5-year cumulative incidence \nof all-cause death or HF hospitalization was 73.6% in the device arm \nof the COAPT study.584 Clinical, laboratory, and echocardiographic \nevaluation every 3 or 6 months, according to the HF stage, is recom-\nmended. Durability of the procedural result, as well as congestion status \nand the need for further GDMT optimization facilitated by SMR reduc-\ntion,613 need to be assessed. Patients and families should be trained in \nmonitoring vital signs, body weight, and HF symptoms to avoid late hos-\npital admissions and facilitate management of possible decompensation. \nAlso, patients must be educated on the importance of not discontinuing \nmedical therapies after intervention since the two treatments (devices \nand drugs) are complementary. \nPatients with ventricular SMR, who are asymptomatic and/or have \nmoderate or dynamic MR, should undergo clinical and echocardio-\ngraphic follow-up at least twice per year. \nTable 7 Clinical and echocardiographic criteria pre-\ndicting outcome improvement in patients with severe \nventricular secondary mitral regurgitation undergoing \nmitral transcatheter edge-to-edge repair  \nAnatomy deemed suitable for M-TEER \nNYHA class ≥II \nLVEF 20%–50% \nLVESD ≤70 mm \nAt least one HF hospitalization within the previous year or increased \nnatriuretic peptide levels (BNP ≥300 pg/mL or NT-proBNP ≥1000 pg/mL) \nSPAP ≤70 mmHg \nNo severe RV dysfunction \nNo Stage D or advanced HF \nNo CAD requiring revascularization \nNo severe AV and/or TV disease \nNo hypertrophic, restrictive, or infiltrative cardiomyopathies \n© ESC/EACTS 2025\nAV, aortic valve; BNP, brain natriuretic peptide; CAD, coronary artery disease; HF, heart \nfailure; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; M-TEER, mitral transcatheter edge-to-edge repair; NT-proBNP, N-terminal \npro-B-type natriuretic protein; NYHA, New York Heart Association; RV, right ventricle/ \nright ventricular; SPAP, systolic pulmonary artery pressure; TV, tricuspid valve.   \n4678                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n9.2.5. Management of atrial secondary mitral \nregurgitation \n9.2.5.1. Medical therapy and rhythm management \nIn patients with atrial SMR, underlying causes need to be recognized and \ntreated. Associated HFpEF and AF should be managed according to the \nrelevant Guidelines.7,340 The use of SGLT2is should be encouraged in \npatients with HFpEF due to their proven efficacy in reducing cardiovas-\ncular death and HF hospitalization.625 Limited data show that rhythm \ncontrol may contribute to reduce atrial SMR severity and reverse LA \ndilatation.626 \n9.2.5.2. Indications for intervention \nRegistry data demonstrate that patients with atrial SMR are typically \nelderly with associated AF. Mitral valve surgery has been recently asso-\nciated with lower rates of HF hospitalizations and mortality compared \nwith GDMT in a matched population, despite a higher risk profile in the \nsurgical arm at baseline.627 Data from several observational studies also \nsuggest that surgical annuloplasty is effective and durable in patients with \natrial SMR, because it counteracts the main mechanism of MR progres-\nsion.628–630 Its combination with surgical AF ablation (Maze procedure) \nand concomitant LAAO may have further advantages,630,631 while the fre-\nquently associated relevant TR can also be addressed during the same pro-\ncedure.627 Transcatheter edge-to-edge repair may also be considered \nbecause observational studies have demonstrated high safety and proced-\nural success,588–590,632,633 as well as compared with surgery in a small sub-\ngroup (n = 34) of the MATTERHORN RCT.634 However, the risk of \nincreased gradient due to planar leaflet coaptation, large regurgitant jet, \nand limited MV area (MVA) needs to be taken into consideration.592,635 \nFurther studies are warranted to investigate the treatment modalities of \npatients with atrial SMR. \n9.2.5.3. Follow-up \nPatients with atrial SMR undergoing surgical or transcatheter interven-\ntion should be followed up on a yearly basis, including clinical and echo-\ncardiographic evaluation. In cases of HFpEF, as an underlying cause of \natrial SMR, consultation with an HF specialist is necessary. \nAsymptomatic patients with severe atrial SMR not fulfilling the cri-\nteria for an intervention should undergo clinical and echocardiographic \nfollow-up at least once per year. \n10. Mitral stenosis \n10.1. Prevalence and aetiology \nThe aetiology of MS is most frequently rheumatic or degenerative, \nwhile rare forms can be drug-induced, inflammatory, or \ncarcinoid-related. Rheumatic fever is the most common cause of \nMS and death due to VHD worldwide. Its prevalence has decreased \nin high- and middle-income countries, but remains a major health-\ncare problem in low-income countries, where it predominantly \naffects young patients.12,187,644 Degenerative MS related to MAC \nis \na \ndistinct \nage-dependent \npathology \nrequiring \ndifferent \ntreatment strategies.645–647 Both aetiologies are more frequent in \nfemales.648 \n10.2. Rheumatic mitral stenosis \n10.2.1. Evaluation \nEchocardiography is the preferred method for screening in endemic re-\ngions and the assessment of the severity, extent of anatomical lesions, \nand haemodynamic consequences of MS. Involvement of other valves, \nparticularly secondary TR, should be identified. Mitral valve area using \nRecommendation Table 7 — Recommendations on in-\ndications \nfor \nintervention \nin \nsecondary \nmitral \nregurgitation (see also Supplementary data online, \nEvidence Tables 17–20) \nRecommendations \nClassa \nLevelb \nSevere atrial secondary mitral regurgitation  \nMV surgery, surgical AF ablation, if indicated, and \nLAAO should be considered in symptomatic patients \nwith severe atrial SMR under optimal medical \ntherapy.627–630,636,637 \nIIa \nB \nTEER may be considered in symptomatic patients \nwith severe atrial SMR not eligible for surgery after \noptimization of medical therapy including rhythm \ncontrol, when appropriate.588,590,638,639 \nIIb \nB                                                                                                   \nContinued \nVentricular secondary mitral regurgitation and concomitant \ncoronary artery disease \nMV surgery is recommended in patients with severe \nventricular SMR undergoing CABG.640 \nI \nB \nMV surgery may be considered in patients with \nmoderate SMR undergoing CABG.622–624,641,642 \nIIb \nB \nPCI followed by TEER after re-evaluation of MR may \nbe considered in symptomatic patients with chronic \nsevere ventricular SMR and non-complex CAD.150 \nIIb \nC \nSevere ventricular secondary mitral regurgitation without \nconcomitant coronary artery disease \nTEER is recommended to reduce HF hospitalizations \nand improve quality of life in haemodynamically \nstable, symptomatic patients with impaired LVEF \n(<50%) and persistent severe ventricular SMR, \ndespite optimized GDMT and CRT (if indicated), \nfulfilling specific clinical and echocardiographic \ncriteria.c 583,584,606,608,643 \nI \nA \nTEER may be considered for symptom improvement \nin selected symptomatic patients with severe \nventricular SMR not fulfilling the specific clinical and \nechocardiographic criteria,c after careful evaluation \nof LVAD or HTx.203,608–610 \nIIb \nB \nMV surgery may be considered in symptomatic \npatients with severe ventricular SMR without \nadvanced HF who are not suitable for TEER.617 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; \nCRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, \nheart failure; HTx, heart transplantation; LAAO, left atrial appendage occlusion; LVAD, \nleft ventricular assist device; LVEF, left ventricular ejection faction; MR, mitral \nregurgitation; MV, mitral valve; PCI, percutaneous coronary intervention; SMR, \nsecondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. \naClass of recommendation. \nbLevel of evidence. \ncSee Table 7.   \nESC Guidelines                                                                                                                                                                                          4679 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 37",
          "page": 37,
          "content": "Recommendations | Classa | Levelb\nSAVR is recommended in symptomatic and\nasymptomatic patients with severe AS undergoing\nCABG or surgical intervention on the ascending\naorta. | I | C\nSAVR should be considered in symptomatic and\nasymptomatic patients with moderate ASc\nundergoing CABG or surgical intervention on the\nascending aorta. | IIa | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 40",
          "page": 40,
          "content": "Recommendations | Classa | Levelb\nMV repair is the recommended surgical technique to\ntreat patients with severe PMR when the result is\nexpected to be durable.26,532,533,559,560 | I | B\nMV surgery is recommended in symptomatic\npatients with severe PMR considered operable by\nthe Heart Team.26,532,533,561 | I | B\nMV surgery is recommended in asymptomatic\npatients with severe PMR and LV dysfunction\n(LVESD ≥40 mm or LVESDi ≥20 mm/m2 or\nLVEF ≤60%).522,544,545 | I | B",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 41",
          "page": 41,
          "content": "Surgical MV repair is recommended in low-risk\nasymptomatic patients with severe PMR without LV\ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2,\nand LVEF >60%) when a durable result is likely, if at\nleast three of the following criteria are\nfulfliled:517,547,562–564\n• AF\n• SPAP at rest >50 mmHg\n• LA dilatation (LAVI ≥60 mL/m2 or LA\ndiameter ≥55 mm)\n• Concomitant secondary TR ≥ moderate. | I | B\nMV surgery should be considered in asymptomatic\npatients with severe PMR without LV dysfunction\n(LVESD <40 mm, LVESDi <20 mm/m2, and LVEF\n>60%) in the presence of PH (SPAP at rest\n>50 mmHg), or AF secondary to MR.517,518,562,565 | Ila | B\nSurgical MV repair should be considered in low-risk\nasymptomatic patients with severe PMR without LV\ndysfunction (LVESD <40 mm, LVESDi <20 mm/m2,\nand LVEF >60%) in the presence of significant LA\ndilatation (LAVI ≥60 mL/m2 or LA\ndiameter ≥55 mm), when performed in a Heart\nValve Centre and a durable repair is likely.517,565 | IIa | B\nTEER should be considered in symptomatic patients\nwith severe PMR who are anatomically suitable and\nat high surgical risk according to the Heart\nTeam.538,540,566 | IIa | B\nMinimally invasive MV surgery may be considered at\nexperienced centres to reduce the length of stay and\naccelerate recovery.557,567 | IIb | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": " | Ventricular secondary mitral regurgitation and concomitant\ncoronary artery disease |  |  | \nMV surgery is recommended in patients with severe\nventricular SMR undergoing CABG.640 |  | I | B | \nMV surgery may be considered in patients with\nmoderate SMR undergoing CABG.622–624,641,642 |  | IIb | B | \nPCI followed by TEER after re-evaluation of MR may\nbe considered in symptomatic patients with chronic\nsevere ventricular SMR and non-complex CAD.150 |  | IIb | C | \n | Severe ventricular secondary mitral regurgitation without\nconcomitant coronary artery disease |  |  | \nTEER is recommended to reduce HF hospitalizations\nand improve quality of life in haemodynamically\nstable, symptomatic patients with impaired LVEF\n(<50%) and persistent severe ventricular SMR,\ndespite optimized GDMT and CRT (if indicated),\nfulfilling specific clinical and echocardiographic\ncriteria.c 583,584,606,608,643 |  | I | A | \nTEER may be considered for symptom improvement\nin selected symptomatic patients with severe\nventricular SMR not fulfliling the specifci clinical and\nechocardiographic criteria,c after careful evaluation\nof LVAD or HTx.203,608–610 |  | IIb | B | \nMV surgery may be considered in symptomatic\npatients with severe ventricular SMR without\nadvanced HF who are not suitable for TEER.617 |  | IIb | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": "Recommendations | Classa | Levelb\nSevere atrial secondary mitral regurgitation |  | \nMV surgery, surgical AF ablation, if indicated, and\nLAAO should be considered in symptomatic patients\nwith severe atrial SMR under optimal medical\ntherapy.627–630,636,637 | IIa | B\nTEER may be considered in symptomatic patients\nwith severe atrial SMR not eligible for surgery after\noptimization of medical therapy including rhythm\ncontrol, when appropriate.588,590,638,639 | IIb | B",
          "rows": 4,
          "cols": 3
        }
      ],
      "keywords": [
        "moderate",
        "mitral regurgitation",
        "myocardial infarction",
        "intervention",
        "prognosis",
        "echo",
        "ct",
        "follow-up",
        "asymptomatic",
        "mild",
        "surgery",
        "severe",
        "symptomatic",
        "treatment",
        "mitral",
        "regurgitation"
      ]
    },
    {
      "number": "11",
      "title": "10. Mitral stenosis",
      "start_page": 45,
      "end_page": 48,
      "content": "9.2.5. Management of atrial secondary mitral \nregurgitation \n9.2.5.1. Medical therapy and rhythm management \nIn patients with atrial SMR, underlying causes need to be recognized and \ntreated. Associated HFpEF and AF should be managed according to the \nrelevant Guidelines.7,340 The use of SGLT2is should be encouraged in \npatients with HFpEF due to their proven efficacy in reducing cardiovas-\ncular death and HF hospitalization.625 Limited data show that rhythm \ncontrol may contribute to reduce atrial SMR severity and reverse LA \ndilatation.626 \n9.2.5.2. Indications for intervention \nRegistry data demonstrate that patients with atrial SMR are typically \nelderly with associated AF. Mitral valve surgery has been recently asso-\nciated with lower rates of HF hospitalizations and mortality compared \nwith GDMT in a matched population, despite a higher risk profile in the \nsurgical arm at baseline.627 Data from several observational studies also \nsuggest that surgical annuloplasty is effective and durable in patients with \natrial SMR, because it counteracts the main mechanism of MR progres-\nsion.628–630 Its combination with surgical AF ablation (Maze procedure) \nand concomitant LAAO may have further advantages,630,631 while the fre-\nquently associated relevant TR can also be addressed during the same pro-\ncedure.627 Transcatheter edge-to-edge repair may also be considered \nbecause observational studies have demonstrated high safety and proced-\nural success,588–590,632,633 as well as compared with surgery in a small sub-\ngroup (n = 34) of the MATTERHORN RCT.634 However, the risk of \nincreased gradient due to planar leaflet coaptation, large regurgitant jet, \nand limited MV area (MVA) needs to be taken into consideration.592,635 \nFurther studies are warranted to investigate the treatment modalities of \npatients with atrial SMR. \n9.2.5.3. Follow-up \nPatients with atrial SMR undergoing surgical or transcatheter interven-\ntion should be followed up on a yearly basis, including clinical and echo-\ncardiographic evaluation. In cases of HFpEF, as an underlying cause of \natrial SMR, consultation with an HF specialist is necessary. \nAsymptomatic patients with severe atrial SMR not fulfilling the cri-\nteria for an intervention should undergo clinical and echocardiographic \nfollow-up at least once per year. \n10. Mitral stenosis \n10.1. Prevalence and aetiology \nThe aetiology of MS is most frequently rheumatic or degenerative, \nwhile rare forms can be drug-induced, inflammatory, or \ncarcinoid-related. Rheumatic fever is the most common cause of \nMS and death due to VHD worldwide. Its prevalence has decreased \nin high- and middle-income countries, but remains a major health-\ncare problem in low-income countries, where it predominantly \naffects young patients.12,187,644 Degenerative MS related to MAC \nis \na \ndistinct \nage-dependent \npathology \nrequiring \ndifferent \ntreatment strategies.645–647 Both aetiologies are more frequent in \nfemales.648 \n10.2. Rheumatic mitral stenosis \n10.2.1. Evaluation \nEchocardiography is the preferred method for screening in endemic re-\ngions and the assessment of the severity, extent of anatomical lesions, \nand haemodynamic consequences of MS. Involvement of other valves, \nparticularly secondary TR, should be identified. Mitral valve area using \nRecommendation Table 7 — Recommendations on in-\ndications \nfor \nintervention \nin \nsecondary \nmitral \nregurgitation (see also Supplementary data online, \nEvidence Tables 17–20) \nRecommendations \nClassa \nLevelb \nSevere atrial secondary mitral regurgitation  \nMV surgery, surgical AF ablation, if indicated, and \nLAAO should be considered in symptomatic patients \nwith severe atrial SMR under optimal medical \ntherapy.627–630,636,637 \nIIa \nB \nTEER may be considered in symptomatic patients \nwith severe atrial SMR not eligible for surgery after \noptimization of medical therapy including rhythm \ncontrol, when appropriate.588,590,638,639 \nIIb \nB                                                                                                   \nContinued \nVentricular secondary mitral regurgitation and concomitant \ncoronary artery disease \nMV surgery is recommended in patients with severe \nventricular SMR undergoing CABG.640 \nI \nB \nMV surgery may be considered in patients with \nmoderate SMR undergoing CABG.622–624,641,642 \nIIb \nB \nPCI followed by TEER after re-evaluation of MR may \nbe considered in symptomatic patients with chronic \nsevere ventricular SMR and non-complex CAD.150 \nIIb \nC \nSevere ventricular secondary mitral regurgitation without \nconcomitant coronary artery disease \nTEER is recommended to reduce HF hospitalizations \nand improve quality of life in haemodynamically \nstable, symptomatic patients with impaired LVEF \n(<50%) and persistent severe ventricular SMR, \ndespite optimized GDMT and CRT (if indicated), \nfulfilling specific clinical and echocardiographic \ncriteria.c 583,584,606,608,643 \nI \nA \nTEER may be considered for symptom improvement \nin selected symptomatic patients with severe \nventricular SMR not fulfilling the specific clinical and \nechocardiographic criteria,c after careful evaluation \nof LVAD or HTx.203,608–610 \nIIb \nB \nMV surgery may be considered in symptomatic \npatients with severe ventricular SMR without \nadvanced HF who are not suitable for TEER.617 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; CABG, coronary artery bypass grafting; CAD, coronary artery disease; \nCRT, cardiac resynchronization therapy; GDMT, guideline-directed medical therapy; HF, \nheart failure; HTx, heart transplantation; LAAO, left atrial appendage occlusion; LVAD, \nleft ventricular assist device; LVEF, left ventricular ejection faction; MR, mitral \nregurgitation; MV, mitral valve; PCI, percutaneous coronary intervention; SMR, \nsecondary mitral regurgitation; TEER, transcatheter edge-to-edge repair. \naClass of recommendation. \nbLevel of evidence. \ncSee Table 7.   \nESC Guidelines                                                                                                                                                                                          4679 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n2D planimetry is the most commonly used measurement to assess \nstenosis severity, but 3D TTE and TOE have additional diagnostic \nvalue.649 An MVA of ≤1.5 cm2 in conjunction with clinical factors \n(symptoms, high risk of thromboembolism, or haemodynamic decom-\npensation) is indicative of clinically severe MS. Mean transvalvular gradi-\nent and pulmonary pressures reflect its consequences and have \nprognostic value.649,650 Leaflet thickening and fibrosis, along with com-\nmissural fusion and shortening of the subvalvular apparatus, are the \nmost important pathomechanisms of stenosis associated with RHD. \nThe presence and extent of leaflet and subvalvular calcifications influ-\nence treatment decisions. Scoring systems have been developed to as-\nsess the suitability of patients for percutaneous mitral commissurotomy \n(PMC) (see Supplementary data online, Table S3).651–653 \nExercise testing is indicated in asymptomatic patients or patients \nwith symptoms that are equivocal or discordant with the severity of \nstenosis. Exercise echocardiography provides additional information \non exercise capacity and related changes in mitral gradient and pulmon-\nary artery pressure, and is preferred over DSE, especially when there \nare contraindications to dobutamine.654 Transoesophageal echocardi-\nography should be systematically performed in PMC candidates to ex-\nclude LA thrombus or after an embolic episode, and may play an \nessential role for procedural guidance.52,655 \n10.2.2. Medical therapy \nDiuretics, beta-blockers, digoxin, non-dihydropyridine calcium channel \nblockers, and ivabradine can improve symptoms by controlling volume \noverload and heart rate. Anticoagulation with a VKA with a target inter-\nnational normalized ratio (INR) between 2 and 3 is indicated in patients \nwith AF, and DOACs should be avoided in patients with an MVA of \n≤2.0 cm2 according to current evidence.165,656,657 Interventions to re-\nstore sinus rhythm (cardioversion or catheter pulmonary vein isolation) \nare unlikely to be successful in patients with untreated severe MS. If AF \nis of recent onset and the LA moderately enlarged, cardioversion can be \nattempted soon after successful intervention or in patients with mod-\nerate MS combined with amiodarone treatment.658,659 In patients in \nsinus rhythm, OAC is indicated after systemic embolism or if a throm-\nbus is present in the LA, and should also be considered when TOE \nshows dense spontaneous echocardiographic contrast or an enlarged \nLA (M-mode diameter >50 mm or LA volume >60 mL/m2).660 \nProphylaxis of infective endocarditis is indicated as appropriate.5 \n10.2.3. Indications for intervention \nThe type (PMC or surgery) and timing of treatment should be decided \nbased on clinical characteristics, the anatomy of the valve and subvalv-\nular apparatus, and local expertise.661–663 The management of clinically \nsevere rheumatic MS is summarized in Figure 14 and Recommendation \nTable 8. \nIn general, indication for intervention should be limited to patients \nwith clinically severe rheumatic MS (MVA <1.5 cm2) in whom PMC is \nexpected to have a significant impact on clinical outcome. In higher- \nincome countries, where the incidence of rheumatic fever and the num-\nber of PMCs performed is low, this treatment should be restricted to \nexpert operators in specialized centres to improve safety and proced-\nural success rate.661,664 Efforts should be made to increase the availabil-\nity of PMC in lower-income countries, where access to treatment is \nlimited for economic reasons.665,666 Percutaneous mitral commissurotomy \nmay be also considered in symptomatic patients with an MVA of \n>1.5 cm2, if symptoms cannot be explained by another cause and \nif the anatomy is favourable (see Table 8). Percutaneous mitral \ncommissurotomy should be considered as a first-line treatment for pa-\ntients with anatomically suitable rheumatic MS and mild-to-moderate \ncalcification without severe subvalvular impairment. Selected patients \nwith unfavourable anatomical and clinical characteristics can still benefit \nfrom PMC, particularly if they are at increased surgical risk. When \nsymptomatic restenosis occurs after surgical commissurotomy or \nPMC, reintervention in most cases requires surgical valve replacement, \nbut redo PMC can be proposed in selected candidates with favourable \ncharacteristics, if the predominant mechanism is commissural refusion. \nLong-term follow-up has shown favourable results following PMC des-\npite a growing number of elderly patients with suboptimal clinical and \nanatomical characteristics.663–665 \nFor patients in whom PMC is contraindicated (Table 8), surgical MV \nrepair or, more frequently, replacement are good alternatives. \nAlthough repair is much more challenging than for PMR, it can be at-\ntempted at experienced centres.663 \nFor patients with multiple VHD including MS, a comprehensive \nevaluation by the Heart Team and an individualized approach is neces-\nsary. Surgery is preferable to PMC in patients with severe MS and se-\nvere AV disease, unless the surgical risk is high. In selected cases with \nsevere MS and moderate AV disease, PMC can be performed to post-\npone surgical treatment of both valves. \nIn high-risk cases with concomitant severe TR, PMC may be consid-\nered in selected patients with sinus rhythm, moderate atrial enlarge-\nment, and secondary TR due to post-capillary PH. In non-high-risk \ncases, surgery on both valves is preferred.651,652,662,667 Treatment of \npatients with low-gradient severe MS (MVA <1.5 cm2, mean gradient  \n<10 mmHg) is challenging, because these patients are often older \nand have unfavourable anatomy.668,669 \n10.2.4. Follow-up \nAsymptomatic patients with clinically severe MS who have not under-\ngone intervention should be followed up yearly by TTE, and at longer in-\ntervals (2–3 years) in cases of moderate stenosis. After PMC, the \npost-procedural MVA and mean mitral gradient are important para-\nmeters that influence long-term clinical outcomes. Follow-up of patients \nafter successful PMC is necessary because asymptomatic restenosis may \noccur. Progressive rheumatic involvement of other valves should be peri-\nodically assessed, irrespective of the therapy modality. Finally, education \nand the engagement of the family is key in patients with rheumatic MS, \nsince it usually affects young individuals and women of childbearing age. \n10.3. Degenerative mitral stenosis with \nmitral annular calcification \nPatients presenting with MAC are elderly and have significant comorbid-\nities, including disease of other valves. Mitral annular calcification is also an \nindicator of cardiovascular disease severity and is associated with an in-\ncreased risk of AF, stroke, and death.670,671 The incidence of MAC varies \nsubstantially, depending on the age of the studied population and the im-\naging modality used. It can be a consequence of many different patho-\nlogical processes and, depending on the underlying disease, can be \naccompanied by stenosis, regurgitation, or both. However, most patients \nwith MAC do not have significant valvular dysfunction.647,672 \nGenerally, MS occurs due to calcific extension into the MV leaflets or \nsubvalvular apparatus, and in some patients it is associated with com-\nbined MR.673 Treatment options (including transcatheter and surgical \napproaches) are high-risk procedures and evidence from RCTs is \nlacking.  \n4680                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n10.3.1. Evaluation \nEchocardiography is used for initial evaluation, but is frequently limited \nby acoustic shadowing due to severe calcification. Evaluation of MVA by \nplanimetry is less reliable than in rheumatic MS, and TOE should \ntherefore be used liberally. Degenerative MS can coexist with varying \ndegrees of MR. Mean transmitral gradient has been shown to be asso-\nciated with increased mortality irrespective of MR severity.674 \nElectrocardiogram-gated CCT is necessary to assess the degree and lo-\ncations of calcifications, especially if an intervention is planned.647,674–676 \nCalcifications are usually more prominent at the posterior aspect of the \nannulus. \n10.3.2. Indications for intervention \nIntervention is recommended in symptomatic patients who are not re-\nsponsive to medical therapy, weighing the potential benefits of the pro-\ncedure against its associated risks. In elderly patients with degenerative MS \nand MAC, surgery is technically challenging and high risk. However, \nContraindication\nor high risk\nfor surgery\nFavourable\nclinical\ncharacteristicsc\nFavourable\nanatomical\ncharacteristicsc\nPatient with rheumatic mitral stenosis and mitral valve area ≤1.5 cm2\nSurgeryd\nSymptoms\nSymptoms\nExercise testing\nSurgery\nSurgery\nPMC\nFollow-up\nPMC\nContraindication\nto PMCb\nHigh risk of embolism\nor haemodynamic\ndecompensationa\nContraindication to\nor unfavourable\ncharacteristics for PMC\nFigure 14 Management of clinically severe rheumatic mitral stenosis (mitral valve area ≤1.5 cm2). AF, atrial fibrillation; LA, left atrium; MS, mitral \nstenosis; MV, mitral valve; MVA, mitral valve area; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary hypertension; \nPMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary artery pressure; TR, tricuspid regurgitation. aHigh thromboembolic risk: history \nof systemic embolism, dense spontaneous contrast in the LA, new-onset AF. High-risk of haemodynamic decompensation: SPAP >50 mmHg at rest, \nneed for major NCS, desire for pregnancy or pregnant. bSee Table 8. cFavourable = absence of unfavourable characteristics for PMC defined by un-\nfavourable anatomical characteristics [echocardiographic score >8, Cormier score 3 (calcification of MV of any extent as assessed by fluoroscopy), \nsevere TR] or unfavourable clinical characteristics (old age, history of commissurotomy, NYHA class IV, permanent AF, severe PH) (for the definition \nof scores see Supplementary data online, Table S3). dIf operative risk is low.   \nESC Guidelines                                                                                                                                                                                          4681 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nsurgical MV repair or replacement with extensive decalcification and \npatch reconstruction of the annulus can be performed in selected patients \nat experienced centres (e.g. young patients post-chest radiation), where \nmortality rates of <5% have been reported.677–679 \nDegenerative MS is not amenable to PMC because commissural fu-\nsion is absent. In symptomatic high-risk patients with suitable anat-\nomy, transcatheter implantation of a TAVI prosthesis in the mitral \nposition is feasible but associated with frequent complications, includ-\ning LVOT obstruction, valve embolization, stroke, and haemolysis due \nto PVL. Open surgical valve replacement via the LA with a TAVI device \nis an alternative that allows complete anterior leaflet removal;680 \nhowever, mortality remains high. The use of dedicated TMVI devices \nis therefore encouraged because it appears to be safer.542,681 Heart \nTeam evaluation should guide the choice of treatment avoiding futility, \nbecause mortality remains high, even after successful treatment \n(10%–30% within 1 year). \n11. Tricuspid regurgitation \n11.1. Prevalence and aetiology \nTR is a common echocardiographic finding in the general population, \nwith higher prevalence in women and older patients. Trivial or mild \nTR is mostly a benign condition. Significant TR (≥ moderate) has a re-\nported age- and sex-adjusted prevalence of 0.55% (4% in people aged \n≥75 years).682 Severe TR is associated with increased risk of death \nand HF, independent of comorbidities, ventricular function, and pul-\nmonary pressures.683–686 \nOnly 8%–10% of patients with TR present with clear anatomical ab-\nnormalities of the TV apparatus (primary TR), which can be due to infect-\nive endocarditis, RHD, carcinoid syndrome, congenital abnormalities (e.g. \nEbstein’s anomaly), chest radiation, or myxomatous disease, as well as \ntrauma or iatrogenic valve damage (e.g. after endomyocardial biopsy).682 \nCardiac implantable electronic device (CIED)-related TR represents a \nseparate entity requiring a specific diagnostic approach and manage-\nment.687 In patients with a CIED, diagnostic efforts should be made to \nclarify if the lead is the cause of TR (CIED-related TR) or incidental \n(CIED-associated TR).688 \nIn patients with secondary TR, TV leaflets are structurally normal and \nregurgitation is caused by annular dilatation and/or leaflet tethering due \nto RA dilatation, and/or RV dilation and dysfunction. Based on the main \nmorphological and haemodynamic characteristics, two phenotypes of \nsecondary TR have been proposed:689 (i) atrial secondary TR, mainly \ndue to AF and characterized by the absence of significant leaflet tether-\ning, but with marked RA and annular dilatation along with preserved RV \nsize/function, pulmonary pressure, and LV function; and (ii) ventricular \nsecondary TR, due to annular dilatation and leaflet tethering as a con-\nsequence of left-sided ventricular or valvular disease (post-capillary \nPH), pre-capillary PH, or primary RV cardiomyopathy/ischaemia (also \nafter left-sided valve surgery).690 At an advanced disease stage, these \ntwo phenotypes may no longer be distinguishable, and therefore early \ncharacterization is key to determine outcome.691,692 Evidence of an im-\npact on patient management is currently lacking; therefore, current \nrecommendations for intervention consider mainly primary vs second-\nary TR. \nRecommendation Table 8 — Recommendations on \nindications for percutaneous mitral commissurotomy, \nmitral valve surgery, and transcatheter intervention \nin clinically severe rheumatic and degenerative mitral \nstenosis \n(see \nalso \nSupplementary \ndata \nonline, \nEvidence Table 21) \nRecommendations \nClassa \nLevelb  \nPMC is recommended in symptomatic patients in the \nabsence of unfavourable characteristics for PMC.c \n651–653,662,665 \nI \nB \nPMC is recommended in any symptomatic patients \nwith a contraindication or at high risk for surgery. \nI \nC \nMV surgery is recommended in symptomatic \npatients who are not suitable for PMC. \nI \nC \nPMC should be considered as initial treatment in \nsymptomatic patients with suboptimal anatomy but \nno unfavourable clinical characteristics for PMC.c \nIIa \nC \nPMC should be considered in asymptomatic patients \nwithout unfavourable clinical and anatomical \ncharacteristics for PMC, and: \n• High thromboembolic risk (history of systemic \nembolism, dense spontaneous contrast in the LA, \nnew-onset or paroxysmal AF), and/or \n• High risk of haemodynamic decompensation \n(SPAP >50 mmHg at rest, need for major NCS, \npregnant or desire for pregnancy). \nIIa \nC \nTMVI may be considered in symptomatic patients \nwith extensive MAC and severe MV dysfunction at \nexperienced Heart Valve Centres with expertise in \ncomplex MV surgery and transcatheter \ninterventions.542,680,681 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; LA, left atrium/left atrial; MAC, mitral annular calcification; MV, mitral \nvalve; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary \nhypertension; PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary \nartery pressure; TMVI, transcatheter mitral valve implantation; TR, tricuspid regurgitation. \naClass of recommendation. \nbLevel of evidence. \ncUnfavourable characteristics for PMC can be defined by the presence of several of the \nfollowing characteristics: clinical characteristics (old age, history of commissurotomy, NYHA \nclass IV, permanent AF, severe PH); anatomical characteristics [echocardiographic score >8, \nCormier score group 3 (calcification of MV of any extent as assessed by fluoroscopy), \nsevere TR] (for the definition of scores see Supplementary data online, Table S3).  \nTable 8 Contraindications for percutaneous mitral \ncommissurotomy in rheumatic mitral stenosis \nContraindications  \nMVA >1.5 cm2 a \nLA thrombusb \nMore than mild MR \nSevere or bi-commissural calcification \nAbsence of commissural fusion \nSevere concomitant AV disease, or severe combined tricuspid stenosis and \nregurgitation requiring surgery \nConcomitant CAD requiring bypass surgery \n© ESC/EACTS 2025\nAV, aortic valve; CAD, coronary artery disease; LA, left atrium/left atrial; MR, mitral \nregurgitation; MVA, mitral valve area; OAC, oral anticoagulation; PMC, percutaneous \nmitral commissurotomy; TOE, transoesophageal echocardiography. \naPMC may be considered in patients with MVA of >1.5 cm2 with symptoms that cannot be \nexplained by another cause and if the anatomy is favourable. \nbWhen the thrombus is located in the LA appendage, PMC may be considered in patients \nwith contraindications to surgery or those without urgent need for intervention, in whom \nOAC can be safely given for 1–3 months, provided repeat TOE confirms resolution of \nthrombus.   \n4682                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 45",
          "page": 45,
          "content": " | Ventricular secondary mitral regurgitation and concomitant\ncoronary artery disease |  |  | \nMV surgery is recommended in patients with severe\nventricular SMR undergoing CABG.640 |  | I | B | \nMV surgery may be considered in patients with\nmoderate SMR undergoing CABG.622–624,641,642 |  | IIb | B | \nPCI followed by TEER after re-evaluation of MR may\nbe considered in symptomatic patients with chronic\nsevere ventricular SMR and non-complex CAD.150 |  | IIb | C | \n | Severe ventricular secondary mitral regurgitation without\nconcomitant coronary artery disease |  |  | \nTEER is recommended to reduce HF hospitalizations\nand improve quality of life in haemodynamically\nstable, symptomatic patients with impaired LVEF\n(<50%) and persistent severe ventricular SMR,\ndespite optimized GDMT and CRT (if indicated),\nfulfilling specific clinical and echocardiographic\ncriteria.c 583,584,606,608,643 |  | I | A | \nTEER may be considered for symptom improvement\nin selected symptomatic patients with severe\nventricular SMR not fulfliling the specifci clinical and\nechocardiographic criteria,c after careful evaluation\nof LVAD or HTx.203,608–610 |  | IIb | B | \nMV surgery may be considered in symptomatic\npatients with severe ventricular SMR without\nadvanced HF who are not suitable for TEER.617 |  | IIb | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 45",
          "page": 45,
          "content": "Recommendations | Classa | Levelb\nSevere atrial secondary mitral regurgitation |  | \nMV surgery, surgical AF ablation, if indicated, and\nLAAO should be considered in symptomatic patients\nwith severe atrial SMR under optimal medical\ntherapy.627–630,636,637 | IIa | B\nTEER may be considered in symptomatic patients\nwith severe atrial SMR not eligible for surgery after\noptimization of medical therapy including rhythm\ncontrol, when appropriate.588,590,638,639 | IIb | B",
          "rows": 4,
          "cols": 3
        },
        {
          "title": "Table on page 48",
          "page": 48,
          "content": "Recommendations | Classa | Levelb\nPMC is recommended in symptomatic patients in the\nabsence of unfavourable characteristics for PMC.c\n651–653,662,665 | I | B\nPMC is recommended in any symptomatic patients\nwith a contraindication or at high risk for surgery. | I | C\nMV surgery is recommended in symptomatic\npatients who are not suitable for PMC. | I | C\nPMC should be considered as initial treatment in\nsymptomatic patients with suboptimal anatomy but\nno unfavourable clinical characteristics for PMC.c | IIa | C\nPMC should be considered in asymptomatic patients\nwithout unfavourable clinical and anatomical\ncharacteristics for PMC, and:\n• High thromboembolic risk (history of systemic\nembolism, dense spontaneous contrast in the LA,\nnew-onset or paroxysmal AF), and/or\n• High risk of haemodynamic decompensation\n(SPAP >50 mmHg at rest, need for major NCS,\npregnant or desire for pregnancy). | IIa | C\nTMVI may be considered in symptomatic patients\nwith extensive MAC and severe MV dysfunction at\nexperienced Heart Valve Centres with expertise in\ncomplex MV surgery and transcatheter\ninterventions.542,680,681 | IIb | C",
          "rows": 7,
          "cols": 3
        }
      ],
      "keywords": [
        "stenosis",
        "intervention",
        "ct",
        "echo",
        "asymptomatic",
        "follow-up",
        "surgery",
        "risk",
        "sglt2",
        "mitral stenosis",
        "severe",
        "ablation",
        "symptomatic",
        "indication",
        "treatment",
        "mitral"
      ]
    },
    {
      "number": "12",
      "title": "11. Tricuspid regurgitation",
      "start_page": 48,
      "end_page": 53,
      "content": "surgical MV repair or replacement with extensive decalcification and \npatch reconstruction of the annulus can be performed in selected patients \nat experienced centres (e.g. young patients post-chest radiation), where \nmortality rates of <5% have been reported.677–679 \nDegenerative MS is not amenable to PMC because commissural fu-\nsion is absent. In symptomatic high-risk patients with suitable anat-\nomy, transcatheter implantation of a TAVI prosthesis in the mitral \nposition is feasible but associated with frequent complications, includ-\ning LVOT obstruction, valve embolization, stroke, and haemolysis due \nto PVL. Open surgical valve replacement via the LA with a TAVI device \nis an alternative that allows complete anterior leaflet removal;680 \nhowever, mortality remains high. The use of dedicated TMVI devices \nis therefore encouraged because it appears to be safer.542,681 Heart \nTeam evaluation should guide the choice of treatment avoiding futility, \nbecause mortality remains high, even after successful treatment \n(10%–30% within 1 year). \n11. Tricuspid regurgitation \n11.1. Prevalence and aetiology \nTR is a common echocardiographic finding in the general population, \nwith higher prevalence in women and older patients. Trivial or mild \nTR is mostly a benign condition. Significant TR (≥ moderate) has a re-\nported age- and sex-adjusted prevalence of 0.55% (4% in people aged \n≥75 years).682 Severe TR is associated with increased risk of death \nand HF, independent of comorbidities, ventricular function, and pul-\nmonary pressures.683–686 \nOnly 8%–10% of patients with TR present with clear anatomical ab-\nnormalities of the TV apparatus (primary TR), which can be due to infect-\nive endocarditis, RHD, carcinoid syndrome, congenital abnormalities (e.g. \nEbstein’s anomaly), chest radiation, or myxomatous disease, as well as \ntrauma or iatrogenic valve damage (e.g. after endomyocardial biopsy).682 \nCardiac implantable electronic device (CIED)-related TR represents a \nseparate entity requiring a specific diagnostic approach and manage-\nment.687 In patients with a CIED, diagnostic efforts should be made to \nclarify if the lead is the cause of TR (CIED-related TR) or incidental \n(CIED-associated TR).688 \nIn patients with secondary TR, TV leaflets are structurally normal and \nregurgitation is caused by annular dilatation and/or leaflet tethering due \nto RA dilatation, and/or RV dilation and dysfunction. Based on the main \nmorphological and haemodynamic characteristics, two phenotypes of \nsecondary TR have been proposed:689 (i) atrial secondary TR, mainly \ndue to AF and characterized by the absence of significant leaflet tether-\ning, but with marked RA and annular dilatation along with preserved RV \nsize/function, pulmonary pressure, and LV function; and (ii) ventricular \nsecondary TR, due to annular dilatation and leaflet tethering as a con-\nsequence of left-sided ventricular or valvular disease (post-capillary \nPH), pre-capillary PH, or primary RV cardiomyopathy/ischaemia (also \nafter left-sided valve surgery).690 At an advanced disease stage, these \ntwo phenotypes may no longer be distinguishable, and therefore early \ncharacterization is key to determine outcome.691,692 Evidence of an im-\npact on patient management is currently lacking; therefore, current \nrecommendations for intervention consider mainly primary vs second-\nary TR. \nRecommendation Table 8 — Recommendations on \nindications for percutaneous mitral commissurotomy, \nmitral valve surgery, and transcatheter intervention \nin clinically severe rheumatic and degenerative mitral \nstenosis \n(see \nalso \nSupplementary \ndata \nonline, \nEvidence Table 21) \nRecommendations \nClassa \nLevelb  \nPMC is recommended in symptomatic patients in the \nabsence of unfavourable characteristics for PMC.c \n651–653,662,665 \nI \nB \nPMC is recommended in any symptomatic patients \nwith a contraindication or at high risk for surgery. \nI \nC \nMV surgery is recommended in symptomatic \npatients who are not suitable for PMC. \nI \nC \nPMC should be considered as initial treatment in \nsymptomatic patients with suboptimal anatomy but \nno unfavourable clinical characteristics for PMC.c \nIIa \nC \nPMC should be considered in asymptomatic patients \nwithout unfavourable clinical and anatomical \ncharacteristics for PMC, and: \n• High thromboembolic risk (history of systemic \nembolism, dense spontaneous contrast in the LA, \nnew-onset or paroxysmal AF), and/or \n• High risk of haemodynamic decompensation \n(SPAP >50 mmHg at rest, need for major NCS, \npregnant or desire for pregnancy). \nIIa \nC \nTMVI may be considered in symptomatic patients \nwith extensive MAC and severe MV dysfunction at \nexperienced Heart Valve Centres with expertise in \ncomplex MV surgery and transcatheter \ninterventions.542,680,681 \nIIb \nC \n© ESC/EACTS 2025\nAF, atrial fibrillation; LA, left atrium/left atrial; MAC, mitral annular calcification; MV, mitral \nvalve; NCS, non-cardiac surgery; NYHA, New York Heart Association; PH, pulmonary \nhypertension; PMC, percutaneous mitral commissurotomy; SPAP, systolic pulmonary \nartery pressure; TMVI, transcatheter mitral valve implantation; TR, tricuspid regurgitation. \naClass of recommendation. \nbLevel of evidence. \ncUnfavourable characteristics for PMC can be defined by the presence of several of the \nfollowing characteristics: clinical characteristics (old age, history of commissurotomy, NYHA \nclass IV, permanent AF, severe PH); anatomical characteristics [echocardiographic score >8, \nCormier score group 3 (calcification of MV of any extent as assessed by fluoroscopy), \nsevere TR] (for the definition of scores see Supplementary data online, Table S3).  \nTable 8 Contraindications for percutaneous mitral \ncommissurotomy in rheumatic mitral stenosis \nContraindications  \nMVA >1.5 cm2 a \nLA thrombusb \nMore than mild MR \nSevere or bi-commissural calcification \nAbsence of commissural fusion \nSevere concomitant AV disease, or severe combined tricuspid stenosis and \nregurgitation requiring surgery \nConcomitant CAD requiring bypass surgery \n© ESC/EACTS 2025\nAV, aortic valve; CAD, coronary artery disease; LA, left atrium/left atrial; MR, mitral \nregurgitation; MVA, mitral valve area; OAC, oral anticoagulation; PMC, percutaneous \nmitral commissurotomy; TOE, transoesophageal echocardiography. \naPMC may be considered in patients with MVA of >1.5 cm2 with symptoms that cannot be \nexplained by another cause and if the anatomy is favourable. \nbWhen the thrombus is located in the LA appendage, PMC may be considered in patients \nwith contraindications to surgery or those without urgent need for intervention, in whom \nOAC can be safely given for 1–3 months, provided repeat TOE confirms resolution of \nthrombus.   \n4682                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n11.2. Evaluation \nEchocardiography is recommended to assess patients with TR45 and \nshould include evaluation of severity and aetiology (including character-\nization of left-sided heart disease and, if applicable, CIED lead location \nand interaction with the valve apparatus), the impact of TR on the right- \nsided chambers (RV and RA size and function), and assessment of cen-\ntral venous (inferior vena cava) and pulmonary pressures. Transthoracic \nechocardiography provides sufficient diagnostic information in most \npatients. Transoesophageal echocardiography is necessary for when \nvisualization of the TV apparatus. In candidates for an intervention, ad-\nvanced techniques, such as strain analysis and 3D echocardiography, \nshould also be applied when available. \nAssessment of TR severity should be ideally performed in euvolae-\nmic status, with optimized pulmonary and systemic pressures, and \nbased on an integrative approach considering multiple qualitative and \nquantitative parameters (Figure 15).45,693 A grading scheme extending \nbeyond severe, including ‘massive’ and ‘torrential’ grades, has been pro-\nposed to refine TR reduction assessment after transcatheter interven-\ntions and has been used in several studies.694,695 Although this \nfive-grade scale may be associated with a proportional increase in \nsymptoms and event risk,694,695 an intervention should be considered \nwithout delay, as soon as TR is severe, with the aim of reducing TR \nto moderate or less.696,697 \nEchocardiographic assessment of the RV is challenging due to its \ncomplex geometry, imaging constraints, and the high dependency on \nloading conditions. When accurate measurements of RV size and func-\ntion, as well as RV volume, are necessary for decision-making, CMR \nshould be used because of its high accuracy and reproducibility.698,699 \nIn Figure 15, upper limits of normal for different RV size parameters \nare provided to guide definition of RV dilatation and remodelling. In \nthe setting of severe TR, RV function is often overestimated and there-\nfore the most conservative/cautious thresholds are suggested for the \ncurrently used echocardiographic parameters to identify RV dysfunc-\ntion at the earliest stage possible. Cut-off values for severe RV dysfunc-\ntion are also provided to indicate high-risk or possibly futile \ninterventions. Although robust validation is lacking, all these reference \nvalues are chosen based on large multicentre reports of normative data \nand outcomes.60,697,700–704 \nEchocardiography often underestimates pulmonary pressures in \ncases of severe TR.705 Right heart catheterization is therefore recom-\nmended in all candidates for an intervention to assess the haemo-\ndynamic consequences of TR on the RA and venous circulation (e.g. \nventricularization of the RA pressure curves), measure end-diastolic \nRV pressure, and document volume overload. The assessment of pul-\nmonary pressures and vascular resistance are key to exclude masked \nsevere pre-capillary PH.706 \nRV–pulmonary artery coupling refers to the ability of the RV systolic \nperformance to match a given pulmonary afterload maintaining ad-\nequate cardiac output, and can be measured invasively or approxi-\nmated using echocardiography [i.e. tricuspid annular plane systolic \nexcursion (TAPSE)/SPAP].707,708 RV–pulmonary artery uncoupling \n(low TAPSE/SPAP) occurs when sustained increases in afterload can-\nnot be matched by RV contractile reserve and has been associated \nwith poor prognosis in different HF conditions, including severe TR. \nAlthough not yet prospectively validated, this index may improve \nrisk stratification. \nElectrocardiogram-gated CCT with dedicated protocols ensuring \nsufficient contrast enhancement of the right heart cavities provides de-\ntailed characterization of the RA, RV, and vena cava anatomy, the loca-\ntion of the right coronary artery, and is crucial to assess suitability and \ndevice sizing for several transcatheter interventions.689,697 \nBefore any intervention is considered, careful evaluation of TR aeti-\nology, disease stage (TR severity, RV and LV dysfunction, and PH), pa-\ntient operative risk, and likelihood of recovery by a dedicated \ncollaborative Heart Team is recommended (Figure 16). Dedicated clin-\nical risk scores for TR patients have been described recently. The \nTRI-SCORE709 and the STS isolated TV risk calculator710 take into con-\nsideration clinical and echocardiographic signs of RV dysfunction, and \nsecondary organ (particularly hepatic and renal) impairment. They \nboth allow improved estimates of peri-procedural risk in patients \nwith severe TR undergoing surgery and possibly help to avoid futile in-\nterventions.84,711 The importance of risk stratification was demon-\nstrated in a recent registry analysis (n = 2413) comparing any \ninterventions with conservative management. Early TV intervention \n(transcatheter valve repair or surgery) was associated with improved \nmid-term survival in patients with a low or intermediate TRI-SCORE \n(up to 5 points), while patients with a high TRI-SCORE (≥6) did not de-\nrive any benefit compared with conservative management.696 \nMoreover, isolated TV surgery (repair or replacement) improved sur-\nvival at 10 years in patients with a low TRI-SCORE (≤3). The same \nbenefit was observed in patients with an intermediate TRI-SCORE \n(4–5) after successful TV repair only.689,697,709 Patients with moderate \nor severe TR should be regularly followed up clinically and by echocar-\ndiography at least every 6 months. \n11.3. Medical therapy \nPatients with relevant TR should be first treated according to the as-\nsumed aetiology, including optimal HF treatment, pulmonary vasodila-\ntors for PH, and rhythm control for AF.339,693 \nIn the case of HF symptoms, diuretics should be initiated in a step-\nwise approach,339 beginning with loop diuretics eventually combined \nwith aldosterone antagonists, thiazide diuretics, and/or SGLT2is.712 \nHowever, according to current knowledge, medical therapy has very \nlimited effect on the evolution of TR severity and none of these mea-\nsures should delay evaluation of an intervention at an expert centre.713 \n11.4. Indications for intervention \n11.4.1. Surgery \nPatients are often referred too late for surgery when significant RV and \nother organ failure have occurred. Isolated TV surgery has therefore \nbeen considered to be generally high risk, with in-hospital mortality \nrates of 8%–10% in several reports,714,715 but contemporary cohorts \nhave demonstrated improved outcomes when patients are referred \nearlier and more effective techniques are used.716 Valve repair using \nan annuloplasty ring is preferred over replacement, whenever technic-\nally feasible, especially in low-risk patients with suitable anatomy.709 \nHowever, TV replacement may be necessary in cases of advanced dis-\nease with marked annular dilatation and leaflet tethering.688,717 For \nCIED-related TR, preparation of any entrapped tricuspid leaflet and \npossibly lead extraction with implantation of an epicardial system has \nbeen associated with improved TV function.688,717  \nESC Guidelines                                                                                                                                                                                          4683 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n\u001f\u001e\u001d\u001c\u001b\u001e\u001a\u0019\u0018\u0017\n\u0016\u0015\u0014\u0013\u0012\u001e\u0011\u0010\u001b\u000f\u0011\u000e\u0019\u0018\u0017\n\r\u0011\f\u000b\n\u000e\u001b\u001e\u001a\u0019\u0018\u0017\n\u0017\t\u0019\u000e\u001d\u0010\u001b\u000f\u001b\u000f\u001d\u000b\n\u001b\n\u0017\t\u0019\u000e\u001a\b\u0007\u0006\n\f\u000f\u001d\u000b\n\u001b\n\u001f\u0006\u0010\u001c\u000b\n\u001b\u001e\u001a\u0019\u0005\u001e\u0011\b\b\u0006\u001e\u0011\b\n\u0016\u001b\u001e\u000e\u001d\u000b\u0004\u001b\b\f\u0006\u0010\u001b\u001e\u0019\f\u0003\u001b\n\u0002\u0011\b\n\u0001\u0006\u001b\u0010\u001d\u000f\u001b\u000f\u001d\u0004\u0011\n\u001f\u001e\u001d\u001c\u001b\u001a\u001b\u0019\u001d\u0018\u0017\u001b\u0016\u0015\u0014\u0015\u0013\u001d\u0017\u0012\u0018\u0015\u0011\u0010\n\u0019\u001c\u001c\u001c\n\u001f\u001e\u001d\u0015\u0012\u0018\u000f\u001a\u000e\u001a\u0014\r\u0019\u0017\f\n\u000b\r\u0019\n\u0016\u0015\u001d\u0017\u0012\u0018\u0015\u0011\u0010\n\u0019\u001c \u001c\n\u001f\u001e\u001d\u0015\u0012\u0018\u000f\u0018\u0017\u001b\u001a\u0014\r\u0019\u0017\f\n\u000b\r\u0019\n\u0016\u0015\u001d\u0017\u0012\u0018\u0015\u0011\u0010\n­\u0019\u001c \u001c\n\t\u0013\u0017\f\n\u001a\b\u0017\u0018\u001d\u001b\u0012\u0012\n\u0019\n\u001a\u001d\u0017\u0012\u0018\u0015\u0011\u0010\n\u0019\u001c\u001c\u001c\n\u001f\u001e\u001d\u0016\u0017\u0018\u000f\u0018\u0017\u001b\u0016\u0015\u0014\u0015\u0013\u001d\u0017\u0012\u0018\u0015\u0011\u0010\n\u0019\u001c\u001c\u001c\n\u001f\u001e\u001d\u0018\u000e\u001a\u0007\n\u0012\f\u0014\u0017\r\u0012\u0010\n\u0018\u001f\r\u0014\u0019\u0019 \u0019\u0019\u0019\u0019\u001c\u001c\n\u0017\t\u0019\u0018\u0013\u0015\u0019\b\u0019\u0019\u0019\u0019\u0019\f\u001c\b\n\u0017\t\u0019\r\u0019 \u0019\u0019\u0019\n\u0017\t\u0019 \r\u0019 \u0019\u0019\u0019\n\u0013\u0019\u0017\t\u0019\u0014\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\n\u0016\u0019\n\u0019\u0019\u0019≤\n\u0018\u001f\r\u0014\u0019\u0019 \u0019\u0019\u0019\u0019\u001c\u001c\n\u0017\t\u0019\u0018\u0013\u0015\u0019\b\u0019\u0019\u0019\u0019\u0019\f\u001c\b\n\u0017\t\u0019\r\u0019 \u0019\u0019\u0019\n\u0017\t\u0019 \r\u0019 \u0019\u0019\u0019­\n\u0013\u0019\u0017\t\u0019\u0014\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\u0019\n\u0016\u0019\n\u0019\u0019\u0019≤\n\u0006\u0015\u000b\u0015\u0013\u0015\u001d\u001f\u001e\u001d\u0018\u000e\u001a\u0007\n\u0012\f\u0014\u0017\r\u0012\u0010\n\u0005\u0013\u0015\u000f\f\u001b\b\u0017\u0019\u0019\u001b\u0013\u000e\u001d\u0005\u0004\u0010\n\u001c\u001f\u001f\u0019\n\u0019\u001c\u001c\u0002\n\u001f\u001f\u0019\n≤\u0019\u001c\u001c\u0002\n\u001f\t\u0017\u0019\n\u0019\n\u0005\r\u001a\u0014\u000f\f\u001b\b\u0017\u0019\u0019\u001b\u0013\u000e\u001d\u0005\u0004\u0010\n\u001c\u001f\u001f\u0019\n\u0019\u001c\u001c\u0002\n\u001f\u001f\u0019\n>\u0019\u001c\u001c\u0002\n\u001f\t\u0017\u0019\n≤\u0019\n\u001f\t\u0017\u0019\n\u0019\n\u001c\u001f\u001f\u0019\u0019 \u0019\u001c\u001c\u0002\n\u0006\u0015\u000b\u0015\u0013\u0015\u001d\u0005\u0004\u0010\n\r\u0011\u001c\u001d\u0012\u0006\u001b\n\u000f\u001d\u000f\u001b\u000f\u001d\u0004\u0011\n\u0001\u0006\u001b\n\u000f\u001d\u000f\u001b\u000f\u001d\u0004\u0011\n\u0014\u0017\u0019\u0019\n≥ \u0019\u001c\u001c\n\u0017\t\u000b\u0010\u0019\u0019\n≥\u0019\u001c \u0011\u001b\u000f\n\u0017\u0019\u0019\n≥\n\u0013\u0019\t\u0016\u0019\u0019≥\u0019\u001c\u001c\n\u001f\u0015\r\u0019\u001e\u001b\u000e\u001d\u0006\b\u0019≥­\u0019\u001c\u001c\u0019\u001b\u000f\u0019\u001a\u0006\u001d\b\u000f\u0019\u0019\f\u001c\b\n\t\u0011\n\u001b\u0019\f\u000b\n\u000f\u001e\u001b\f\u000f\u001b\u0019\u001d\u000e\u000f\u0003\u0019≥\u0019\u001c\u001c\n\u0011\u0005\u001b\u000f\u001d\f\u0019\u0004\u0011\u001d\n\u0019\b\u001a\b\u000f\u000b\u0010\u001d\f\u0019\u000b\u0019\u001e\u0011\u0004\u0011\u001e\b\u001b\u0010\n\u0010\u001b\u001d\u0010\u0019\u0010\u0011\u001b\u0011\u000f\u0019\u0010\u001b\u001e\u0002\u0011\u0019\f\u000b\u001b\u0005\u000f\u001b\u000f\u001d\u000b\n\u0019\u000e\u0011\u0007\u0011\f\u000f\u0019\b\u0011\u0004\u0011\u001e\u0011\u0019\u000f\u0011\n\u000f\u001d\n\u0002\n \u001b\u001e\u0002\u0011\u0019\f\u0011\n\u000f\u001e\u001b\u0010\u0019\u0011\u000f\n \u001b\u001e\u0002\u0011\u0019\u0003\u000b\u0010\u000b\b\u001a\b\u000f\u000b\u0010\u001d\f\u0019\f\u000b\n\u0004\u0011\u001e\u0002\u0011\n\f\u0011\u0019\u000b\n\u0011\n\u0013\u0011\n\b\u0011\u0019\u000f\u001e\u001d\u001b\n\u0002\u0006\u0010\u001b\u001e\u0019\u0016\u0019\u0013\u000b\u0005\u0005\u0010\u0011\u001e\u0019\u0011\u000f\u0019\u001d\u000f\u0003\u0019\u0011\u001b\u001e\u0010\u001a\u0019\u0005\u0011\u001b\u001d\n\u0002\n\b\b\u0011\b\b\u001c\u0011\n\u000f\u0019\u000b\u0007\u0019\u0018\u0017\n\u0014\f\u0003\u000b\f\u001b\u001e\u000e\u001d\u000b\u0002\u001e\u001b\u0005\u0003\u001d\f\n\f\u001e\u001d\u000f\u0011\u001e\u001d\u001b\u0019\u0007\u000b\u001e\u0019\b\u0011\u0004\u0011\u001e\u0011\u0019\u0018\u0017\n\u0011\f\u0003\u001b\n\u001d\b\u001c\b\nFigure 15 Echocardiographic and invasive assessment of tricuspid regurgitation. 3D, three-dimensional; CIED, cardiac implantable electronic device; \nCW, continuous-wave; EROA, effective regurgitant orifice area; FAC, fractional area change; FWS, free wall strain; GLS, global longitudinal strain; mPAP, \nmean pulmonary artery pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PISA, proximal isovelocity surface area; PVR, \npulmonary vascular resistance; RF, regurgitant fraction; RV, right ventricle/ventricular; RVEF, right ventricular ejection fraction; RVol, regurgitant volume; \nTAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TR, tricuspid regurgitation; VCA, vena contracta area; WU, wood unit. \naRV apical focused view.   \n4684                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n11.4.1.1. Patients without indication for left-sided valve  \nsurgery \nIn patients with severe TR but without the need for left-sided valve sur-\ngery, surgical intervention is recommended in operable symptomatic \npatients with primary TR (Figure 17; Recommendation Table 9).718 \nFurthermore, it should be considered in symptomatic patients with sec-\nondary TR, or in asymptomatic patients with primary or secondary TR \nand signs of RV dilatation or RV function deterioration.719 However, \npatients with severe LV/RV dysfunction or PH do not qualify due to \nhigh operative risk.84,686,720 \n11.4.1.2. Patients with indication for left-sided valve surgery \nSevere primary or secondary TR is unlikely to improve after isolated \nsurgical treatment of left-sided valve disease, and reoperation for \nTR treatment is associated with high peri-operative mortality.721 \nTherefore, TV surgery is recommended at the time of the index \nprocedure. \nMild TR with associated significant annular dilatation or moderate \nTR, if left uncorrected at the time of left-sided valve surgery, will pro-\ngress in approximately one-quarter of patients and is associated with \nworse outcome.690,722 In patients with moderate TR, TV repair annu-\nloplasty during MV surgery should be considered, because large retro-\nspective studies723,724 and two recent RCTs have shown beneficial \neffects on TR progression and RV remodelling over time.725,726 \nHowever, no effects on mortality, HF events, or reoperation were ob-\nserved in the repair group.725,727 Concomitant TV repair has also \nbeen associated with a higher risk of conduction disturbances requir-\ning pacemaker implantation (up to 14%),725,728 with potential negative \nimpacts on longer-term outcomes.729,730 In patients with mild TR and \nannular dilatation (≥40 mm or >21 mm/m2) undergoing left-sided \nvalve surgery, previous observational studies have demonstrated a \nbenefit of concomitant TV repair in terms of TR progression723,724 \nand RV function,731 and a trend towards improved long-term survival.724 \nHowever, a subanalysis of a recent RCT did not identify any difference in \nthe progression of TR or other outcomes in this category of patients \n\u001f\u001e\u001d\u001c\u001b\u001a\u001d\u0019\u0018\u001c\u0017\u001d\u0016\u0015\u0014\n\u001e\u001a\u0013\u0019\u0017\u0014\u0012\u0011\u001d\u0016\u0012\u0017\n\u0010\u0016\u001a\u000f\u0015\u0012\u001e\u001d\u001c\u0016\u001a\u0019\u0016\u000e\n\u0013\u001c\u0017\u001b\u001e\u0017\u001b\u0019\u0017\u001b\r\u001b\u0015\u001c\u001d\u0014\n\f\r\u001e\u000b\n\u001e\u001d\u001c\u0016\u001a\u0019\u0016\u000e\u0019\u0013\u001c\u0017\u001b\u001e\u0017\u001b\n\u001e\u001b\u001d\u001c\u0016\u000b\u0016\t\u0014\b\u0012\u001b\u0007\u0018\u001e\u001a\u001c\u0017\u0012\n\u0006\u0017\u0017\u001b\u0017\u0017\u0012\u001b\u001a\u001d\u0019\u0016\u000e\n\u0005\u0004\u0019\u000e\n\u001a\u0007\u001d\u001c\u0016\u001a\n\u0005\u001c\t\u0018\u001d\u0019\u0018\u001b\u001e\u0015\u001d\n\u0007\u001e\u001d\u0018\u001b\u001d\u001b\u0015\u001c\u0003\u001e\u001d\u001c\u0016\u001a\n\u0006\u001a\u001e\u001d\u0016\u0012\u001c\u0007\u001e\u000b\n\u0017\n\u001c\u001d\u001e\u0002\u001c\u000b\u001c\u001d\u0014\n\u0010\u0016\u0012\u0016\u0015\u0002\u001c\u0013\u001c\u001d\u001c\u001b\u0017\n\u0005\u001c\u0017\u0001\u0019\u001e\u0017\u0017\u001b\u0017\u0017\u0012\u001b\u001a\u001d\n\u001b\u001e\u0015\u001d\u0019\u001b\u001e\u0012\u0019\u001d\u0015\u001b\u001e\u001d\u0012\u001b\u001a\u001d\u0019\u0015\u001b\u0007\u0016\u0012\u0012\u001b\u001a\u0013\u001e\u001d\u001c\u0016\u001a\n\u0010\u000b\u001e\u0017\u0017\u0019\n\u0005 \u0010­\u0005\f\u001e\nFigure 16 Stepwise evaluation of patients with tricuspid regurgitation. RV, right ventricle/right ventricular. aSee Supplementary data online, Table S4.   \nESC Guidelines                                                                                                                                                                                          4685 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nduring a 2-year follow-up period.725 In turn, the need of pacemaker im-\nplantation after surgery led to a subsequent increase in HF hospita-\nlizations, endocarditis, and mortality.729 Annuloplasty may therefore \nbe considered after careful evaluation of the risk factors for progres-\nsive annular dilatation and TR (AF, RA size, pulmonary pressures, \netc.), balancing against the risk of possible pacemaker implantation \n(Supplementary data online, Table S5).732 \n11.4.2. Transcatheter techniques \nSeveral transcatheter approaches for the treatment of TR have been \ndeveloped, including TEER, direct annuloplasty, and orthotopic and het-\nerotopic TV replacement. Data from large multicentre registries, single- \narm clinical trials, and two recent RCTs in patients with severe TR at \nintermediate and high risk for surgery have shown the safety of trans-\ncatheter repair, as well as the ability to reduce TR to moderate or less in \nPatient with tricuspid regurgitation\nNeed for left-sided valve surgery\nSevere primary\nor secondary TR\nRV dilatation or\nRV function\ndeterioration\nAppropriate for surgery\naccording to\nthe Heart Team\nModerate or severe\nprimary or secondary TR\nSevere RV/LV\ndysfunction or\nsevere pre-capillary\npulmonary hypertension\nMild\nsecondary TR\nNo concomitant\nTV surgery\nMedical therapy\nTranscatheter\ntherapya\nTV surgeryb\nTA dilatation\n(≥40 mm or >21 mm/m2)\nSymptomatic\nSeverity/aetiology of TR\nSeverity/aetiology of TR\nFigure 17 Management of patients with tricuspid regurgitation. LV, left ventricle/left ventricular; RV, right ventricle/right ventricular; TA, tricuspid \nannulus; TR, tricuspid regurgitation; TV, tricuspid valve. aThe Heart Team with expertise in the treatment of TV disease evaluates anatomical eligibility \nfor transcatheter therapy including jet location, coaptation gap, leaflet tethering, and potential interference with pacing lead. bRepair whenever possible, \nparticularly in cases of moderate TR or mild TR with significant TA dilatation.   \n4686                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nmore than 80% of cases when anatomical suitability was con-\nfirmed.713,733–735 The Clinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the Tricuspid Valve Repair \nSystem (TRILUMINATE) Pivotal Trial showed also a lower incidence \nof the composite endpoint of death from any cause or TV surgery, \nHF hospitalization, and improvement in quality of life as measured \nwith the KCCQ score after tricuspid TEER compared with medical \ntreatment that was exclusively driven by improved quality of life \n[11.7 points (95% CI, 6.8–16.6); P <0.001].713 At 2 years, a lower inci-\ndence of HF hospitalizations has been observed in the intervention \ngroup, despite a high rate of crossovers (59%).736 \nAnother investigator-initiated RCT (the Tri.Fr trial) demonstrated \nthe benefit of tricuspid TEER in combination with GDMT over medical \ntherapy alone, for a composite score driven by improved PROMs.737 \nAnother recent RCT (the Edwards EVOQUE Transcatheter \nTricuspid Valve Replacement: Pivotal Clinical Investigation of Safety \nand Clinical Efficacy using a Novel Device (TRISCEND) II trial), compar-\ning transcatheter TV replacement with optimized medical therapy in \npatients with symptomatic severe TR, showed similar results with a \nwin ratio favouring TV replacement mainly explained by symptom \nand quality-of-life improvement. In these studies, reverse RV remodel-\nling was also observed. However, the safety profile of transcatheter TV \nreplacement was less favourable, including higher risk for major bleed-\ning (15%) and post-procedural pacemaker implantation in about one- \nquarter of the pacemaker-naïve patients after 12 months of follow- \nup.738 Based on these data, transcatheter treatment should be consid-\nered to improve quality of life and RV remodelling in high-risk patients \nwith symptomatic severe TR, despite optimal medical therapy, but \nwithout severe RV dysfunction or pre-capillary PH. \nTransvenous CIED lead repositioning or extraction can be consid-\nered in selected patients to improve TR or avoid lead jailing before \nany tricuspid interventions, although the efficacy of this procedure is \nuncertain and the risk of damaging the TV not negligible.688,717,739 \nRecurrent TR after previous tricuspid annuloplasty usually requires car-\ndiac reoperation for surgical TV replacement. Transcatheter valve-in-ring \nimplantation is an off-label procedure to treat residual TR in high-risk pa-\ntients. Challenges are the non-circular shape and the open form of the sur-\ngical annuloplasty ring.740 However, transcatheter tricuspid valve-in-valve \nprocedures have been performed with satisfactory results.741 \nTranscatheter TV procedures should be performed at an ex-\nperienced Heart Valve Centre with expertise in the treatment of \nTV disease (Table 6). Careful evaluation of clinical and anatomical \nsuitability is key for appropriate patient and device selection to \nachieve optimal TR reduction and symptomatic response to the \ntherapy. \n12. Tricuspid stenosis \n12.1. Prevalence and aetiology \nTricuspid stenosis (TS) is a relatively rare disease that is most commonly \nassociated with congenital conditions or enzymatic disorders, such as \nWhipple’s or Fabry’s disease. It can also be acquired as an isolated mani-\nfestation of RHD or occur in combination with aortic and/or MV involve-\nment. Moreover, TS can be the consequence of carcinoid disease due to \nserotonin-mediated proliferation, causing apposition of fibroblasts and \nextracellular matrix on the valve leaflets and the subvalvular apparatus. \nRare causes include medications (e.g. fenfluramine or methysergide) or in-\nflow obstruction due to CIED-associated thrombus formation or endo-\ncarditis with large vegetations. \n12.2. Evaluation \nValve evaluation and diagnosis of TS is based on echocardiography, and \nconsists of the anatomical assessment of the leaflet tissue and the sub-\nvalvular apparatus. Leaflet thickening with or without calcifications and \nRecommendation Table 9 — Recommendations on in-\ndications for intervention in tricuspid regurgitation (see \nalso Supplementary data online, Evidence Tables 22 and 23) \nRecommendations \nClassa \nLevelb  \nCareful evaluation of TR aetiology, stage of the \ndisease (i.e. degree of TR severity, RV and LV \ndysfunction, and PH), patient operative risk, and \nlikelihood of recovery by a multidisciplinary Heart \nTeam is recommended in patients with severe TR \nprior to intervention.691,742 \nI \nC                                                                                                   \nContinued \nPatients with tricuspid regurgitation and left-sided valvular \nheart disease requiring surgery \nConcomitant TV surgeryc is recommended in \npatients with severe primary or secondary \nTR.725,731,743,744 \nI \nB \nConcomitant TV repair should be considered in \npatients with moderate primary or secondary TR, to \navoid progression of TR and RV \nremodelling.723,724,726,731 \nIIa \nB \nConcomitant TV repair may be considered \nin selected patients with mild secondary TR \nand tricuspid annulus dilatation (≥40 mm or \n>21 mm/m2), to avoid progression of TR and RV \nremodelling.723–726,731,743 \nIIb \nB \nPatients with severe tricuspid regurgitation without left-sided \nvalvular heart disease requiring surgery \nTV surgeryc is recommended in symptomatic \npatients with severe primary TR without severe RV \ndysfunction or severe PH. \nI \nC \nTV surgeryc should be considered in asymptomatic \npatients with severe primary TR who have RV \ndilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or severe PH. \nIIa \nC \nTV surgeryc should be considered in patients with \nsevere secondary TR who are symptomatic or have \nRV dilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or PH.685,720,745–747 \nIIa \nB \nTranscatheter TV treatment should be considered to \nimprove quality of life and RV remodelling in high-risk \npatients with symptomatic severe TR despite optimal \nmedical therapy in the absence of severe RV \ndysfunction or pre-capillary PH.713,733,735,738,748–751 \nIIa \nA \n© ESC/EACTS 2025\nLV, left ventricle/left ventricular; PH, pulmonary hypertension; RV, right ventricle/right \nventricular; TR, tricuspid regurgitation; TV, tricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncValve repair whenever possible.   \nESC Guidelines                                                                                                                                                                                          4687 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 48",
          "page": 48,
          "content": "Recommendations | Classa | Levelb\nPMC is recommended in symptomatic patients in the\nabsence of unfavourable characteristics for PMC.c\n651–653,662,665 | I | B\nPMC is recommended in any symptomatic patients\nwith a contraindication or at high risk for surgery. | I | C\nMV surgery is recommended in symptomatic\npatients who are not suitable for PMC. | I | C\nPMC should be considered as initial treatment in\nsymptomatic patients with suboptimal anatomy but\nno unfavourable clinical characteristics for PMC.c | IIa | C\nPMC should be considered in asymptomatic patients\nwithout unfavourable clinical and anatomical\ncharacteristics for PMC, and:\n• High thromboembolic risk (history of systemic\nembolism, dense spontaneous contrast in the LA,\nnew-onset or paroxysmal AF), and/or\n• High risk of haemodynamic decompensation\n(SPAP >50 mmHg at rest, need for major NCS,\npregnant or desire for pregnancy). | IIa | C\nTMVI may be considered in symptomatic patients\nwith extensive MAC and severe MV dysfunction at\nexperienced Heart Valve Centres with expertise in\ncomplex MV surgery and transcatheter\ninterventions.542,680,681 | IIb | C",
          "rows": 7,
          "cols": 3
        },
        {
          "title": "Table on page 53",
          "page": 53,
          "content": " | Patients with tricuspid regurgitation and left-sided valvular\nheart disease requiring surgery |  |  | \nConcomitant TV surgeryc is recommended in\npatients with severe primary or secondary\nTR.725,731,743,744 |  | I | B | \nConcomitant TV repair should be considered in\npatients with moderate primary or secondary TR, to\navoid progression of TR and RV\nremodelling.723,724,726,731 |  | IIa | B | \nConcomitant TV repair may be considered\nin selected patients with mild secondary TR\nand tricuspid annulus dilatation (≥40 mm or\n>21 mm/m2), to avoid progression of TR and RV\nremodelling.723–726,731,743 |  | IIb | B | \n | Patients with severe tricuspid regurgitation without left-sided\nvalvular heart disease requiring surgery |  |  | \nTV surgeryc is recommended in symptomatic\npatients with severe primary TR without severe RV\ndysfunction or severe PH. |  | I | C | \nTV surgeryc should be considered in asymptomatic\npatients with severe primary TR who have RV\ndilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or severe PH. |  | IIa | C | \nTV surgeryc should be considered in patients with\nsevere secondary TR who are symptomatic or have\nRV dilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or PH.685,720,745–747 |  | IIa | B | \nTranscatheter TV treatment should be considered to\nimprove quality of life and RV remodelling in high-risk\npatients with symptomatic severe TR despite optimal\nmedical therapy in the absence of severe RV\ndysfunction or pre-capillary PH.713,733,735,738,748–751 |  | IIa | A | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 53",
          "page": 53,
          "content": "Recommendations | Classa | Levelb\nCareful evaluation of TR aetiology, stage of the\ndisease (i.e. degree of TR severity, RV and LV\ndysfunction, and PH), patient operative risk, and\nlikelihood of recovery by a multidisciplinary Heart\nTeam is recommended in patients with severe TR\nprior to intervention.691,742 | I | C",
          "rows": 2,
          "cols": 3
        }
      ],
      "keywords": [
        "moderate",
        "ct",
        "echo",
        "tricuspid",
        "tricuspid regurgitation",
        "mild",
        "risk",
        "tavi",
        "severe",
        "symptomatic",
        "treatment",
        "regurgitation"
      ]
    },
    {
      "number": "13",
      "title": "12. Tricuspid stenosis",
      "start_page": 53,
      "end_page": 54,
      "content": "more than 80% of cases when anatomical suitability was con-\nfirmed.713,733–735 The Clinical Trial to Evaluate Cardiovascular \nOutcomes in Patients Treated With the Tricuspid Valve Repair \nSystem (TRILUMINATE) Pivotal Trial showed also a lower incidence \nof the composite endpoint of death from any cause or TV surgery, \nHF hospitalization, and improvement in quality of life as measured \nwith the KCCQ score after tricuspid TEER compared with medical \ntreatment that was exclusively driven by improved quality of life \n[11.7 points (95% CI, 6.8–16.6); P <0.001].713 At 2 years, a lower inci-\ndence of HF hospitalizations has been observed in the intervention \ngroup, despite a high rate of crossovers (59%).736 \nAnother investigator-initiated RCT (the Tri.Fr trial) demonstrated \nthe benefit of tricuspid TEER in combination with GDMT over medical \ntherapy alone, for a composite score driven by improved PROMs.737 \nAnother recent RCT (the Edwards EVOQUE Transcatheter \nTricuspid Valve Replacement: Pivotal Clinical Investigation of Safety \nand Clinical Efficacy using a Novel Device (TRISCEND) II trial), compar-\ning transcatheter TV replacement with optimized medical therapy in \npatients with symptomatic severe TR, showed similar results with a \nwin ratio favouring TV replacement mainly explained by symptom \nand quality-of-life improvement. In these studies, reverse RV remodel-\nling was also observed. However, the safety profile of transcatheter TV \nreplacement was less favourable, including higher risk for major bleed-\ning (15%) and post-procedural pacemaker implantation in about one- \nquarter of the pacemaker-naïve patients after 12 months of follow- \nup.738 Based on these data, transcatheter treatment should be consid-\nered to improve quality of life and RV remodelling in high-risk patients \nwith symptomatic severe TR, despite optimal medical therapy, but \nwithout severe RV dysfunction or pre-capillary PH. \nTransvenous CIED lead repositioning or extraction can be consid-\nered in selected patients to improve TR or avoid lead jailing before \nany tricuspid interventions, although the efficacy of this procedure is \nuncertain and the risk of damaging the TV not negligible.688,717,739 \nRecurrent TR after previous tricuspid annuloplasty usually requires car-\ndiac reoperation for surgical TV replacement. Transcatheter valve-in-ring \nimplantation is an off-label procedure to treat residual TR in high-risk pa-\ntients. Challenges are the non-circular shape and the open form of the sur-\ngical annuloplasty ring.740 However, transcatheter tricuspid valve-in-valve \nprocedures have been performed with satisfactory results.741 \nTranscatheter TV procedures should be performed at an ex-\nperienced Heart Valve Centre with expertise in the treatment of \nTV disease (Table 6). Careful evaluation of clinical and anatomical \nsuitability is key for appropriate patient and device selection to \nachieve optimal TR reduction and symptomatic response to the \ntherapy. \n12. Tricuspid stenosis \n12.1. Prevalence and aetiology \nTricuspid stenosis (TS) is a relatively rare disease that is most commonly \nassociated with congenital conditions or enzymatic disorders, such as \nWhipple’s or Fabry’s disease. It can also be acquired as an isolated mani-\nfestation of RHD or occur in combination with aortic and/or MV involve-\nment. Moreover, TS can be the consequence of carcinoid disease due to \nserotonin-mediated proliferation, causing apposition of fibroblasts and \nextracellular matrix on the valve leaflets and the subvalvular apparatus. \nRare causes include medications (e.g. fenfluramine or methysergide) or in-\nflow obstruction due to CIED-associated thrombus formation or endo-\ncarditis with large vegetations. \n12.2. Evaluation \nValve evaluation and diagnosis of TS is based on echocardiography, and \nconsists of the anatomical assessment of the leaflet tissue and the sub-\nvalvular apparatus. Leaflet thickening with or without calcifications and \nRecommendation Table 9 — Recommendations on in-\ndications for intervention in tricuspid regurgitation (see \nalso Supplementary data online, Evidence Tables 22 and 23) \nRecommendations \nClassa \nLevelb  \nCareful evaluation of TR aetiology, stage of the \ndisease (i.e. degree of TR severity, RV and LV \ndysfunction, and PH), patient operative risk, and \nlikelihood of recovery by a multidisciplinary Heart \nTeam is recommended in patients with severe TR \nprior to intervention.691,742 \nI \nC                                                                                                   \nContinued \nPatients with tricuspid regurgitation and left-sided valvular \nheart disease requiring surgery \nConcomitant TV surgeryc is recommended in \npatients with severe primary or secondary \nTR.725,731,743,744 \nI \nB \nConcomitant TV repair should be considered in \npatients with moderate primary or secondary TR, to \navoid progression of TR and RV \nremodelling.723,724,726,731 \nIIa \nB \nConcomitant TV repair may be considered \nin selected patients with mild secondary TR \nand tricuspid annulus dilatation (≥40 mm or \n>21 mm/m2), to avoid progression of TR and RV \nremodelling.723–726,731,743 \nIIb \nB \nPatients with severe tricuspid regurgitation without left-sided \nvalvular heart disease requiring surgery \nTV surgeryc is recommended in symptomatic \npatients with severe primary TR without severe RV \ndysfunction or severe PH. \nI \nC \nTV surgeryc should be considered in asymptomatic \npatients with severe primary TR who have RV \ndilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or severe PH. \nIIa \nC \nTV surgeryc should be considered in patients with \nsevere secondary TR who are symptomatic or have \nRV dilatation/RV function deterioration, but without \nsevere LV/RV dysfunction or PH.685,720,745–747 \nIIa \nB \nTranscatheter TV treatment should be considered to \nimprove quality of life and RV remodelling in high-risk \npatients with symptomatic severe TR despite optimal \nmedical therapy in the absence of severe RV \ndysfunction or pre-capillary PH.713,733,735,738,748–751 \nIIa \nA \n© ESC/EACTS 2025\nLV, left ventricle/left ventricular; PH, pulmonary hypertension; RV, right ventricle/right \nventricular; TR, tricuspid regurgitation; TV, tricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncValve repair whenever possible.   \nESC Guidelines                                                                                                                                                                                          4687 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ncommissural fusions are pathognomonic findings of rheumatic involve-\nment. A mean diastolic transvalvular gradient of >5 mmHg at a normal \nheart rate indicates severe TS.649 \n12.3. Medical therapy \nMedical therapy is a bridge to surgical or transcatheter intervention. \nIntensive sodium restriction and concomitant diuretic therapy can \nlead to symptom improvement and diminish hepatic congestion. \n12.4. Indications for intervention \nAlthough valve repair is preferred in younger patients,752 valve replace-\nment is frequently required (see Recommendation Table 10). Biological \nheart valves have demonstrated adequate mid- and long-term results, \nand are preferred over MHVs because of high thrombogenicity in the \nlow-pressure system.753 In the case of BHV degeneration, transcatheter \nvalve-in-valve procedures are good alternatives to re-replacement.754 \nTranscatheter TV implantation is an emerging field, although limited ex-\nperience is available for the treatment of TS.749,755 In patients with car-\ncinoid disease, a stable oncological situation is a prerequisite for any \nvalve intervention to maximize survival and valve durability.756 \nAlthough data are very limited, TV balloon valvuloplasty can be an \noption in selected patients with TS (and no relevant TR), as well as in \nthose with concomitant mitral and tricuspid rheumatic pathology.757 \nHowever, in contrast to rheumatic MS, tricuspid rheumatic disease \nmore frequently presents as combined stenosis and regurgitation, \nwhich limits the applicability of balloon valvuloplasty. \n13. Multiple and mixed valvular \nheart disease \n13.1. Prevalence and undertreatment \nPatients frequently present with disease of more than one native heart \nvalve [multiple VHD (MVHD)], or coexisting stenosis and regurgitation \nof the same valve (mixed VHD).758 While the main cause of MVHD or \nmixed VHD has shifted to degeneration in high-income countries, the \nleading aetiology in low- and middle-income countries remains \nRHD.758,759 Regurgitation of atrioventricular valves secondary to cardio-\nmyopathy or long-standing primary valve disease, and late effects of radi-\nation therapy, are further causes of MVHD.758,760 Challenges in diagnostic \nevaluation coupled with limited data to guide clinical decisions contribute \nto late referral and undertreatment of patients with MVHD.758 \n13.2. Evaluation and diagnostic pitfalls \nIn view of the complex haemodynamic interplay of multiple and mixed \nvalve lesions, assessment by a Heart Team at a Heart Valve Centre and \nuse of an integrative multimodality approach is key to gain diagnostic \ncertainty, detect cardiac damage, and evaluate therapeutic op-\ntions.761,762 In the light of paucity of data on diagnostic and prognostic \nparameters in patients with MVHD, assessment largely focuses on \npathophysiological considerations and evidence derived from isolated \nvalve lesions. \nEchocardiography is the main tool to diagnose MVHD, assess mech-\nanism, severity, and associated cardiac damage, and monitor disease \nprogression.761 Haemodynamic interdependence between multiple \nvalve defects alters the loading and flow conditions, thereby limiting \nthe diagnostic validity of measures established to grade single valve de-\nfects (Table 9). In the presence of MVHD, low-flow states are frequent. \nThe continuity equation becomes erroneous if transvalvular flows are \nunequal, and pressure half-time (PHT)-derived methods are inaccurate \nif the ventricular compliance or filling is altered.761 In this context, \nTOE can provide important detailed anatomical and mechanistic \nflow-independent information.46,761 \nIf symptoms or echocardiographic findings are equivocal, multimod-\nality diagnostics should be considered on an individual basis to assess \nthe cumulative repercussions of MVHD. \nMeasures obtained during cardiopulmonary exercise testing reflect \nthe effect of MVHD on functional capacity.52,105,654,761,779 Levels of \nnatriuretic peptides such as NT-proBNP correlate with functional \nand echocardiographic parameters, and provide incremental prognos-\ntic value in patients with mixed aortic disease and MVHD.98,780 AV cal-\ncium scoring confirms the diagnosis of true severe AS under low-flow \nconditions, as described in Section 8.2.777 Cardiac magnetic resonance \nimaging enables the independent assessment of valvular regurgitation \nusing volumetric methods or direct flow quantification.45,46,522,762,781 \nImportantly, invasive cardiac output-derived measures based on \nthermodilution or the Fick equation using estimated oxygen uptake \nare inaccurate in low-flow conditions or severe TR, commonly pre-\nsent in MVHD.782 \n13.3. Indications for intervention \nGiven the heterogeneity of clinical scenarios and the lack of evidence on \noptimal treatment pathways, it is recommended that patients with \nMVHD are evaluated for intervention by a collaborative Heart Team \nat a Heart Valve Centre with experience in multimodality imaging \nand treatment of complex VHD.16,764 \nPatients presenting with a lesion fulfilling criteria for an intervention \nbased on recommendations for single VHD should be treated accord-\ningly. In the remaining patients, assessment of symptoms and functional \nstatus, as well as cardiac damage (which may be masked by the conse-\nquences of concomitant lesions and occur before symptoms manifest), \nis required. The risk–benefit ratio of intervention needs to take into \naccount diagnostic (un)certainty, the mechanisms and severity of \nMVHD, and patient-specific factors, as well as procedural options and \nrisks to determine the mode, timing, and sequence of valve treatment. \n13.3.1. Multiple valvular heart disease \nMultiple VHD with primary (as opposed to secondary) valvular disease \nusually requires surgical treatment of all relevant valvular lesions. \nSimultaneous treatment of concomitant severe valve defects is recom-\nmended and treatment of concomitant moderate AS, or moderate TR, \nshould be considered (Recommendation Table 11). \nRecommendation Table 10 — Recommendations on \nindications for intervention in tricuspid stenosis \nRecommendations \nClassa \nLevelb  \nSurgeryc is recommended in symptomatic patients \nwith severe TS.d \nI \nC \nSurgeryc is recommended in patients with severe TS \nundergoing left-sided valve intervention.e \nI \nC \n© ESC/EACTS 2025\nMV, mitral valve; PMC, percutaneous mitral commissurotomy; TS, tricuspid stenosis; TV, \ntricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncUsually TV replacement. \ndPercutaneous balloon valvuloplasty can be attempted as a first approach if TS is isolated. \nePercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the MV.   \n4688                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 53",
          "page": 53,
          "content": " | Patients with tricuspid regurgitation and left-sided valvular\nheart disease requiring surgery |  |  | \nConcomitant TV surgeryc is recommended in\npatients with severe primary or secondary\nTR.725,731,743,744 |  | I | B | \nConcomitant TV repair should be considered in\npatients with moderate primary or secondary TR, to\navoid progression of TR and RV\nremodelling.723,724,726,731 |  | IIa | B | \nConcomitant TV repair may be considered\nin selected patients with mild secondary TR\nand tricuspid annulus dilatation (≥40 mm or\n>21 mm/m2), to avoid progression of TR and RV\nremodelling.723–726,731,743 |  | IIb | B | \n | Patients with severe tricuspid regurgitation without left-sided\nvalvular heart disease requiring surgery |  |  | \nTV surgeryc is recommended in symptomatic\npatients with severe primary TR without severe RV\ndysfunction or severe PH. |  | I | C | \nTV surgeryc should be considered in asymptomatic\npatients with severe primary TR who have RV\ndilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or severe PH. |  | IIa | C | \nTV surgeryc should be considered in patients with\nsevere secondary TR who are symptomatic or have\nRV dilatation/RV function deterioration, but without\nsevere LV/RV dysfunction or PH.685,720,745–747 |  | IIa | B | \nTranscatheter TV treatment should be considered to\nimprove quality of life and RV remodelling in high-risk\npatients with symptomatic severe TR despite optimal\nmedical therapy in the absence of severe RV\ndysfunction or pre-capillary PH.713,733,735,738,748–751 |  | IIa | A | ",
          "rows": 9,
          "cols": 5
        },
        {
          "title": "Table on page 53",
          "page": 53,
          "content": "Recommendations | Classa | Levelb\nCareful evaluation of TR aetiology, stage of the\ndisease (i.e. degree of TR severity, RV and LV\ndysfunction, and PH), patient operative risk, and\nlikelihood of recovery by a multidisciplinary Heart\nTeam is recommended in patients with severe TR\nprior to intervention.691,742 | I | C",
          "rows": 2,
          "cols": 3
        },
        {
          "title": "Table on page 54",
          "page": 54,
          "content": "Recommendations | Classa | Levelb\nSurgeryc is recommended in symptomatic patients\nwith severe TS.d | I | C\nSurgeryc is recommended in patients with severe TS\nundergoing left-sided valve intervention.e | I | C",
          "rows": 3,
          "cols": 3
        }
      ],
      "keywords": [
        "stenosis",
        "intervention",
        "ct",
        "tricuspid",
        "surgery",
        "risk",
        "pacemaker",
        "severe",
        "symptomatic",
        "treatment"
      ]
    },
    {
      "number": "14",
      "title": "13. Multiple and mixed valvular heart disease",
      "start_page": 54,
      "end_page": 56,
      "content": "commissural fusions are pathognomonic findings of rheumatic involve-\nment. A mean diastolic transvalvular gradient of >5 mmHg at a normal \nheart rate indicates severe TS.649 \n12.3. Medical therapy \nMedical therapy is a bridge to surgical or transcatheter intervention. \nIntensive sodium restriction and concomitant diuretic therapy can \nlead to symptom improvement and diminish hepatic congestion. \n12.4. Indications for intervention \nAlthough valve repair is preferred in younger patients,752 valve replace-\nment is frequently required (see Recommendation Table 10). Biological \nheart valves have demonstrated adequate mid- and long-term results, \nand are preferred over MHVs because of high thrombogenicity in the \nlow-pressure system.753 In the case of BHV degeneration, transcatheter \nvalve-in-valve procedures are good alternatives to re-replacement.754 \nTranscatheter TV implantation is an emerging field, although limited ex-\nperience is available for the treatment of TS.749,755 In patients with car-\ncinoid disease, a stable oncological situation is a prerequisite for any \nvalve intervention to maximize survival and valve durability.756 \nAlthough data are very limited, TV balloon valvuloplasty can be an \noption in selected patients with TS (and no relevant TR), as well as in \nthose with concomitant mitral and tricuspid rheumatic pathology.757 \nHowever, in contrast to rheumatic MS, tricuspid rheumatic disease \nmore frequently presents as combined stenosis and regurgitation, \nwhich limits the applicability of balloon valvuloplasty. \n13. Multiple and mixed valvular \nheart disease \n13.1. Prevalence and undertreatment \nPatients frequently present with disease of more than one native heart \nvalve [multiple VHD (MVHD)], or coexisting stenosis and regurgitation \nof the same valve (mixed VHD).758 While the main cause of MVHD or \nmixed VHD has shifted to degeneration in high-income countries, the \nleading aetiology in low- and middle-income countries remains \nRHD.758,759 Regurgitation of atrioventricular valves secondary to cardio-\nmyopathy or long-standing primary valve disease, and late effects of radi-\nation therapy, are further causes of MVHD.758,760 Challenges in diagnostic \nevaluation coupled with limited data to guide clinical decisions contribute \nto late referral and undertreatment of patients with MVHD.758 \n13.2. Evaluation and diagnostic pitfalls \nIn view of the complex haemodynamic interplay of multiple and mixed \nvalve lesions, assessment by a Heart Team at a Heart Valve Centre and \nuse of an integrative multimodality approach is key to gain diagnostic \ncertainty, detect cardiac damage, and evaluate therapeutic op-\ntions.761,762 In the light of paucity of data on diagnostic and prognostic \nparameters in patients with MVHD, assessment largely focuses on \npathophysiological considerations and evidence derived from isolated \nvalve lesions. \nEchocardiography is the main tool to diagnose MVHD, assess mech-\nanism, severity, and associated cardiac damage, and monitor disease \nprogression.761 Haemodynamic interdependence between multiple \nvalve defects alters the loading and flow conditions, thereby limiting \nthe diagnostic validity of measures established to grade single valve de-\nfects (Table 9). In the presence of MVHD, low-flow states are frequent. \nThe continuity equation becomes erroneous if transvalvular flows are \nunequal, and pressure half-time (PHT)-derived methods are inaccurate \nif the ventricular compliance or filling is altered.761 In this context, \nTOE can provide important detailed anatomical and mechanistic \nflow-independent information.46,761 \nIf symptoms or echocardiographic findings are equivocal, multimod-\nality diagnostics should be considered on an individual basis to assess \nthe cumulative repercussions of MVHD. \nMeasures obtained during cardiopulmonary exercise testing reflect \nthe effect of MVHD on functional capacity.52,105,654,761,779 Levels of \nnatriuretic peptides such as NT-proBNP correlate with functional \nand echocardiographic parameters, and provide incremental prognos-\ntic value in patients with mixed aortic disease and MVHD.98,780 AV cal-\ncium scoring confirms the diagnosis of true severe AS under low-flow \nconditions, as described in Section 8.2.777 Cardiac magnetic resonance \nimaging enables the independent assessment of valvular regurgitation \nusing volumetric methods or direct flow quantification.45,46,522,762,781 \nImportantly, invasive cardiac output-derived measures based on \nthermodilution or the Fick equation using estimated oxygen uptake \nare inaccurate in low-flow conditions or severe TR, commonly pre-\nsent in MVHD.782 \n13.3. Indications for intervention \nGiven the heterogeneity of clinical scenarios and the lack of evidence on \noptimal treatment pathways, it is recommended that patients with \nMVHD are evaluated for intervention by a collaborative Heart Team \nat a Heart Valve Centre with experience in multimodality imaging \nand treatment of complex VHD.16,764 \nPatients presenting with a lesion fulfilling criteria for an intervention \nbased on recommendations for single VHD should be treated accord-\ningly. In the remaining patients, assessment of symptoms and functional \nstatus, as well as cardiac damage (which may be masked by the conse-\nquences of concomitant lesions and occur before symptoms manifest), \nis required. The risk–benefit ratio of intervention needs to take into \naccount diagnostic (un)certainty, the mechanisms and severity of \nMVHD, and patient-specific factors, as well as procedural options and \nrisks to determine the mode, timing, and sequence of valve treatment. \n13.3.1. Multiple valvular heart disease \nMultiple VHD with primary (as opposed to secondary) valvular disease \nusually requires surgical treatment of all relevant valvular lesions. \nSimultaneous treatment of concomitant severe valve defects is recom-\nmended and treatment of concomitant moderate AS, or moderate TR, \nshould be considered (Recommendation Table 11). \nRecommendation Table 10 — Recommendations on \nindications for intervention in tricuspid stenosis \nRecommendations \nClassa \nLevelb  \nSurgeryc is recommended in symptomatic patients \nwith severe TS.d \nI \nC \nSurgeryc is recommended in patients with severe TS \nundergoing left-sided valve intervention.e \nI \nC \n© ESC/EACTS 2025\nMV, mitral valve; PMC, percutaneous mitral commissurotomy; TS, tricuspid stenosis; TV, \ntricuspid valve. \naClass of recommendation. \nbLevel of evidence. \ncUsually TV replacement. \ndPercutaneous balloon valvuloplasty can be attempted as a first approach if TS is isolated. \nePercutaneous balloon valvuloplasty can be attempted if PMC can be performed on the MV.   \n4688                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTranscatheter treatment options are established for severe AS \n(TAVI), rheumatic MS (PMC), and primary MR and TR (TEER or trans-\ncatheter replacement) in patients with MVHD at high surgical risk, if \nanatomy is suitable.401,783 In the context of a transcatheter strategy, \na staged approach—typically beginning with the downstream lesion \n(aortic, followed by mitral and tricuspid)—is generally preferred to \navoid potential haemodynamic deterioration.784,785 \nMVHD with severe secondary regurgitation of both atrioventricular \nvalves is usually the consequence of either HFrEF with ventricular SMR \nand secondary TR, or atrial dilatation leading to both atrial MR and TR \nTable 9 Echocardiographic pitfalls, robust measures, and complementary multimodality imaging parameters in mul-\ntiple or mixed valvular heart disease  \nValve lesion to be assessed  \nAS \nAR \nMS \nMR  \nConcomitant  \nvalve lesion \nAS \n— \nPHT unreliable \nLV volume increase less \npronounced \n(hypertrophy, \ndisproportionate diastolic LV \npressure overload763) \nPHT unreliable \n(LV compliance ↓ 764) \nLow gradient due to low \nflow possible \n(low-flow state669) \nRegurgitant volume ↑ \nMR colour-flow jet area ↑ \n(increased afterload and \ntransmitral systolic pressure \ngradient46) \nAR \nSimplified Bernoulli \nequation overestimates \ngradient if LVOT  \nvelocity ↑ 765 \n— \nPHT unreliable \n(gradient ↓, altered LV \ncompliance766) \nMVA by continuity \nequation using aortic \nforward flow unreliable46 \nDoppler volumetric \nmethod using net aortic \nforward flow invalid \nMitral-to-aortic VTI ratio \nunreliable \n(increased transaortic \nflow46) \nMS \nLow-flow low-gradient \npossible \n(low-flow state761) \nLV volume increase less \npronounced \n(reduced preload761) \n— \nMitral-to-aortic VTI ratio \nunreliable \n(increased mitral VTI due to \nstenosis767) \nCalcifications may shadow \njet area \nMR \nLow-flow low-gradient \n(MR-induced low-flow \nstate768) \nAS confused with MR jet \nPHT unreliable \n(altered LV compliance763) \nDoppler volumetric \nmethod using net mitral \nforward flow invalid \n(increased flow46) \nPHT unreliable \n(altered LA and LV \ncompliance769,770) \nContinuity equation  \nunreliable \n(increased transmitral  \nflow761) \n— \nTR \nLow-flow low-gradient \npossible \n(TR induced low-flow \nstate771) \n— \nLow gradient possible \n(low-flow state668) \nPHT may be less reliable \n(impaired LV filling due to \nventricular \ninterdependence772,773) \nRegurgitant volume↓ in \nSMR possible \n(decreased preload774) \nRobust echocardiography \nmeasurements \nAVA (continuity equation), \nDVI761 \nIn mixed AR and AS: Vmax \nand mean gradient reflect \ncombined burden765 \nEROA (PISA), vena \ncontracta46,761 \nPlanimetry and 3D \nMVA (TOE)529,775 \nIn mixed MR & MS: \nmean gradient reflects \ncombined burden674,776 \nEROA (PISA), vena \ncontracta46,761 \nAlternative imaging  \nmodalities \nCT: AV calcium  \nscoring777 \nCMR: regurgitant volume \nand fraction45,46 \n— \nCMR: regurgitant volume \nand fraction45,46 \n© ESC/EACTS 2025\nMeasures reported refer to assessment of the valve lesions listed in the columns. Adapted from 761. \n3D, three-dimensional; AR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; CMR, cardiac magnetic resonance; CT, computed tomography; DVI, Doppler \nvelocity index; EROA, effective regurgitant orifice area; LA, left atrium/left atrial; LV, left ventricle/left ventricular; LVOT, left ventricular outflow tract; MR, mitral regurgitation; MS, mitral \nstenosis; MVA, mitral valve area; PHT, pressure half-time; PISA, proximal isovelocity surface area; SMR, secondary mitral regurgitation; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; VHD, valvular heart disease; Vmax, peak transvalvular velocity; VTI, velocity time integral; ↑, increase; ↓, decrease; —, none.   \nESC Guidelines                                                                                                                                                                                          4689 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n(often TR > MR). While surgery aims to address all relevant valve lesions \nin a single procedure, a stepwise transcatheter strategy offers the possi-\nbility of reassessing the upstream valve(s) under altered loading condi-\ntions, usually 3 months after the initial intervention. In very selected \ncases simultaneous transcatheter valve treatment may be consid-\nered.788,789 However, evidence is limited and primarily derived from \nmodestly sized observational studies.786–789 \n13.3.2. Mixed aortic valve disease \nThe severity of mixed AV disease is often underestimated and patients \nwith balanced moderate AR and AS show adverse event rates compar-\nable to patients with severe isolated AS.790,791 \nTransvalvular gradients measured by Doppler reflect the overall \nhaemodynamic burden of both regurgitation and stenosis, and are strong-\nly associated with adverse outcomes.765,791–793 Therefore, the presence \nof high transvalvular gradients justifies valve intervention in patients \nwith moderate mixed AV disease, even if regurgitation is graded as mod-\nerate and the calculated or planimetric AVA is >1 cm2 (Recommendation \nTable 12). Patients presenting with mixed AV disease, but with gradients \nbelow thresholds for intervention, should undergo careful multimodality \ndiagnostics including assessment of cardiac damage to inform individual \ntreatment strategies. Global longitudinal strain and natriuretic peptides \nhave shown incremental prognostic value beyond symptom status and \nsingle lesion severity in patients with preserved LVEF.762,794–796 \n13.3.3. Mixed mitral valve disease \nMixed MV disease is usually present in patients with rheumatic valve dis-\nease or MAC. If MVA is ≤1.5 cm2, recommendations for isolated MS \napply. However, patients with an MVA of >1.5 cm2 and moderate \nMR may be evaluated for valve replacement based on symptoms, ana-\ntomical characteristics, transmitral gradient, and signs of cardiac damage \nsuch as LA dilatation, AF, or PH.529,674,776,797 \n13.4. Follow-up \nDue to the cumulative haemodynamic impact of MVHD or mixed \nVHD, progression of its severity and the development of cardiac dam-\nage may be faster than in single VHD.761 Therefore, follow-up intervals \nshould be adjusted according to individual patient characteristics. \n14. Management of patients with \nprosthetic valves or valve repair \n14.1. Choice of prosthetic valve \nWhen choosing between an MHV and a BHV prosthesis for an individual \npatient, age, life expectancy, lifestyle, bleeding and thromboembolic risks, \npossibility of pregnancy, and patient preference should be considered. \nLife expectancy is estimated according to age, sex, comorbidities, ethnicity, \nand geographical area.798 An MHV is preferred in younger patients with \nlonger life expectancy and in those with a pre-existing indication for long- \nterm OAC (Recommendation Table 13). Generally, a BHV is implanted in \npatients with shorter life expectancy, increased bleeding risk due to frailty \nor comorbidities, in women contemplating pregnancy, and in patients in \nwhom stable INRs with adequate times in therapeutic range are unlikely.799 \nImportantly, the performance of different BHV prostheses can vary consid-\nerably.800 The impact of the aetiology of the native valve disease, if any, on \nthe choice between an MHV and a BHV remains unexplored. \nSeveral large observational studies, smaller RCTs, and meta-analyses \nhave compared long-term mortality with BHV and MHV prostheses in \npatients aged 50–70 years.376,801–805 Some of the studies showed \nlower mortality with an MHV in AV patients <60 years and MV patients \n<65 years old,801,804 while others failed to show any differ-\nences.376,802,803 Most of these studies were limited by their observa-\ntional nature and missing information on the type of prostheses \nimplanted. RCTs with sufficient statistical power comparing biological \nand mechanical prostheses are warranted. \nReplacement of the AV using an autograft (Ross procedure) is an \nalternative to an MHV in young patients that should be performed \nat experienced centres by operators with dedicated expertise (see \nalso Section 8).806 General recommendations are summarized in  \nRecommendation Table 13. \nRecommendation Table 11 — Recommendations on \nindications for surgery of concomitant left-sided valvu-\nlar heart diseasea \nRecommendations \nClassb \nLevelc \nConcomitant aortic stenosis  \nSAVR is recommended in patients with severe AS \nundergoing surgery for another valve. \nI \nC \nSAVR should be considered in patients with \nmoderate ASd undergoing surgery for another valve. \nIIa \nC \nConcomitant aortic regurgitation \nAV surgery is recommended in patients with severe \nAR undergoing surgery for another valve. \nI \nC \nConcomitant mitral regurgitation \nMV surgery is recommended in patients with severe \nMR undergoing surgery for another valve. \nI \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; MR, mitral \nregurgitation; MV, mitral valve; SAVR, surgical aortic valve replacement; TV, tricuspid valve. \naRecommendations for surgery of concomitant TV disease are listed in Section 11 and Section 12. \nbClass of recommendation. \ncLevel of evidence. \ndDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal-flow \nconditions. Clinical assessment is essential to determine whether SAVR is appropriate for an \nindividual patient.  \nRecommendation Table 12 — Recommendations on \nindications for intervention in patients with mixed mod-\nerate aortic stenosis and moderate aortic regurgitation \n(see also Supplementary data online, Evidence Table 24) \nRecommendations \nClassa \nLevelb  \nIntervention is recommended in symptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s.790–793 \nI \nB \nIntervention is recommended in asymptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation with Vmax ≥4.0 m/s, and \nLVEF <50% not attributable to other cardiac \ndisease.791 \nI \nC \n© ESC/EACTS 2025\nAV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; Vmax, peak \ntransvalvular velocity. \naClass of recommendation. \nbLevel of evidence. \ncAVA >1 cm2.   \n4690                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 54",
          "page": 54,
          "content": "Recommendations | Classa | Levelb\nSurgeryc is recommended in symptomatic patients\nwith severe TS.d | I | C\nSurgeryc is recommended in patients with severe TS\nundergoing left-sided valve intervention.e | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 55",
          "page": 55,
          "content": " |  | Valve lesion to be assessed |  |  | \n |  | AS | AR | MS | MR\nConcomitant\nvalve lesion | AS | — | PHT unreliable\nLV volume increase less\npronounced\n(hypertrophy,\ndisproportionate diastolic LV\npressure overload763) | PHT unreliable\n(LV compliance ↓ 764)\nLow gradient due to low\nfol w possible\n(low-flow state669) | Regurgitant volume ↑\nMR colour-flow jet area ↑\n(increased afterload and\ntransmitral systolic pressure\ngradient46)\n | AR | Simplified Bernoulli\nequation overestimates\ngradient if LVOT\nvelocity ↑ 765 | — | PHT unreliable\n(gradient ↓, altered LV\ncompliance766)\nMVA by continuity\nequation using aortic\nforward flow unreliable46 | Doppler volumetric\nmethod using net aortic\nforward flow invalid\nMitral-to-aortic VTI ratio\nunreliable\n(increased transaortic\nflow46)\n | MS | Low-flow low-gradient\npossible\n(low-flow state761) | LV volume increase less\npronounced\n(reduced preload761) | — | Mitral-to-aortic VTI ratio\nunreliable\n(increased mitral VTI due to\nstenosis767)\nCalcifications may shadow\njet area\n | MR | Low-flow low-gradient\n(MR-induced low-flow\nstate768)\nAS confused with MR jet | PHT unreliable\n(altered LV compliance763)\nDoppler volumetric\nmethod using net mitral\nforward flow invalid\n(increased flow46) | PHT unreliable\n(altered LA and LV\ncompliance769,770)\nContinuity equation\nunreliable\n(increased transmitral\nflow761) | —\n | TR | Low-fol w low-gradient\npossible\n(TR induced low-flow\nstate771) | — | Low gradient possible\n(low-flow state668)\nPHT may be less reliable\n(impaired LV filling due to\nventricular\ninterdependence772,773) | Regurgitant volume↓ in\nSMR possible\n(decreased preload774)\nRobust echocardiography\nmeasurements |  | AVA (continuity equation),\nDVI761\nIn mixed AR and AS: V\nmax\nand mean gradient reflect\ncombined burden765 | EROA (PISA), vena\ncontracta46,761 | Planimetry and 3D\nMVA (TOE)529,775\nIn mixed MR & MS:\nmean gradient reflects\ncombined burden674,776 | EROA (PISA), vena\ncontracta46,761\nAlternative imaging\nmodalities |  | CT: AV calcium\nscoring777 | CMR: regurgitant volume\nand fraction45,46 | — | CMR: regurgitant volume\nand fraction45,46",
          "rows": 9,
          "cols": 6
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations | Classa | Levelb\nIntervention is recommended in symptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.790–793\nmax | I | B\nIntervention is recommended in asymptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation with V ≥4.0 m/s, and\nmax\nLVEF <50% not attributable to other cardiac\ndisease.791 | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations |  | Classb | Levelc | \nConcomitant aortic stenosis |  |  |  | \nSAVR is recommended in patients with severe AS\nundergoing surgery for another valve. |  | I | C | \nSAVR should be considered in patients with\nmoderate ASd undergoing surgery for another valve. |  | IIa | C | \n | Concomitant aortic regurgitation |  |  | \nAV surgery is recommended in patients with severe\nAR undergoing surgery for another valve. |  | I | C | \n | Concomitant mitral regurgitation |  |  | \nMV surgery is recommended in patients with severe\nMR undergoing surgery for another valve. |  | I | C | ",
          "rows": 8,
          "cols": 5
        }
      ],
      "keywords": [
        "multiple",
        "echocardiography",
        "intervention",
        "ct",
        "echo",
        "valvular",
        "diuretic",
        "disease",
        "severe",
        "heart",
        "mixed",
        "treatment",
        "indication",
        "recommendation"
      ]
    },
    {
      "number": "15",
      "title": "14. Management of patients with prosthetic valves or valve repair",
      "start_page": 56,
      "end_page": 66,
      "content": "(often TR > MR). While surgery aims to address all relevant valve lesions \nin a single procedure, a stepwise transcatheter strategy offers the possi-\nbility of reassessing the upstream valve(s) under altered loading condi-\ntions, usually 3 months after the initial intervention. In very selected \ncases simultaneous transcatheter valve treatment may be consid-\nered.788,789 However, evidence is limited and primarily derived from \nmodestly sized observational studies.786–789 \n13.3.2. Mixed aortic valve disease \nThe severity of mixed AV disease is often underestimated and patients \nwith balanced moderate AR and AS show adverse event rates compar-\nable to patients with severe isolated AS.790,791 \nTransvalvular gradients measured by Doppler reflect the overall \nhaemodynamic burden of both regurgitation and stenosis, and are strong-\nly associated with adverse outcomes.765,791–793 Therefore, the presence \nof high transvalvular gradients justifies valve intervention in patients \nwith moderate mixed AV disease, even if regurgitation is graded as mod-\nerate and the calculated or planimetric AVA is >1 cm2 (Recommendation \nTable 12). Patients presenting with mixed AV disease, but with gradients \nbelow thresholds for intervention, should undergo careful multimodality \ndiagnostics including assessment of cardiac damage to inform individual \ntreatment strategies. Global longitudinal strain and natriuretic peptides \nhave shown incremental prognostic value beyond symptom status and \nsingle lesion severity in patients with preserved LVEF.762,794–796 \n13.3.3. Mixed mitral valve disease \nMixed MV disease is usually present in patients with rheumatic valve dis-\nease or MAC. If MVA is ≤1.5 cm2, recommendations for isolated MS \napply. However, patients with an MVA of >1.5 cm2 and moderate \nMR may be evaluated for valve replacement based on symptoms, ana-\ntomical characteristics, transmitral gradient, and signs of cardiac damage \nsuch as LA dilatation, AF, or PH.529,674,776,797 \n13.4. Follow-up \nDue to the cumulative haemodynamic impact of MVHD or mixed \nVHD, progression of its severity and the development of cardiac dam-\nage may be faster than in single VHD.761 Therefore, follow-up intervals \nshould be adjusted according to individual patient characteristics. \n14. Management of patients with \nprosthetic valves or valve repair \n14.1. Choice of prosthetic valve \nWhen choosing between an MHV and a BHV prosthesis for an individual \npatient, age, life expectancy, lifestyle, bleeding and thromboembolic risks, \npossibility of pregnancy, and patient preference should be considered. \nLife expectancy is estimated according to age, sex, comorbidities, ethnicity, \nand geographical area.798 An MHV is preferred in younger patients with \nlonger life expectancy and in those with a pre-existing indication for long- \nterm OAC (Recommendation Table 13). Generally, a BHV is implanted in \npatients with shorter life expectancy, increased bleeding risk due to frailty \nor comorbidities, in women contemplating pregnancy, and in patients in \nwhom stable INRs with adequate times in therapeutic range are unlikely.799 \nImportantly, the performance of different BHV prostheses can vary consid-\nerably.800 The impact of the aetiology of the native valve disease, if any, on \nthe choice between an MHV and a BHV remains unexplored. \nSeveral large observational studies, smaller RCTs, and meta-analyses \nhave compared long-term mortality with BHV and MHV prostheses in \npatients aged 50–70 years.376,801–805 Some of the studies showed \nlower mortality with an MHV in AV patients <60 years and MV patients \n<65 years old,801,804 while others failed to show any differ-\nences.376,802,803 Most of these studies were limited by their observa-\ntional nature and missing information on the type of prostheses \nimplanted. RCTs with sufficient statistical power comparing biological \nand mechanical prostheses are warranted. \nReplacement of the AV using an autograft (Ross procedure) is an \nalternative to an MHV in young patients that should be performed \nat experienced centres by operators with dedicated expertise (see \nalso Section 8).806 General recommendations are summarized in  \nRecommendation Table 13. \nRecommendation Table 11 — Recommendations on \nindications for surgery of concomitant left-sided valvu-\nlar heart diseasea \nRecommendations \nClassb \nLevelc \nConcomitant aortic stenosis  \nSAVR is recommended in patients with severe AS \nundergoing surgery for another valve. \nI \nC \nSAVR should be considered in patients with \nmoderate ASd undergoing surgery for another valve. \nIIa \nC \nConcomitant aortic regurgitation \nAV surgery is recommended in patients with severe \nAR undergoing surgery for another valve. \nI \nC \nConcomitant mitral regurgitation \nMV surgery is recommended in patients with severe \nMR undergoing surgery for another valve. \nI \nC \n© ESC/EACTS 2025\nAR, aortic regurgitation; AS, aortic stenosis; AV, aortic valve; AVA, aortic valve area; MR, mitral \nregurgitation; MV, mitral valve; SAVR, surgical aortic valve replacement; TV, tricuspid valve. \naRecommendations for surgery of concomitant TV disease are listed in Section 11 and Section 12. \nbClass of recommendation. \ncLevel of evidence. \ndDefined as an AVA of 1.0–1.5 cm2 (or mean aortic gradient of 25–40 mmHg) in normal-flow \nconditions. Clinical assessment is essential to determine whether SAVR is appropriate for an \nindividual patient.  \nRecommendation Table 12 — Recommendations on \nindications for intervention in patients with mixed mod-\nerate aortic stenosis and moderate aortic regurgitation \n(see also Supplementary data online, Evidence Table 24) \nRecommendations \nClassa \nLevelb  \nIntervention is recommended in symptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s.790–793 \nI \nB \nIntervention is recommended in asymptomatic \npatients with mixed moderate AV stenosisc and \nmoderate regurgitation with Vmax ≥4.0 m/s, and \nLVEF <50% not attributable to other cardiac \ndisease.791 \nI \nC \n© ESC/EACTS 2025\nAV, aortic valve; AVA, aortic valve area; LVEF, left ventricular ejection fraction; Vmax, peak \ntransvalvular velocity. \naClass of recommendation. \nbLevel of evidence. \ncAVA >1 cm2.   \n4690                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n14.2. Follow-up of patients with prosthetic \nvalves \nAll patients with prosthetic valves require lifelong clinical and echocar-\ndiographic follow-up to detect deterioration of prosthetic function, \nassociated cardiac damage, or progressive disease of another valve. \nSerial TTE measurements of transprosthetic gradients, calculation of \nthe effective valve area, and evaluation of leaflet motion and morph-\nology should be performed in patients receiving a BHV within \n3 months after valve implantation, again at 1 year, and annually there-\nafter, or sooner if new cardiovascular symptoms occur.812 TOE is re-\ncommended in all cases of suspected prosthetic valve dysfunction or \nendocarditis. In the latter case, CCT and PET-CT are also recom-\nmended, if the diagnosis is unclear, and to identify primary or second-\nary infection foci.5 \nCinefluoroscopy for MHVs and CCT provide useful additional infor-\nmation, if valve thrombus or pannus is suspected.812 Imaging should be \nrepeated in the case of thrombolytic and antithrombotic treatment of \nMVH thrombosis, even if gradients are normalized.813 \n14.3. Antithrombotic therapy in patients \nwith treated valvular heart disease \n14.3.1. Mechanical heart valves \n14.3.1.1. Post-operative anticoagulation and therapeutic targets \nMechanical heart valves require lifelong treatment with a VKA \nguided by the INR. Bridging with either therapeutic unfractionated \nheparin (UFH) or low-molecular-weight heparin (LMWH) and \nVKA should be initiated within 24 h after MHV implantation, or as \nsoon as considered safe. Heparin can be stopped when the INR is \ndocumented for 2 consecutive days within the therapeutic range \n(Figure 18).814 Two meta-analyses and a prospective study have sug-\ngested slightly lower bleeding rates using UFH bridging compared \nwith LMWH after MHV replacement or cardiac surgery.814–816 \nHowever, RCTs comparing the timing and dosage of each bridging \nstrategy are lacking. \nFor all patients with an MHV, lifelong VKA is recommended to \navoid major thrombotic complications, since cardioembolic or valve \nthrombosis rates without anticoagulation are substantial (12% per \nyear and 22% per year for first-generation aortic and mitral MHVs, \nrespectively).817 The INR target and range should be chosen consid-\nering the type, position, and number of valves, the patient’s thrombot-\nic risk, and comorbidities (see Table 10 and Recommendation \nTable 14). In patients with an MHV developing a major thrombo-\nembolic complication despite adequate INR and time in therapeutic \nrange (TTR, usually defined as >60%),820 either increased VKA inten-\nsity (e.g. INR target and range increased by 0.5 units) or the addition \nof low-dose acetylsalicylic acid (ASA) (75–100 mg/day) should be con-\nsidered.818 Direct oral anticoagulants or dual antiplatelet therapy \n(DAPT) are contraindicated to prevent thromboembolism in patients \nwith an MHV.821–824 \nGiven the complexity of lifelong VKA therapy due to high intra- \nand interpatient variability, the need for monitoring, drug and food \ninteractions,825,826 the narrow therapeutic window, influence of co-\nmorbidities, and non-modifiable characteristics (e.g. ageing, genetics, \nand ethnicity), RCTs have shown that patient’s education, as well \nas disease and treatment awareness, significantly improves anticoa-\ngulation quality and adherence.827–830 International normalized ra-\ntio self-monitoring and/or self-management increase efficacy, but \nnot safety, as compared with a standard approach; INR self- \nmonitoring can be used by motivated patients after adequate \ntraining.827–830 \nThe indication for VKA and DAPT combination in MHV patients \npresenting with acute coronary syndrome is described in the corre-\nsponding ESC Guidelines.151,831 In patients with an MHV and an in-\ndication for single antiplatelet therapy (SAPT) due to symptomatic \nmajor atherosclerotic diseases and low bleeding risk, low-dose \nASA in combination with a VKA should be considered, because \nthis strategy has been shown to significantly lower the incidence \nof major adverse cardiovascular events.818 However, the combin-\nation of antiplatelet agents (single or dual) and VKA increases the \nrisk of bleeding,825 and therefore their use should be carefully \nweighted. In a large meta-analysis that included MHV patients, the \ncombination of VKA with either ASA or clopidogrel increased clin-\nically relevant bleeding compared with VKA alone (clopidogrel odds \nratio, 3.55; 95% CI, 2.78–4.54; ASA odds ratio, 1.50; 95% CI, 1.29– \n1.74), which may be aggravated because of potential pharmacoki-\nnetic drug interactions on the cytochrome P (CYP)450s 2C19 and \n3A4.825 \nRecommendation Table 13 — Recommendations for \nprosthetic valve selection \nRecommendations \nClassa \nLevelb \nMechanical heart valve  \nAn MHV is recommended according to the desire of \nthe informed patient and if there is no \ncontraindication to long-term anticoagulation. \nI \nC \nAn MHV should be considered in patients with an \nestimated long life expectancy,c if there are no \ncontraindications for long-term OAC.801,807–811 \nIIa \nB \nAn MHV should be considered in patients aged \n<60 years for prostheses in the aortic position and \naged <65 years for prostheses in the mitral \nposition.801,807–811 \nIIa \nC \nAn MHV should be considered in patients with a \npre-existing MHV in another position. \nIIa \nC \nAn MHV may be considered in patients with a clear \nindication for long-term OAC. \nIIb \nC \nBiological heart valve \nA BHV is recommended according to the desire of \nthe informed patient. \nI \nC \nA BHV is recommended when an adequate quality of \nanticoagulation with VKA is unlikely, in patients at \nhigh bleeding risk, or with estimated short life \nexpectancy.c \nI \nC \nA BHV should be considered in patients aged \n>65 years for prostheses in the aortic position or \naged >70 years for prostheses in the mitral position. \nIIa \nC \nA BHV should be considered in women \ncontemplating pregnancy. \nIIa \nC \n© ESC/EACTS 2025\nBHV, biological heart valve; MHV, mechanical heart valve; OAC, oral anticoagulation; VKA, \nvitamin K antagonist. \naClass of recommendation. \nbLevel of evidence. \ncLife expectancy should be estimated according to age, sex, comorbidities, ethnicity, and \ngeographical area.   \nESC Guidelines                                                                                                                                                                                          4691 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nContinue VKA\n(Class I)\nMechanical heart valve replacement\nStart UFH or LMWH bridging and VKA within 24 h or as soon as considered safe\n(Class I)\nLifelong VKA with INR based on individual patient proﬁle and valve characteristics\nPromote patient education and training for self-monitoring to improve TTR\n(Class I) \nSpeciﬁc clinical scenarios\nElective NCS \nor invasive\nprocedures\nMinor or minimally\ninvasive \ninterventionsa\nIf documented adequate\nINR, increase INR target,\nor add low-dose ASA\n(Class IIa) \nAdd low-dose ASA\nbased on individual\nbleeding proﬁle \n(Class IIa)\nSymptomatic\natherosclerotic\ndisease\nCardioembolic\ncomplication\nThromboembolic risk factorsb\nHeparin\nbridgingc\n(Class IIa)\nVKA interruption at least\n4 days before surgery and\nresumption within 24 h or\nas soon as considered safe\n(Class I)\nVKA interruption (3–4 days\nbefore surgery) and resumption\n(within 24 h) without bridging\n(Class IIb)\nFigure 18 Antithrombotic therapy following mechanical heart valve implantation. AF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normal-\nized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS, \nmitral stenosis; N, no; NCS, non-cardiac surgery; TTR, time in therapeutic range; UFH: unfractionated heparin; VKA, vitamin K antagonist; Y, yes. aSkin; minor \neye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; and diagnostic cardiac catheter-\nization. bMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF  \n<35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism). \ncBridging needs to be started as soon as INR reaches a sub-therapeutic value and on the first postoperative day or as soon as considered safe.   \n4692                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n14.3.1.2. Prevention and management of bleeding \nSince patients with MHVs receive lifelong VKA, strategies to prevent \nbleeding need to be implemented. Proton pump inhibitors reduce \nthe risk of upper gastrointestinal bleeding by approximately 40% in pa-\ntients taking VKAs825,839,840 and should therefore be prescribed to pa-\ntients with MHVs, particularly in those with additional bleeding risk \nfactors (e.g. elderly, antiplatelet agent co-administration, chronic use \nof non-steroidal anti-inflammatory drugs, high INR, or alcohol abuse). \nRandomized controlled trials and a meta-analysis did not demonstrate \na benefit of oral vitamin K1 supplementation in addition to temporary \nVKA cessation in non-bleeding patients with a supratherapeutic INR \n(4.5–10.0), with a trend toward reduced safety, which may be relevant \nfor MHV patients.841,842 For non-bleeding patients with an INR of \n>10.0, oral vitamin K1 (2.0–3.0 mg) should be administered, avoiding \novercorrection.841,843 \nIn cases of uncontrolled life-threatening or other major bleeding,844 \nVKA use must be interrupted and reversal with non-activated \nfour-factor prothrombin complex concentrates is preferred over fresh \nfrozen plasma, because of higher safety and effectiveness.845–848 A reduced \nstarting dose (12.5 rather than 25 IU/kg) in patients with more thrombo-\ngenic MHVs may be considered.849 In addition, vitamin K1 should be ad-\nministered to reverse the effect of VKA. Intravenous route corrects \nINR ∼4 h faster than oral administration,850 with no differences at 24 h \nand an unknown clinical impact. VKA should be restarted as soon as major \nbleeding is controlled. \n14.3.1.3. Management of anticoagulation therapy before and after \nnon-cardiac invasive procedures \nIn patients with an MHV, VKA treatment should not be interrupted for: \nminor or minimally invasive procedures on the skin or eyes (including \ncataract with topical anaesthesia); dental cleaning, treatment of caries, \nand dental extractions; pacemaker implantation; cardiac catheterization; \nand endoscopic procedures (Recommendation Table 15; Table 11).851–856 \nTopical antifibrinolytic or haemostatic agents may improve local \nhaemostasis.853 \nIn patients with an MHV and high thromboembolic risk \n(Recommendation Table 16; Table 11) undergoing non-cardiac, elective \nmajor invasive procedures with high risk of bleeding (see  \nSupplementary data online, Table S6), VKA treatment must be inter-\nrupted at least 4 days before the procedure, bridging with LMWH \nshould be started as soon as the INR reaches a subtherapeutic value, \nand the INR should be <1.5 on the day of surgery.816,857,858 \nMeasuring anti-Xa activity at peak and trough may be appropriate to \nmanage LMWH dosing in selected patients, such as those with severe \nobesity or underweight.859 In cases of urgent, major invasive proce-\ndures, four-factor prothrombin complex concentrate should be admi-\nnistrated to timely correct the INR for the intervention, if needed. For \nthe management of antithrombotic drugs in patients undergoing major \ncardiac surgery, please refer to recent EACTS Guidelines.860 \nRecommendation Table 14 — Recommendations for the management of antithrombotic therapy in patients with a \nmechanical heart valve \nRecommendations \nClassa \nLevelb  \nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as \nconsidered safe.815,816,832–834 \nI \nB \nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications.821–823,835–838 \nI \nA \nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve \nefficacy.827,828 \nI \nA \nIt is recommended that INR targets are based on the type and position of the MHV, patient risk factors, and comorbidities.c 818,819,835–838 \nI \nA \nPatient education is recommended to improve the quality of OAC.827–830 \nI \nA \nThe addition of low-dose ASA (75–100 mg/day) to VKA should be considered in selected patients with MHVs in case of concomitant \nsymptomatic atherosclerotic disease considering the individual bleeding risk profile.818 \nIIa \nB \nEither an increase in INR target or the addition of low-dose ASA (75–100 mg/day) should be considered in patients with MHVs who \ndevelop a major thromboembolic complication despite documented adequate INR.818 \nIIa \nC \nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV.821–824 \nIII \nA \n© ESC/EACTS 2025\nASA, acetylsalicylic acid; DAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; MHV, \nmechanical heart valve; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence. \ncSee Table 10 for details.  \nTable 10 International normalized ratio targets and \ntherapeutic ranges for patients with a mechanical heart \nvalve \nMHV type and position \nAdditional \npro-thrombotic \nfactorsa \nINR target \nand (range)  \nFirst-line treatment with VKA only \nBall-in cage, tilting disc valve \nin any position, all MHV in \nmitral/tricuspid position \nNo \n3 (2.5–3.5) \nYes \n3.5 (3–4)b \nBileaflet, current-generation \nsingle-tilting aortic MHV \nNo \n2.5 (2–3)c \nYes \n3 (2.5–3.5) \n© ESC/EACTS 2025\nAF, atrial fibrillation; ASA, acetylsalicylic acid; INR, international normalized ratio; LV, left \nventricle/left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart \nvalve; MS, mitral stenosis; VKA, vitamin K antagonist. \naInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with \nsignificant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, \ndeep vein thrombosis, pulmonary embolism). \nbIn patients at very high thrombotic risk, low-dose ASA may be added instead.818 \ncIn patients at high bleeding risk, INR target could be maintained at a lower interval: \n2 (1.5–2.5).819   \nESC Guidelines                                                                                                                                                                                          4693 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nRecommendation Table 15 — Recommendations for the management of antithrombotic therapy in patients with a \nmechanical heart valve undergoing elective non-cardiac surgery or invasive procedures \nRecommendations \nClassa \nLevelb  \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventionsc associated with no or minimal \nbleeding.851–856 \nI \nA \nIt is recommended to discontinue VKA at least 4 days before major non-cardiac elective surgery, aiming for an INR <1.5, and to resume VKA \ntreatment within 24 h after surgery, or as soon as considered safe.816,857,858 \nI \nB \nVKA interruption and resumption with bridgingd should be considered in patients with an MHV and thromboembolic risk factorse \nundergoing major NCS.816,857,858 \nIIa \nB \nInterruption (3–4 days before surgery) and resumption of VKA without bridging may be considered to reduce bleeding in patients with \nnew-generation aortic MHVs and no other thromboembolic risk factorse undergoing major NCS or invasive procedures.816,857,858,861–864 \nIIb \nB \n© ESC/EACTS 2025\nAF, atrial fibrillation; h, hour; INR, international normalized ratio; LV, left ventricular; LVEF, left ventricular ejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac \nsurgery; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence. \ncSkin; minor eye surgery including cataract; dental cleaning, treatment of caries, and dental extractions; pacemaker or device implantation; diagnostic cardiac catheterization; gastroscopic, \ncolonoscopic, bronchoscopic, or genitourinary diagnostic or therapeutic procedures considered at low bleeding risk. \ndBridging needs to be started as soon as INR reaches a subtherapeutic value and on the first post-operative day or as soon as considered safe. \neMHV in mitral or tricuspid position, older MHV generations in any position, inherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent \n(<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein thrombosis, pulmonary embolism).  \nTable 11 Peri-operative management of antithrombotic treatment in patients with a mechanical heart valve undergo-\ning non-cardiac surgery based on type of procedure and underlying risk  \nMinimally invasive proceduresa \nMajor NCS or invasive proceduresa \nPre-procedure \nPost-procedure \nPre-procedure \nPost-procedure  \nLow thromboembolic risk \nNew-generation aortic \nMHV and no additional \nrisk factorsb \nOAC \nNo interruption \nof VKA \nContinue VKA \nInterrupt VKA at least 3– \n4 days prior to procedure \nwith target INR <1.5 on \nthe day of surgery \nResume VKA as soon as \nfeasible, within 24 h \nBridging \n— \n— \nNo bridging may be \nconsidered \nNo bridging may be \nconsidered, unless unable \nto administer OAC \nSupporting \nmeasures \n— \nTopical antifibrinolytic or \nhaemostatic agents may \nbe considered to improve \nlocal haemostasis \n— \nMechanical and \npharmacological VTE \nprophylaxis, if indicated \nModerate-to-high thromboembolic risk \nMHV in mitral or \ntricuspid position or \nother thromboembolic  \nrisk factorsb \nOAC \nNo interruption \nof VKA \nContinue VKA \nInterrupt VKA at least \n4 days prior to procedure \nwith target INR <1.5 the \nday of the procedure \nResume VKA within 24 h \nBridging \n— \n— \nBridging with LMWH or \nUFH if CKD stage IV or V, \nstarting at INR below the \ntherapeutic range \nBridging with UFH or \nLMWH post-operatively \nwithin 24 h \nSupporting \nmeasures \n— \nTopical antifibrinolytic or \nhaemostatic agents may \nbe considered to improve \nlocal haemostasis \n— \nAppropriate mechanical \nand pharmacological \nVTE prophylaxis \n© ESC/EACTS 2025\nAF, atrial fibrillation; CKD, chronic kidney disease; h, hour; INR, international normalized ratio; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular \nejection fraction; MHV, mechanical heart valve; MS, mitral stenosis; NCS, non-cardiac surgery; OAC, oral anticoagulation; UFH, unfractionated heparin; VKA, vitamin K antagonist; VTE, \nvenous thromboembolism. \naSee Supplementary Table S6. \nbInherited or acquired hypercoagulable state, LV dysfunction (LVEF <35%), AF with significant MS, recent (<12 months) major thrombotic event (i.e. cardioembolic stroke, deep vein \nthrombosis, pulmonary embolism).   \n4694                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nFor patients with an MHV and low cardioembolic risk (e.g. a new- \ngeneration MHV in the aortic position without additional risk factors) \nundergoing elective major NCS or invasive procedures, VKA interrup-\ntion (3–4 days before surgery)816,857,858,861–864 and resumption861–863 \nwithin 24 h may be performed without bridging to reduce post-surgical \nbleeding without increasing the risk of thrombosis (see Figure 18). \n14.3.2. Biological heart valves \nThe management of antithrombotic treatment after BHV implantation \nor valve repair is summarized in Recommendation Table 16 and Figure 19. \n14.3.2.1. Patients with a surgical biological heart valve and no \nindication for oral anticoagulation \nThe optimal antithrombotic strategy early after surgical implantation of \nan aortic BHV remains controversial due to the lack of high-quality evi-\ndence. Multiple observational studies support the short-term use of \nVKAs to reduce the risk of thromboembolism,865,866 while data on \nDOACs are missing. A small RCT and a meta-analysis found that \nVKA treatment for 3 months significantly increased major bleeding \ncompared with low-dose ASA, without reducing mortality or \nthromboembolic events, but statistical power was low.867,868 \nTherefore, both strategies (OAC or ASA) are reasonable within \n3 months of surgical aortic BHV implantation. In the absence of rando-\nmized evidence, patients undergoing mitral or tricuspid BHV implant-\nation should receive OAC for at least 3 months due to the increased \nrisk of AF and thromboembolisms. \n14.3.2.2. Patients with a transcatheter heart valve and no indication \nfor oral anticoagulation \nBased on evidence from RCTs, lifelong low-dose ASA is the recom-\nmended antithrombotic treatment after TAVI in patients without \nOAC indication. In the Antiplatelet Therapy for Patients Undergoing \nTranscatheter Aortic Valve Implantation (POPular TAVI) trial (cohort \nA), the incidence of bleeding and the composite of bleeding or \nthromboembolic events were both reduced with ASA compared \nwith DAPT at 1 year.869 One RCT [Global multicenter, open-label, ran-\ndomized, \nevent-driven, \nactive-controlled \nstudy \ncomparing \na \nrivAroxaban-based antithrombotic strategy to an antipLatelet-based \nstrategy after transcatheter aortIc vaLve rEplacement (TAVR) to \nOptimize clinical outcomes, GALILEO], which investigated a systematic \nOAC\nfor 3 months\n(Class IIa) \nASA\nfor 3 months\n(Class IIb) \nMV/TV\nsurgical repair\nOAC\nlong term\n(Class I) \nOAC\nlong term\n(Class I) \nASA for \n12 months\n(Class I)\nOAC\nlong term\n(Class I) \nOAC\nlong term\n(Class I) \nOAC\nlong term\n(Class I) \nOAC\nfor 3 months\n(Class IIa) \nASA long term\nafter ﬁrst\n12 months\n(Class IIa)\nASA long term\naccording to bleeding risk\n(Class IIb) \nASA or OAC\nfor 3 months\n(Class IIa) \nASA\nfor 3 months\n(Class IIa) \nTAVI\nSAVR\nMVR/TVR\nAortic\nsurgical repair\nIndication for long-term anticoagulation\nHigh bleeding risk\nFigure 19 Antithrombotic therapy following biological heart valve implantation or surgical valve repair. ASA, acetylsalicylic acid; MV, mitral valve; \nMVR, mitral valve replacement; OAC, oral anticoagulation; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation; \nTV, tricuspid valve; TVR, tricuspid valve replacement.   \nESC Guidelines                                                                                                                                                                                          4695 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nantithrombotic strategy of rivaroxaban (10 mg/day) in combination \nwith low-dose ASA compared with DAPT with clopidogrel for the first \n3 months, was halted prematurely due to an increased risk of death or \nthromboembolic complications, and an increased risk of bleeding in \nthe rivaroxaban/ASA group.870 The systematic use of DOACs after \nTAVI in patients without indication for OAC is therefore not recom-\nmended. Data on antithrombotic management after implantation of \ntranscatheter mitral BHVs or tricuspid BHVs are limited. Vitamin K an-\ntagonist treatment for ≥3 months is commonly prescribed, while \nDOACs may represent an alternative allowing for earlier discharge \nand a lower risk of short-term bleeding complications (median follow- \nup, 4.7 months).871 \nFor patients without baseline OAC undergoing mitral or tricuspid \ntranscatheter valve implantation, OAC (either with DOAC or VKA) \nis initiated and usually pursued for at least 6 months or indefinitely \n(in particular after valve implantation in the tricuspid position), while \npatients undergoing TEER usually receive single long-term antiplatelet \ntherapy with ASA. \n14.3.2.3. Patients with a surgical biological heart valve and an \nindication for oral anticoagulation \nLifelong OAC is recommended for patients with surgical BHVs with \nother indications for OAC. The evidence supports the use of \nDOACs in preference to VKAs in patients with AF, even during the \nearly post-operative period.872–877 A previously existing therapy with \na DOAC may be continued after BHV implantation and should be re-\nstarted, as soon as considered surgically safe, usually within 2–3 days of \nsurgery.860 \n14.3.2.4. Patients with a transcatheter biological heart valve and an \nindication for oral anticoagulation \nIn the POPular TAVI trial (cohort B), the incidence of bleeding over a per-\niod of 1 month or 1 year was lower with OAC than with OAC plus clo-\npidogrel.878 Oral anticoagulation alone was non-inferior to OAC plus \nclopidogrel with respect to ischaemic events, but the non-inferiority mar-\ngin was large. In Edoxaban vs Standard of Care and Their Effects on \nClinical Outcomes in Patients Having Undergone Transcatheter Aortic \nValve Implantation–Atrial Fibrillation (ENVISAGE-TAVI-AF),879 edoxaban \nwas non-inferior to VKA regarding the composite primary endpoint \n(death from any cause, myocardial infarction, ischaemic stroke, systemic \nthromboembolic event, valve thrombosis, or major bleeding), but the in-\ncidence of major bleeding was higher with edoxaban than with VKA. The \nAnti-Thrombotic Strategy to Lower All Cardiovascular and Neurologic \nIschemic and Hemorrhagic Events after Trans-Aortic Valve Implantation \nfor Aortic Stenosis (ATLANTIS) trial880 showed that apixaban was not \nsuperior to VKA after TAVI when there was a pre-existing indication \nfor OAC, and there was a signal of higher non-cardiovascular mortality \nwith apixaban. Therefore, no definitive recommendation can be made \nconcerning the use of VKAs vs DOACs in patients who have undergone \nTAVI with a pre-existing indication for OAC. \nAntithrombotic therapy after transcatheter MV or TV implantation \nremains empirical because data are limited. A high proportion of pa-\ntients are already under OAC because of AF (almost 50% of the popu-\nlation with MR and 80%–90% of the candidates for TR treatment). \nCommon practice is to continue the pre-existing anticoagulation regi-\nmen. Vitamin K antagonists and DOACs have been used in this setting \nwith or without combination with ASA.871 However, the high bleeding \nrisk of this usually elderly population needs to be taken into \nconsideration. \nRecommendation Table 16 — Recommendations for \nthe management of antithrombotic therapy in patients \nwith a biological heart valve or valve repair \nRecommendations \nClassa \nLevelb  \nSurgical biological heart valve without indication for oral \nanticoagulation \nLow-dose ASA (75–100 mg/day) or OAC \nusing a VKA should be considered for the first \n3 months after surgical implantation of an aortic \nBHV in patients without clear indication for \nOAC.865,866 \nIIa \nB \nA VKA should be considered for the first 3 months \nafter surgical implantation of a mitral or tricuspid \nBHV in patients without clear indication for \nOAC.867,868 \nIIa \nB \nLifelong low-dose ASA (75–100 mg/day) may be \nconsidered 3 months after surgical implantation of an \naortic or mitral BHV in patients without clear \nindication for OAC. \nIIb \nC \nTranscatheter aortic valve implantation without indication for \noral anticoagulation \nLow-dose ASA (75–100 mg/day) is recommended \nfor 12 months after TAVI in patients without \nindication for OAC.869,880–883 \nI \nA \nLong-term (after the first 12 months) low-dose ASA \n(75–100 mg/day) should be considered after TAVI in \npatients without clear indication for OAC. \nIIa \nC \nDAPT is not recommended to prevent thrombosis \nafter TAVI, unless there is a clear indication.881 \nIII \nB \nRoutine use of OAC is not recommended after TAVI \nin patients without baseline indication.869,880 \nIII \nA \nSurgical repair without indication for oral anticoagulation \nOAC, with either VKAs or DOACs, should be \nconsidered during the first 3 months after surgical \nMV or TV repair.884–888 \nIIa \nB \nLow-dose ASA (75–100 mg/day) should be \nconsidered for the first 3 months after surgical AV \nrepair in patients without indication for OAC. \nIIa \nC \nLow-dose ASA (75–100 mg/day) may be considered \nafter surgical MV or TV repair in preference to OAC \nin patients without clear indication for OAC and at \nhigh bleeding risk.884–888 \nIIb \nB \nSurgical biological heart valve with indication for oral \nanticoagulation \nOAC continuation is recommended in patients with \na clear indication for OAC undergoing surgical BHV \nimplantation.877,889,890 \nI \nB \nDOACs should be considered over VKAs after \n3 months following surgical implantation of a BHV in \npatients with AF.872–874,876,891 \nIIa \nB \nDOAC continuation may be considered after \nsurgical BHV implantation in patients with an \nindication for DOAC. 877,889,890 \nIIb \nB                         \nContinued  \n4696                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n14.4. Management of prosthetic valve \ndysfunction and complications \nProsthetic valve dysfunction can occur due to intrinsic permanent \nchanges to the prosthetic valve (defined as SVD) or non-structural valve \ndysfunction resulting from any abnormality not intrinsic to the pros-\nthetic valve itself. Valve thrombosis and endocarditis are considered \nseparate entities due to their specific presentation and management, \nbut may both result in SVD. \n14.4.1. Structural valve deterioration \nStructural valve deterioration has been defined by several consensus \ndocuments812,895,896 and includes wear and tear, leaflet disruption, \nleaflet fibrosis or calcification, and stent or strut fracture or deform-\nation. BHV (transcatheter or surgical) SVD is more frequent than \nMHV SVD. The incidence of SVD may be underestimated by the simple \nanalysis of patients with valve-related deaths or those undergoing rein-\ntervention. To ensure timely diagnosis, serial measurement should be \nperformed and compared with the TTE performed at discharge, or \nwithin 1–3 months after valve implantation. \nThe criteria for haemodynamic deterioration associated with \naortic and mitral SVD can be found in Table 12.895,896 The diagno-\nsis of moderate or severe haemodynamic deterioration should \nprompt referral to an experienced Heart Valve Centre for evalu-\nation and treatment, and to exclude all causes of non-structural \nvalve dysfunction, particularly PVL or PPM, as well as thrombosis \nand endocarditis. This step requires the use of advanced \nimaging techniques (TOE, CCT, and/or PET-CT) to document \nSVD-related morphological changes and elucidate its mechanism. \nStructural valve deterioration associated with corresponding clinic-\nal criteria (e.g. new onset or worsening of symptoms, LV or RV \ndilation/dysfunction, or PH) indicates BHV failure with potential \nneed for reintervention. Decisions about the treatment modality \n(redo surgery or transcatheter valve-in-valve implantation) should \nbe made within the interdisciplinary Heart Team, depending on re-\noperation risk and anatomical considerations,445,897 including the \nrisk of coronary obstruction,144,442,446,461 as well as prosthesis \ntype and size.898–900 When considering a valve-in-valve procedure \nfor a degenerated aortic BHV, the possibility of creating a PPM in \nsmall valves should be anticipated and may impact intervention or \nvalve selection.448 \nGiven the larger sizes of BHVs in mitral or tricuspid positions, trans-\nfemoral/transseptal valve-in-valve implantation represents an attractive \nalternative to redo open surgery.570,900–903 In the case of mitral \nvalve-in-valve implantation the risk of LVOT obstruction, although \nTranscatheter biological heart valve with indication for oral \nanticoagulation \nOAC is recommended for TAVI patients who have \nother indications for OAC.879,892–894 \nI \nB \nSurgical repair with indication for oral anticoagulation and/or \nantiplatelet therapy \nContinuation of OAC or antiplatelet therapy should \nbe considered after surgical valve repair in patients \nwith a clear indication for an antithrombotic \ntherapy.890 \nIIa \nB \n© ESC/EACTS 2025\nAF, atrial fibrillation; ASA, acetylsalicylic acid; AV, aortic valve; BHV, biological heart valve; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulant; MV, mitral valve; OAC, \noral anticoagulation; TAVI, transcatheter aortic valve implantation; TV, tricuspid valve; VKA, \nvitamin K antagonist. \naClass of recommendation. \nbLevel of evidence.  \nTable 12 Criteria for the diagnosis of moderate or severe aortic and mitral haemodynamic valve deterioration  \nModerate \nSevere  \nAortic BHV \nSVD or non-structural valve \ndysfunction (except PVL or PPM),a \nthrombosis, or endocarditis \nIncrease in mean transvalvular gradient ≥10 mmHg \nresulting in mean gradient ≥20 mmHg \nIncrease in mean transvalvular gradient ≥20 mmHg \nresulting in mean gradient ≥30 mmHg \nAND \nAND \nDecrease in EOA ≥0.3 cm2 or ≥25%, and/or decrease in \nDVI ≥0.1 or ≥20%, compared with echocardiographic \nassessment performed 1–3 months post-procedure \nDecrease in EOA ≥0.6 cm2 or ≥50%, and/or decrease in \nDVI ≥0.2 or ≥40%, compared with echocardiographic \nassessment performed 1–3 months post-procedure \nOR \nOR \nNew occurrence or increase of ≥1 grade of \nintraprosthetic AR resulting in ≥ moderate AR \nNew occurrence or increase of ≥2 grades of intraprosthetic \nAR resulting in ≥ moderate-to-severe AR \nMitral BHV \nSVD or non-structural valve \ndysfunction (except PVL or PPM),b \nthrombosis, or endocarditis \nIncrease in DVI ≥0.4 or ≥20%, resulting in DVI ≥2.2, or \ndecrease in EOA ≥0.5 cm2 or ≥25%, resulting in EOA  \n<1.5 cm2, usually associated with increase of transmitral \ngradient ≥5 mmHg \nIncrease in DVI ≥0.8 or ≥40%, resulting in DVI ≥2.7, or \ndecrease in EOA ≥1.0 cm2 or ≥50%, resulting in EOA  \n<1 cm2, usually associated with increase of transmitral \ngradient ≥10 mmHg \nOR \nOR \nNew occurrence or increase of ≥1 grade of \nintraprosthetic MR resulting in ≥moderate MR \nNew occurrence or increase of ≥2 grades of intraprosthetic \nMR resulting in ≥moderate-to-severe MR \n© ESC/EACTS 2025\nAdapted from 895,896. \nAR, aortic regurgitation; AV, aortic valve; BHV, biological heart valve; DVI, Doppler velocity index; EOA, effective orifice area; MR, mitral regurgitation; PPM, prosthesis–patient mismatch; \nPVL, paravalvular leak; SVD, structural valve deterioration. \naObstruction by pannus; dilatation of the aortic root after stentless BHV; or AV-sparing operations. \nbLeaflet entrapment by pannus, chordae, or suture.   \nESC Guidelines                                                                                                                                                                                          4697 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ninfrequent, should be carefully ruled out, especially in patients with \nsmall and hypertrophic ventricles.904 \n14.4.2. Non-structural valve dysfunction \n14.4.2.1. Prosthesis–patient mismatch \nProsthesis–patient mismatch should be prevented whenever pos-\nsible after either transcatheter or surgical valve-replacement pro-\ncedures (see Section 8.5.1.2). When occurring in the aortic \nposition, severe PPM is associated with decreased quality of life, in-\ncreased rate of rehospitalization and reintervention, and possible \nreduction in long-term survival, although findings are not consistent \nthroughout all studies.454,905–909 Moderate PPM is more common, \nbut seems to have a limited impact on outcomes. The projected \nindexed EOA may be predicted prior to valve implantation to \navoid severe PPM,908 although this concept has been challenged.910 \nLess is known about the prevalence and consequences of PPM in \nthe mitral and tricuspid positions, and established definitions are \nlacking. \nProsthesis–patient mismatch is an infrequent indication for rein-\ntervention. However, reoperation should be considered in symp-\ntomatic patients with severe PPM, particularly if the patient is low \nrisk.394,437,438 \n14.4.2.2. Paravalvular leak and haemolysis \nThe diagnosis of PVL requires systematic TOE, because TTE may be \ninconclusive. Haemolytic anaemia can often be detected in patients \nwith prosthetic valves and is best assessed by measuring lactate de-\nhydrogenase and haptoglobin serum levels, but rarely leads to symp-\ntoms. Intervention is needed if a PVL causes haemolysis requiring \nblood transfusions or symptoms, or if secondary to valve endocarditis. \nTranscatheter PVL closure is a valid alternative to surgery in the case \nof significant regurgitation or haemolysis, if feasible depending on the \nsize and location of the leak, but requires specific expertise and plan-\nning. Care must be taken not to interfere with mechanical leaflet mo-\ntion in MHV patients. Reported results for transcatheter PVL closure \nare inconsistent, with several patients returning with recurrent PVL \nand/or haemolysis.911 When surgery or transcatheter intervention \nare contraindicated, medical therapy aims to counteract the effect \nof haemolysis (iron supplementation and erythropoietin) or reduce \nit (beta-blockers).912 \n14.4.3. Endocarditis \nAntibiotic prophylaxis is recommended in all patients with a pros-\nthetic valve (including transcatheter valve prostheses) and after valve \nrepair using prosthetic material or with previous episode(s) of infect-\nive endocarditis, and should also be considered after transcatheter \nMV or TV repair.5 It is recommended in such patients when under-\ngoing dental extractions, oral surgery, or other procedures requiring \nmanipulation of the gingival or peri-apical region of the teeth. \nParticular attention to dental and cutaneous hygiene, and strict \naseptic measures during any invasive procedure, are also advised in \nthis population. Additional details on endocarditis prophylaxis are \nmentioned in the 2023 ESC Guidelines for the management of \nendocarditis.5 \n14.4.4. Valve thrombosis \nValve thrombosis occurs mainly in MHVs,913,914 but can also be ob-\nserved in BHVs.915,916 The spectrum of BHV thrombosis ranges \nfrom incidental CCT findings, such as hypo-attenuated leaflet thick-\nening (HALT) with or without reduced leaflet motion but normal \ngradients, to clinically apparent presentations with elevated \ngradients, symptoms of valve obstruction, or thromboembolic \nevents.917–919 \n14.4.4.1. Hypo-attenuated leaflet thickening \nHypo-attenuated leaflet thickening is detected by CCT in 10%–30% of \naortic BHVs depending on antithrombotic management, the definition \nof HALT, the timepoint of assessment, and the type of valve.917,919–921 \nThe significance and clinical implications of these findings with respect \nto thromboembolic risk and valve durability remain uncertain. \nAccordingly, routine use of CCT to detect HALT is not indi-\ncated.918–920 In patients with relevant increases in gradients, in \nwhom HALT and restricted leaflet motion is confirmed by CCT, \nelective use of DOACs or VKAs should be considered to resolve leaf-\nlet thrombosis.918,921,922 \n14.4.4.2. Clinically significant valve thrombosis \nObstructive valve thrombosis should be suspected in any patient \nwith any type of prosthetic valve who presents with new-onset \ndyspnoea or HF symptoms, an embolic event, or an unexpected in-\ncrease in transvalvular gradients. If TTE findings are uncertain, the \ndiagnosis should be confirmed by TOE and/or CCT to distinguish \nbetween \nthrombus, \npannus, \nand \ndegeneration.923–925 \nCinefluoroscopy can detect impaired MHV leaflet motion and re-\nduced opening angles. \nAdequate anticoagulation must be promptly restored in all patients \nwith MHV thrombosis and subtherapeutic INR. Although surgery re-\nmains the first-line option in critically ill patients, emergency valve re-\nplacement is associated with increased risk, whereas bleeding and \nsystemic embolism are increased with fibrinolysis.926–928 Slow, low- \ndose infusion appears to lower complication rates, while preserving \nthrombolytic success rates.928–931a It is recommended that the deci-\nsion between surgery and fibrinolysis is taken within the Heart \nTeam, and individualized by weighing clinical factors and local expert-\nise (Figure 20). \nManagement of non-obstructive thrombosis or obstructive \nthrombosis of an MHV without pronounced HF symptoms de-\npends mainly on the occurrence of a thromboembolic event \nand the size of the thrombus. Surgery should be considered for \na large (>10 mm) non-obstructive prosthetic valve thrombus \nthat is complicated by embolism or persists despite optimal \nOAC.913,932,933 \nAnticoagulation using a VKA is the first-line treatment for clinically \nrelevant BHV thrombosis, unless urgent reintervention or fibrinoly-\nsis is required due to progressive acute HF or haemodynamic \ninstability.934–938 Because clinically relevant BHV thrombosis is asso-\nciated with recurrence and may contribute to prosthetic degener-\nation, indefinite anticoagulation may be considered after a \nconfirmed episode, but this strategy must be balanced against the \nrisk of bleeding.936,939  \n4698                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nOR\nSigns and symptoms of MHV thrombosis\nLarge thrombus (≥10 mm)\ncomplicated by embolism\nAcute heart failure with NYHA Class III or IV\ndue to obstructive thrombosis\nEvidence for inadequate OAC\nFibrinolysis\n(low-dose slow infusion)\nFavoured if:\n• High surgical risk\n• Right-sided valve prosthesis\nSurgery\nFavoured if:\n• Recurrent event\n• Possible pannus\n• Cardiogenic shock\n• Large thrombus\n• Thromboembolic event\n• Contraindication to ﬁbrinolysis\nSurgery\n(Class IIa)\nHeart Team evaluation\n(Class I)\nHeart Team evaluation\nBridge until target INR,\nidentify and correct causes\nof inadequate OAC\nContinue VKA ± ASA with more intense monitoring\nRepeat imaging for monitoring of thrombus resolution \nor persistence\nPersistent thrombus with \nclinically relevant obstruction or \nthromboembolic event\nIncrease VKA intensity or\nadd low-dose ASA\n(Class IIa)\nTTE plus \nTOE and/or CCT or ﬂuoroscopy (Class I)\nFigure 20 Management of left-sided obstructive and non-obstructive mechanical heart valve thrombosis. ASA, acetylsalicylic acid; CCT, cardiac com-\nputed tomography; INR, international normalized ratio; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral anticoagulation; \nTOE, transoesophageal echocardiography; TTE, transthoracic echocardiography; VKA, vitamin K antagonist.   \nESC Guidelines                                                                                                                                                                                          4699 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n15. Management during \nnon-cardiac surgery \nIn patients with significant VHD who undergo NCS, the risk of peri- \noperative cardiovascular complications is increased and related to \nboth the timing of the procedure (i.e. urgent vs non-urgent) and type \nof surgery (low, intermediate, or high risk), as well as patient-specific \nfactors (type and severity of VHD, LV function, etc.).194,957–959 \nDetailed recommendations related to NCS are available in the 2022 \nESC Guidelines on cardiovascular assessment and management of patients \nundergoing non-cardiac surgery.960 \n15.1. Pre-operative evaluation \nEchocardiography should be performed in all patients with VHD requiring \nNCS. Patient- and surgery-specific factors, along with risk calculators, can \nbe used to guide the treatment strategy. Determination of functional cap-\nacity is a pivotal step for pre-operative risk assessment, measured either by \nthe ability to perform activities in daily life or by exercise testing. Screening \nfor frailty using validated tools is advisable.90 Decisions on pre- and peri- \noperative management, surveillance, and continuation of chronic cardio-\nvascular medical treatment should be taken after multidisciplinary discus-\nsion involving cardiologists, surgeons, and cardiac anaesthesiologists, as \nwell as the team who will be in charge of the NCS. Patients receiving \nOAC treatment should be managed as described in Section 14. \n15.2. Specific valve lesions \n15.2.1. Aortic stenosis \nIn patients with severe symptomatic AS, the treatment depends on the \nurgency and risk of NCS. If life-saving time-sensitive NCS is needed, it \nshould be performed under careful haemodynamic monitoring avoiding \nrapid changes of volume status, with prompt treatment of arrhythmia re-\ngardless of AS severity. In cases of urgent high-risk NCS, TAVI or balloon \naortic valvuloplasty should be considered in patients with critical AS prior \nto surgery, considering the risk of developing severe acute AR after \nRecommendation Table 17 — Recommendations for the management of prosthetic valve dysfunction (see also  \nSupplementary data online, Evidence Table 25) \nRecommendations \nClassa \nLevelb \nHaemolysis and paravalvular leak  \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team \nevaluation, including patient risk, leak morphology, and local expertise. \nI \nC \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF \nsymptoms. \nI \nC \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 \nIIa \nB \nMechanical heart valve failure \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nBiological heart valve failure \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve \ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart \nTeam.447,448,450,451,941 \nIIa \nB \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction \nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 \nIIa \nB \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. \nIIa \nC \nValve thrombosis \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945–948 \nI \nC \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926–929,931,949–954 \nI \nB \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 \nIIa \nC \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 \nI \nB \nOAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until \nresolution.918,920–922 \nIIa \nB \n© ESC/EACTS 2025\n4D, four-dimensional; BHV, biological heart valve; CT, computed tomography; HF, heart failure; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral \nanticoagulation; PVL, paravalvular leak; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence.   \n4700                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations | Classa | Levelb\nIntervention is recommended in symptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.790–793\nmax | I | B\nIntervention is recommended in asymptomatic\npatients with mixed moderate AV stenosisc and\nmoderate regurgitation with V ≥4.0 m/s, and\nmax\nLVEF <50% not attributable to other cardiac\ndisease.791 | I | C",
          "rows": 3,
          "cols": 3
        },
        {
          "title": "Table on page 56",
          "page": 56,
          "content": "Recommendations |  | Classb | Levelc | \nConcomitant aortic stenosis |  |  |  | \nSAVR is recommended in patients with severe AS\nundergoing surgery for another valve. |  | I | C | \nSAVR should be considered in patients with\nmoderate ASd undergoing surgery for another valve. |  | IIa | C | \n | Concomitant aortic regurgitation |  |  | \nAV surgery is recommended in patients with severe\nAR undergoing surgery for another valve. |  | I | C | \n | Concomitant mitral regurgitation |  |  | \nMV surgery is recommended in patients with severe\nMR undergoing surgery for another valve. |  | I | C | ",
          "rows": 8,
          "cols": 5
        },
        {
          "title": "Table on page 57",
          "page": 57,
          "content": "Recommendations |  | Classa | Levelb | \nMechanical heart valve |  |  |  | \nAn MHV is recommended according to the desire of\nthe informed patient and if there is no\ncontraindication to long-term anticoagulation. |  | I | C | \nAn MHV should be considered in patients with an\nestimated long life expectancy,c if there are no\ncontraindications for long-term OAC.801,807–811 |  | IIa | B | \nAn MHV should be considered in patients aged\n<60 years for prostheses in the aortic position and\naged <65 years for prostheses in the mitral\nposition.801,807–811 |  | IIa | C | \nAn MHV should be considered in patients with a\npre-existing MHV in another position. |  | IIa | C | \nAn MHV may be considered in patients with a clear\nindication for long-term OAC. |  | IIb | C | \n | Biological heart valve |  |  | \nA BHV is recommended according to the desire of\nthe informed patient. |  | I | C | \nA BHV is recommended when an adequate quality of\nanticoagulation with VKA is unlikely, in patients at\nhigh bleeding risk, or with estimated short life\nexpectancy.c |  | I | C | \nA BHV should be considered in patients aged\n>65 years for prostheses in the aortic position or\naged >70 years for prostheses in the mitral position. |  | IIa | C | \nA BHV should be considered in women\ncontemplating pregnancy. |  | IIa | C | ",
          "rows": 12,
          "cols": 5
        },
        {
          "title": "Table on page 59",
          "page": 59,
          "content": "Recommendations | Classa | Levelb\nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as\nconsidered safe.815,816,832–834 | I | B\nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications.821–823,835–838 | I | A\nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve\nefficacy.827,828 | I | A\nIt is recommended that INR targets are based on the type and position of the MHV, patient risk factors, and comorbidities.c 818,819,835–838 | I | A\nPatient education is recommended to improve the quality of OAC.827–830 | I | A\nThe addition of low-dose ASA (75–100 mg/day) to VKA should be considered in selected patients with MHVs in case of concomitant\nsymptomatic atherosclerotic disease considering the individual bleeding risk profile.818 | IIa | B\nEither an increase in INR target or the addition of low-dose ASA (75–100 mg/day) should be considered in patients with MHVs who\ndevelop a major thromboembolic complication despite documented adequate INR.818 | IIa | C\nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV.821–824 | III | A",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 59",
          "page": 59,
          "content": "MHV type and position | Additional\npro-thrombotic\nfactorsa | INR target\nand (range)\nFirst-line treatment with VKA only |  | \nBall-in cage, tilting disc valve\nin any position, all MHV in\nmitral/tricuspid position | No | 3 (2.5–3.5)\n | Yes | 3.5 (3–4)b\nBileaflet, current-generation\nsingle-tilting aortic MHV | No | 2.5 (2–3)c\n | Yes | 3 (2.5–3.5)",
          "rows": 6,
          "cols": 3
        },
        {
          "title": "Table on page 60",
          "page": 60,
          "content": "Recommendations | Classa | Levelb\nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventionsc associated with no or minimal\nbleeding.851–856 | I | A\nIt is recommended to discontinue VKA at least 4 days before major non-cardiac elective surgery, aiming for an INR <1.5, and to resume VKA\ntreatment within 24 h after surgery, or as soon as considered safe.816,857,858 | I | B\nVKA interruption and resumption with bridgingd should be considered in patients with an MHV and thromboembolic risk factorse\nundergoing major NCS.816,857,858 | IIa | B\nInterruption (3–4 days before surgery) and resumption of VKA without bridging may be considered to reduce bleeding in patients with\nnew-generation aortic MHVs and no other thromboembolic risk factorse undergoing major NCS or invasive procedures.816,857,858,861–864 | IIb | B",
          "rows": 5,
          "cols": 3
        },
        {
          "title": "Table on page 60",
          "page": 60,
          "content": " |  |  |  | Minimally invasive proceduresa |  | Major NCS or invasive proceduresa | \n |  |  |  | Pre-procedure | Post-procedure | Pre-procedure | Post-procedure\nLow thromboembolic risk |  |  |  |  |  |  | \nNew-generation aortic\nMHV and no additional\nrisk factorsb |  |  | OAC | No interruption\nof VKA | Continue VKA | Interrupt VKA at least 3–\n4 days prior to procedure\nwith target INR <1.5 on\nthe day of surgery | Resume VKA as soon as\nfeasible, within 24 h\n |  |  | Bridging | — | — | No bridging may be\nconsidered | No bridging may be\nconsidered, unless unable\nto administer OAC\n |  |  | Supporting\nmeasures | — | Topical antifibrinolytic or\nhaemostatic agents may\nbe considered to improve\nlocal haemostasis | — | Mechanical and\npharmacological VTE\nprophylaxis, if indicated\nModerate-to-high thromboembolic risk |  |  |  |  |  |  | \n | MHV in mitral or\ntricuspid position or\nother thromboembolic\nrisk factorsb |  | OAC | No interruption\nof VKA | Continue VKA | Interrupt VKA at least\n4 days prior to procedure\nwith target INR <1.5 the\nday of the procedure | Resume VKA within 24 h\n |  |  | Bridging | — | — | Bridging with LMWH or\nUFH if CKD stage IV or V,\nstarting at INR below the\ntherapeutic range | Bridging with UFH or\nLMWH post-operatively\nwithin 24 h\n |  |  | Supporting\nmeasures | — | Topical antifbi rinolytic or\nhaemostatic agents may\nbe considered to improve\nlocal haemostasis | — | Appropriate mechanical\nand pharmacological\nVTE prophylaxis",
          "rows": 10,
          "cols": 8
        },
        {
          "title": "Table on page 62",
          "page": 62,
          "content": "Recommendations |  | Classa | Levelb | \n | Surgical biological heart valve without indication for oral\nanticoagulation |  |  | \nLow-dose ASA (75–100 mg/day) or OAC\nusing a VKA should be considered for the first\n3 months after surgical implantation of an aortic\nBHV in patients without clear indication for\nOAC.865,866 |  | IIa | B | \nA VKA should be considered for the first 3 months\nafter surgical implantation of a mitral or tricuspid\nBHV in patients without clear indication for\nOAC.867,868 |  | IIa | B | \nLifelong low-dose ASA (75–100 mg/day) may be\nconsidered 3 months after surgical implantation of an\naortic or mitral BHV in patients without clear\nindication for OAC. |  | IIb | C | \n | Transcatheter aortic valve implantation without indication for\noral anticoagulation |  |  | \nLow-dose ASA (75–100 mg/day) is recommended\nfor 12 months after TAVI in patients without\nindication for OAC.869,880–883 |  | I | A | \nLong-term (after the frist 12 months) low-dose ASA\n(75–100 mg/day) should be considered after TAVI in\npatients without clear indication for OAC. |  | IIa | C | \nDAPT is not recommended to prevent thrombosis\nafter TAVI, unless there is a clear indication.881 |  | III | B | \nRoutine use of OAC is not recommended after TAVI\nin patients without baseline indication.869,880 |  | III | A | \n | Surgical repair without indication for oral anticoagulation |  |  | \nOAC, with either VKAs or DOACs, should be\nconsidered during the frist 3 months after surgical\nMV or TV repair.884–888 |  | IIa | B | \nLow-dose ASA (75–100 mg/day) should be\nconsidered for the frist 3 months after surgical AV\nrepair in patients without indication for OAC. |  | IIa | C | \nLow-dose ASA (75–100 mg/day) may be considered\nafter surgical MV or TV repair in preference to OAC\nin patients without clear indication for OAC and at\nhigh bleeding risk.884–888 |  | IIb | B | \n | Surgical biological heart valve with indication for oral\nanticoagulation |  |  | \nOAC continuation is recommended in patients with\na clear indication for OAC undergoing surgical BHV\nimplantation.877,889,890 |  | I | B | \nDOACs should be considered over VKAs after\n3 months following surgical implantation of a BHV in\npatients with AF.872–874,876,891 |  | IIa | B | \nDOAC continuation may be considered after\nsurgical BHV implantation in patients with an\nindication for DOAC. 877,889,890 |  | IIb | B | ",
          "rows": 18,
          "cols": 5
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": " | Transcatheter biological heart valve with indication for oral\nanticoagulation |  |  | \nOAC is recommended for TAVI patients who have\nother indications for OAC.879,892–894 |  | I | B | \n | Surgical repair with indication for oral anticoagulation and/or\nantiplatelet therapy |  |  | \nContinuation of OAC or antiplatelet therapy should\nbe considered after surgical valve repair in patients\nwith a clear indication for an antithrombotic\ntherapy.890 |  | IIa | B | ",
          "rows": 4,
          "cols": 5
        },
        {
          "title": "Table on page 63",
          "page": 63,
          "content": " | Moderate | Severe\nAortic BHV\nSVD or non-structural valve\ndysfunction (except PVL or PPM),a\nthrombosis, or endocarditis | Increase in mean transvalvular gradient ≥10 mmHg\nresulting in mean gradient ≥20 mmHg | Increase in mean transvalvular gradient ≥20 mmHg\nresulting in mean gradient ≥30 mmHg\n | AND | AND\n | Decrease in EOA ≥0.3 cm2 or ≥25%, and/or decrease in\nDVI ≥0.1 or ≥20%, compared with echocardiographic\nassessment performed 1–3 months post-procedure | Decrease in EOA ≥0.6 cm2 or ≥50%, and/or decrease in\nDVI ≥0.2 or ≥40%, compared with echocardiographic\nassessment performed 1–3 months post-procedure\n | OR | OR\n | New occurrence or increase of ≥1 grade of\nintraprosthetic AR resulting in ≥ moderate AR | New occurrence or increase of ≥2 grades of intraprosthetic\nAR resulting in ≥ moderate-to-severe AR\nMitral BHV\nSVD or non-structural valve\ndysfunction (except PVL or PPM),b\nthrombosis, or endocarditis | Increase in DVI ≥0.4 or ≥20%, resulting in DVI ≥2.2, or\ndecrease in EOA ≥0.5 cm2 or ≥25%, resulting in EOA\n<1.5 cm2, usually associated with increase of transmitral\ngradient ≥5 mmHg | Increase in DVI ≥0.8 or ≥40%, resulting in DVI ≥2.7, or\ndecrease in EOA ≥1.0 cm2 or ≥50%, resulting in EOA\n<1 cm2, usually associated with increase of transmitral\ngradient ≥10 mmHg\n | OR | OR\n | New occurrence or increase of ≥1 grade of\nintraprosthetic MR resulting in ≥moderate MR | New occurrence or increase of ≥2 grades of intraprosthetic\nMR resulting in ≥moderate-to-severe MR",
          "rows": 9,
          "cols": 3
        },
        {
          "title": "Table on page 66",
          "page": 66,
          "content": "Recommendations |  | Classa | Levelb | \nHaemolysis and paravalvular leak |  |  |  | \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team\nevaluation, including patient risk, leak morphology, and local expertise. |  | I | C | \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF\nsymptoms. |  | I | C | \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 |  | IIa | B | \n | Mechanical heart valve failure |  |  | \nReoperation is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Biological heart valve failure |  |  | \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. |  | I | C | \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve\ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart\nTeam.447,448,450,451,941 |  | IIa | B | \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction\nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 |  | IIa | B | \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. |  | IIa | C | \n | Valve thrombosis |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confrim the diagnosis.914,918,923,925,945–948 |  | I | C | \n | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis).923,926–929,931,949–954 |  | I | B | \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 |  | IIa | C | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 |  | I | B | \nOAC should be considered in patients with leaflet thickening and reduced leafel t motion leading to elevated gradients at least until\nresolution.918,920–922 |  | IIa | B | ",
          "rows": 20,
          "cols": 5
        }
      ],
      "keywords": [
        "moderate",
        "intervention",
        "ct",
        "follow-up",
        "valve",
        "management",
        "surgery",
        "risk",
        "severe",
        "patients",
        "valves",
        "repair",
        "prosthetic",
        "indication",
        "treatment",
        "recommendation"
      ]
    },
    {
      "number": "16",
      "title": "15. Management during non-cardiac surgery",
      "start_page": 66,
      "end_page": 68,
      "content": "15. Management during \nnon-cardiac surgery \nIn patients with significant VHD who undergo NCS, the risk of peri- \noperative cardiovascular complications is increased and related to \nboth the timing of the procedure (i.e. urgent vs non-urgent) and type \nof surgery (low, intermediate, or high risk), as well as patient-specific \nfactors (type and severity of VHD, LV function, etc.).194,957–959 \nDetailed recommendations related to NCS are available in the 2022 \nESC Guidelines on cardiovascular assessment and management of patients \nundergoing non-cardiac surgery.960 \n15.1. Pre-operative evaluation \nEchocardiography should be performed in all patients with VHD requiring \nNCS. Patient- and surgery-specific factors, along with risk calculators, can \nbe used to guide the treatment strategy. Determination of functional cap-\nacity is a pivotal step for pre-operative risk assessment, measured either by \nthe ability to perform activities in daily life or by exercise testing. Screening \nfor frailty using validated tools is advisable.90 Decisions on pre- and peri- \noperative management, surveillance, and continuation of chronic cardio-\nvascular medical treatment should be taken after multidisciplinary discus-\nsion involving cardiologists, surgeons, and cardiac anaesthesiologists, as \nwell as the team who will be in charge of the NCS. Patients receiving \nOAC treatment should be managed as described in Section 14. \n15.2. Specific valve lesions \n15.2.1. Aortic stenosis \nIn patients with severe symptomatic AS, the treatment depends on the \nurgency and risk of NCS. If life-saving time-sensitive NCS is needed, it \nshould be performed under careful haemodynamic monitoring avoiding \nrapid changes of volume status, with prompt treatment of arrhythmia re-\ngardless of AS severity. In cases of urgent high-risk NCS, TAVI or balloon \naortic valvuloplasty should be considered in patients with critical AS prior \nto surgery, considering the risk of developing severe acute AR after \nRecommendation Table 17 — Recommendations for the management of prosthetic valve dysfunction (see also  \nSupplementary data online, Evidence Table 25) \nRecommendations \nClassa \nLevelb \nHaemolysis and paravalvular leak  \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team \nevaluation, including patient risk, leak morphology, and local expertise. \nI \nC \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF \nsymptoms. \nI \nC \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 \nIIa \nB \nMechanical heart valve failure \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nBiological heart valve failure \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve \ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart \nTeam.447,448,450,451,941 \nIIa \nB \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction \nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 \nIIa \nB \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. \nIIa \nC \nValve thrombosis \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis.914,918,923,925,945–948 \nI \nC \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis).923,926–929,931,949–954 \nI \nB \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 \nIIa \nC \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 \nI \nB \nOAC should be considered in patients with leaflet thickening and reduced leaflet motion leading to elevated gradients at least until \nresolution.918,920–922 \nIIa \nB \n© ESC/EACTS 2025\n4D, four-dimensional; BHV, biological heart valve; CT, computed tomography; HF, heart failure; MHV, mechanical heart valve; NYHA, New York Heart Association; OAC, oral \nanticoagulation; PVL, paravalvular leak; TOE, transoesophageal echocardiography; VKA, vitamin K antagonist. \naClass of recommendation. \nbLevel of evidence.   \n4700                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nballoon aortic valvuloplasty.194,961 Urgent low- and intermediate-risk \nNCS can be performed relatively safely in patients with severe AS.962 \nPatients in whom NCS can be deferred (i.e. non-urgent NCS) \nshould undergo pre-operative Heart Team evaluation to determine \nwhether SAVR or TAVI is preferable. TAVI may be preferred to \nSAVR if faster recovery plays a role, particularly in elderly patients \nin whom complex or high-risk NCS is planned.963 The treatment of \nasymptomatic patients with severe AS should be individualized \n(Figure 21).964 \n15.2.2. Mitral stenosis \nHeart rate and fluid balance should be controlled to prevent pulmonary \noedema during NCS and arterial vasodilators should be avoided. \nNon-cardiac surgery is safe in patients with an MVA of >1.5 cm2, and in \nasymptomatic patients with MVA ≤1.5 cm2 and SPAP of <50 mmHg. \nSymptomatic patients or those with SPAP of >50 mmHg should undergo \nPMC or other appropriate valve intervention before high-risk NCS, if pos-\nsible.965,966 Asymptomatic patients with MVA ≤1.5 cm2 can undergo \nlow-to-moderate-risk NCS under careful monitoring, especially if PMC \nis unsuitable. Multidisciplinary management is advised for patients with sig-\nnificant MS who are ineligible for valve intervention. \n15.2.3. Aortic and mitral regurgitation \nNon-cardiac surgery can usually be performed safely in asymptomatic pa-\ntients with severe MR or AR and preserved LV function. If NCS is urgent, \npatients should undergo surgery under strict haemodynamic monitoring, \nregardless of symptom status. In cases of elective (non-urgent) NCS in \npatients with severe ventricular SMR, medical therapy should be opti-\nmized. If symptoms persist and NCS is intermediate or high risk, TEER \nshould be considered after Heart Team discussion based on clinical \nPatient with severe AS requiring NCS\nLOW-MODERATE\nUrgent NCS\nHIGH\nHIGH\nHIGH\nLOW\nElective NCS\nSymptoms\nor LV dysfunction\nConsider TAVI\nor balloon aortic \nvalvuloplasty \nbefore NCS\nif doable, or NCS\nunder strict \nmonitoring\nNCS\nNCS under\nstrict monitoring\nHeart Team\ndecision:\nSAVR or TAVI\nRisk of NCS\nRisk of NCS\nPatient risk for\nAV procedure\n(TAVI/SAVR)\nFigure 21 Management of non-cardiac surgery in patients with severe aortic stenosis. AS, aortic stenosis; AV, aortic valve; LV, left ventricular; NCS, \nnon-cardiac surgery; SAVR, surgical aortic valve replacement; TAVI, transcatheter aortic valve implantation.   \nESC Guidelines                                                                                                                                                                                          4701 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nand anatomical selection criteria.194,584 Valve treatment should be per-\nformed for patients with AR meeting the criteria for valve intervention \nbefore any elective intermediate- or high-risk NCS.966,967 \n15.3. Peri-operative monitoring \nHeart rate control (particularly in MS) and careful fluid management \n(particularly in AS and MR with reduced LVEF) are needed throughout \nthe procedure. The involvement of specialized cardiovascular anaesthe-\nsiologists should be considered in complex situations because TOE \nmonitoring may be considered. Pulmonary artery catheterization is \nnot routinely used. \n16. Management of valvular heart \ndisease during pregnancy \nSpecific ESC Guidelines on this topic are available (the 2025 ESC \nGuidelines on cardiovascular disease during pregnancy) and should be con-\nsulted for further details.968 Pregnancies in patients with VHD should \nbe considered high risk and managed under the close supervision of a \ncardiologist and a multidisciplinary Pregnancy Heart Team. The import-\nance of midwives and other specialized nursing personnel is increasingly \nrecognized for high-quality direct patient interactions. Shared decision- \nmaking is especially important when addressing the cardiovascular risk \nof pregnancy and the benefit–risk ratios of therapeutic options and \nmodes of delivery (Figure 22). \n16.1. Management before pregnancy \nIdeally, women should undergo a thorough physical examination by \ntheir general practitioner for VHD screening prior to pregnancy. A spe-\ncialized evaluation including TTE should be performed by a cardiologist \nin the case of clinical suspicion.968,969 \nIf VHD is diagnosed, pre-pregnancy counselling is imperative. \nUnplanned pregnancies in patients with VHD should be discouraged. \nContraception methods should be recommended after discussion \nwith the patient in the presence of a significant maternal and/or foetal \nrisk. In patients contemplating pregnancy, the maternal risk should be \nassessed using the modified WHO classification and other scores such \nas the CARPREG or DEVI risk score (see Supplementary data online,  \nTable S7).970 \n\u001f\u001e\u001d\u001c\u001b\u001c\u001a\u0019\u0018\u001d\n\u0017\u001a\u0019\u0016\u0015\u001a\u0014\u0013\u0018\u0015\u001a\u001b\n\u0012\u0019\u0011\u0010\u0019\u000f\u001b\u001d\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u000e\u000b\u001a\u001d\u0019\u000e\n\u0013\t\u001b\u001a\u001d\r\u000e\u000e\u001b\b\n\u0007\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\r\b\r\n\u0019\u001d\u001c\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u001d\t\u001b\u0018\u0019\u0015\b\u0019\u001d\u001c\u001d\n\u0006\u0015\u001a\u0011\u0019\r\b\r\n\u0014\n\u001f\n\u001e\n\u001d\n\u001c\n\u001b\n\u001a\n\u001b\n\u0019\n\u0018\n\u0017\n\u0016\n\u001d\n\u001a\n\u001e\n\u0015\u0017\n\u0014\n\u001d\n\u001a\n\u0013\n\u0017\n\u0005\n\f\n\u0015\n\u001a\n\u001b\n\u0011\n\u0013\n\u0011\n\u001b\n\u0018\n\u0019\u001d\n\u0019\n\r\n\u000e\n\u0004\n\u0016\n\u0015\n\u0003\u0019\n\u000e\n\n\u0013\n\u0010\n\u0019\u001c\n\f\n\u0013\u001c\n\f\n\u001b\n\u0013\n\t\n\u0015\n\u001c\u0019\n\u001b\n\u000e\n\u001c\n\u001f\u001e\u001d\u0012\u0019\u0011\u001b\u0019\u001d\u0010\u0015\u000f\u0011\u001b\u0017\u001a\u000e\u000e\u001d\u000e\u000e\u0013\u001d\u001b\u0015\n\u0006\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u0018\u001a\u001b\u001b\u000e\u0019\u000e\n\u0002\u0013\f\u0019\u001d\u001c\r\u001a\u0014\u0001\u0013\t\f\u0014\u001d\u0019\u0018\u0015\b\u0013\n\u001b\u0015\u0016\u0019\u000e\u0015\u001c\u0019\r\u000e\u0001\u0013\u0006\n\u0013\u0018\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u000b\u001d\t\u0019\u0018\u0019\r\u000e\u0013\r\u0013 ­\u0002\u0013\u0001\u0013\u001b\u001b\u001a\u0018\u0019\u001d\u001b\n\u0018\u0015\t\u0015\u0018\u0019\u001c\u0014\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u000e\u0013\u0018\u0015\u001d\u001b\u0013\r\u0013\u0011\u001b\u000e\u0019\u001c\u001b\u0013 ­\u0002\u0013\u001a\u0019\u001d\u0003\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u0016 \u001f\u0001\u0013\u0006\u0007\u0017\u0013\u0001\u0013­\n\u0006\r\u001a\u001a\u001b\u0018\u001c\u0019\r\u000e\u0013\r\u0013\u001d\u001b\u000f\u001b\u001a\u001b\u0013\u0012\u0005\u0001\u0013\u0007\u0005\u0001\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\b\u0015\u001c\u0015\u001c\u0019\r\u000e\n\u0010\u0019\u001c\f\u0013\f\u0019\n\f\u0013\u001a\u0019\u001d\u0003\u0013\r\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\u001d\u001d\u001b\u0018\u001c\u0019\r\u000e\n\r\u001d\f\u000f\u000b\u001d\u001e\u0018\n\u0010\u0011\u000e\u0015\u0012\u0010\u001a\u001e\u0015\t\u0013\n\u0015\n\u0019\u000e\u0015\b\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u000b\u001d\u000b\u0015\b\b\u0014\u0013\t\u001a\u001b\u001b\u001a\u001a\u001b\u0011\n\u001b\n\u0019\r\u000e\u0015\b\u0013\u0015\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\u0015\n\u0012\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u0011\u000b\u001a\u0019\u000e\n\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u0015\u000e\u0011\u0013\u001b\u0015\u001a\b\u0014\n\t\r\u001d\u001c\u0004\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\n\u001c\u001b\u000e\u0011\u001b\u0011\u0013\u0019\u000e\u0004\f\r\u001d\t\u0019\u001c\u0015\b\u0013\u001d\u000b\u001a\u000f\u001b\u0019\b\b\u0015\u000e\u0018\u001b\u001c\u001a\u001b\u0015\u001c\u0016\u001b\u000e\u001c\n\b\u001a\u001b\u001a\u001c\u001d\u0013\u001d\u001b\u0015\u0017\u0007\t\u001e\u000f\u001b\u001c\u0017\u0010\u001e\u001d\u001c\u001b\u001a\u001b\u0019\u0018\n\u0005\u001b\u001a\u0019\u0015\b\u0013\u0016\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u001d\u0014\u0016\t\u001c\r\u0016\u001d\u0001\u0013\u001e\u0019\r\u0016\u0015\u001a\u0003\u001b\u001a\u001d\u0001\u0013\n­\u001a\u000b\n\u0013\u001c\f\u001b\u001a\u0015\t\u0014\u0013\u0015\u000e\u001c\u0019\u0018\r\u0015\n\u000b\b\u0015\u001c\u0019\r\u000e\nFigure 22 The Pregnancy Heart Team model of care. AS, aortic stenosis; ECG, electrocardiogram; MS, mitral stenosis; TTE, transthoracic echocar-\ndiography; VHD, valvular heart disease.   \n4702                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 66",
          "page": 66,
          "content": "Recommendations |  | Classa | Levelb | \nHaemolysis and paravalvular leak |  |  |  | \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team\nevaluation, including patient risk, leak morphology, and local expertise. |  | I | C | \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF\nsymptoms. |  | I | C | \nTranscatheter closure should be considered for suitable PVLs with clinically significant regurgitation and/or haemolysis.940 |  | IIa | B | \n | Mechanical heart valve failure |  |  | \nReoperation is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Biological heart valve failure |  |  | \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. |  | I | C | \nTranscatheter, transfemoral valve-in-valve implantation in the aortic position should be considered in patients with significant valve\ndysfunction who are at intermediate or high surgical risk, and have suitable anatomical and prosthesis features, as assessed by the Heart\nTeam.447,448,450,451,941 |  | IIa | B | \nTranscatheter transvenous mitral or tricuspid valve-in-valve implantation should be considered in patients with significant valve dysfunction\nat intermediate or high surgical risk, if the anatomy is suitable.569,570,681,942–944 |  | IIa | B | \nReoperation should be considered in asymptomatic patients with significant prosthetic dysfunction, if surgical risk is low. |  | IIa | C | \n | Valve thrombosis |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confrim the diagnosis.914,918,923,925,945–948 |  | I | C | \n | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis).923,926–929,931,949–954 |  | I | B | \nSurgery should be considered for large (>10 mm) prosthetic thrombus complicated by embolism.913,932,933 |  | IIa | C | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention.867,934–937,955,956 |  | I | B | \nOAC should be considered in patients with leaflet thickening and reduced leafel t motion leading to elevated gradients at least until\nresolution.918,920–922 |  | IIa | B | ",
          "rows": 20,
          "cols": 5
        }
      ],
      "keywords": [
        "echocardiography",
        "intervention",
        "ct",
        "echo",
        "cardiac",
        "monitoring",
        "during",
        "management",
        "surgery",
        "aortic stenosis",
        "tavi",
        "risk",
        "severe",
        "symptomatic",
        "treatment",
        "recommendation"
      ]
    },
    {
      "number": "17",
      "title": "16. Management of valvular heart disease during pregnancy",
      "start_page": 68,
      "end_page": 69,
      "content": "and anatomical selection criteria.194,584 Valve treatment should be per-\nformed for patients with AR meeting the criteria for valve intervention \nbefore any elective intermediate- or high-risk NCS.966,967 \n15.3. Peri-operative monitoring \nHeart rate control (particularly in MS) and careful fluid management \n(particularly in AS and MR with reduced LVEF) are needed throughout \nthe procedure. The involvement of specialized cardiovascular anaesthe-\nsiologists should be considered in complex situations because TOE \nmonitoring may be considered. Pulmonary artery catheterization is \nnot routinely used. \n16. Management of valvular heart \ndisease during pregnancy \nSpecific ESC Guidelines on this topic are available (the 2025 ESC \nGuidelines on cardiovascular disease during pregnancy) and should be con-\nsulted for further details.968 Pregnancies in patients with VHD should \nbe considered high risk and managed under the close supervision of a \ncardiologist and a multidisciplinary Pregnancy Heart Team. The import-\nance of midwives and other specialized nursing personnel is increasingly \nrecognized for high-quality direct patient interactions. Shared decision- \nmaking is especially important when addressing the cardiovascular risk \nof pregnancy and the benefit–risk ratios of therapeutic options and \nmodes of delivery (Figure 22). \n16.1. Management before pregnancy \nIdeally, women should undergo a thorough physical examination by \ntheir general practitioner for VHD screening prior to pregnancy. A spe-\ncialized evaluation including TTE should be performed by a cardiologist \nin the case of clinical suspicion.968,969 \nIf VHD is diagnosed, pre-pregnancy counselling is imperative. \nUnplanned pregnancies in patients with VHD should be discouraged. \nContraception methods should be recommended after discussion \nwith the patient in the presence of a significant maternal and/or foetal \nrisk. In patients contemplating pregnancy, the maternal risk should be \nassessed using the modified WHO classification and other scores such \nas the CARPREG or DEVI risk score (see Supplementary data online,  \nTable S7).970 \n\u001f\u001e\u001d\u001c\u001b\u001c\u001a\u0019\u0018\u001d\n\u0017\u001a\u0019\u0016\u0015\u001a\u0014\u0013\u0018\u0015\u001a\u001b\n\u0012\u0019\u0011\u0010\u0019\u000f\u001b\u001d\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u000e\u000b\u001a\u001d\u0019\u000e\n\u0013\t\u001b\u001a\u001d\r\u000e\u000e\u001b\b\n\u0007\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\r\b\r\n\u0019\u001d\u001c\u0013\u0015\u000e\u0011\n\r\u001c\f\u001b\u001a\u0013\u001d\t\u001b\u0018\u0019\u0015\b\u0019\u001d\u001c\u001d\n\u0006\u0015\u001a\u0011\u0019\r\b\r\n\u0014\n\u001f\n\u001e\n\u001d\n\u001c\n\u001b\n\u001a\n\u001b\n\u0019\n\u0018\n\u0017\n\u0016\n\u001d\n\u001a\n\u001e\n\u0015\u0017\n\u0014\n\u001d\n\u001a\n\u0013\n\u0017\n\u0005\n\f\n\u0015\n\u001a\n\u001b\n\u0011\n\u0013\n\u0011\n\u001b\n\u0018\n\u0019\u001d\n\u0019\n\r\n\u000e\n\u0004\n\u0016\n\u0015\n\u0003\u0019\n\u000e\n\n\u0013\n\u0010\n\u0019\u001c\n\f\n\u0013\u001c\n\f\n\u001b\n\u0013\n\t\n\u0015\n\u001c\u0019\n\u001b\n\u000e\n\u001c\n\u001f\u001e\u001d\u0012\u0019\u0011\u001b\u0019\u001d\u0010\u0015\u000f\u0011\u001b\u0017\u001a\u000e\u000e\u001d\u000e\u000e\u0013\u001d\u001b\u0015\n\u0006\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u0018\u001a\u001b\u001b\u000e\u0019\u000e\n\u0002\u0013\f\u0019\u001d\u001c\r\u001a\u0014\u0001\u0013\t\f\u0014\u001d\u0019\u0018\u0015\b\u0013\n\u001b\u0015\u0016\u0019\u000e\u0015\u001c\u0019\r\u000e\u0001\u0013\u0006\n\u0013\u0018\b\u0019\u000e\u0019\u0018\u0015\b\u0013\u001d\u000b\u001d\t\u0019\u0018\u0019\r\u000e\u0013\r\u0013 ­\u0002\u0013\u0001\u0013\u001b\u001b\u001a\u0018\u0019\u001d\u001b\n\u0018\u0015\t\u0015\u0018\u0019\u001c\u0014\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u000e\u0013\u0018\u0015\u001d\u001b\u0013\r\u0013\u0011\u001b\u000e\u0019\u001c\u001b\u0013 ­\u0002\u0013\u001a\u0019\u001d\u0003\u0013\u0015\u001d\u001d\u001b\u001d\u001d\u0016\u001b\u000e\u001c\n\u0016 \u001f\u0001\u0013\u0006\u0007\u0017\u0013\u0001\u0013­\n\u0006\r\u001a\u001a\u001b\u0018\u001c\u0019\r\u000e\u0013\r\u0013\u001d\u001b\u000f\u001b\u001a\u001b\u0013\u0012\u0005\u0001\u0013\u0007\u0005\u0001\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\b\u0015\u001c\u0015\u001c\u0019\r\u000e\n\u0010\u0019\u001c\f\u0013\f\u0019\n\f\u0013\u001a\u0019\u001d\u0003\u0013\r\u0013\u0015\r\u001a\u001c\u0019\u0018\u0013\u0011\u0019\u001d\u001d\u001b\u0018\u001c\u0019\r\u000e\n\r\u001d\f\u000f\u000b\u001d\u001e\u0018\n\u0010\u0011\u000e\u0015\u0012\u0010\u001a\u001e\u0015\t\u0013\n\u0015\n\u0019\u000e\u0015\b\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u000b\u001d\u000b\u0015\b\b\u0014\u0013\t\u001a\u001b\u001b\u001a\u001a\u001b\u0011\n\u001b\n\u0019\r\u000e\u0015\b\u0013\u0015\u000e\u0015\u001b\u001d\u001c\f\u001b\u001d\u0019\u0015\n\u0012\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u0011\u000b\u001a\u0019\u000e\n\u0013\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\u0013\u0015\u000e\u0011\u0013\u001b\u0015\u001a\b\u0014\n\t\r\u001d\u001c\u0004\u0011\u001b\b\u0019\u000f\u001b\u001a\u0014\n\u001c\u001b\u000e\u0011\u001b\u0011\u0013\u0019\u000e\u0004\f\r\u001d\t\u0019\u001c\u0015\b\u0013\u001d\u000b\u001a\u000f\u001b\u0019\b\b\u0015\u000e\u0018\u001b\u001c\u001a\u001b\u0015\u001c\u0016\u001b\u000e\u001c\n\b\u001a\u001b\u001a\u001c\u001d\u0013\u001d\u001b\u0015\u0017\u0007\t\u001e\u000f\u001b\u001c\u0017\u0010\u001e\u001d\u001c\u001b\u001a\u001b\u0019\u0018\n\u0005\u001b\u001a\u0019\u0015\b\u0013\u0016\r\u000e\u0019\u001c\r\u001a\u0019\u000e\n\u0013\u001d\u0014\u0016\t\u001c\r\u0016\u001d\u0001\u0013\u001e\u0019\r\u0016\u0015\u001a\u0003\u001b\u001a\u001d\u0001\u0013\n­\u001a\u000b\n\u0013\u001c\f\u001b\u001a\u0015\t\u0014\u0013\u0015\u000e\u001c\u0019\u0018\r\u0015\n\u000b\b\u0015\u001c\u0019\r\u000e\nFigure 22 The Pregnancy Heart Team model of care. AS, aortic stenosis; ECG, electrocardiogram; MS, mitral stenosis; TTE, transthoracic echocar-\ndiography; VHD, valvular heart disease.   \n4702                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nBefore recommending pregnancy, the following conditions need to \nbe corrected: \n• MS with MVA <1.5 cm2, even when asymptomatic.971 \n• Severe AS with symptoms, or abnormal exercise test, or LV systolic \ndysfunction.972 \n• Heritable aortic disorders and high risk of aortic dissection: prophylactic \naortic repair is recommended prior to pregnancy in women with \nMarfan syndrome and an aortic diameter of >45 mm, and may be con-\nsidered in women with an aortic diameter between 40 and 45 mm \nwhen risk factors for dissection exist.973 Aneurysmal dilation in women \nwith BAV should be corrected when the aortic diameter is ≥50 mm.974 \nClose follow-up in dedicated units and beta-blocker therapy during \npregnancy and post-partum are recommended unless contraindicated, \nalthough strong evidence is only available for Marfan syndrome.  \nValvular regurgitant lesions are generally well tolerated during preg-\nnancy. Prophylactic intervention is therefore not recommended in the \nabsence of class I or IIa indications. \nThe first therapeutic option for MS in a woman considering preg-\nnancy should be PMC. When implantation of a prosthetic valve is ne-\ncessary, BHVs are recommended, although early SVD remains a \nserious concern.975 Mechanical heart valves must be avoided due to \nthe high risk of maternal and foetal complications linked to the potential \nteratogenic effects of VKAs, as well as the increased risk of bleeding.976 \nThe Ross procedure may be considered for the treatment of AV dis-\nease at centres with expertise. \n16.2. Management during pregnancy \n16.2.1. Patients with native valve disease \nPregnancy can worsen the clinical course of left-sided stenotic valvular \nlesions because increased cardiac output causes an increment of trans-\nvalvular gradient of ∼50%, mainly between the first and second trime-\nsters. Regurgitant lesions are less likely to cause complications, except \nin high-risk cases (LV systolic dysfunction, PH, and cardiac events before \npregnancy).977 \nMild MS is generally well tolerated.978 Heart failure occurs in \none-third of pregnant women with an MVA of <1.5 cm2 and in one-half \nof those with an MVA of <1.0 cm2, most often during the second tri-\nmester.971 Percutaneous mitral commissurotomy should be consid-\nered if symptoms or SPAP of >50 mmHg persist despite optimal \nmedical therapy (diuretics and beta-1-selective beta-blockers), prefer-\nably after the 20th week of pregnancy. \nRegarding AS, pregnancy is generally well tolerated if prior exercise \ntolerance was normal, even in severe AS, while HF has been reported \nto occur in up to 25% of symptomatic patients.972 In symptomatic \npatients despite medical therapy (i.e. diuretics), TAVI seems to be \nthe preferred option in very selected patients, although evidence is \nlacking. Percutaneous balloon valvuloplasty may be an alternative op-\ntion. Procedures should be performed in an experienced valve \ncentre.972,979,980 \nSurgery under cardiopulmonary bypass is associated with a high rate \nof foetal loss and should be restricted to conditions that threaten the \nmother’s life if transcatheter intervention is not possible or has failed. \nVaginal delivery is the first choice for the majority of patients. \nCaesarean section is preferred if there is an obstetric indication, \nand in the case of severe MS or AS, ascending aortic diameter of \n>45 mm, severe PH, or if delivery starts while the patient is being \ntreated with OAC. \n16.2.2. Patients with prosthetic valves \nPregnant patients with MHVs should be followed in a centre with cor-\nresponding expertise. In a cohort of 212 women with MHVs, valve \nthrombosis occurred in 10 (4.7%) pregnancies and haemorrhagic \nevents occurred in 49 (23.1%).976 Therapeutic OAC during pregnancy \nis essential to avoid thrombosis. The higher efficacy of VKAs compared \nwith LMWH to prevent thrombosis must be balanced against increased \nfoetal risks.981 \nIn patients requiring ≤5 mg/day of warfarin, OAC with warfarin \nthroughout pregnancy, changing to UFH before delivery, is advocated, \nin order to reduce the risk of thrombosis. In patients requiring higher \ndoses, switching to dose-adjusted LMWH at least twice per day with \nstrict anti-Xa monitoring during the first trimester is recommended \nto avoid the teratogenic effect of VKAs (for corresponding flowcharts \nsee the 2025 ESC Guidelines for the management of cardiovascular dis-\neases during pregnancy968). \nLifetime management of women with a BHV considering pregnancy \nis central and transcatheter valve-in-valve implantation may be consid-\nered as a bridge to MHV implantation.982 \n17. Sex-specific considerations \nin patients with valvular heart \ndisease \nAlthough men and women are equally likely to experience VHD, sex- \nspecific prevalence exists according to valve type and disease patho-\nphysiology.644,648,983 Women more frequently suffer from MV disease \nsuch as prolapse, RHD or TR, while men more often present with AS or \nAR, especially associated with BAV.984 Men also suffer from endocardi-\ntis of any valve more frequently.985 \nFemale sex is associated with higher mortality in the presence of vari-\nous VHDs,986 including early post-treatment,987 and is included as a \nrisk factor in surgical risk prediction tools such as the STS and \nEuroSCORE calculators. However, risk scores are often derived \nfrom populations including a majority of men.988 In addition, risk pre-\ndiction scores are susceptible to referral bias that results in a well- \nestablished higher risk of undertreatment or delayed treatment of \nVHD in women.983,984,986 \n17.1. Aortic valve disease \nFemale patients with severe AS present more often with shortness of \nbreath, whereas males more frequently have angina, presumably due to \nthe higher incidence of CAD.989 The pathophysiology of AS seems to \ndiffer according to sex, with women having less calcium and more fibro-\nsis.990 Concentric ventricular hypertrophy and remodelling are also \nmore frequently observed in women than in men, resulting in higher \nLVEF but smaller LV cavity and stroke volume.991 Consequently, para-\ndoxical low-flow, low-gradient constellations are frequent and may \nboth contribute to the underdiagnosis of severe AS in women and delay \nan intervention.992 The use of sex-specific thresholds to define flow \nlimitation (<40 mL/m2 for men and <32 mL/m2 for women) has there-\nfore been suggested,292 and the use of CCT to quantify the calcium \nscore should be performed in women with discordant echocardio-\ngraphic parameters.777 \nWomen are less likely to be referred to a cardiologist and \nundergo investigations. Surgical aortic valve replacement is per-\nformed less frequently in women, especially if echocardiographic \nparameters are discordant.993 In patients presenting with severe  \nESC Guidelines                                                                                                                                                                                          4703 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "valvular",
        "intervention",
        "ct",
        "pregnancy",
        "monitoring",
        "during",
        "catheterization",
        "management",
        "disease",
        "aortic stenosis",
        "risk",
        "heart",
        "treatment"
      ]
    },
    {
      "number": "18",
      "title": "17. Sex-specific considerations in patients with valvular heart disease",
      "start_page": 69,
      "end_page": 70,
      "content": "Before recommending pregnancy, the following conditions need to \nbe corrected: \n• MS with MVA <1.5 cm2, even when asymptomatic.971 \n• Severe AS with symptoms, or abnormal exercise test, or LV systolic \ndysfunction.972 \n• Heritable aortic disorders and high risk of aortic dissection: prophylactic \naortic repair is recommended prior to pregnancy in women with \nMarfan syndrome and an aortic diameter of >45 mm, and may be con-\nsidered in women with an aortic diameter between 40 and 45 mm \nwhen risk factors for dissection exist.973 Aneurysmal dilation in women \nwith BAV should be corrected when the aortic diameter is ≥50 mm.974 \nClose follow-up in dedicated units and beta-blocker therapy during \npregnancy and post-partum are recommended unless contraindicated, \nalthough strong evidence is only available for Marfan syndrome.  \nValvular regurgitant lesions are generally well tolerated during preg-\nnancy. Prophylactic intervention is therefore not recommended in the \nabsence of class I or IIa indications. \nThe first therapeutic option for MS in a woman considering preg-\nnancy should be PMC. When implantation of a prosthetic valve is ne-\ncessary, BHVs are recommended, although early SVD remains a \nserious concern.975 Mechanical heart valves must be avoided due to \nthe high risk of maternal and foetal complications linked to the potential \nteratogenic effects of VKAs, as well as the increased risk of bleeding.976 \nThe Ross procedure may be considered for the treatment of AV dis-\nease at centres with expertise. \n16.2. Management during pregnancy \n16.2.1. Patients with native valve disease \nPregnancy can worsen the clinical course of left-sided stenotic valvular \nlesions because increased cardiac output causes an increment of trans-\nvalvular gradient of ∼50%, mainly between the first and second trime-\nsters. Regurgitant lesions are less likely to cause complications, except \nin high-risk cases (LV systolic dysfunction, PH, and cardiac events before \npregnancy).977 \nMild MS is generally well tolerated.978 Heart failure occurs in \none-third of pregnant women with an MVA of <1.5 cm2 and in one-half \nof those with an MVA of <1.0 cm2, most often during the second tri-\nmester.971 Percutaneous mitral commissurotomy should be consid-\nered if symptoms or SPAP of >50 mmHg persist despite optimal \nmedical therapy (diuretics and beta-1-selective beta-blockers), prefer-\nably after the 20th week of pregnancy. \nRegarding AS, pregnancy is generally well tolerated if prior exercise \ntolerance was normal, even in severe AS, while HF has been reported \nto occur in up to 25% of symptomatic patients.972 In symptomatic \npatients despite medical therapy (i.e. diuretics), TAVI seems to be \nthe preferred option in very selected patients, although evidence is \nlacking. Percutaneous balloon valvuloplasty may be an alternative op-\ntion. Procedures should be performed in an experienced valve \ncentre.972,979,980 \nSurgery under cardiopulmonary bypass is associated with a high rate \nof foetal loss and should be restricted to conditions that threaten the \nmother’s life if transcatheter intervention is not possible or has failed. \nVaginal delivery is the first choice for the majority of patients. \nCaesarean section is preferred if there is an obstetric indication, \nand in the case of severe MS or AS, ascending aortic diameter of \n>45 mm, severe PH, or if delivery starts while the patient is being \ntreated with OAC. \n16.2.2. Patients with prosthetic valves \nPregnant patients with MHVs should be followed in a centre with cor-\nresponding expertise. In a cohort of 212 women with MHVs, valve \nthrombosis occurred in 10 (4.7%) pregnancies and haemorrhagic \nevents occurred in 49 (23.1%).976 Therapeutic OAC during pregnancy \nis essential to avoid thrombosis. The higher efficacy of VKAs compared \nwith LMWH to prevent thrombosis must be balanced against increased \nfoetal risks.981 \nIn patients requiring ≤5 mg/day of warfarin, OAC with warfarin \nthroughout pregnancy, changing to UFH before delivery, is advocated, \nin order to reduce the risk of thrombosis. In patients requiring higher \ndoses, switching to dose-adjusted LMWH at least twice per day with \nstrict anti-Xa monitoring during the first trimester is recommended \nto avoid the teratogenic effect of VKAs (for corresponding flowcharts \nsee the 2025 ESC Guidelines for the management of cardiovascular dis-\neases during pregnancy968). \nLifetime management of women with a BHV considering pregnancy \nis central and transcatheter valve-in-valve implantation may be consid-\nered as a bridge to MHV implantation.982 \n17. Sex-specific considerations \nin patients with valvular heart \ndisease \nAlthough men and women are equally likely to experience VHD, sex- \nspecific prevalence exists according to valve type and disease patho-\nphysiology.644,648,983 Women more frequently suffer from MV disease \nsuch as prolapse, RHD or TR, while men more often present with AS or \nAR, especially associated with BAV.984 Men also suffer from endocardi-\ntis of any valve more frequently.985 \nFemale sex is associated with higher mortality in the presence of vari-\nous VHDs,986 including early post-treatment,987 and is included as a \nrisk factor in surgical risk prediction tools such as the STS and \nEuroSCORE calculators. However, risk scores are often derived \nfrom populations including a majority of men.988 In addition, risk pre-\ndiction scores are susceptible to referral bias that results in a well- \nestablished higher risk of undertreatment or delayed treatment of \nVHD in women.983,984,986 \n17.1. Aortic valve disease \nFemale patients with severe AS present more often with shortness of \nbreath, whereas males more frequently have angina, presumably due to \nthe higher incidence of CAD.989 The pathophysiology of AS seems to \ndiffer according to sex, with women having less calcium and more fibro-\nsis.990 Concentric ventricular hypertrophy and remodelling are also \nmore frequently observed in women than in men, resulting in higher \nLVEF but smaller LV cavity and stroke volume.991 Consequently, para-\ndoxical low-flow, low-gradient constellations are frequent and may \nboth contribute to the underdiagnosis of severe AS in women and delay \nan intervention.992 The use of sex-specific thresholds to define flow \nlimitation (<40 mL/m2 for men and <32 mL/m2 for women) has there-\nfore been suggested,292 and the use of CCT to quantify the calcium \nscore should be performed in women with discordant echocardio-\ngraphic parameters.777 \nWomen are less likely to be referred to a cardiologist and \nundergo investigations. Surgical aortic valve replacement is per-\nformed less frequently in women, especially if echocardiographic \nparameters are discordant.993 In patients presenting with severe  \nESC Guidelines                                                                                                                                                                                          4703 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nAS and Class I indications for SAVR, a significantly higher proportion \nof men than women are referred for evaluation by a cardiac \nsurgeon.994,995 \nMale patients derive a clearer benefit from SAVR compared with wo-\nmen, who have higher in-hospital and long-term mortality and morbid-\nity,987,996 possibly explained by more severe concentric hypertrophy991 \nand a smaller aortic annulus predisposing to PPM.997 Conversely, in a \nrandomized trial (RHEIA) that compared TAVI with SAVR in 443 wo-\nmen with a mean age of 73 years, TAVI was superior in reducing the \nprimary endpoint composed of death, stroke, or rehospitalization at \n1 year, predominantly driven by a reduction in rehospitalization for \nvalve- or procedure-related symptoms or worsening HF.998 Several ob-\nservational studies suggest that elderly women have lower mortality \nafter TAVI,999 even if the rates of major vascular complications and \nbleeding tend to be higher.997 \nIndexed cut-offs to indicate treatment of AR are validated, but only \npartially account for sex differences. Newer studies using echocardio-\ngraphic volumes1000 and CMR1001 suggest that women may experience \nhigher event rates at lower cut-offs compared with men, but this re-\nquires further investigation. \n17.2. Mitral valve disease \nPatients with RHD are often young women and have a high prevalence \nof major cardiovascular complications with far-reaching impacts on re-\nproductive health and access to care.282 Although women experience \nfavourable outcomes compared with men when treated by percutan-\neous balloon valvuloplasty, access to these procedures is still limited \nin low-income countries.662 \nFibroelastic disease with MV prolapse is also more frequent in wo-\nmen, and may be accompanied by morphological abnormalities of \nthe MA associated with fibrosis of the papillary muscles or the infer-\nobasal LV that may act as the substrate for sudden cardiac death, \neven in the absence of severe MR.1002 Recent evidence has sup-\nported considering lower women-specific cut-offs for intervention \nwith regard to LVESD (36 mm; indexed LVESD, 1.8 cm/m2), while \nthe LVEF cut-off was similar to men (58%), albeit with higher \nmortality.548 \nVentricular SMR associated with low LVEF is more frequent in men \nwith HF,1003 while atrial SMR due to chronic AF and/or HFpEF affects \nmore women (58% vs 42% male).579 \nFemale sex is a risk factor for the development of MAC and was re-\nported to account for 68% of the patients included in a large-scale \ntranscatheter MV replacement in MAC registry.1004 Furthermore, wo-\nmen present with a faster disease progression.1005 \n17.3. Tricuspid valve disease \nTricuspid regurgitation is more prevalent in women,208 and female \nsex is associated with accelerated disease progression.1006–1008 \nHypotheses to explain these observations include the overall higher \nprevalence of HFpEF and AF in women.1009 Women are usually \ndiagnosed at an older age and the cause of TR is most frequently \na consequence of left valvular disease or annular dilatation attributable \nto RA dilatation.1010 No differences have been detected to date \nin terms of adverse events after surgery1011 or transcatheter TV \ninterventions.1012,1013 \n18. Key messages \nHeart Team and Heart Valve Centre \n• An integrated regional Heart Valve Network incorporating out-\npatient Heart Valve Clinics and specialist Heart Valve Centres allows \noptimal patient care. \n• Heart Valve Centres should fulfil institutional and local statutory re-\nquirements, and strive for high procedural volume and excellent clin-\nical outcomes. \n• Heart Team recommendations should be based upon these guideline \nrecommendations, relevant updated evidence, key medical consid-\nerations, and patient preferences. \n• Core members of the Heart Team include the primary clinical cardi-\nologist, cardiologists with subspecialty expertise in VHD, specialists in \nadvanced cardiovascular imaging and peri-procedural imaging guid-\nance, and surgeons and interventional cardiologists with training \nand expertise in valve interventions. \n• A network approach that distinguishes between higher- and \nlower-volume centres is appropriate, with more complex proce-\ndures focused in the most experienced (i.e. upper quartile) \ncentres. Information on the network organization should be com-\nmunicated to patients, as well as referring cardiologists and general \npractitioners.  \nAortic regurgitation \n• Assessment of AR severity with TTE remains challenging and current \ncut-offs for intervention are mostly based on 2D measurements, al-\nthough 3D echocardiography and CMR allow more accurate evalu-\nation of LV volumes and LVEF. \n• Mechanisms of AR may be closely related to the aortic diameters that \nshould be measured accurately at all levels of the aortic root (annulus, \nsinuses, and sinotubular junction). \n• Indication for operation is based on symptoms, LV volumes, LVEF, \nand aortic diameters. Although valve replacement remains the stand-\nard treatment, AV repair (or AV sparing when associated with root \naneurysm) is being increasingly used to avoid prosthesis-related com-\nplications, especially in experienced centres. \n• Current transcatheter options for AR are limited and applicable only \nin patients who are ineligible for surgery.  \nAortic stenosis \n• Diagnosis of severe AS requires integrative evaluation of pressure \ngradients (the most robust measurements), AVA, flow conditions, \nthe extent of valve calcification, and LV function. \n• Selection of the most appropriate mode of intervention should take \ninto account clinical characteristics (age and estimated life expect-\nancy, concomitant conditions), access and valve anatomy (particularly \nthe feasibility of transfemoral TAVI and calcification patterns), and \nsurgical risk, as well as repeat procedure options and risks (lifetime \nmanagement).  \nMitral regurgitation \n• The echocardiographic diagnostic workup of patients with MR in-\ncludes multiparametric assessment of MR severity, evaluation of  \n4704                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "valvular",
        "asymptomatic",
        "considerations",
        "class i",
        "follow-up",
        "disease",
        "tavi",
        "indication",
        "intervention",
        "heart",
        "treatment",
        "ct",
        "heart failure",
        "mild",
        "surgery",
        "risk",
        "diuretic",
        "severe",
        "symptomatic",
        "specific"
      ]
    },
    {
      "number": "19",
      "title": "18. Key messages",
      "start_page": 70,
      "end_page": 71,
      "content": "AS and Class I indications for SAVR, a significantly higher proportion \nof men than women are referred for evaluation by a cardiac \nsurgeon.994,995 \nMale patients derive a clearer benefit from SAVR compared with wo-\nmen, who have higher in-hospital and long-term mortality and morbid-\nity,987,996 possibly explained by more severe concentric hypertrophy991 \nand a smaller aortic annulus predisposing to PPM.997 Conversely, in a \nrandomized trial (RHEIA) that compared TAVI with SAVR in 443 wo-\nmen with a mean age of 73 years, TAVI was superior in reducing the \nprimary endpoint composed of death, stroke, or rehospitalization at \n1 year, predominantly driven by a reduction in rehospitalization for \nvalve- or procedure-related symptoms or worsening HF.998 Several ob-\nservational studies suggest that elderly women have lower mortality \nafter TAVI,999 even if the rates of major vascular complications and \nbleeding tend to be higher.997 \nIndexed cut-offs to indicate treatment of AR are validated, but only \npartially account for sex differences. Newer studies using echocardio-\ngraphic volumes1000 and CMR1001 suggest that women may experience \nhigher event rates at lower cut-offs compared with men, but this re-\nquires further investigation. \n17.2. Mitral valve disease \nPatients with RHD are often young women and have a high prevalence \nof major cardiovascular complications with far-reaching impacts on re-\nproductive health and access to care.282 Although women experience \nfavourable outcomes compared with men when treated by percutan-\neous balloon valvuloplasty, access to these procedures is still limited \nin low-income countries.662 \nFibroelastic disease with MV prolapse is also more frequent in wo-\nmen, and may be accompanied by morphological abnormalities of \nthe MA associated with fibrosis of the papillary muscles or the infer-\nobasal LV that may act as the substrate for sudden cardiac death, \neven in the absence of severe MR.1002 Recent evidence has sup-\nported considering lower women-specific cut-offs for intervention \nwith regard to LVESD (36 mm; indexed LVESD, 1.8 cm/m2), while \nthe LVEF cut-off was similar to men (58%), albeit with higher \nmortality.548 \nVentricular SMR associated with low LVEF is more frequent in men \nwith HF,1003 while atrial SMR due to chronic AF and/or HFpEF affects \nmore women (58% vs 42% male).579 \nFemale sex is a risk factor for the development of MAC and was re-\nported to account for 68% of the patients included in a large-scale \ntranscatheter MV replacement in MAC registry.1004 Furthermore, wo-\nmen present with a faster disease progression.1005 \n17.3. Tricuspid valve disease \nTricuspid regurgitation is more prevalent in women,208 and female \nsex is associated with accelerated disease progression.1006–1008 \nHypotheses to explain these observations include the overall higher \nprevalence of HFpEF and AF in women.1009 Women are usually \ndiagnosed at an older age and the cause of TR is most frequently \na consequence of left valvular disease or annular dilatation attributable \nto RA dilatation.1010 No differences have been detected to date \nin terms of adverse events after surgery1011 or transcatheter TV \ninterventions.1012,1013 \n18. Key messages \nHeart Team and Heart Valve Centre \n• An integrated regional Heart Valve Network incorporating out-\npatient Heart Valve Clinics and specialist Heart Valve Centres allows \noptimal patient care. \n• Heart Valve Centres should fulfil institutional and local statutory re-\nquirements, and strive for high procedural volume and excellent clin-\nical outcomes. \n• Heart Team recommendations should be based upon these guideline \nrecommendations, relevant updated evidence, key medical consid-\nerations, and patient preferences. \n• Core members of the Heart Team include the primary clinical cardi-\nologist, cardiologists with subspecialty expertise in VHD, specialists in \nadvanced cardiovascular imaging and peri-procedural imaging guid-\nance, and surgeons and interventional cardiologists with training \nand expertise in valve interventions. \n• A network approach that distinguishes between higher- and \nlower-volume centres is appropriate, with more complex proce-\ndures focused in the most experienced (i.e. upper quartile) \ncentres. Information on the network organization should be com-\nmunicated to patients, as well as referring cardiologists and general \npractitioners.  \nAortic regurgitation \n• Assessment of AR severity with TTE remains challenging and current \ncut-offs for intervention are mostly based on 2D measurements, al-\nthough 3D echocardiography and CMR allow more accurate evalu-\nation of LV volumes and LVEF. \n• Mechanisms of AR may be closely related to the aortic diameters that \nshould be measured accurately at all levels of the aortic root (annulus, \nsinuses, and sinotubular junction). \n• Indication for operation is based on symptoms, LV volumes, LVEF, \nand aortic diameters. Although valve replacement remains the stand-\nard treatment, AV repair (or AV sparing when associated with root \naneurysm) is being increasingly used to avoid prosthesis-related com-\nplications, especially in experienced centres. \n• Current transcatheter options for AR are limited and applicable only \nin patients who are ineligible for surgery.  \nAortic stenosis \n• Diagnosis of severe AS requires integrative evaluation of pressure \ngradients (the most robust measurements), AVA, flow conditions, \nthe extent of valve calcification, and LV function. \n• Selection of the most appropriate mode of intervention should take \ninto account clinical characteristics (age and estimated life expect-\nancy, concomitant conditions), access and valve anatomy (particularly \nthe feasibility of transfemoral TAVI and calcification patterns), and \nsurgical risk, as well as repeat procedure options and risks (lifetime \nmanagement).  \nMitral regurgitation \n• The echocardiographic diagnostic workup of patients with MR in-\ncludes multiparametric assessment of MR severity, evaluation of  \n4704                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nMV anatomy (often with 3D TOE), identification of the mechanism \n(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac \ndamage. \n• Surgical MV repair is the preferred method of treatment in severe \nPMR. Transcatheter edge-to-edge repair is recommended in patients \nwho are inoperable or high risk according to the Heart Team. \n• Surgical MV repair is the procedure of choice for asymptomatic pa-\ntients with primary MR and signs of cardiac damage, including mod-\nerate or more TR. \n• In patients with ventricular SMR, GDMT (including CRT if indicated) \nis the initial and essential treatment step. In symptomatic patients \nwithout CAD needing revascularization, M-TEER is recommended. \nIn patients with concomitant complex CAD and those not suitable \nfor TEER, mitral surgery may be considered. \n• In patients with atrial SMR, MV surgery, AF ablation if indicated, and \nLAAO should be considered after optimization of medical therapy. \nTranscatheter edge-to-edge repair may be considered in patients at \nhigh surgical risk.  \nMitral stenosis \n• Most patients with severe rheumatic MS and favourable valve anat-\nomy should undergo PMC, which is the standard of care. Surgery \nis recommended for symptomatic patients with contraindications \nor unfavourable anatomical and clinical characteristics for PMC. \n• Decision-making in patients with unfavourable anatomy should take \ninto account local PMC experience. \n• In selected patients with clinically severe degenerative MS and MAC, \ntranscatheter intervention or surgery may improve symptoms.  \nTricuspid regurgitation \n• Concomitant TV repair is the preferred method for patients with \nleft-sided valve pathology and associated moderate or severe TR. \n• The use of risk scores for the assessment of RV and secondary organ \ndysfunction should be strongly encouraged in patients with isolated \nsevere TV disease. \n• In isolated severe TR without severe RV dysfunction, surgery should \nbe performed at an early stage in patients at low operative risk. \n• In isolated severe TR patients at increased surgical risk, tricuspid \nTEER or transcatheter replacement should be considered to im-\nprove quality of life and RV remodelling, in the absence of severe \nRV dysfunction or pre-capillary PH.  \nTricuspid stenosis \n• TS is a very rare manifestation of acquired VHD in high-income \ncountries. \n• TS is mainly associated with rheumatic valve disease, carcinoid syn-\ndrome, or enzymatic disorders such as Fabry’s or Whipple’s disease. \n• Treatment of symptomatic TS mainly involves surgical TV \nreplacement.  \nMultiple and mixed valvular heart disease \n• Transvalvular gradients and velocities reflect the combined burden of \nregurgitation and stenosis in mixed aortic and mitral disease. \n• Treatment decisions should be based on the assessment of symptom \nand functional status, cardiac damage, anatomical suitability, and the \nrisk–benefit ratio of intervention and lifetime management \nconsiderations. \n• Patients with mixed moderate AS and AR have similar detrimental \noutcomes compared with those with severe isolated AS. \n• In transcatheter procedures, which allow a sequential approach, \ndownstream lesions should be treated first to prevent potential \nhaemodynamic deterioration and allow improvement of upstream \nlesions due to changing loading conditions and reverse \nremodelling.  \nAntithrombotic treatment in patients with a mechanical \nheart valve \n• International normalized ratio therapeutic range should be balanced \nto the type and anatomical site of MHV, as well to the thrombotic risk \nprofile of the individual patient. \n• Patient training, self-monitoring, and education can increase INR sta-\nbility and TTR. \n• Minor or minimally invasive NCS procedures do not require VKA \ninterruption in patients with an MHV. \n• In patients with an MHV undergoing elective major NCS, bridging \nmay be omitted if the thromboembolic risk is low.  \nNon-cardiac surgery \n• The risk of peri-operative cardiovascular complications related to \nsurgery and to patient-specific factors should be evaluated and com-\nmunicated to the patient and surgical team. \n• In patients with symptomatic severe AS requiring urgent high-risk \nNCS, BAV or TAVI should be considered prior to surgery. In patients \nplanned for elective NCS, AV intervention is recommended prior to \nNCS.  \nPregnancy \n• In women with VHD, decisions regarding management before and dur-\ning pregnancy should be taken after discussion by the multidisciplinary \nPregnancy Heart Team. Unplanned pregnancies should be discouraged. \n• The following conditions should be corrected prior to considering \npregnancy: \n– clinically severe MS (MVA <1.5 cm2), even when asymptomatic \n– severe symptomatic AS, or asymptomatic patients with impaired \nLV function or a pathological exercise test \n– heritable aortic disorders and high risk of aortic dissection. \n• Vaginal delivery is the first choice for the majority of patients. \nIndications for Caesarean section include pre-term labour in patients \non OAC, severe MS or AS, aggressive aortic pathology, acute intract-\nable HF, and severe PH. \n• Women with MHVs should be managed in expert centres.  \n19. Gaps in evidence \nGeneral aspects \n• Patient-reported outcome measures are infrequently reported \nin VHD studies. Patient-reported outcome measure-oriented studies \nare required to improve quality of life and patient satisfaction. \n• Methods to address underdiagnosis and undertreatment of VHD \nneed to be identified and implemented.  \nESC Guidelines                                                                                                                                                                                          4705 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "intervention",
        "ct",
        "echo",
        "tricuspid regurgitation",
        "messages",
        "class i",
        "risk",
        "tavi",
        "severe",
        "savr",
        "indication",
        "treatment"
      ]
    },
    {
      "number": "20",
      "title": "19. Gaps in evidence",
      "start_page": 71,
      "end_page": 73,
      "content": "MV anatomy (often with 3D TOE), identification of the mechanism \n(PMR, ventricular SMR, or atrial SMR), and evaluation of cardiac \ndamage. \n• Surgical MV repair is the preferred method of treatment in severe \nPMR. Transcatheter edge-to-edge repair is recommended in patients \nwho are inoperable or high risk according to the Heart Team. \n• Surgical MV repair is the procedure of choice for asymptomatic pa-\ntients with primary MR and signs of cardiac damage, including mod-\nerate or more TR. \n• In patients with ventricular SMR, GDMT (including CRT if indicated) \nis the initial and essential treatment step. In symptomatic patients \nwithout CAD needing revascularization, M-TEER is recommended. \nIn patients with concomitant complex CAD and those not suitable \nfor TEER, mitral surgery may be considered. \n• In patients with atrial SMR, MV surgery, AF ablation if indicated, and \nLAAO should be considered after optimization of medical therapy. \nTranscatheter edge-to-edge repair may be considered in patients at \nhigh surgical risk.  \nMitral stenosis \n• Most patients with severe rheumatic MS and favourable valve anat-\nomy should undergo PMC, which is the standard of care. Surgery \nis recommended for symptomatic patients with contraindications \nor unfavourable anatomical and clinical characteristics for PMC. \n• Decision-making in patients with unfavourable anatomy should take \ninto account local PMC experience. \n• In selected patients with clinically severe degenerative MS and MAC, \ntranscatheter intervention or surgery may improve symptoms.  \nTricuspid regurgitation \n• Concomitant TV repair is the preferred method for patients with \nleft-sided valve pathology and associated moderate or severe TR. \n• The use of risk scores for the assessment of RV and secondary organ \ndysfunction should be strongly encouraged in patients with isolated \nsevere TV disease. \n• In isolated severe TR without severe RV dysfunction, surgery should \nbe performed at an early stage in patients at low operative risk. \n• In isolated severe TR patients at increased surgical risk, tricuspid \nTEER or transcatheter replacement should be considered to im-\nprove quality of life and RV remodelling, in the absence of severe \nRV dysfunction or pre-capillary PH.  \nTricuspid stenosis \n• TS is a very rare manifestation of acquired VHD in high-income \ncountries. \n• TS is mainly associated with rheumatic valve disease, carcinoid syn-\ndrome, or enzymatic disorders such as Fabry’s or Whipple’s disease. \n• Treatment of symptomatic TS mainly involves surgical TV \nreplacement.  \nMultiple and mixed valvular heart disease \n• Transvalvular gradients and velocities reflect the combined burden of \nregurgitation and stenosis in mixed aortic and mitral disease. \n• Treatment decisions should be based on the assessment of symptom \nand functional status, cardiac damage, anatomical suitability, and the \nrisk–benefit ratio of intervention and lifetime management \nconsiderations. \n• Patients with mixed moderate AS and AR have similar detrimental \noutcomes compared with those with severe isolated AS. \n• In transcatheter procedures, which allow a sequential approach, \ndownstream lesions should be treated first to prevent potential \nhaemodynamic deterioration and allow improvement of upstream \nlesions due to changing loading conditions and reverse \nremodelling.  \nAntithrombotic treatment in patients with a mechanical \nheart valve \n• International normalized ratio therapeutic range should be balanced \nto the type and anatomical site of MHV, as well to the thrombotic risk \nprofile of the individual patient. \n• Patient training, self-monitoring, and education can increase INR sta-\nbility and TTR. \n• Minor or minimally invasive NCS procedures do not require VKA \ninterruption in patients with an MHV. \n• In patients with an MHV undergoing elective major NCS, bridging \nmay be omitted if the thromboembolic risk is low.  \nNon-cardiac surgery \n• The risk of peri-operative cardiovascular complications related to \nsurgery and to patient-specific factors should be evaluated and com-\nmunicated to the patient and surgical team. \n• In patients with symptomatic severe AS requiring urgent high-risk \nNCS, BAV or TAVI should be considered prior to surgery. In patients \nplanned for elective NCS, AV intervention is recommended prior to \nNCS.  \nPregnancy \n• In women with VHD, decisions regarding management before and dur-\ning pregnancy should be taken after discussion by the multidisciplinary \nPregnancy Heart Team. Unplanned pregnancies should be discouraged. \n• The following conditions should be corrected prior to considering \npregnancy: \n– clinically severe MS (MVA <1.5 cm2), even when asymptomatic \n– severe symptomatic AS, or asymptomatic patients with impaired \nLV function or a pathological exercise test \n– heritable aortic disorders and high risk of aortic dissection. \n• Vaginal delivery is the first choice for the majority of patients. \nIndications for Caesarean section include pre-term labour in patients \non OAC, severe MS or AS, aggressive aortic pathology, acute intract-\nable HF, and severe PH. \n• Women with MHVs should be managed in expert centres.  \n19. Gaps in evidence \nGeneral aspects \n• Patient-reported outcome measures are infrequently reported \nin VHD studies. Patient-reported outcome measure-oriented studies \nare required to improve quality of life and patient satisfaction. \n• Methods to address underdiagnosis and undertreatment of VHD \nneed to be identified and implemented.  \nESC Guidelines                                                                                                                                                                                          4705 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nHeart Team and Heart Valve Centre \n• Structured research is required to investigate the relationship be-\ntween procedural volume and clinical outcomes, in order to define \nminimum annual thresholds for individual operators and institutions \nundertaking surgical and transcatheter valve interventions. \n• There is a pressing need to ensure higher dispersion and adoption of \ninterventions for VHD, especially in middle- and low-income countries.  \nConditions associated with valvular heart disease \n• CAD: \n– The prognostic value of functional assessment of stable, moderate \ncoronary stenosis in VHD patients remains to be determined. \n– The optimal strategy (invasive vs non-invasive) for CAD assess-\nment in specific VHD populations remains to be elucidated. \n– The optimal timing of PCI in patients with CAD undergoing TAVI \nis yet to be determined. \n– The benefit of complete coronary revascularization with CABG in \npatients with combined VHD and CAD requires further research. \n• AF: \n– It is unclear which patients with chronic persistent AF and con-\ncomitant VHD are deemed to be suitable for rhythm control \ntherapy. \n– The protective effect against stroke of OAC with VKA or DOACs \nin patients after surgical or transcatheter LAAO remains to be \ndetermined. \n• Cardiogenic shock and acute HF: \n– The optimal treatment strategy in VHD patients presenting with \ncardiogenic shock and acute HF is unknown.  \nAortic regurgitation \n• Impact of early LV remodelling on prognosis in asymptomatic AR pa-\ntients is unknown. \n• Prognostic value of CMR-derived indices in asymptomatic patients \nneeds to be determined. \n• More data are required on long-term results of surgical AV repair for AR. \n• More evidence is required on transcatheter treatment options for \nAR, in particular using dedicated devices.  \nAortic stenosis \n• Better understanding of the pathophysiology of AS is needed to pro-\npose innovative medical therapy. \n• Further research is required on: \n– Refined prognostic markers to guide timing of intervention in \nasymptomatic patients. \n– The role of revascularization in patients with severe AS and asymp-\ntomatic concomitant CAD. \n– Further data on the long-term durability of transcatheter valves in \ncomparison with surgical BHVs in younger patients. \n– The role of TAVI in patients with BAV AS and patients <70 years \nof age. \n– Results of intervention (valve or coronary) after TAVI or SAVR. \n– Determining the optimal lifetime management strategy for AS \npatients.  \nMitral regurgitation \n• The association between primary MR and ventricular arrhythmias re-\nquires more investigation, including the impact of intervention on \nventricular arrhythmias. \n• More data are required on the role of TEER in patients with advanced HF. \n• Long-term results of TEER need to be further assessed, including the \nclinical relevance of transmitral gradients after treatment of both pri-\nmary and secondary MR. \n• Results of ongoing trials comparing MV surgery with TEER in non- \nhigh risk primary MR patients are awaited. \n• Data on the mid- and long-term clinical impacts of transcatheter MV \nreplacement are required. \n• More data on the clinical impacts of surgical and transcatheter treat-\nment of atrial SMR are required.  \nMitral stenosis \n• The potential role of TMVI using dedicated devices in high-risk \npatients is to be determined, particularly those with severe \nMAC.  \nTricuspid regurgitation \n• The long-term risks and benefits of concomitant TV surgery in pa-\ntients with less than moderate TR and annular dilatation undergoing \nleft-sided valve surgery need to be determined. \n• Further investigations are required on the outcomes of TV interven-\ntion in asymptomatic patients with severe TR and RV dysfunction or \nsignificant dilation. \n• The importance of addressing concomitant AF in patients with TR \nneeds to be investigated. \n• More data are required on the indications, timing, and long-term out-\ncomes of TV repair and replacement for TV disease. \n• Better understanding is required of the respective role of surgery vs \ntranscatheter TV therapy for TR treatment.  \nTricuspid stenosis \n• The role of transcatheter TV replacement remains unexplored in pa-\ntients with TS. The most efficient way to achieve ventricular pacing in \npatients after TV replacement needs to be investigated.  \nMultiple and mixed valvular heart disease \n• Further evaluation of the impact on outcomes and indication for \nintervention, as well as timing and modalities of intervention, is \nrequired.  \nProsthetic valves \n• Further development of current prosthetic valve devices is required \nto address their main complications (e.g. improved tissue processing \nto reduce degeneration of bioprostheses or new mechanical valve \ndesigns to reduce risk of thrombosis). \n• Antithrombotic drugs in MHV patients: \n– Whether UFH or LMWH should be preferred as bridging therapy \nafter MHV implantation, as well as their timing and dosage, remains \nto be established. \n– For patients with MHV undergoing major NCS, the optimal post- \noperative management and bridging of VKA needs further \ninvestigation. \n– The role of pharmacogenomics for VKORC1, CYP2C9, and \nCYP4F2 in patients with highly variable INR, and low TTR or major \nvascular complications despite good adherence, should be further \ninvestigated. \n– More data on the risks and benefits of slow thrombolysis for valve \nthrombosis are required.  \n4706                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nPregnancy \n• More data are required on optimal management of anticoagulation in \npregnant women with MHVs. Prospective studies comparing differ-\nent antithrombotic regimens are lacking.  \nNon-cardiac surgery \n• Clinical utility of scales for peri-operative risk evaluation needs to be \ndetermined.  \nSex-specific considerations \n• The development of sex-adjusted surgical risk prediction tools is required. \n• Additional data are needed to validate sex-specific cut-offs indicating \ninterventions. \n• Further research is needed to investigate sex-related differences in \nthe prognosis and treatment of specific valve diseases, especially \nTR.  \n20. ‘What to do’ and ‘What not \nto do’ messages from the \nGuidelines \nClass I and Class III recommendations from throughout the guideline \ndocument are summarized in Table 13. \nTable 13 ‘What to do’ and ‘what not to do’ \nRecommendations \nClassa \nLevelb  \nRecommendations for the management of coronary artery disease in patients with valvular heart disease \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. \nI \nB \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of \nobstructive CAD. \nI \nC \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. \nI \nC \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. \nI \nC \nRecommendations for the management of atrial fibrillation in patients with native valvular heart disease \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. \nI \nA \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent \nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. \nI \nA \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent \ncardioembolic stroke and systemic thromboembolism. \nI \nB \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. \nIII \nB \nRecommendations on indications for surgery in severe aortic regurgitation \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. \nI \nB \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients \nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. \nI \nB \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable \nresults are expected. \nI \nB \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending \naorta. \nI \nC \nRecommendations for intervention and mode of intervention in severe aortic stenosis \nSymptomatic patients with severe aortic stenosis \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, and \nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. \nI \nB \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF \n(<50%) after careful confirmation that AS is severe. \nI \nB \nAsymptomatic patients with severe aortic stenosis \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. \nI \nB \nMode of intervention in patients with symptomatic severe aortic stenosis \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have \non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. \nI \nC \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural \ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4707 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 73",
          "page": 73,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for the management of coronary artery disease in patients with valvular heart disease |  |  | \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. |  | I | B | \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of\nobstructive CAD. |  | I | C | \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. |  | I | C | \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. |  | I | C | \n | Recommendations for the management of atrial fibrillation in patients with native valvular heart disease |  |  | \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. |  | I | A | \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent\nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. |  | I | A | \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent\ncardioembolic stroke and systemic thromboembolism. |  | I | B | \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. |  | III | B | \n | Recommendations on indications for surgery in severe aortic regurgitation |  |  | \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. |  | I | B | \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients\nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. |  | I | B | \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable\nresults are expected. |  | I | B | \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending\naorta. |  | I | C | \nRecommendations for intervention and mode of intervention in severe aortic stenosis |  |  |  | \nSymptomatic patients with severe aortic stenosis |  |  |  | \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s, and\nmax\nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. |  | I | B | \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF\n(<50%) after careful confrimation that AS is severe. |  | I | B | \n | Asymptomatic patients with severe aortic stenosis |  |  | \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. |  | I | B | \n | Mode of intervention in patients with symptomatic severe aortic stenosis |  |  | \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have\non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. |  | I | C | \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural\ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. |  | I | C | ",
          "rows": 25,
          "cols": 5
        }
      ],
      "keywords": [
        "moderate",
        "intervention",
        "ct",
        "asymptomatic",
        "tricuspid regurgitation",
        "contraindication",
        "gaps",
        "surgery",
        "risk",
        "severe",
        "mitral stenosis",
        "symptomatic",
        "ablation",
        "evidence",
        "indication",
        "treatment",
        "crt"
      ]
    },
    {
      "number": "21",
      "title": "20. ‘What to do’ and ‘What not to do’ messages from the Guidelines",
      "start_page": 73,
      "end_page": 76,
      "content": "Pregnancy \n• More data are required on optimal management of anticoagulation in \npregnant women with MHVs. Prospective studies comparing differ-\nent antithrombotic regimens are lacking.  \nNon-cardiac surgery \n• Clinical utility of scales for peri-operative risk evaluation needs to be \ndetermined.  \nSex-specific considerations \n• The development of sex-adjusted surgical risk prediction tools is required. \n• Additional data are needed to validate sex-specific cut-offs indicating \ninterventions. \n• Further research is needed to investigate sex-related differences in \nthe prognosis and treatment of specific valve diseases, especially \nTR.  \n20. ‘What to do’ and ‘What not \nto do’ messages from the \nGuidelines \nClass I and Class III recommendations from throughout the guideline \ndocument are summarized in Table 13. \nTable 13 ‘What to do’ and ‘what not to do’ \nRecommendations \nClassa \nLevelb  \nRecommendations for the management of coronary artery disease in patients with valvular heart disease \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. \nI \nB \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of \nobstructive CAD. \nI \nC \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. \nI \nC \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. \nI \nC \nRecommendations for the management of atrial fibrillation in patients with native valvular heart disease \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. \nI \nA \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent \nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. \nI \nA \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent \ncardioembolic stroke and systemic thromboembolism. \nI \nB \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. \nIII \nB \nRecommendations on indications for surgery in severe aortic regurgitation \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. \nI \nB \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients \nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. \nI \nB \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable \nresults are expected. \nI \nB \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending \naorta. \nI \nC \nRecommendations for intervention and mode of intervention in severe aortic stenosis \nSymptomatic patients with severe aortic stenosis \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, Vmax ≥4.0 m/s, and \nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. \nI \nB \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF \n(<50%) after careful confirmation that AS is severe. \nI \nB \nAsymptomatic patients with severe aortic stenosis \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. \nI \nB \nMode of intervention in patients with symptomatic severe aortic stenosis \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have \non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. \nI \nC \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural \ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4707 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nTAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable. \nI \nA \nSAVR is recommended in patients <70 years of age, if the surgical risk is low. \nI \nB \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. \nI \nB \nConcomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery \nSAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the \nascending aorta. \nI \nC \nRecommendations for intervention in severe mitral regurgitation \nPrimary mitral regurgitation \nMV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. \nI \nB \nMV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. \nI \nB \nMV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or \nLVEF ≤60%). \nI \nB \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi  \n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfilled: \n• AF \n• SPAP at rest >50 mmHg \n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm) \n• concomitant TR ≥ moderate. \nI \nB \nVentricular secondary mitral regurgitation and concomitant coronary artery disease \nMV surgery is recommended in patients with severe ventricular SMR undergoing CABG. \nI \nB \nVentricular secondary mitral regurgitation without concomitant coronary artery disease \nTEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with \nimpaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specific clinical and \nechocardiographic criteria. \nI \nA \nRecommendations for mitral stenosis \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis \nPMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. \nI \nB \nPMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. \nI \nC \nMV surgery is recommended in symptomatic patients who are not suitable for PMC. \nI \nC \nRecommendations for tricuspid regurgitation \nIndications for intervention in tricuspid regurgitation \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk, \nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. \nI \nC \nPatients with left-sided valvular heart disease requiring tricuspid valve surgery \nConcomitant TV surgery is recommended in patients with severe primary or secondary TR. \nI \nB \nPatients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery) \nTV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. \nI \nC \nRecommendations on tricuspid stenosis \nSurgery is recommended in symptomatic patients with severe TS. \nI \nC \nSurgery is recommended in patients with severe TS undergoing left-sided valve intervention. \nI \nC \nRecommendations for surgery of concomitant left-sided valvular heart disease \nConcomitant aortic stenosis \nSAVR is recommended in patients with severe AS undergoing surgery for another valve. \nI \nC \nConcomitant aortic regurgitation \nAV surgery is recommended in patients with severe AR undergoing surgery for another valve. \nI \nC \nConcomitant mitral regurgitation \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. \nI \nC                         \nContinued  \n4708                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nRecommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean \ngradient ≥40 mmHg or Vmax ≥4.0 m/s. \nI \nB \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with Vmax ≥4.0 m/s, \nand LVEF <50% not attributable to other cardiac disease. \nI \nC \nRecommendations for prosthetic valve selection \nMechanical heart valves \nAn MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. \nI \nC \nBiological heart valves \nA BHV is recommended according to the desire of the informed patient. \nI \nC \nA BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated \nshort life expectancy. \nI \nC \nRecommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement \nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. \nI \nA \nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve efficacy. \nI \nA \nIt is recommended that INR targets are based on the type and position of the MHV, and the patient’s risk factors and comorbidities. \nI \nA \nPatient education is recommended to improve the quality of OAC. \nI \nA \nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as \nconsidered safe. \nI \nB \nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. \nIII \nA \nRecommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective \nnon-cardiac surgery or invasive procedures \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or \nminimal bleeding. \nI \nA \nIt is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment \nwithin 24 h after surgery, or as soon as considered safe. \nI \nB \nRecommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair \nTranscatheter aortic valve implantation without indication for oral anticoagulation \nLow-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. \nI \nA \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. \nIII \nA \nRoutine use of OAC is not recommended after TAVI in patients without baseline indication. \nIII \nA \nSurgical biological heart valve with indication for oral anticoagulation \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. \nI \nB \nTranscatheter biological heart valve with indication for oral anticoagulation \nOAC is recommended for TAVI patients who have other indications for OAC. \nI \nB \nRecommendations on management of prosthetic valve dysfunction \nHaemolysis and paravalvular leak \nIt is recommended that the decision between transcatheter or surgical closure of clinically significant PVLs is based on Heart Team \nevaluation, including patient risk, leak morphology, and local expertise. \nI \nC \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF \nsymptoms. \nI \nC \nMechanical heart valve failure \nReoperation is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nBiological heart valve failure \nReintervention is recommended in symptomatic patients with significant valve dysfunction not attributable to valve thrombosis. \nI \nC \nValve thrombosis \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. \nI \nC                       \nContinued  \nESC Guidelines                                                                                                                                                                                          4709 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 73",
          "page": 73,
          "content": "Recommendations |  | Classa | Levelb | \n | Recommendations for the management of coronary artery disease in patients with valvular heart disease |  |  | \nCCTA is recommended before valve intervention in patients with moderate or lower (≤50%) pre-test likelihood of obstructive CAD. |  | I | B | \nInvasive coronary angiography is recommended before valve intervention in patients with high and very high (>50%) pre-test likelihood of\nobstructive CAD. |  | I | C | \nInvasive coronary angiography is recommended in the evaluation of CAD in patients with severe ventricular SMR. |  | I | C | \nCABG is recommended in patients with a primary indication for valve surgery and coronary artery diameter stenosis ≥70%. |  | I | C | \n | Recommendations for the management of atrial fibrillation in patients with native valvular heart disease |  |  | \nDOACs are recommended for stroke prevention in preference to VKAs in patients with AF and AS, AR, or MR who are eligible for OAC. |  | I | A | \nConcomitant surgical ablation is recommended in patients undergoing MV surgery with AF suitable for a rhythm control strategy to prevent\nsymptoms and recurrence of AF, according to an experienced team of electrophysiologists and arrhythmia surgeons. |  | I | A | \nSurgical closure of the LA appendage is recommended as an adjunct to OAC in patients with AF undergoing valve surgery to prevent\ncardioembolic stroke and systemic thromboembolism. |  | I | B | \nThe use of DOACs is not recommended in patients with AF and rheumatic MS with an MVA ≤2.0 cm2. |  | III | B | \n | Recommendations on indications for surgery in severe aortic regurgitation |  |  | \nAV surgery is recommended in symptomatic patients with severe AR regardless of LV function. |  | I | B | \nAV surgery is recommended in asymptomatic patients with severe AR and LVESD >50 mm or LVESDi >25 mm/m2 [especially in patients\nwith small body size (BSA <1.68 m2)] or resting LVEF ≤50%. |  | I | B | \nValve-sparing aortic root replacement is recommended in young patients with aortic root dilatation at experienced centres when durable\nresults are expected. |  | I | B | \nAV surgery is recommended in symptomatic and asymptomatic patients with severe AR undergoing CABG or surgery of the ascending\naorta. |  | I | C | \nRecommendations for intervention and mode of intervention in severe aortic stenosis |  |  |  | \nSymptomatic patients with severe aortic stenosis |  |  |  | \nIntervention is recommended in symptomatic patients with severe, high-gradient AS [mean gradient ≥40 mmHg, V ≥4.0 m/s, and\nmax\nAVA ≤1.0 cm2 (or ≤0.6 cm2/m2 BSA)]. |  | I | B | \nIntervention is recommended in symptomatic patients with low-flow (SVi ≤35 mL/m2), low-gradient (<40 mmHg) AS with reduced LVEF\n(<50%) after careful confrimation that AS is severe. |  | I | B | \n | Asymptomatic patients with severe aortic stenosis |  |  | \nIntervention is recommended in asymptomatic patients with severe AS and LVEF <50% without another cause. |  | I | B | \n | Mode of intervention in patients with symptomatic severe aortic stenosis |  |  | \nIt is recommended that AV interventions are performed in Heart Valve Centres that report their local expertise and outcome data, have\non-site interventional cardiology and cardiac surgical programmes, and a structured collaborative Heart Team. |  | I | C | \nIt is recommended that the mode of intervention is based on Heart Team assessment of individual clinical, anatomical, and procedural\ncharacteristics, incorporating lifetime management considerations and estimated life expectancy. |  | I | C | ",
          "rows": 25,
          "cols": 5
        },
        {
          "title": "Table on page 74",
          "page": 74,
          "content": "TAVI is recommended in patients ≥70 years of age with tricuspid AV stenosis, if the anatomy is suitable. |  | I | A | \nSAVR is recommended in patients <70 years of age, if the surgical risk is low. |  | I | B | \nSAVR or TAVI are recommended for all remaining candidates for an aortic BHV according to Heart Team assessment. |  | I | B | \n | Concomitant aortic valve surgery at the time of coronary artery bypass grafting or ascending aorta surgery |  |  | \nSAVR is recommended in symptomatic and asymptomatic patients with severe AS undergoing CABG or surgical intervention on the\nascending aorta. |  | I | C | \nRecommendations for intervention in severe mitral regurgitation |  |  |  | \nPrimary mitral regurgitation |  |  |  | \nMV repair is the recommended surgical technique to treat patients with severe PMR when the result is expected to be durable. |  | I | B | \nMV surgery is recommended in symptomatic patients with severe PMR considered operable by the Heart Team. |  | I | B | \nMV surgery is recommended in asymptomatic patients with severe PMR with LV dysfunction (LVESD ≥40 mm or LVESDi ≥20 mm/m2 or\nLVEF ≤60%). |  | I | B | \nSurgical MV repair is recommended in low-risk asymptomatic patients with severe PMR without LV dysfunction (LVESD <40 mm, LVESDi\n<20 mm/m2, and LVEF >60%) when a durable result is likely, if at least three of the following criteria are fulfliled:\n• AF\n• SPAP at rest >50 mmHg\n• LA dilatation (LAVI ≥60 mL/m2 or LA diameter ≥55 mm)\n• concomitant TR ≥ moderate. |  | I | B | \n | Ventricular secondary mitral regurgitation and concomitant coronary artery disease |  |  | \nMV surgery is recommended in patients with severe ventricular SMR undergoing CABG. |  | I | B | \n | Ventricular secondary mitral regurgitation without concomitant coronary artery disease |  |  | \nTEER is recommended to reduce HF hospitalizations and improve quality of life in haemodynamically stable, symptomatic patients with\nimpaired LVEF (<50%) and persistent severe ventricular SMR, despite optimized GDMT and CRT (if indicated), fulfilling specifci clinical and\nechocardiographic criteria. |  | I | A | \nRecommendations for mitral stenosis |  |  |  | \nIndications for mitral valve surgery and transcatheter intervention in clinically severe rheumatic and degenerative mitral stenosis |  |  |  | \nPMC is recommended in symptomatic patients in the absence of unfavourable characteristics for PMC. |  | I | B | \nPMC is recommended in any symptomatic patients with a contraindication or a high risk for surgery. |  | I | C | \nMV surgery is recommended in symptomatic patients who are not suitable for PMC. |  | I | C | \nRecommendations for tricuspid regurgitation |  |  |  | \nIndications for intervention in tricuspid regurgitation |  |  |  | \nCareful evaluation of TR aetiology, stage of the disease (i.e. degree of TR severity, RV and LV dysfunction, and PH), patient operative risk,\nand likelihood of recovery by a multidisciplinary Heart Team is recommended in patients with severe TR prior to intervention. |  | I | C | \n | Patients with left-sided valvular heart disease requiring tricuspid valve surgery |  |  | \nConcomitant TV surgery is recommended in patients with severe primary or secondary TR. |  | I | B | \n | Patients with severe tricuspid regurgitation (without left-sided valvular heart disease requiring surgery) |  |  | \nTV surgery is recommended in symptomatic patients with severe primary TR without severe RV dysfunction or severe PH. |  | I | C | \n | Recommendations on tricuspid stenosis |  |  | \nSurgery is recommended in symptomatic patients with severe TS. |  | I | C | \nSurgery is recommended in patients with severe TS undergoing left-sided valve intervention. |  | I | C | \nRecommendations for surgery of concomitant left-sided valvular heart disease |  |  |  | \nConcomitant aortic stenosis |  |  |  | \nSAVR is recommended in patients with severe AS undergoing surgery for another valve. |  | I | C | \n | Concomitant aortic regurgitation |  |  | \nAV surgery is recommended in patients with severe AR undergoing surgery for another valve. |  | I | C | \n | Concomitant mitral regurgitation |  |  | \nMV surgery is recommended in patients with severe MR undergoing surgery for another valve. |  | I | C | ",
          "rows": 37,
          "cols": 5
        },
        {
          "title": "Table on page 75",
          "page": 75,
          "content": " | Recommendations on indications for intervention in patients with mixed moderate aortic stenosis and moderate aortic regurgitation |  |  | \nIntervention is recommended in symptomatic patients with mixed moderate AV stenosis and moderate regurgitation, and a mean\ngradient ≥40 mmHg or V ≥4.0 m/s.\nmax |  | I | B | \nIntervention is recommended in asymptomatic patients with mixed moderate AV stenosis and moderate regurgitation with V ≥4.0 m/s,\nmax\nand LVEF <50% not attributable to other cardiac disease. |  | I | C | \nRecommendations for prosthetic valve selection |  |  |  | \nMechanical heart valves |  |  |  | \nAn MHV is recommended according to the desire of the informed patient and if there is no contraindication to long-term anticoagulation. |  | I | C | \n | Biological heart valves |  |  | \nA BHV is recommended according to the desire of the informed patient. |  | I | C | \nA BHV is recommended when an adequate quality of anticoagulation with VKA is unlikely, in patients at high bleeding risk, or with estimated\nshort life expectancy. |  | I | C | \n | Recommendations for the management of antithrombotic therapy in patients with a mechanical heart valve replacement |  |  | \nLifelong OAC with a VKA is recommended for all patients with MHVs to prevent thromboembolic complications. |  | I | A | \nINR self-monitoring and self-management are recommended over standard monitoring in selected, trained patients to improve effci acy. |  | I | A | \nIt is recommended that INR targets are based on the type and position of the MHV, and the patient’s risk factors and comorbidities. |  | I | A | \nPatient education is recommended to improve the quality of OAC. |  | I | A | \nFollowing cardiac surgery with MHV implantation, it is recommended to start UFH or LMWH bridging and VKA within 24 h, or as soon as\nconsidered safe. |  | I | B | \nDOACs and/or DAPT are not recommended to prevent thrombosis in patients with an MHV. |  | III | A | \n | Recommendations for the management of antithrombotic therapy in patients with mechanical heart valves undergoing elective\nnon-cardiac surgery or invasive procedures |  |  | \nContinuing VKA treatment is recommended in patients with an MHV for minor or minimally invasive interventions associated with no or\nminimal bleeding. |  | I | A | \nIt is recommended to discontinue VKA at least 4 days before major elective NCS, aiming for an INR <1.5, and to resume VKA treatment\nwithin 24 h after surgery, or as soon as considered safe. |  | I | B | \nRecommendations for the management of antithrombotic therapy in patients with a biological heart valve or valve repair |  |  |  | \nTranscatheter aortic valve implantation without indication for oral anticoagulation |  |  |  | \nLow-dose ASA (75–100 mg/day) is recommended for 12 months after TAVI in patients without indication for OAC. |  | I | A | \nDAPT is not recommended to prevent thrombosis after TAVI, unless there is a clear indication. |  | III | A | \nRoutine use of OAC is not recommended after TAVI in patients without baseline indication. |  | III | A | \n | Surgical biological heart valve with indication for oral anticoagulation |  |  | \nOAC continuation is recommended in patients with a clear indication for OAC undergoing surgical BHV implantation. |  | I | B | \n | Transcatheter biological heart valve with indication for oral anticoagulation |  |  | \nOAC is recommended for TAVI patients who have other indications for OAC. |  | I | B | \nRecommendations on management of prosthetic valve dysfunction |  |  |  | \nHaemolysis and paravalvular leak |  |  |  | \nIt is recommended that the decision between transcatheter or surgical closure of clinically signifci ant PVLs is based on Heart Team\nevaluation, including patient risk, leak morphology, and local expertise. |  | I | C | \nReoperation is recommended if a PVL is related to endocarditis, or causes haemolysis requiring repeated blood transfusion or leading to HF\nsymptoms. |  | I | C | \n | Mechanical heart valve failure |  |  | \nReoperation is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Biological heart valve failure |  |  | \nReintervention is recommended in symptomatic patients with signifci ant valve dysfunction not attributable to valve thrombosis. |  | I | C | \n | Valve thrombosis |  |  | \nTOE and/or 4D-CT are recommended in patients with suspected valve thrombosis to confirm the diagnosis. |  | I | C | ",
          "rows": 38,
          "cols": 5
        },
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "prognosis",
        "asymptomatic",
        "class iii",
        "class i",
        "cabg",
        "doac",
        "ablation",
        "indication",
        "atrial fibrillation",
        "intervention",
        "messages",
        "class ii",
        "treatment",
        "aortic regurgitation",
        "recommendation",
        "moderate",
        "anticoagulation",
        "ct",
        "surgery",
        "risk"
      ]
    },
    {
      "number": "22",
      "title": "21. Evidence tables",
      "start_page": 76,
      "end_page": 76,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "surgery",
        "tables",
        "evidence"
      ]
    },
    {
      "number": "23",
      "title": "22. Data availability statement",
      "start_page": 76,
      "end_page": 76,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "surgery",
        "statement",
        "availability",
        "data"
      ]
    },
    {
      "number": "24",
      "title": "23. Author information",
      "start_page": 76,
      "end_page": 76,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "surgery",
        "information",
        "author"
      ]
    },
    {
      "number": "25",
      "title": "Appendix",
      "start_page": 76,
      "end_page": 77,
      "content": "21. Evidence tables \nEvidence tables are available at European Heart Journal online. \n22. Data availability statement \nNo new data were generated or analysed in support of this research. \n23. Author information \nJonas Lanz, Department of Cardiology, Bern University Hospital, \nBern, \nSwitzerland; \nMateo \nMarin-Cuartas, \nUniversity \nDepartment of Cardiac Surgery, Leipzig Heart Center, Leipzig, \nGermany; Ana Abreu, Faculdade de Medicina da Universidade de \nLisboa (FMUL), ISAMB, IMPSP, CCUL, CAML, Lisboa, Portugal; \nServiço Cardiologia, Unidade de Reabilitação Cardiovascular, ULS \nSanta Maria/FMUL, Lisboa, Portugal; Marianna Adamo, Institute \nof Cardiology, ASST Spedali Civili, Brescia, Italy; Department of \nmedical and surgical specialties, radiological sciences, and public \nhealth, University of Brescia, Italy; Nina Ajmone Marsan, \nDepartment of Cardiology, Leiden University Medical Center, \nLeiden, Netherlands; Fabio Barili, Department of Biomedical and \nClinical Sciences, Università Degli Studi Di Milano, Milan, Italy; \nUniversity Cardiac Surgery Unit, IRCCS Ospedale Galeazzi - \nSant’Ambrogio, Milan, Italy; Department of Epidemiology, Harvard \nT.H. Chan School of Public Health Boston, MA, United States of \nAmerica; Nikolaos Bonaros, Department of Cardiac Surgery, \nMedical University of Innsbruck, Innsbruck, Austria; University \nHospital Innsbruck, Innsbruck, Austria; Bernard Cosyns, \nCardiology department, Universitair Ziekenhuis Brussel, Brussels, \nBelgium; Ruggero De Paulis, Department of cardiac surgery, \nEuropean Hospital, Rome, Italy; Unicamillus University, Rome, \nItaly; Habib Gamra, Cardiology University of Monastir, Monastir, \nTunisia; Marjan Jahangiri, Cardiac Surgery, St George’s Hospital, \nLondon, United Kingdom; Anders Jeppsson, Cardiothoracic sur-\ngery, Sahlgrenska University Hospital, Gothenburg, Sweden; \nMolecular and clinical medicine, Institute of medicine, Sahlgrenska \nAcademy, University of Gothenburg, Gothenburg, Sweden; \nRobert J.M. Klautz, Department of Cardiothoracic Surgery, \nLeiden \nUniversity \nMedical \nCenter, \nLeiden, \nNetherlands; \nDepartment of Cardiothoracic Surgery, Amsterdam University \nMedical Center, Amsterdam, Netherlands; Benoit Mores, \n(Belgium), ESC Patient Forum, Sophia Antipolis, France; Esther \nPérez-David, Cardiology Department, Hospital Universitario La \nPaz, IdiPaz (Hospital la Paz Research Institute), Facultad de \nMedicina Universidad Europea de Madrid, Madrid, Spain; Janine \nPöss, Department of internal medicine/cardiology, Heart Centre \nLeipzig at University of Leipzig, Leipzig, Germany; Bernard \nD. Prendergast, Heart Vascular & Thoracic Institute, Cleveland \nClinic London, London, United Kingdom; Department of \nCardiology, St Thomas’ Hospital, London, United Kingdom; \nBianca Rocca, Department of Medicine and Surgery, LUM \nUniversity Casamassima (Ba), Italy; Xavier Rossello, Cardiology \nDepartment, Hospital Universitari Son Espases, Palma de Mallorca, \nSpain; Health Research Institute of the Balearic Islands (IdISBa), \nUniversitat de les Illes Balears (UIB), Palma de Mallorca, Spain; \nMikio Suzuki, (Serbia), ESC Patient Forum, Sophia Antipolis, \nFrance; Holger Thiele, Department of Internal Medicine/ \nCardiology, Heart Centre Leipzig at Leipzig University, Leipzig, \nGermany; Leipzig Heart Science, Leipzig, Germany; Christophe \nMichel Tribouilloy, Cardiology department, Amiens University \nHospital, Amiens, France; and Wojtek Wojakowski, Division of \nCardiology and Structural Heart Diseases, Medical University of \nSilesia, Katowice, Poland. \n24. Appendix \nESC/EACTS Scientific Document Group \nIncludes Document Reviewers, ESC National Cardiac Societies and \nEACTS Network of National Cardiac Surgery Societies \nDocument \nReviewers: \nAlec \nVahanian \n(ESC \nReview \nCo-ordinator) \n(France), \nCarlos-A. \nMestres \n(EACTS \nReview \nCo-ordinator) (South Africa), Leila Abid (Tunisia), Suleman Aktaa \n(United Kingdom), Elena Arbelo (Spain), Folkert W. Asselbergs \n(Netherlands), Emanuele Barbato (Italy), Giuseppe Boriani (Italy), \nMargarita Brida (Croatia), Sergio Buccheri (Sweden), Robert Byrne \n(Republic of Ireland), Ovidiu Chioncel (Romania), Lenard Conradi \n(Germany), Michele De Bonis (Italy), Victoria Delgado (Spain), Enoch \nF. Akowuah (United Kingdom), Anna Franzone (Italy), Kristina \nHermann Haugaa (Norway), Bettina Heidecker (Germany), Borja \nIbanez (Spain), Bernard Iung (France), Stefan James (Sweden), Lars \nKøber (Denmark), Konstantinos C. Koskinas (Switzerland), Ulf \nMechanical heart valve thrombosis \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine \nappropriate management (repeat valve replacement or low-dose slow infusion fibrinolysis). \nI \nB \nBiological heart valve thrombosis \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. \nI \nB \n© ESC/EACTS 2025\n4D, four-dimensional; AF, atrial fibrillation; AR, aortic regurgitation; AS, aortic stenosis; ASA, acetylsalicylic acid; AV, aortic valve; AVA, aortic valve area; BHV, biological heart valve; BSA, body \nsurface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CCTA, coronary CT angiography; CRT, cardiac resynchronization therapy; CT, computed tomography; \nDAPT, dual antiplatelet therapy; DOAC, direct oral anticoagulation; GDMT, guideline-directed medical therapy; h, hour; HF, heart failure; INR, international normalized ratio; LA, left atrium/ \nleft atrial; LAVI, left atrial volume index; LMWH, low-molecular-weight heparin; LV, left ventricle/left ventricular; LVEF, left ventricular ejection fraction; LVESD, left ventricular end-systolic \ndiameter; LVESDi, left ventricular end-systolic diameter indexed to BSA; MHV, mechanical heart valve; MR, mitral regurgitation; MS, mitral stenosis; MV, mitral valve; MVA, mitral valve area; \nNCS, non-cardiac surgery; NYHA, New York Heart Association; OAC, oral anticoagulation; PH, pulmonary hypertension; PMC, percutaneous mitral commissurotomy; PMR, primary mitral \nregurgitation; PVL, paravalvular leak; RV, right ventricle/right ventricular; SAVR, surgical aortic valve replacement; SMR, secondary mitral regurgitation; SPAP, systolic pulmonary artery \npressure; SVi, stroke volume index; TAVI, transcatheter aortic valve implantation; TEER, transcatheter edge-to-edge repair; TOE, transoesophageal echocardiography; TR, tricuspid \nregurgitation; TS, tricuspid stenosis; TV, tricuspid valve; UFH, unfractionated heparin; VKA, vitamin K antagonist; Vmax, peak transvalvular velocity. \naClass of recommendation. \nbLevel of evidence.   \n4710                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nLandmesser (Germany), Gregory Y.H. Lip (United Kingdom), John \nWilliam McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham \n(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen \n(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet \n(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), \nEduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba \n(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina \nUrena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints \n(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), \nAdam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) \nContributor either withdrew or was engaged in only a part of the re-\nview process: Davide Capodanno \nESC National Cardiac Societies actively involved in the review \nprocess of the 2025 ESC/EACTS Guidelines for the management for \nvalvular heart disease: \nAlbania: Albanian Society of Cardiology, Naltin Shuka; Algeria: \nAlgerian Society of Cardiology, Brahim Kichou; Armenia: Armenian \nCardiologists Association, Aram L. Chilingaryan; Austria: Austrian \nSociety of Cardiology, Philipp Emanuel Bartko; Azerbaijan: \nAzerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian \nSociety of Cardiology, Caroline M. Van de Heyning; Bosnia and \nHerzegovina: Association of Cardiologists of Bosnia and \nHerzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of \nCardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko \nBulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; \nCzechia: Czech Society of Cardiology, Hana Linkova; Denmark: \nDanish Society of Cardiology, Emil Fosbøl; Egypt: Egyptian Society \nof Cardiology, Hesham Bahaa; Estonia: Estonian Society of \nCardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko \nPiuhola; France: French Society of Cardiology, Erwan Donal; \nGeorgia: Georgian Society of Cardiology, Shalva Petriashvili; \nGermany: German Cardiac Society, Tanja Katharina Rudolph; \nGreece: Hellenic Society of Cardiology, Maria Drakopoulou; \nHungary: Hungarian Society of Cardiology, Attila Kertész; Iceland: \nIcelandic Society of Cardiology, Hjalti Guðmundsson; Ireland: Irish \nCardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy \nCarasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; \nKazakhstan: Association of Cardiologists of Kazakhstan, Madina \nSugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, \nGani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina \nKerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; \nLithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; \nLuxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; \nMalta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova \n(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; \nNetherlands: Netherlands Society of Cardiology, Sebastian \nStreukens; North Macedonia: National Society of Cardiology of \nNorth Macedonia, Emilija Antova; Norway: Norwegian Society of \nCardiology, Håvard Dalen; Poland: Polish Cardiac Society, Tomasz \nKukulski; Portugal: Portuguese Society of Cardiology, Cristina \nGavina; Romania: Romanian Society of Cardiology, Bogdan \nA. Popescu; San Marino: San Marino Society of Cardiology, \nRoberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; \nSlovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia: \nSlovenian Society of Cardiology, Matjaž Bunc; Spain: Spanish Society \nof Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of \nCardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss \nSociety of Cardiology, Raban Jeger; Tunisia: Tunisian Society of \nCardiology and Cardio-Vascular Surgery, Leila Abid; Türkiye: \nTurkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: \nUkrainian Association of Cardiology, Elena G. Nesukay; United \nKingdom of Great Britain and Northern Ireland: British \nCardiovascular Society, Madalina Garbi; Uzbekistan: Association of \nCardiologists of Uzbekistan, Guzal Mullabayeva. \nEACTS Network of National Cardiac Surgery Societies ac-\ntively involved in the review process of the 2025 ESC/EACTS \nGuidelines for the management for valvular heart disease: \nAustria: Austrian Society of Cardiac and Thoracic Vascular \nSurgery, Martin Grabenwoeger; Belgium: Belgian Association for \nCardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The \nCzech Society for Cardiovascular Surgery, Jan Vojacek; France: The \nFrench Society for Thoracic and Cardiovascular Surgery; André \nVincentelli; \nGermany: \nGerman \nSociety \nfor \nThoracic \nand \nCardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of \nThoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian \nSociety for Cardiac Surgery, Alessandro Parolari; Netherlands: \nNetherlands Association for Cardio-thoracic surgery, Jerry Braun; \nNorth Macedonia: North Macedonian Society of Cardiac \nSurgery, Aleksandar Nikolic; Norway: Norwegian Association for \nCardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade \nPortuguesa de Cirurgia Cardíaca Torácica e Vascular, Miguel Sousa-Uva; \nSerbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic; \nSpain: Sociedad Española de Cirugía Cardiovascular y Endovascular, \nJuan J. Legarra; Switzerland: Swiss Society for Thoracic and \nCardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society \nfor Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani \nESC Clinical Practice Guidelines (CPG) Committee: \nUlf \nLandmesser \n(Chairperson) \n(Germany), \nStefan \nJames \n(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa \n(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin \nBaigent (United Kingdom), Michael A. Borger (Germany), Giuseppe \nBoriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), \nEstelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja \nHennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United \nKingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy \n(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard \n(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), \nBianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino \n(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski \n(Poland), and Katja Zeppenfeld (Netherlands) \nEACTS Council: Volkmar Falk (President) (Germany), Patrick \nMyers (Secretary General) (Switzerland), Joseph Bavaria (United \nStates of America), Korkut Bostanci (Türkiye), Filip Casselman \n(Belgium), Mario Gaudino (United States of America), Jurgen Hoerer \n(Germany), Nabil Hussein (United Kingdom), Virginia Litle (United \nStates of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian \nSchoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya \nWarburton (United Kingdom) \n25. References \n1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter \naortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J \nMed 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052 \n2. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter \naortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: \n1949–960. https://doi.org/10.1056/NEJMoa2307447 \n3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. \nSurgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl \nJ Med 2017;376:1321–31. https://doi.org/10.1056/NEJMoa1700456  \nESC Guidelines                                                                                                                                                                                          4711 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [
        {
          "title": "Table on page 76",
          "page": 76,
          "content": " | Mechanical heart valve thrombosis |  |  | \nHeart Team evaluation is recommended in patients with acute HF (NYHA class III or IV) due to obstructive MHV thrombosis to determine\nappropriate management (repeat valve replacement or low-dose slow infusion fbi rinolysis). |  | I | B | \n | Biological heart valve thrombosis |  |  | \nOAC using VKA is recommended in BHV thrombosis before considering reintervention. |  | I | B | ",
          "rows": 4,
          "cols": 5
        }
      ],
      "keywords": [
        "surgery",
        "appendix"
      ]
    },
    {
      "number": "26",
      "title": "References",
      "start_page": 77,
      "end_page": 77,
      "content": "Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), John \nWilliam McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham \n(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen \n(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet \n(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), \nEduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba \n(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina \nUrena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints \n(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), \nAdam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) \nContributor either withdrew or was engaged in only a part of the re-\nview process: Davide Capodanno \nESC National Cardiac Societies actively involved in the review \nprocess of the 2025 ESC/EACTS Guidelines for the management for \nvalvular heart disease: \nAlbania: Albanian Society of Cardiology, Naltin Shuka; Algeria: \nAlgerian Society of Cardiology, Brahim Kichou; Armenia: Armenian \nCardiologists Association, Aram L. Chilingaryan; Austria: Austrian \nSociety of Cardiology, Philipp Emanuel Bartko; Azerbaijan: \nAzerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian \nSociety of Cardiology, Caroline M. Van de Heyning; Bosnia and \nHerzegovina: Association of Cardiologists of Bosnia and \nHerzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of \nCardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko \nBulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; \nCzechia: Czech Society of Cardiology, Hana Linkova; Denmark: \nDanish Society of Cardiology, Emil Fosbøl; Egypt: Egyptian Society \nof Cardiology, Hesham Bahaa; Estonia: Estonian Society of \nCardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko \nPiuhola; France: French Society of Cardiology, Erwan Donal; \nGeorgia: Georgian Society of Cardiology, Shalva Petriashvili; \nGermany: German Cardiac Society, Tanja Katharina Rudolph; \nGreece: Hellenic Society of Cardiology, Maria Drakopoulou; \nHungary: Hungarian Society of Cardiology, Attila Kertész; Iceland: \nIcelandic Society of Cardiology, Hjalti Guðmundsson; Ireland: Irish \nCardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy \nCarasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; \nKazakhstan: Association of Cardiologists of Kazakhstan, Madina \nSugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, \nGani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina \nKerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; \nLithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; \nLuxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; \nMalta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova \n(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; \nNetherlands: Netherlands Society of Cardiology, Sebastian \nStreukens; North Macedonia: National Society of Cardiology of \nNorth Macedonia, Emilija Antova; Norway: Norwegian Society of \nCardiology, Håvard Dalen; Poland: Polish Cardiac Society, Tomasz \nKukulski; Portugal: Portuguese Society of Cardiology, Cristina \nGavina; Romania: Romanian Society of Cardiology, Bogdan \nA. Popescu; San Marino: San Marino Society of Cardiology, \nRoberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; \nSlovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia: \nSlovenian Society of Cardiology, Matjaž Bunc; Spain: Spanish Society \nof Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of \nCardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss \nSociety of Cardiology, Raban Jeger; Tunisia: Tunisian Society of \nCardiology and Cardio-Vascular Surgery, Leila Abid; Türkiye: \nTurkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: \nUkrainian Association of Cardiology, Elena G. Nesukay; United \nKingdom of Great Britain and Northern Ireland: British \nCardiovascular Society, Madalina Garbi; Uzbekistan: Association of \nCardiologists of Uzbekistan, Guzal Mullabayeva. \nEACTS Network of National Cardiac Surgery Societies ac-\ntively involved in the review process of the 2025 ESC/EACTS \nGuidelines for the management for valvular heart disease: \nAustria: Austrian Society of Cardiac and Thoracic Vascular \nSurgery, Martin Grabenwoeger; Belgium: Belgian Association for \nCardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The \nCzech Society for Cardiovascular Surgery, Jan Vojacek; France: The \nFrench Society for Thoracic and Cardiovascular Surgery; André \nVincentelli; \nGermany: \nGerman \nSociety \nfor \nThoracic \nand \nCardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of \nThoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian \nSociety for Cardiac Surgery, Alessandro Parolari; Netherlands: \nNetherlands Association for Cardio-thoracic surgery, Jerry Braun; \nNorth Macedonia: North Macedonian Society of Cardiac \nSurgery, Aleksandar Nikolic; Norway: Norwegian Association for \nCardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade \nPortuguesa de Cirurgia Cardíaca Torácica e Vascular, Miguel Sousa-Uva; \nSerbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic; \nSpain: Sociedad Española de Cirugía Cardiovascular y Endovascular, \nJuan J. Legarra; Switzerland: Swiss Society for Thoracic and \nCardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society \nfor Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani \nESC Clinical Practice Guidelines (CPG) Committee: \nUlf \nLandmesser \n(Chairperson) \n(Germany), \nStefan \nJames \n(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa \n(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin \nBaigent (United Kingdom), Michael A. Borger (Germany), Giuseppe \nBoriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), \nEstelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja \nHennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United \nKingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy \n(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard \n(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), \nBianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino \n(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski \n(Poland), and Katja Zeppenfeld (Netherlands) \nEACTS Council: Volkmar Falk (President) (Germany), Patrick \nMyers (Secretary General) (Switzerland), Joseph Bavaria (United \nStates of America), Korkut Bostanci (Türkiye), Filip Casselman \n(Belgium), Mario Gaudino (United States of America), Jurgen Hoerer \n(Germany), Nabil Hussein (United Kingdom), Virginia Litle (United \nStates of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian \nSchoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya \nWarburton (United Kingdom) \n25. References \n1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter \naortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J \nMed 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052 \n2. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter \naortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: \n1949–960. https://doi.org/10.1056/NEJMoa2307447 \n3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. \nSurgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl \nJ Med 2017;376:1321–31. https://doi.org/10.1056/NEJMoa1700456  \nESC Guidelines                                                                                                                                                                                          4711 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "references",
        "ct"
      ]
    },
    {
      "number": "27",
      "title": "References",
      "start_page": 77,
      "end_page": 91,
      "content": "Landmesser (Germany), Gregory Y.H. Lip (United Kingdom), John \nWilliam McEvoy (Ireland), Gil Meltzer (Israel), David Messika-Zeitoun \n(Canada), Borislava Mihaylova (United Kingdom), Richard Mindham \n(United Kingdom), Inge Moelgaard (Denmark), Jens Cosedis Nielsen \n(Denmark), Gareth Owens (United Kingdom), Agnes A. Pasquet \n(Belgium), Thomas Pilgrim (Switzerland), Eva Prescott (Denmark), \nEduard Quintana (Spain), Volker Rudolph (Germany), Rafael Sadaba \n(Spain), Anna Sannino (Germany), Felix C. Tanner (Switzerland), Marina \nUrena (France), Ilonca Vaartjes (Netherlands), Christiaan Vrints \n(Belgium), Alexander Wahba (Norway), Thomas Walther (Germany), \nAdam Witkowski (Poland), and Katja Zeppenfeld (Netherlands) \nContributor either withdrew or was engaged in only a part of the re-\nview process: Davide Capodanno \nESC National Cardiac Societies actively involved in the review \nprocess of the 2025 ESC/EACTS Guidelines for the management for \nvalvular heart disease: \nAlbania: Albanian Society of Cardiology, Naltin Shuka; Algeria: \nAlgerian Society of Cardiology, Brahim Kichou; Armenia: Armenian \nCardiologists Association, Aram L. Chilingaryan; Austria: Austrian \nSociety of Cardiology, Philipp Emanuel Bartko; Azerbaijan: \nAzerbaijan Society of Cardiology, Fuad Samadov; Belgium: Belgian \nSociety of Cardiology, Caroline M. Van de Heyning; Bosnia and \nHerzegovina: Association of Cardiologists of Bosnia and \nHerzegovina, Zumreta Kusljugic; Bulgaria: Bulgarian Society of \nCardiology, Elena Kinova; Croatia: Croatian Cardiac Society, Josko \nBulum; Cyprus: Cyprus Society of Cardiology, Christos Eftychiou; \nCzechia: Czech Society of Cardiology, Hana Linkova; Denmark: \nDanish Society of Cardiology, Emil Fosbøl; Egypt: Egyptian Society \nof Cardiology, Hesham Bahaa; Estonia: Estonian Society of \nCardiology, Jaagup Truusalu; Finland: Finnish Cardiac Society, Jarkko \nPiuhola; France: French Society of Cardiology, Erwan Donal; \nGeorgia: Georgian Society of Cardiology, Shalva Petriashvili; \nGermany: German Cardiac Society, Tanja Katharina Rudolph; \nGreece: Hellenic Society of Cardiology, Maria Drakopoulou; \nHungary: Hungarian Society of Cardiology, Attila Kertész; Iceland: \nIcelandic Society of Cardiology, Hjalti Guðmundsson; Ireland: Irish \nCardiac Society, Ben Cole; Israel: Israel Heart Society, Shemy \nCarasso; Italy: Italian Federation of Cardiology, Alessandro Navazio; \nKazakhstan: Association of Cardiologists of Kazakhstan, Madina \nSugralimova; Kosovo (Republic of): Kosovo Society of Cardiology, \nGani Bajraktari; Kyrgyzstan: Kyrgyz Society of Cardiology, Alina \nKerimkulova; Libya: Libyan Cardiac Society, Elham Omran Elgdhafi; \nLithuania: Lithuanian Society of Cardiology, Sigita Glaveckaite; \nLuxembourg: Luxembourg Society of Cardiology, Frederic Lebrun; \nMalta: Maltese Cardiac Society, Daniela Cassar Demarco; Moldova \n(Republic of): Moldavian Society of Cardiology, Dorin Mihail Lisii; \nNetherlands: Netherlands Society of Cardiology, Sebastian \nStreukens; North Macedonia: National Society of Cardiology of \nNorth Macedonia, Emilija Antova; Norway: Norwegian Society of \nCardiology, Håvard Dalen; Poland: Polish Cardiac Society, Tomasz \nKukulski; Portugal: Portuguese Society of Cardiology, Cristina \nGavina; Romania: Romanian Society of Cardiology, Bogdan \nA. Popescu; San Marino: San Marino Society of Cardiology, \nRoberto Bini; Serbia: Cardiology Society of Serbia, Igor Ivanov; \nSlovakia: Slovak Society of Cardiology, Martin Hudec; Slovenia: \nSlovenian Society of Cardiology, Matjaž Bunc; Spain: Spanish Society \nof Cardiology, Thomas Javier Bermejo; Sweden: Swedish Society of \nCardiology, Carl Johan Cronstedt Meurling; Switzerland: Swiss \nSociety of Cardiology, Raban Jeger; Tunisia: Tunisian Society of \nCardiology and Cardio-Vascular Surgery, Leila Abid; Türkiye: \nTurkish Society of Cardiology, Muzaffer M. Degertekin; Ukraine: \nUkrainian Association of Cardiology, Elena G. Nesukay; United \nKingdom of Great Britain and Northern Ireland: British \nCardiovascular Society, Madalina Garbi; Uzbekistan: Association of \nCardiologists of Uzbekistan, Guzal Mullabayeva. \nEACTS Network of National Cardiac Surgery Societies ac-\ntively involved in the review process of the 2025 ESC/EACTS \nGuidelines for the management for valvular heart disease: \nAustria: Austrian Society of Cardiac and Thoracic Vascular \nSurgery, Martin Grabenwoeger; Belgium: Belgian Association for \nCardio-Thoracic Surgery, Frederic Vanden Eynden; Czechia: The \nCzech Society for Cardiovascular Surgery, Jan Vojacek; France: The \nFrench Society for Thoracic and Cardiovascular Surgery; André \nVincentelli; \nGermany: \nGerman \nSociety \nfor \nThoracic \nand \nCardiovascular Surgery, Volkmar Falk; Greece: Hellenic Society of \nThoracic and Cardiovascular Surgeons, Panagiotis Dedeilias; Italy: Italian \nSociety for Cardiac Surgery, Alessandro Parolari; Netherlands: \nNetherlands Association for Cardio-thoracic surgery, Jerry Braun; \nNorth Macedonia: North Macedonian Society of Cardiac \nSurgery, Aleksandar Nikolic; Norway: Norwegian Association for \nCardiothoracic Surgery, Vegard S. Ellensen; Portugal: Sociedade \nPortuguesa de Cirurgia Cardíaca Torácica e Vascular, Miguel Sousa-Uva; \nSerbia: Serbian Society for Cardiovascular Surgery, Slobodan Micovic; \nSpain: Sociedad Española de Cirugía Cardiovascular y Endovascular, \nJuan J. Legarra; Switzerland: Swiss Society for Thoracic and \nCardiovascular Surgery, Enrico Ferrari; United Kingdom: The Society \nfor Cardiothoracic Surgery in Great Britain and Ireland, Narain Moorjani \nESC Clinical Practice Guidelines (CPG) Committee: \nUlf \nLandmesser \n(Chairperson) \n(Germany), \nStefan \nJames \n(Co-Chairperson) (Sweden), Marianna Adamo (Italy), Suleman Aktaa \n(United Kingdom), Folkert W. Asselbergs (Netherlands), Colin \nBaigent (United Kingdom), Michael A. Borger (Germany), Giuseppe \nBoriani (Italy), Margarita Brida (Croatia), Robert A. Byrne (Ireland), \nEstelle Gandjbakhch (France), Bettina Heidecker (Germany), Anja \nHennemuth (Germany), Borja Ibanez (Spain), Peter Jüni (United \nKingdom), Gregory Y.H. Lip (United Kingdom), John William McEvoy \n(Ireland), Borislava Mihaylova (United Kingdom), Inge Moelgaard \n(Denmark), Lis Neubeck (United Kingdom), Eva Prescott (Denmark), \nBianca Rocca (Italy), Xavier Rossello (Spain), Anna Sannino \n(Germany), Felix C. Tanner (Switzerland), Wojtek Wojakowski \n(Poland), and Katja Zeppenfeld (Netherlands) \nEACTS Council: Volkmar Falk (President) (Germany), Patrick \nMyers (Secretary General) (Switzerland), Joseph Bavaria (United \nStates of America), Korkut Bostanci (Türkiye), Filip Casselman \n(Belgium), Mario Gaudino (United States of America), Jurgen Hoerer \n(Germany), Nabil Hussein (United Kingdom), Virginia Litle (United \nStates of America), Franca Melfi (Italy), Rafael Sadaba (Spain), Florian \nSchoenhoff (Switzerland), Matthias Siepe (Switzerland), and Tanya \nWarburton (United Kingdom) \n25. References \n1. Mack MJ, Leon MB, Thourani VH, Makkar R, Kodali SK, Russo M, et al. Transcatheter \naortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J \nMed 2019;380:1695–705. https://doi.org/10.1056/NEJMoa1814052 \n2. Mack MJ, Leon MB, Thourani VH, Pibarot P, Hahn RT, Genereux P, et al. Transcatheter \naortic-valve replacement in low-risk patients at five years. N Engl J Med 2023;389: \n1949–960. https://doi.org/10.1056/NEJMoa2307447 \n3. Reardon MJ, Van Mieghem NM, Popma JJ, Kleiman NS, Sondergaard L, Mumtaz M, et al. \nSurgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl \nJ Med 2017;376:1321–31. https://doi.org/10.1056/NEJMoa1700456  \nESC Guidelines                                                                                                                                                                                          4711 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n4. Forrest JK, Deeb GM, Yakubov SJ, Gada H, Mumtaz MA, Ramlawi B, et al. 4-Year out-\ncomes of patients with aortic stenosis in the Evolut low risk trial. J Am Coll Cardiol 2023; \n82:2163–65. https://doi.org/10.1016/j.jacc.2023.09.813 \n5. Delgado V, Ajmone Marsan N, de Waha S, Bonaros N, Brida M, Burri H, et al. 2023 \nESC Guidelines for the management of endocarditis. Eur Heart J 2023;44: \n3948–4042. https://doi.org/10.1093/eurheartj/ehad193 \n6. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, et al. 2024 ESC \nGuidelines for the management of chronic coronary syndromes: developed by the \ntask force for the management of chronic coronary syndromes of the European \nSociety of Cardiology (ESC) Endorsed by the European Association for \nCardio-Thoracic Surgery (EACTS). Eur Heart J 2024;45:3415–537. https://doi.org/ \n10.1093/eurheartj/ehae177 \n7. Van Gelder IC, Rienstra M, Bunting KV, Casado-Arroyo R, Caso V, Crijns H, et al. 2024 \nESC Guidelines for the management of atrial fibrillation developed in collaboration \nwith the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J \n2024;45:3314–414. https://doi.org/10.1093/eurheartj/ehae176 \n8. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, et al. 2024 ESC \nGuidelines for the management of peripheral arterial and aortic diseases. Eur Heart J \n2024;45:3538–700. https://doi.org/10.1093/eurheartj/ehae179 \n9. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller G-P, et al. \n2020 ESC Guidelines for the management of adult congenital heart disease: the Task \nForce for the management of adult congenital heart disease of the European Society of \nCardiology (ESC). Endorsed by: Association for European Paediatric and Congenital \nCardiology (AEPC), International Society for Adult Congenital Heart Disease \n(ISACHD). Eur Heart J 2020;42:563–645. https://doi.org/10.1093/eurheartj/ehaa554 \n10. Généreux P, Sharma RP, Cubeddu RJ, Aaron L, Abdelfattah OM, Koulogiannis KP, et al. \nThe mortality burden of untreated aortic stenosis. J Am Coll Cardiol 2023;82:2101–9.  \nhttps://doi.org/10.1016/j.jacc.2023.09.796 \n11. d’Arcy JL, Coffey S, Loudon MA, Kennedy A, Pearson-Stuttard J, Birks J, et al. \nLarge-scale community echocardiographic screening reveals a major burden of undiag-\nnosed valvular heart disease in older people: the OxVALVE Population Cohort Study. \nEur Heart J 2016;37:3515–22. https://doi.org/10.1093/eurheartj/ehw229 \n12. Iung B, Delgado V, Rosenhek R, Price S, Prendergast B, Wendler O, et al. \nContemporary presentation and management of valvular heart disease: the \nEURObservational research programme valvular heart disease II survey. Circulation \n2019;140:1156–69. https://doi.org/10.1161/CIRCULATIONAHA.119.041080 \n13. Gaede L, Di Bartolomeo R, van der Kley F, Elsässer A, Iung B, Möllmann H. Aortic valve \nstenosis: what do people know? A heart valve disease awareness survey of over 8,800 \npeople aged 60 or over. EuroIntervention 2016;12:883–9. https://doi.org/10.4244/ \neijy16m06_02 \n14. Lancellotti P, Magne J, Dulgheru R, Clavel MA, Donal E, Vannan MA, et al. Outcomes of \npatients with asymptomatic aortic stenosis followed up in heart valve clinics. JAMA \nCardiol 2018;3:1060–8. https://doi.org/10.1001/jamacardio.2018.3152 \n15. Lancellotti P, Rosenhek R, Pibarot P, Iung B, Otto CM, Tornos P, et al. ESC Working \nGroup on Valvular Heart Disease Position Paper—heart valve clinics: organization, \nstructure, and experiences. Eur Heart J 2013;34:1597–606. https://doi.org/10.1093/ \neurheartj/ehs443 \n16. Chambers JB, Prendergast B, Iung B, Rosenhek R, Zamorano JL, Pierard LA, et al. \nStandards defining a ‘Heart Valve Centre’: ESC Working Group on Valvular Heart \nDisease and European Association for Cardiothoracic Surgery Viewpoint. Eur Heart \nJ 2017;38:2177–83. https://doi.org/10.1093/eurheartj/ehx370 \n17. Nishimura RA, O’Gara PT, Bavaria JE, Brindis RG, Carroll JD, Kavinsky CJ, et al. 2019 \nAATS/ACC/ASE/SCAI/STS Expert Consensus Systems of Care document: a proposal \nto optimize care for patients with valvular heart disease: a joint report of the American \nAssociation for Thoracic Surgery, American College of Cardiology, American Society \nof Echocardiography, Society for Cardiovascular Angiography and Interventions, and \nSociety of Thoracic Surgeons. J Am Coll Cardiol 2019;73:2609–35. https://doi.org/10. \n1016/j.jacc.2018.10.007 \n18. Dreyfus G, Windecker S. How to shape the future of cardiology and cardiac surgery? \nEur Heart J 2020;41:3693–701. https://doi.org/10.1093/eurheartj/ehaa707 \n19. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, et al. 2021 ESC/ \nEACTS Guidelines for the management of valvular heart disease. Eur Heart J 2022;43: \n561–632. https://doi.org/10.1093/eurheartj/ehab395 \n20. Leonardi S, Capodanno D, Sousa-Uva M, Vrints C, Rex S, Guarracino F, et al. \nComposition, structure, and function of heart teams: a joint position paper of the \nACVC, EAPCI, EACTS, and EACTA focused on the management of patients with \ncomplex coronary artery disease requiring myocardial revascularization. Eur Heart J \nAcute Cardiovasc Care 2021;10:83–93. https://doi.org/10.1093/ehjacc/zuaa013 \n21. Agricola E, Ancona F, Brochet E, Donal E, Dweck M, Faletra F, et al. The structural \nheart disease interventional imager rationale, skills and training: a position paper of \nthe European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging \n2021;22:471–9. https://doi.org/10.1093/ehjci/jeab005 \n22. Hahn RT, Mahmood F, Kodali S, Lang R, Monaghan M, Gillam LD, et al. Core compe-\ntencies in echocardiography for imaging structural heart disease interventions: an ex-\npert consensus statement. JACC Cardiovasc Imaging 2019;12:2560–70. https://doi.org/ \n10.1016/j.jcmg.2019.10.008 \n23. Birkmeyer JD, Stukel TA, Siewers AE, Goodney PP, Wennberg DE, Lucas FL. Surgeon \nvolume and operative mortality in the United States. N Engl J Med 2003;349:2117–27.  \nhttps://doi.org/10.1056/NEJMsa035205 \n24. Khera R, Pandey A, Koshy T, Ayers C, Nallamothu BK, Das SR, et al. Role of hospital \nvolumes in identifying low-performing and high-performing aortic and mitral valve sur-\ngical centers in the United States. JAMA Cardiol 2017;2:1322–31. https://doi.org/10. \n1001/jamacardio.2017.4003 \n25. Gammie JS, O’Brien SM, Griffith BP, Ferguson TB, Peterson ED. Influence of hospital \nprocedural volume on care process and mortality for patients undergoing elective sur-\ngery for mitral regurgitation. Circulation 2007;115:881–7. https://doi.org/10.1161/ \nCIRCULATIONAHA.106.634436 \n26. Chikwe J, Toyoda N, Anyanwu AC, Itagaki S, Egorova NN, Boateng P, et al. Relation of \nmitral valve surgery volume to repair rate, durability, and survival. J Am Coll Cardiol \n2017;69:2397–406. https://doi.org/10.1016/j.jacc.2017.02.026 \n27. Chhatriwalla AK, Vemulapalli S, Szerlip M, Kodali S, Hahn RT, Saxon JT, et al. Operator \nexperience and outcomes of transcatheter mitral valve repair in the United States. J Am \nColl Cardiol 2019;74:2955–65. https://doi.org/10.1016/j.jacc.2019.09.014 \n28. Bonow RO, O’Gara PT, Adams DH, Badhwar V, Bavaria JE, Elmariah S, et al. 2019 \nAATS/ACC/SCAI/STS Expert Consensus Systems of Care document: operator and \ninstitutional recommendations and requirements for transcatheter mitral valve inter-\nvention: a joint report of the American Association for Thoracic Surgery, the \nAmerican College of Cardiology, the Society for Cardiovascular Angiography and \nInterventions, and The Society of Thoracic Surgeons. J Am Coll Cardiol 2020;76: \n96–117. https://doi.org/10.1016/j.jacc.2019.12.002 \n29. Grayburn PA, Mack MJ, Manandhar P, Kosinski AS, Sannino A, Smith RL 2nd, et al. \nComparison of transcatheter edge-to-edge mitral valve repair for primary mitral regur-\ngitation outcomes to hospital volumes of surgical mitral valve repair. Circ Cardiovasc Interv \n2024;17:e013581. https://doi.org/10.1161/circinterventions.123.013581 \n30. Wild MG, Stolz L, Rosch S, Rudolph F, Goebel B, Köll B, et al. Transcatheter valve re-\npair for tricuspid regurgitation: 1-year results from a large European real-world regis-\ntry. J Am Coll Cardiol 2025;85:220–31. https://doi.org/10.1016/j.jacc.2024.10.068 \n31. Carroll JD, Vemulapalli S, Dai D, Matsouaka R, Blackstone E, Edwards F, et al. \nProcedural experience for transcatheter aortic valve replacement and relation to out-\ncomes: the STS/ACC TVT registry. J Am Coll Cardiol 2017;70:29–41. https://doi.org/10. \n1016/j.jacc.2017.04.056 \n32. Mao J, Redberg RF, Carroll JD, Marinac-Dabic D, Laschinger J, Thourani V, et al. \nAssociation between hospital surgical aortic valve replacement volume and transcath-\neter aortic valve replacement outcomes. JAMA Cardiol 2018;3:1070–8. https://doi.org/ \n10.1001/jamacardio.2018.3562 \n33. Vemulapalli S, Carroll JD, Mack MJ, Li Z, Dai D, Kosinski AS, et al. Procedural volume \nand outcomes for transcatheter aortic-valve replacement. N Engl J Med 2019;380: \n2541–50. https://doi.org/10.1056/NEJMsa1901109 \n34. Edwards FH, Ferraris VA, Kurlansky PA, Lobdell KW, He X, O’Brien SM, et al. Failure \nto rescue rates after coronary artery bypass grafting: an analysis from the Society of \nThoracic Surgeons adult cardiac surgery database. Ann Thorac Surg 2016;102: \n458–64. https://doi.org/10.1016/j.athoracsur.2016.04.051 \n35. Wallen T, Habertheuer A, Bavaria JE, Hughes GC, Badhwar V, Jacobs JP, et al. Elective \naortic root replacement in North America: analysis of STS adult cardiac surgery data-\nbase. Ann Thorac Surg 2019;107:1307–12. https://doi.org/10.1016/j.athoracsur.2018. \n12.039 \n36. Geirsson A, Ahlsson A, Franco-Cereceda A, Fuglsang S, Gunn J, Hansson EC, et al. \nHospital volumes and later year of operation correlates with better outcomes in acute \nType A aortic dissection. Eur J Cardiothorac Surg 2018;53:276–81. https://doi.org/10. \n1093/ejcts/ezx231 \n37. Gonzalez AA, Dimick JB, Birkmeyer JD, Ghaferi AA. Understanding the \nvolume-outcome effect in cardiovascular surgery: the role of failure to rescue. JAMA \nSurg 2014;149:119–23. https://doi.org/10.1001/jamasurg.2013.3649 \n38. Wakeam E, Asafu-Adjei D, Ashley SW, Cooper Z, Weissman JS. The association of \nintensivists with failure-to-rescue rates in outlier hospitals: results of a national survey \nof intensive care unit organizational characteristics. J Crit Care 2014;29:930–5. https:// \ndoi.org/10.1016/j.jcrc.2014.06.010 \n39. Ward ST, Dimick JB, Zhang W, Campbell DA, Ghaferi AA. Association between hos-\npital staffing models and failure to rescue. Ann Surg 2019;270:91–4. https://doi.org/10. \n1097/sla.0000000000002744 \n40. Timmis A, Townsend N, Gale CP, Torbica A, Lettino M, Petersen SE, et al. European \nSociety of Cardiology: cardiovascular disease statistics 2019. Eur Heart J 2020;41: \n12–85. https://doi.org/10.1093/eurheartj/ehz859 \n41. Ali N, Aktaa S, Younsi T, Beska B, Batra G, Blackman DJ, et al. European Society of \nCardiology quality indicators for the care and outcomes of adults undergoing trans-\ncatheter aortic valve implantation. Eur Heart J Qual Care Clin Outcomes 2024;10: \n723–36. https://doi.org/10.1093/ehjqcco/qcae006 \n42. Messika-Zeitoun D, Baumgartner H, Burwash IG, Vahanian A, Bax J, Pibarot P, et al. \nUnmet needs in valvular heart disease. Eur Heart J 2023;44:1862–73. https://doi.org/ \n10.1093/eurheartj/ehad121  \n4712                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n43. van Dijk WB, Schuit E, van der Graaf R, Groenwold RHH, Laurijssen S, Casadei B, et al. \nApplicability of European Society of Cardiology guidelines according to gross national \nincome. Eur Heart J 2022;44:598–607. https://doi.org/10.1093/eurheartj/ehac606 \n44. Sengupta PP, Kluin J, Lee SP, Oh JK, Smits A. The future of valvular heart disease as-\nsessment and therapy. Lancet 2024;403:1590–602. https://doi.org/10.1016/s0140- \n6736(23)02754-x \n45. Lancellotti P, Pibarot P, Chambers J, La Canna G, Pepi M, Dulgheru R, et al. \nMulti-modality imaging assessment of native valvular regurgitation: an EACVI and \nESC council of valvular heart disease position paper. Eur Heart J Cardiovasc Imaging \n2022;23:e171–232. https://doi.org/10.1093/ehjci/jeab253 \n46. Zoghbi WA, Adams D, Bonow RO, Enriquez-Sarano M, Foster E, Grayburn PA, et al. \nRecommendations for noninvasive evaluation of native valvular regurgitation: a report \nfrom the American Society of Echocardiography developed in collaboration with the \nSociety for Cardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2017;30: \n303–71. https://doi.org/10.1016/j.echo.2017.01.007 \n47. Popescu BA, Andrade MJ, Badano LP, Fox KF, Flachskampf FA, Lancellotti P, et al. \nEuropean Association of Echocardiography recommendations for training, compe-\ntence, and quality improvement in echocardiography. Eur J Echocardiogr 2009;10: \n893–905. https://doi.org/10.1093/ejechocard/jep151 \n48. Chambers JB, Garbi M, Nieman K, Myerson S, Pierard LA, Habib G, et al. \nAppropriateness criteria for the use of cardiovascular imaging in heart valve disease \nin adults: a European Association of Cardiovascular Imaging report of literature review \nand current practice. Eur Heart J Cardiovasc Imaging 2017;18:489–98. https://doi.org/ \n10.1093/ehjci/jew309 \n49. Agricola E, Ancona F, Bartel T, Brochet E, Dweck M, Faletra F, et al. Multimodality im-\naging for patient selection, procedural guidance, and follow-up of transcatheter inter-\nventions for structural heart disease: a consensus document of the EACVI Task Force \non Interventional Cardiovascular Imaging: part 1: access routes, transcatheter aortic \nvalve implantation, and transcatheter mitral valve interventions. Eur Heart J \nCardiovasc Imaging 2023;24:e209–68. https://doi.org/10.1093/ehjci/jead096 \n50. Zoghbi WA, Jone PN, Chamsi-Pasha MA, Chen T, Collins KA, Desai MY, et al. \nGuidelines for the evaluation of prosthetic valve function with cardiovascular imaging: \na report from the American Society of Echocardiography developed in collaboration \nwith the Society for Cardiovascular Magnetic Resonance and the Society of \nCardiovascular Computed Tomography. J Am Soc Echocardiogr 2024;37:2–63.  \nhttps://doi.org/10.1016/j.echo.2023.10.004 \n51. Faletra FF, Agricola E, Flachskampf FA, Hahn R, Pepi M, Ajmone Marsan N, et al. \nThree-dimensional transoesophageal echocardiography: how to use and when to \nuse—a clinical consensus statement from the European Association of \nCardiovascular Imaging of the European Society of Cardiology. Eur Heart J \nCardiovasc Imaging 2023;24:e119–97. https://doi.org/10.1093/ehjci/jead090 \n52. Picano E, Pibarot P, Lancellotti P, Monin JL, Bonow RO. The emerging role of exercise \ntesting and stress echocardiography in valvular heart disease. J Am Coll Cardiol 2009;54: \n2251–60. https://doi.org/10.1016/j.jacc.2009.07.046 \n53. Genereux P, Pibarot P, Redfors B, Mack MJ, Makkar RR, Jaber WA, et al. Staging clas-\nsification of aortic stenosis based on the extent of cardiac damage. Eur Heart J 2017;38: \n3351–8. https://doi.org/10.1093/eurheartj/ehx381 \n54. Stolz L, Doldi PM, Orban M, Karam N, Puscas T, Wild MG, et al. Staging heart failure \npatients with secondary mitral regurgitation undergoing transcatheter edge-to-edge \nrepair. JACC Cardiovasc Interv 2023;16:140–51. https://doi.org/10.1016/j.jcin.2022.10. \n032 \n55. Dietz MF, Prihadi EA, van der Bijl P, Ajmone Marsan N, Delgado V, Bax JJ. Prognostic \nimplications of staging right heart failure in patients with significant secondary tricuspid \nregurgitation. JACC Heart Fail 2020;8:627–36. https://doi.org/10.1016/j.jchf.2020.02. \n008 \n56. Généreux P, Pibarot P, Redfors B, Bax JJ, Zhao Y, Makkar RR, et al. Evolution and prog-\nnostic impact of cardiac damage after aortic valve replacement. J Am Coll Cardiol 2022; \n80:783–800. https://doi.org/10.1016/j.jacc.2022.05.006 \n57. Genereux P, Cohen DJ, Pibarot P, Redfors B, Bax JJ, Zhao Y, et al. Cardiac damage and \nquality of life after aortic valve replacement in the PARTNER trials. J Am Coll Cardiol \n2023;81:743–52. https://doi.org/10.1016/j.jacc.2022.11.059 \n58. Kwak S, Everett RJ, Treibel TA, Yang S, Hwang D, Ko T, et al. Markers of myocardial \ndamage predict mortality in patients with aortic stenosis. J Am Coll Cardiol 2021;78: \n545–58. https://doi.org/10.1016/j.jacc.2021.05.047 \n59. Magne J, Cosyns B, Popescu BA, Carstensen HG, Dahl J, Desai MY, et al. Distribution \nand prognostic significance of left ventricular global longitudinal strain in asymptomatic \nsignificant aortic stenosis: an individual participant data meta-analysis. JACC Cardiovasc \nImaging 2019;12:84–92. https://doi.org/10.1016/j.jcmg.2018.11.005 \n60. Prihadi EA, van der Bijl P, Dietz M, Abou R, Vollema EM, Marsan NA, et al. Prognostic \nimplications of right ventricular free wall longitudinal strain in patients with significant \nfunctional tricuspid regurgitation. Circ Cardiovasc Imaging 2019;12:e008666. https://doi. \norg/10.1161/CIRCIMAGING.118.008666 \n61. Little SH, Rigolin VH, Garcia-Sayan E, Hahn RT, Hung J, Mackensen GB, et al. \nRecommendations for special competency in echocardiographic guidance of structural \nheart disease interventions: from the American Society of Echocardiography. J Am Soc \nEchocardiogr 2023;36:350–65. https://doi.org/10.1016/j.echo.2023.01.014 \n62. Hahn RT, Saric M, Faletra FF, Garg R, Gillam LD, Horton K, et al. Recommended stan-\ndards for the performance of transesophageal echocardiographic screening for struc-\ntural heart intervention: from the American Society of Echocardiography. J Am Soc \nEchocardiogr 2022;35:1–76. https://doi.org/10.1016/j.echo.2021.07.006 \n63. Nicoara A, Skubas N, Ad N, Finley A, Hahn RT, Mahmood F, et al. Guidelines for the \nuse of transesophageal echocardiography to assist with surgical decision-making in the \noperating room: a surgery-based approach: from the American Society of \nEchocardiography \nin \ncollaboration \nwith \nthe \nSociety \nof \nCardiovascular \nAnesthesiologists and the Society of Thoracic Surgeons. J Am Soc Echocardiogr 2020; \n33:692–734. https://doi.org/10.1016/j.echo.2020.03.002 \n64. Popescu BA, Stefanidis A, Fox KF, Cosyns B, Delgado V, Di Salvo GD, et al. Training, \ncompetence, and quality improvement in echocardiography: the European Association \nof Cardiovascular Imaging Recommendations: update 2020. Eur Heart J Cardiovasc \nImaging 2020;21:1305–19. https://doi.org/10.1093/ehjci/jeaa266 \n65. Iung B, Delgado V, Lazure P, Murray S, Sirnes PA, Rosenhek R, et al. Educational needs \nand application of guidelines in the management of patients with mitral regurgitation. A \nEuropean mixed-methods study. Eur Heart J 2018;39:1295–303. https://doi.org/10. \n1093/eurheartj/ehx763 \n66. Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. \nEuroSCORE II. Eur J Cardiothorac Surg 2012;41:734–44; discussion 744–735. https:// \ndoi.org/10.1093/ejcts/ezs043 \n67. Ad N, Holmes SD, Patel J, Pritchard G, Shuman DJ, Halpin L. Comparison of \nEuroSCORE II, original EuroSCORE, and the Society of Thoracic Surgeons Risk \nScore in Cardiac Surgery Patients. Ann Thorac Surg 2016;102:573–9. https://doi.org/ \n10.1016/j.athoracsur.2016.01.105 \n68. O’Brien SM, Shahian DM, Filardo G, Ferraris VA, Haan CK, Rich JB, et al. The Society of \nThoracic Surgeons 2008 cardiac surgery risk models: part 2—isolated valve surgery. \nAnn Thorac Surg 2009;88:S23–42. https://doi.org/10.1016/j.athoracsur.2009.05.056 \n69. Duchnowski P, Hryniewiecki T, Kuśmierczyk M, Szymanski P. Performance of the \nEuroSCORE II and the Society of Thoracic Surgeons score in patients undergoing aor-\ntic valve replacement for aortic stenosis. J Thorac Dis 2019;11:2076–81. https://doi.org/ \n10.21037/jtd.2019.04.48 \n70. Provenchere S, Chevalier A, Ghodbane W, Bouleti C, Montravers P, Longrois D, et al. \nIs the EuroSCORE II reliable to estimate operative mortality among octogenarians? \nPLoS One 2017;12:e0187056. https://doi.org/10.1371/journal.pone.0187056 \n71. Taleb Bendiab T, Brusset A, Estagnasié P, Squara P, Nguyen LS. Performance of \nEuroSCORE II and Society of Thoracic Surgeons risk scores in elderly patients under-\ngoing aortic valve replacement surgery. Arch Cardiovasc Dis 2021;114:474–81. https:// \ndoi.org/10.1016/j.acvd.2020.12.004 \n72. Roques F, Michel P, Goldstone AR, Nashef SAM. The logistic EuroSCORE. Eur Heart J \n2003;24:882–3. https://doi.org/10.1016/S0195-668X(02)00799-6 \n73. Al-Azizi K, Shih E, DiMaio JM, Squiers JJ, Moubarak G, Kluis A, et al. Assessment of TVT \nand STS risk score performances in patients undergoing transcatheter aortic valve re-\nplacement. JSCAI 2023;2:100600. https://doi.org/10.1016/j.jscai.2023.100600 \n74. Compagnone M, Moretti C, Marcelli C, Taglieri N, Ghetti G, Corsini A, et al. Surgical \nrisk scores applied to transcatheter aortic valve implantation: friends or foes? \nShort-term and long-term outcomes from a single-center registry. J Invasive Cardiol \n2019;31:E282–88. \n75. Tarantini G, Lefèvre T, Terkelsen CJ, Frerker C, Ohlmann P, Mojoli M, et al. One-year \noutcomes of a European transcatheter aortic valve implantation cohort according to \nsurgical risk. Circ Cardiovasc Interv 2019;12:e006724. https://doi.org/10.1161/ \nCIRCINTERVENTIONS.118.006724 \n76. Arnold SV, Reynolds MR, Lei Y, Magnuson EA, Kirtane AJ, Kodali SK, et al. Predictors of \npoor outcomes after transcatheter aortic valve replacement: results from the \nPARTNER (Placement of Aortic Transcatheter Valve) trial. Circulation 2014;129: \n2682–90. https://doi.org/10.1161/circulationaha.113.007477 \n77. Edwards FH, Cohen DJ, O’Brien SM, Peterson ED, Mack MJ, Shahian DM, et al. \nDevelopment and validation of a risk prediction model for in-hospital mortality after \ntranscatheter aortic valve replacement. JAMA Cardiol 2016;1:46–52. https://doi.org/10. \n1001/jamacardio.2015.0326 \n78. Iung B, Laouénan C, Himbert D, Eltchaninoff H, Chevreul K, Donzeau-Gouge P, et al. \nPredictive factors of early mortality after transcatheter aortic valve implantation: indi-\nvidual risk assessment using a simple score. Heart 2014;100:1016–23. https://doi.org/ \n10.1136/heartjnl-2013-305314 \n79. Arnold SV, Afilalo J, Spertus JA, Tang Y, Baron SJ, Jones PG, et al. Prediction of poor \noutcome after transcatheter aortic valve replacement. J Am Coll Cardiol 2016;68: \n1868–77. https://doi.org/10.1016/j.jacc.2016.07.762 \n80. Raposeiras-Roubin S, Adamo M, Freixa X, Arzamendi D, Benito-González T, \nMontefusco A, et al. A score to assess mortality after percutaneous mitral valve repair. \nJ Am Coll Cardiol 2022;79:562–73. https://doi.org/10.1016/j.jacc.2021.11.041 \n81. Shah N, Madhavan MV, Gray WA, Brener SJ, Ahmad Y, Lindenfeld J, et al. Prediction of \ndeath or HF hospitalization in patients with severe FMR: the COAPT risk score. JACC \nCardiovasc Interv 2022;15:1893–905. https://doi.org/10.1016/j.jcin.2022.08.005 \n82. Hausleiter J, Lachmann M, Stolz L, Bedogni F, Rubbio AP, Estévez-Loureiro R, et al. \nArtificial intelligence-derived risk score for mortality in secondary mitral regurgitation  \nESC Guidelines                                                                                                                                                                                          4713 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\ntreated by transcatheter edge-to-edge repair: the EuroSMR risk score. Eur Heart J \n2024;45:922–36. https://doi.org/10.1093/eurheartj/ehad871 \n83. Adamo M, Rubbio AP, Zaccone G, Pighi M, Massussi M, Tomasoni D, et al. Prediction \nof mortality and heart failure hospitalisations in patients undergoing M-TEER: external \nvalidation of the COAPT risk score. EuroIntervention 2023;18:1408–17. https://doi.org/ \n10.4244/EIJ-D-22-00992 \n84. Dreyfus J, Audureau E, Bohbot Y, Coisne A, Lavie-Badie Y, Bouchery M, et al. \nTRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricus-\npid valve surgery. Eur Heart J 2022;43:654–62. https://doi.org/10.1093/eurheartj/ \nehab679 \n85. Dreyfus J, Bohbot Y, Coisne A, Lavie-Badie Y, Flagiello M, Bazire B, et al. Predictive va-\nlue of the TRI-SCORE for in-hospital mortality after redo isolated tricuspid valve sur-\ngery. Heart 2023;109:951–8. https://doi.org/10.1136/heartjnl-2022-322167 \n86. Lantelme P, Aubry M, Peng JC, Riche B, Souteyrand G, Jaafar P, et al. Comorbidities \nmay offset expected improved survival after transcatheter aortic valve replacement. \nEur Heart J Open 2022;2:oeac029. https://doi.org/10.1093/ehjopen/oeac029 \n87. Piankova P, Afilalo J. Prevalence and prognostic implications of frailty in transcatheter aortic \nvalve replacement. Cardiol Clin 2020;38:75–87. https://doi.org/10.1016/j.ccl.2019.09.011 \n88. Kim DH, Afilalo J, Shi SM, Popma JJ, Khabbaz KR, Laham RJ, et al. Evaluation of changes \nin functional status in the year after aortic valve replacement. JAMA Intern Med 2019; \n179:383–91. https://doi.org/10.1001/jamainternmed.2018.6738 \n89. Scotti A, Coisne A, Granada JF, Driggin E, Madhavan MV, Zhou Z, et al. Impact of mal-\nnutrition in patients with heart failure and secondary mitral regurgitation: the COAPT \nTrial. J Am Coll Cardiol 2023;82:128–38. https://doi.org/10.1016/j.jacc.2023.04.047 \n89a. Pagnesi M, Adamo M, Stolz L, Pancaldi E, Kresoja KP, von Stein J, et al. Malnutrition \nand outcomes in patients with tricuspid regurgitation undergoing transcatheter \ntricuspid valve repair. Eur J Heart Fail 2025. https://doi.org/10.1002/ejhf.3623. Epub \nahead of print. PMID: 39980251. \n90. Sündermann SH, Bäck C, Bischoff-Ferrari HA, Dehbi HM, Szekely A, Völler H, et al. \nPreinterventional frailty assessment in patients scheduled for cardiac surgery or trans-\ncatheter aortic valve implantation: a consensus statement of the European Association \nfor Cardio-Thoracic Surgery (EACTS) and the European Association of Preventive \nCardiology (EAPC) of the European Society of Cardiology (ESC). Eur J Cardiothorac \nSurg 2023;64:ezad181. https://doi.org/10.1093/ejcts/ezad181 \n91. Richter D, Guasti L, Walker D, Lambrinou E, Lionis C, Abreu A, et al. Frailty in cardi-\nology: definition, assessment and clinical implications for general cardiology. A consen-\nsus document of the Council for Cardiology Practice (CCP), Association for Acute \nCardio Vascular Care (ACVC), Association of Cardiovascular Nursing and Allied \nProfessions (ACNAP), European Association of Preventive Cardiology (EAPC), \nEuropean Heart Rhythm Association (EHRA), Council on Valvular Heart Diseases \n(VHD), Council on Hypertension (CHT), Council of Cardio-Oncology (CCO), \nWorking Group (WG) Aorta and Peripheral Vascular Diseases, WG e-Cardiology, \nWG Thrombosis, of the European Society of Cardiology, European Primary Care \nCardiology Society (EPCCS). Eur J Prev Cardiol 2022;29:216–27. https://doi.org/10. \n1093/eurjpc/zwaa167 \n92. Kundi H, Popma JJ, Reynolds MR, Strom JB, Pinto DS, Valsdottir LR, et al. Frailty and \nrelated outcomes in patients undergoing transcatheter valve therapies in a nationwide \ncohort. Eur Heart J 2019;40:2231–9. https://doi.org/10.1093/eurheartj/ehz187 \n93. Brusco NK, Atkinson V, Woods J, Myles PS, Hodge A, Jones C, et al. Implementing \nPROMS for elective surgery patients: feasibility, response rate, degree of recovery \nand patient acceptability. J Patient Rep Outcomes 2022;6:73. https://doi.org/10.1186/ \ns41687-022-00483-6 \n94. Arnold SV, Spertus JA, Lei Y, Allen KB, Chhatriwalla AK, Leon MB, et al. Use of the Kansas \nCity Cardiomyopathy Questionnaire for monitoring health status in patients with aortic \nstenosis. Circ Heart Fail 2013;6:61–7. https://doi.org/10.1161/circheartfailure.112.970053 \n95. Arnold SV, Spertus JA, Gosch K, Dunlay SM, Olds DM, Jones PG, et al. Validation of the \nKansas City Cardiomyopathy Questionnaire in patients with tricuspid regurgitation. \nJAMA Cardiol 2025;10:117–25 https://doi.org/10.1001/jamacardio.2024.4266 \n96. Clavel MA, Tribouilloy C, Vanoverschelde JL, Pizarro R, Suri RM, Szymanski C, et al. \nAssociation of B-type natriuretic peptide with survival in patients with degenerative \nmitral regurgitation. J Am Coll Cardiol 2016;68:1297–307. https://doi.org/10.1016/j. \njacc.2016.06.047 \n97. Clavel MA, Malouf J, Michelena HI, Suri RM, Jaffe AS, Mahoney DW, et al. B-type natri-\nuretic peptide clinical activation in aortic stenosis: impact on long-term survival. J Am \nColl Cardiol 2014;63:2016–25. https://doi.org/10.1016/j.jacc.2014.02.581 \n98. Zhang B, Xu H, Zhang H, Liu Q, Ye Y, Hao J, et al. Prognostic value of N-terminal pro– \nB-type natriuretic peptide in elderly patients with valvular heart disease. J Am Coll \nCardiol 2020;75:1659–72. https://doi.org/10.1016/j.jacc.2020.02.031 \n99. Lindman BR, Breyley JG, Schilling JD, Vatterott AM, Zajarias A, Maniar HS, et al. \nPrognostic utility of novel biomarkers of cardiovascular stress in patients with aortic \nstenosis undergoing valve replacement. Heart 2015;101:1382–8. https://doi.org/10. \n1136/heartjnl-2015-307742 \n100. Lindman BR, Clavel MA, Abu-Alhayja’a R, Cote N, Dagenais F, Novak E, et al. \nMultimarker approach to identify patients with higher mortality and rehospitalization \nrate after surgical aortic valve replacement for aortic stenosis. JACC Cardiovasc Interv \n2018;11:2172–81. https://doi.org/10.1016/j.jcin.2018.07.039 \n101. Henri C, Piérard LA, Lancellotti P, Mongeon F-P, Pibarot P, Basmadjian AJ. Exercise \ntesting and stress imaging in valvular heart disease. Can J Cardiol 2014;30:1012–26.  \nhttps://doi.org/10.1016/j.cjca.2014.03.013 \n102. Das P, Rimington H, Chambers J. Exercise testing to stratify risk in aortic stenosis. Eur \nHeart J 2005;26:1309–13. https://doi.org/10.1093/eurheartj/ehi250 \n103. Redfors B, Pibarot P, Gillam LD, Burkhoff D, Bax JJ, Lindman BR, et al. Stress testing in \nasymptomatic aortic stenosis. Circulation 2017;135:1956–76. https://doi.org/10.1161/ \nCIRCULATIONAHA.116.025457 \n104. Lund O, Nielsen TT, Emmertsen K, Flø C, Rasmussen B, Jensen FT, et al. Mortality and \nworsening of prognostic profile during waiting time for valve replacement in aortic \nstenosis. Thorac Cardiovasc Surg 1996;44:289–95. https://doi.org/10.1055/s-2007- \n1012039 \n105. Guazzi M, Arena R, Halle M, Piepoli MF, Myers J, Lavie CJ. 2016 focused update: clinical \nrecommendations for cardiopulmonary exercise testing data assessment in specific pa-\ntient populations. Eur Heart J 2018;39:1144–61. https://doi.org/10.1093/eurheartj/ \nehw180 \n106. Hoedemakers S, Pugliese NR, Stassen J, Vanoppen A, Claessens J, Gojevic T, et al. \nmPAP/CO slope and oxygen uptake add prognostic value in aortic stenosis. \nCirculation \n2024;149:1172–82. \nhttps://doi.org/10.1161/CIRCULATIONAHA.123. \n067130 \n107. Lancellotti P, Dulgheru R, Go YY, Sugimoto T, Marchetta S, Oury C, et al. Stress echo-\ncardiography in patients with native valvular heart disease. Heart 2018;104:807–13.  \nhttps://doi.org/10.1136/heartjnl-2017-311682 \n108. Gentry JL III, Phelan D, Desai MY, Griffin BP. The role of stress echocardiography in \nvalvular heart disease: a current appraisal. Cardiology 2017;137:137–50. https://doi. \norg/10.1159/000460274 \n109. Lancellotti P, Magne J. Stress echocardiography in regurgitant valve disease. Circ \nCardiovasc Imaging 2013;6:840–9. https://doi.org/10.1161/CIRCIMAGING.113.000474 \n110. Lancellotti P, Magne J, Donal E, O’Connor K, Dulgheru R, Rosca M, et al. Determinants \nand prognostic significance of exercise pulmonary hypertension in asymptomatic se-\nvere \naortic \nstenosis. \nCirculation \n2012;126:851–9. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.111.088427 \n111. Coisne A, Aghezzaf S, Galli E, Mouton S, Richardson M, Dubois D, et al. Prognostic va-\nlues of exercise echocardiography and cardiopulmonary exercise testing in patients \nwith primary mitral regurgitation. Eur Heart J Cardiovasc Imaging 2022;23:1552–61.  \nhttps://doi.org/10.1093/ehjci/jeab231 \n112. Saeed S, Rajani R, Seifert R, Parkin D, Chambers JB. Exercise testing in patients with \nasymptomatic moderate or severe aortic stenosis. Heart 2018;104:1836–42. https:// \ndoi.org/10.1136/heartjnl-2018-312939 \n113. Saeed S, Chambers JB. Exercise testing in aortic stenosis: safety, tolerability, clinical \nbenefits and prognostic value. J Clin Med 2022;11:4983. https://doi.org/10.3390/ \njcm11174983 \n114. Scarsini R, Pesarini G, Zivelonghi C, Piccoli A, Ferrero V, Lunardi M, et al. Physiologic \nevaluation of coronary lesions using instantaneous wave-free ratio (iFR) in patients \nwith severe aortic stenosis undergoing transcatheter aortic valve implantation. \nEuroIntervention 2018;13:1512–9. https://doi.org/10.4244/EIJ-D-17-00542 \n115. Pesarini G, Scarsini R, Zivelonghi C, Piccoli A, Gambaro A, Gottin L, et al. Functional \nassessment of coronary artery disease in patients undergoing transcatheter aortic \nvalve implantation: influence of pressure overload on the evaluation of lesions severity. \nCirc Cardiovasc Interv 2016;9:e004088. https://doi.org/10.1161/circinterventions.116. \n004088 \n116. Ahmad Y, Götberg M, Cook C, Howard JP, Malik I, Mikhail G, et al. Coronary hemo-\ndynamics in patients with severe aortic stenosis and coronary artery disease undergo-\ning transcatheter aortic valve replacement: implications for clinical indices of coronary \nstenosis severity. JACC Cardiovasc Interv 2018;11:2019–31. https://doi.org/10.1016/j. \njcin.2018.07.019 \n117. Ardehali A, Segal J, Cheitlin MD. Coronary blood flow reserve in acute aortic regurgi-\ntation. \nJ \nAm \nColl \nCardiol \n1995;25:1387–92. \nhttps://doi.org/10.1016/0735- \n1097(95)00018-Y \n118. Akasaka T, Yoshida K, Hozumi T, Takagi T, Kaji S, Kawamoto T, et al. Restricted cor-\nonary flow reserve in patients with mitral regurgitation improves after mitral recon-\nstructive surgery. J Am Coll Cardiol 1998;32:1923–30. https://doi.org/10.1016/S0735- \n1097(98)00490-2 \n119. D’Alto M, Dimopoulos K, Coghlan JG, Kovacs G, Rosenkranz S, Naeije R. Right heart \ncatheterization for the diagnosis of pulmonary hypertension: controversies and prac-\ntical issues. Heart Fail Clin 2018;14:467–77. https://doi.org/10.1016/j.hfc.2018.03.011 \n120. Lindman BR, Arnold SV, Bagur R, Clarke L, Coylewright M, Evans F, et al. Priorities for \npatient-centered research in valvular heart disease: a report from the National Heart, \nLung, and Blood Institute Working Group. J Am Heart Assoc 2020;9:e015975. https:// \ndoi.org/10.1161/JAHA.119.015975 \n121. Dharmarajan K, Foster J, Coylewright M, Green P, Vavalle JP, Faheem O, et al. The \nmedically managed patient with severe symptomatic aortic stenosis in the TAVR \nera: patient characteristics, reasons for medical management, and quality of shared de-\ncision making at heart valve treatment centers. PLoS One 2017;12:e0175926. https:// \ndoi.org/10.1371/journal.pone.0175926  \n4714                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n122. Ren X, Liu K, Zhang H, Meng Y, Li H, Sun X, et al. Coronary evaluation before heart \nvalvular surgery by using coronary computed tomographic angiography versus invasive \ncoronary angiography. J Am Heart Assoc 2021;10:e019531. https://doi.org/10.1161/ \njaha.120.019531 \n123. Opolski MP, Staruch AD, Jakubczyk M, Min James K, Gransar H, Staruch M, et al. CT \nangiography for the detection of coronary artery stenoses in patients referred for car-\ndiac valve surgery. JACC Cardiovasc Imaging 2016;9:1059–70. https://doi.org/10.1016/j. \njcmg.2015.09.028 \n124. Meijboom Willem B, Mollet Nico R, Van Mieghem Carlos AG, Kluin J, Weustink Annick \nC, Pugliese F, et al. Pre-operative computed tomography coronary angiography to de-\ntect significant coronary artery disease in patients referred for cardiac valve surgery. J \nAm Coll Cardiol 2006;48:1658–65. https://doi.org/10.1016/j.jacc.2006.06.054 \n125. Gatti M, Gallone G, Poggi V, Bruno F, Serafini A, Depaoli A, et al. Diagnostic accuracy of \ncoronary computed tomography angiography for the evaluation of obstructive coron-\nary artery disease in patients referred for transcatheter aortic valve implantation: a sys-\ntematic review and meta-analysis. Eur Radiol 2022;32:5189–200. https://doi.org/10. \n1007/s00330-022-08603-y \n126. Diller GP, Gerwing M, Boroni Grazioli S, De-Torres-Alba F, Radke RM, Vormbrock J, \net al. Utility of coronary computed tomography angiography in patients undergoing \ntranscatheter aortic valve implantation: a meta-analysis and meta-regression based \non published data from 7458 patients. J Clin Med 2024;13:631. https://doi.org/10. \n3390/jcm13020631 \n127. Kondoleon NP, Layoun H, Spilias N, Sipko J, Kanaan C, Harb S, et al. Effectiveness of \npre-TAVR CTA as a screening tool for significant CAD before TAVR. JACC Cardiovasc \nInterv 2023;16:1990–2000. https://doi.org/10.1016/j.jcin.2023.05.030 \n128. Malebranche D, Hoffner MKM, Huber AT, Cicovic A, Spano G, Bernhard B, et al. \nDiagnostic performance of quantitative coronary artery disease assessment using \ncomputed tomography in patients with aortic stenosis undergoing transcatheter \naortic-valve implantation. BMC Cardiovasc Disord 2022;22:178. https://doi.org/10. \n1186/s12872-022-02623-8 \n129. Chieffo A, Giustino G, Spagnolo P, Panoulas VF, Montorfano M, Latib A, et al. Routine \nscreening of coronary artery disease with computed tomographic coronary angiog-\nraphy in place of invasive coronary angiography in patients undergoing transcatheter \naortic valve replacement. Circ Cardiovasc Interv 2015;8:e002025. https://doi.org/10. \n1161/circinterventions.114.002025 \n130. Patel KP, Michail M, Treibel TA, Rathod K, Jones DA, Ozkor M, et al. Coronary revas-\ncularization in patients undergoing aortic valve replacement for severe aortic stenosis. \nJACC Cardiovasc Interv 2021;14:2083–96. https://doi.org/10.1016/j.jcin.2021.07.058 \n131. Miyagawa S, Masai T, Fukuda H, Yamauchi T, Iwakura K, Itoh H, et al. Coronary micro-\ncirculatory dysfunction in aortic stenosis: myocardial contrast echocardiography study. \nAnn Thorac Surg 2009;87:715–9. https://doi.org/10.1016/j.athoracsur.2008.11.078 \n132. Beach JM, Mihaljevic T, Svensson LG, Rajeswaran J, Marwick T, Griffin B, et al. Coronary \nartery disease and outcomes of aortic valve replacement for severe aortic stenosis. J \nAm Coll Cardiol 2013;61:837–48. https://doi.org/10.1016/j.jacc.2012.10.049 \n133. Thalji NM, Suri RM, Daly RC, Greason KL, Dearani JA, Stulak JM, et al. The prognostic \nimpact of concomitant coronary artery bypass grafting during aortic valve surgery: im-\nplications for revascularization in the transcatheter era. J Thorac Cardiovasc Surg 2015; \n149:451–60. https://doi.org/10.1016/j.jtcvs.2014.08.073 \n134. Lønborg J, Jabbari R, Sabbah M, Veien KT, Niemelä M, Freeman P, et al. PCI in patients \nundergoing transcatheter aortic-valve implantation. N Engl J Med 2024;391:2189–200.  \nhttps://doi.org/10.1056/NEJMoa2401513 \n135. Patterson T, Clayton T, Dodd M, Khawaja Z, Morice MC, Wilson K, et al. \nACTIVATION (PercutAneous Coronary inTervention prIor to transcatheter aortic \nVAlve implantaTION): a randomized clinical trial. JACC Cardiovasc Interv 2021;14: \n1965–74. https://doi.org/10.1016/j.jcin.2021.06.041 \n136. Okuno T, Demirel C, Tomii D, Heg D, Häner J, Siontis GCM, et al. Long-term risk of \nunplanned percutaneous coronary intervention after transcatheter aortic valve re-\nplacement. EuroIntervention 2022;18:797–803. https://doi.org/10.4244/eij-d-22-00342 \n137. Persits I, Layoun H, Kondoleon NP, Spilias N, Badwan O, Sipko J, et al. Impact of un-\ntreated chronic obstructive coronary artery disease on outcomes after transcatheter \naortic valve replacement. Eur Heart J 2024;45:1890–900. https://doi.org/10.1093/ \neurheartj/ehae019 \n138. Ogami T, Kliner DE, Toma C, Sanon S, Smith AJC, Serna-Gallegos D, et al. Acute cor-\nonary syndrome after transcatheter aortic valve implantation (results from over \n40,000 patients). Am J Cardiol 2023;193:126–32. https://doi.org/10.1016/j.amjcard. \n2023.02.003 \n139. Mentias A, Desai MY, Saad M, Horwitz PA, Rossen JD, Panaich S, et al. Incidence and \noutcomes of acute coronary syndrome after transcatheter aortic valve replacement. \nJACC Cardiovasc Interv 2020;13:938–50. https://doi.org/10.1016/j.jcin.2019.11.027 \n140. Yassen M, Moustafa A, Venkataramany B, Schodowski E, Royfman R, Eltahawy E. \nClinical outcomes of transcatheter aortic valve replacement with and without percu-\ntaneous coronary intervention—an updated meta-analysis and systematic review. Curr \nProbl Cardiol 2023;48:101980. https://doi.org/10.1016/j.cpcardiol.2023.101980 \n141. Altibi AM, Ghanem F, Hammad F, Patel J, Song HK, Golwala H, et al. Clinical outcomes \nof revascularization with percutaneous coronary intervention prior to transcatheter \naortic valve replacement: a comprehensive meta-analysis. Curr Probl Cardiol 2022;47: \n101339. https://doi.org/10.1016/j.cpcardiol.2022.101339 \n142. Tomii D, Pilgrim T, Borger MA, De Backer O, Lanz J, Reineke D, et al. Aortic stenosis \nand coronary artery disease: decision-making between surgical and transcatheter man-\nagement. Circulation 2024;150:2046–69. https://doi.org/10.1161/circulationaha.124. \n070502 \n143. Tarantini G, Tang G, Nai Fovino L, Blackman D, Van Mieghem NM, Kim WK, et al. \nManagement of coronary artery disease in patients undergoing transcatheter aortic \nvalve implantation. A clinical consensus statement from the European Association of \nPercutaneous Cardiovascular Interventions in collaboration with the ESC Working \nGroup on Cardiovascular Surgery. EuroIntervention 2023;19:37–52. https://doi.org/ \n10.4244/eij-d-22-00958 \n144. Barbanti M, Costa G, Picci A, Criscione E, Reddavid C, Valvo R, et al. Coronary cannu-\nlation after transcatheter aortic valve replacement: the RE-ACCESS study. JACC \nCardiovasc Interv 2020;13:2542–55. https://doi.org/10.1016/j.jcin.2020.07.006 \n145. Costa G, Sammartino S, Strazzieri O, Motta S, Frittitta V, Dipietro E, et al. Coronary \ncannulation following TAVR using self-expanding devices with commissural alignment: \nthe RE-ACCESS 2 study. JACC Cardiovasc Interv 2024;17:727–37. https://doi.org/10. \n1016/j.jcin.2023.12.015 \n146. Tang GHL, Amat-Santos IJ, Backer OD, Avvedimento M, Redondo A, Barbanti M, et al. \nRationale, definitions, techniques, and outcomes of commissural alignment in TAVR. \nJACC Cardiovasc Interv 2022;15:1497–518. https://doi.org/10.1016/j.jcin.2022.06.001 \n147. Campwala SZ, Bansal RC, Wang N, Razzouk A, Pai RG. Factors affecting regression of \nmitral regurgitation following isolated coronary artery bypass surgery. Eur J \nCardiothorac Surg 2005;28:783–7. https://doi.org/10.1016/j.ejcts.2005.10.010 \n148. Castleberry AW, Williams JB, Daneshmand MA, Honeycutt E, Shaw LK, Samad Z, et al. \nSurgical revascularization is associated with maximal survival in patients with ischemic \nmitral regurgitation: a 20-year experience. Circulation 2014;129:2547–56. https://doi. \norg/10.1161/CIRCULATIONAHA.113.005223 \n149. Samad Z, Shaw LK, Phelan M, Ersboll M, Risum N, Al-Khalidi HR, et al. Management and \noutcomes in patients with moderate or severe functional mitral regurgitation and se-\nvere left ventricular dysfunction. Eur Heart J 2015;36:2733–41. https://doi.org/10.1093/ \neurheartj/ehv343 \n150. Yousefzai R, Bajaj N, Krishnaswamy A, Goel SS, Agarwal S, Aksoy O, et al. Outcomes of \npatients with ischemic mitral regurgitation undergoing percutaneous coronary inter-\nvention. Am J Cardiol 2014;114:1011–7. https://doi.org/10.1016/j.amjcard.2014.07.012 \n151. Byrne RA, Rossello X, Coughlan JJ, Barbato E, Berry C, Chieffo A, et al. 2023 ESC \nGuidelines for the management of acute coronary syndromes. Eur Heart J 2023;44: \n3720–826. https://doi.org/10.1093/eurheartj/ehad191 \n152. Thomas KL, Jackson LR 2nd, Shrader P, Ansell J, Fonarow GC, Gersh B, et al. \nPrevalence, characteristics, and outcomes of valvular heart disease in patients with at-\nrial fibrillation: insights from the ORBIT-AF (outcomes registry for better informed \ntreatment for atrial fibrillation). J Am Heart Assoc 2017;6:e006475. https://doi.org/10. \n1161/jaha.117.006475 \n153. Naser JA, Castrichini M, Ibrahim HH, Scott CG, Lin G, Lee E, et al. Secondary tricuspid \nregurgitation: incidence, types, and outcomes in atrial fibrillation vs. sinus rhythm. Eur \nHeart J 2024;45:2878–90. https://doi.org/10.1093/eurheartj/ehae346 \n154. Naser JA, Pislaru C, Roslan A, Ciobanu AO, Jouni H, Nkomo VT, et al. Unfavorable \ntricuspid annulus dynamics: a novel concept to explain development of tricuspid regur-\ngitation in atrial fibrillation. J Am Soc Echocardiogr 2022;35:664–6. https://doi.org/10. \n1016/j.echo.2022.02.009 \n155. Vinereanu D, Wang A, Mulder H, Lopes RD, Jansky P, Lewis BS, et al. Outcomes in \nanticoagulated patients with atrial fibrillation and with mitral or aortic valve disease. \nHeart 2018;104:1292–9. https://doi.org/10.1136/heartjnl-2017-312272 \n156. Avezum A, Lopes RD, Schulte PJ, Lanas F, Gersh BJ, Hanna M, et al. Apixaban in com-\nparison with warfarin in patients with atrial fibrillation and valvular heart disease: find-\nings from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in \nAtrial Fibrillation (ARISTOTLE) trial. Circulation 2015;132:624–32. https://doi.org/10. \n1161/CIRCULATIONAHA.114.014807 \n157. Ezekowitz MD, Nagarakanti R, Noack H, Brueckmann M, Litherland C, Jacobs M, et al. \nComparison of dabigatran and warfarin in patients with atrial fibrillation and valvular \nheart disease: the RE-LY trial (randomized evaluation of long-term anticoagulant ther-\napy). Circulation 2016;134:589–98. https://doi.org/10.1161/CIRCULATIONAHA.115. \n020950 \n158. De Caterina R, Renda G, Carnicelli AP, Nordio F, Trevisan M, Mercuri MF, et al. \nValvular heart disease patients on edoxaban or warfarin in the ENGAGE AF-TIMI \n48 trial. J Am Coll Cardiol 2017;69:1372–82. https://doi.org/10.1016/j.jacc.2016.12.031 \n159. Breithardt G, Baumgartner H, Berkowitz SD, Hellkamp AS, Piccini JP, Stevens SR, et al. \nClinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with \nnon-valvular atrial fibrillation but underlying native mitral and aortic valve disease par-\nticipating in the ROCKET AF trial. Eur Heart J 2014;35:3377–85. https://doi.org/10. \n1093/eurheartj/ehu305 \n160. Whitlock RP, Belley-Cote EP, Paparella D, Healey JS, Brady K, Sharma M, et al. Left at-\nrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med 2021; \n384:2081–91. https://doi.org/10.1056/NEJMoa2101897  \nESC Guidelines                                                                                                                                                                                          4715 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n161. Martín Gutiérrez E, Castaño M, Gualis J, Martinez-Comendador JM, Maiorano P, \nCastillo L, et al. Beneficial effect of left atrial appendage closure during cardiac surgery: \na meta-analysis of 280 585 patients. Eur J Cardiothorac Surg 2020;57:252–62. https://doi. \norg/10.1093/ejcts/ezz289 \n162. Connolly SJ, Healey JS, Belley-Cote EP, Balasubramanian K, Paparella D, Brady K, et al. \nOral anticoagulation use and left atrial appendage occlusion in LAAOS III. Circulation \n2023;148:1298–304. https://doi.org/10.1161/CIRCULATIONAHA.122.060315 \n163. Kapadia SR, Krishnaswamy A, Whisenant B, Potluri S, Iyer V, Aragon J, et al. \nConcomitant left atrial appendage occlusion and transcatheter aortic valve replace-\nment among patients with atrial fibrillation. Circulation 2024;149:734–43. https://doi. \norg/10.1161/circulationaha.123.067312 \n164. Dawwas GK, Dietrich E, Cuker A, Barnes GD, Leonard CE, Lewis JD. Effectiveness and \nsafety of direct oral anticoagulants versus warfarin in patients with valvular atrial fibril-\nlation: a population-based cohort study. Ann Intern Med 2021;174:910–9. https://doi. \norg/10.7326/m20-6194 \n165. Connolly SJ, Karthikeyan G, Ntsekhe M, Haileamlak A, El Sayed A, El Ghamrawy A, \net al. Rivaroxaban in rheumatic heart disease-associated atrial fibrillation. N Engl J \nMed 2022;387:978–88. https://doi.org/10.1056/NEJMoa2209051 \n166. Rankin JS, Grau-Sepulveda MV, Ad N, Damiano RJ Jr, Gillinov AM, Brennan JM, et al. \nAssociations between surgical ablation and operative mortality after mitral valve pro-\ncedures. Ann Thorac Surg 2018;105:1790–6. https://doi.org/10.1016/j.athoracsur.2017. \n12.035 \n167. Badhwar V, Rankin JS, Ad N, Grau-Sepulveda M, Damiano RJ, Gillinov AM, et al. \nSurgical ablation of atrial fibrillation in the United States: trends and propensity \nmatched outcomes. Ann Thorac Surg 2017;104:493–500. https://doi.org/10.1016/j. \nathoracsur.2017.05.016 \n168. Gillinov AM, Gelijns AC, Parides MK, DeRose JJ Jr, Moskowitz AJ, Voisine P, et al. \nSurgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med 2015; \n372:1399–409. https://doi.org/10.1056/NEJMoa1500528 \n169. Huffman MD, Karmali KN, Berendsen MA, Andrei AC, Kruse J, McCarthy PM, et al. \nConcomitant atrial fibrillation surgery for people undergoing cardiac surgery. \nCochrane Database Syst Rev 2016;2016:CD011814. https://doi.org/10.1002/ \n14651858.CD011814.pub2 \n170. Wang H, Han J, Wang Z, Yin Z, Liu Z, Jin Y, et al. A prospective randomized trial of the \ncut-and-sew Maze procedure in patients undergoing surgery for rheumatic mitral valve \ndisease. J Thorac Cardiovasc Surg 2018;155:608–17. https://doi.org/10.1016/j.jtcvs.2017. \n07.084 \n171. Lawrance CP, Henn MC, Miller JR, Sinn LA, Schuessler RB, Maniar HS, et al. A minimally \ninvasive Cox maze IV procedure is as effective as sternotomy while decreasing major \nmorbidity and hospital stay. J Thorac Cardiovasc Surg 2014;148:955–61; discussion \n962–952. https://doi.org/10.1016/j.jtcvs.2014.05.064 \n172. Cheng DC, Ad N, Martin J, Berglin EE, Chang BC, Doukas G, et al. Surgical ablation for \natrial fibrillation in cardiac surgery: a meta-analysis and systematic review. Innovations \n(Phila) 2010;5:84–96. https://doi.org/10.1097/IMI.0b013e3181d9199b \n173. McClure GR, Belley-Cote EP, Jaffer IH, Dvirnik N, An KR, Fortin G, et al. Surgical ab-\nlation of atrial fibrillation: a systematic review and meta-analysis of randomized con-\ntrolled trials. Europace 2018;20:1442–50. https://doi.org/10.1093/europace/eux336 \n174. Yoo JS, Kim JB, Ro SK, Jung Y, Jung SH, Choo SJ, et al. Impact of concomitant surgical \natrial fibrillation ablation in patients undergoing aortic valve replacement. Circ J 2014; \n78:1364–71. https://doi.org/10.1253/circj.cj-13-1533 \n175. Malaisrie SC, Lee R, Kruse J, Lapin B, Wang EC, Bonow RO, et al. Atrial fibrillation ab-\nlation in patients undergoing aortic valve replacement. J Heart Valve Dis 2012;21: \n350–7. \n176. Gujral DM, Lloyd G, Bhattacharyya S. Radiation-induced valvular heart disease. Heart \n2016;102:269–76. https://doi.org/10.1136/heartjnl-2015-308765 \n177. Lee C, Hahn RT. Valvular heart disease associated with radiation therapy: a contem-\nporary review. Struct Heart 2023;7:100104. https://doi.org/10.1016/j.shj.2022.100104 \n178. Lancellotti P, Nkomo VT, Badano LP, Bergler-Klein J, Bogaert J, Davin L, et al. Expert \nconsensus for multi-modality imaging evaluation of cardiovascular complications of \nradiotherapy in adults: a report from the European Association of Cardiovascular \nImaging and the American Society of Echocardiography. J Am Soc Echocardiogr 2013; \n26:1013–32. https://doi.org/10.1016/j.echo.2013.07.005 \n179. Wu W, Masri A, Popovic ZB, Smedira NG, Lytle BW, Marwick TH, et al. Long-term \nsurvival of patients with radiation heart disease undergoing cardiac surgery: a cohort \nstudy. Circulation 2013;127:1476–85. https://doi.org/10.1161/CIRCULATIONAHA. \n113.001435 \n180. Donnellan E, Masri A, Johnston DR, Pettersson GB, Rodriguez LL, Popovic ZB, et al. \nLong-term outcomes of patients with mediastinal radiation-associated severe aortic \nstenosis and subsequent surgical aortic valve replacement: a matched cohort study. J \nAm Heart Assoc 2017;6:e005396. https://doi.org/10.1161/JAHA.116.005396 \n181. Donnellan E, Alashi A, Johnston DR, Gillinov AM, Pettersson GB, Svensson LG, et al. \nOutcomes of patients with mediastinal radiation-associated mitral valve disease under-\ngoing cardiac surgery. Circulation 2019;140:1288–90. https://doi.org/10.1161/ \nCIRCULATIONAHA.119.040546 \n182. Lyon AR, López-Fernández T, Couch LS, Asteggiano R, Aznar MC, Bergler-Klein J, et al. \n2022 ESC Guidelines on cardio-oncology developed in collaboration with the \nEuropean Hematology Association (EHA), the European Society for Therapeutic \nRadiology and Oncology (ESTRO) and the International Cardio-Oncology Society \n(IC-OS). Eur Heart J 2022;43:4229–361. https://doi.org/10.1093/eurheartj/ehac244 \n183. Yazdchi F, Hirji SA, Nohria A, Percy E, Harloff M, Malarczyk A, et al. Transcatheter \ncompared with surgical aortic valve replacement in patients with previous chest- \ndirected radiation therapy. JACC CardioOncol 2021;3:397–407. https://doi.org/10. \n1016/j.jaccao.2021.07.005 \n184. Zafar MR, Mustafa SF, Miller TW, Alkhawlani T, Sharma UC. Outcomes after trans-\ncatheter aortic valve replacement in cancer survivors with prior chest radiation ther-\napy: a systematic review and meta-analysis. Cardiooncology 2020;6:8. https://doi.org/10. \n1186/s40959-020-00062-y \n185. Ullah W, Thalambedu N, Zahid S, Muhammadzai Hamza Zahid U, Sandhyavenu H, \nKumar A, et al. Trends and outcomes of TAVI and SAVR in cancer and noncancer pa-\ntients. JACC Adv 2023;2:100167. https://doi.org/10.1016/j.jacadv.2022.100167 \n186. Lind A, Totzeck M, Mahabadi AA, Janosi RA, El Gabry M, Ruhparwar A, et al. Impact of \ncancer in patients undergoing transcatheter aortic valve replacement: a single-center \nstudy. JACC CardioOncol 2020;2:735–43. https://doi.org/10.1016/j.jaccao.2020.11.008 \n187. Yadgir S, Johnson CO, Aboyans V, Adebayo OM, Adedoyin RA, Afarideh M, et al. \nGlobal, regional, and national burden of calcific aortic valve and degenerative mitral \nvalve diseases, 1990–2017. Circulation 2020;141:1670–80. https://doi.org/10.1161/ \nCIRCULATIONAHA.119.043391 \n188. Rwebembera J, Marangou J, Mwita JC, Mocumbi AO, Mota C, Okello E, et al. 2023 \nWorld Heart Federation guidelines for the echocardiographic diagnosis of rheumatic \nheart disease. Nat Rev Cardiol 2023;21:250–63. https://doi.org/10.1038/s41569-023- \n00940-9 \n189. Karki P, Uranw S, Bastola S, Mahato R, Shrestha NR, Sherpa K, et al. Effectiveness of \nsystematic echocardiographic screening for rheumatic heart disease in Nepalese \nschoolchildren: a cluster randomized clinical trial. JAMA Cardiol 2021;6:420–26.  \nhttps://doi.org/10.1001/jamacardio.2020.7050 \n190. Beaton A, Okello E, Rwebembera J, Grobler A, Engelman D, Alepere J, et al. Secondary \nantibiotic prophylaxis for latent rheumatic heart disease. N Engl J Med 2022;386: \n230–40. https://doi.org/10.1056/NEJMoa2102074 \n191. Kumar RK, Antunes MJ, Beaton A, Mirabel M, Nkomo VT, Okello E, et al. \nContemporary diagnosis and management of rheumatic heart disease: implications \nfor closing the gap: a scientific statement from the American Heart Association. \nCirculation 2020;142:e337–57. https://doi.org/10.1161/cir.0000000000000921 \n192. World Health Organization. WHO Guideline on the Prevention and Diagnosis of \nRheumatic Fever and Rheumatic Heart Disease. https://www.who.int/publications/i/ \nitem/9789240100077 (28 March 2025, date last accessed). \n193. Chioncel O, Adamo M, Nikolaou M, Parissis J, Mebazaa A, Yilmaz MB, et al. Acute heart \nfailure and valvular heart disease: a scientific statement of the Heart Failure \nAssociation, the Association for Acute CardioVascular Care and the European \nAssociation of Percutaneous Cardiovascular Interventions of the European Society \nof Cardiology. Eur J Heart Fail 2023;25:1025–48. https://doi.org/10.1002/ejhf.2918 \n194. Lüsebrink E, Lanz H, Kellnar A, Karam N, Kapadia S, Makkar R, et al. (December 11, \n2024) Management of acute decompensated valvular heart disease. Eur J Heart Fail,  \nhttps://doi.org/10.1002/ejhf.3549 \n195. Kolte D, Khera S, Vemulapalli S, Dai D, Heo S, Goldsweig AM, et al. Outcomes follow-\ning urgent/emergent transcatheter aortic valve replacement: insights from the STS/ \nACC TVT registry. JACC Cardiovasc Interv 2018;11:1175–85. https://doi.org/10.1016/ \nj.jcin.2018.03.002 \n196. Elbadawi A, Elgendy IY, Mentias A, Saad M, Mohamed AH, Choudhry MW, et al. \nOutcomes of urgent versus nonurgent transcatheter aortic valve replacement. \nCatheter Cardiovasc Interv 2020;96:189–95. https://doi.org/10.1002/ccd.28563 \n197. Masha L, Vemulapalli S, Manandhar P, Balan P, Shah P, Kosinski AS, et al. Demographics, \nprocedural characteristics, and clinical outcomes when cardiogenic shock precedes \nTAVR in the United States. JACC Cardiovasc Interv 2020;13:1314–25. https://doi.org/ \n10.1016/j.jcin.2020.02.033 \n198. Goel K, Shah P, Jones BM, Korngold E, Bhardwaj A, Kar B, et al. Outcomes of trans-\ncatheter aortic valve replacement in patients with cardiogenic shock. Eur Heart J \n2023;44:3181–95. https://doi.org/10.1093/eurheartj/ehad387 \n199. Buchwald AB, Meyer T, Scholz K, Schorn B, Unterberg C. Efficacy of balloon valvulo-\nplasty in patients with critical aortic stenosis and cardiogenic shock—the role of shock \nduration. Clin Cardiol 2001;24:214–8. https://doi.org/10.1002/clc.4960240308 \n200. Moreno PR, Jang IK, Newell JB, Block PC, Palacios IF. The role of percutaneous aortic \nballoon valvuloplasty in patients with cardiogenic shock and critical aortic stenosis. J Am \nColl Cardiol 1994;23:1071–5. https://doi.org/10.1016/0735-1097(94)90592-4 \n201. Llah ST, Sharif S, Ullah S, Sheikh SA, Shah MA, Shafi OM, et al. TAVR vs balloon aortic \nvalvotomy for severe aortic stenosis and cardiogenic shock: an insight from the nation-\nal inpatient sample database. Cardiovasc Revasc Med 2023;55:1–7. https://doi.org/10. \n1016/j.carrev.2023.05.006 \n202. Tang GHL, Estevez-Loureiro R, Yu Y, Prillinger JB, Zaid S, Psotka MA. Survival following \nedge-to-edge transcatheter mitral valve repair in patients with cardiogenic shock: a na-\ntionwide analysis. J Am Heart Assoc 2021;10:e019882. https://doi.org/10.1161/jaha.120. \n019882  \n4716                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n203. Haberman D, Estevez-Loureiro R, Benito-Gonzalez T, Denti P, Arzamendi D, Adamo \nM, et al. Conservative, surgical, and percutaneous treatment for mitral regurgitation \nshortly after acute myocardial infarction. Eur Heart J 2021;43:641–50. https://doi. \norg/10.1093/eurheartj/ehab496 \n204. Hill L, Prager Geller T, Baruah R, Beattie JM, Boyne J, de Stoutz N, et al. Integration of a \npalliative approach into heart failure care: a European Society of Cardiology Heart \nFailure Association position paper. Eur J Heart Fail 2020;22:2327–39. https://doi.org/ \n10.1002/ejhf.1994 \n205. Kyriakou M, Middleton N, Ktisti S, Philippou K, Lambrinou E. Supportive care interven-\ntions to promote health-related quality of life in patients living with heart failure: a sys-\ntematic review and meta-analysis. Heart Lung Circ 2020;29:1633–47. https://doi.org/10. \n1016/j.hlc.2020.04.019 \n206. Fendler TJ, Swetz KM, Allen LA. Team-based palliative and end-of-life care for heart \nfailure. Heart Fail Clin 2015;11:479–98. https://doi.org/10.1016/j.hfc.2015.03.010 \n207. Brännström M, Boman K. Effects of person-centred and integrated chronic heart fail-\nure and palliative home care. PREFER: a randomized controlled study. Eur J Heart Fail \n2014;16:1142–51. https://doi.org/10.1002/ejhf.151 \n208. Singh JP, Evans JC, Levy D, Larson MG, Freed LA, Fuller DL, et al. Prevalence and clinical \ndeterminants of mitral, tricuspid, and aortic regurgitation (the Framingham Heart \nStudy). Am J Cardiol 1999;83:897–902. https://doi.org/10.1016/s0002-9149(98) \n01064-9 \n209. Lee JKT, Franzone A, Lanz J, Siontis GCM, Stortecky S, Gräni C, et al. Early detection of \nsubclinical myocardial damage in chronic aortic regurgitation and strategies for timely \ntreatment of asymptomatic patients. Circulation 2018;137:184–96. https://doi.org/10. \n1161/circulationaha.117.029858 \n210. Alashi A, Khullar T, Mentias A, Gillinov AM, Roselli EE, Svensson LG, et al. Long-term \noutcomes after aortic valve surgery in patients with asymptomatic chronic aortic re-\ngurgitation and preserved LVEF: impact of baseline and follow-up global longitudinal \nstrain. JACC Cardiovasc Imaging 2020;13:12–21. https://doi.org/10.1016/j.jcmg.2018. \n12.021 \n211. deCampos D, Teixeira R, Saleiro C, Botelho A, Gonçalve L. Global longitudinal strain in \nchronic asymptomatic aortic regurgitation: systematic review. Echo Res Pract 2020;7: \n39–48. https://doi.org/10.1530/erp-20-0024 \n212. Lee SY, Park SJ, Kim EK, Chang SA, Lee SC, Ahn JH, et al. Predictive value of exercise \nstress echocardiography in asymptomatic patients with severe aortic regurgitation and \npreserved left ventricular systolic function without LV dilatation. Int J Cardiovasc \nImaging 2019;35:1241–7. https://doi.org/10.1007/s10554-019-01565-1 \n213. Pizarro R, Bazzino OO, Oberti PF, Falconi ML, Arias AM, Krauss JG, et al. Prospective \nvalidation of the prognostic usefulness of B-type natriuretic peptide in asymptomatic \npatients with chronic severe aortic regurgitation. J Am Coll Cardiol 2011;58:1705–14.  \nhttps://doi.org/10.1016/j.jacc.2011.07.016 \n214. Kočková R, Línková H, Hlubocká Z, Mědílek K, Tuna M, Vojáček J, et al. Multiparametric \nstrategy to predict early disease decompensation in asymptomatic severe aortic regur-\ngitation. Circ Cardiovasc Imaging 2022;15:e014901. https://doi.org/10.1161/circimaging. \n122.014901 \n215. Goldstein SA, Evangelista A, Abbara S, Arai A, Asch FM, Badano LP, et al. Multimodality \nimaging of diseases of the thoracic aorta in adults: from the American Society of \nEchocardiography and the European Association of Cardiovascular Imaging: endorsed \nby the Society of Cardiovascular Computed Tomography and Society for \nCardiovascular Magnetic Resonance. J Am Soc Echocardiogr 2015;28:119–82. https:// \ndoi.org/10.1016/j.echo.2014.11.015 \n216. Czerny M, Grabenwöger M, Berger T, Aboyans V, Della Corte A, Chen EP, et al. \nEACTS/STS Guidelines for diagnosing and treating acute and chronic syndromes of \nthe aortic organ. Eur J Cardiothorac Surg 2024;65:ezad426. https://doi.org/10.1093/ \nejcts/ezad426 \n217. le Polain de Waroux JB, Pouleur AC, Goffinet C, Vancraeynest D, Van Dyck M, Robert \nA, et al. Functional anatomy of aortic regurgitation: accuracy, prediction of surgical re-\npairability, and outcome implications of transesophageal echocardiography. Circulation \n2007;116:I264–9. https://doi.org/10.1161/CIRCULATIONAHA.106.680074 \n218. Lansac E, Di Centa I, Raoux F, Al Attar N, Acar C, Joudinaud T, et al. A lesional clas-\nsification to standardize surgical management of aortic insufficiency towards valve re-\npair. Eur J Cardiothorac Surg 2008;33:872–8; discussion 878–880. https://doi.org/10. \n1016/j.ejcts.2007.12.033 \n219. Michelena HI, Della Corte A, Evangelista A, Maleszewski JJ, Edwards WD, Roman MJ, \net al. International consensus statement on nomenclature and classification of the con-\ngenital bicuspid aortic valve and its aortopathy, for clinical, surgical, interventional and \nresearch purposes. Eur J Cardiothorac Surg 2021;60:448–76. https://doi.org/10.1093/ \nejcts/ezab038 \n220. Ehrlich T, de Kerchove L, Vojacek J, Boodhwani M, El-Hamamsy I, De Paulis R, et al. \nState-of-the art bicuspid aortic valve repair in 2020. Prog Cardiovasc Dis 2020;63: \n457–64. https://doi.org/10.1016/j.pcad.2020.04.010 \n221. Evangelista Masip A, Galian-Gay L, Guala A, Lopez-Sainz A, Teixido-Turà G, Ruiz \nMuñoz A, et al. Unraveling bicuspid aortic valve enigmas by multimodality imaging: clin-\nical implications. J Clin Med 2022;11:456. https://doi.org/10.3390/jcm11020456 \n222. Elder DHJ, Wei L, Szwejkowski BR, Libianto R, Nadir A, Pauriah M, et al. The impact of \nrenin-angiotensin-aldosterone system blockade on heart failure outcomes and \nmortality in patients identified to have aortic regurgitation: a large population cohort \nstudy. J Am Coll Cardiol 2011;58:2084–91. https://doi.org/10.1016/j.jacc.2011.07.043 \n223. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, et al. \nClinical practice update on heart failure 2019: pharmacotherapy, procedures, devices \nand patient management. An expert consensus meeting report of the Heart Failure \nAssociation of the European Society of Cardiology. Eur J Heart Fail 2019;21: \n1169–86. https://doi.org/10.1002/ejhf.1531 \n224. Chaliki HP, Mohty D, Avierinos JF, Scott CG, Schaff HV, Tajik AJ, et al. Outcomes after \naortic valve replacement in patients with severe aortic regurgitation and markedly re-\nduced left ventricular function. Circulation 2002;106:2687–93. https://doi.org/10.1161/ \n01.cir.0000038498.59829.38 \n225. Kaneko T, Ejiofor JI, Neely RC, McGurk S, Ivkovic V, Stevenson LW, et al. Aortic re-\ngurgitation with markedly reduced left ventricular function is not a contraindication \nfor aortic valve replacement. Ann Thorac Surg 2016;102:41–7. https://doi.org/10. \n1016/j.athoracsur.2015.12.068 \n226. Tornos P, Sambola A, Permanyer-Miralda G, Evangelista A, Gomez Z, Soler-Soler J. \nLong-term outcome of surgically treated aortic regurgitation: influence of guideline ad-\nherence toward early surgery. J Am Coll Cardiol 2006;47:1012–7. https://doi.org/10. \n1016/j.jacc.2005.10.049 \n227. Klodas E, Enriquez-Sarano M, Tajik AJ, Mullany CJ, Bailey KR, Seward JB. Optimizing \ntiming of surgical correction in patients with severe aortic regurgitation: role of symp-\ntoms. J Am Coll Cardiol 1997;30:746–52. https://doi.org/10.1016/s0735-1097(97) \n00205-2 \n228. Dujardin KS, Enriquez-Sarano M, Schaff HV, Bailey KR, Seward JB, Tajik AJ. Mortality \nand morbidity of aortic regurgitation in clinical practice. A long-term follow-up study. \nCirculation 1999;99:1851–7. https://doi.org/10.1161/01.cir.99.14.1851 \n229. Fiedler AG, Bhambhani V, Laikhter E, Picard MH, Wasfy MM, Tolis G, et al. Aortic valve \nreplacement associated with survival in severe regurgitation and low ejection fraction. \nHeart 2018;104:835–40. https://doi.org/10.1136/heartjnl-2017-312024 \n230. Tribouilloy CM, Enriquez-Sarano M, Schaff HV, Orszulak TA, Fett SL, Bailey KR, et al. \nExcess mortality due to coronary artery disease after valve surgery. Secular trends in \nvalvular regurgitation and effect of internal mammary artery bypass. Circulation 1998; \n98:II108–15. \n231. Forman R, Firth BG, Barnard MS. Prognostic significance of preoperative left ventricu-\nlar ejection fraction and valve lesion in patients with aortic valve replacement. Am J \nCardiol 1980;45:1120–5. https://doi.org/10.1016/0002-9149(80)90468-3 \n232. Bonow RO, Lakatos E, Maron BJ, Epstein SE. Serial long-term assessment of the natural \nhistory of asymptomatic patients with chronic aortic regurgitation and normal left ven-\ntricular systolic function. Circulation 1991;84:1625–35. https://doi.org/10.1161/01.cir. \n84.4.1625 \n233. Bhudia SK, McCarthy PM, Kumpati GS, Helou J, Hoercher KJ, Rajeswaran J, et al. \nImproved outcomes after aortic valve surgery for chronic aortic regurgitation with se-\nvere left ventricular dysfunction. J Am Coll Cardiol 2007;49:1465–71. https://doi.org/10. \n1016/j.jacc.2007.01.026 \n234. Sambola A, Tornos P, Ferreira-Gonzalez I, Evangelista A. Prognostic value of preopera-\ntive indexed end-systolic left ventricle diameter in the outcome after surgery in pa-\ntients with chronic aortic regurgitation. Am Heart J 2008;155:1114–20. https://doi. \norg/10.1016/j.ahj.2007.12.025 \n235. Yang LT, Michelena HI, Scott CG, Enriquez-Sarano M, Pislaru SV, Schaff HV, et al. \nOutcomes in chronic hemodynamically significant aortic regurgitation and limitations \nof current guidelines. J Am Coll Cardiol 2019;73:1741–52. https://doi.org/10.1016/j.jacc. \n2019.01.024 \n236. Mentias A, Feng K, Alashi A, Rodriguez LL, Gillinov AM, Johnston DR, et al. Long-term \noutcomes in patients with aortic regurgitation and preserved left ventricular ejection \nfraction. J Am Coll Cardiol 2016;68:2144–53. https://doi.org/10.1016/j.jacc.2016.08.045 \n237. de Meester C, Gerber BL, Vancraeynest D, Pouleur AC, Noirhomme P, Pasquet A, \net al. Do guideline-based indications result in an outcome penalty for patients with se-\nvere aortic regurgitation? JACC Cardiovasc Imaging 2019;12:2126–38. https://doi.org/ \n10.1016/j.jcmg.2018.11.022 \n238. Yang LT, Anand V, Zambito EI, Pellikka PA, Scott CG, Thapa P, et al. Association of \nechocardiographic left ventricular end-systolic volume and volume-derived ejection \nfraction with outcome in asymptomatic chronic aortic regurgitation. JAMA Cardiol \n2021;6:189–98. https://doi.org/10.1001/jamacardio.2020.5268 \n239. Yang LT, Lee CC, Su CH, Amano M, Nabeshima Y, Kitano T, et al. Analysis of left ven-\ntricular indexes and mortality among Asian adults with hemodynamically significant \nchronic aortic regurgitation. JAMA Netw Open 2023;6:e234632. https://doi.org/10. \n1001/jamanetworkopen.2023.4632 \n240. Hashimoto G, Enriquez-Sarano M, Stanberry LI, Oh F, Wang M, Acosta K, et al. \nAssociation of left ventricular remodeling assessment by cardiac magnetic resonance \nwith outcomes in patients with chronic aortic regurgitation. JAMA Cardiol 2022;7: \n924–33. https://doi.org/10.1001/jamacardio.2022.2108 \n241. Malahfji M, Crudo V, Kaolawanich Y, Nguyen DT, Telmesani A, Saeed M, et al. Influence \nof cardiac remodeling on clinical outcomes in patients with aortic regurgitation. J Am \nColl Cardiol 2023;81:1885–98. https://doi.org/10.1016/j.jacc.2023.03.001 \n242. Vermes E, Iacuzio L, Levy F, Bohbot Y, Renard C, Gerber B, et al. Role of cardiovascular \nmagnetic resonance in native valvular regurgitation: a comprehensive review of  \nESC Guidelines                                                                                                                                                                                          4717 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nprotocols, grading of severity, and prediction of valve surgery. Front Cardiovasc Med \n2022;9:881141. https://doi.org/10.3389/fcvm.2022.881141 \n243. Flynn CD, Tian DH, Wilson-Smith A, David T, Matalanis G, Misfeld M, et al. Systematic \nreview and meta-analysis of surgical outcomes in Marfan patients undergoing aortic \nroot surgery by composite-valve graft or valve sparing root replacement. Ann \nCardiothorac Surg 2017;6:570–81. https://doi.org/10.21037/acs.2017.11.06 \n244. Chauvette V, Kluin J, de Kerchove L, El Khoury G, Schäfers HJ, Lansac E, et al. \nOutcomes of valve-sparing surgery in heritable aortic disorders: results from the \nAVIATOR registry. Eur J Cardiothorac Surg 2022;62:ezac366. https://doi.org/10.1093/ \nejcts/ezac366 \n245. Wilson-Smith AR, Wilson-Smith CJ, Strode Smith J, Ng D, Muston BT, Eranki A, et al. \nThe outcomes of three decades of the David and Yacoub procedures in bicuspid aortic \nvalve patients—a systematic review and meta-analysis. Ann Cardiothorac Surg 2023;12: \n286–94. https://doi.org/10.21037/acs-2023-avs2-19 \n246. Zuo Y, Tan R, Qin C. Outcomes of valve-sparing aortic root replacement in patients \nwith bicuspid aortic valve and tricuspid aortic valve: a systematic review and \nmeta-analysis. J Cardiothorac Surg 2023;18:206. https://doi.org/10.1186/s13019-023- \n02329-8 \n247. Mastrobuoni S, Govers PJ, Veen KM, Jahanyar J, van Saane S, Segreto A, et al. \nValve-sparing aortic root replacement using the reimplantation (David) technique: a \nsystematic review and meta-analysis on survival and clinical outcome. Ann \nCardiothorac Surg 2023;12:149–58. https://doi.org/10.21037/acs-2023-avs1-0038 \n248. Aicher D, Fries R, Rodionycheva S, Schmidt K, Langer F, Schafers HJ. Aortic valve repair \nleads to a low incidence of valve-related complications. Eur J Cardiothorac Surg 2010;37: \n127–32. https://doi.org/10.1016/j.ejcts.2009.06.021 \n249. de Meester C, Pasquet A, Gerber BL, Vancraeynest D, Noirhomme P, El Khoury G, \net al. Valve repair improves the outcome of surgery for chronic severe aortic regurgi-\ntation: a propensity score analysis. J Thorac Cardiovasc Surg 2014;148:1913–20. https:// \ndoi.org/10.1016/j.jtcvs.2014.02.010 \n250. Klotz S, Stock S, Sievers HH, Diwoky M, Petersen M, Stierle U, et al. Survival and re-\noperation pattern after 20 years of experience with aortic valve-sparing root replace-\nment in patients with tricuspid and bicuspid valves. J Thorac Cardiovasc Surg 2018;155: \n1403–11.e1401. https://doi.org/10.1016/j.jtcvs.2017.12.039 \n251. Elbatarny M, Tam DY, Edelman JJ, Rocha RV, Chu MWA, Peterson MD, et al. \nValve-sparing root replacement versus composite valve grafting in aortic root dilation: \na meta-analysis. Ann Thorac Surg 2020;110:296–306. https://doi.org/10.1016/j. \nathoracsur.2019.11.054 \n252. Leontyev S, Schamberger L, Davierwala PM, Von Aspern K, Etz C, Lehmann S, et al. \nEarly and late results after David vs Bentall procedure: a propensity matched analysis. \nAnn Thorac Surg 2019;110:120–6. https://doi.org/10.1016/j.athoracsur.2019.10.020 \n253. Mastrobuoni S, de Kerchove L, Navarra E, Watremez C, Vancraeynest D, Rubay J, et al. \nLong-term experience with valve-sparing reimplantation technique for the treatment \nof aortic aneurysm and aortic regurgitation. J Thorac Cardiovasc Surg 2019;158:14–23.  \nhttps://doi.org/10.1016/j.jtcvs.2018.10.155 \n254. Lansac E, Di Centa I, Sleilaty G, Lejeune S, Khelil N, Berrebi A, et al. Long-term results \nof external aortic ring annuloplasty for aortic valve repair. Eur J Cardiothorac Surg 2016; \n50:350–60. https://doi.org/10.1093/ejcts/ezw070 \n255. Lee H, Cho YH, Sung K, Kim WS, Park KH, Jeong DS, et al. Clinical outcomes of root \nreimplantation and Bentall procedure: propensity score matching analysis. Ann Thorac \nSurg 2018;106:539–47. https://doi.org/10.1016/j.athoracsur.2018.02.057 \n256. Norton EL, Patel PM, Levine D, Wei JW, Binongo JN, Leshnower BG, et al. Bentall ver-\nsus valve-sparing aortic root replacement for root pathology with moderate-to-severe \naortic insufficiency: a propensity-matched analysis. Eur J Cardiothorac Surg 2023;64: \nezad231. https://doi.org/10.1093/ejcts/ezad231 \n257. Arabkhani B, Klautz RJM, de Heer F, De Kerchove L, El Khoury G, Lansac E, et al. A \nmulticentre, propensity score matched analysis comparing a valve-sparing approach \nto valve replacement in aortic root aneurysm: insight from the AVIATOR database. \nEur J Cardiothorac Surg 2023;63:ezac514. https://doi.org/10.1093/ejcts/ezac514 \n258. Levine D, Patel P, Zhao Y, Chung M, Singh S, Childress P, et al. Valve-sparing aortic root \nreplacement versus composite valve graft with bioprosthesis in patients under age 50. J \nThorac Cardiovasc Surg 2023;168:992–1002.e1. https://doi.org/10.1016/j.jtcvs.2023.07. \n016 \n259. Schneider U, Hofmann C, Schöpe J, Niewald AK, Giebels C, Karliova I, et al. Long-term \nresults of differentiated anatomic reconstruction of bicuspid aortic valves. JAMA Cardiol \n2020;5:1366–73. https://doi.org/10.1001/jamacardio.2020.3749 \n260. Mazine A, Rocha RV, El-Hamamsy I, Ouzounian M, Yanagawa B, Bhatt DL, et al. Ross \nprocedure vs mechanical aortic valve replacement in adults: a systematic review and \nmeta-analysis. JAMA Cardiol 2018;3:978–87. https://doi.org/10.1001/jamacardio.2018. \n2946 \n261. Takkenberg JJM, Klieverik LMA, Schoof PH, van Suylen RJ, van Herwerden LA, \nZondervan PE, et al. The Ross procedure: a systematic review and meta-analysis. \nCirculation \n2009;119:222–8. \nhttps://doi.org/10.1161/CIRCULATIONAHA.107. \n726349 \n262. Yokoyama Y, Kuno T, Toyoda N, Fujisaki T, Takagi H, Itagaki S, et al. Ross procedure \nversus mechanical versus bioprosthetic aortic valve replacement: a network \nmeta-analysis. J Am Heart Assoc 2023;12:e8066. https://doi.org/10.1161/jaha.122. \n027715 \n263. El-Hamamsy I, Toyoda N, Itagaki S, Stelzer P, Varghese R, Williams EE, et al. \nPropensity-matched comparison of the Ross procedure and prosthetic aortic valve re-\nplacement in adults. J Am Coll Cardiol 2022;79:805–15. https://doi.org/10.1016/j.jacc. \n2021.11.057 \n264. Sawaya FJ, Deutsch MA, Seiffert M, Yoon SH, Codner P, Wickramarachchi U, et al. \nSafety and efficacy of transcatheter aortic valve replacement in the treatment of \npure aortic regurgitation in native valves and failing surgical bioprostheses: results \nfrom an international registry study. JACC Cardiovasc Interv 2017;10:1048–56. https:// \ndoi.org/10.1016/j.jcin.2017.03.004 \n265. Yoon SH, Schmidt T, Bleiziffer S, Schofer N, Fiorina C, Munoz-Garcia AJ, et al. \nTranscatheter aortic valve replacement in pure native aortic valve regurgitation. J \nAm Coll Cardiol 2017;70:2752–63. https://doi.org/10.1016/j.jacc.2017.10.006 \n266. Poletti E, De Backer O, Scotti A, Costa G, Bruno F, Fiorina C, et al. Transcatheter aor-\ntic valve replacement for pure native aortic valve regurgitation: the PANTHEON inter-\nnational project. JACC Cardiovasc Interv 2023;16:1974–85. https://doi.org/10.1016/j.jcin. \n2023.07.026 \n267. Garcia S, Ye J, Webb J, Reardon M, Kleiman N, Goel S, et al. Transcatheter treatment \nof native aortic valve regurgitation: the North American experience with a novel de-\nvice. JACC Cardiovasc Interv 2023;16:1953–60. https://doi.org/10.1016/j.jcin.2023.05. \n018 \n268. Adam M, Tamm AR, Wienemann H, Unbehaun A, Klein C, Arnold M, et al. \nTranscatheter aortic valve replacement for isolated aortic regurgitation using a new \nself-expanding TAVR system. JACC Cardiovasc Interv 2023;16:1965–73. https://doi. \norg/10.1016/j.jcin.2023.07.038 \n269. Vahl TP, Thourani VH, Makkar RR, Hamid N, Khalique OK, Daniels D, et al. \nTranscatheter aortic valve implantation in patients with high-risk symptomatic native \naortic regurgitation (ALIGN-AR): a prospective, multicentre, single-arm study. Lancet \n2024;403:1451–9. https://doi.org/10.1016/s0140-6736(23)02806-4 \n270. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, et al. Should \nthe ascending aorta be replaced more frequently in patients with bicuspid aortic valve \ndisease? J Thorac Cardiovasc Surg 2004;128:677–83. https://doi.org/10.1016/j.jtcvs. \n2004.07.009 \n271. Coady MA, Rizzo JA, Hammond GL, Mandapati D, Darr U, Kopf GS, et al. What is the \nappropriate size criterion for resection of thoracic aortic aneurysms? J Thorac \nCardiovasc Surg 1997;113:476–91; discussion 489–491. https://doi.org/10.1016/ \nS0022-5223(97)70360-X \n272. Davies RR, Goldstein LJ, Coady MA, Tittle SL, Rizzo JA, Kopf GS, et al. Yearly rupture \nor dissection rates for thoracic aortic aneurysms: simple prediction based on size. Ann \nThorac Surg 2002;73:17–27; discussion 27–18. https://doi.org/10.1016/s0003- \n4975(01)03236-2 \n273. Zafar MA, Li Y, Rizzo JA, Charilaou P, Saeyeldin A, Velasquez CA, et al. Height alone, \nrather than body surface area, suffices for risk estimation in ascending aortic aneurysm. \nJ Thorac Cardiovasc Surg 2018;155:1938–50. https://doi.org/10.1016/j.jtcvs.2017.10.140 \n274. Popović ZB, Desai MY, Griffin BP. Decision making with imaging in asymptomatic aor-\ntic regurgitation. JACC Cardiovasc Imaging 2018;11:1499–513. https://doi.org/10.1016/j. \njcmg.2018.05.027 \n275. Evangelista A, Sitges M, Jondeau G, Nijveldt R, Pepi M, Cuellar H, et al. Multimodality \nimaging in thoracic aortic diseases: a clinical consensus statement from the European \nAssociation of Cardiovascular Imaging and the European Society of Cardiology work-\ning group on aorta and peripheral vascular diseases. Eur Heart J Cardiovasc Imaging \n2023;24:e65–85. https://doi.org/10.1093/ehjci/jead024 \n276. Weisenberg D, Omelchenko A, Shapira Y, Vaturi M, Monakier D, Bental T, et al. \nMid-term echocardiographic progression of patients with moderate aortic regurgita-\ntion: implications for aortic valve surgery. J Heart Valve Dis 2013;22:192–4. \n277. Budts W, Pieles GE, Roos-Hesselink JW, Sanz de la Garza M, D’Ascenzi F, \nGiannakoulas G, et al. Recommendations for participation in competitive sport in ado-\nlescent and adult athletes with Congenital Heart Disease (CHD): position statement of \nthe Sports Cardiology & Exercise Section of the European Association of Preventive \nCardiology (EAPC), the European Society of Cardiology (ESC) Working Group on \nAdult Congenital Heart Disease and the Sports Cardiology, Physical Activity and \nPrevention Working Group of the Association for European Paediatric and \nCongenital Cardiology (AEPC). Eur Heart J 2020;41:4191–9. https://doi.org/10.1093/ \neurheartj/ehaa501 \n278. Robertson EN, van der Linde D, Sherrah AG, Vallely MP, Wilson M, Bannon PG, et al. \nFamilial non-syndromal thoracic aortic aneurysms and dissections—incidence and \nfamily screening outcomes. Int J Cardiol 2016;220:43–51. https://doi.org/10.1016/j. \nijcard.2016.06.086 \n279. Bray JJH, Freer R, Pitcher A, Kharbanda R. Family screening for bicuspid aortic valve and \naortic dilatation: a meta-analysis. Eur Heart J 2023;44:3152–64. https://doi.org/10.1093/ \neurheartj/ehad320 \n280. Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic \nvalves in adults having isolated aortic valve replacement for aortic stenosis, with or \nwithout associated aortic regurgitation. Circulation 2005;111:920–5. https://doi.org/ \n10.1161/01.Cir.0000155623.48408.C5  \n4718                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n281. Verma S, Siu SC. Aortic dilatation in patients with bicuspid aortic valve. N Engl J Med \n2014;370:1920–9. https://doi.org/10.1056/NEJMra1207059 \n282. Zühlke L, Engel ME, Karthikeyan G, Rangarajan S, Mackie P, Cupido B, et al. \nCharacteristics, complications, and gaps in evidence-based interventions in rheumatic \nheart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). Eur \nHeart J 2015;36:1115–22a. https://doi.org/10.1093/eurheartj/ehu449 \n283. Willner N, Prosperi-Porta G, Lau L, Nam Fu AY, Boczar K, Poulin A, et al. Aortic sten-\nosis progression: a systematic review and meta-analysis. JACC Cardiovasc Imaging 2023; \n16:314–28. https://doi.org/10.1016/j.jcmg.2022.10.009 \n284. Dweck MR, Loganath K, Bing R, Treibel TA, McCann GP, Newby DE, et al. \nMulti-modality imaging in aortic stenosis: an EACVI clinical consensus document. Eur \nHeart J Cardiovasc Imaging 2023;24:1430–43. https://doi.org/10.1093/ehjci/jead153 \n285. Jaiswal V, Agrawal V, Khulbe Y, Hanif M, Huang H, Hameed M, et al. Cardiac amyloid-\nosis and aortic stenosis: a state-of-the-art review. Eur Heart J Open 2023;3:oead106.  \nhttps://doi.org/10.1093/ehjopen/oead106 \n286. Desai MY, Alashi A, Popovic ZB, Wierup P, Griffin BP, Thamilarasan M, et al. \nOutcomes in patients with obstructive hypertrophic cardiomyopathy and concomi-\ntant aortic stenosis undergoing surgical myectomy and aortic valve replacement. J \nAm Heart Assoc 2021;10:e018435. https://doi.org/10.1161/JAHA.120.018435 \n287. Baumgartner H, Hung J, Bermejo J, Chambers JB, Edvardsen T, Goldstein S, et al. \nRecommendations on the echocardiographic assessment of aortic valve stenosis: a fo-\ncused update from the European Association of Cardiovascular Imaging and the \nAmerican Society of Echocardiography. J Am Soc Echocardiogr 2017;30:372–92.  \nhttps://doi.org/10.1016/j.echo.2017.02.009 \n288. Rusinaru D, Bohbot Y, Djelaili F, Delpierre Q, Altes A, Serbout S, et al. Normative ref-\nerence values of cardiac output by pulsed-wave Doppler echocardiography in adults. \nAm J Cardiol 2021;140:128–33. https://doi.org/10.1016/j.amjcard.2020.10.046 \n289. Annabi MS, Touboul E, Dahou A, Burwash IG, Bergler-Klein J, Enriquez-Sarano M, et al. \nDobutamine stress echocardiography for management of low-flow, low-gradient aor-\ntic stenosis. J Am Coll Cardiol 2018;71:475–85. https://doi.org/10.1016/j.jacc.2017.11. \n052 \n290. Clavel MA, Burwash IG, Mundigler G, Dumesnil JG, Baumgartner H, Bergler-Klein J, \net al. Validation of conventional and simplified methods to calculate projected valve \narea at normal flow rate in patients with low flow, low gradient aortic stenosis: the \nmulticenter TOPAS (True or Pseudo Severe Aortic Stenosis) study. J Am Soc \nEchocardiogr 2010;23:380–6. https://doi.org/10.1016/j.echo.2010.02.002 \n291. Ash J, Sandhu GS, Arriola-Montenegro J, Agakishiev D, Clavel MA, Pibarot P, et al. \nPerformance of computed tomographic angiography-based aortic valve area for as-\nsessment of aortic stenosis. J Am Heart Assoc 2023;12:e029973. https://doi.org/10. \n1161/jaha.123.029973 \n292. Guzzetti E, Poulin A, Annabi MS, Zhang B, Kalavrouziotis D, Couture C, et al. \nTransvalvular flow, sex, and survival after valve replacement surgery in patients with \nsevere aortic stenosis. J Am Coll Cardiol 2020;75:1897–909. https://doi.org/10.1016/j. \njacc.2020.02.065 \n293. Mehrotra P, Jansen K, Flynn AW, Tan TC, Elmariah S, Picard MH, et al. Differential left \nventricular remodelling and longitudinal function distinguishes low flow from normal- \nflow preserved ejection fraction low-gradient severe aortic stenosis. Eur Heart J 2013; \n34:1906–14. https://doi.org/10.1093/eurheartj/eht094 \n294. Tribouilloy C, Rusinaru D, Marechaux S, Castel AL, Debry N, Maizel J, et al. \nLow-gradient, low-flow severe aortic stenosis with preserved left ventricular ejection \nfraction: characteristics, outcome, and implications for surgery. J Am Coll Cardiol 2015; \n65:55–66. https://doi.org/10.1016/j.jacc.2014.09.080 \n295. Jander N, Minners J, Holme I, Gerdts E, Boman K, Brudi P, et al. Outcome of patients \nwith low-gradient “severe” aortic stenosis and preserved ejection fraction. Circulation \n2011;123:887–95. https://doi.org/10.1161/CIRCULATIONAHA.110.983510 \n296. Bohbot Y, Kubala M, Rusinaru D, Maréchaux S, Vanoverschelde JL, Tribouilloy C. \nSurvival and management of patients with discordant high-gradient aortic stenosis: a \npropensity-matched study. JACC Cardiovasc Imaging 2021;14:1672–4. https://doi.org/ \n10.1016/j.jcmg.2021.02.010 \n297. Unger P, Powers A, Le Nezet E, Lacasse-Rioux E, Galloo X, Clavel MA. Prevalence and \noutcomes of patients with discordant high-gradient aortic stenosis. J Am Coll Cardiol \n2024;83:1109–19. https://doi.org/10.1016/j.jacc.2024.01.025 \n298. Ito S, Oh JK, Michelena HI, Egbe AC, Connolly HM, Pellikka PA, et al. High-gradient \naortic stenosis with valve area >1.0 cm2: the “forgotten” discordant hemodynamic \nphenotype. JACC Cardiovasc Imaging 2025;18:166–76. https://doi.org/10.1016/j.jcmg. \n2024.07.025 \n299. Ribeiro HB, Lerakis S, Gilard M, Cavalcante JL, Makkar R, Herrmann HC, et al. \nTranscatheter aortic valve replacement in patients with low-flow, low-gradient aortic \nstenosis: the TOPAS-TAVI registry. J Am Coll Cardiol 2018;71:1297–308. https://doi. \norg/10.1016/j.jacc.2018.01.054 \n300. Clavel MA, Pibarot P, Messika-Zeitoun D, Capoulade R, Malouf J, Aggarval S, et al. \nImpact of aortic valve calcification, as measured by MDCT, on survival in patients \nwith aortic stenosis: results of an international registry study. J Am Coll Cardiol 2014; \n64:1202–13. https://doi.org/10.1016/j.jacc.2014.05.066 \n301. Tastet L, Enriquez-Sarano M, Capoulade R, Malouf J, Araoz PA, Shen M, et al. Impact of \naortic valve calcification and sex on hemodynamic progression and clinical outcomes in \nAS. J Am Coll Cardiol 2017;69:2096–8. https://doi.org/10.1016/j.jacc.2017.02.037 \n302. Clavel MA, Messika-Zeitoun D, Pibarot P, Aggarwal SR, Malouf J, Araoz PA, et al. The \ncomplex nature of discordant severe calcified aortic valve disease grading: new insights \nfrom combined Doppler echocardiographic and computed tomographic study. J Am \nColl Cardiol 2013;62:2329–38. https://doi.org/10.1016/j.jacc.2013.08.1621 \n303. Pawade T, Clavel MA, Tribouilloy C, Dreyfus J, Mathieu T, Tastet L, et al. Computed \ntomography aortic valve calcium scoring in patients with aortic stenosis. Circ Cardiovasc \nImaging 2018;11:e007146. https://doi.org/10.1161/CIRCIMAGING.117.007146 \n304. Shen M, Oh JK, Guzzetti E, Singh GK, Pawade T, Tastet L, et al. Computed tomography \naortic valve calcium scoring in patients with bicuspid aortic valve stenosis. Struct Heart \n2022;6:100027. https://doi.org/10.1016/j.shj.2022.100027 \n305. Shen M, Tastet L, Capoulade R, Larose É, Bédard É, Arsenault M, et al. Effect of age and \naortic valve anatomy on calcification and haemodynamic severity of aortic stenosis. \nHeart 2017;103:32–9. https://doi.org/10.1136/heartjnl-2016-309665 \n306. Wanchaitanawong W, Kanjanavanit R, Srisuwan T, Wongcharoen W, Phrommintikul \nA. Diagnostic role of aortic valve calcium scoring in various etiologies of aortic stenosis. \nSci Rep 2023;13:8019. https://doi.org/10.1038/s41598-023-34118-7 \n307. Ye Z, Clavel MA, Foley TA, Pibarot P, Enriquez-Sarano M, Michelena HI. Computed \ntomography calcium scoring in aortic stenosis: bicuspid versus tricuspid morphology. \nHeart 2024;110:594–602. https://doi.org/10.1136/heartjnl-2023-323281 \n308. Maznyczka A, Tomii D, Angellotti D, Baekke PS, Nakase M, Samim D, et al. Fibrotic vs \ncalcific aortic stenosis: characteristics and outcomes in patients undergoing transcath-\neter aortic valve replacement. JACC Cardiovasc Interv 2024;17:2969–71. https://doi.org/ \n10.1016/j.jcin.2024.09.041 \n309. Rusinaru D, Malaquin D, Marechaux S, Debry N, Tribouilloy C. Relation of dimension-\nless index to long-term outcome in aortic stenosis with preserved LVEF. JACC \nCardiovasc Imaging 2015;8:766–75. https://doi.org/10.1016/j.jcmg.2015.01.023 \n310. Thellier N, Altes A, Rietz M, Menet A, Layec J, Outteryck F, et al. Additive prognostic \nvalue of left ventricular dispersion and deformation in patients with severe aortic sten-\nosis. JACC Cardiovasc Imaging 2023;17:235–45. https://doi.org/10.1016/j.jcmg.2023.09. \n010 \n311. Vollema EM, Amanullah MR, Prihadi EA, Ng ACT, van der Bijl P, Sin YK, et al. \nIncremental value of left ventricular global longitudinal strain in a newly proposed sta-\nging classification based on cardiac damage in patients with severe aortic stenosis. Eur \nHeart J Cardiovasc Imaging 2020;21:1248–58. https://doi.org/10.1093/ehjci/jeaa220 \n312. Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and \nconsequences of longitudinal LV dysfunction assessed by 2D strain echocardiography \nin cardiac amyloidosis. JACC Cardiovasc Imaging 2016;9:126–38. https://doi.org/10. \n1016/j.jcmg.2015.05.014 \n313. Harada K, Saitoh T, Tanaka J, Shibayama K, Berdejo J, Shiota T. Valvuloarterial imped-\nance, but not aortic stenosis severity, predicts syncope in patients with aortic stenosis. \nCirc Cardiovasc Imaging 2013;6:1024–31. https://doi.org/10.1161/circimaging.113. \n000584 \n314. Hachicha Z, Dumesnil JG, Pibarot P. Usefulness of the valvuloarterial impedance to \npredict adverse outcome in asymptomatic aortic stenosis. J Am Coll Cardiol 2009;54: \n1003–11. https://doi.org/10.1016/j.jacc.2009.04.079 \n315. Pibarot P, Salaun E, Dahou A, Avenatti E, Guzzetti E, Annabi MS, et al. \nEchocardiographic results of transcatheter versus surgical aortic valve replacement \nin low-risk patients: the PARTNER 3 trial. Circulation 2020;141:1527–37. https://doi. \norg/10.1161/circulationaha.119.044574 \n316. Zamorano JL, Badano LP, Bruce C, Chan KL, Goncalves A, Hahn RT, et al. EAE/ASE \nrecommendations for the use of echocardiography in new transcatheter interventions \nfor valvular heart disease. Eur Heart J 2011;32:2189–214. https://doi.org/10.1093/ \neurheartj/ehr259 \n317. Bergler-Klein J, Klaar U, Heger M, Rosenhek R, Mundigler G, Gabriel H, et al. \nNatriuretic peptides predict symptom-free survival and postoperative outcome in se-\nvere aortic stenosis. Circulation 2004;109:2302–8. https://doi.org/10.1161/01.CIR. \n0000126825.50903.18 \n318. Rafique AM, Biner S, Ray I, Forrester JS, Tolstrup K, Siegel RJ. Meta-analysis of prognos-\ntic value of stress testing in patients with asymptomatic severe aortic stenosis. Am J \nCardiol 2009;104:972–7. https://doi.org/10.1016/j.amjcard.2009.05.044 \n319. Lancellotti P, Lebois F, Simon M, Tombeux C, Chauvel C, Pierard LA. Prognostic im-\nportance of quantitative exercise Doppler echocardiography in asymptomatic valvular \naortic stenosis. Circulation 2005;112:I377–82. https://doi.org/10.1161/circulationaha. \n104.523274 \n320. Le VD, Jensen GV, Kjøller-Hansen L. Prognostic usefulness of cardiopulmonary exer-\ncise testing for managing patients with severe aortic stenosis. Am J Cardiol 2017;120: \n844–9. https://doi.org/10.1016/j.amjcard.2017.05.047 \n321. Hoedemakers S, Verwerft J, Reddy YNV, Delvaux R, Stroobants S, Jogani S, et al. \nCardiac dysfunction rather than aortic valve stenosis severity drives exercise intoler-\nance and adverse hemodynamics. Eur Heart J Cardiovasc Imaging 2023;25:302–12.  \nhttps://doi.org/10.1093/ehjci/jead276  \nESC Guidelines                                                                                                                                                                                          4719 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n322. Bing R, Cavalcante JL, Everett RJ, Clavel MA, Newby DE, Dweck MR. Imaging and im-\npact of myocardial fibrosis in aortic stenosis. JACC Cardiovasc Imaging 2019;12:283–96.  \nhttps://doi.org/10.1016/j.jcmg.2018.11.026 \n323. Everett RJ, Treibel TA, Fukui M, Lee H, Rigolli M, Singh A, et al. Extracellular myocardial \nvolume in patients with aortic stenosis. J Am Coll Cardiol 2020;75:304–16. https://doi. \norg/10.1016/j.jacc.2019.11.032 \n324. Thornton GD, Vassiliou VS, Musa TA, Aziminia N, Craig N, Dattani A, et al. Myocardial \nscar and remodelling predict long-term mortality in severe aortic stenosis beyond 10 \nyears. Eur Heart J 2024;45:2019–22. https://doi.org/10.1093/eurheartj/ehae067 \n325. Nitsche C, Scully PR, Patel KP, Kammerlander AA, Koschutnik M, Dona C, et al. \nPrevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis. J \nAm Coll Cardiol 2021;77:128–39. https://doi.org/10.1016/j.jacc.2020.11.006 \n326. Maurer MS, Bokhari S, Damy T, Dorbala S, Drachman BM, Fontana M, et al. Expert \nconsensus recommendations for the suspicion and diagnosis of transthyretin cardiac \namyloidosis. Circ Heart Fail 2019;12:e006075. https://doi.org/10.1161/circheartfailure. \n119.006075 \n327. Cannata F, Chiarito M, Pinto G, Villaschi A, Sanz-Sánchez J, Fazzari F, et al. \nTranscatheter aortic valve replacement in aortic stenosis and cardiac amyloidosis: a \nsystematic review and meta-analysis. ESC Heart Fail 2022;9:3188–97. https://doi.org/ \n10.1002/ehf2.13876 \n328. Blanke P, Weir-McCall JR, Achenbach S, Delgado V, Hausleiter J, Jilaihawi H, et al. \nComputed tomography imaging in the context of Transcatheter Aortic Valve \nImplantation (TAVI)/Transcatheter Aortic Valve Replacement (TAVR). JACC \nCardiovasc Imaging 2019;12:1–24. https://doi.org/10.1016/j.jcmg.2018.12.003 \n329. Khan JM, Kamioka N, Lisko JC, Perdoncin E, Zhang C, Maini A, et al. Coronary obstruc-\ntion from TAVR in native aortic stenosis: development and validation of multivariate \nprediction model. JACC Cardiovasc Interv 2023;16:415–25. https://doi.org/10.1016/j. \njcin.2022.11.018 \n330. Reindl M, Lechner I, Holzknecht M, Tiller C, Fink P, Oberhollenzer F, et al. Cardiac mag-\nnetic resonance imaging versus computed tomography to guide transcatheter aortic \nvalve replacement: a randomized, open-label, noninferiority trial. Circulation 2023; \n148:1220–30. https://doi.org/10.1161/CIRCULATIONAHA.123.066498 \n331. Gleitman S, Elbaz-Greener G, Ghanim D, Kusniec F, Rabin A, Sudarsky D, et al. Similar \nprocedural success of transcutaneous aortic valve replacement with prosthesis valve \nsizing by either three-dimensional transesophageal echocardiography modeling or \ncomputed tomography. J Am Soc Echocardiogr 2020;33:1149–51. https://doi.org/10. \n1016/j.echo.2020.05.026 \n332. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, et al. Intensive \nlipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008;359: \n1343–56. https://doi.org/10.1056/NEJMoa0804602 \n333. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, et al. A ran-\ndomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med \n2005;352:2389–97. https://doi.org/10.1056/NEJMoa043876 \n334. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J. Effect of lipid lowering with rosuvastatin on \nprogression of aortic stenosis: results of the aortic stenosis progression observation: \nmeasuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121: \n306–14. https://doi.org/10.1161/CIRCULATIONAHA.109.900027 \n335. Pawade TA, Doris MK, Bing R, White AC, Forsyth L, Evans E, et al. Effect of denosumab \nor alendronic acid on the progression of aortic stenosis: a double-blind randomized \ncontrolled trial. Circulation 2021;143:2418–27. https://doi.org/10.1161/CIRCU \nLATIONAHA.121.053708 \n336. Diederichsen ACP, Lindholt JS, Möller S, Øvrehus KA, Auscher S, Lambrechtsen J, et al. \nVitamin K2 and D in patients with aortic valve calcification: a randomized double- \nblinded \nclinical \ntrial. \nCirculation \n2022;145:1387–97. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.121.057008 \n337. McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al. 2024 \nESC Guidelines for the management of elevated blood pressure and hypertension. Eur \nHeart J 2024;45:3912–4018. https://doi.org/10.1093/eurheartj/ehae178 \n338. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al. 2021 ESC \nGuidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2021; \n42:3227–337. https://doi.org/10.1093/eurheartj/ehab484 \n339. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 \nESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: de-\nveloped by the Task Force for the diagnosis and treatment of acute and chronic heart \nfailure of the European Society of Cardiology (ESC) with the special contribution of \nthe Heart Failure Association (HFA) of the ESC. Eur Heart J 2021;42:3599–726.  \nhttps://doi.org/10.1093/eurheartj/ehab368 \n340. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2023 \nFocused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute \nand chronic heart failure: developed by the Task Force for the diagnosis and treatment \nof acute and chronic heart failure of the European Society of Cardiology (ESC) with \nthe special contribution of the Heart Failure Association (HFA) of the ESC. Eur \nHeart J 2023;44:3627–39. https://doi.org/10.1093/eurheartj/ehad195 \n341. Monin JL, Quéré JP, Monchi M, Petit H, Baleynaud S, Chauvel C, et al. Low-gradient \naortic stenosis: operative risk stratification and predictors for long-term outcome: a \nmulticenter study using dobutamine stress hemodynamics. Circulation 2003;108: \n319–24. https://doi.org/10.1161/01.CIR.0000079171.43055.46 \n342. Tribouilloy C, Levy F, Rusinaru D, Gueret P, Petit-Eisenmann H, Baleynaud S, et al. \nOutcome after aortic valve replacement for low-flow/low-gradient aortic stenosis \nwithout contractile reserve on dobutamine stress echocardiography. J Am Coll \nCardiol 2009;53:1865–73. https://doi.org/10.1016/j.jacc.2009.02.026 \n343. Quere JP, Monin JL, Levy F, Petit H, Baleynaud S, Chauvel C, et al. Influence of pre-\noperative left ventricular contractile reserve on postoperative ejection fraction in low- \ngradient aortic stenosis. Circulation 2006;113:1738–44. https://doi.org/10.1161/ \ncirculationaha.105.568824 \n344. Fougeres E, Tribouilloy C, Monchi M, Petit-Eisenmann H, Baleynaud S, Pasquet A, et al. \nOutcomes of pseudo-severe aortic stenosis under conservative treatment. Eur Heart J \n2012;33:2426–33. https://doi.org/10.1093/eurheartj/ehs176 \n345. Levy F, Laurent M, Monin JL, Maillet JM, Pasquet A, Le Tourneau T, et al. Aortic valve \nreplacement for low-flow/low-gradient aortic stenosis operative risk stratification and \nlong-term outcome: a European multicenter study. J Am Coll Cardiol 2008;51:1466–72.  \nhttps://doi.org/10.1016/j.jacc.2007.10.067 \n346. Maes F, Lerakis S, Barbosa Ribeiro H, Gilard M, Cavalcante JL, Makkar R, et al. \nOutcomes from transcatheter aortic valve replacement in patients with low-flow, low- \ngradient aortic stenosis and left ventricular ejection fraction less than 30%: a substudy \nfrom the TOPAS-TAVI registry. JAMA Cardiol 2019;4:64–70. https://doi.org/10.1001/ \njamacardio.2018.4320 \n347. Sato K, Sankaramangalam K, Kandregula K, Bullen JA, Kapadia SR, Krishnaswamy A, \net al. Contemporary outcomes in low-gradient aortic stenosis patients who under-\nwent dobutamine stress echocardiography. J Am Heart Assoc 2019;8:e011168.  \nhttps://doi.org/10.1161/JAHA.118.011168 \n348. Ueyama H, Kuno T, Harrington M, Takagi H, Krishnamoorthy P, Sharma SK, et al. \nImpact of surgical and transcatheter aortic valve replacement in low-gradient aortic \nstenosis: a meta-analysis. JACC Cardiovasc Interv 2021;14:1481–92. https://doi.org/10. \n1016/j.jcin.2021.04.038 \n349. Clavel MA, Dumesnil JG, Capoulade R, Mathieu P, Senechal M, Pibarot P. Outcome of \npatients with aortic stenosis, small valve area, and low-flow, low-gradient despite pre-\nserved left ventricular ejection fraction. J Am Coll Cardiol 2012;60:1259–67. https://doi. \norg/10.1016/j.jacc.2011.12.054 \n350. Chadha G, Bohbot Y, Rusinaru D, Marechaux S, Tribouilloy C. Outcome of normal- \nflow low-gradient severe aortic stenosis with preserved left ventricular ejection frac-\ntion: a propensity-matched study. J Am Heart Assoc 2019;8:e012301. https://doi.org/10. \n1161/JAHA.119.012301 \n351. Pellikka PA, Sarano ME, Nishimura RA, Malouf JF, Bailey KR, Scott CG, et al. Outcome \nof 622 adults with asymptomatic, hemodynamically significant aortic stenosis during \nprolonged \nfollow-up. \nCirculation \n2005;111:3290–5. \nhttps://doi.org/10.1161/ \ncirculationaha.104.495903 \n352. Heuvelman HJ, van Geldorp MW, Kappetein AP, Geleijnse ML, Galema TW, Bogers AJ, \net al. Clinical course of patients diagnosed with severe aortic stenosis in the Rotterdam \narea: insights from the AVARIJN study. Neth Heart J 2012;20:487–93. https://doi.org/ \n10.1007/s12471-012-0309-3 \n353. Otto CM, Burwash IG, Legget ME, Munt BI, Fujioka M, Healy NL, et al. Prospective \nstudy of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exer-\ncise predictors of outcome. Circulation 1997;95:2262–70. https://doi.org/10.1161/01. \ncir.95.9.2262 \n354. Bohbot Y, de Meester de Ravenstein C, Chadha G, Rusinaru D, Belkhir K, Trouillet C, \net al. Relationship between left ventricular ejection fraction and mortality in asymp-\ntomatic and minimally symptomatic patients with severe aortic stenosis. JACC \nCardiovasc Imaging 2019;12:38–48. https://doi.org/10.1016/j.jcmg.2018.07.029 \n355. Capoulade R, Le Ven F, Clavel MA, Dumesnil JG, Dahou A, Thebault C, et al. \nEchocardiographic predictors of outcomes in adults with aortic stenosis. Heart \n2016;102:934–42. https://doi.org/10.1136/heartjnl-2015-308742 \n356. Dahl JS, Eleid MF, Michelena HI, Scott CG, Suri RM, Schaff HV, et al. Effect of left ven-\ntricular ejection fraction on postoperative outcome in patients with severe aortic sten-\nosis undergoing aortic valve replacement. Circ Cardiovasc Imaging 2015;8:e002917.  \nhttps://doi.org/10.1161/CIRCIMAGING.114.002917 \n357. Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, Murata K, et al. Prognostic \nimpact of left ventricular ejection fraction in patients with severe aortic stenosis. JACC \nCardiovasc Interv 2018;11:145–57. https://doi.org/10.1016/j.jcin.2017.08.036 \n358. Ito S, Miranda WR, Nkomo VT, Connolly HM, Pislaru SV, Greason KL, et al. Reduced \nleft ventricular ejection fraction in patients with aortic stenosis. J Am Coll Cardiol 2018; \n71:1313–21. https://doi.org/10.1016/j.jacc.2018.01.045 \n359. De Azevedo D, Boute M, Tribouilloy C, Maréchaux S, Pouleur AC, Bohbot Y, et al. \nQuantifying the survival loss linked to late therapeutic indication in high-gradient se-\nvere aortic stenosis. JACC Adv 2024;3:100830. https://doi.org/10.1016/j.jacadv.2024. \n100830 \n360. Généreux P, Schwartz A, Oldemeyer JB, Pibarot P, Cohen DJ, Blanke P, et al. \nTranscatheter aortic-valve replacement for asymptomatic severe aortic stenosis. N \nEngl J Med 2024;392:217–27. https://doi.org/10.1056/NEJMoa2405880 \n361. Loganath K, Craig NJ, Everett RJ, Bing R, Tsampasian V, Molek P, et al. Early interven-\ntion in patients with asymptomatic severe aortic stenosis and myocardial fibrosis: the  \n4720                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nEVOLVED randomized clinical trial. JAMA 2024;333:213–21. https://doi.org/10.1001/ \njama.2024.22730 \n362. Kang DH, Park SJ, Lee SA, Lee S, Kim DH, Kim HK, et al. Early surgery or conservative \ncare for asymptomatic aortic stenosis. N Engl J Med 2020;382:111–9. https://doi.org/ \n10.1056/NEJMoa1912846 \n363. Banovic M, Putnik S, Penicka M, Doros G, Deja MA, Kockova R, et al. Aortic valve re-\nplacement versus conservative treatment in asymptomatic severe aortic stenosis: the \nAVATAR \nTrial. \nCirculation \n2022;145:648–58. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.121.057639 \n364. Rosenhek R, Binder T, Porenta G, Lang I, Christ G, Schemper M, et al. Predictors of \noutcome in severe, asymptomatic aortic stenosis. N Engl J Med 2000;343:611–7.  \nhttps://doi.org/10.1056/NEJM200008313430903 \n365. Nakatsuma K, Taniguchi T, Morimoto T, Shiomi H, Ando K, Kanamori N, et al. B-type \nnatriuretic peptide in patients with asymptomatic severe aortic stenosis. Heart 2019; \n105:384–90. https://doi.org/10.1136/heartjnl-2018-313746 \n366. Parikh V, Kim C, Siegel RJ, Arsanjani R, Rader F. Natriuretic peptides for risk stratifica-\ntion of patients with valvular aortic stenosis. Circ Heart Fail 2015;8:373–80. https://doi. \norg/10.1161/CIRCHEARTFAILURE.114.001649 \n367. Banovic M, Putnik S, Da Costa BR, Penicka M, Deja MA, Kotrc M, et al. Aortic valve \nreplacement versus conservative treatment in asymptomatic severe aortic stenosis: \nlong-term follow-up of the AVATAR trial. Eur Heart J 2024;45:4526–35. https://doi. \norg/10.1093/eurheartj/ehae585 \n368. Généreux P, Banovic M, Kang DH, Giustino G, Prendergast BD, Lindman BR, et al. \nAortic valve replacement vs clinical surveillance in asymptomatic severe aortic stenosis: \na systematic review and meta-analysis. J Am Coll Cardiol 2024;85:912–22. https://doi. \norg/10.1016/j.jacc.2024.11.006 \n369. Smith WTI, Ferguson TBJ, Ryan T, Landolfo CK, Peterson ED. Should coronary artery \nbypass graft surgery patients with mild or moderate aortic stenosis undergo concomi-\ntant aortic valve replacement? A decision analysis approach to the surgical dilemma. J \nAm Coll Cardiol 2004;44:1241–7. https://doi.org/10.1016/j.jacc.2004.06.031 \n370. Jean G, Van Mieghem NM, Gegenava T, van Gils L, Bernard J, Geleijnse ML, et al. \nModerate aortic stenosis in patients with heart failure and reduced ejection fraction. \nJ Am Coll Cardiol 2021;77:2796–803. https://doi.org/10.1016/j.jacc.2021.04.014 \n371. Jacquemyn X, Strom JB, Strange G, Playford D, Stewart S, Kutty S, et al. Moderate aor-\ntic valve stenosis is associated with increased mortality rate and lifetime loss: system-\natic review and meta-analysis of reconstructed time-to-event data of 409 680 patients. \nJ Am Heart Assoc 2024;13:e033872. https://doi.org/10.1161/jaha.123.033872 \n372. Amanullah MR, Pio SM, Ng ACT, Sin KYK, Marsan NA, Ding ZP, et al. Prognostic im-\nplications of associated cardiac abnormalities detected on echocardiography in pa-\ntients with moderate aortic stenosis. JACC Cardiovasc Imaging 2021;14:1724–37.  \nhttps://doi.org/10.1016/j.jcmg.2021.04.009 \n373. Van Mieghem NM, Elmariah S, Spitzer E, Pibarot P, Nazif TM, Bax JJ, et al. \nTranscatheter aortic valve replacement in patients with systolic heart failure and mod-\nerate aortic stenosis: TAVR UNLOAD. J Am Coll Cardiol 2024;85:878–90. https://doi. \norg/10.1016/j.jacc.2024.10.070 \n374. Graversen PL, Butt JH, Østergaard L, Jensen AD, Warming PE, Strange JE, et al. \nChanges in aortic valve replacement procedures in Denmark from 2008 to 2020. \nHeart 2023;109:557–63. https://doi.org/10.1136/heartjnl-2022-321594 \n375. Johnston DR, Soltesz EG, Vakil N, Rajeswaran J, Roselli EE, Sabik JF 3rd, et al. Long-term \ndurability of bioprosthetic aortic valves: implications from 12,569 implants. Ann Thorac \nSurg 2015;99:1239–47. https://doi.org/10.1016/j.athoracsur.2014.10.070 \n376. Goldstone AB, Chiu P, Baiocchi M, Lingala B, Patrick WL, Fischbein MP, et al. \nMechanical or biologic prostheses for aortic-valve and mitral-valve replacement. N \nEngl J Med 2017;377:1847–57. https://doi.org/10.1056/NEJMoa1613792 \n377. Mazine A, David TE, Stoklosa K, Chung J, Lafreniere-Roula M, Ouzounian M. Improved \noutcomes following the Ross procedure compared with bioprosthetic aortic valve re-\nplacement. J Am Coll Cardiol 2022;79:993–1005. https://doi.org/10.1016/j.jacc.2021.12. \n026 \n378. Notenboom ML, Melina G, Veen KM, De Robertis F, Coppola G, De Siena P, et al. \nLong-term clinical and echocardiographic outcomes following the Ross procedure: a \npost hoc analysis of a randomized clinical trial. JAMA Cardiology 2023;9:6–14. https:// \ndoi.org/10.1001/jamacardio.2023.4090 \n379. Alkhouli M, Zack CJ, Sarraf M, Bashir R, Nishimura RA, Eleid MF, et al. Morbidity and \nmortality associated with balloon aortic valvuloplasty: a national perspective. Circ \nCardiovasc Interv 2017;10:e004481. https://doi.org/10.1161/CIRCINTERVENTIONS. \n116.004481 \n380. Sharma T, Krishnan AM, Lahoud R, Polomsky M, Dauerman HL. National trends in \nTAVR and SAVR for patients with severe isolated aortic stenosis. J Am Coll Cardiol \n2022;80:2054–6. https://doi.org/10.1016/j.jacc.2022.08.787 \n381. Gaede L, Blumenstein J, Eckel C, Grothusen C, Tiyerili V, Sötemann D, et al. \nTranscatheter-based aortic valve replacement vs. isolated surgical aortic valve replace-\nment in 2020. Clin Res Cardiol 2022;111:924–33. https://doi.org/10.1007/s00392-022- \n02006-1 \n382. Nguyen V, Willner N, Eltchaninoff H, Burwash IG, Michel M, Durand E, et al. Trends in \naortic valve replacement for aortic stenosis: a French nationwide study. Eur Heart J \n2022;43:666–79. https://doi.org/10.1093/eurheartj/ehab773 \n383. Mori M, Gupta A, Wang Y, Vahl T, Nazif T, Kirtane AJ, et al. Trends in transcatheter \nand surgical aortic valve replacement among older adults in the United States. J Am Coll \nCardiol 2021;78:2161–72. https://doi.org/10.1016/j.jacc.2021.09.855 \n384. Pilgrim T, Windecker S. Expansion of transcatheter aortic valve implantation: new in-\ndications and socio-economic considerations. Eur Heart J 2018;39:2643–45. https:// \ndoi.org/10.1093/eurheartj/ehy228 \n385. Durko AP, Osnabrugge RL, Van Mieghem NM, Milojevic M, Mylotte D, Nkomo VT, \net al. Annual number of candidates for transcatheter aortic valve implantation per \ncountry: current estimates and future projections. Eur Heart J 2018;39:2635–42.  \nhttps://doi.org/10.1093/eurheartj/ehy107 \n386. Barbato E, Noc M, Baumbach A, Dudek D, Bunc M, Skalidis E, et al. Mapping interven-\ntional cardiology in Europe: the European Association of Percutaneous Cardiovascular \nInterventions (EAPCI) Atlas project. Eur Heart J 2020;41:2579–88. https://doi.org/10. \n1093/eurheartj/ehaa475 \n387. Benfari G, Essayagh B, Michelena HI, Ye Z, Inojosa JM, Ribichini FL, et al. Severe aortic \nstenosis: secular trends of incidence and outcomes. Eur Heart J 2024;45:1877–86.  \nhttps://doi.org/10.1093/eurheartj/ehad887 \n388. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, et al. Transcatheter \naortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N \nEngl J Med 2010;363:1597–607. https://doi.org/10.1056/NEJMoa1008232 \n389. Gleason TG, Reardon MJ, Popma JJ, Deeb GM, Yakubov SJ, Lee JS, et al. 5-Year out-\ncomes of self-expanding transcatheter versus surgical aortic valve replacement in high- \nrisk patients. J Am Coll Cardiol 2018;72:2687–96. https://doi.org/10.1016/j.jacc.2018.08. \n2146 \n390. Mack MJ, Leon MB, Smith CR, Miller DC, Moses JW, Tuzcu EM, et al. 5-Year outcomes \nof transcatheter aortic valve replacement or surgical aortic valve replacement for high \nsurgical risk patients with aortic stenosis (PARTNER 1): a randomised controlled trial. \nLancet 2015;385:2477–84. https://doi.org/10.1016/S0140-6736(15)60308-7 \n391. Smith CR, Leon MB, Mack MJ, Miller DC, Moses JW, Svensson LG, et al. Transcatheter \nversus surgical aortic-valve replacement in high-risk patients. N Engl J Med 2011;364: \n2187–98. https://doi.org/10.1056/NEJMoa1103510 \n392. Leon MB, Smith CR, Mack MJ, Makkar RR, Svensson LG, Kodali SK, et al. Transcatheter \nor surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 2016; \n374:1609–20. https://doi.org/10.1056/NEJMoa1514616 \n393. Toff WD, Hildick-Smith D, Kovac J, Mullen MJ, Wendler O, Mansouri A, et al. Effect of \ntranscatheter aortic valve implantation vs surgical aortic valve replacement on all-cause \nmortality in patients with aortic stenosis: a randomized clinical trial. JAMA 2022;327: \n1875–87. https://doi.org/10.1001/jama.2022.5776 \n394. Popma JJ, Deeb GM, Yakubov SJ, Mumtaz M, Gada H, O’Hair D, et al. Transcatheter \naortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J \nMed 2019;380:1706–15. https://doi.org/10.1056/NEJMoa1816885 \n395. Blankenberg S, Seiffert M, Vonthein R, Baumgartner H, Bleiziffer S, Borger MA, et al. \nTranscatheter or surgical treatment of aortic-valve stenosis. N Engl J Med 2024;390: \n1572–83. https://doi.org/10.1056/NEJMoa2400685 \n396. Makkar RR, Thourani VH, Mack MJ, Kodali SK, Kapadia S, Webb JG, et al. Five-year out-\ncomes of transcatheter or surgical aortic-valve replacement. N Engl J Med 2020;382: \n799–809. https://doi.org/10.1056/NEJMoa1910555 \n397. Van Mieghem NM, Deeb GM, Søndergaard L, Grube E, Windecker S, Gada H, et al. \nSelf-expanding transcatheter vs surgical aortic valve replacement in intermediate-risk \npatients: 5-year outcomes of the SURTAVI randomized clinical trial. JAMA Cardiol \n2022;7:1000–8. https://doi.org/10.1001/jamacardio.2022.2695 \n398. Thyregod HGH, Jørgensen TH, Ihlemann N, Steinbrüchel DA, Nissen H, Kjeldsen BJ, \net al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the \nNOTION trial. Eur Heart J 2024;45:1116–24. https://doi.org/10.1093/eurheartj/ \nehae043 \n399. Ahmad Y, Howard JP, Arnold AD, Madhavan MV, Cook CM, Alu M, et al. \nTranscatheter versus surgical aortic valve replacement in lower-risk and higher-risk pa-\ntients: a meta-analysis of randomized trials. Eur Heart J 2023;44:836–52. https://doi. \norg/10.1093/eurheartj/ehac642 \n400. Barili F, Brophy JM, Ronco D, Myers PO, Uva MS, Almeida RMS, et al. Risk of bias in \nrandomized clinical trials comparing transcatheter and surgical aortic valve replace-\nment: a systematic review and meta-analysis. JAMA Netw Open 2023;6:e2249321.  \nhttps://doi.org/10.1001/jamanetworkopen.2022.49321 \n401. Siontis GCM, Overtchouk P, Cahill TJ, Modine T, Prendergast B, Praz F, et al. \nTranscatheter aortic valve implantation vs. surgical aortic valve replacement for treat-\nment of symptomatic severe aortic stenosis: an updated meta-analysis. Eur Heart J \n2019;40:3143–53. https://doi.org/10.1093/eurheartj/ehz275 \n402. Pibarot P, Hahn RT, Weissman NJ, Arsenault M, Beaudoin J, Bernier M, et al. \nAssociation of paravalvular regurgitation with 1-year outcomes after transcatheter \naortic valve replacement with the SAPIEN 3 valve. JAMA Cardiol 2017;2:1208–16.  \nhttps://doi.org/10.1001/jamacardio.2017.3425 \n403. Kodali S, Pibarot P, Douglas PS, Williams M, Xu K, Thourani V, et al. Paravalvular re-\ngurgitation after transcatheter aortic valve replacement with the Edwards sapien valve \nin the PARTNER trial: characterizing patients and impact on outcomes. Eur Heart J \n2015;36:449–56. https://doi.org/10.1093/eurheartj/ehu384  \nESC Guidelines                                                                                                                                                                                          4721 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n404. Lerman TT, Levi A, Kornowski R. Meta-analysis of short- and long-term clinical out-\ncomes of the self-expanding Evolut R/pro valve versus the balloon-expandable \nSapien 3 valve for transcatheter aortic valve implantation. Int J Cardiol 2023;371: \n100–8. https://doi.org/10.1016/j.ijcard.2022.09.035 \n405. Faroux L, Chen S, Muntané-Carol G, Regueiro A, Philippon F, Sondergaard L, et al. \nClinical impact of conduction disturbances in transcatheter aortic valve replacement \nrecipients: a systematic review and meta-analysis. Eur Heart J 2020;41:2771–81.  \nhttps://doi.org/10.1093/eurheartj/ehz924 \n406. Greason KL, Lahr BD, Stulak JM, Cha YM, Rea RF, Schaff HV, et al. Long-term mortality \neffect of early pacemaker implantation after surgical aortic valve replacement. Ann \nThorac Surg 2017;104:1259–64. https://doi.org/10.1016/j.athoracsur.2017.01.083 \n407. Rück A, Saleh N, Glaser N. Outcomes following permanent pacemaker implantation \nafter transcatheter aortic valve replacement: SWEDEHEART observational study. \nJACC Cardiovasc Interv 2021;14:2173–81. https://doi.org/10.1016/j.jcin.2021.07.043 \n408. Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, et al. \nCost-effectiveness of transcatheter versus surgical aortic valve replacement in patients \nwith severe aortic stenosis at intermediate risk. Circulation 2019;139:877–88. https:// \ndoi.org/10.1161/CIRCULATIONAHA.118.035236 \n409. Tam DY, Azizi PM, Fremes SE, Chikwe J, Gaudino M, Wijeysundera HC. The cost- \neffectiveness of transcatheter aortic valve replacement in low surgical risk patients \nwith severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes 2021;7:556–63.  \nhttps://doi.org/10.1093/ehjqcco/qcaa058 \n410. Pibarot P, Ternacle J, Jaber WA, Salaun E, Dahou A, Asch FM, et al. Structural deteri-\noration of transcatheter versus surgical aortic valve bioprostheses in the PARTNER-2 \ntrial. J Am Coll Cardiol 2020;76:1830–43. https://doi.org/10.1016/j.jacc.2020.08.049 \n411. Fatima B, Mohananey D, Khan FW, Jobanputra Y, Tummala R, Banerjee K, et al. \nDurability data for bioprosthetic surgical aortic valve: a systematic review. JAMA \nCardiol 2019;4:71–80. https://doi.org/10.1001/jamacardio.2018.4045 \n412. Kedhi E, Hermanides RS, Dambrink JE, Singh SK, Ten Berg JM, van Ginkel D, et al. \nTransCatheter aortic valve implantation and fractional flow reserve-guided percutan-\neous coronary intervention versus conventional surgical aortic valve replacement and \ncoronary bypass grafting for treatment of patients with aortic valve stenosis and com-\nplex or multivessel coronary disease (TCW): an international, multicentre, prospect-\nive, open-label, non-inferiority, randomised controlled trial. Lancet 2025;404: \n2593–602. https://doi.org/10.1016/s0140-6736(24)02100-7 \n413. Martinsson A, Nielsen SJ, Milojevic M, Redfors B, Omerovic E, Tonnessen T, et al. Life \nexpectancy after surgical aortic valve replacement. J Am Coll Cardiol 2021;78:2147–57.  \nhttps://doi.org/10.1016/j.jacc.2021.09.861 \n414. Glaser N, Persson M, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. Loss in \nlife expectancy after surgical aortic valve replacement: SWEDEHEART study. J Am Coll \nCardiol 2019;74:26–33. https://doi.org/10.1016/j.jacc.2019.04.053 \n415. Attinger-Toller A, Ferrari E, Tueller D, Templin C, Muller O, Nietlispach F, et al. \nAge-related outcomes after transcatheter aortic valve replacement: insights from \nthe SwissTAVI registry. JACC Cardiovasc Interv 2021;14:952–60. https://doi.org/10. \n1016/j.jcin.2021.01.042 \n416. Jørgensen TH, Thyregod HGH, Savontaus M, Willemen Y, Bleie Ø, Tang M, et al. \nTranscatheter aortic valve implantation in low-risk tricuspid or bicuspid aortic sten-\nosis: the NOTION-2 trial. Eur Heart J 2024;45:3804–14. https://doi.org/10.1093/ \neurheartj/ehae331 \n417. Dahle TG, Kaneko T, McCabe JM. Outcomes following subclavian and axillary artery \naccess for transcatheter aortic valve replacement: Society of the Thoracic Surgeons/ \nAmerican College of Cardiology TVT registry report. JACC Cardiovasc Interv 2019; \n12:662–9. https://doi.org/10.1016/j.jcin.2019.01.219 \n418. Gleason TG, Schindler JT, Hagberg RC, Deeb GM, Adams DH, Conte JV, et al. \nSubclavian/axillary access for self-expanding transcatheter aortic valve replacement \nrenders equivalent outcomes as transfemoral. Ann Thorac Surg 2018;105:477–83.  \nhttps://doi.org/10.1016/j.athoracsur.2017.07.017 \n419. Kirker E, Korngold E, Hodson RW, Jones BM, McKay R, Cheema M, et al. Transcarotid \nversus subclavian/axillary access for transcatheter aortic valve replacement with \nSAPIEN 3. Ann Thorac Surg 2020;110:1892–7. https://doi.org/10.1016/j.athoracsur. \n2020.05.141 \n420. Debry N, Trimech TR, Gandet T, Vincent F, Hysi I, Delhaye C, et al. Transaxillary com-\npared with transcarotid access for TAVR: a propensity-matched comparison from a \nFrench multicentre registry. EuroIntervention 2020;16:842–9. https://doi.org/10.4244/ \neij-d-20-00117 \n421. Beurtheret S, Karam N, Resseguier N, Houel R, Modine T, Folliguet T, et al. Femoral \nversus nonfemoral peripheral access for transcatheter aortic valve replacement. J Am \nColl Cardiol 2019;74:2728–39. https://doi.org/10.1016/j.jacc.2019.09.054 \n422. Greenbaum AB, Babaliaros VC, Chen MY, Stine AM, Rogers T, O’Neill WW, et al. \nTranscaval access and closure for transcatheter aortic valve replacement: a prospect-\nive investigation. J Am Coll Cardiol 2017;69:511–21. https://doi.org/10.1016/j.jacc.2016. \n10.024 \n423. Lederman RJ, Babaliaros VC, Lisko JC, Rogers T, Mahoney P, Foerst JR, et al. Transcaval \nversus transaxillary TAVR in contemporary practice: a propensity-weighted analysis. \nJACC Cardiovasc Interv 2022;15:965–75. https://doi.org/10.1016/j.jcin.2022.03.014 \n424. Okuno T, Asami M, Heg D, Lanz J, Praz F, Hagemeyer D, et al. Impact of left ventricular \noutflow tract calcification on procedural outcomes after transcatheter aortic valve re-\nplacement. JACC Cardiovasc Interv 2020;13:1789–99. https://doi.org/10.1016/j.jcin. \n2020.04.015 \n425. Barbanti M, Yang TH, Rodès Cabau J, Tamburino C, Wood DA, Jilaihawi H, et al. \nAnatomical and procedural features associated with aortic root rupture during \nballoon-expandable transcatheter aortic valve replacement. Circulation 2013;128: \n244–53. https://doi.org/10.1161/circulationaha.113.002947 \n426. Kirmani BH, Jones SG, Muir A, Malaisrie SC, Chung DA, Williams RJ, et al. Limited ver-\nsus full sternotomy for aortic valve replacement. Cochrane Database Syst Rev 2023;12: \nCD011793. https://doi.org/10.1002/14651858.CD011793.pub3 \n427. Paparella D, Malvindi PG, Santarpino G, Moscarelli M, Guida P, Fattouch K, et al. Full \nsternotomy and minimal access approaches for surgical aortic valve replacement: a \nmulticentre propensity-matched study. Eur J Cardiothorac Surg 2020;57:709–16.  \nhttps://doi.org/10.1093/ejcts/ezz286 \n428. Vincent F, Ternacle J, Denimal T, Shen M, Redfors B, Delhaye C, et al. Transcatheter \naortic valve replacement in bicuspid aortic valve stenosis. Circulation 2021;143: \n1043–61. https://doi.org/10.1161/CIRCULATIONAHA.120.048048 \n429. Alperi A, Voisine P, Kalavrouziotis D, Dumont E, Dagenais F, Perron J, et al. Aortic \nvalve replacement in low-risk patients with severe aortic stenosis outside randomized \ntrials. J Am Coll Cardiol 2021;77:111–23. https://doi.org/10.1016/j.jacc.2020.10.056 \n430. Makkar RR, Yoon SH, Leon MB, Chakravarty T, Rinaldi M, Shah PB, et al. Association \nbetween transcatheter aortic valve replacement for bicuspid vs tricuspid aortic sten-\nosis and mortality or stroke. JAMA 2019;321:2193–202. https://doi.org/10.1001/jama. \n2019.7108 \n431. Halim SA, Edwards FH, Dai D, Li Z, Mack MJ, Holmes DR, et al. Outcomes of trans-\ncatheter aortic valve replacement in patients with bicuspid aortic valve disease: a re-\nport from the Society of Thoracic Surgeons/American College of Cardiology \nTranscatheter Valve Therapy Registry. Circulation 2020;141:1071–9. https://doi.org/ \n10.1161/CIRCULATIONAHA.119.040333 \n432. Forrest JK, Kaple RK, Ramlawi B, Gleason TG, Meduri CU, Yakubov SJ, et al. \nTranscatheter aortic valve replacement in bicuspid versus tricuspid aortic valves \nfrom the STS/ACC TVT registry. JACC Cardiovasc Interv 2020;13:1749–59. https:// \ndoi.org/10.1016/j.jcin.2020.03.022 \n433. Montalto C, Sticchi A, Crimi G, Laricchia A, Khokhar AA, Giannini F, et al. Outcomes \nafter transcatheter aortic valve replacement in bicuspid versus tricuspid anatomy: a \nsystematic review and meta-analysis. JACC Cardiovasc Interv 2021;14:2144–55.  \nhttps://doi.org/10.1016/j.jcin.2021.07.052 \n434. Yoon SH, Bleiziffer S, De Backer O, Delgado V, Arai T, Ziegelmueller J, et al. Outcomes \nin transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve \nstenosis. J Am Coll Cardiol 2017;69:2579–89. https://doi.org/10.1016/j.jacc.2017.03.017 \n435. Jilaihawi H, Chen M, Webb J, Himbert D, Ruiz CE, Rodés-Cabau J, et al. A bicuspid aor-\ntic valve imaging classification for the TAVR era. JACC Cardiovasc Imaging 2016;9: \n1145–58. https://doi.org/10.1016/j.jcmg.2015.12.022 \n436. Sá MPBO, Zhigalov K, Cavalcanti LRP, Escorel Neto AC, Rayol SC, Weymann A, et al. \nImpact of aortic annulus enlargement on the outcomes of aortic valve replacement: a \nmeta-analysis. Semin Thorac Cardiovasc Surg 2021;33:316–25. https://doi.org/10.1053/j. \nsemtcvs.2020.06.046 \n437. Head SJ, Reardon MJ, Deeb GM, Van Mieghem NM, Popma JJ, Gleason TG, et al. \nComputed tomography-based indexed aortic annulus size to predict prosthesis- \npatient mismatch. Circ Cardiovasc Interv 2019;12:e007396. https://doi.org/10.1161/ \ncircinterventions.118.007396 \n438. Herrmann HC, Mehran R, Blackman DJ, Bailey S, Möllmann H, Abdel-Wahab M, et al. \nSelf-expanding or balloon-expandable TAVR in patients with a small aortic annulus. N \nEngl J Med 2024;390:1959–71. https://doi.org/10.1056/NEJMoa2312573 \n439. Yokoyama Y, Kuno T, Zaid S, Kaneko T, Takagi H, Tang GHL, et al. Surgical explant-\nation of transcatheter aortic bioprosthesis: a systematic review and meta-analysis. \nJTCVS Open 2021;8:207–27. https://doi.org/10.1016/j.xjon.2021.09.023 \n440. Marin-Cuartas M, Tang GHL, Kiefer P, Fukuhara S, Lange R, Harrington KB, et al. \nTranscatheter heart valve explant with infective endocarditis-associated prosthesis \nfailure and outcomes: the EXPLANT-TAVR international registry. Eur Heart J 2024; \n45:2519–32. https://doi.org/10.1093/eurheartj/ehae292 \n441. Hirji SA, Percy ED, McGurk S, Malarczyk A, Harloff MT, Yazdchi F, et al. Incidence, \ncharacteristics, predictors, and outcomes of surgical explantation after transcatheter \naortic valve replacement. J Am Coll Cardiol 2020;76:1848–59. https://doi.org/10.1016/ \nj.jacc.2020.08.048 \n442. Jawitz OK, Gulack BC, Grau-Sepulveda MV, Matsouaka RA, Mack MJ, Holmes DR Jr, \net al. Reoperation after transcatheter aortic valve replacement: an analysis of the \nSociety of Thoracic Surgeons database. JACC Cardiovasc Interv 2020;13:1515–25.  \nhttps://doi.org/10.1016/j.jcin.2020.04.029 \n443. Hawkins RB, Deeb GM, Sukul D, Patel HJ, Gualano SK, Chetcuti SJ, et al. Redo surgical \naortic valve replacement after prior transcatheter versus surgical aortic valve replace-\nment. JACC Cardiovasc Interv 2023;16:942–53. https://doi.org/10.1016/j.jcin.2023.03. \n015 \n444. Bapat VN, Zaid S, Fukuhara S, Saha S, Vitanova K, Kiefer P, et al. Surgical explantation \nafter TAVR failure: mid-term outcomes from the EXPLANT-TAVR international  \n4722                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\nregistry. JACC Cardiovasc Interv 2021;14:1978–91. https://doi.org/10.1016/j.jcin.2021. \n07.015 \n445. Bowdish ME, Habib RH, Kaneko T, Thourani VH, Badhwar V. Cardiac surgery after \ntranscatheter aortic valve replacement: trends and outcomes. Ann Thorac Surg 2024; \n118:155–62. https://doi.org/10.1016/j.athoracsur.2024.03.024 \n446. Landes U, Webb JG, De Backer O, Sondergaard L, Abdel-Wahab M, Crusius L, et al. \nRepeat transcatheter aortic valve replacement for transcatheter prosthesis dysfunc-\ntion. J Am Coll Cardiol 2020;75:1882–93. https://doi.org/10.1016/j.jacc.2020.02.051 \n447. Tam DY, Dharma C, Rocha RV, Ouzounian M, Wijeysundera HC, Austin PC, et al. \nTranscatheter ViV versus redo surgical AVR for the management of failed biological \nprosthesis: early and late outcomes in a propensity-matched cohort. JACC Cardiovasc \nInterv 2020;13:765–74. https://doi.org/10.1016/j.jcin.2019.10.030 \n448. Sá MBPO, Van den Eynde J, Simonato M, Cavalcanti LRP, Doulamis IP, Weixler V, et al. \nValve-in-valve transcatheter aortic valve replacement versus redo surgical aortic valve \nreplacement: an updated meta-analysis. JACC Cardiovasc Interv 2021;14:211–20. https:// \ndoi.org/10.1016/j.jcin.2020.10.020 \n449. Percy ED, Harloff MT, Hirji S, McGurk S, Yazdchi F, Newell P, et al. Nationally repre-\nsentative repeat transcatheter aortic valve replacement outcomes: report from the \ncenters for Medicare and Medicaid services. JACC Cardiovasc Interv 2021;14: \n1717–26. https://doi.org/10.1016/j.jcin.2021.06.011 \n450. Makkar RR, Kapadia S, Chakravarty T, Cubeddu RJ, Kaneko T, Mahoney P, et al. \nOutcomes of repeat transcatheter aortic valve replacement with balloon-expandable \nvalves: a registry study. Lancet 2023;402:1529–40. https://doi.org/10.1016/s0140- \n6736(23)01636-7 \n451. Deharo P, Bisson A, Herbert J, Lacour T, Etienne CS, Porto A, et al. Transcatheter \nvalve-in-valve aortic valve replacement as an alternative to surgical re-replacement. J \nAm Coll Cardiol 2020;76:489–99. https://doi.org/10.1016/j.jacc.2020.06.010 \n452. Dismorr M, Glaser N, Franco-Cereceda A, Sartipy U. Effect of prosthesis-patient mis-\nmatch on long-term clinical outcomes after bioprosthetic aortic valve replacement. J \nAm Coll Cardiol 2023;81:964–75. https://doi.org/10.1016/j.jacc.2022.12.023 \n453. Head SJ, Mokhles MM, Osnabrugge RL, Pibarot P, Mack MJ, Takkenberg JJ, et al. The \nimpact of prosthesis-patient mismatch on long-term survival after aortic valve replace-\nment: a systematic review and meta-analysis of 34 observational studies comprising 27 \n186 patients with 133 141 patient-years. Eur Heart J 2012;33:1518–29. https://doi.org/ \n10.1093/eurheartj/ehs003 \n454. Herrmann HC, Daneshvar SA, Fonarow GC, Stebbins A, Vemulapalli S, Desai ND, \net al. Prosthesis–patient mismatch in patients undergoing transcatheter aortic valve re-\nplacement: from the STS/ACC TVT registry. J Am Coll Cardiol 2018;72:2701–11.  \nhttps://doi.org/10.1016/j.jacc.2018.09.001 \n455. Ternacle J, Pibarot P, Herrmann HC, Kodali S, Leipsic J, Blanke P, et al. \nProsthesis-patient mismatch after aortic valve replacement in the PARTNER 2 trial \nand registry. JACC Cardiovasc Interv 2021;14:1466–77. https://doi.org/10.1016/j.jcin. \n2021.03.069 \n456. Akodad M, Sellers S, Landes U, Meier D, Tang Gilbert HL, Gada H, et al. \nBalloon-expandable valve for treatment of Evolut valve failure. JACC Cardiovasc Interv \n2022;15:368–77. https://doi.org/10.1016/j.jcin.2021.12.021 \n457. Ribeiro HB, Rodés-Cabau J, Blanke P, Leipsic J, Kwan Park J, Bapat V, et al. Incidence, \npredictors, and clinical outcomes of coronary obstruction following transcatheter aor-\ntic valve replacement for degenerative bioprosthetic surgical valves: insights from the \nVIVID registry. Eur Heart J 2018;39:687–95. https://doi.org/10.1093/eurheartj/ehx455 \n458. Ochiai T, Oakley L, Sekhon N, Komatsu I, Flint N, Kaewkes D, et al. Risk of coronary \nobstruction due to sinus sequestration in redo transcatheter aortic valve replacement. \nJACC Cardiovasc Interv 2020;13:2617–27. https://doi.org/10.1016/j.jcin.2020.09.022 \n459. Akodad M, Sellers S, Gulsin GS, Tzimas G, Landes U, Chatfield Andrew G, et al. Leaflet \nand neoskirt height in transcatheter heart valves. JACC Cardiovasc Interv 2021;14: \n2298–300. https://doi.org/10.1016/j.jcin.2021.07.034 \n460. Tang GH, Spencer J, Rogers T, Grubb KJ, Gleason P, Gada H, et al. Feasibility of cor-\nonary access following redo-TAVR for Evolut failure: a computed tomography simu-\nlation study. Circ Cardiovasc Interv 2023;16:e013238. https://doi.org/10.1161/ \nCIRCINTERVENTIONS.123.013238 \n461. De Backer O, Landes U, Fuchs A, Yoon SH, Mathiassen ON, Sedaghat A, et al. \nCoronary access after TAVR-in-TAVR as evaluated by multidetector computed tom-\nography. JACC Cardiovasc Interv 2020;13:2528–38. https://doi.org/10.1016/j.jcin.2020. \n06.016 \n462. Fukui M, Okada A, Thao KR, Burns MR, Koike H, Wang C, et al. Feasibility of redo- \ntranscatheter aortic valve replacement in Sapien valves based on in vivo computed \ntomography assessment. Circ Cardiovasc Interv 2023;16:e013497. https://doi.org/10. \n1161/CIRCINTERVENTIONS.123.013497 \n463. Chhatriwalla AK, Allen KB, Depta JP, Rodriguez E, Thourani VH, Whisenant BK, et al. \nOutcomes of bioprosthetic valve fracture in patients undergoing valve-in-valve TAVR. \nJACC Cardiovasc Interv 2023;16:530–9. https://doi.org/10.1016/j.jcin.2022.12.019 \n464. Khan JM, Babaliaros VC, Greenbaum AB, Spies C, Daniels D, Depta JP, et al. Preventing \ncoronary obstruction during transcatheter aortic valve replacement: results from the \nmulticenter international BASILICA registry. JACC Cardiovasc Interv 2021;14:941–8.  \nhttps://doi.org/10.1016/j.jcin.2021.02.035 \n465. Jørgensen TH, Thyregod HGH, Ihlemann N, Nissen H, Petursson P, Kjeldsen BJ, et al. \nEight-year outcomes for patients with aortic valve stenosis at low surgical risk rando-\nmized to transcatheter vs. surgical aortic valve replacement. Eur Heart J 2021;42: \n2912–9. https://doi.org/10.1093/eurheartj/ehab375 \n466. O’Hair D, Yakubov SJ, Grubb KJ, Oh JK, Ito S, Deeb GM, et al. Structural valve deteri-\noration after self-expanding transcatheter or surgical aortic valve implantation in pa-\ntients at intermediate or high risk. JAMA Cardiol 2023;8:111–9. https://doi.org/10. \n1001/jamacardio.2022.4627 \n467. Rodriguez-Gabella T, Voisine P, Puri R, Pibarot P, Rodés-Cabau J. Aortic bioprosthetic \nvalve durability: incidence, mechanisms, predictors, and management of surgical and \ntranscatheter valve degeneration. J Am Coll Cardiol 2017;70:1013–28. https://doi.org/ \n10.1016/j.jacc.2017.07.715 \n468. Pibarot P, Magne J, Leipsic J, Cote N, Blanke P, Thourani VH, et al. Imaging for predict-\ning and assessing prosthesis-patient mismatch after aortic valve replacement. JACC \nCardiovasc Imaging 2019;12:149–62. https://doi.org/10.1016/j.jcmg.2018.10.020 \n469. Freitas-Ferraz Afonso B, Tirado-Conte G, Dagenais F, Ruel M, Al-Atassi T, Dumont E, \net al. Aortic stenosis and small aortic annulus. Circulation 2019;139:2685–702. https:// \ndoi.org/10.1161/CIRCULATIONAHA.118.038408 \n470. Tang GHL, Zaid S, Fuchs A, Yamabe T, Yazdchi F, Gupta E, et al. Alignment of trans-\ncatheter aortic-valve neo-commissures (ALIGN TAVR): impact on final valve orienta-\ntion and coronary artery overlap. JACC Cardiovasc Interv 2020;13:1030–42. https://doi. \norg/10.1016/j.jcin.2020.02.005 \n471. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-Year out-\ncomes of transcatheter aortic valve replacement compared with standard treatment \nfor patients with inoperable aortic stenosis (PARTNER 1): a randomised controlled \ntrial. Lancet 2015;385:2485–91. https://doi.org/10.1016/S0140-6736(15)60290-2 \n472. Makkar RR, Fontana GP, Jilaihawi H, Kapadia S, Pichard AD, Douglas PS, et al. \nTranscatheter aortic-valve replacement for inoperable severe aortic stenosis. N Engl \nJ Med 2012;366:1696–704. https://doi.org/10.1056/NEJMoa1202277 \n473. Turina J, Hess O, Sepulcri F, Krayenbuehl HP. Spontaneous course of aortic valve dis-\nease. Eur Heart J 1987;8:471–83. https://doi.org/10.1093/oxfordjournals.eurheartj. \na062307 \n474. Pellikka PA, Nishimura RA, Bailey KR, Tajik AJ. The natural history of adults with \nasymptomatic, hemodynamically significant aortic stenosis. J Am Coll Cardiol 1990;15: \n1012–7. https://doi.org/10.1016/0735-1097(90)90234-g \n475. Mangner N, Stachel G, Woitek F, Haussig S, Schlotter F, Hollriegel R, et al. Predictors of \nmortality and symptomatic outcome of patients with low-flow severe aortic stenosis \nundergoing transcatheter aortic valve replacement. J Am Heart Assoc 2018;7:e007977.  \nhttps://doi.org/10.1161/JAHA.117.007977 \n476. Eleid MF, Padang R, Al-Hijji M, Pislaru SV, Greason KL, Maltais S, et al. Hemodynamic \nresponse in low-flow low-gradient aortic stenosis with preserved ejection fraction \nafter TAVR. J Am Coll Cardiol 2019;73:1731–2. https://doi.org/10.1016/j.jacc.2019.01. \n034 \n477. Rusinaru D, Bohbot Y, Ringle A, Marechaux S, Diouf M, Tribouilloy C. Impact of low \nstroke volume on mortality in patients with severe aortic stenosis and preserved left \nventricular ejection fraction. Eur Heart J 2018;39:1992–9. https://doi.org/10.1093/ \neurheartj/ehy123 \n478. Zheng Q, Djohan AH, Lim E, Ding ZP, Ling LH, Shi L, et al. Effects of aortic valve re-\nplacement on severe aortic stenosis and preserved systolic function: systematic review \nand network meta-analysis. Sci Rep 2017;7:5092. https://doi.org/10.1038/s41598-017- \n05021-9 \n479. Salaun E, Clavel MA, Hahn RT, Jaber WA, Asch FM, Rodriguez L, et al. Outcome of \nflow-gradient patterns of aortic stenosis after aortic valve replacement: an analysis \nof the PARTNER 2 trial and registry. Circ Cardiovasc Interv 2020;13:e008792. https:// \ndoi.org/10.1161/CIRCINTERVENTIONS.119.008792 \n480. Annabi MS, Côté N, Dahou A, Bartko PE, Bergler-Klein J, Burwash IG, et al. \nComparison of early surgical or transcatheter aortic valve replacement versus conser-\nvative management in low-flow, low-gradient aortic stenosis using inverse probability \nof treatment weighting: results from the TOPAS prospective observational cohort \nstudy. J Am Heart Assoc 2020;9:e017870. https://doi.org/10.1161/jaha.120.017870 \n481. Mosleh W, Amer MR, Ding Y, Megaly M, Mather JF, McMahon S, et al. Benefit of trans-\ncatheter aortic valve replacement in patients with paradoxical low-flow low-gradient \nversus high-gradient aortic stenosis and preserved left ventricular function. Circ \nCardiovasc Interv 2021;14:e010042. https://doi.org/10.1161/circinterventions.120. \n010042 \n482. Bohbot Y, Kowalski C, Rusinaru D, Ringle A, Marechaux S, Tribouilloy C. Impact of \nmean transaortic pressure gradient on long-term outcome in patients with severe aor-\ntic stenosis and preserved left ventricular ejection fraction. J Am Heart Assoc 2017;6: \ne005850. https://doi.org/10.1161/JAHA.117.005850 \n483. Costa GNF, Cardoso JFL, Oliveiros B, Gonçalves L, Teixeira R. Early surgical interven-\ntion versus conservative management of asymptomatic severe aortic stenosis: a sys-\ntematic review and meta-analysis. Heart 2023;109:314–21. https://doi.org/10.1136/ \nheartjnl-2022-321411 \n484. Bohbot Y, Rusinaru D, Delpierre Q, Marechaux S, Tribouilloy C. Risk stratification of \nsevere aortic stenosis with preserved left ventricular ejection fraction using peak aortic  \nESC Guidelines                                                                                                                                                                                          4723 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\njet velocity: an outcome study. Circ Cardiovasc Imaging 2017;10:e006760. https://doi. \norg/10.1161/CIRCIMAGING.117.006760 \n485. Adams DH, Popma JJ, Reardon MJ. Transcatheter aortic-valve replacement with a self- \nexpanding prosthesis. N Engl J Med 2014;371:967–8. https://doi.org/10.1056/ \nNEJMc1408396 \n486. Thyregod HGH, Steinbrüchel DA, Ihlemann N, Nissen H, Kjeldsen BJ, Petursson P, \net al. Transcatheter versus surgical aortic valve replacement in patients with severe \naortic valve stenosis: 1-year results from the all-comers NOTION randomized clinical \ntrial. J Am Coll Cardiol 2015;65:2184–94. https://doi.org/10.1016/j.jacc.2015.03.014 \n487. Thourani VH, Suri RM, Gunter RL, Sheng S, O’Brien SM, Ailawadi G, et al. \nContemporary real-world outcomes of surgical aortic valve replacement in 141,905 \nlow-risk, intermediate-risk, and high-risk patients. Ann Thorac Surg 2015;99:55–61.  \nhttps://doi.org/10.1016/j.athoracsur.2014.06.050 \n488. Thourani VH, Kodali S, Makkar RR, Herrmann HC, Williams M, Babaliaros V, et al. \nTranscatheter aortic valve replacement versus surgical valve replacement in \nintermediate-risk patients: a propensity score analysis. Lancet 2016;387:2218–25.  \nhttps://doi.org/10.1016/s0140-6736(16)30073-3 \n489. Coylewright M, Grubb KJ, Arnold SV, Batchelor W, Dhoble A, Horne A Jr, et al. \nOutcomes of balloon-expandable transcatheter aortic valve replacement in younger \npatients in the low-risk era. JAMA Cardiol 2025;10:127–35. https://doi.org/10.1001/ \njamacardio.2024.4237 \n490. Ullah W, DiMeglio M, Sana MK, Muhammadzai HZU, Kochar K, Zahid S, et al. \nOutcomes after transcatheter aortic valve implantation in patients excluded from clin-\nical trials. JACC Adv 2023;2:100271. https://doi.org/10.1016/j.jacadv.2023.100271 \n491. Reents W, Barth S, Griese DP, Winkler S, Babin-Ebell J, Kerber S, et al. Transfemoral \nversus transapical transcatheter aortic valve implantation: a single-centre experience. \nEur J Cardiothorac Surg 2019;55:744–50. https://doi.org/10.1093/ejcts/ezy363 \n492. Allen KB, Chhatriwalla AK, Cohen D, Saxon J, Hawa Z, Kennedy KF, et al. Transcarotid \nversus transapical and transaortic access for transcatheter aortic valve replacement. \nAnn Thorac Surg 2019;108:715–22. https://doi.org/10.1016/j.athoracsur.2019.02.007 \n493. Overtchouk P, Folliguet T, Pinaud F, Fouquet O, Pernot M, Bonnet G, et al. \nTranscarotid approach for transcatheter aortic valve replacement with the Sapien 3 \nprosthesis. JACC Cardiovasc Interv 2019;12:413–9. https://doi.org/10.1016/j.jcin.2018. \n11.014 \n494. Kumar N, Khera R, Fonarow GC, Bhatt DL. Comparison of outcomes of transfemoral \nversus transapical approach for transcatheter aortic valve implantation. Am J Cardiol \n2018;122:1520–6. https://doi.org/10.1016/j.amjcard.2018.07.025 \n495. van Wely M, van Nieuwkerk AC, Rooijakkers M, van der Wulp K, Gehlmann H, \nVerkroost M, et al. Transaxillary versus transfemoral access as default access in \nTAVI: a propensity matched analysis. Int J Cardiol 2024;394:131353. https://doi.org/ \n10.1016/j.ijcard.2023.131353 \n496. Allen KB, Watson D, Vora AN, Mahoney P, Chhatriwalla AK, Schwartz JG, et al. \nTranscarotid versus transaxillary access for transcatheter aortic valve replacement \nwith a self-expanding valve: a propensity-matched analysis. JTCVS Tech 2023;21: \n45–55. https://doi.org/10.1016/j.xjtc.2023.07.019 \n497. Salihu A, Ferlay C, Kirsch M, Shah PB, Skali H, Fournier S, et al. Outcomes and safety of \ntranscaval transcatheter aortic valve replacement: a systematic review and \nmeta-analysis. Can J Cardiol 2024;40:2054–62. https://doi.org/10.1016/j.cjca.2024.05. \n016 \n498. Abraham B, Sous M, Sedhom R, Megaly M, Roman S, Sweeney J, et al. Meta-analysis on \ntranscarotid versus transfemoral and other alternate accesses for transcatheter aortic \nvalve implantation. Am J Cardiol 2023;192:196–205. https://doi.org/10.1016/j.amjcard. \n2023.01.023 \n499. Williams MR, Jilaihawi H, Makkar R, O’Neill WW, Guyton R, Malaisrie SC, et al. The \nPARTNER 3 bicuspid registry for transcatheter aortic valve replacement in \nlow-surgical-risk patients. JACC Cardiovasc Interv 2022;15:523–32. https://doi.org/10. \n1016/j.jcin.2022.01.279 \n500. Waksman R, Craig PE, Torguson R, Asch FM, Weissman G, Ruiz D, et al. Transcatheter \naortic valve replacement in low-risk patients with symptomatic severe bicuspid aortic \nvalve stenosis. JACC Cardiovasc Interv 2020;13:1019–27. https://doi.org/10.1016/j.jcin. \n2020.02.008 \n501. Elbadawi A, Saad M, Elgendy IY, Barssoum K, Omer MA, Soliman A, et al. Temporal \ntrends and outcomes of transcatheter versus surgical aortic valve replacement for bi-\ncuspid aortic valve stenosis. JACC Cardiovasc Interv 2019;12:1811–22. https://doi.org/ \n10.1016/j.jcin.2019.06.037 \n502. Tchétché D, Ziviello F, De Biase C, De Backer O, Hovasse T, Leroux L, et al. \nTranscatheter aortic valve implantation with the Evolut platform for bicuspid aortic \nvalve stenosis: the international, multicentre, prospective BIVOLUTX registry. \nEuroIntervention 2023;19:502–11. https://doi.org/10.4244/eij-d-23-00021 \n503. Yang L-T, Boler A, Medina-Inojosa Jose R, Scott Christopher G, Maurer Matthew J, \nEleid Mackram F, et al. Aortic stenosis progression, cardiac damage, and survival. \nJACC Cardiovasc Imaging 2021;14:1113–26. https://doi.org/10.1016/j.jcmg.2021.01.017 \n504. Strange G, Stewart S, Celermajer D, Prior D, Scalia GM, Marwick T, et al. Poor long- \nterm survival in patients with moderate aortic stenosis. J Am Coll Cardiol 2019;74: \n1851–63. https://doi.org/10.1016/j.jacc.2019.08.004 \n505. Samad Z, Vora AN, Dunning A, Schulte PJ, Shaw LK, Al-Enezi F, et al. Aortic valve sur-\ngery and survival in patients with moderate or severe aortic stenosis and left ventricu-\nlar dysfunction. Eur Heart J 2016;37:2276–86. https://doi.org/10.1093/eurheartj/ \nehv701 \n506. Oz A, Tsoumas I, Lampropoulos K, Xanthos T, Karpettas N, Papadopoulos D. Cardiac \nrehabilitation after TAVI—a systematic review and meta-analysis. Curr Probl Cardiol \n2023;48:101531. https://doi.org/10.1016/j.cpcardiol.2022.101531 \n507. Monteagudo Ruiz JM, Galderisi M, Buonauro A, Badano L, Aruta P, Swaans MJ, et al. \nOverview of mitral regurgitation in Europe: results from the European Registry of mi-\ntral regurgitation (EuMiClip). Eur Heart J Cardiovasc Imaging 2018;19:503–7. https://doi. \norg/10.1093/ehjci/jey011 \n508. Nalliah CJ, Mahajan R, Elliott AD, Haqqani H, Lau DH, Vohra JK, et al. Mitral valve pro-\nlapse and sudden cardiac death: a systematic review and meta-analysis. Heart 2019; \n105:144–51. https://doi.org/10.1136/heartjnl-2017-312932 \n509. Van der Bijl P, Stassen J, Haugaa KH, Essayagh B, Basso C, Thiene G, et al. Mitral annular \ndisjunction in the context of mitral valve prolapse: identifying the at-risk patient. JACC \nCardiovasc Imaging 2024;17:1229–45. https://doi.org/10.1016/j.jcmg.2024.03.006 \n510. Antoine C, Benfari G, Michelena HI, Maalouf JF, Nkomo VT, Thapa P, et al. Clinical out-\ncome of degenerative mitral regurgitation. Circulation 2018;138:1317–26. https://doi. \norg/10.1161/CIRCULATIONAHA.117.033173 \n511. Enriquez-Sarano M, Avierinos JF, Messika-Zeitoun D, Detaint D, Capps M, Nkomo V, \net al. Quantitative determinants of the outcome of asymptomatic mitral regurgitation. \nN Engl J Med 2005;352:875–83. https://doi.org/10.1056/NEJMoa041451 \n512. O’Gara PT, Grayburn PA, Badhwar V, Afonso LC, Carroll JD, Elmariah S, et al. 2017 \nACC Expert Consensus Decision Pathway on the management of mitral regurgitation: \na report of the American College of Cardiology Task Force on Expert Consensus \nDecision Pathways. J Am Coll Cardiol 2017;70:2421–49. https://doi.org/10.1016/j.jacc. \n2017.09.019 \n513. Dziadzko V, Dziadzko M, Medina-Inojosa JR, Benfari G, Michelena HI, Crestanello JA, \net al. Causes and mechanisms of isolated mitral regurgitation in the community: clinical \ncontext and outcome. Eur Heart J 2019;40:2194–202. https://doi.org/10.1093/ \neurheartj/ehz314 \n514. Samad Z, Shaw LK, Phelan M, Glower DD, Ersboll M, Toptine JH, et al. Long-term out-\ncomes of mitral regurgitation by type and severity. Am Heart J 2018;203:39–48. https:// \ndoi.org/10.1016/j.ahj.2018.05.001 \n515. Bakkestrom R, Banke A, Christensen NL, Pecini R, Irmukhamedov A, Andersen M, \net al. Hemodynamic characteristics in significant symptomatic and asymptomatic pri-\nmary mitral valve regurgitation at rest and during exercise. Circ Cardiovasc Imaging \n2018;11:e007171. https://doi.org/10.1161/CIRCIMAGING.117.007171 \n516. Utsunomiya H, Hidaka T, Susawa H, Izumi K, Harada Y, Kinoshita M, et al. \nExercise-stress echocardiography and effort intolerance in asymptomatic/minimally \nsymptomatic patients with degenerative mitral regurgitation combined invasive- \nnoninvasive hemodynamic monitoring. Circ Cardiovasc Imaging 2018;11:e007282.  \nhttps://doi.org/10.1161/CIRCIMAGING.117.007282 \n517. Butcher SC, Essayagh B, Steyerberg EW, Benfari G, Antoine C, Grigioni F, et al. Factors \ninfluencing post-surgical survival in degenerative mitral regurgitation. Eur Heart J 2023; \n44:871–81. https://doi.org/10.1093/eurheartj/ehad004 \n518. Grigioni F, Clavel MA, Vanoverschelde JL, Tribouilloy C, Pizarro R, Huebner M, et al. \nThe MIDA mortality risk score: development and external validation of a prognostic \nmodel for early and late death in degenerative mitral regurgitation. Eur Heart J 2018; \n39:1281–91. https://doi.org/10.1093/eurheartj/ehx465 \n519. Del Rio-Pertuz G, Nugent K, Argueta-Sosa E. Right heart catheterization in clinical \npractice: a review of basic physiology and important issues relevant to interpretation. \nAm J Cardiovasc Dis 2023;13:122–37. \n520. Mentias A, Patel K, Patel H, Gillinov AM, Rodriguez LL, Svensson LG, et al. Prognostic \nutility of brain natriuretic peptide in asymptomatic patients with significant mitral re-\ngurgitation and preserved left ventricular ejection fraction. Am J Cardiol 2016;117: \n258–63. https://doi.org/10.1016/j.amjcard.2015.10.040 \n521. Cawley PJ, Hamilton-Craig C, Owens DS, Krieger EV, Strugnell WE, Mitsumori L, et al. \nProspective comparison of valve regurgitation quantitation by cardiac magnetic reson-\nance imaging and transthoracic echocardiography. Circ Cardiovasc Imaging 2013;6: \n48–57. https://doi.org/10.1161/CIRCIMAGING.112.975623 \n522. Penicka M, Vecera J, Mirica DC, Kotrc M, Kockova R, Van Camp G. Prognostic implica-\ntions of magnetic resonance-derived quantification in asymptomatic patients with or-\nganic mitral regurgitation: comparison with Doppler echocardiography-derived \nintegrative \napproach. \nCirculation \n2018;137:1349–60. \nhttps://doi.org/10.1161/ \nCIRCULATIONAHA.117.029332 \n523. Naoum C, Blanke P, Cavalcante JL, Leipsic J. Cardiac computed tomography and mag-\nnetic resonance imaging in the evaluation of mitral and tricuspid valve disease. Circ \nCardiovasc Imaging 2017;10:e005331. https://doi.org/10.1161/CIRCIMAGING.116. \n005331 \n524. Kitkungvan D, Nabi F, Kim RJ, Bonow RO, Khan MA, Xu J, et al. Myocardial fibrosis in \npatients with primary mitral regurgitation with and without prolapse. J Am Coll Cardiol \n2018;72:823–34. https://doi.org/10.1016/j.jacc.2018.06.048  \n4724                                                                                                                                                                                         \nESC Guidelines \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026\n\n\n525. Garg P, Swift AJ, Zhong L, Carlhall CJ, Ebbers T, Westenberg J, et al. Assessment of \nmitral valve regurgitation by cardiovascular magnetic resonance imaging. Nat Rev \nCardiol 2020;17:298–312. https://doi.org/10.1038/s41569-019-0305-z \n526. Feuchtner GM, Alkadhi H, Karlo C, Sarwar A, Meier A, Dichtl W, et al. Cardiac CT \nangiography for the diagnosis of mitral valve prolapse: comparison with echocardiog-\nraphy. Radiology 2010;254:374–83. https://doi.org/10.1148/radiol.2541090393 \n527. Gollmann-Tepeköylü C, Nägele F, Höfer D, Holfeld J, Hirsch J, Oezpeker CU, et al. A \nqualitative improvement program for minimally invasive mitral surgery: technical ad-\nvancements ameliorate outcome and operative times. Interdiscip Cardiovasc Thorac \nSurg 2023;36:ivad030. https://doi.org/10.1093/icvts/ivad030 \n528. Tarzia P, Ciampi P, Lanza O, Canali E, Canestrelli S, Calò L. Multi-modality imaging for \npre-procedural planning of transcatheter mitral valve interventions. Eur Heart J Suppl \n2023;25:C205–11. https://doi.org/10.1093/eurheartjsupp/suad021 \n529. Eleid MF, Foley TA, Said SM, Pislaru SV, Rihal CS. Severe mitral annular calcification: \nmultimodality imaging for therapeutic strategies and interventions. JACC Cardiovasc \nImaging 2016;9:1318–37. https://doi.org/10.1016/j.jcmg.2016.09.001 \n530. Roselli C, Yu M, Nauffal V, Georges A, Yang Q, Love K, et al. Genome-wide association \nstudy reveals novel genetic loci: a new polygenic risk score for mitral valve prolapse. Eur \nHeart J 2022;43:1668–80. https://doi.org/10.1093/eurheartj/ehac049 \n531. Badhwar V, Chikwe J, Gillinov AM, Vemulapalli S, O’Gara PT, Mehaffey JH, et al. Risk of \nsurgical mitral valve repair for primary mitral regurgitation. J Am Coll Cardiol 2023;81: \n636–48. https://doi.org/10.1016/j.jacc.2022.11.017 \n532. Lazam S, Vanoverschelde JL, Tribouilloy C, Grigioni F, Suri RM, Avierinos JF, et al. \nTwenty-year outcome after mitral repair versus replacement for severe degenerative \nmitral regurgitation: analysis of a large, prospective, multicenter, international registry. \nCirculation \n2017;135:410–22. \nhttps://doi.org/10.1161/CIRCULATIONAHA.116. \n023340 \n533. David TE, David CM, Tsang W, Lafreniere-Roula M, Manlhiot C. Long-term results of \nmitral valve repair for regurgitation due to leaflet prolapse. J Am Coll Cardiol 2019;74: \n1044–53. https://doi.org/10.1016/j.jacc.2019.06.052 \n534. Deja MA, Malinowski M, Widenka K, Stozynski N, Bartus K, Kapelak B, et al. \nComparison of repair vs replacement in calcific and rheumatic mitral disease. Ann \nThorac Surg 2023;116:954–61. https://doi.org/10.1016/j.athoracsur.2023.04.048 \n535. Brescia AA, Watt TMF, Murray SL, Rosenbloom LM, Kleeman KC, Allgeyer H, et al. \nRheumatic mitral valve repair or replacement in the valve-in-valve era. J Thorac \nCardiovasc Surg 2022;163:591–602.e1. https://doi.org/10.1016/j.jtcvs.2020.04.118 \n536. Chen SW, Chen CY, Chien-Chia Wu V, Chou AH, Cheng YT, Chang SH, et al. Mitral \nvalve repair versus replacement in patients with rheumatic heart disease. J Thorac \nCardiovasc Surg 2022;164:57–67.e11. https://doi.org/10.1016/j.jtcvs.2020.07.117 \n537. Yun KL, Sintek CF, Miller DC, Pfeffer TA, Kochamba GS, Khonsari S, et al. Randomized \ntrial comparing partial versus complete chordal-sparing mitral valve replacement: ef-\nfects on left ventricular volume and function. J Thorac Cardiovasc Surg 2002;123: \n707–14. https://doi.org/10.1067/mtc.2002.121048 \n538. Makkar RR, Chikwe J, Chakravarty T, Chen Q, O’Gara PT, Gillinov M, et al. \nTranscatheter mitral valve repair for degenerative mitral regurgitation. JAMA 2023; \n329:1778–88. https://doi.org/10.1001/jama.2023.7089 \n539. von Bardeleben RS, Mahoney P, Morse MA, Price MJ, Denti P, Maisano F, et al. 1-Year \noutcomes with fourth-generation mitral valve transcatheter edge-to-edge repair from \nthe EXPAND G4 study. JACC Cardiovasc Interv 2023;16:2600–10. https://doi.org/10. \n1016/j.jcin.2023.09.029 \n540. Zahr F, Smith RL, Gillam LD, Chadderdon S, Makkar R, von Bardeleben RS, et al. \nOne-year outcomes from the CLASP IID randomized trial for degenerative mitral re-\ngurgitation. JACC Cardiovasc Interv 2023;15:2803–16. https://doi.org/10.1016/j.jcin. \n2023.10.002 \n541. Kaneko T, Hirji S, Zaid S, Lange R, Kempfert J, Conradi L, et al. Mitral valve surgery after \ntranscatheter edge-to-edge repair: mid-term outcomes from the CUTTING-EDGE \ninternational registry. JACC Cardiovasc Interv 2021;14:2010–21. https://doi.org/10. \n1016/j.jcin.2021.07.029 \n542. Wild MG, Kreidel F, Hell MM, Praz F, Mach M, Adam M, et al. Transapical mitral valve \nimplantation for treatment of symptomatic mitral valve disease: a real-world multicen-\ntre experience. Eur J Heart Fail 2022;24:899–907. https://doi.org/10.1002/ejhf.2434 \n543. Ludwig S, Perrin N, Coisne A, Ben Ali W, Weimann J, Duncan A, et al. Clinical out-\ncomes of transcatheter mitral valve replacement: two-year results of the \nCHOICE-MI Registry. EuroIntervention 2023;19:512–25. https://doi.org/10.4244/EIJ- \nD-22-01037 \n544. Suri RM, Vanoverschelde JL, Grigioni F, Schaff HV, Tribouilloy C, Avierinos J-F, et al. \nAssociation between early surgical intervention vs watchful waiting and outcomes \nfor mitral regurgitation due to flail mitral valve leaflets. JAMA 2013;310:609–16.  \nhttps://doi.org/10.1001/jama.2013.8643 \n545. Tribouilloy C, Grigioni F, Avierinos JF, Barbieri A, Rusinaru D, Szymanski C, et al. \nSurvival implication of left ventricular end-systolic diameter in mitral regurgitation \ndue to flail leaflets a long-term follow-up multicenter study. J Am Coll Cardiol 2009; \n54:1961–68. https://doi.org/10.1016/j.jacc.2009.06.047 \n546. Tribouilloy C, Rusinaru D, Grigioni F, Avierinos JF, Vanoverschelde JL, Benfari G, et al. \nIndexing left ventricular end-systolic dimension to body size: association with mortality \nin patients with degenerative mitral regurgitation. Eur J Heart Fail 2024;26:2563–9.  \nhttps://doi.org/10.1002/ejhf.3393 \n547. Essayagh B, Antoine C, Benfari G, Messika-Zeitoun D, Michelena H, Le Tourneau T, \net al. Prognostic implications of left atrial enlargement in degenerative mitral regurgi-\ntation. J Am Coll Cardiol 2019;74:858–70. https://doi.org/10.1016/j.jacc.2019.06.032 \n548. Abadie BQ, Cremer PC, Vakamudi S, Gillinov AM, Svensson LG, Cho L. Sex-specific \nprognosis of left ventricular size and function following repair of degenerative mitral \nregurgitation. J Am Coll Cardiol 2024;83:303–12. https://doi.org/10.1016/j.jacc.2023. \n10.033 \n549. Dejgaard LA, Skjolsvik ET, Lie OH, Ribe M, Stokke MK, Hegbom F, et al. The mitral \nannulus disjunction arrhythmic syndrome. J Am Coll Cardiol 2018;72:1600–9. https:// \ndoi.org/10.1016/j.jacc.2018.07.070 \n550. Essayagh B, Sabbag A, Antoine C, Benfari G, Batista R, Yang LT, et al. The mitral annular \ndisjunction of mitral valve prolapse: presentation and outcome. JACC Cardiovasc \nImaging 2021;14:2073–87. https://doi.org/10.1016/j.jcmg.2021.04.029 \n551. Essayagh B, Sabbag A, Antoine C, Benfari G, Yang LT, Maalouf J, et al. Presentation and \noutcome of arrhythmic mitral valve prolapse. J Am Coll Cardiol 2020;76:637–49. https:// \ndoi.org/10.1016/j.jacc.2020.06.029 \n552. Weiner MM, Boateng P, Pandis D, Miller MA, Adams DH. Impact of mitral valve repair \non the Pickelhaube sign. Eur Heart J 2019;40:2267. https://doi.org/10.1093/eurheartj/ \nehy458 \n553. Pandis D, David N, Ei-Eshmawi A, Miller MA, Boateng P, Costa AC, et al. Noncomplex \nventricular arrhythmia associated with greater freedom from recurrent ectopy at 1 \nyear after mitral repair surgery. JTCVS Open 2024;19:94–113. https://doi.org/10. \n1016/j.xjon.2024.04.005 \n554. Bonaros N, Hoefer D, Oezpeker C, Gollmann-Tepekoylu C, Holfeld J, Dumfarth J, \net al. Predictors of safety and success in minimally invasive surgery for degenerative mi-\ntral disease. Eur J Cardiothorac Surg 2022;61:637–44. https://doi.org/10.1093/ejcts/ \nezab438 \n555. Berretta P, Kempfert J, Van Praet F, Salvador L, Lamelas J, Nguyen TC, et al. \nRisk-related clinical outcomes after minimally invasive mitral valve surgery: insights \nfrom the Mini-Mitral International Registry. Eur J Cardiothorac Surg 2023;63:ezad090.  \nhttps://doi.org/10.1093/ejcts/ezad090 \n556. Pfannmueller B, Misfeld M, Verevkin A, Garbade J, Holzhey DM, Davierwala P, et al. \nLoop neochord versus leaflet resection techniques for minimally invasive mitral valve \nrepair: long-term results. Eur J Cardiothorac Surg 2021;59:180–6. https://doi.org/10. \n1093/ejcts/ezaa255 \n557. Akowuah EF, Maier RH, Hancock HC, Kharatikoopaei E, Vale L, Fernandez-Garcia C, \net al. Minithoracotomy vs conventional sternotomy for mitral valve repair: a rando-\nmized clinical trial. JAMA 2023;329:1957–66. https://doi.org/10.1001/jama.2023.7800 \n558. Olsthoorn JR, Heuts S, Houterman S, Maessen JG, Sardari Nia P. Effect of minimally \ninvasive mitral valve surgery compared to sternotomy on short- and long-term out-\ncomes: a retrospective multicentre interventional cohort study based on \nNetherlands Heart Registration. Eur J Cardiothorac Surg 2022;61:1099–106. https:// \ndoi.org/10.1093/ejcts/ezab507 \n559. Lang M, Vitanova K, Voss B, Feirer N, Rheude T, Krane M, et al. Beyond the 10-year \nhorizon: mitral valve repair solely with chordal replacement and annuloplasty. Ann \nThorac Surg 2023;115:96–103. https://doi.org/10.1016/j.athoracsur.2022.05.036 \n560. Newell P, Percy E, Hirji S, Harloff M, McGurk S, Malarczyk A, et al. Outcomes of mitral \nvalve repair among high- and low-volume surgeons within a high-volume institution. \nAnn Thorac Surg 2023;115:412–19. https://doi.org/10.1016/j.athoracsur.2022.05.057 \n561. Rosenhek R, Rader F, Klaar U, Gabriel H, Krejc M, Kalbeck D, et al. Outcome of watch-\nful waiting in asymptomatic severe mitral regurgitation. Circulation 2006;113:2238–44.  \nhttps://doi.org/10.1161/CIRCULATIONAHA.105.599175 \n562. Grigioni F, Benfari G, Vanoverschelde JL, Tribouilloy C, Avierinos JF, Bursi F, et al. \nLong-term implications of atrial fibrillation in patients with degenerative mitral regur-\ngitation. J Am Coll Cardiol 2019;73:264–74. https://doi.org/10.1016/j.jacc.2018.10.067 \n563. Ratwatte S, Strange G, Playford D, Stewart S, Celermajer DS. Prevalence of pulmonary \nhypertension in mitral regurgitation and its influence on outcomes. Open Heart 2023; \n10:e002268. https://doi.org/10.1136/openhrt-2023-002268 \n564. Essayagh B, Antoine C, Benfari G, Maalouf J, Michelena HI, Crestanello JA, et al. \nFunctional tricuspid regurgitation of degenerative mitral valve disease: a crucial deter-\nminant of survival. Eur Heart J 2020;41:1918–29. https://doi.org/10.1093/eurheartj/ \nehaa192 \n565. Essayagh B, Benfari G, Antoine C, Grigioni F, Le Tourneau T, Roussel JC, et al. The \nMIDA-Q mortality risk score: a quantitative prognostic tool for the mitral valve pro-\nlapse spectrum. Circulation 2023;147:798–811. https://doi.org/10.1161/CIRCULA \nTIONAHA.122.062612 \n566. Benfari G, Sorajja P, Pedrazzini G, Taramasso M, Gavazzoni M, Biasco L, et al. \nAssociation of transcatheter edge-to-edge repair with improved survival in older pa-\ntients with severe, symptomatic degenerative mitral regurgitation. Eur Heart J 2022; \n43:1626–35. https://doi.org/10.1093/eurheartj/ehab910 \n567. Speziale G, Nasso G, Esposito G, Conte M, Greco E, Fattouch K, et al. Results of mitral \nvalve repair for Barlow disease (bileaflet prolapse) via right minithoracotomy versus \nconventional median sternotomy: a randomized trial. J Thorac Cardiovasc Surg 2011; \n142:77–83. https://doi.org/10.1016/j.jtcvs.2010.08.033  \nESC Guidelines                                                                                                                                                                                          4725 \nDownloaded from https://academic.oup.com/eurheartj/article/46/44/4635/8234488 by guest on 14 January 2026",
      "tables": [],
      "keywords": [
        "references",
        "ct"
      ]
    }
  ]
}